
<html lang="en"     class="pb-page"  data-request-id="a0485dec-0f21-486f-a28b-0dd8c2fc5cfc"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-5;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01845;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties" /></meta><meta name="dc.Creator" content="Peter S.  Dragovich" /></meta><meta name="dc.Creator" content="Thomas H.  Pillow" /></meta><meta name="dc.Creator" content="Robert A.  Blake" /></meta><meta name="dc.Creator" content="Jack D.  Sadowsky" /></meta><meta name="dc.Creator" content="Emel  Adaligil" /></meta><meta name="dc.Creator" content="Pragya  Adhikari" /></meta><meta name="dc.Creator" content="Sunil  Bhakta" /></meta><meta name="dc.Creator" content="Nicole  Blaquiere" /></meta><meta name="dc.Creator" content="Jinhua  Chen" /></meta><meta name="dc.Creator" content="Josefa  dela Cruz-Chuh" /></meta><meta name="dc.Creator" content="Karen E.  Gascoigne" /></meta><meta name="dc.Creator" content="Steven J.  Hartman" /></meta><meta name="dc.Creator" content="Mingtao  He" /></meta><meta name="dc.Creator" content="Susan  Kaufman" /></meta><meta name="dc.Creator" content="Tracy  Kleinheinz" /></meta><meta name="dc.Creator" content="Katherine R.  Kozak" /></meta><meta name="dc.Creator" content="Liang  Liu" /></meta><meta name="dc.Creator" content="Liling  Liu" /></meta><meta name="dc.Creator" content="Qi  Liu" /></meta><meta name="dc.Creator" content="Ying  Lu" /></meta><meta name="dc.Creator" content="Fanwei  Meng" /></meta><meta name="dc.Creator" content="Melinda M.  Mulvihill" /></meta><meta name="dc.Creator" content="Aimee  O’Donohue" /></meta><meta name="dc.Creator" content="Rebecca K.  Rowntree" /></meta><meta name="dc.Creator" content="Leanna R.  Staben" /></meta><meta name="dc.Creator" content="Steven T.  Staben" /></meta><meta name="dc.Creator" content="John  Wai" /></meta><meta name="dc.Creator" content="Jian  Wang" /></meta><meta name="dc.Creator" content="BinQing  Wei" /></meta><meta name="dc.Creator" content="Catherine  Wilson" /></meta><meta name="dc.Creator" content="Jianfeng  Xin" /></meta><meta name="dc.Creator" content="Zijin  Xu" /></meta><meta name="dc.Creator" content="Hui  Yao" /></meta><meta name="dc.Creator" content="Donglu  Zhang" /></meta><meta name="dc.Creator" content="Hongyan  Zhang" /></meta><meta name="dc.Creator" content="Hao  Zhou" /></meta><meta name="dc.Creator" content="Xiaoyu  Zhu" /></meta><meta name="dc.Description" content="The biological and medicinal impacts of proteolysis-targeting chimeras (PROTACs) and related chimeric molecules that effect intracellular degradation of target proteins via ubiquitin ligase-mediate..." /></meta><meta name="Description" content="The biological and medicinal impacts of proteolysis-targeting chimeras (PROTACs) and related chimeric molecules that effect intracellular degradation of target proteins via ubiquitin ligase-mediate..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 17, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01845" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01845" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01845" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01845" /></link>
        
    
    

<title>Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01845" /></meta><meta property="og:title" content="Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0030.jpeg" /></meta><meta property="og:description" content="The biological and medicinal impacts of proteolysis-targeting chimeras (PROTACs) and related chimeric molecules that effect intracellular degradation of target proteins via ubiquitin ligase-mediated ubiquitination continue to grow. However, these chimeric entities are relatively large compounds that often possess molecular characteristics, which may compromise oral bioavailability, solubility, and/or in vivo pharmacokinetic properties. We therefore explored the conjugation of such molecules to monoclonal antibodies using technologies originally developed for cytotoxic payloads so as to provide alternate delivery options for these novel agents. In this report, we describe the first phase of our systematic development of antibody–drug conjugates (ADCs) derived from bromodomain-containing protein 4 (BRD4)-targeting chimeric degrader entities. We demonstrate the antigen-dependent delivery of the degrader payloads to PC3-S1 prostate cancer cells along with related impacts on MYC transcription and intracellular BRD4 levels. These experiments culminate with the identification of one degrader conjugate, which exhibits antigen-dependent antiproliferation effects in LNCaP prostate cancer cells." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01845"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01845">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01845&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01845&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01845&amp;href=/doi/10.1021/acs.jmedchem.0c01845" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2534-2575</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01766" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01846" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Peter S. Dragovich</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter S. Dragovich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#a1c5d3c0c6ced7c8c2c98fd1c4d5c4d3e1c6c4cfc48fc2cecc"><span class="__cf_email__" data-cfemail="8beff9eaece4fde2e8e3a5fbeeffeef9cbeceee5eea5e8e4e6">[email protected]</span></a>. Phone: 650-467-6854.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+S.++Dragovich">Peter S. Dragovich</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7372-2862" title="Orcid link">http://orcid.org/0000-0001-7372-2862</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas H. Pillow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas H. Pillow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+H.++Pillow">Thomas H. Pillow</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert A. Blake</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert A. Blake</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Blake">Robert A. Blake</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jack D. Sadowsky</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jack D. Sadowsky</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jack+D.++Sadowsky">Jack D. Sadowsky</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0712-5450" title="Orcid link">http://orcid.org/0000-0002-0712-5450</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emel Adaligil</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emel Adaligil</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emel++Adaligil">Emel Adaligil</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pragya Adhikari</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pragya Adhikari</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pragya++Adhikari">Pragya Adhikari</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sunil Bhakta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sunil Bhakta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sunil++Bhakta">Sunil Bhakta</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicole Blaquiere</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicole Blaquiere</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicole++Blaquiere">Nicole Blaquiere</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jinhua Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinhua Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinhua++Chen">Jinhua Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Josefa dela Cruz-Chuh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Josefa dela Cruz-Chuh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Josefa++dela+Cruz-Chuh">Josefa dela Cruz-Chuh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karen E. Gascoigne</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen E. Gascoigne</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen+E.++Gascoigne">Karen E. Gascoigne</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven J. Hartman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven J. Hartman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven+J.++Hartman">Steven J. Hartman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingtao He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingtao He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing, Co. Ltd., 6 Tai He Road, BDA, Beijing 100176, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingtao++He">Mingtao He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan Kaufman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan Kaufman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Kaufman">Susan Kaufman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tracy Kleinheinz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tracy Kleinheinz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tracy++Kleinheinz">Tracy Kleinheinz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katherine R. Kozak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katherine R. Kozak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+R.++Kozak">Katherine R. Kozak</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing, Co. Ltd., 6 Tai He Road, BDA, Beijing 100176, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liang++Liu">Liang Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liling Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liling Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liling++Liu">Liling Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qi Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qi Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing, Co. Ltd., 6 Tai He Road, BDA, Beijing 100176, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qi++Liu">Qi Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ying Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ying Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ying++Lu">Ying Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fanwei Meng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fanwei Meng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing, Co. Ltd., 6 Tai He Road, BDA, Beijing 100176, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fanwei++Meng">Fanwei Meng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melinda M. Mulvihill</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melinda M. Mulvihill</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melinda+M.++Mulvihill">Melinda M. Mulvihill</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aimee O’Donohue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aimee O’Donohue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aimee++O%E2%80%99Donohue">Aimee O’Donohue</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rebecca K. Rowntree</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rebecca K. Rowntree</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rebecca+K.++Rowntree">Rebecca K. Rowntree</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Leanna R. Staben</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leanna R. Staben</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leanna+R.++Staben">Leanna R. Staben</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven T. Staben</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven T. Staben</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven+T.++Staben">Steven T. Staben</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Wai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Wai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Wai">John Wai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Wang">Jian Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">BinQing Wei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">BinQing Wei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=BinQing++Wei">BinQing Wei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Catherine Wilson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Catherine Wilson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Catherine++Wilson">Catherine Wilson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianfeng Xin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianfeng Xin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing, Co. Ltd., 6 Tai He Road, BDA, Beijing 100176, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianfeng++Xin">Jianfeng Xin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zijin Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zijin Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zijin++Xu">Zijin Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui Yao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Yao">Hui Yao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Donglu Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donglu Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donglu++Zhang">Donglu Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongyan Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongyan Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongyan++Zhang">Hongyan Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Zhou">Hao Zhou</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Xiaoyu Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoyu Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyu++Zhu">Xiaoyu Zhu</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01845&amp;href=/doi/10.1021%2Facs.jmedchem.0c01845" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2534–2575</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 17, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 October 2020</li><li><span class="item_label"><b>Published</b> online</span>17 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01845" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01845</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2534%26pageCount%3D42%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPeter%2BS.%2BDragovich%252C%2BThomas%2BH.%2BPillow%252C%2BRobert%2BA.%2BBlake%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D5%26contentID%3Dacs.jmedchem.0c01845%26title%3DAntibody-Mediated%2BDelivery%2Bof%2BChimeric%2BBRD4%2BDegraders.%2BPart%2B1%253A%2BExploration%2Bof%2BAntibody%2BLinker%252C%2BPayload%2BLoading%252C%2Band%2BPayload%2BMolecular%2BProperties%26numPages%3D42%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2575%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01845"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3134</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01845" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;S. Dragovich&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;H. Pillow&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Blake&quot;},{&quot;first_name&quot;:&quot;Jack&quot;,&quot;last_name&quot;:&quot;D. Sadowsky&quot;},{&quot;first_name&quot;:&quot;Emel&quot;,&quot;last_name&quot;:&quot;Adaligil&quot;},{&quot;first_name&quot;:&quot;Pragya&quot;,&quot;last_name&quot;:&quot;Adhikari&quot;},{&quot;first_name&quot;:&quot;Sunil&quot;,&quot;last_name&quot;:&quot;Bhakta&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;Blaquiere&quot;},{&quot;first_name&quot;:&quot;Jinhua&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Josefa&quot;,&quot;last_name&quot;:&quot;dela Cruz-Chuh&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;E. Gascoigne&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;J. Hartman&quot;},{&quot;first_name&quot;:&quot;Mingtao&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Kaufman&quot;},{&quot;first_name&quot;:&quot;Tracy&quot;,&quot;last_name&quot;:&quot;Kleinheinz&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;R. Kozak&quot;},{&quot;first_name&quot;:&quot;Liang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Liling&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Qi&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Ying&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Fanwei&quot;,&quot;last_name&quot;:&quot;Meng&quot;},{&quot;first_name&quot;:&quot;Melinda&quot;,&quot;last_name&quot;:&quot;M. Mulvihill&quot;},{&quot;first_name&quot;:&quot;Aimee&quot;,&quot;last_name&quot;:&quot;O’Donohue&quot;},{&quot;first_name&quot;:&quot;Rebecca&quot;,&quot;last_name&quot;:&quot;K. Rowntree&quot;},{&quot;first_name&quot;:&quot;Leanna&quot;,&quot;last_name&quot;:&quot;R. Staben&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;T. Staben&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Wai&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;BinQing&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Catherine&quot;,&quot;last_name&quot;:&quot;Wilson&quot;},{&quot;first_name&quot;:&quot;Jianfeng&quot;,&quot;last_name&quot;:&quot;Xin&quot;},{&quot;first_name&quot;:&quot;Zijin&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Donglu&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Hongyan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Xiaoyu&quot;,&quot;last_name&quot;:&quot;Zhu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2534-2575&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01845&quot;},&quot;abstract&quot;:&quot;The biological and medicinal impacts of proteolysis-targeting chimeras (PROTACs) and related chimeric molecules that effect intracellular degradation of target proteins via ubiquitin ligase-mediated ubiquitination continue to grow. However, these chimeric entities are relatively large compounds that often possess molecular characteristics, which may compromise oral bioavailability, solubility, and/or in vivo pharmacokinetic properties. We therefore explored the conjugation of such molecules to monoclonal antibodies using technologies originally developed for cytotoxic payloads so as to provide alternate delivery options for these novel agents. In this report, we describe the first phase of our systematic development of antibody–drug conjugates (ADCs) derived from bromodomain-containing protein 4 (BRD4)-targeting chimeric degrader entities. We demonstrate the antigen-dependent delivery of the degrader payloads to PC3-S1 prostate cancer cells along with related impacts on MYC transcription and intracellular BRD&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01845&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01845" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01845&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01845" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01845&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01845" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01845&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01845&amp;href=/doi/10.1021/acs.jmedchem.0c01845" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01845" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01845" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01845%26sid%3Dliteratum%253Aachs%26pmid%3D33596065%26genre%3Darticle%26aulast%3DDragovich%26date%3D2021%26atitle%3DAntibody-Mediated%2BDelivery%2Bof%2BChimeric%2BBRD4%2BDegraders.%2BPart%2B1%253A%2BExploration%2Bof%2BAntibody%2BLinker%252C%2BPayload%2BLoading%252C%2Band%2BPayload%2BMolecular%2BProperties%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D5%26spage%3D2534%26epage%3D2575%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/jmcmar.2021.64.issue-5/20210311/jmcmar.2021.64.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0030.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The biological and medicinal impacts of proteolysis-targeting chimeras (PROTACs) and related chimeric molecules that effect intracellular degradation of target proteins via ubiquitin ligase-mediated ubiquitination continue to grow. However, these chimeric entities are relatively large compounds that often possess molecular characteristics, which may compromise oral bioavailability, solubility, and/or in vivo pharmacokinetic properties. We therefore explored the conjugation of such molecules to monoclonal antibodies using technologies originally developed for cytotoxic payloads so as to provide alternate delivery options for these novel agents. In this report, we describe the first phase of our systematic development of antibody–drug conjugates (ADCs) derived from bromodomain-containing protein 4 (BRD4)-targeting chimeric degrader entities. We demonstrate the antigen-dependent delivery of the degrader payloads to PC3-S1 prostate cancer cells along with related impacts on MYC transcription and intracellular BRD4 levels. These experiments culminate with the identification of one degrader conjugate, which exhibits antigen-dependent antiproliferation effects in LNCaP prostate cancer cells.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03156" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03156" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The bromodomain and extraterminal (BET) family of proteins consists of four members (BRD2, BRD3, BRD4, and BRDT), which function as epigenetic “readers” of acetylated histone lysine residues.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In the case of BRD4, such interactions are mediated by the protein’s two bromodomain motifs (BD1 and BD2), and disruption of the BRD4–histone affinity is currently viewed as an attractive strategy for the development of novel anticancer agents.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> One of the earliest reported BRD4/BET inhibitors was <i>tert</i>-butyl (<i>S</i>)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetate (JQ1, compound <b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), and the compound has been extensively profiled in many biological assessments since its initial disclosure.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> As a result of these and other research activities, multiple BRD4/BET inhibitors have been advanced to clinical-stage evaluations as possible treatments for various oncology indications.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> These molecules include (<i>S</i>)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamide (TEN-010, RO6870810, compound <b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which is structurally similar to compound <b>1</b>. Unfortunately, thrombocytopenia frequently limits the clinical applications of BRD4/BET inhibitors,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and this unwanted side effect may be associated with the mechanism-of-action of the compounds.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Encouragingly, several next-generation BRD4 inhibitors with improved selectivities relative to first-generation compounds are currently undergoing clinical evaluation, and results from these studies are beginning to emerge.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0002.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative BRD4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Heterobifunctional molecules, which form ternary complexes between various ubiquitin ligases (e.g., Von Hippel–Lindau tumor suppressor (VHL),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> cereblon (CRBN),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> X-linked inhibitor of apoptosis protein (XIAP),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> mouse double minute 2 homolog (MDM2)<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a>) and BRD4, were recently shown to potently degrade the BRD4 protein (and sometimes other BET family members) and thereby offer possible therapeutic advantages relative to simple BRD4/BET inhibitors. Such biological enhancements may be due to the ability of these compounds to exhibit broader transcriptional impacts compared to related inhibitors that do not degrade the BRD4 protein.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> One possible drawback of such chimeric molecules is their relatively large molecular size, which may impart physicochemical characteristics that compromise oral bioavailability, solubility, and/or in vivo pharmacokinetic (PK) properties.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Accordingly, the chimeric BRD4/BET-targeting molecules described in the literature have typically been delivered to animals via subcutaneous (SC)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> or intraperitoneal (IP)<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> administration routes, although examples of intravenously (IV) and orally (PO) administered chimeric degrader compounds that target other proteins have recently appeared.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a></div><div class="NLM_p last">In an attempt to provide additional in vivo delivery options for chimeric BET degraders, we wished to explore conjugation of these entities to antibodies using technologies that were originally developed for cytotoxic payloads.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In addition to overcoming potential delivery challenges associated with the BET degraders, we were curious to determine whether the described antibody-conjugates might afford improved outcomes in preclinical assessments of thrombocytopenia risks relative to unconjugated anti-BET agents. In this report, we describe our initial explorations of antibody linkers, drug-loading parameters, and payload molecular properties in an effort to maximize BRD4 degradation activity and thereby drive antiproliferation effects. A subsequent disclosure in this journal issue describes the continuation of these activities and culminates with the identification of BET–degrader conjugates that exhibit potent antiproliferation properties in cells and strong efficacy in mouse xenograft models in vivo.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> These endeavors leverage our prior experiences with creating antibody-conjugates using ERα-targeting chimeric degrader molecules,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and a preliminary account of our BET-related research was recently published.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Other researchers have also added to this growing field by disclosing their own independent efforts to create alternate chimeric BRD4-degrader antibody–drug conjugates (ADCs).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Although various nomenclatures have been employed in the literature to describe the chimeric degrader molecules (e.g., proteolysis-targeting chimeras (PROTACs), specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs), degronimers), for consistency and simplicity purposes, the terms “chimeric degraders” and “degraders” are used to describe such BRD4-targeting entities throughout the remainder of this work. We also did not typically characterize the ability of the chimeric molecules employed in this research to degrade BET family members in addition to BRD4. Such entities are hereafter referred to as “BRD4 degraders” to simply reflect the extent of our characterization activities as opposed to implying selective BET family degradation properties.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We began our exploration of BRD4-degrader antibody-conjugates by utilizing the maleimide-containing linker-drug <b>3a</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) to attach compound <b>3</b><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (the well-known BRD4-targeting and VHL-dependent chimeric degrader “MZ1” that is structurally related to BRD4 inhibitors <b>1</b> and <b>2</b>) to an antibody that recognizes the six transmembrane epithelial antigen of the prostate 1 (STEAP1) cell surface antigen. The STEAP1 protein is known to be overexpressed in a number of human cancers, with levels in prostate cancers being especially high.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Importantly, it also exhibits a relatively low expression in a majority of normal human tissues.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Cytotoxic antibody–drug conjugates targeting STEAP1 display a strong in vivo efficacy against patient-derived prostate cancer models in an antigen-dependent manner that generally reflects the expression level of the STEAP1 protein and the corresponding ADC cellular uptake.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In addition, inhibition and/or degradation of BRD4 by small interfering RNA (siRNA),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> small-molecule bromodomain binders,<a onclick="showRef(event, 'cit6a ref25'); return false;" href="javascript:void(0);" class="ref cit6a ref25">(6a,25)</a> and chimeric degraders<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> is known to potently inhibit the growth of prostate cancer cell lines in vitro and to afford potent in vivo efficacy in related mouse tumor models. Collectively, these data suggest that STEAP1-targeting antibody-conjugates, which incorporate BRD4-degrading chimeric degraders, have good potential to exhibit antiproliferative effects against STEAP1-expressing prostate cancer cell lines and mouse xenograft tumor models.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0003.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of chimeric BRD4 degrader <b>3</b> (MZ1) and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As expected, based on the prior disclosures mentioned above, compound <b>3</b> was a potent and near-complete BRD4 degrader when tested using a PC3 prostate cancer cell line that was engineered to express elevated levels of the STEAP1 antigen<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (PC3-S1 cell line–see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S1a</a>; PC3-S1 BRD4 DC<sub>50</sub> and PC3-S1 BRD4 <i>S</i><sub>inf</sub> values–<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S2a</a>). Consistent with protein degraders often exhibiting more pronounced cellular phenotypes in comparison to simple inhibitors,<a onclick="showRef(event, 'ref11 ref27'); return false;" href="javascript:void(0);" class="ref ref11 ref27">(11,27)</a> compound <b>3</b> displayed more potent (IC<sub>50</sub>) and more extensive (max inhibition) suppression of MYC gene transcription relative to the related BRD4 inhibitor <b>1</b> when tested in a separate assessment using MV4-11 AML cells (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S3</a>; see ref <a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> for information regarding the relationship between BRD4 inhibition and suppression of MYC gene transcription). Compound <b>3</b> also exhibited a more potent antiproliferation activity relative to <b>1</b> when tested against the PC3-S1 cell line (PC3-S1 IC<sub>50</sub>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S4</a>). As both degrader <b>3</b> and compound <b>1</b> bound to BRD4 with approximately the same affinity (for BRD4 BD2 IC<sub>50</sub> values, see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S5</a>; for BRD4 BD1 IC<sub>50</sub> values, see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S1 and Figure S5</a>), the improved cellular outcomes observed for the former molecule presumably resulted from its ability to degrade the BRD4 protein instead of simply inhibiting its function.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biological Activities of Unconjugated Chimeric Degraders Described in This Work<a class="ref internalNav" href="#t1fn13" aria-label="m">m</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">Log <i>k</i> IAM<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">BRD4 BD2 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">VHL FP IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">ternary complex SPR <i>T</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">MYC IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">MYC max inhib (%)<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">PC3-S1 BRD4 DC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center">PC3-S1 BRD4 <i>S</i><sub>inf</sub> (%)<a class="ref internalNav" href="#t1fn8" aria-label="h">h</a></th><th class="colsep0 rowsep0" align="center" char=".">PC3-S1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn9" aria-label="i">i</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t1fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t1fn11" aria-label="k">k</a></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char=".">79</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">>20 000</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char=".">380</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">1.71</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="left">310</td><td class="colsep0 rowsep0" align="left">199</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="char" char=".">140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">1.26</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="char" char=".">107</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">>20 000</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char=".">5000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">1.96</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">610</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="char" char=".">81</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="char" char=".">930</td><td class="colsep0 rowsep0" align="left">79</td><td class="colsep0 rowsep0" align="char" char=".">2600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">1.24</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">720</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">780</td><td class="colsep0 rowsep0" align="left">99</td><td class="colsep0 rowsep0" align="char" char=".">2800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">2.65</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">520</td><td class="colsep0 rowsep0" align="left">127</td><td class="colsep0 rowsep0" align="char" char=".">70</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="char" char=".">350</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char=".">2700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="left">135</td><td class="colsep0 rowsep0" align="left">250</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="char" char=".">1300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b><a class="ref internalNav" href="#t1fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">2.73</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="left">570</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">280</td><td class="colsep0 rowsep0" align="left">88</td><td class="colsep0 rowsep0" align="char" char=".">3800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">2.01</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="left">440</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">87</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char=".">480</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">1.10</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="char" char=".">2100</td><td class="colsep0 rowsep0" align="char" char=".">78</td><td class="colsep0 rowsep0" align="char" char=".">6500</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char=".">11 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">1.89</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="left">470</td><td class="colsep0 rowsep0" align="left">250</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="left">99</td><td class="colsep0 rowsep0" align="char" char=".">67</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Cell-membrane permeability assessment (larger values predict increased intracellular compound concentrations).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">BRD4 BD2 bromodomain binding affinity; for BD1 binding affinities, see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S1</a>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">VHL-binding affinity.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Surface plasmon resonance (SPR) half-life of the BRD4/VHL/compound ternary complex (sum of half-lives determined using BRD4 BD1 and BD2 bromodomains; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S3</a> for individual values).</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Concentration that suppresses MYC gene transcript 50% in MV4-11 AML cells; time point = 4 h.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Maximum suppression of MYC gene transcript.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">Concentration that achieves 50% degradation of BRD4; time point = 4 h.</p></div><div class="footnote" id="t1fn8"><sup><sup>h</sup></sup><p class="last">Maximum reduction of BRD4 protein levels relative to dimethyl sulfoxide (DMSO)-treated controls.</p></div><div class="footnote" id="t1fn9"><sup><sup>i</sup></sup><p class="last">Antiproliferation activity; time point = 6 days.</p></div><div class="footnote" id="t1fn10"><sup><sup>j</sup></sup><p class="last">Approximately a 2:1 mixture of cis-diastereomers (spacer fragment).</p></div><div class="footnote" id="t1fn11"><sup><sup>k</sup></sup><p class="last">NA, not applicable.</p></div><div class="footnote" id="t1fn12"><sup><sup>l</sup></sup><p class="last">ND, not determined.</p></div><div class="footnote" id="t1fn13"><sup><sup>m</sup></sup><p class="last">See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for a discussion on the error associated with each assay. Full chemical structures are depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S4</a>.</p></div></div></div><div class="NLM_p">In our initial conjugation experiments, the maleimide portion of linker-drug <b>3a</b> was conjugated to a STEAP1-targeting monoclonal antibody (mAb) that contained two engineered Cys residues at the LC-K149 location to afford an ADC (STEAP1–<b>3a</b>-D2) with a drug–antibody ratio (DAR) of close to 2 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Scheme S1</a>; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for experimental details and full ADC characterization information).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The use of such engineered Cys residues enables the generation of highly homogeneous antibody–drug conjugates and is one of the several site-specific conjugation approaches currently employed by the ADC field.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Importantly, the LC-K149 mAb attachment site was known from our previous studies of ADCs employing cytotoxic payloads to provide maleimide-derived conjugates, which exhibited excellent in vivo stability properties and which displayed potent efficacy in mouse xenograft tumor models.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Accordingly, we anticipated that conjugation of degrader-containing linker-drugs such as <b>3a</b> to the LC-K149 attachment site would afford ADCs with similarly favorable in vivo stability properties.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biological Activities of Chimeric Degrader Conjugates Described in This Work<a class="ref internalNav" href="#t2fn11" aria-label="k">k</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0029.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">conjugate</th><th class="colsep0 rowsep0" align="center" char=".">DAR<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">PC3-S1 BRD4 DC<sub>50</sub> (μg/mL)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">PC3-S1 BRD4 DC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">PC3-S1 BRD4 <i>S</i><sub>inf</sub> (%)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">DC<sub>50</sub> ratio<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">PC3-S1 IC<sub>50</sub> (μg/mL)<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">PC3-S1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>3a</b>-D2</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">556</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>230</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>3a</b>-D2</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>1100</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">>2.0</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>220</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>3a</b>-D6</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">0.21</td><td class="colsep0 rowsep0" align="left">7.9</td><td class="colsep0 rowsep0" align="left">70</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>750</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>3a</b>-D6</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">1900</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">240</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>710</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>3a</b>-D6<a class="ref internalNav" href="#t2fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t2fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>3b</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">0.051</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>3b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">0.40</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">8.0</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>3c</b></td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="left">0.29</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>770</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>3c</b></td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="left">0.74</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>760</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>3d</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">0.71</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>770</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>3d</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="left">115</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>780</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>4a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>710</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>4a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3900</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>67</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>780</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>4b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">3900</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>4b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3900</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>1.0</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>5a</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">0.017</td><td class="colsep0 rowsep0" align="left">0.67</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>5a</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">0.26</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>5a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3900</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>5800</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>5b</b></td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">0.034</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>750</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>5b</b></td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">1300</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>760</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>5b</b></td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">2100</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">1615</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>740</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>6a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="left">113</td><td class="colsep0 rowsep0" align="left">88</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>760</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>6a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>780</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>6b</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">149</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>770</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>6b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3900</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>26</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>6b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3900</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>26</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>7a</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>7a</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">4000</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">400</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>7a</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3900</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>390</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>7b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">87</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>7b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3900</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>75</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>7b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">1500</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>8a</b>-D2</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>1300</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>260</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>8a</b>-D2</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>1300</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>260</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>8a</b>-D6</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">0.11</td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>720</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>8a</b>-D6</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3000</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>680</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>760</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>8a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>9a</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">591</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–-<b>9a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">3900</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">6.6</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>760</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>9b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">942</td><td class="colsep0 rowsep0" align="left">74</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>9b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">3900</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>10a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>750</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>10a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3600</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>75</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>730</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2–<b>10a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3700</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>77</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>750</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>10b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">835</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–1<b>0b</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">974</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>780</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>11a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3900</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>780</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>1a</b></td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3900</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>790</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>12a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>710</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>12a</b></td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>3700</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>86</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>750</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>12b</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">0.038</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">710</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>12b</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">6.8</td><td class="colsep0 rowsep0" align="left">96</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">770</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>12c</b></td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="left">0.078</td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">510</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>12c</b></td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="left">0.27</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STEAP1–<b>12d</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">8.4</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>780</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLL1–<b>12d</b></td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>780</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Drug-to-antibody ratio.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Absolute concentration of conjugate that achieves 50% degradation of BRD4; time point = 72 h.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Concentration of conjugated chimeric degrader that achieves 50% BRD4 degradation (drug-equivalent units; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for unit conversion details).</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Maximum degradation of BRD4 protein levels relative to DMSO-treated controls.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Ratio of C-type lectin-like molecule-1 (CLL1) or human epidermal growth factor receptor 2 (HER2) and STEAP1 DC<sub>50</sub> values for a given linker-drug and DAR.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">Antiproliferation activity of conjugate, absolute concentration; time point = 6 days.</p></div><div class="footnote" id="t2fn7"><sup><sup>g</sup></sup><p class="last">Antiproliferation activity, conjugated chimeric degrader drug-equivalents.</p></div><div class="footnote" id="t2fn8"><sup><sup>h</sup></sup><p class="last">Tested in whole-blood stability assessment but not in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> assays.</p></div><div class="footnote" id="t2fn9"><sup><sup>i</sup></sup><p class="last">NA, not applicable.</p></div><div class="footnote" id="t2fn10"><sup><sup>j</sup></sup><p class="last">ND, not determined.</p></div><div class="footnote" id="t2fn11"><sup><sup>k</sup></sup><p class="last">See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for a discussion on the error associated with each assay. Full chemical structures are depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S4</a>.</p></div></div></div><div class="NLM_p">Linker-drug <b>3a</b> contains a methylene alkoxy carbamate moiety, which enabled creation of a covalent attachment between the secondary alcohol present in <b>3</b> and the remainder of the linker entity. Similar functionality and payload attachment strategies were described previously by others to afford ADCs derived from auristatins and topoisomerase inhibitors that displayed strong, antigen-dependent in vivo activity in mouse xenograft models.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In addition, the linker portion of <b>3a</b> incorporates a peptidomimetic fragment that was previously shown to be cleaved intracellularly by cathepsin B to efficiently release a variety of attached payloads.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> STEAP1 conjugates derived from <b>3a</b> were envisioned to release degrader <b>3</b> inside a targeted cell following antigen binding, internalization, trafficking to the lysosome, and subsequent proteolytic degradation of the antibody and/or linker cleavage (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Scheme S2</a> for additional details regarding the mechanism by which <b>3a</b>-conjugates are expected to release compound <b>3</b>). However, since the methylene alkoxy carbamate linker had not been previously applied to chimeric degrader molecules, we were unsure at the outset of our research how efficiently these processes would take place.</div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S2b</a>, treatment of STEAP1-expressing PC3-S1 prostate cancer cells with the STEAP1–<b>3a</b>-D2 conjugate for 72 h afforded measurable degradation of the BRD4 protein as quantified by an immunofluorescence assay. However, the extent of such an activity (<i>S</i><sub>inf</sub>) plateaued at roughly half of the near-complete BRD4 degradation that was observed for the unconjugated chimeric degrader <b>3</b> in a related experiment (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S2a</a>). When normalized for the drug–antibody ratio to reflect the loading of <b>3</b>, the DC<sub>50</sub> value observed for the STEAP1–<b>3a</b>-D2 conjugate was considerably weaker than that noted for unconjugated <b>3</b> (556 versus 23 nM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for details regarding how this normalization was performed). In addition, a control conjugate derived from <b>3a</b> that recognized the CLL1 cell surface antigen<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> in lieu of STEAP1 exhibited slightly weaker but similar BRD4 degradation activity in the PC3-S1 cell assessment (CLL1–<b>3a</b>-D2, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S2b</a>). Since CLL1 was not expected to be present at high levels on the surface of the PC3-S1 cells (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S1b</a>), the collective results were inconsistent with the desired delivery of degrader <b>3</b> by the STEAP1–<b>3a</b>-D2 conjugate to the PC3-S1 cells in an antigen-dependent manner (as evidenced by a CLL1/STEAP1 DC<sub>50</sub> ratio of <10, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). These outcomes indicated that additional studies were required to improve the biological properties of the STEAP1-targeting conjugates.</div><div class="NLM_p">One approach to achieve the desired potency improvements was to increase the number of degrader molecules associated with a given ADC. Such “high-DAR” antibody-conjugates should deliver greater quantities of the attached payloads to the interiors of targeted cells relative to the DAR2 ADCs described above. However, it was well-known that appending large numbers of hydrophobic payloads to the surfaces of antibodies often compromised the physiochemical (e.g., aggregation potential) and/or pharmacokinetic properties of the corresponding biologics.<a onclick="showRef(event, 'ref16 ref34'); return false;" href="javascript:void(0);" class="ref ref16 ref34">(16,34)</a> Accordingly, various technologies have recently emerged that enable reliable generation of “high-DAR” ADCs that also exhibit acceptable pharmacokinetic performance.<a onclick="showRef(event, 'cit31b ref35'); return false;" href="javascript:void(0);" class="ref cit31b ref35">(31b,35)</a></div><div class="NLM_p">To further our BRD4-degrader antibody-conjugate efforts via a unique “high-DAR” strategy, we engineered Cys residues into the LC-K149, HC-L174, and HC-Y373 sites of the STEAP1-targeting monoclonal antibody employed in the studies described above.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Like the LC-K149 location, the HC-L174 and HC-Y373 sites were known from our previous research to independently afford DAR2 maleimide-derived conjugates with excellent in vivo stability properties.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Conjugation of the triple mutant STEAP1 mAb with linker-drug <b>3a</b> afforded an ADC with a DAR value of almost six (STEAP1–<b>3a</b>-D6). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S2b</a>, treatment of PC3-S1 cells with STEAP1–<b>3a</b>-D6 afforded improved BRD4 degradation effects as compared to the outcomes previously observed with the STEAP1–<b>3a</b>-D2 DAR2 conjugate. These enhancements included a more potent normalized DC<sub>50</sub> value for STEAP1–<b>3a</b>-D6 relative to STEAP1–<b>3a</b>-D2 (7.9 versus 556 nM, respectively) as well as a greater extent of BRD4 degradation (<i>S</i><sub>inf</sub> = 70 versus 55%, respectively). Importantly, the BRD4 degradation potency of STEAP1–<b>3a</b>-D6 was clearly separated from that exhibited by the corresponding high-DAR control conjugate (CLL1–<b>3a</b>-D6; <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S2b</a>), indicating that the higher payload loading was now consistent with antigen-dependent delivery of the chimeric degrader. In addition, and in agreement with our previous studies,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> a second control DAR6 conjugate related to STEAP1–<b>3a</b>-D6 (HER2–<b>3a</b>-D6; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S1c</a> for evidence of low HER2 expression in PC3-S1 cells) exhibited excellent in vitro stability properties in independent experiments conducted using whole blood from mice, rats, cynomolgus monkeys, and humans (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S2</a>). These data suggested that conjugates such as STEAP1–<b>3a</b>-D6 were likely to exhibit acceptable in vivo stability properties in the various species since our previous ADC studies established (1) a reasonable in vitro to in vivo correlation, and (2) the antigen recognized by a given conjugate did not significantly impact the whole-blood stability outcomes.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> As a result of the above findings, we focused our subsequent efforts on DAR6 ADCs derived from the engineered LC-K149, HC-L174, and HC-Y373 triple mutant STEAP1 monoclonal antibody. Thus, unless otherwise indicated, all subsequent conjugates described in this work are “high-DAR” (DAR6) entities. For simplicity and clarity purposes, the “D6” nomenclature will be omitted from the names of these conjugates unless a corresponding DAR2 ADC was also prepared (e.g., the conjugates derived from linker-drug <b>8a</b> below).</div><div class="NLM_p">In spite of the ability of both STEAP1–<b>3a</b>-D2 and STEAP1–<b>3a</b>-D6 to degrade BRD4 inside PC3-S1 cells, neither conjugate exhibited measurable antiproliferation effects when tested against this cancer line in vitro (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). These results contrasted with outcomes observed for unconjugated degrader <b>3</b>, which afforded moderate PC3-S1 growth inhibition when assessed in vitro (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). One possibility for such disparities was that the degree of BRD4 degradation (<i>S</i><sub>inf</sub>) exhibited by STEAP1–<b>3a</b>-D2 and STEAP1–<b>3a</b>-D6 was not sufficiently complete to drive antiproliferation effects in the PC3-S1 cells. Simple examination of the dose–response curves associated with degrader <b>3</b> in both the BRD4 degradation and antiproliferation assessments suggested that an <i>S</i><sub>inf</sub> value of at least 85% (measured after 4 h) was required to impact 6 day cell growth parameters (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S6</a>). Accordingly, we continued to explore the BRD4-degrader antibody-conjugates with the dual goals of further increasing BRD4 <i>S</i><sub>inf</sub> values while maintaining potent DC<sub>50</sub> activities.</div><div class="NLM_p">Linker-drugs <b>3b</b>–<b>d</b> were then examined as alternate means to attach chimeric degrader <b>3</b> to the STEAP1-targeting antibody (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The methanethiosulfonate (MTS) moiety contained in these entities efficiently reacts with Cys residues on the surfaces of engineered monoclonal antibodies and thereby connects the linker-drugs to the biologics via new disulfide bonds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Scheme S1</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Like the maleimide-derived attachments described above, such disulfide connections formed with engineered LC-K149, HC-L174, and HC-Y373 mAb Cys residues exhibited favorable stability properties in both in vitro and in vivo experiments.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Our previous studies demonstrated that related conjugates bearing carbamate-containing disulfide linkers could efficiently release attached cytotoxic payloads following internalization into targeted cells, disulfide reduction, and subsequent linker self-immolation.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> However, at the time the current research was conducted, we had little experience with the analogous carbonate-containing disulfide linkers depicted in structures <b>3b</b>–<b>d</b>. Thus, although ADCs constructed from these entities might rapidly release the associated chimeric degrader molecules after cellular internalization in a manner analogous to the legacy carbamate-derived conjugates (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Scheme S3</a>), we were concerned that the carbonate moieties present in <b>3b</b>–<b>d</b> might undergo facile hydrolysis while the related ADCs circulated in vivo. We were therefore curious to learn how BRD4-targeting degrader conjugates containing these carbonate-based disulfide linkers performed in both in vitro potency and stability assessments.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, treatment of PC3-S1 cells with the DAR6 STEAP1–<b>3b</b>, STEAP1–<b>3c</b>, and STEAP1–<b>3d</b> conjugates in independent experiments afforded potent and extensive degradation of the BRD4 protein. In contrast to what was observed for the STEAP1–<b>3a</b>-D2 and STEAP1–<b>3a</b>-D6 conjugates above, relatively minimal separations in DC<sub>50</sub> values were noted for the disulfide-containing ADCs when compared to the corresponding control conjugates (CLL1–<b>3b</b>, CLL1–<b>3c</b>, and CLL1–<b>3d</b>; <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Similarly muted antigen-dependent effects were observed in some of our previous in vitro studies employing disulfide-linked ADCs, and the phenomenon was shown in those cases to be caused by partial thiol-mediated extracellular cleavage of the disulfide-based antibody attachments under the assay conditions.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> We suspected that similar assay-related instability was responsible for the strong activity exhibited by the CLL1–<b>3b</b>, CLL1–<b>3c</b>, and CLL1–<b>3d</b> control conjugates described above (but did not confirm this possibility via experiment). Importantly, however, ADCs derived from all three linker-drugs exhibited encouraging in vitro stability properties toward whole blood from multiple species with the most-hindered analog (CLL1–<b>3d</b>) displaying the most stable outcomes (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S2</a>). These results suggested that STEAP1 and CLL1 conjugates derived from linker-drugs <b>3b</b>–<b>d</b> would exhibit favorable stability properties if assessed in vivo.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In spite of achieving DC<sub>50</sub> and <i>S</i><sub>inf</sub> values that were similar to those observed for unconjugated degrader <b>3</b>, none of the STEAP1 conjugates containing the disulfide linkers exhibited meaningful antiproliferation effects against the PC3-S1 cell line. The origin of this discrepancy is not known with certainty, but the phenomenon may be related to the different time points employed to measure the BRD4 degradation properties of the conjugated and unconjugated entities (72 versus 4 h, respectively). Given this lack of antiproliferation activity, we continued our efforts in search of more promising BRD4-degrader conjugates.</div><div class="NLM_p">Although some precedent exists for linker-drugs containing the methylene alkoxy carbamate and carbonate moieties described above to afford biologically active conjugates, the use of these functional groups to attach payloads to antibodies is relatively limited in the ADC field. As such, the ability of these functionalities to efficiently release the attached payloads following internalization of the BRD4-degrader conjugates into cells was not known with certainty. We therefore wished to explore conjugates that utilized carbamates or amides derived from anilines or primary or secondary amines for such attachment purposes. When combined with protease-cleavable linkers (which often include <i>para</i>-amino-benzyloxy (PAB) moieties, which separate the cleavage site from the attached payload), these attachment functionalities are well-known to enable efficient release of attached cytotoxic molecules from antibody–drug conjugates and thereby afford highly active ADCs.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> However, as compound <b>3</b> does not contain anilines or amines in its chemical structure, we sought to introduce these functional groups into the degrader without negatively impacting the biological potencies of the resulting molecules. Analysis of the known crystal structure of compound <b>1</b> bound to BRD4<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> indicated that the <i>para</i>-Cl moiety was oriented toward the solvent and made relatively minimal contact with the protein (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Related <i>para</i>-aniline-containing derivatives of compound <b>1</b> are known in the patent literature, although their affinities for BRD4 have not been reported.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In addition, functionally active chimeric BRD4 degraders have been described in the patent literature in which a poly(ethylene glycol) (PEG) spacer was attached to the para-position of compound <b>1</b> via displacement of the Cl group.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Collectively, this information suggested that replacement of the <i>para</i>-Cl present in <b>1</b> with aniline or propargyl amine functionalities could be tolerated in the BRD4-binding pocket, and our own molecular docking studies supported this conclusion (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S7a,b</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0004.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of compound <b>1</b> bound to the BD1 bromodomain of BRD4. The <i>para</i>-Cl moiety is highlighted in the pink circle. The pink arrow indicates a vector from the bound molecule that protrudes away from the protein and out into the solvent. The figure was created using the published structure: PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MXF">3MXF</a> (ref <a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Accordingly, we synthesized chimeric degraders <b>4</b> and <b>5</b>, which, respectively, contained the aniline and propargyl amine functional groups as <i>para</i>-Cl replacements but otherwise duplicated the chemical structure of compound <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the affinity of <b>4</b> for BRD4 was somewhat attenuated relative to that observed for <b>3</b>. However, a similar assessment of <b>5</b> revealed minimal BRD4 potency alterations (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition, the affinity of <b>5</b> for the VHL protein was determined by a fluorescence polarization assessment to be within twofold of that exhibited by degrader <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S8</a>; consistent with the two compounds containing identical VHL-binding moieties). We also utilized surface plasmon resonance (SPR) methods to examine the ability of both <b>4</b> and <b>5</b> to, respectively, form ternary complexes with the BRD4 and VHL proteins. Such formation was considered a prerequisite for efficient BRD4 degradation, and similar SPR-based techniques were employed by others to assess related BRD4-degrader complexes.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Since <b>4</b> and <b>5</b> bound to either of the BRD4 BD1 and BD2 bromodomains with reasonably potent affinities (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S1</a>), we measured the half-lives of the BRD4/VHL ternary complexes formed between the degraders and either of these bromodomains in separate, independent SPR experiments (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S9 and Table S3</a>). As we did not know which ternary complex was responsible for the compounds’ intracellular BRD4 degradation activities, we chose to combine (via summation) the separately measured BD1 and BD2 SPR half-lives into a single ternary complex half-life parameter for each degrader compound so examined.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0005.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of chimeric BRD4 degraders <b>4</b> and <b>5</b> and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Both <b>4</b> and <b>5</b> formed BRD4/VHL ternary complexes that were considerably less stable than the one generated by <b>3</b> as evidenced by the significantly shorter combined SPR half-lives observed for complexes generated by the former two compounds (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). As a likely result, much weaker activity was observed for <b>4</b> and <b>5</b> relative to <b>3</b> in cell-based assessments of MYC activity, BRD4 degradation (both DC<sub>50</sub> and <i>S</i><sub>inf</sub> values), and antiproliferation effects. It is currently unknown exactly why degraders <b>4</b> and <b>5</b> afforded less stable BRD4/VHL ternary complexes relative to <b>3</b>. However, retrospective analysis of the BRD4/<b>3</b>/VHL crystal structure,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> which was not available when <b>4</b> and <b>5</b> were originally synthesized, indicated that the polar moieties appended to the BRD4-binding moiety in both <b>4</b> and <b>5</b> may clash with favorable BRD4–VHL interactions in the complex. In general, a reasonable correlation existed between the half-life determined for a given degrader compound in the BRD4/VHL ternary complex assessment and the corresponding BRD4 degradation activity measured in PC3-S1 cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). However, the extent of these relationships was not fully apparent until the majority of the degrader molecules described in this work were appropriately profiled.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0006.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Correlation between SPR half-life of the ternary complex formed between the listed chimeric degrader molecules, BRD4 (BD1 + BD2), and VHL and PC3-S1 BRD4 degradation pDC<sub>50</sub> values. To generate the values depicted on the <i>x</i>-axis, the SPR half-lives determined independently for each compound with the BRD4 BD1 and BD2 bromodomains (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S3</a>) were added together. The number next to each point indicates the compound number from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Most compounds exhibited BRD4 degradation <i>S</i><sub>inf</sub> values >85% with the exception of <b>5</b> (<i>S</i><sub>inf</sub> = 79%). <i>R</i><sup>2</sup> = 0.61. See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for a discussion of the assay error.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also suspected that the weaker cell-based activities of <b>4</b> and <b>5</b> relative to <b>3</b> might be partially due to impaired cell penetration properties related to the introduced polar aniline and amine functional groups. Consistent with this hypothesis, the PC3-S1 antiproliferation properties of chimeric degraders <b>4</b> and <b>5</b> were considerably weaker than those exhibited by the less-polar reversible inhibitor <b>1</b>, which bound to BRD4 with a similar affinity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Accordingly, we profiled the degraders using an immobilized artificial membrane (IAM) assessment for which higher binding (i.e., larger Log <i>k</i> IAM values) was shown by others to correlate well with an increased intracellular compound concentration.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Based on these assessments, compound <b>4</b> was predicted to be significantly less cell-permeable relative to degraders <b>3</b> and <b>5</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The relatively high cell permeability predicted by IAM for compound <b>5</b> was somewhat surprising and may reflect either a conformational organization of the molecule that masks the polarity of the propargyl amine moiety or a preferential affinity of basic amines for the phospholipids, which comprise the IAM columns (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for additional details). Interestingly, the correlation described above between SPR half-life and BRD4 degradation activity could be slightly improved by taking the predicted cell permeability of the chimeric degraders into account via a simple multiplication function (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S10a</a>; cf., <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>; caveat: different number of data points in each figure). In addition, performing the same analysis using only SPR data associated with BD2 (the BRD4 bromodomain that consistently afforded the longest half-lives; <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S3</a>) resulted in a somewhat poorer correlation (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S10b</a>). This outcome suggested that, at least for some of the tested compounds, binding to both BRD4 bromodomains contributed to the degradation results. As mentioned above, the strengths of the described correlations were not fully known during the early phases of our research activities. In addition, we recognized that poor degrader cell permeability properties might be overcome through the antibody-mediated delivery approach that we were exploring. We therefore continued with our plans to prepare and characterize conjugates derived from <b>4</b> and <b>5</b> to determine whether antibody-mediated delivery of these degrader molecules would afford favorable cell-based outcomes.</div><div class="NLM_p">As depicted in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, a STEAP1-targeting conjugate that incorporated <b>4</b> by directly attaching a protease-cleavable linker to the degrader’s aniline moiety (STEAP1–<b>4a</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) exhibited measurable BRD4 degradation activity that was well-separated from that displayed by the corresponding control ADC (HER2–<b>4a</b>). However, the observed DC<sub>50</sub> value for the STEAP1 conjugate was relatively weak, and the maximal extent of BRD4 degradation (<i>S</i><sub>inf</sub>) was significantly curtailed as compared to that observed for unconjugated compound <b>3</b>. Although some precedent existed for directly attaching protease-cleavable linkers to aniline-containing ADC payloads,<a onclick="showRef(event, 'cit41b'); return false;" href="javascript:void(0);" class="ref cit41b">(41b)</a> we speculated that these outcomes might be related to inefficient protease-mediated release of degrader <b>4</b> due to the close proximity of the <b>4a</b> cleavage site to the BRD4-binding moiety (cf., <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Scheme S4</a>). Introduction of a self-immolating <i>para</i>-amino-benzyloxy (PAB) group into peptide-based ADC linkers is an established approach to increase separation between protease-cleavage sites and the attached payloads (cf., <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Scheme S5</a>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Application of this strategy to linker-drug <b>4a</b> and the corresponding ADC afforded a new conjugate that exhibited near-complete degradation of the BRD4 protein (STEAP1–<b>4b</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). However, these effects were only observed at relatively high concentrations, which did not enable meaningful separation from the control conjugate (HER2–<b>4b</b>) up to the maximum concentrations routinely tested in our degradation assessments.</div><div class="NLM_p">Encouragingly, a conjugate bearing degrader <b>5</b> and the same protease-cleavable linker employed for STEAP1–<b>4a</b> exhibited a much more potent BRD4 DC<sub>50</sub> value and a more extensive BRD4 degradation outcome (<i>S</i><sub>inf</sub>) relative to the previously studied ADC (STEAP1–<b>5a</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). These improvements potentially resulted from the propargyl amine moiety present in <b>5a</b> better distancing the linker’s protease-cleavage site from the chimeric degrader relative to the <b>4a</b> and <b>4b</b> linkers (see the additional discussion below for alternate possibilities regarding the observed enhancements). Incorporation of a noncleavable linker into the conjugate design led to STEAP1–<b>5b</b>, which exhibited a BRD4 DC<sub>50</sub> potency similar to that displayed by STEAP1–<b>5a</b> and further improved the extent of BRD4 degradation exhibited by the latter ADC (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In contrast to conjugates bearing cleavable linkers, which are designed to release the native chimeric degraders following intracellular internalization, ADCs such as STEAP1–<b>5b</b> derived from noncleavable linkers were expected to be catabolized in the lysosome into highly polar molecules, which retained a cysteine residue from the antibody in their chemical structures (cf., <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Scheme S6</a>). Based on studies by others of related catabolites, these polar entities were presumed to exhibit poor cell-membrane-permeability properties but were nevertheless expected to effectively transition from the lysosome to the cytosol via mechanisms that might involve active transport.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> At this juncture in our studies, we did not know whether such impaired cell membrane permeability would improve the degradation outcomes of BRD4 degrader conjugates, possibly by concentrating the nonpermeable catabolites inside a targeted cell,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> or hinder such activity by limiting bystander effects in nearby cells that were not targeted by the ADC.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> We also did not attempt to identify or synthesize the intracellular catabolite(s) produced from STEAP1–<b>5b</b> and thus did not assess the ability of such entities to form long-lived BRD4/VHL ternary complexes. The BRD4 degradation results exhibited by the STEAP1–<b>5a</b> and STEAP1–<b>5b</b> conjugates did not obviously differentiate the cleavable and noncleavable linkers. We therefore continued to incorporate both variants in our BRD4-degrader ADC designs, and a detailed comparison of the two linker classes is presented near the end of this work (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). In addition, none of the STEAP1-targeting ADCs derived from <b>4a</b>, <b>4b</b>, <b>5a</b>, or <b>5b</b> exhibited both a potent DC<sub>50</sub> value and the desired >85% BRD4 degradation extent (<i>S</i><sub>inf</sub>) mentioned above (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Based on these outcomes, it was not surprising that all such conjugates failed to demonstrate meaningful antiproliferation activity against the PC3-S1 cell line when tested to relatively high concentrations (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">As depicted in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, introduction of the aniline and amine groups into the BRD4-binding region of compound <b>3</b> significantly impaired BRD4/degrader/VHL ternary complex formation in our SPR assessments (compare compounds <b>4</b> and <b>5</b> to <b>3</b>). We therefore sought to introduce these linker-attachment moieties into other locations within the compound <b>3</b> structure with the goal of retaining favorable ternary complex formation properties. Accordingly, we next examined chimeric degraders in which secondary amine functional groups were incorporated into the VHL-binding portion of the molecules (<b>6</b> and <b>7</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Such introduction preserved the BRD4-binding region of degrader <b>3</b> in its native form but instead risked negatively altering the VHL affinities of the new compounds (and thus the ability to form productive ternary complexes with BRD4). The ortho position of the benzylic fragment present in <b>3</b> was selected for the introduction of the new functional groups since (1) examination of known cocrystal structures of VHL in complex with related ligands indicated that this vector protruded away from the protein into the solvent (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S11</a>) and (2) related derivatization of this position afforded functional chimeric degraders directed at multiple protein targets.<a onclick="showRef(event, 'ref43 ref51'); return false;" href="javascript:void(0);" class="ref ref43 ref51">(43,51)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, a molecule containing an <i>ortho</i>-alkoxy substituent that terminated in an <i>N</i>-Me amine moiety displayed a 2–3-fold loss in VHL affinity relative to degrader <b>3</b> (compound <b>6</b>). A related molecule bearing an <i>ortho</i>-piperidine-alkoxy substituent exhibited VHL affinity that was within twofold that displayed by <b>3</b> (compound <b>7</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). As expected based on their identical BRD4-binding domains, both degraders <b>6</b> and <b>7</b> exhibited BRD4-binding properties that were indistinguishable from <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). When examined in our SPR-based BRD4/VHL ternary complex assessment, compound <b>7</b> displayed a somewhat weaker ternary complex half-life relative to degrader <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>; compound <b>6</b> was not similarly evaluated). Encouragingly, however, the SPR half-life of degrader <b>7</b> was substantially improved relative to the values determined above for compounds <b>4</b> and <b>5</b>, which incorporated the polar linker-attachment groups into the BRD4-binding portions of their chemical structures. As a likely result of this improvement, degrader <b>7</b> exhibited more potent and more extensive BRD4 degradation properties relative to <b>4</b> and <b>5</b> in the PC3-S1 cell-based assessment (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The greater cell permeability predicted by IAM for <b>7</b> as compared to <b>4</b> and <b>5</b> may also have contributed to these outcomes (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>; larger Log <i>k</i> IAM values = increased intracellular compound concentration). However, as discussed for compound <b>5</b> above, the IAM results for <b>7</b> may be misleading due to the basic amine moiety contained in the molecule’s chemical structure.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0007.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of chimeric BRD4 degraders <b>6</b> and <b>7</b> and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">STEAP1-targeting conjugates prepared from either <b>6</b> or <b>7</b> using protease-cleavable (STEAP1–<b>6a</b> and STEAP1–<b>7a</b>) or noncleavable (STEAP1–<b>6b</b> and STEAP1–<b>7b</b>) linkers were active BRD4 degraders in the PC3-S1 cell-based assessment with DC<sub>50</sub> values ranging from 0.25 to 3.8 μg/mL (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In addition, the extent of BRD4 degradation (<i>S</i><sub>inf</sub>) exhibited by these ADCs was generally strong (>85%) although the effects produced by STEAP1–<b>6b</b> were considerably less impressive. Importantly, the activities observed for all of these STEAP1-targeting conjugates were separated by at least 10-fold from the degradation outcomes displayed by the corresponding CLL1 and/or HER2 control ADCs (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, some examples exhibited considerably greater separations). Although many of the tested conjugates afforded relatively potent and extensive BRD4 degradation activity (especially STEAP1–<b>7b</b>), none were active in PC3-S1 antiproliferation experiments when examined up to fairly high concentrations. Based on these outcomes, we began to suspect that an even greater BRD4 degradation potency and/or extent of protein depletion would be required for the conjugates under study to exhibit antiproliferation effects (see the discussion below for more details). However, we were also encouraged that altering the location of the polar linker-attachment moieties within the chimeric degrader chemical structure could produce new BRD4-degrader conjugates with favorable biological properties. In addition, we were pleased that the CLL1–<b>6b</b>, HER2–<b>7a</b>, and HER2–<b>7b</b> conjugates all displayed favorable stability outcomes when tested in the in vitro whole-blood assessment regardless of which species the blood originated from (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S2</a>). These results demonstrated the suitability for conjugates derived from linker-drugs <b>6b</b>, <b>7a</b>, and <b>7b</b> to be advanced into subsequent in vivo experiments.</div><div class="NLM_p">We next examined incorporating aniline and amino groups into the spacer moiety that connected the BRD4 and VHL-binding fragments in the chimeric degrader molecules. Such a location was expected to have minimal impact on the BRD4 and VHL-binding affinities of the resulting compounds but could still interfere with productive formation of the desired BRD4/degrader/VHL ternary complexes. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, inclusion of an aniline or a piperidine moiety in the degrader spacer region afforded compounds (<b>8</b> and <b>9</b>) that exhibited BRD4 and VHL-binding properties, which were similar to those displayed by degrader <b>3</b>. Both <b>8</b> and <b>9</b> were also capable of forming ternary complexes with BRD4/VHL in the SPR-based assessments. Interestingly, the ternary complex half-life displayed by the former molecule was superior (longer) to that exhibited by <b>3</b>, while the half-life corresponding to the latter degrader was significantly impaired (shorter; <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">S10</a>). These differences were likely reflected in subsequent PC3-S1 assessments of BRD4 degradation and antiproliferation in which compound <b>8</b> displayed improved activities relative to <b>9</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Chimeric BRD4 degraders that contained various aryl and heteroaryl moieties (but not anilines) in their spacer regions were known in the patent literature, and the potent biological activities noted for many such molecules were consistent with what we observed for compound <b>8</b> in the current studies.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In addition, the large Log <i>k</i> IAM value measured for degrader <b>9</b> suggested high intracellular concentrations of the compound. However, as discussed for degraders <b>5</b> and <b>7</b> above, this outcome may artifactually reflect the presence of a basic amine moiety in the compound <b>9</b> chemical structure.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0008.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of chimeric BRD4 degraders <b>8</b> and <b>9</b> and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As part of this phase of our research, we also explored chimeric degraders in which the spacer element was attached to the para-position of the phenyl moiety present in the BRD4-binding fragment (compound <b>10</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>; cf., <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This alternate degrader construction was envisioned to diversify the risks of incorporating the polar aniline linker-attachment group in the spacer region via the formation of alternate BRD4/VHL ternary complexes relative to those associated with compounds <b>8</b> and <b>9</b>. The new design also enabled the carboxamide moiety present in the BRD4-binding portion of the previously examined molecules (to which the spacer was attached) to be replaced with a thiazole isostere in an effort to further diversify the molecules. The described alterations were supported by our previous analysis of published structural and biological data suggesting that active BRD4 binders and chimeric degraders could be created via derivatization of the <i>para</i>-phenyl position (see the discussion surrounding <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> above). An additional literature report demonstrated the feasibility of incorporating heterocycles as carboxamide replacements in related BRD4 inhibitors but did not specifically explore thiazoles in this capacity.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Degrader <b>10</b> exhibited BRD4 and VHL-binding properties that were similar to those displayed by <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). However, the half-life of <b>10</b> in the SPR ternary complex assessment was considerably shorter than that of <b>3</b>, and as a likely result, the former compound exhibited a somewhat weaker activity relative to the latter in the MYC suppression and PC3-S1 BRD4 degradation and antiproliferation assays (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0009.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of chimeric BRD4 degraders <b>10</b> and <b>11</b> and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>10</b> was nevertheless a relatively active BRD4 degrader, and we therefore utilized its alternate design to explore the effects of introducing a strongly acidic sulfonic acid group into the chimeric molecular structure (compound <b>11</b>). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, degrader <b>11</b> displayed BRD4-binding properties that were slightly improved relative to <b>10</b> and also formed a BRD4/VHL ternary complex with a very similar SPR half-life. However, due to the strong ionization of the sulfonic acid group at physiological pH, the cell penetration properties predicted for <b>11</b> by IAM assessment were the poorest of all of the compounds studied in this work (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Accordingly, compound <b>11</b> was not active in the cell-based MYC suppression, PC3-S1 BRD4 degradation, and PC3-S1 antiproliferation assays up to the highest concentration tested. Based on these outcomes, degrader <b>11</b> provided us with an opportunity to evaluate the performance of BRD4-degrader-ADCs, which released cell-impermeable payloads that would complement the studies we performed above with conjugates constructed using noncleavable linkers (e.g., those derived from <b>5b</b>, <b>6b</b>, <b>7b</b>, and <b>9b</b>).</div><div class="NLM_p">A DAR2 STEAP1-targeting ADC that incorporated degrader <b>8</b> using a protease-cleavable linker failed to show measurable BRD4 degradation activity when assessed in PC3-S1 cells (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, STEAP1–<b>8a</b>-D2). In contrast, a DAR6 STEAP1 conjugate constructed using the same linker-drug moiety was active in the degradation assessment, although the extent of BRD4 depletion was less than our 85% target value (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, STEAP1–<b>8a</b>-D6). This outcome provided a second head-to-head comparison of DAR2 and DAR6 conjugates, and it underscored the importance of the higher payload loading in achieving meaningful BRD4 degradation results (cf., STEAP1–<b>3a</b>-D2 versus STEAP1–<b>3a</b>-D6 in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and the corresponding discussion above). DAR6 STEAP1 conjugates derived from the piperidine-containing degrader <b>9</b> using either a protease-cleavable (STEAP1–<b>9a</b>) or a noncleavable (STEAP1–<b>9b</b>) linker displayed significantly less potent DC<sub>50</sub> values relative to STEAP1–<b>8a</b>-D6 but also degraded the BRD4 protein more extensively (<i>S</i><sub>inf</sub>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The STEAP-targeting ADCs that incorporated chimeric degraders bearing the alternate BRD4 binder connection design (STEAP1–<b>10a</b> and STEAP1–<b>10b</b>) displayed similarly inferior DC<sub>50</sub> values as compared to STEAP1–<b>8a</b>-D6 but with comparable <i>S</i><sub>inf</sub> outcomes (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">The weaker biological activity observed for DAR6 conjugates derived from degraders <b>9</b> and <b>10</b> relative to that prepared from <b>8</b> may be due to the impaired ability of the two former molecules to form long-lived ternary complexes with the BRD4 and VHL proteins relative to the latter compound (cf., <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Importantly, the conjugate bearing the cell-impermeable, sulfonic acid-containing degrader molecule and a protease-cleavable linker (STEAP1–<b>11a</b>) was completely inert in the PC3-S1 BRD4 degradation assessments (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). This result, and the relatively favorable anti-BRD4 activity exhibited by STEAP1–<b>8a</b>-D6, which released a structurally related cell-permeable degrader payload via the identical linker, indicated that preserving some measure of cell permeability in the chimeric degrader payload was an important component of creating an active ADC capable of degrading BRD4 (see the additional discussion below related to cleavable versus noncleavable linkers). Consistent with results for the HER2–<b>7a</b> conjugate, the HER2–<b>8a</b>-D6 ADC, which contains a similar protease-cleavable linker, displayed excellent in vitro stability properties when exposed to whole blood from various species for 24 h (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S2</a>).</div><div class="NLM_p">All of the newly constructed chimeric BRD4 degraders explored to this point in this work exhibited weaker cell-based potencies in the MYC suppression, PC3-S1 BRD4 degradation, and PC3-S1 antiproliferation assessments relative to compound <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compounds <b>4</b>–<b>11</b>). These differences were likely the result of the polar aniline and amine functional groups that were introduced into the chimeric degrader structures to facilitate antibody attachment. Such additions worsened the ability of the new degrader molecules to form long-lived BRD4/VHL-derived ternary complexes compared to <b>3</b> (<b>4</b>, <b>5</b>, and <b>9</b>–<b>11</b>) and/or impaired their cell permeability (<b>4</b>, <b>6</b>, and <b>11</b>). To conclude this phase of our research, we wished to also examine at least one chimeric BRD4 degrader that was more potent than <b>3</b> in the cell-based assays. Accordingly, we identified compound <b>12</b>, which replaced the PEG spacer group present in <b>3</b> with a more-rigid bis-alkyne moiety (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, related chimeric BRD4 degraders are also known in the patent literature<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>). In our SPR assessments, degrader <b>12</b> formed a ternary complex with BRD4 and VHL that was somewhat longer-lived relative to the complex formed by <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Consistent with ternary complex stability influencing biological activity, degrader <b>12</b> was also 2–3-fold more potent than <b>3</b> in cell-based assessments of MYC suppression, BRD4 degradation, and antiproliferation (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Disappointingly, a STEAP1-targeting conjugate prepared from <b>12</b> using the same methylene alkoxy carbamate linker employed to construct the STEAP1–<b>3a</b>-D6 ADC described above exhibited weaker and less-extensive BRD4 degradation effects relative to the previously studied conjugate (STEAP1–<b>12a</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). ADCs derived from <b>12</b> and carbonate-based disulfide linkers were somewhat more potent in the PC3-S1 BRD4 degradation assessments relative to the corresponding conjugates prepared from degrader <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, respectively, compare STEAP1–<b>12b</b>, STEAP1–<b>12c</b>, and STEAP1–<b>12d</b> with STEAP1–<b>3b</b>, STEAP1–<b>3c</b>, and STEAP1–<b>3d</b>). However, as was noted for the ADCs related to degrader <b>3</b>, the BRD4 degradation activities observed for the disulfide-containing STEAP1 conjugates derived from <b>12</b> were not well-separated from the results obtained for the corresponding CLL1 controls and may reflect partial cleavage of the disulfide linkers in the cell culture assay media.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0010.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of chimeric BRD4 degrader <b>12</b> and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Chimeric protein degraders are relatively complicated modalities in comparison to typical small-molecule therapeutics, and their development requires the precise balancing of multiple biological parameters (target and ligase binding affinities, the ability to form productive ternary complexes, cell permeabilities, etc.).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Antibody–drug conjugates are similarly complex entities, which also require addressing multiple parameters to afford meaningful in vitro and in vivo activities (target antigen, conjugation method, drug loading, linker-attachment and release mechanisms, etc.).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This work describes the combination of these two modalities to produce even more-complicated agents in which many independent parameters likely contribute to the observed biological outcomes. Since no prior descriptions of systematic development of such antibody–degrader conjugates existed, we performed extensive analysis of the data presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> in an effort to better understand the drivers of antibody-mediated in vitro BRD4 degradation. Through such analysis, we sought to (1) identify trends that could further improve the activities of the ADCs of the present study and (2) provide strategies for the development of additional chimeric degrader conjugates that target proteins other than BRD4.</div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> presents a graphical depiction of the BRD4 DC<sub>50</sub> and <i>S</i><sub>inf</sub> values for the conjugates described in this work (cf., <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The ADCs are grouped in the figure according to their linker release mechanisms and, in the case of protease-cleavable linkers, are further organized by the functional group employed for linker-attachment purposes. When the data are viewed in this manner, several important trends become apparent. First, and most importantly, nearly all of the STEAP1-targeting conjugates exhibited more potent BRD4 DC<sub>50</sub> values relative to the corresponding CLL1 and HER2 control conjugates with meaningful separations noted between the different outcomes (i.e., purple dots in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> were almost always lower on the <i>y</i>-axis relative to blue and/or yellow dots for a given linker-drug). This trend clearly demonstrated the repeated and general antigen-dependent delivery of the chimeric degraders to the STEAP1-expressing PC3-S1 cells, which was a key objective of this research. In addition, no single linker release mechanism appeared to provide an optimal combination of BRD4 DC<sub>50</sub> potency, extent of BRD4 degradation (<i>S</i><sub>inf</sub>), and wide separation from control ADCs. Within a particular release mechanism class, DC<sub>50</sub> and <i>S</i><sub>inf</sub> outcomes often varied considerably and were likely influenced by other parameters such as the ability of the released degraders to form long-lived BRD4/VHL ternary complexes (cf., <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> above and associated discussion). One clear trend in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> was that conjugates derived from glutathione (GSH)-cleavable disulfide linkers exhibited the most potent and most extensive BRD4 degradation properties (<b>3b</b>–<b>d</b> and <b>12b</b>–<b>d</b>). However, as discussed above, these activities were narrowly separated from those associated with the corresponding control ADCs and may result from partial linker cleavage in the cell culture media under the assay conditions. Interestingly, although the majority of chimeric degraders <b>3</b>–<b>12</b> exhibited near-complete BRD4 degradation outcomes when tested in the unconjugated form (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <i>S</i><sub>inf</sub> > 95%; exceptions are <b>5</b> and <b>9</b>), the same molecules often afforded significantly less-extensive degradation results when delivered via the STEAP1-targeting antibodies (some examples are <b>4a</b>, <b>8a</b>, <b>10a</b>, and <b>12a</b>). As a possible consequence, there was no obvious correlation between DC<sub>50</sub> potency and the extent of BRD4 degradation (<i>S</i><sub>inf</sub>) for the tested conjugates (i.e., the purple dots in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> that were the lowest on the <i>y</i>-axis were not always the largest in size). Once again, the observed lack of correlation was likely due to the influence of many other parameters on these biological outcomes.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0011.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Graphical depiction of the BRD4 DC<sub>50</sub> and <i>S</i><sub>inf</sub> values for the DAR6 conjugates described in this work (grouped by the conjugation method). The >85% BRD4 <i>S</i><sub>inf</sub> threshold was purposefully chosen to highlight the suspected requirement for achieving antiproliferation activity (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S6</a>). See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for a discussion of the assay error.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> depicts the <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> BRD4 DC<sub>50</sub> and <i>S</i><sub>inf</sub> outcomes similar to <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> but instead groups the linker-drugs to enable easy comparison of cleavable and noncleavable linkers (only ADCs for which both linker versions were prepared and tested are included). Conjugates derived from the noncleavable linkers were always less potent than the corresponding cleavable entities (sometimes considerably so) but occasionally exhibited somewhat more extensive BRD4 degradation <i>S</i><sub>inf</sub> properties (compare <b>5a</b> with <b>5b</b>, <b>6a</b> with <b>6b</b>, <b>7a</b> with <b>7b</b>, <b>9a</b> with <b>9b</b>, and <b>10a</b> with <b>10b</b>). As discussed above and as depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Scheme S6</a>, ADCs derived from noncleavable linkers are expected to produce highly polar intracellular catabolites that are unlikely to enter neighboring cells not targeted by the conjugate. This lack of “bystander” effects may have contributed to the weaker DC<sub>50</sub> values noted above for the ADCs bearing noncleavable linkers and was consistent with the inactivity of the STEAP1–11a conjugate, which released a polar cell-impermeable degrader (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). As the noncleavable linkers appeared to offer no obvious advantages relative to cleavable options, we chose to deprioritize the use of the former entities in our future BRD4 degrader conjugate development efforts.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0012.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Graphical depiction of the BRD4 DC<sub>50</sub> and <i>S</i><sub>inf</sub> values for selected DAR6 conjugates described in this work (comparison of cleavable and noncleavable linkers). The >85% BRD4 <i>S</i><sub>inf</sub> threshold was purposefully chosen to highlight the suspected requirement for achieving antiproliferation activity (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S6</a>). See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for a discussion of the assay error.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As mentioned several times throughout this work, none of the STEAP1-targeting BRD4 degrader conjugates were active in antiproliferation assessments conducted in PC3-S1 cells (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In contrast, the corresponding unconjugated chimeric degraders <b>3</b>–<b>12</b> exhibited measurable antiproliferation activities when tested against the same cell line (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). However, the cell-killing potencies of these molecules were significantly weaker than those associated with successful cytotoxic ADC payloads, which often resided in the low-nanomolar to picomolar range.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Accordingly, we suspected that conjugation of more-potent degraders with improved BRD4 DC<sub>50</sub> values and/or antiproliferation properties relative to <b>3</b>–<b>12</b> would be required to produce STEAP1-targeting ADCs with the desired cell-killing activities.</div><div class="NLM_p">A plot of unconjugated chimeric degrader BRD4 degradation potency versus conjugate DC<sub>50</sub> values revealed a loose trend that suggested that improvements in the former parameter could also improve the latter (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). This pattern was apparent even if the conjugates derived from GSH-cleavable linkers, whose activities may be influenced by cell-media linker cleavage, were removed from the analysis. Many of the outliers to the general trend were associated with ADCs bearing noncleavable linkers (e.g., <b>5b</b>, <b>9b</b>, and <b>10b</b>) and, as described above, such entities were not envisioned to be incorporated into our future development plans. The disparate performance of conjugates STEAP1–<b>5a</b> and STEAP1–<b>5b</b> relative to unconjugated degrader <b>5</b> was notable with the former two entities exhibiting much more active BRD4 degradation properties in PC3-S1 cells relative to the latter molecule. These outcomes suggested that additional (non-VHL-based) BRD4 degradation mechanisms might be associated with the propargyl amine moiety present in <b>5</b> and that these properties were somehow enhanced via antibody-mediated delivery. However, additional studies are required to fully understand the observed phenomenon.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0013.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Graphical correlation of BRD4 DC<sub>50</sub> values for unconjugated chimeric degraders <b>3</b>–<b>12</b> and the corresponding DAR6 STEAP1 conjugates described in this work. The number next to each point indicates the linker-drug employed to prepare each DAR6 STEAP1 conjugate (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>–<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). The <i>x</i>-axis location of a given point reflects the PC3-S1 DC<sub>50</sub> value of the unconjugated degrader, which corresponds to a depicted linker-drug (e.g., the DC<sub>50</sub> value of unconjugated degrader <b>12</b> establishes the <i>x</i>-axis location of conjugates derived from linker-drugs <b>12a</b>–<b>d</b>; see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> for DC<sub>50</sub> values of all unconjugated degraders). The BRD4 degradation <i>S</i><sub>inf</sub> values of the conjugates are depicted by the point sizes in the figure. See <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> for DC<sub>50</sub> and <i>S</i><sub>inf</sub> values of all conjugated degraders. Unconjugated degrader time point is 4 h. Conjugated degrader time point is 72 h. The >85% BRD4 <i>S</i><sub>inf</sub> threshold was purposefully chosen to highlight the suspected requirement for achieving antiproliferation activity (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S6</a>). See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for a discussion of the assay error.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further support the conclusion that conjugation of more potent chimeric BRD4 degraders would be required to achieve STEAP1 ADCs with PC3-S1 cell-killing properties, we compared the intracellular concentrations of compound <b>8</b> that resulted from various forms of antibody-mediated delivery to those associated with non-antibody-mediated transport of the unconjugated molecule. As shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, exposure of PC3-S1 cells to media containing unconjugated <b>8</b> afforded high intracellular compound concentrations that were similar when measured at 4 and 22 h. These observations were consistent with rapid diffusion of the molecule across the cell membranes, but we did not investigate whether such diffusion was passive or transporter-mediated in nature. The depicted intracellular concentrations were also not corrected for compound binding to intracellular proteins or other entities in that environment, and the measured values do not inform regarding the compound <b>8</b> levels in any subcellular compartment (e.g., nucleus, lysosome, cytosol, etc.). The intracellular-to-extracellular concentration ratios observed for <b>8</b> were consistent with those reported previously by others for a panel of structurally unrelated neutral molecules.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> In contrast, the ratios for <b>8</b> were somewhat lower compared to those determined by us for the well-known cytotoxic ADC payload monomethyl auristatin E (MMAE, which contains a basic amine) using a quantitation method similar to that described in this work (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S12</a>). Importantly, the caveats mentioned above associated with the described intracellular quantitation methodology should be considered throughout the subsequent discussion regarding antibody-mediated delivery of compound <b>8</b>.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0014.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Intracellular quantitation of chimeric degrader <b>8</b> in PC3-S1 cells following non-antibody-mediated delivery or delivery via STEAP1–<b>8a</b>-D2 or STEAP1–<b>8a</b>-D6 ADCs. Time points are listed at the top of each plot. Non-antibody-mediated delivery: compound <b>8</b> (solid purple). ADC delivery: STEAP1–<b>8a</b>-D2 (solid blue), CLL1–<b>8a</b> (dashed blue), STEAP1–<b>8a</b>-D6 (solid red), CLL1–<b>8a</b>-D6 (dashed red). Extracellular conjugate concentrations were absolute (i.e., not the drug-equivalent concentrations employed elsewhere in this work). For comparison purposes, an extracellular conjugate concentration of 100 nM corresponds to approximately 15 μg/mL. Intracellular values for compound <b>8</b> associated with the 0.1 nM concentrations of the test articles were often below the 0.002 nM lower limit of quantification (LLOQ) and are not depicted in the plots.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The data shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a> suggested that extracellular concentrations of <b>8</b>, which corresponded to the compound’s measured BRD4 DC<sub>50</sub> value (85 nM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), resulted in intracellular concentrations of roughly 10 000 nM at either time point. As also depicted in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, the intracellular levels of <b>8</b> observed 4 and 22 h after treatment of PC3-S1 cells with the DAR2 STEAP1–<b>8a</b>-D2 conjugate at all tested concentrations were much lower than this 10 000 nM threshold. These levels were consistent with our related intracellular quantitation of MMAE following antibody-mediated delivery to WSU-DLCL2 cells.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The results also helped explain the inability of STEAP1–<b>8a</b>-D2 to afford measurable PC3-S1 BRD4 degradation activity even when examined at high concentrations (cf., <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In contrast, and consistent with its higher payload loading, the DAR6 STEAP1–<b>8a</b>-D6 ADC afforded higher intracellular PC3-S1 levels of <b>8</b> relative to STEAP1–<b>8a</b>-D2, which increased significantly between the 4 and 22 h time points. Since we did not assess compound <b>8</b> intracellular concentrations beyond 22 h, it remains unknown whether the levels associated with STEAP1–<b>8a</b>-D6 exceeded the 10 000 nM threshold mentioned above after longer time periods. As the extent of BRD4 degradation displayed by STEAP1–<b>8a</b>-D6 in the PC3-S1 cells was attenuated relative to the unconjugated compound (43 versus 98%; <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, respectively), we suspected that such levels may not have reached the 10 000 nM value or may have done so only near the end of the 72 h assay window employed for the STEAP1-conjugate BRD4 degradation assessments. The origins of the nonlinear increases in compound <b>8</b> intracellular concentrations afforded by the STEAP1–<b>8a</b>-D6 conjugate relative to STEAP1–<b>8a</b>-D2 (particularly at the 22 h time point) are currently not known but may involve differences in ADC trafficking, payload release efficiencies, and/or STEAP1 antigen recycling properties. Reassuringly, and consistent with STEAP1 antigen-mediated delivery of the chimeric degrader payloads, CLL1-targeted ADCs corresponding to STEAP1–<b>8a</b>-D2 and STEAP1–<b>8a</b>-D6 afforded lower intracellular concentrations of compound <b>8</b> in related quantitation experiments (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, dashed lines).</div><div class="NLM_p">Further analysis of the <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a> data for unconjugated compound <b>8</b> indicated that intracellular concentrations in excess of 50 000 nM were associated with the compound’s extracellular PC3-S1 antiproliferation IC<sub>50</sub> parameter (1300 nM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Based on the results shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, the intracellular levels of <b>8</b> corresponding to STEAP1–<b>8a</b>-D6 did not reach these lofty values after 22 h and likely never did even following multiday exposures. As with the BRD4 degradation outcomes discussed above, the collective data helped explain why even the DAR6 STEAP1–<b>8a</b>-D6 conjugate was unable to demonstrate PC3-S1 antiproliferation effects when tested to high concentrations. This observation also supported the strategy of conjugating more potent BRD4 degraders to the STEAP1-targeting antibodies as one means of achieving the desired antiproliferation outcomes. Assuming that the intracellular concentrations associated with unconjugated compound <b>8</b> were representative of most chimeric BRD4 degraders, a more potent antiproliferation IC<sub>50</sub> value (i.e., a leftward shift on the <i>x</i>-axis of <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) would translate to lower intracellular concentrations that might better approximate those achievable via delivery by a DAR6 ADC. Alternate approaches involving higher DAR loadings and/or increased intracellular unbound degrader concentrations were also considered but not pursued during this portion of our studies. The search for chimeric BRD4 degraders with improved antiproliferation properties relative to <b>8</b> (or any other degrader described in this work) therefore became a central focus of the next phase of our research activities.</div><div class="NLM_p">As one means of testing this hypothesis, we examined the antiproliferation activity of the STEAP1–<b>8a</b>-D6 conjugate using the LNCaP prostate cancer line. In the unconjugated form, compound <b>8</b> displayed more potent antiproliferation effects against the LNCaP line relative to its potency toward PC3-S1 cells (250 versus 1300 nM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">S3</a>). The LNCaP cells also expressed significantly higher levels of the STEAP1 antigen as compared to the PC3-S1 line (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S1a</a>). Encouragingly, the STEAP1–<b>8a</b>-D6 conjugate exhibited measurable antiproliferation activity when tested using LNCaP cells that was clearly separated from effects associated with the corresponding CLL1–<b>8a</b>-D6 control ADC (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). It is currently unknown if these outcomes resulted from the stronger antiproliferation potency of unconjugated <b>8</b> toward LNCaP cells relative to the PC3-S1 line, the higher STEAP1 antigen expression in the former cells compared to the latter, or a combination of both differences. In addition, western blot analysis demonstrated the ability of STEAP1–<b>8a</b>-D6 (but not a related HER2–<b>8a</b>-D6 control ADC) to degrade BRD4 in a dose-dependent manner at concentrations that approximated the conjugate’s antiproliferation IC<sub>50</sub> value (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S13</a>). Unfortunately, STEAP1–<b>8a</b>-D6 was the only ADC described in this work to display meaningful LNCaP antiproliferation activity (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S3</a>). Thus, although promising, these initial LNCaP antiproliferation outcomes illustrated the need for further development of the chimeric BRD4 degrader compounds and the related antibody-conjugates under study.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0015.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Antiproliferation activity of STEAP1–<b>8a</b>-D6 (blue trace) and CLL1–<b>8a</b>-D6 (red trace) in LNCaP cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To complete this phase of our research, we examined the in vivo stability and pharmacokinetic properties of selected ADCs that were prepared during the studies described above. Although these conjugates were not sufficiently potent to warrant their evaluation in efficacy experiments, we wished to confirm that (1) the employed linkers remained connected to the antibodies during circulation in vivo and (2) attachment of multiple chimeric degrader payloads to the mAb surfaces did not negatively alter the expected pharmacokinetic profiles. As shown in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, the CLL1–<b>8a</b>-D6 and CLL1–<b>12d</b> ADCs displayed good stability properties over the course of several days following IV administration of each conjugate to mice. Analysis of the corresponding mass spectrometry data indicated that CLL1–<b>8a</b>-D6 DAR loss was associated with biotransformation of one of the attached chimeric degrader molecules (amide cleavage; <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S14a,b</a>). Encouragingly, minimal loss of the attached linker-drugs via retro-Michael reactions was observed during the course of the multiday experiment (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Similarly, the CLL1–<b>12d</b> ADC also exhibited good in vivo stability properties with the majority of its DAR changes related to carbonate cleavages noted for the LC-K149 and/or HC-L174 mAb attachment sites (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">S15a,b</a>). Our prior studies demonstrated that in vivo ADC stability outcomes were independent of the administered dose and the target antigen.<a onclick="showRef(event, 'ref30 ref36'); return false;" href="javascript:void(0);" class="ref ref30 ref36">(30,36)</a> Accordingly, the described results provided confidence that STEAP1-targeting conjugates derived from maleimide and disulfide-containing linker-drugs related to <b>8a</b> and <b>12d</b> would also afford favorable in vivo stability properties.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0016.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. In vivo stabilities of CLL1–<b>8a</b>-D6 (5 mg/kg) and CLL1–<b>12d</b> (10 mg/kg) following single IV administration of the indicated dose to mice (normalized Ave DAR plot).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a> depicts the total antibody pharmacokinetic profile of ADC CLL1–<b>8a</b>-D6 as determined using a liquid chromatography with tandem mass spectrometry (LCMS/MS)-based assessment following a single IV administration to mice. Over the course of the 7 day study, the in vivo behavior of the conjugate appeared to be similar to that observed for the corresponding unconjugated CLL1 antibody whose mouse pharmacokinetic profile was determined in a separate experiment.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The outcomes noted for CLL1–<b>8a</b>-D6, coupled with the conjugate’s favorable stability profile mentioned above, encouragingly indicated that the ADC’s pharmacokinetic profile was not dramatically changed relative to that associated with the unconjugated mAb, which lacked the attached chimeric degrader payloads. However, since the sampling in the CLL1–<b>8a</b>-D6 experiment was sparse and fairly limited, pharmacokinetic studies involving additional data points and/or longer durations are required to fully compare the conjugate with its CLL1 mAb counterpart. Related profiling of alternate ADCs bearing chimeric degrader payloads and linkers that differ from those present in <b>8a</b> is also required to determine whether attachment of those linker-drugs negatively impacts antibody pharmacokinetics. In spite of these caveats, the encouraging in vivo profiles of CLL1–<b>8a</b>-D6 and CLL1–<b>12d</b> further motivated us to continue our exploration of the chimeric BRD4 degrader conjugates.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0017.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Pharmacokinetic properties of conjugate CLL1–<b>8a</b>-D6 and corresponding unconjugated mAb following single administrations of a 5 mg/kg IV dose of each entity to mice (analyte = total antibody).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The unconjugated chimeric degraders described in this work and the corresponding linker-drugs required for ADC syntheses were generated by a variety of methods that are depicted in the following schemes. The preparation of linker-drugs <b>3a</b>–<b>d</b> is shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Deprotection of the <i>tert</i>-butyl ester present in compound <b>1</b><a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> under acidic conditions afforded acid <b>13</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). This crude material was converted to the corresponding <i>N</i>-hydroxysuccinimide ester and then coupled to amine <b>15</b> (HCl salt; prepared in one step from commercially available <b>14</b>) to give intermediate <b>16</b>. As depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, the known Boc-protected VHL-binding moiety <b>17</b><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> was derivatized with bromoacetic acid to give intermediate <b>18</b>. Removal of the Boc group from <b>18</b> followed by hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU)-mediated coupling of the resulting amine salt (not shown) with intermediate <b>16</b> provided the chimeric intermediate <b>19</b> after prep-high-performance liquid chromatography (HPLC) purification. Transformation of <b>19</b> to linker-drug <b>3a</b> was then accomplished by sequential treatment with diphenylphosphoryl azide (DPPA) (to generate the corresponding acyl azide, not shown) and subsequent tin-catalyzed coupling with benzyl alcohol <b>20</b>.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Preparation of linker-drugs <b>3b</b>–<b>d</b> was achieved by, respectively, coupling alcohols <b>21</b>, <b>22</b>, and <b>23</b> with <b>17</b> to give the corresponding carbonates <b>24</b>, <b>25</b>, and <b>26</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Alcohols <b>21</b> and <b>22</b> were synthesized from the known 5-nitro-2-pyridine-disulfide analogs<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> in one step as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, while alcohol <b>23</b> was prepared from commercial starting materials. Deprotection of intermediates <b>24</b> and <b>25</b> under acidic conditions and coupling of the resulting amine salts with carboxylic acid <b>16</b>, respectively, afforded linker-drugs <b>3b</b> and <b>3c</b>. In contrast, compound <b>3d</b> was synthesized from <b>26</b> via iterative deprotection/coupling cycles involving carboxylic acids <b>14</b> and <b>13</b>, which proceeded through intermediate <b>27</b>.</div><figure id="sch1" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0018.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Several Key Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) trifluoroacetic acid (TFA), dichloromethane (DCM), 23 °C, 1 h, 97%; (b) HCl, 1:1 DCM/ethyl acetate (EtOAc), 23 °C, 1 h, 100%; (c) <i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide (DCC), <i>N</i>-hydroxysuccinimide, <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA), tetrahydrofuran (THF), 23 °C, 12 h, 100%; then, <b>15</b>, DIEA, dimethylformamide (DMF), 17 °C, 6 h, 38%.</p></p></figure><figure id="sch2" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0019.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Linker-Drugs <b>3a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, BrCH<sub>2</sub>CO<sub>2</sub>H, THF, 23 °C, 2 h, 57%; (b) HCl, 1:1 DCM/EtOAc, 23 °C, 1 h, 71%; (c) HATU, DIEA, <b>16</b>, DMF, 23 °C, 2 h, 17–83%; (d) Et<sub>3</sub>N, DPPA, DMF, 23 °C, 1 h; then, <b>20</b>, dibutyltin dilaurate, DMF, 80 °C, 1 h, 6%; (e) <b>21</b>, <b>22</b>, or <b>23</b>, triphosgene, pyridine, DCM, 15 °C, 30 min; then, <b>17</b>, Et<sub>3</sub>N, DCM, 15–23 °C, 2 h, 32–44%; (f) TFA, 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP), 23 °C, 1 h, 87–100%.</p></p></figure><div class="NLM_p">The preparation of chimeric degrader <b>4</b> and the related linker-drugs <b>4a</b> and <b>4b</b> is depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Compound <b>1</b> was converted into aniline <b>28</b> in good yield using a two-step procedure. Protection of the aniline moiety present in <b>28</b> as the corresponding 2,2,2-trifluoroacetamide (<b>29</b>) followed by acidic deprotection of the <i>tert</i>-butyl ester then afforded carboxylic acid <b>30</b>. This material was subjected to HATU-mediated coupling with amine <b>31</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and subsequent aniline deprotection via mild basic hydrolysis to give chimeric degrader <b>4</b>. Conversion of <b>4</b> to linker-drug <b>4a</b> was accomplished by derivatization of the aniline present in the former compound with fluorenylmethoxycarbonyl (Fmoc)-protected <span class="smallcaps smallerCapital">l</span>-citrulline to provide intermediate <b>32</b> followed by Fmoc deprotection and coupling of the resulting amine (not shown) with carboxylic acid <b>33</b><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Alternatively, compound <b>28</b> was converted to the corresponding isocyanate (not shown) by treatment with triphosgene, and this new entity was condensed with alcohol <b>20</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> to give intermediate <b>34</b>. Removal of the <i>tert</i>-butyl ester present in <b>34</b> under acidic conditions and HATU-mediated coupling of the resulting carboxylic acid (<b>35</b>) with amine <b>31</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> subsequently afforded linker-drug <b>4b</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0020.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Chimeric Degrader <b>4</b> and Linker-Drugs <b>4a</b> and <b>4b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ph<sub>2</sub>C═NH, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, SPhos, toluene, 110 °C, 16 h, 60%; (b) 1 M HCl, THF, 23 °C, 3 h, 95%; (c) trifluoroacetic anhydride (TFAA), pyridine, 23 °C, 12 h, 78%; (d) 4 M HCl, EtOAc, 23 °C, 3 h, 98%; (e) HATU, DIEA, <b>31</b>, DMF, 23 °C, 2 h, 76%; (f) LiOH·H<sub>2</sub>O, 1:1 MeOH/THF, 50 °C, 12 h, 45%; (g) Fmoc-<span class="smallcaps smallerCapital">l</span>-Cit-OH, <i>N</i>-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), DMF, 23 °C, 48 h, 48%; (h) piperidine, DMF, 23 °C, 2 h, 96%; (i) HATU, DIEA, <b>33</b>, DMF, 23 °C, 12 h, 24%; (j) triphosgene, THF, 40 °C, 2 h; then, <b>20</b>, Et<sub>3</sub>N, DCM, 23 °C, 4 h, 8%; (k) 1:1 TFA/DCM, 23 °C, 2 h, 99%; (l) HATU, DIEA, <b>31</b>, DMF, 23 °C, 2 h, 12%.</p></p></figure><div class="NLM_p">The synthesis of chimeric degrader <b>5</b> and linker-drugs <b>5a</b> and <b>5b</b> is shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Palladium-mediated coupling of compound <b>1</b> with propargyl amine under microwave conditions provided intermediate <b>36</b>. Fmoc-protection of the amine moiety of <b>36</b> (to give <b>37</b>) followed by acidic cleavage of the <i>tert</i>-butyl ester then afforded carboxylic acid <b>38</b>. Coupling of <b>38</b> with amine <b>31</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> was accomplished using HATU, and the Fmoc group present in the resulting product (not shown) was deprotected under mild basic conditions to give compound <b>5</b>. Alternatively, coupling of <b>36</b> with Fmoc-protected <span class="smallcaps smallerCapital">l</span>-citrulline provided intermediate <b>39</b>. This entity was deprotected under basic conditions, and the resulting amine (not shown) was coupled with carboxylic acid <b>33</b><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> to give <b>40</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Removal of the <i>tert</i>-butyl group present in 40 followed by coupling of the resulting carboxylic acid (<b>41</b>) with amine <b>31</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> gave linker-drug <b>5a</b>. Linker-drug <b>5b</b> was prepared by derivatization of <b>36</b> with commercially available <b>42</b> to provide intermediate <b>43</b> followed by acidic <i>tert</i>-butyl deprotection and HATU-mediated coupling of the resulting carboxylic acid (<b>44</b>) with amine <b>31</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0021.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Chimeric Degrader <b>5</b> and Linker-Drugs <b>5a</b> and <b>5b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) propargyl amine, Pd(Cy*Phine)<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C (microwave), 1 h, 24%; (b) Fmoc-Cl, Na<sub>2</sub>CO<sub>3</sub>, 1:1 THF/H<sub>2</sub>O, 23 °C, 4 h, 61%; (c) TFA, DCM, 23 °C, 1 h, 97–99%; (d) HATU, DIEA, <b>31</b>, DMF, 23 °C, 3 h, 33–59%; (e) piperidine, DMF, 23 °C, 2 h, 43–99%; (f) Fmoc-<span class="smallcaps smallerCapital">l</span>-Cit-OH, HATU, DIEA, DMF, 23 °C, 12 h, 78%; (g) HATU, DIEA, <b>33</b>, DMF, 23 °C, 12 h, 58%; (h) HATU, DIEA, <b>31</b>, DMF, 23 °C, 12 h, 43%; (i) DIEA, <b>42</b>, DMF, 23 °C, 2 h, 94%.</p></p></figure><div class="NLM_p">Chimeric degrader <b>6</b> and linker-drugs <b>6a</b> and <b>6b</b> were prepared using the methods depicted in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. The known benzyl amine fragment <b>45</b><a onclick="showRef(event, 'cit51c ref61'); return false;" href="javascript:void(0);" class="ref cit51c ref61">(51c,61)</a> was protected as the corresponding Boc derivative (<b>46</b>), and this entity was coupled with commercially available benzyl <i>N</i>-(2-hydroxyethyl)-<i>N</i>-methyl-carbamate (not shown) under Mitsunobu conditions at elevated temperature to give intermediate <b>47</b>. Removal of the Boc group present in <b>47</b> followed by coupling of the resulting amine (HCl salt, <b>48</b>) with the known dipeptide fragment <b>49</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> then gave intermediate <b>50</b>. This compound was subjected to iterative Boc deprotection and HATU-mediated coupling cycles involving carboxylic acids <b>14</b> and <b>13</b> to provide intermediate <b>52</b> (via Boc-protected <b>51</b>). Removal of the benzyloxycarbonyl (Cbz) protecting group present in <b>52</b> by treatment with iodotrimethylsilane (TMSI) then afforded chimeric degrader <b>6</b>. This entity was transformed into linker-drug <b>6a</b> by coupling with the mixed carbonate <b>53</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> under mild basic conditions (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Derivatization of <b>6</b> with commercially available compound <b>42</b> alternatively generated linker-drug <b>6b</b> following prep-HPLC purification (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0022.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Chimeric Degrader <b>6</b> and Linker-Drugs <b>6a</b> and <b>6b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, Et<sub>3</sub>N, THF, 23 °C, 2 h, 48%; (b) CbzN(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>OH, PPh<sub>3</sub>, diisopropyl azodicarboxylate (DIAD), 0–70 °C, 16 h, 64%; (c) 4 M HCl in EtOAc, 23 °C, 1 h, 38%; (d) HATU, DIEA, <b>49</b>, DMF, 23 °C, 1 h, 53%; (e) TFA, HFIP, 23 °C, 1 h, 100%; (f) HATU, DIEA, <b>14</b>, DMF, 23 °C, 15 h, 81%; (g) HATU, DIEA, <b>13</b>, DMF, 23 °C, 15 h, 33%; (h) TMSI, DCM, 23 °C, 16 h, 12%; (i) DIEA, <b>53</b>, DMF, 23 °C, 12 h, 46%; (j) DIEA, <b>42</b>, DMF, 23 °C, 12 h, 68%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a> depicts the preparation of chimeric degrader <b>7</b> and the related linker-drugs <b>7a</b> and <b>7b</b>. The phenol present in the known compound <b>54</b><a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> was coupled to <i>ortho</i>-nitro-phenylsulfonate <b>55</b> (prepared in one step from Cbz-protected 4-hydroxy-piperidine) to give intermediate <b>56</b>. Deprotection of the Boc group contained in <b>56</b> followed by coupling of the resulting amine <b>57</b> (TFA salt) with carboxylic acid <b>14</b> afforded intermediate <b>58</b>. Removal of the Boc group from this compound and coupling of the amine thus produced (TFA salt, not shown) with carboxylic acid <b>13</b> gave the chimeric product <b>59</b>. The Cbz protecting group present in <b>59</b> was then cleaved by treatment with TMSI to provide degrader 7. This material was independently coupled with mixed carbonate <b>53</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> or commercially available compound <b>42</b> to, respectively, give linker-drugs <b>7a</b> and <b>7b</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0023.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Chimeric Degrader <b>7</b> and Linker-Drugs <b>7a</b> and <b>7b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>o</i>-NO<sub>2</sub>PhSO<sub>2</sub>Cl, Et<sub>3</sub>N, 4-dimethylaminopyridine (DMAP), DCM, 23 °C, 12 h, 36%; (b) Cs<sub>2</sub>CO<sub>3</sub>, <b>55</b>, DMF, 50 °C, 13 h, 53%; (c) TFA, DCM, 23 °C, 0.5 or 2 h, 97–98%; (d) HATU, DIEA, <b>14</b>, DMF, 23 °C, 2 h, 74%; (e) HATU, DIEA, <b>13</b>, DMF, 23 °C, 2 h, 80%; (f) TMSI, DCM, 23 °C, 20 min, 13%; (g) DIEA, <b>53</b>, DMF, 23 °C, 12 h, 12%; (h) DIEA, <b>42</b>, DMF, 23 °C, 3 h, 17%.</p></p></figure><div class="NLM_p">The syntheses of chimeric degrader <b>8</b> and the corresponding linker-drug <b>8a</b> are shown in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Dibenzyl-protected alcohol <b>60</b><a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> was coupled with <i>tert</i>-butyl 2-bromoacetate to give ester <b>61</b>. The benzyl groups present in this intermediate were removed via hydrogenation, and the diphenol compound thus obtained (<b>62</b>) was monoalkylated with Cbz-protected 2-bromoethylamine in moderate yield to afford <b>63</b>. The phenol moiety contained in <b>63</b> was then transformed into the corresponding Boc-protected aniline (compound <b>65</b>) via sequential conversion to the trifluoromethylsulfonate (<b>64</b>) and Pd-catalyzed coupling of this entity with <i>tert</i>-butyl carbamate. Cleavage of the Cbz group contained in <b>65</b> afforded the deprotected amine (not shown), and this intermediate was subjected to HATU-mediated coupling with carboxylic acid <b>13</b> to give compound <b>66</b>. Simultaneous removal of the Boc and <i>tert</i>-butyl protecting groups under acidic conditions afforded aniline-acid <b>67</b>, and this entity was coupled to the known amine <b>68</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> to give the chimeric degrader <b>8</b>. Derivatization of the aniline present in <b>8</b> by sequential transformation to the corresponding isocyanate (not shown) and treatment with alcohol <b>20</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> then provided linker-drug <b>8a</b> following prep-HPLC purification.</div><figure id="sch7" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0024.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Chimeric Degrader <b>8</b> and Linker-Drug <b>8a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BrCH<sub>2</sub>CO<sub>2</sub><i>t</i>Bu, NaOH, <i>n</i>Bu<sub>4</sub>HSO<sub>4</sub>, 1:2 toluene/H<sub>2</sub>O, 23 °C, 2 h, 64%; (b) Pd/C, H<sub>2</sub>, MeOH, 23 °C, 16 h, 87%; (c) CbzNHCH<sub>2</sub>CH<sub>2</sub>Br, K<sub>2</sub>CO<sub>3</sub>, KI, MeCN, 70 °C, 12 h, 26%; (d) Tf<sub>2</sub>O, pyridine, 23 °C, 1 h, 100%; (e) BocNH<sub>2</sub>, Xphos, Cs<sub>2</sub>CO<sub>3</sub>, Pd(OAc)<sub>2</sub>, 1,4-dioxane, 100 °C, 16 h, 43%; (f) Pd/C, H<sub>2</sub>, THF, 23 °C, 1 h, 91%; (g) HATU, DIEA, <b>13</b>, DMF, 23 °C, 2 h, 73%; (h) 4 M HCl, EtOAc, 23 °C, 1 h, 100%; (i) HATU, DIEA, <b>68</b>, DMF, 23 °C, 1 h, 17%; (j) triphosgene, 4 Å sieves, Et<sub>3</sub>N, DCM, 23 °C, 30 min; then, <b>20</b>, Et<sub>3</sub>N, DMF, 23 °C, 12 h, 6%.</p></p></figure><div class="NLM_p">Chimeric degrader <b>9</b> and the related linker-drugs <b>9a</b> and <b>9b</b> were prepared by the methods shown in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>. Commercially available compound <b>69</b> was hydrogenated in the presence of PtO<sub>2</sub> to give the <i>cis</i>-diester <b>70</b>. Boc protection of this intermediate (to give <b>71</b>) followed by reduction with diisobutylaluminium hydride (DIBAL-H) then afforded the mixture of <i>cis</i>-piperidine isomers. The alcohol present in <b>73</b> was derivatized with Cbz-protected aziridine <b>74</b><a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> to give the racemic intermediate <b>75</b> and the C diol <b>72</b>. This material was monoalkylated with ethyl 2-diazoacetate under rhodium-catalyzed conditions to provide ester-alcohol <b>73</b> in moderate yield as a racembz group contained therein was subsequently removed via hydrogenation. The resulting racemic amine (<b>76</b>) was coupled with carboxylic acid <b>13</b> via a HATU-mediated protocol, and the ester-containing intermediate thus obtained (<b>77</b>, 1:1 mix of diastereomers) was hydrolyzed under mild basic conditions to afford carboxylic acid <b>78</b> (1:1 mix of diastereomers). Coupling of this entity with the known amine <b>68</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> then gave the chimeric intermediate <b>79</b>, and the Boc group contained in this material was removed under acidic conditions to give degrader <b>9</b> (1:1 mixture of diastereomers) as a HCl salt. Coupling of <b>9</b> with the mixed carbonate <b>53</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> or with commercially available compound <b>42</b>, respectively, provided linker-drugs <b>9a</b> and <b>9b</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).</div><figure id="sch8" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0025.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Chimeric Degrader <b>9</b> and Linker-Drugs <b>9a</b> and <b>9b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PtO<sub>2</sub>·H<sub>2</sub>O, H<sub>2</sub>, AcOH, 45 °C, 12 h, 97%; (b) Boc<sub>2</sub>O, NaHCO<sub>3</sub>, 4:1 THF/H<sub>2</sub>O, 23 °C, 2 h, 75%; (c) DIBAL-H, THF, −78 °C, 2 h, 38%; (d) N<sub>2</sub>CHCO<sub>2</sub>Et, Rh<sub>2</sub>(OAc)<sub>4</sub>, DCM, 0 to 23 °C, 12 h, 30%; (e) <b>74</b>, Sc(OTf)<sub>3</sub>, DCM, −78 to 23 °C, 12 h, 13%; (f) Pd/C, H<sub>2</sub>, THF, 23 °C, 1 h, 100%; (g) HATU, DIEA, <b>13</b>, DMF, 23 °C, 1 h, 92%; (h) LiOH·H<sub>2</sub>O, 5:1:1 THF/MeOH/H<sub>2</sub>O, 23 °C, 1 h, 58%; (i) HATU, DIEA, <b>68</b>, DMF, 50 °C, 6 h, 36%; (j) HCl, EtOAc, 23 °C, 1 h, 85%; (k) DIEA, <b>53</b>, DMF, 23 °C, 12 h, 43%; (l) DIEA, <b>42</b>, DMF, 23 °C, 12 h, 23%. Intermediates <b>73</b>–<b>76</b> are racemic cis-isomers. Intermediates <b>77</b>–<b>79</b> and compounds <b>9</b>, <b>9a</b>, and <b>9b</b> are 1:1 mixtures of diastereomers.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a> depicts the synthesis of chimeric degrader compound <b>10</b> and the related linker-drugs <b>10a</b> and <b>10b</b>. Carboxylic acid <b>13</b> was transformed into the thiazole-containing compound <b>82</b> by a three-step process involving (1) conversion to the corresponding primary amide (<b>80</b>), (2) treatment with Lawesson’s reagent to generate intermediate <b>81</b>, and (3) condensation with 2-bromo-1,1-diethoxyethane under acidic conditions. The central portion of <b>10</b> and related compounds was constructed by converting commercially available carboxylic acid <b>83</b> to alcohol <b>84</b> via reduction with borane. Alkylation of <b>84</b> with <i>tert</i>-butyl 2-bromoacetate using phase-transfer methods afforded ester <b>85</b>, which was subsequently converted to carboxylic acid <b>86</b> by treatment with TFA. Reduction of the acid group present in <b>86</b> with the borane dimethyl sulfide complex provided alcohol <b>87</b>, which was then protected as the corresponding <i>tert</i>-butyldimethylsilyl (TBS) ether to give <b>88</b>. Palladium-catalyzed coupling of one bromide group present in <b>88</b> with <i>tert</i>-butyl acrylate afforded intermediate <b>89</b>, and the remaining bromide moiety present in this entity was converted to Boc-protected aniline <b>90</b> via a second Pd-catalyzed transformation. Hydrogenation of <b>90</b> at elevated temperature reduced the olefin contained in the molecule and simultaneously cleaved the TBS ether to provide alcohol <b>91</b>. This intermediate was alkylated with propargyl bromide to give <b>92</b>, and this new entity was coupled with the thiazole-containing compound <b>82</b> (prepared above) using a palladium-catalyzed method under microwave conditions to provide <b>93</b>. Simultaneous cleavage of the Boc and <i>tert</i>-butyl groups present in <b>93</b> via treatment with TFA afforded carboxylic acid <b>94</b>, and this material was subjected to HATU-mediated coupling with amine <b>68</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> to provide chimeric degrader <b>10</b>. Conversion of <b>10</b> to linker-drug <b>10a</b> was accomplished by treatment with mixed carbonate <b>53</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> under a mild basic condition (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). Similarly, coupling of <b>10</b> with commercially available <b>42</b> generated linker-drug <b>10b</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>).</div><figure id="sch9" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0026.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Chimeric Degrader <b>10</b> and Linker-Drugs <b>10a</b> and <b>10b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>4</sub>Cl, HATU, DIEA, DMF, 23 °C, 2 h, 98%; (b) Lawesson’s reagent, THF, 40 °C, 2 h, 71%; (c) BrCH<sub>2</sub>CH(OCH<sub>3</sub>)<sub>2</sub>, TsOH, AcOH, 90 °C, 1 h, 87%; (d) BH<sub>3</sub>, THF, 23 °C, 12 h, 99%; (e) BrCH<sub>2</sub>CO<sub>2</sub><i>t</i>Bu, <i>n</i>Bu<sub>4</sub>NHSO<sub>4</sub>, NaOH, 1:3 toluene/H<sub>2</sub>O, 23 °C, 3 h, 98%; (f) TFA, DCM, 23 °C, 16 h, 95%; (g) BH<sub>3</sub>·S(CH<sub>3</sub>)<sub>2</sub> THF, 23 °C, 12 h, 91%; (h) <i>tert</i>-butyldimethylsilyl chloride (TBSCl), imidazole, DCM, 23 °C, 4 h, 84%; (i) CH<sub>2</sub>═CHCO<sub>2</sub><i>t</i>Bu, <i>n</i>Bu<sub>4</sub>NBr, NaHCO<sub>3</sub>, Pd(OAc)<sub>2</sub>, DMF, 105 °C, 24 h, 81%; (j) BocNH<sub>2</sub>, Xphos, Cs<sub>2</sub>CO<sub>3</sub>, Pd(OAc)<sub>2</sub>, 1,4-dioxane, 100 °C, 16 h, 89%; (k) Pd/C, H<sub>2</sub>, MeOH, 50 °C, 16 h, >100%; (l) propargyl bromide, <i>t-</i>BuONa, THF, 0–23 °C, 12 h, 68%; (m) <b>82</b>, Pd-Cy*Phine, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 105 °C, microwave, 1 h, 45%; (n) TFA, 1,2-dichloroethane, 23 °C, 2 h, 99%; (o) HATU, DIEA, <b>68</b>, DMF, 23 °C, 1 h, 11%; (p) DIEA, <b>53</b>, hydroxybenzotriazole (HOBt), DMF, 50 °C, 16 h, 27%; (q) DIEA, <b>42</b>, DMF, 60 °C, 48 h, 9%.</p></p></figure><div class="NLM_p">The methods employed to prepare chimeric degrader <b>11</b> and the linker-drug <b>11a</b> are shown in <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>. Palladium-catalyzed coupling of alkyne intermediate <b>92</b> with the known BRD4-binding molecule <b>95</b><a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> under microwave conditions provided compound <b>96</b>. The Boc and <i>tert</i>-butyl groups present in this entity were simultaneously removed by treatment with TFA, and the aniline contained in the resulting intermediate (<b>97</b>) was then reprotected as the corresponding Boc derivative (<b>98</b>). HATU-mediated coupling of <b>98</b> with the known amine <b>68</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> subsequently provided the chimeric molecule <b>99</b>. The methyl ester present in <b>99</b> was hydrolyzed under mild basic conditions, and the resulting carboxylic acid (<b>100</b>) was coupled with 2-aminoethanesulfonic acid to afford intermediate <b>101</b>. Removal of the Boc group contained in this entity was accomplished by treatment with TFA to give chimeric degrader <b>11</b>. Subsequent derivatization of the aniline present in <b>11</b> with the mixed carbonate <b>53</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> provided linker-drug <b>11a</b> (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>).</div><figure id="sch10" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0027.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Chimeric Degrader <b>11</b> and Linker-Drug <b>11a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>92</b>, Pd-Cy*Phine, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 100 °C, microwave, 1 h, 74%; (b) TFA, DCM, 23 °C, 2 h, 80–99%; (c) Boc<sub>2</sub>O, DIEA, DCM, 23 °C, 16 h, 62%; (d) HATU, DIEA, <b>68</b>, DMF, 23 °C, 2 h, 48%; (e) LiOH·H<sub>2</sub>O, 3:1 THF/H<sub>2</sub>O, 23 °C, 2 h, 51%; (f) H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), HOBt, DIEA, 23 °C, 18 h, 47%; (g) <b>53</b>, pyridine, HOBt, 50 °C, 24 h, 19%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a> illustrates the methods used to prepare chimeric degrader <b>12</b> and the related linker-drugs <b>12a</b>–<b>d</b>. Commercially available diol <b>102</b> was monoalkylated with <i>tert</i>-butyl 2-bromoacetate to give intermediate <b>103</b>. This entity was transformed into amine <b>105</b> via conversion to the corresponding phthalimide derivative <b>104</b> and subsequent exposure to hydrazine hydrate at elevated temperature. Coupling of amine <b>105</b> with carboxylic acid <b>13</b> then provided intermediate <b>106</b>, and the <i>tert</i>-butyl group contained therein was subsequently cleaved under acidic conditions to afford carboxylic acid <b>107</b>. This material was subjected to HATU-mediated coupling with amine <b>68</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> to give chimeric degrader <b>12</b>. Derivatization of the secondary hydroxyl group present in <b>12</b> with bromoacetic acid afforded intermediate <b>108</b>. This entity was then transformed into linker-drug <b>12</b>a via conversion to the corresponding acyl azide (<b>109</b>) and subsequent tin-catalyzed coupling with benzyl alcohol <b>20</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Alternatively, carboxylic acid <b>107</b> was coupled with the amine salts obtained by acidic deprotection of intermediates <b>24</b>, <b>25</b>, and <b>26</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) to, respectively, provide linker-drugs <b>12b</b>, <b>12c</b>, and <b>12d</b>.</div><figure id="sch11" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0028.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Chimeric Degrader <b>12</b> and Linker-Drugs <b>12a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, BrCH<sub>2</sub>CO<sub>2</sub><i>t</i>Bu, THF, 0–23 °C, 8 h, 36%; (b) phthalimide, PPh<sub>3</sub>, DIAD, THF, 23 °C, 12 h, 89%; (c) H<sub>2</sub>NNH<sub>2</sub>·H<sub>2</sub>O, ethyl alcohol (EtOH), 80 °C, 1 h, 99%; (d) HATU, DIEA, <b>13</b>, DMF, 23 °C, 2 h, 88%; (e) TFA, DCM, 23 °C, 2 h, 99%; (f) HATU, DIEA, <b>68</b>, DMF, 23 °C, 2 h, 87%; (g) NaH, BrCH<sub>2</sub>CO<sub>2</sub>H, THF, 23 °C, 2 h, 94%; (h) (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>OC(O)Cl, Et<sub>3</sub>N, NaN<sub>3</sub>, acetone, 23 °C, 1 h; (i) <b>20</b>, dibutyltin dilaurate, DMF, 60 °C, 1 h, 3% over two steps; (j) TFA, HFIP, 23 °C, 1 h, 87–100%; (k) HATU, DIEA, DMF, 23 °C, 1–2 h, 12–30%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">This work describes the first detailed account of the systematic exploration of antibody–drug conjugates that incorporate chimeric degrader payloads. A variety of approaches and strategies to improve the biological potencies of these entities were employed including (1) the use of novel carbonate-containing disulfide linkers to connect the degraders to the antibodies, (2) the introduction of “chemical handles” into the degraders to enable antibody attachment with well-precedented linkers, and (3) the use of SPR techniques to assess the compound degradation potential via BRD4–VHL ternary complex quantitation. As multiple interdependent parameters likely contributed to the biological outcomes associated with the new ADCs, it was often difficult to isolate and study a given chimeric degrader or conjugate property during the course of this work. The reported ability of BRD4 degradation to reduce STEAP1 expression levels (which we did not confirm in our studies) may also have contributed to the biological outcomes.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The described process is therefore best described as semiempirical in nature.</div><div class="NLM_p">In spite of these challenges, the results contained in this initial disclosure provided several key conclusions that heavily influenced the next phase of this research.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Intracellular quantitation of one particular payload (compound <b>8</b>) following antibody-mediated delivery indicated that the amounts of the released chimeric degrader were insufficient to drive antiproliferation effects in the cells. The same experiments also demonstrated that increased antibody loading of the payload (i.e., higher DAR value) increased the amounts of the chimeric degrader <b>8</b> delivered to the cells. Head-to-head comparison of two DAR2 conjugates with their DAR6 counterparts confirmed the ability of the higher-DAR conjugates to exhibit stronger BRD4 degradation activities in the PC3-S1 experiments (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>; STEAP1–<b>3a</b> and STEAP1–<b>8a</b> conjugates). An objective of conjugating more potent BRD4 degraders to the antibodies with a preference for DAR6 drug loading was therefore carried into the next phase of our research.</div><div class="NLM_p">The data contained in this report also indicated that conjugates prepared using cleavable peptidomimetic or disulfide-based linkers and maleimide or disulfide-derived antibody attachment chemistries exhibited acceptable in vivo stability properties. Such linking and attachment approaches were therefore retained in our subsequent studies. However, the results from this phase of our experiments also indicated that no additional benefits were achieved through the use of noncleavable linkers, and such entities were therefore not explored in our follow-on efforts. In addition, the data demonstrated that introduction of the “chemical handles” into the chimeric degraders for antibody attachment purposes often impaired the biological potencies of the resulting molecules relative to the unmodified compounds. This observation underscored the need to improve the intrinsic activities of the chimeric molecules that were conjugated and also prioritized the use of linkers that did not require the modified chemical handles. Both of these strategies were pursued in the next phase of this research.</div><div class="NLM_p last">Most importantly, as depicted in the analysis presented in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, the collective results clearly indicated the ability of the chimeric degrader antibody-conjugates to consistently exhibit antigen-dependent BRD4 degradation effects in the targeted PC3-S1 cells. This observation indicated that the described conjugates functioned as selective delivery agents in the in vitro experiments and, coupled with their favorable in vivo performance, provided good confidence to continue the improvement of such entities with the goal of achieving in vivo antitumor activity. The results from these continued studies, including demonstration of the sought-after in vivo antitumor efficacy, are described in a second manuscript, which immediately follows this report in this issue of the journal.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48470" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48470" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Chemistry Methods</h3><div class="NLM_p">Unless otherwise indicated, all reagents and solvents were purchased from commercial sources and were used without further purification. Moisture- or oxygen-sensitive reactions were conducted under an atmosphere of argon or nitrogen gas. Unless otherwise stated, <sup>1</sup>H NMR spectra were recorded at 300 or 400 MHz using Varian or Bruker instruments operating at the indicated frequencies. Chemical shifts are expressed in parts per million (ppm) (δ) relative to an internal standard; tetramethylsilane (ppm = 0.00). The following abbreviations are used: br, broad signal; s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; p, pentet; m, multiplet. Purification by silica gel chromatography was carried out using Biotage systems with prepacked cartridges. Analytical LCMS methods are provided in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S5</a>). Chemical purities were ≥95% for all final compounds as assessed by LCMS analysis at UV 220 and 254 nm.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (<i>S</i>)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetic Acid (<b>13</b>)</h4><div class="NLM_p last">To a solution of compound <b>1</b><a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> (1000 mg, 2.19 mmol) in DCM (30 mL) was added TFA (5.0 mL). The mixture was stirred at 23 °C for 1 h and then concentrated to give compound <b>13</b> (850 mg, 97% yield) as a yellow solid. This material was used without additional purification in the next step. LCMS (5–95, AB, 1.5 min): RT = 0.84 min, <i>m</i>/<i>z</i> = 401.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)acetic Acid (<b>15</b>)</h4><div class="NLM_p last">A solution of HCl (1.55 mL, 4 M in EtOAc) was slowly added to a solution of 2-[2-[2-[2-(<i>tert</i>-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]acetic acid <b>14</b> (950 mg, 3.09 mmol) in DCM (2 mL) at 23 °C. The resulting mixture was stirred at 23 °C for 1 h whereupon thin-layer chromatography (TLC) analysis showed the starting material was consumed (10% MeOH in DCM, <i>R</i><sub>f</sub> = 0.3). The mixture was concentrated in vacuo to give compound <b>15</b> (HCl salt; 750 mg, 100%) as a colorless oil. This material was used without additional purification in the next step.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (<i>S</i>)-1-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-oic Acid (<b>16</b>)</h4><div class="NLM_p last">A solution of DCC (453 mg, 2.2 mmol) and compound <b>13</b> (800 mg, 2 mmol), <i>N</i>-hydroxysuccinimide (253 mg, 2.2 mmol), and DIEA (258 mg, 2.0 mmol) in THF (10 mL) was stirred at 23 °C for 12 h. The reaction mixture was filtered, and the filtrate was concentrated to give the crude <i>N</i>-hydroxysuccinimide ester (structure not shown; 990 mg, 100%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.83 min, <i>m</i>/<i>z</i> = 498.0 [M + H]<sup>+</sup>. A solution of this crude material (990 mg, 1.99 mmol), compound <b>15</b> (727 mg, 2.98 mmol), and DIEA (257 mg, 1.99 mmol) in DMF (15 mL) was stirred at 17 °C for 6 h. The reaction mixture was concentrated to dryness, and the residue was purified by reverse-phase chromatography (MeCN 32–52/0.225% TFA in H<sub>2</sub>O) to afford compound <b>16</b> (450 mg, 38%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.81 min, <i>m</i>/<i>z</i> = 590.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 2-(((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)acetic Acid (<b>18</b>)</h4><div class="NLM_p last">NaH (226 mg, 60% in mineral oil, 5.65 mmol) was suspended in THF (4 mL), and a solution of compound <b>17</b><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> (300 mg, 0.57 mmol) in THF (3 mL) was added dropwise at 23 °C. The reaction mixture was stirred at 23 °C for 2 h; then, a solution of 2-bromoacetic acid (118 mg, 0.85 mmol) in THF (3 mL) was added. The resulting mixture was stirred at 23 °C for 2 h and then was quenched with H<sub>2</sub>O (10 mL) and extracted with EtOAc (10 mL). The aqueous layer was acidified with 2 M HCl to pH = 3 and then extracted with 10% MeOH in DCM (2 × 10 mL). The DCM layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product <b>18</b> (190 mg, 57%) as a brown oil. This material was used in the next step without additional purification. LCMS (5–95, AB, 1.5 min): RT = 0.74 min, <i>m</i>/<i>z</i> = 589.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-(((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)acetic Acid (<b>19</b>)</h4><div class="NLM_p last">To a solution of compound <b>18</b> (190 mg, 0.36 mmol) in DCM (5 mL) was added 4 M HCl in EtOAc (5 mL). The reaction mixture was stirred at 23 °C for 2 h and then concentrated to give the crude amine product (HCl salt, not shown; 120 mg, 71%) as a gray solid. A solution of compound <b>16</b> (152 mg, 0.26 mmol), DIEA (66 mg, 0.51 mmol), and HATU (98 mg, 0.26 mmol) in anhydrous DMF (3 mL) was stirred at 23 °C for 15 min; then, the crude amine HCl salt (90 mg, 0.17 mmol) was added. The resulting mixture was stirred at 23 °C for 2 h and was filtered. The filtrate was purified by reverse-phase HPLC (MeCN 40–60/0.225% formic acid (FA) in H<sub>2</sub>O) to afford compound <b>19</b> (35 mg, 19%) as a gray solid. LCMS (5–95, AB, 1.5 min): RT = 0.88 min, <i>m</i>/<i>z</i> = 1060.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl ((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)methyl)carbamate (<b>3a</b>)</h4><div class="NLM_p last">Triethylamine (8.6 mg, 0.08 mmol) was added to a solution of compound <b>19</b> (30 mg, 0.03 mmol) and DPPA (12 mg, 0.04 mmol) in DMF (2 mL). The resulting mixture was stirred at 23 °C for 1 h and then partitioned between H<sub>2</sub>O (5 mL) and toluene (2 × 3 mL). The combined organic layers were sequentially dried over Na<sub>2</sub>SO<sub>4</sub> and 4 Å molecular sieves and were then used in the next step. To this solution was added a solution of compound <b>20</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (16 mg, 0.03 mmol) in DMF (2 mL), followed by addition of dibutyltin dilaurate (1.75 mg, 0.003 mmol). The mixture was stirred at 80 °C for 1 h and then cooled to 23 °C and filtered. The filtrate was concentrated and the residue was purified by prep-TLC (10% of MeOH in DCM, <i>R</i><sub>f</sub> = 0.3) to afford compound <b>3a</b> (2.5 mg, 5.6%) as a gray solid. LCMS (5–95, AB, 1.5 min): RT = 0.76 min, <i>m</i>/<i>z</i> = 815.3 [M/2 + H]<sup>+</sup>; LCMS (10–80, AB, 7.0 min): RT = 4.03 min, <i>m</i>/<i>z</i> = 815.3 [M/2 + H]<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>R</i>)-<i>S</i>-(1-Hydroxypropan-2-yl)methanesulfonothioate (<b>21</b>)</h4><div class="NLM_p last">Sodium methanesulfinate (415 mg, 4.06 mmol) and iodine (515 mg, 2.03 mmol) were added sequentially to a solution of (<i>R</i>)-2-((5-nitropyridin-2-yl)disulfanyl)propan-1-ol<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (500 mg, 2.03 mmol) in DCM (10 mL) at 23 °C. The reaction mixture was stirred at 40 °C for 12 h and then cooled to 23 °C and filtered. The filtrate was concentrated in vacuo and the residue was purified by prep-TLC (33% EtOAc in petroleum ether) to give compound <b>21</b> (234 mg, 68%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.90–3.85 (m, 1H), 3.74–3.67 (m, 2H), 3.40 (s, 3H), 1.45 (d, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>S</i>-(1-Hydroxy-2-methylpropan-2-yl)methanesulfonothioate (<b>22</b>)</h4><div class="NLM_p last">Sodium methanesulfinate (784 mg, 7.68 mmol) and iodine (975 mg, 3.84 mmol) were added sequentially to a solution of 2-methyl-2-((5-nitropyridin-2-yl)disulfanyl)propan-1-ol<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (1000 mg, 3.84 mmol) in DCM (20 mL) at 23 °C. The reaction mixture was stirred at 40 °C for 24 h and then cooled to 23 °C and filtered. The filtrate was concentrated in vacuo and the residue was purified by prep-TLC (33% EtOAc in petroleum ether) to give compound <b>22</b> (118 mg, 17%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.54 (s, 2H), 3.50 (s, 3H), 1.44 (s, 6H).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>S</i>-(3-Hydroxybutan-2-yl)methanesulfonothioate (<b>23</b>)</h4><div class="NLM_p last">To a solution of 3-mercaptobutan-2-ol (2000 mg, 18.8 mmol) in anhydrous DCM (40 mL) was added MnO<sub>2</sub> (2460 mg, 28.3 mmol). The reaction mixture was stirred at 23 °C for 1 h whereupon TLC analysis (33% EtOAc in petroleum ether, <i>R</i><sub>f</sub> = 0.4) showed that a new spot was formed and the starting material was consumed. The mixture was filtered, and the filtrate was concentrated in vacuo to afford 3,3′-disulfanediylbis(butan-2-ol) (1:1 mixture of diastereomers; 1970 mg, 99%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.13–4.08 and 3.83–3.78 (m, 2H), 2.94–2.91 and 2.82–2.78 (m, 2H), 2.38–2.26 and 2.14–2.02 (m, 2H), 1.35–1.22 (m, 12H). To a solution of crude 3,3′-disulfanediylbis(butan-2-ol) (1970 mg, 9.36 mmol) in anhydrous DCM (50 mL) were added sodium methanesulfinate (1910 mg, 18.7 mmol) and iodine (2380 mg, 9.36 mmol). The reaction mixture was stirred in the dark at 23 °C for 1 day and then filtered. The filtrate was concentrated and the residue was purified by chromatography on silica eluting with 0–5% MeOH in DCM to afford compound <b>23</b> (1:1 mixture of diastereomers; 1200 mg, 70%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.13–4.11 and 3.96–3.93 (m, 1H), 3.77–3.73 and 3.51–3.47 (m, 1H), 3.42 and 3.39 (s, 3H), 2.04 and 1.96 (brs, 1H), 1.53 and 1.42 (d, <i>J</i> = 7.2 Hz, 3H), 1.33 and 1.23 (d, <i>J</i> = 6.0 Hz, 3H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>S</i>-((<i>R</i>)-1-(((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)propan-2-yl)methanesulfonothioate (<b>24</b>)</h4><div class="NLM_p last">To a 15 °C solution of triphosgene (70 mg, 0.23 mmol) in DCM (2 mL) was added a solution of pyridine (37 mg, 0.47 mmol) and compound <b>21</b> (80 mg, 0.47 mmol) in DCM (2 mL). The reaction mixture was stirred at 15 °C for 30 min and then concentrated to dryness. The crude material thus obtained was diluted with DCM (4 mL) and a solution of Et<sub>3</sub>N (38 mg, 0.38 mmol), and compound <b>17</b><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> (100 mg, 0.19 mmol) in DCM (2 mL) was added. The reaction mixture was stirred at 15 °C for 2 h and then concentrated in vacuo. The residue was purified by column chromatography eluting with 10% MeOH in DCM to give compound <b>24</b> (86 mg, 32%) as a colorless oil. LCMS (5–95, AB,1.5 min): RT = 0.83 min, <i>m</i>/<i>z</i> = 727.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>S</i>-((<i>R</i>)-1-(((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)propan-2-yl)methanesulfonothioate (<b>3b</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>24</b> (86 mg, 0.12 mmol) in HFIP (2 mL) was added TFA (0.1 mL). The reaction mixture was stirred at 23 °C for 1 h and then concentrated in vacuo to give the crude TFA salt (not shown, 76 mg, 87%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.61 min, <i>m</i>/<i>z</i> = 627.0 [M + H]<sup>+</sup>. A mixture of compound <b>16</b> (60 mg, 0.08 mmol), DIEA (31 mg, 0.24 mmol), and HATU (40 mg, 0.11 mmol) in anhydrous DMF (5 mL) was stirred at 23 °C for 10 min; then, the crude TFA salt (62 mg, 0.11 mmol) was added. The resulting mixture was stirred at 23 °C for 2 h and then directly purified by prep-HPLC (MeCN 46–76/0.225% FA in H<sub>2</sub>O) to give compound <b>3b</b> (17 mg, 17%) as a white solid. LCMS (10–80, AB, 7.0 min): RT = 4.24 min, <i>m</i>/<i>z</i> = 1198.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>S</i>-(1-(((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)-2-methylpropan-2-yl)methanesulfonothioate (<b>25</b>)</h4><div class="NLM_p last">To a 15 °C solution of triphosgene (95 mg, 0.32 mmol) in DCM (2 mL) was added a solution of pyridine (51 mg, 0.64 mmol) and compound <b>22</b> (118 mg, 0.64 mmol) in DCM (2 mL). The reaction mixture was stirred at 15 °C for 30 min and then concentrated to dryness. The crude material thus obtained was diluted with DCM (8 mL) and a solution of Et<sub>3</sub>N (50 mg, 0.49 mmol), and compound <b>17</b><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> (130 mg, 0.24 mmol) in DCM (2 mL) was added. The formed mixture was stirred at 23 °C for 2 h and then concentrated in vacuo. The residue was purified by column chromatography eluting with 0–10% MeOH in DCM to give compound <b>25</b> (107 mg, 44%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.81 min, <i>m</i>/<i>z</i> = 741.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>S</i>-(1-(((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)-2-methylpropan-2-yl)methanesulfonothioate (<b>3c</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>25</b> (107 mg, 0.14 mmol) in HFIP (1.9 mL) was added TFA (0.1 mL). The reaction mixture was stirred at 23 °C for 1 h and then concentrated in vacuo to give the corresponding crude TFA salt (not shown, 109 mg, 100%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.63 min, <i>m</i>/<i>z</i> = 641.0 [M + H]<sup>+</sup>. A solution of compound <b>16</b> (60 mg, 0.10 mmol), DIEA (40 mg, 0.31 mmol), and HATU (58 mg, 0.15 mmol) in anhydrous DMF (10 mL) was stirred at 23 °C for 10 min, and the crude TFA salt (100 mg, 0.13 mmol) was subsequently added. The resulting mixture was stirred at 23 °C for 2 h and then directly purified by prep-HPLC (MeCN 39–69/0.1% TFA in H<sub>2</sub>O) to give compound <b>3c</b> (43 mg, 33%) as a white solid. LCMS (10–80, AB, 7.0 min): RT = 4.31 min, <i>m</i>/<i>z</i> = 1212.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>S</i>-(3-(((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)butan-2-yl)methanesulfonothioate (<b>26</b>)</h4><div class="NLM_p last">To a mixture of triphosgene (112 mg, 0.38 mmol) and 4 Å molecular sieves (100 mg) in anhydrous DCM (10 mL) was added a solution of compound <b>23</b> (139 mg, 0.75 mmol) and pyridine (179 mg, 2.26 mmol) in anhydrous DCM (5 mL) slowly at 23 °C. The reaction mixture was stirred at 23 °C for 30 min and then concentrated in vacuo. The residue was diluted with anhydrous DCM (15 mL), and Et<sub>3</sub>N (114 mg, 1.13 mmol) and compound <b>17</b><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> (200 mg, 0.38 mmol) were added sequentially. The reaction mixture was stirred at 23 °C for another 2 h, diluted with DCM (20 mL), and washed with H<sub>2</sub>O (3 × 20 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by prep-TLC (8% MeOH in DCM, <i>R</i><sub>f</sub> = 0.6) to afford compound <b>26</b> (100 mg, 35%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.88 min, <i>m</i>/<i>z</i> = 763.0 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>S</i>-(3-(((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-18-(<i>tert</i>-Butyl)-2,2-dimethyl-4,16-dioxo-3,8,11,14-tetraoxa-5,17-diazanonadecan-19-oyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)butan-2-yl)methanesulfonothioate (<b>27</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>26</b> (90 mg, 0.12 mmol) in HFIP (6.0 mL) was added TFA (0.3 mL). The reaction solution was stirred at 23 °C for 1 h and then concentrated in vacuo to afford the crude TFA salt (not shown, 90 mg, 98%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.74 min, <i>m</i>/<i>z</i> = 641.1 [M + H]<sup>+</sup>. To a solution of compound <b>14</b> (55 mg, 0.18 mmol) in DMF (6 mL) were added DIEA (77 mg, 0.60 mmol) and HATU (91 mg, 0.24 mmol). The resulting solution was stirred at 23 °C for 15 min; then, the crude TFA salt (90 mg, 0.12 mmol) was added. The resulting reaction solution was stirred at 23 °C for 30 min and then concentrated in vacuo to remove the solvent. The residue was purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub>f</sub> = 0.7) to afford compound <b>27</b> (100 mg, 83%) as a white solid. LCMS (10–80, AB, 7.0 min): RT = 4.03 min, <i>m</i>/<i>z</i> = 952.3 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>S</i>-(3-(((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)butan-2-yl)methanesulfonothioate (<b>3d</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>27</b> (90 mg, 0.10 mmol) in HFIP (7.0 mL) was added TFA (0.35 mL). The reaction solution was stirred at 23 °C for 1 h and then concentrated in vacuo to remove the solvent and provide the crude TFA salt (not shown, 90 mg, 99%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.76 min, <i>m</i>/<i>z</i> = 830.5 [M + H]<sup>+</sup>. To a solution of compound <b>13</b> (57 mg, 0.14 mmol) in DMF (4 mL) were added DIEA (62 mg, 0.48 mmol) and HATU (62 mg, 0.16 mmol). The reaction mixture was stirred at 23 °C for 15 min; then, the crude TFA salt (90 mg, 0.10 mmol) was added. The resulting solution was stirred at 23 °C for 1 h and then directly purified by prep-HPLC (Xtimate C<sub>18</sub> 150 × 25 mm<sup>2</sup> × 5 μm, MeCN 56–66/0.225% FA in H<sub>2</sub>O) to afford compound <b>3d</b> (30 mg, 25%) as a white solid. LCMS (10–80, AB, 7.0 min): RT = 4.33 min, <i>m</i>/<i>z</i> = 1234.7 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.99 (s, 1H), 8.64 (brs, 1H), 8.29 (t, <i>J</i> = 5.6 Hz, 1H), 7.45–7.40 (m, 9H), 5.23 (brs, 1H), 4.98–4.95 (m, 1H), 4.53–4.38 (m, 4H), 4.30–4.24 (m, 1H), 4.12–4.07 (m, 1H), 3.96 (s, 2H), 3.86–3.84 (m, 1H), 3.74–3.71 (m, 1H), 3.59–3.53 (m, 12H), 3.31–3.18 (m, 3H), 2.59 (s, 3H), 2.45 (s, 3H), 2.40 (s, 3H), 2.37–2.33 (m, 1H), 2.17–2.10 (m, 1H), 1.61 (s, 3H), 1.44–1.37 (m, 3H), 1.34–1.25 (m, 3H), 0.95 (s, 9H).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>tert</i>-Butyl (<i>S</i>)-2-(4-(4-Aminophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetate (<b>28</b>)</h4><div class="NLM_p last">A mixture of compound <b>1</b> (300 mg, 0.66 mmol), diphenylmethanimine (178 mg, 0.98 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (60 mg, 0.07 mmol), <i>S</i>-Phos (27 mg, 0.07 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (642 mg, 1.97 mmol) in toluene (20 mL) was stirred at 110 °C under nitrogen for 16 h. The mixture was cooled to 23 °C and filtered, and the filtrate was concentrated under a vacuum. The residue was purified by flash chromatography on silica gel eluting with 0–100% EtOAc in petroleum ether to afford the coupled imine product (not shown, 350 mg, 60%) as a yellow oil. LCMS (5–95, AB, 1.5 min): RT = 1.05 min, <i>m</i>/<i>z</i> = 602.2 [M + H]<sup>+</sup>. A mixture of this material (350 mg, 0.58 mmol) in THF (20 mL) and aqueous HCl (1 M, 5.0 mL) was stirred at 23 °C for 3 h. The THF was removed under a vacuum, and the aqueous remainder was basified with saturated aqueous NaHCO<sub>3</sub> to pH = 7.0 and extracted with EtOAc (4 × 25 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by chromatography on silica eluting with 0–5% MeOH in DCM to afford compound <b>28</b> (250 mg, 95%) as a yellow oil. LCMS (5–95, AB, 1.5 min): RT = 0.74 min, <i>m</i>/<i>z</i> = 460.0 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>tert</i>-Butyl (<i>S</i>)-2-(2,3,9-Trimethyl-4-(4-(2,2,2-trifluoroacetamido)phenyl)-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetate (<b>29</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>28</b> (180 mg, 0.41 mmol) in pyridine (97 mg, 1.23 mmol) was added TFAA (129.6 mg, 0.62 mmol). The reaction mixture was stirred at 23 °C for 12 h. The reaction mixture was diluted with EtOAc (20 mL), and the resulting solution was washed sequentially with H<sub>2</sub>O (2 × 20 mL) and brine (1 × 20 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by prep-TLC (5% MeOH in DCM, <i>R</i><sub>f</sub> = 0.3) to afford compound <b>29</b> (170 mg, 78%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.83 min, <i>m</i>/<i>z</i> = 534.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-2-(2,3,9-Trimethyl-4-(4-(2,2,2-trifluoroacetamido)phenyl)-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetic Acid (<b>30</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>29</b> (80 mg, 0.15 mmol) in EtOAc (1 mL) was added 4 N HCl (0.95 mL) in EtOAc. The mixture was stirred at 23 °C for 3 h and then concentrated to afford the crude compound <b>30</b> (70 mg, 98%) as a yellow oil. This material was used in the next step without additional purification.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-17-((<i>S</i>)-4-(4-Aminophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-2-(<i>tert</i>-butyl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (<b>4</b>)</h4><div class="NLM_p last">A solution of compound <b>30</b> (70 mg, 0.15 mmol), DIEA (0.05 mL, 0.29 mmol), and HATU (111 mg, 0.29 mmol) in anhydrous DMF (2.5 mL) was stirred at 23 °C for 20 min. Compound <b>31</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> (100 mg, 0.16 mmol) was then added, and the resulting mixture was stirred at 23 °C for 2 h. The reaction solution was directly purified by flash chromatography eluting with 0–100% EtOAc in petroleum ether to afford the coupled product (not shown, 120 mg, 76%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.69 min, <i>m</i>/<i>z</i> =1101.6 [M + Na]<sup>+</sup>. This material (120 mg, 0.11 mmol) was dissolved in 1:1 MeOH/THF (3.6 mL), and LiOH·H<sub>2</sub>O (23 mg, 0.56 mmol) was added. The reaction mixture was stirred at 50 °C for 12 h whereupon LCMS analysis showed good conversion to the desired product. The reaction mixture was cooled to 23 °C and was concentrated. Purification of the residue by prep-HPLC (MeCN 20–50/0.225% FA in H<sub>2</sub>O) afforded compound <b>4</b> (52 mg, 45%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.96 min, <i>m</i>/<i>z</i> = 492.4 [M/2 + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 8.97(s, 1H), 8.61 (t, <i>J</i> = 6.0 Hz, 1H), 8.41–8.36 (m, 1H), 7.45–7.42 (m, 2H), 7.41–7.38 (m, 4H), 7.24–7.16 (m, 2H), 6.62 (d, <i>J</i> = 8.4 Hz, 1H), 4.58–4.54 (m, 1H), 4.52–4.43 (m, 2H), 4.42–4.40 (m, 2H), 4.39–4.35 (m, 1H), 4.01–3.81 (m, 2H), 3.75–3.69 (m, 2H), 3.68–3.45 (m, 14H), 3.78–3.71 (m, 2H), 2.61 (s, 3H), 2.43 (s, 6H), 2.05–2.03(m, 1H), 1.91–1.88 (m, 1H), 1.71 (s, 3H), 0.94 (s, 9H).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (9<i>H</i>-Fluoren-9-yl)methyl ((<i>S</i>)-1-((4-((<i>S</i>)-6-((<i>S</i>)-16-((2<i>S</i>,4<i>R</i>)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)carbamate (<b>32</b>)</h4><div class="NLM_p last">A mixture of Fmoc-<span class="smallcaps smallerCapital">l</span>-Cit-OH (18 mg, 0.05 mmol) and EEDQ (15 mg, 0.06 mmol) in DMF (2 mL) was stirred at 23 °C for 30 min. The resulting mixture was then added to a solution of compound <b>4</b> (15 mg, 0.02 mmol) in DMF (2 mL) at 23 °C. The new reaction mixture was stirred at that temperature for 48 h and then filtered. The filtrate was directly purified by prep-HPLC (MeCN 33–63/0.225% FA in H<sub>2</sub>O) to give compound <b>32</b> (10 mg, 48%) as a white solid. LCMS (10–80, AB, 7.0 min): RT = 3.70 min, <i>m</i>/<i>z</i> = 682.1 [M/2 + H]<sup>+</sup>.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)-<i>N</i>-((<i>S</i>)-1-((4-((<i>S</i>)-6-((<i>S</i>)-16-((2<i>S</i>,4<i>R</i>)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)cyclobutane-1,1-dicarboxamide (<b>4a</b>)</h4><div class="NLM_p last">To a solution of compound <b>32</b> (10 mg, 0.01 mmol) in DMF (2 mL) was added piperidine (2.5 mg, 0.03 mmol) at 23 °C. The reaction mixture was stirred at that temperature for 2 h and then concentrated. The crude material thus obtained was washed with methyl <i>tert</i>-butyl ether (MTBE) (2 × 2 mL) to give the deprotected product (not shown, 8 mg, 96%) as a gray solid. LCMS (5–95, AB, 1.5 min): RT = 0.61 min, <i>m</i>/<i>z</i> = 571.1 [M/2 + H]<sup>+</sup>. Separately, HATU (6 mg, 0.015 mmol) and DIEA (4 mg, 0.03 mmol) were added to a solution of compound <b>33</b><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> (4.5 mg, 0.015 mmol) in DMF (3 mL) at 23 °C. The reaction mixture was stirred at that temperature for 10 min, and then, the crude deprotected amine derived above from <b>32</b> (8 mg, 0.01 mmol) was added. The reaction mixture was stirred at 23 °C for 12 h and then partitioned between H<sub>2</sub>O (5 mL) and EtOAc (10 mL). The organic layer was washed sequentially with H<sub>2</sub>O (2 × 5 mL) and brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The residue was purified by prep-HPLC (MeCN 31–51/0.225% FA in H<sub>2</sub>O) to give compound <b>4a</b> (2.5 mg, 24%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.66 min, <i>m</i>/<i>z</i> = 716.3 [M/2 + H]<sup>+</sup>.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>tert</i>-Butyl 2-((<i>S</i>)-4-(4-((((4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl)oxy)carbonyl)amino)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetate (<b>34</b>)</h4><div class="NLM_p last">To a solution of triphosgene (27 mg, 0.09 mmol) in THF (5 mL) was added a solution of compound <b>28</b> (40 mg, 0.09 mmol) in THF (5 mL) at 23 °C under N<sub>2</sub>. The reaction mixture was stirred at 40 °C for 2 h and then cooled to 23 °C and concentrated. The crude isocyanate thus obtained was dissolved in DCM (5 mL) at 23 °C, and a solution of compound <b>20</b> (59 mg, 0.10 mmol) and Et<sub>3</sub>N (26 mg, 0.26 mmol) in DMF (1 mL) was added. The reaction mixture was stirred at 23 °C for 4 h and then concentrated. The residue was purified by prep-HPLC (MeCN 44–74/0.225% FA in H<sub>2</sub>O) to give compound <b>34</b> (7.0 mg, 7.8%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.86 min, <i>m</i>/<i>z</i> = 1056.2 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-((<i>S</i>)-4-(4-((((4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl)oxy)carbonyl)amino)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetic Acid (<b>35</b>)</h4><div class="NLM_p last">A solution of compound <b>34</b> (10 mg, 0.01 mmol) in 1:1 TFA/DCM (4 mL) was stirred at 23 °C for 2 h. The reaction mixture was then concentrated to give crude compound <b>35</b> (9.4 mg, 99%) as a yellow solid. This material was used in the next step without additional purification. LCMS (5–95, AB, 1.5 min): RT = 0.78 min, <i>m</i>/<i>z</i> = 978.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl (4-((<i>S</i>)-6-((<i>S</i>)-16-((2<i>S</i>,4<i>R</i>)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)-3,9-dimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)carbamate (<b>4b</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>35</b> (9.4 mg, 0.01 mmol) in DMF (5 mL) were added HATU (4.5 mg, 0.01 mmol) and DIEA (3.7 mg, 0.03 mmol). The reaction mixture was stirred at 23 °C for 10 min whereupon compound <b>31</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> (8.5 mg, 0.01 mmol) was added and stirring was continued at 23 °C for an additional 12 h. The mixture was then directly purified by prep-HPLC (MeCN 30–60/0.225% FA in MeCN) to afford compound <b>4b</b> (1.8 mg, 12%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.82 min, <i>m</i>/<i>z</i> = 790.6 [M/2 + H]<sup>+</sup>.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>tert</i>-Butyl (<i>S</i>)-2-(4-(4-(3-Aminoprop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetate (<b>36</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>1</b> (50 mg, 0.11 mmol) in DMF (2 mL) were added Pd(Cy*Phine)<sub>2</sub>Cl<sub>2</sub> (7.0 mg, 0.01 mmol), Cs<sub>2</sub>CO<sub>3</sub> (107 mg, 0.33 mmol), and propargyl amine (30 mg, 0.55 mmol). The mixture was then stirred at 120 °C in a microwave reactor under N<sub>2</sub> for 1 h. The reaction mixture was cooled to 23 °C and filtered, and the filtrate was concentrated. The residue was purified by prep-TLC (5% MeOH in DCM, <i>R</i><sub>f</sub> = 0.4) to give compound <b>36</b> (16 mg, 24%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.778 min, <i>m</i>/<i>z</i> = 476.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39 (brs, 4H), 4.56 (t, <i>J</i> = 6.4 Hz, 1H), 3.73 (brs, H), 3.55–3.53 (m, 2H), 2.69 (s, 3H), 2.40 (s, 3H), 1.66 (s, 3H), 1.49 (s, 9H).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>tert</i>-Butyl (<i>S</i>)-2-(4-(4-(3-((((9<i>H</i>-Fluoren-9-yl)methoxy)carbonyl)amino)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetate (<b>37</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>36</b> (16 mg, 0.03 mmol) and Na<sub>2</sub>CO<sub>3</sub> (3.6 mg, 0.03 mmol) in a 1:1 mixture of THF/H<sub>2</sub>O (4 mL) was added Fmoc-Cl (11 mg, 0.04 mmol). The reaction mixture was stirred at 23 °C for 4 h; then, the solvent was removed in vacuo. The residue was partitioned between H<sub>2</sub>O (5 mL) and EtOAc (3 × 5 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by prep-TLC (66% EtOAc in petroleum ether, <i>R</i><sub>f</sub> = 0.3) to afford compound <b>37</b> (15 mg, 61%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.89 min, <i>m</i>/<i>z</i> = 698.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>S</i>)-2-(4-(4-(3-((((9<i>H</i>-Fluoren-9-yl)methoxy)carbonyl)amino)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetic Acid (<b>38</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>37</b> (15 mg, 0.02 mmol) in DCM (2 mL) was added TFA (0.5 mL). The mixture was stirred at 23 °C for 1 h and then concentrated to give compound <b>38</b> (13.5 mg, 98%) as a yellow oil. This material was used in the next step without further purification. LCMS (5–95, AB, 1.5 min): RT = 0.78 min, <i>m</i>/<i>z</i> = 642.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-17-((<i>S</i>)-4-(4-(3-Aminoprop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-2-(<i>tert</i>-butyl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (<b>5</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>38</b> (10 mg, 0.02 mmol), HATU (7.7 mg, 0.02 mmol), and DIEA (0.01 mL, 0.057 mmol) in DMF (3 mL) was added compound <b>31</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> (12 mg, 0.02 mmol). The reaction mixture was stirred at 23 °C for 3 h and then diluted with DCM (15 mL). The resulting solution was washed with H<sub>2</sub>O (15 mL) and brine (20 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub>f</sub> = 0.4) to give the coupled product (not shown, 12 mg, 59%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.79 min, <i>m</i>/<i>z</i> = 1243.5 [M + H]<sup>+</sup>. A mixture of this product (12 mg, 0.01 mmol) and piperidine (1.0 mL, 0.03 mmol) in DMF (2 mL) was stirred at 23 °C for 2 h and then directly purified by prep-HPLC (MeCN 20–45/0.225% FA in H<sub>2</sub>O) to afford compound <b>5</b> (4.3 mg, 43%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.62 min, <i>m</i>/<i>z</i> = 1021.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>tert</i>-Butyl 2-((<i>S</i>)-4-(4-(3-((<i>S</i>)-2-((((9<i>H</i>-Fluoren-9-yl)methoxy)carbonyl)amino)-5-ureidopentanamido)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetate (<b>39</b>)</h4><div class="NLM_p last">To a 23 °C solution of Fmoc-<span class="smallcaps smallerCapital">l</span>-Cit-OH (30 mg, 0.08 mmol) in DMF (10 mL) were added HATU (48 mg, 0.13 mmol) and DIEA (20 mg, 0.15 mmol). The reaction mixture was stirred at 23 °C for 10 min; then, compound <b>36</b> (30 mg, 0.06 mmol) was added, and stirring was continued at that temperature for 12 h. The reaction mixture was partitioned between H<sub>2</sub>O (10 mL) and EtOAc (10 mL), and the organic layer was washed sequentially with H<sub>2</sub>O (2 × 20 mL) and brine (20 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub>f</sub> = 0.4) to afford compound <b>39</b> (45 mg, 78%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.89 min, <i>m</i>/<i>z</i> = 877.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>tert</i>-Butyl 2-((<i>S</i>)-4-(4-(3-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetate (<b>40</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>39</b> (45 mg, 0.05 mmol) in DMF (5 mL) was added piperidine (0.02 mL, 0.16 mmol). The mixture was stirred at 23 °C for 2 h and then concentrated to dryness to give the deprotected amine (not shown, 33 mg, 99% yield) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.74 min, <i>m</i>/<i>z</i> = 655.1 [M + Na]<sup>+</sup>. To a solution of compound <b>33</b><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> (19 mg, 0.06 mmol) in DMF (6 mL) were added HATU (40 mg, 0.10 mmol) and DIEA (20 mg, 0.15 mmol) at 23 °C. The reaction mixture was stirred at that temperature for 10 min; then, the crude deprotected amine derived above from <b>39</b> (33 mg, 0.05 mmol) was added. The reaction mixture was stirred at 23 °C for 12 h and then partitioned between H<sub>2</sub>O (10 mL) and EtOAc (10 mL). The organic layer was washed sequentially with H<sub>2</sub>O (2 × 20 mL) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The residue was purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub>f</sub> = 0.2) to afford compound <b>40</b> (30 mg, 58%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.83 min, <i>m</i>/<i>z</i> = 945.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 2-((<i>S</i>)-4-(4-(3-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetic Acid (<b>41</b>)</h4><div class="NLM_p last">A solution of compound <b>40</b> (30 mg, 0.03 mmol) in 1:1 TFA/DCM (6 mL) was stirred at 23 °C for 2 h. The reaction mixture was concentrated to give compound <b>41</b> (28 mg, 99%) as a yellow solid, which was used directly in the next step. LCMS (5–95, AB, 1.5 min): RT = 0.601 min, <i>m</i>/<i>z</i> = 434.3 [M/2 + H]<sup>+</sup>.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)-<i>N</i>-((<i>S</i>)-1-((3-(4-((<i>S</i>)-6-((<i>S</i>)-16-((2<i>S</i>,4<i>R</i>)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)prop-2-yn-1-yl)amino)-1-oxo-5-ureidopentan-2-yl)cyclobutane-1,1-dicarboxamide (<b>5a</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>41</b> (28 mg, 0.03 mmol) in DMF (10 mL) were added HATU (24.6 mg, 0.06 mmol) and DIEA (12.5 mg, 0.10 mmol). The reaction mixture was stirred at 23 °C for 10 min; then, compound <b>31</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> (20 mg, 0.03 mmol) was added and stirring was continued at that temperature for 12 h. The reaction was partitioned between H<sub>2</sub>O (30 mL) and EtOAc (30 mL), and the organic layer was washed sequentially with H<sub>2</sub>O (2 × 20 mL) and brine (20 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Purification of the residue by prep-TLC (20% MeOH in DCM, <i>R</i><sub>f</sub> = 0.5) afforded compound <b>5a</b> (21 mg, 43%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.78 min, <i>m</i>/<i>z</i> = 757.0 [M/2 + Na]<sup>+</sup>.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>tert</i>-Butyl (<i>S</i>)-2-(4-(4-(3-(6-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamido)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetate (<b>43</b>)</h4><div class="NLM_p last">To a 23 °C solution of commercially available compound <b>42</b> (39 mg, 0.13 mmol) and DIEA (0.06 mL, 0.34 mmol) in DMF (5 mL) was added compound <b>36</b> (40 mg, 0.08 mmol). The resulting mixture was stirred at 23 °C for 2 h and then concentrated and directly purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub>f</sub> = 0.3) to give compound <b>43</b> (55 mg, 94%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.86 min, <i>m</i>/<i>z</i> = 691.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>S</i>)-2-(4-(4-(3-(6-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamido)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetic Acid (<b>44</b>)</h4><div class="NLM_p last">A 23 °C solution of compound <b>43</b> (55 mg, 0.08 mmol) in 1:3 TFA/DCM (4 mL) was stirred at that temperature for 30 min. The reaction mixture was then concentrated to give compound <b>44</b> (49 mg, 97%) as a colorless oil, which was used directly in the next step. LCMS (5–95, AB, 1.5 min): RT = 0.80 min, <i>m</i>/<i>z</i> = 613.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-(3-(6-(2,5-dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamido)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (<b>5b</b>)</h4><div class="NLM_p last">To a solution of compound <b>44</b> (49 mg, 0.08 mmol) in DMF (5 mL) were added HATU (61 mg, 0.16 mmol) and DIEA (31 mg, 0.24 mmol) at 23 °C. The reaction mixture was stirred at 23 °C for 10 min, after which compound <b>31</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> (55 mg, 0.09 mmol) was added. The resulting solution was stirred at 23 °C for 12 h and then partitioned between H<sub>2</sub>O (30 mL) and EtOAc (30 mL). The organic layer was washed sequentially with H<sub>2</sub>O (2 × 20 mL) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The residue was purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub>f</sub> = 0.2) to afford <b>5b</b> (34 mg, 33%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.82 min, <i>m</i>/<i>z</i> = 1214.6 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 11.04 (brs, 1H), 8.60 (s, 1H), 7.85 (brs, 1H), 7.44–7.41 (m, 1H), 7.30–7.25 (m, 6H), 7.19 (s, 2H), 6.59 (s, 2H), 5.87 (brs, 1H), 4.72 (t, <i>J</i> = 7.6 Hz, 1H), 4.61–4.59 (m, 2H), 4.46–4.38 (m, 2H), 4.25–4.16 (m, 3H), 4.09–4.02 (m, 1H), 3.62–3.51 (m, 12H), 3.43 (t, <i>J</i> = 7.2 Hz, 2H), 3.38 (d, <i>J</i> = 8.8 Hz, 1H), 3.38–3.30 (m, 2H), 3.05–3.02 (m, 3H), 2.54 (s, 2H), 2.43 (s, 2H), 2.31 (s, 2H), 2.14 (t, <i>J</i> = 7.6 Hz, 2H), 1.61–1.49 (m, 5H), 1.41–1.37 (m, 12H), 1.32 (d, <i>J</i> = 6.4 Hz, 8H), 1.28–1.18 (m, 4H), 0.9 (s, 9H).</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>tert</i>-Butyl (2-Hydroxy-4-(4-methylthiazol-5-yl)benzyl)carbamate (<b>46</b>)</h4><div class="NLM_p last">Boc<sub>2</sub>O (1490 mg, 6.81 mmol) was added to a 23 °C solution of amine <b>45</b><a onclick="showRef(event, 'cit51c ref61'); return false;" href="javascript:void(0);" class="ref cit51c ref61">(51c,61)</a> (1000 mg, 4.54 mmol) and Et<sub>3</sub>N (1.91 mL, 13.6 mmol) in THF (10 mL). The reaction mixture was stirred at 23 °C for 2 h, at which point TLC analysis (50% EtOAc in petroleum ether <i>R</i><sub>f</sub> = 0.5) showed consumption of the starting material. The solvent was removed under reduced pressure, and the residue was purified by flash column chromatography on silica gel eluting with 0–45% EtOAc in petroleum ether to give compound <b>46</b> (710 mg, 48%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.72 min, <i>m</i>/<i>z</i> = 321.4 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.22 (brs, 1H), 8.67 (s, 1H), 7.11 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (s, 1H), 6.92 (d, <i>J</i> = 7.6 Hz, 1H), 5.30 (br, 1H), 4.27 (d, <i>J</i> = 7.2 Hz, 2H), 2.55 (s, 3H), 1.47 (s, 9H).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Benzyl (2-(2-(((<i>tert</i>-Butoxycarbonyl)amino)methyl)-5-(4-methylthiazol-5-yl)phenoxy)ethyl)(methyl)carbamate (<b>47</b>)</h4><div class="NLM_p last">DIAD (1260 mg, 6.24 mmol) was added slowly to a 0 °C solution of compound <b>46</b> (1000 mg, 3.12 mmol), Ph<sub>3</sub>P (1640 mg, 6.24 mmol), and benzyl <i>N</i>-(2-hydroxyethyl)-<i>N</i>-methyl-carbamate (980 mg, 4.68 mmol) in THF (30 mL). The reaction mixture was then warmed to 70 °C and stirred at that temperature for 16 h. After cooling to 23 °C, the mixture was concentrated in vacuo, and the residue was purified via flash chromatography on silica gel eluting with 0–50% EtOAc in petroleum ether to afford compound <b>47</b> (3.0 g, 64%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.91 min, <i>m</i>/<i>z</i> = 512.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.67 (s, 1H), 7.36–7.33 (m, 6H), 7.00 (d, <i>J</i> = 7.6 Hz, 1H), 6.86–6.81 (m, 1H), 5.31 (br, 0.5H), 5.15 (s, 2H), 4.96 (br, 0.5H), 4.27–4.25 (m, 2H), 4.15–4.10 (m, 2H), 3.75–3.72 (m, 3H), 3.07 (s, 3H), 2.51 (s, 3H), 1.40 (s, 9H).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Benzyl (2-(2-(Aminomethyl)-5-(4-methylthiazol-5-yl)phenoxy)ethyl)(methyl)carbamate (<b>48</b>)</h4><div class="NLM_p last">HCl (16 mL, 4 M in EtOAc) was added to compound <b>47</b> (3000 mg, 5.86 mmol) at 23 °C, and the resulting mixture was stirred at that temperature for 1 h. The mixture was then filtered, and the collected solid was washed with EtOAc (2 × 5 mL) to give compound <b>48</b> (HCl salt, 1000 mg, 38%) as a white solid.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Benzyl (2-(2-(((2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)ethyl)(methyl)carbamate (<b>50</b>)</h4><div class="NLM_p last">IEA (1.84 mL, 11.2 mmol) was added to a 23 °C solution of compound <b>49</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> (700 mg, 2.03 mmol), HATU (1273 mg, 3.35 mmol), and compound <b>48</b> (HCl salt, 1000 mg, 2.23 mmol) in DMF (10 mL). The mixture was stirred at 23 °C for 1 h and then concentrated under reduced pressure. The residue was purified by prep-HPLC (MeCN 20–75/0.225% FA in H<sub>2</sub>O) to afford compound <b>50</b> (900 mg, 53%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.870 min, <i>m</i>/<i>z</i> = 760.7 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Benzyl (2-(2-(((2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-18-(<i>tert</i>-Butyl)-2,2-dimethyl-4,16-dioxo-3,8,11,14-tetraoxa-5,17-diazanonadecan-19-oyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)ethyl)(methyl)carbamate (<b>51</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>50</b> (280 mg, 0.38 mmol) in HFIP (20 mL) was added trifluoroacetic acid (4 mL). The mixture was stirred at 23 °C for 1 h and then concentrated to give the Boc-deprotected amine (TFA salt, not shown, 241 mg, 100%) as a brown oil. To a 23 °C solution of compound <b>14</b> (241 mg, 0.38 mmol) in DMF (2.4 mL) were added HATU (158 mg, 0.41 mmol), the crude TFA salt derived from compound <b>50</b> (116 mg, 0.38 mmol), and DIEA (0.25 mL, 1.4 mmol). The mixture was stirred at 23 °C for 15 h and then partitioned between H<sub>2</sub>O (20 mL) and EtOAc (3 × 20). The combined organic layers were washed sequentially with H<sub>2</sub>O (3 × 15 mL) and brine (15), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The residue was purified by column chromatography on silica gel (0–5% MeOH in DCM) to give compound <b>51</b> (282 mg, 81%) as a yellow oil. LCMS (5–95, AB, 1.5 min): RT = 0.85 min, <i>m</i>/<i>z</i> = 949.4 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Benzyl (2-(2-(((2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)ethyl)(methyl)carbamate (<b>52</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>51</b> (282 mg, 0.30 mmol) in HFIP (20 mL) was added trifluoroacetic acid (7.7 mL, 3.04 mmol). The mixture was stirred at 23 °C for 1 h and then concentrated to give the Boc-deprotected amine (TFA salt, not shown, 251 mg, 100%) as a brown solid. This crude material was dissolved in DMF (2 mL), and compound <b>13</b> (196 mg, 1.52 mmol), HATU (1267 mg, 0.33 mmol), and DIEA (0.25 mL, 1.4 mmol) were sequentially added. The mixture was stirred at 23 °C for 15 h and then partitioned between H<sub>2</sub>O (20 mL) and EtOAc (3 × 20 mL). The combined organic layers were washed sequentially with H<sub>2</sub>O (3 × 15 mL) and brine (15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography on silica gel (0–5% MeOH in DCM) to give compound <b>52</b> (120 mg, 33%) as a yellow oil.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (2<i>S</i>,4<i>R</i>)-<i>N</i>-(2-(2-Aminoethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<i>S</i>)-2-(<i>tert</i>-butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxypyrrolidine-2-carboxamide (<b>6</b>)</h4><div class="NLM_p last">To a solution of compound <b>52</b> (200 mg, 0.17 mmol) in DCM (5 mL) was added iodotrimethylsilane (165 mg, 0.83 mmol) at 23 °C. After stirring for 16 h at that temperature, the reaction was quenched by addition of aqueous HCl (2 M, 2 mL) and the resulting mixture was directly purified by prep-HPLC (MeCN 20–50/0.225% FA in H<sub>2</sub>O) to give compound <b>6</b> (21 mg, 12%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.77 min, <i>m</i>/<i>z</i> = 1075.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 9.00 (s, 2H), 8.56 (s, 1H), 8.64–8.45 (m, 5H), 8.29 (s, 2H), 7.52–7.40 (m, 7H), 7.04 (s, 2H), 7.00 (d, <i>J</i> = 7.6 Hz, 1H), 4.56 (d, <i>J</i> = 9.6 Hz, 2H), 4.54–4.45 (m, 4H), 3.98 (s, 3H), 3.72–3.52 (m, 14H), 3.33–3.13 (m, 1H), 2.77 (d, <i>J</i> = 4.8 Hz, 1H), 2.69 (t, <i>J</i> = 5.2 Hz, 3H), 2.60 (s, 3H), 2.45 (s, 3H), 2.41 (s, 3H), 2.33 (s, 2H), 2.06 (d, <i>J</i> = 7.6 Hz, 4H), 1.96–1.83 (m, 5H), 1.62 (s, 4H), 0.92 (s, 7H), 0.98–0.84 (m, 1H).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl (2-(2-(((2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)ethyl)(methyl)carbamate (<b>6a</b>)</h4><div class="NLM_p last">DIEA (1.5 mg, 0.012 mmol) was added to a 23 °C solution of compound <b>6</b> (3.0 mg, 0.0028 mmol) and compound <b>53</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (3.1 mg, 0.0030 mmol) in DMF (2 mL). The mixture was stirred at 23 °C for 12 h and then directly purified by prep-HPLC (MeCN 38–68/0.225% FA in H<sub>2</sub>O) to afford compound <b>6a</b> (2.2 mg, 46%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.84 min, <i>m</i>/<i>z</i> = 858.9 [M/2 + Na]<sup>+</sup>. High-resolution mass spectrometry (HRMS) (electrospray ionization (ESI)), <i>m</i>/<i>z</i> = 1670.66 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-<i>N</i>-(2-(2-(6-(2,5-dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)-<i>N</i>-methylhexanamido)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide (<b>6b</b>)</h4><div class="NLM_p last">DIEA (1.3 mg, 0.010 mmol) was added to a 23 °C solution of compound <b>6</b> (3.0 mg, 0.0028 mmol) and compound <b>42</b> (1.3 mg, 0.0028 mmol) in DMF (2 mL). The mixture was stirred at 23 °C for 12 h and then directly purified by prep-HPLC (MeCN 38–68/0.225% FA in H<sub>2</sub>O) to afford compound <b>6b</b> (2.4 mg, 68%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.85 min, <i>m</i>/<i>z</i> = 1291.7 [M + Na]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> = 1290.48 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Benzyl 4-(((2-Nitrophenyl)sulfonyl)oxy)piperidine-1-carboxylate (<b>55</b>)</h4><div class="NLM_p last">Benzyl 4-hydroxypiperidine-1-carboxylate (2260 mg, 10.2 mmol) in DCM (10 mL) was added dropwise to a solution of 2-nitrobenzene-1-sulfonyl chloride (2000 mg, 8.5 mmol), Et<sub>3</sub>N (2150 mg, 21.3 mmol), and DMAP (52 mg, 0.43 mmol) in DCM (50 mL) at 0 °C. The reaction mixture was warmed to 23 °C and was stirred at that temperature for 12 h. The reaction solution was then concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel eluting with 0–50% EtOAc in petroleum ether to afford compound <b>55</b> (1300 mg, 36%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.89 min, <i>m</i>/<i>z</i> = 442.9 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.17 (d, <i>J</i> = 6.8 Hz, 1H), 7.85–7.77 (m, 3H), 7.37–7.32 (m, 5H), 5.13-5.06 (m, 3H), 3.69–3.64 (m, 2H), 3.56–3.49 (m, 2H), 1.92–1.90 (m, 4H).</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Benzyl 4-(2-(((2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)piperidine-1-carboxylate (<b>56</b>)</h4><div class="NLM_p last">A mixture of Cs<sub>2</sub>CO<sub>3</sub> (596 mg, 1.83 mmol), compound <b>54</b><a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> (500 mg, 0.91 mmol), and compound <b>55</b> (1150 mg, 2.74 mmol) in DMF (20 mL) was stirred at 50 °C for 13 h. The reaction solution was cooled to 23 °C and then partitioned between H<sub>2</sub>O (10 mL) and EtOAc (3 × 30 mL). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified via flash chromatography on silica gel eluting with 0–90% EtOAc in petroleum ether to give compound <b>56</b> (370 mg, 53%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.90 min, <i>m</i>/<i>z</i> = 786.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Benzyl 4-(2-(((2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)piperidine-1-carboxylate (<b>57</b>)</h4><div class="NLM_p last">A solution of compound <b>56</b> (50 mg, 0.07 mmol) in 1:5 TFA/DCM (6 mL) was stirred at 23 °C for 2 h. The reaction mixture was concentrated to give compound <b>57</b> (TFA salt, 50 mg, 98%, yellow solid), and this material was used in the next step without additional purification. LCMS (5–95, AB, 1.5 min): RT = 0.76 min, <i>m</i>/<i>z</i> = 664.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Benzyl 4-(2-(((2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-18-(<i>tert</i>-Butyl)-2,2-dimethyl-4,16-dioxo-3,8,11,14-tetraoxa-5,17-diazanonadecan-19-oyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)piperidine-1-carboxylate (<b>58</b>)</h4><div class="NLM_p last">A solution of compound <b>57</b> (150 mg, 0.23 mmol), compound <b>14</b> (76 mg, 0.25 mmol), HATU (172 mg, 0.45 mmol), and DIEA (0.07 mL, 0.45 mmol) in anhydrous DMF (3 mL) was stirred at 23 °C for 2 h. The reaction mixture was then directly purified by prep-HPLC (MeCN 31–61/0.01% NH<sub>4</sub>Cl in H<sub>2</sub>O) to afford compound <b>58</b> (160 mg, 74%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.89 min, <i>m</i>/<i>z</i> = 975.2 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Benzyl 4-(2-(((2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)piperidine-1-carboxylate (<b>59</b>)</h4><div class="NLM_p last">A solution of compound <b>58</b> (150 mg, 0.16 mmol) in 1:3 TFA/DCM (4 mL) was stirred at 23 °C for 30 min. The reaction mixture was then concentrated to give the crude Boc-deprotected amine (not shown, TFA salt, 130 mg, 97%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.78 min, <i>m</i>/<i>z</i> = 875.1 [M + Na]<sup>+</sup>. Separately, DIEA (0.07 mL, 0.40 mmol) was added to a 23 °C solution of compound <b>13</b> (67 mg, 0.17 mmol) and HATU (116 mg, 0.30 mmol) in anhydrous DMF (2 mL), and the resulting mixture was stirred at that temperature for 20 min. The crude Boc-deprotected amine obtained from <b>58</b> (TFA salt, 130 mg, 0.15 mmol) was then added, and stirring was continued at 23 °C for 2 h. The reaction was partitioned between H<sub>2</sub>O (20 mL) and EtOAc (3 × 20 mL), and the combined organic layers were washed with brine (2 × 20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash chromatography (0–100% EtOAc in petroleum ether) to afford compound <b>59</b> (150 mg, 80%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.91 min, <i>m</i>/<i>z</i> = 1257.9 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)-2-(piperidin-4-yloxy)benzyl)pyrrolidine-2-carboxamide (<b>7</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>59</b> in DCM (2 mL) was added iodotrimethylsilane (152 mg, 0.76 mmol). The mixture was stirred at 23 °C for 20 min and then directly purified by prep-HPLC (MeCN 26–56/0.225% FA in H<sub>2</sub>O) to afford chimeric degrader <b>7</b> (21 mg, 13%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.79 min, <i>m</i>/<i>z</i> = 1101.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.97 (s, 1H), 8.49–8.45 (m, 1H), 8.39 (s, 1H), 8.29–8.26 (m, 1H), 7.48–7.39 (m, 6H), 7.07 (s, 1H), 6.80 (d, <i>J</i> = 7.6 Hz, 1H), 4.65–4.63 (s, 1H), 4.56 (d, <i>J</i> = 10.0 Hz, 1H), 4.50–4.46 (m, 2H), 4.35 (s, 1H), 4.32–4.21 (m, 1H), 3.97 (s, 1H), 3.75–3.60 (m, 2H), 3.58–3.54 (m, 8H), 3.40–3.22 (m, 9H), 3.11–2.91 (m, 2H), 2.81–2.71 (m, 2H), 2.62–2.51 (m, 4H), 2.43 (s, 3H), 2.40(s, 3H), 2.06–2.01 (m, 1H), 2.00–1.91 (m, 3H), 1.68–1.65 (m, 2H), 1.61 (s, 3H), 0.93 (s, 9H).</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl 4-(2-(((2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)piperidine-1-carboxylate (<b>7a</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>53</b> (8.5 mg, 0.01 mmol) and compound <b>7</b> (8.5 mg, 0.01 mmol) in DMF (5 mL) was added DIEA (0.01 mL, 0.03 mmol). The mixture was stirred at 23 °C for 12 h and then directly purified by prep-HPLC (MeCN 12–47/0.225% FA in H<sub>2</sub>O) to afford compound <b>7a</b> (1.6 mg, 12%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.85 min, <i>m</i>/<i>z</i> = 850.0 [M/2 + H]<sup>+</sup>.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(<i>tert</i>-Butyl)-17-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-<i>N</i>-(2-((1-(6-(2,5-dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanoyl)piperidin-4-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide (<b>7b</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>7</b> (22 mg, 0.02 mmol) and compound <b>42</b> (9.2 mg, 0.03 mmol) in DMF (10 mL) was added DIEA (7.7 mg, 0.06 mmol). The mixture was stirred at 23 °C for 3 h and then directly purified by prep-HPLC (MeCN 38–68/0.225% FA in H<sub>2</sub>O) to afford compound <b>7b</b> (4.5 mg, 17%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.87 min, <i>m</i>/<i>z</i> = 1294.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> <i>tert</i>-Butyl 2-(3,5-Bis(benzyloxy)phenethoxy)acetate (<b>61</b>)</h4><div class="NLM_p last">A solution of NaOH (28 g, 718 mmol) in H<sub>2</sub>O (180 mL) was added to a 23 °C solution of compound <b>60</b><a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> (3.0 g, 8.97 mmol) in toluene (80 mL) followed by sequential addition of <i>tert</i>-butyl 2-bromoacetate (14 g, 72 mmol) and <i>n</i>Bu<sub>4</sub>HSO<sub>4</sub> (2.45 g, 7.18 mmol). The mixture was stirred at 23 °C for 2 h and then partitioned between H<sub>2</sub>O (100 mL) and EtOAc (2 × 200 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated. The residue was purified by silica gel column eluting with 0–10% EtOAc in petroleum ether to afford compound <b>61</b> (3000 mg, 64%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42–7.31 (m, 10H), 6.51–6.48 (m, 3H), 5.01 (s, 4H), 3.94 (s, 2H), 3.72 (t, <i>J</i> = 7.2 Hz, 2H), 2.88 (t, <i>J</i> = 7.2 Hz, 2H), 1.47 (s, 9H).</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> <i>tert</i>-Butyl 2-(3,5-Dihydroxyphenethoxy)acetate (<b>62</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>61</b> (3000 mg, 6.69 mmol) in MeOH (40 mL) was added 10% palladium on carbon (710 mg). The mixture was stirred at 23 °C under H<sub>2</sub> (1 atm) for 16 h and then filtered. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography eluting with 50% EtOAc in petroleum ether to afford compound <b>62</b> (1600 mg, 87%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.26 (d, <i>J</i> = 2.0 Hz, 2H), 6.21 (d, <i>J</i> = 2 Hz, 1H), 3.96 (s, 2H), 3.69 (t, <i>J</i> = 7.2 Hz, 2H), 2.77 (t, <i>J</i> = 7.2 Hz, 2H), 1.46 (s, 9H).</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>tert</i>-Butyl 2-(3-(2-(((Benzyloxy)carbonyl)amino)ethoxy)-5-hydroxyphenethoxy)acetate (<b>63</b>)</h4><div class="NLM_p last">To a 23 °C solution of CbzNHC<sub>2</sub>CH<sub>2</sub>Br (770 mg, 2.98 mmol) and compound <b>62</b> (800 mg, 2.98 mmol) in MeCN (20 mL) were added K<sub>2</sub>CO<sub>3</sub> (660 mg, 4.77 mmol) and KI (50 mg, 0.30 mmol). The mixture was warmed to 70 °C and stirred at that temperature for 12 h. After cooling to 23 °C, the reaction mixture was diluted with EtOAc (250 mL) and washed with H<sub>2</sub>O (3 × 50 mL). The organic layer was concentrated, and the residue was purified by prep-HPLC (MeCN 25–75/0.225% FA in H<sub>2</sub>O) to give compound <b>63</b> (340 mg, 26%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.81 min, <i>m</i>/<i>z</i> = 468.0 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.33 (m, 5H), 6.35 (s, 2H), 6.24 (s, 1H), 5.21 (br, 1H), 5.11 (s, 2H), 4.01–3.99 (t, <i>J</i> = 4.8 Hz, 2H), 3.96 (s, 2H), 3.71 (t, <i>J</i> = 7.2 Hz, 2H), 3.59–3.57 (m, 2H), 2.84 (t, <i>J</i> = 6.8 Hz, 2H), 1.47 (s, 9H).</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>tert</i>-Butyl 2-(3-(2-(((Benzyloxy)carbonyl)amino)ethoxy)-5-(((trifluoromethyl)sulfonyl)oxy)phenethoxy)acetate (<b>64</b>)</h4><div class="NLM_p last">Pyridine (0.31 mL, 3.82 mmol) and trifluoromethanesulfonic anhydride (0.26 mL, 1.53 mmol) were added sequentially to a 23 °C solution of compound <b>63</b> (340 mg, 0.76 mmol) in DCM (10 mL). The mixture was stirred at 23 °C for 1 h, diluted with EtOAc (80 mL), and washed with saturated aqueous citric acid (3 × 30 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated to give crude compound <b>64</b> (440 mg, 100%). This material was used directly in the next step. LCMS (5–95, AB, 1.5 min): RT = 1.14 min, <i>m</i>/<i>z</i> = 600.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> <i>tert</i>-Butyl 2-(3-(2-(((Benzyloxy)carbonyl)amino)ethoxy)-5-((<i>tert</i>-butoxycarbonyl)amino)phenethoxy)acetate (<b>65</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>64</b> (440 mg, 0.76 mmol) and <i>tert</i>-butyl carbamate (446 mg, 3.81 mmol) in 1,4-dioxane (20 mL) were added XPhos (73 mg, 0.15 mmol), Cs<sub>2</sub>CO<sub>3</sub> (745 mg, 2.29 mmol), and Pd(OAc)<sub>2</sub> (17 mg, 0.08 mmol). The mixture was stirred at 100 °C for 16 h, cooled to 23 °C, and then concentrated. The residue was purified by flash chromatography (0–20% EtOAc in petroleum ether) to give compound <b>65</b> (180 mg, 43%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.92 min, <i>m</i>/<i>z</i> = 567.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> <i>tert</i>-Butyl (<i>S</i>)-2-(3-((<i>tert</i>-Butoxycarbonyl)amino)-5-(2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethoxy)phenethoxy)acetate (<b>66</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>65</b> (180 mg, 0.33 mmol) in THF (15 mL) was added 10% palladium on carbon (35 mg, 0.33 mmol). The mixture was stirred at 23 °C under H<sub>2</sub> (15 psi) for 1 h and then filtered. The filtrate was concentrated under reduced pressure to give the corresponding deprotected primary amine (not shown, 135 mg, 91% yield) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.66 min, <i>m</i>/<i>z</i> = 411 [M + H]<sup>+</sup>. This crude material was dissolved in DMF (10 mL) at 23 °C, and DIEA (0.23 mL, 1.32 mmol), compound <b>13</b> (158 mg, 0.39 mmol), and HATU (153 mg, 0.40 mmol) were sequentially added. The mixture was stirred at 23 °C for 1 h and then concentrated under reduced pressure. The residue was purified by flash column chromatography (0–10% MeOH in DCM) to give compound <b>66</b> (200 mg, 73%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.90 min, <i>m</i>/<i>z</i> = 793.2 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (<i>S</i>)-2-(3-Amino-5-(2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethoxy)phenethoxy)acetic Acid (<b>67</b>)</h4><div class="NLM_p last">A mixture of compound <b>66</b> (200 mg, 0.25 mmol) in 4.0 M HCl in EtOAc (2.0 mL) was stirred at 23 °C for 1 h. The mixture was then concentrated under reduced pressure to afford compound <b>67</b> (HCl salt, 169 mg, 100%) as a white solid. This material was used in the next step without additional purification.</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(2-(3-Amino-5-(2-(2-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethoxy)phenethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (<b>8</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>68</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> (227 mg, 0.53 mmol), compound <b>67</b> (HCl salt, 169 mg, 0.25 mmol), and HATU (104 mg, 0.28 mmol) in DMF (10 mL) was added DIEA (0.21 mL, 1.25 mmol). The mixture was stirred at 23 °C for 1 h and then directly purified by prep-HPLC (MeCN 31–51/0.225% FA in H<sub>2</sub>O) to give compound <b>8</b> (45 mg, 17%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.81 min, <i>m</i>/<i>z</i> = 1049.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.69 (s, 1H), 7.62–7.56 (m, 1H) 7.40 (d, <i>J</i> = 8.0 Hz, 2H), 7.32–7.26 (m, 6H), 7.11 (d, <i>J</i> = 7.6 Hz, 1H), 6.74 (brs, 1H), 6.65 (brs, 1H), 6.53 (brs, 1H), 4.76–4.73 (m, 1H), 4.63–4.56 (m, 2H), 4.51–4.38 (m, 2H), 4.08–3.96 (m, 5H), 3.84–3.68 (m, 4H), 3.64–3.54 (m, 2H), 3.50–3.42 (m, 3H), 3.36–3.24 (m, 2H), 2.82 (brs, 2H), 2.65 (s, 2H), 2.50 (s, 6H), 2.42 (s, 6H), 2.26 (br, 1H), 0.95 (s, 9H).</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl (3-(2-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethoxy)-5-(2-(2-(((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethyl)phenyl)carbamate (<b>8a</b>)</h4><div class="NLM_p last">To a 23 °C mixture of triphosgene (14 mg, 0.05 mmol) and 4 Å molecular sieves in DCM (2 mL) was added a solution of compound <b>8</b> (50 mg, 0.05 mmol) and Et<sub>3</sub>N (15 mg, 0.14 mmol) in DCM (2 mL). The mixture was stirred at 23 °C for 30 min and then concentrated under reduced pressure. The residue was dissolved in DCM (5 mL) at 23 °C, and a solution of compound <b>20</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (82 mg, 0.14 mmol) and Et<sub>3</sub>N (15 mg, 0.14 mmol) in DMF (2 mL) was added. The reaction mixture was stirred at 23 °C for 12 h and then concentrated under reduced pressure. The residue was purified by prep-HPLC (MeCN 38–68/0.225% FA in H<sub>2</sub>O) to give compound <b>8a</b> (5 mg, 6%) as a white solid. LCMS (10–80, AB, 7.0 min): RT = 3.93 min, <i>m</i>/<i>z</i> = 824.5 [M/2 + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> = 1645.64 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>cis</i>-Dimethyl-piperidine-3,5-dicarboxylate (<b>70</b>)</h4><div class="NLM_p last">To a solution of commercially available <b>69</b> (6.0 g, 31 mmol) in acetic acid (50 mL) at 23 °C was added 85% PtO<sub>2</sub>·H<sub>2</sub>O (700 mg). The resulting suspension was hydrogenated at 50 psi and 45 °C for 12 h. After cooling to 23 °C, the catalyst was removed by filtration through silica gel. The filtrate was concentrated under reduced pressure to afford compound <b>70</b> (6.0 g, 97%) as a colorless oil. This material was used directly in the next step without further purification.</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>cis</i>-1-(<i>tert</i>-Butyl)-3,5-dimethyl-piperidine-1,3,5-tricarboxylate (<b>71</b>)</h4><div class="NLM_p last">To a solution of compound <b>70</b> (6.0 g, 30 mmol) in 4:1 THF/H<sub>2</sub>O (25 mL) at 23 °C were added NaHCO<sub>3</sub> (10 g, 119 mmol) and Boc<sub>2</sub>O (9.75 g, 45 mmol). The mixture was stirred at 23 °C for 2 h and then partitioned between H<sub>2</sub>O (15 mL) and EtOAc (3 × 15 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography (5–30% EtOAc in petroleum ether) to afford compound <b>71</b> (7.2 g, 75%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.87 min, <i>m</i>/<i>z</i> = 324.0 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> <i>cis</i>-<i>tert</i>-Butyl 3,5-Bis(hydroxymethyl)piperidine-1-carboxylate (<b>72</b>)</h4><div class="NLM_p last">To a −78 °C solution of compound <b>71</b> (7.2 g, 24 mmol) in THF (40 mL) was added DIBAL-H (1 M in toluene, 96 mL, 96 mmol). The mixture was stirred at −78 °C for 2 h, warmed to −25 °C, quenched with MeOH (25 mL), and stirred for 5 min at that temperature. An aqueous solution of potassium sodium tartrate tetrahydrate (Rochelle salt; 60 mL, 20% w/w in H<sub>2</sub>O) was added, and stirring was continued for another 1 h at 23 °C. The mixture was extracted with EtOAc (2 × 15 mL), and the combined organic layers were washed with water (2 × 30 mL) and brine (2 × 30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by flash column chromatography (0–10% MeOH in DCM) to give compound <b>72</b> (2.7 g, 38%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.84 min, <i>m</i>/<i>z</i> = 268.0 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> <i>cis</i>-<i>tert</i>-Butyl 3-((2-Ethoxy-2-oxoethoxy)methyl)-5-(hydroxymethyl)piperidine-1-carboxylate (<b>73</b>)</h4><div class="NLM_p last">To a 0 °C solution of rhodium diacetate (0.45 g, 2.04 mmol) and compound <b>72</b> (2.5 g, 10.2 mmol) in DCM (40 mL) was added ethyl 2-diazoacetate (1.07 mL, 10.2 mmol). The mixture was warmed to 23 °C and was stirred for 12 h at that temperature. The reaction was quenched with H<sub>2</sub>O (10 mL), and the mixture was extracted with DCM (3 × 10 mL). The combined organic layers were washed with H<sub>2</sub>O (3 × 10 mL) and brine (3 × 10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The residue was purified by column chromatography (0–1% MeOH in DCM) to afford compound <b>73</b> (racemic, 1.0 g, 30%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.81 min, <i>m</i>/<i>z</i> = 354.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> <i>cis</i>-<i>tert</i>-Butyl 3-((2-(((Benzyloxy)carbonyl)amino)ethoxy)methyl)-5-((2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (<b>75</b>)</h4><div class="NLM_p last">A solution of compound <b>74</b><a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> (800 mg, 4.53 mmol) in DCM (3 mL) was added dropwise to a −78 °C mixture of compound <b>73</b> (1000 mg, 3.02 mmol) and Sc(OTf)<sub>3</sub> (149 mg, 0.30 mmol) in DCM (10 mL). The reaction mixture was stirred at −78 °C for 4 h and then maintained at 23 °C for 12 h. After concentrating the reaction solution under reduced pressure, the residue was purified by flash chromatography on silica gel eluting with 0–5% MeOH in DCM to give a partially pure product. This material was further purified by prep-HPLC (MeCN 50–80%/10 mM NH<sub>4</sub>HCO<sub>3</sub> in H<sub>2</sub>O) to afford compound <b>75</b> (racemic, 200 mg, 13%) as a brown oil. LCMS (5–95, AB, 1.5 min): RT = 0.90 min, <i>m</i>/<i>z</i> = 409.0 [M – 100 + H]<sup>+</sup>.</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> <i>cis</i>-<i>tert</i>-Butyl 3-((2-Aminoethoxy)methyl)-5-((2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (<b>76</b>)</h4><div class="NLM_p last">To a 23 °C suspension of 10% Pd on carbon (36 mg) in THF (10 mL) was added compound <b>75</b> (170 mg, 0.33 mmol). The mixture was stirred at 23 °C under H<sub>2</sub> (15 psi) for 1 h and then filtered. The filter cake was washed with MeOH (3 × 10 mL), and the combined filtrate and washings were concentrated to afford compound <b>76</b> (racemic, 125 mg, 100%) as a yellow oil. This material was used in the next step without additional purification. LCMS (5–95, AB, 1.5 min): RT = 0.71 min, <i>m</i>/<i>z</i> = 375.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> <i>tert</i>-Butyl 3-((2-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethoxy)methyl)-5-((2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (<b>77</b>)</h4><div class="NLM_p last">To a 0 °C solution of compound <b>13</b> (161 mg, 0.40 mmol), HATU (190 mg, 0.50 mmol), and DIEA (0.17 mL, 1 mmol) in DMF (5 mL) was added compound <b>76</b> (125 mg, 0.33 mmol). The reaction mixture was warmed to 23 °C and was stirred at that temperature for 1 h. After concentrating the reaction solution under reduced pressure, the residue was purified by prep-TLC (5% MeOH in DCM, <i>R</i><sub>f</sub> = 0.3) to afford compound <b>77</b> (∼2:1 mix of cis-diastereomers, 240 mg, 92%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.92 min, <i>m</i>/<i>z</i> = 757.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 2-((1-(<i>tert</i>-Butoxycarbonyl)-5-((2-(2-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethoxy)methyl)piperidin-3-yl)methoxy)acetic Acid (<b>78</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>77</b> (180 mg, 0.24 mmol) in 5:1:1 THF/MeOH/H<sub>2</sub>O (7 mL) was added LiOH·H<sub>2</sub>O (50 mg, 1.19 mmol). The mixture was stirred at 23 °C for 1 h and then partitioned between H<sub>2</sub>O (10 mL) and EtOAc (3 × 10 mL). The aqueous layer was acidified with citric acid to pH = 4, and the resulting mixture was extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by prep-HPLC (MeCN 25–55%/10 mM NH<sub>4</sub>HCO<sub>3</sub> in H<sub>2</sub>O) to afford compound <b>78</b> (∼2:1 mix of cis-diastereomers, 100 mg, 58%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.84 min, <i>m</i>/<i>z</i> = 751.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>tert</i>-Butyl 3-((2-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethoxy)methyl)-5-((2-(((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)methyl)piperidine-1-carboxylate (<b>79</b>)</h4><div class="NLM_p last">A solution of compound <b>78</b> (80 mg, 0.11 mmol), compound <b>68</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> (71 mg, 0.16 mmol), DIEA (71 mg, 0.55 mmol), and HATU (50 mg, 0.13 mmol) in DMF (4 mL) was stirred at 50 °C for 12 h. The mixture was cooled to 23 °C and concentrated. The residue was purified by reverse-phase chromatography (MeCN 40–70%/10 mM NH<sub>4</sub>HCO<sub>3</sub> in H<sub>2</sub>O) to afford compound <b>79</b> (∼2:1 mix of cis-diastereomers, 80 mg, 64%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.89 min, <i>m</i>/<i>z</i> = 1142.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(2-((5-((2-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethoxy)methyl)piperidin-3-yl)methoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (<b>9</b>)</h4><div class="NLM_p last">A mixture of compound <b>79</b> (25 mg, 0.02 mmol) in 4 M HCl in EtOAc (9.8 mL) was stirred at 23 °C for 1 h. The mixture was concentrated, and the residue was washed with EtOAc (2 × 10 mL) and DCM (2 × 10 mL) to afford compound <b>9</b> (HCl salt, ∼2:1 mix of cis-diastereomers, 20 mg, 85%) as a yellow solid. LCMS (10–80, AB, 7.0 min): RT = 3.23 min, <i>m</i>/<i>z</i> = 521.6 [M/2 + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 9.56 (s, 1H), 7.43–7.38 (m, 4H), 7.36–7.33 (m, 4H), 4.53–4.46 (m, 3H), 4.38–4.37 (m, 2H), 4.05–3.96 (m, 2H), 3.90–3.87 (m, 1H), 3.77–3.75 (m, 1H), 3.59–3.57 (m, 3H), 3.49–3.32 (m, 9H), 2.69–2.65 (m, 4H), 2.46 (s, 3H), 2.33–1.88 (m, 10H), 1.67–1.63 (m, 1H), 1.52 (s, 3H), 1.19–1.13 (m, 1H), 0.88–0.86 (m, 9H).</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl-3-((2-(2-((<i>S</i>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethoxy)methyl)-5-((2-(((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)methyl)piperidine-1-carboxylate (<b>9a</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>53</b><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> (9.1 mg, 0.01 mmol) in anhydrous DMF (2 mL) were added compound <b>9</b> (8.9 mg, 0.01 mmol) and DEIA (5.3 mg, 0.04 mmol). The reaction mixture was stirred at 23 °C for 12 h and then concentrated under reduced pressure. The residue was purified by sequential prep-HPLC runs (#1: MeCN 38–58%/10 mM NH<sub>4</sub>HCO<sub>3</sub> in H<sub>2</sub>O; #2: MeCN 39–59/0.225% FA in H<sub>2</sub>O)  to afford compound <b>9a</b> (∼2:1 mix of cis-diastereomers, 4.1 mg, 43%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.84 min, <i>m</i>/<i>z</i> = 820.0 [M/2 + H]<sup>+</sup>.</div></div><div id="sec4_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(2-(5-((2-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethoxy)methyl)-1-(6-(2,5-dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanoyl)piperidin-3-yl)methoxy)acetamido)-3,3-dimethylbutanoyl-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (<b>9b</b>)</h4><div class="NLM_p last">To a 23 °C solution of commercially available compound <b>42</b> (6.4 mg, 0.02 mmol) in anhydrous DMF (2 mL) was added compound <b>9</b> (15 mg, 0.01 mmol) and DIEA (9.0 mg, 0.07 mmol). The resulting mixture was stirred at 23 °C for 12 h and then concentrated in vacuo. The residue was purified by prep-HPLC (MeCN 45–75/0.225% FA in H<sub>2</sub>O) to afford compound <b>9b</b> (∼2:1 mix of cis-diastereomers, 4.0 mg, 23%) as a white solid. LCMS (5–95, AB, 1.5 min): RT =0.85 min, <i>m</i>/<i>z</i> = 618.3 [M/2 + H]<sup>+</sup>.</div></div><div id="sec4_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> (<i>S</i>)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamide (<b>80</b>)</h4><div class="NLM_p last">To a 23 °C mixture of compound <b>13</b> (0.87 g, 2.11 mmol), NH<sub>4</sub>Cl (338 mg, 6.32 mmol), and HATU (1600 mg, 4.21 mmol) in DMF (20 mL) was added DIEA (1.74 mL, 10.5 mmol). The mixture was stirred at 23 °C for 2 h and then concentrated, and the residue was purified by flash column chromatography eluting with 0–5% MeOH in DCM to give compound <b>80</b> (0.84 g, 98%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.77 min, <i>m</i>/<i>z</i> = 421.9 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> (<i>S</i>)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)ethanimidothioic Acid (<b>81</b>)</h4><div class="NLM_p last">To a solution of compound <b>80</b> (840 mg, 2.10 mmol) in THF (50 mL) was added Lawesson’s reagent (1.70 g, 4.20 mmol) at 23 °C. The mixture was warmed to 40 °C and stirred at that temperature for 2 h. After cooling to 23 °C, the reaction solution was diluted with EtOAc (250 mL) and washed with H<sub>2</sub>O (3 × 50 mL) and brine (50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography eluting with 5–10% MeOH in DCM to give compound <b>81</b> (630 mg, 71%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.89 min, <i>m</i>/<i>z</i> = 416.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> (<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6-(thiazol-2-ylmethyl)-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepine (<b>82</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>81</b> (630 mg, 1.51 mmol) and 2-bromo-1,1-diethoxyethane (448 mg, 2.27 mmol) in HOAc (5 mL) was added TsOH (26 mg, 0.15 mmol). The mixture was stirred at 90 °C for 1 h, cooled to 23 °C, and concentrated under reduced pressure. Purification of the residue by flash column chromatography eluting with 5–10% MeOH in DCM gave compound <b>82</b> (600 mg, 87%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.85 min, <i>m</i>/<i>z</i> = 461.9 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 2-(3,5-Dibromophenyl)ethan-1-ol (<b>84</b>)</h4><div class="NLM_p last">To a 23 °C solution of 2-(3,5-dibromophenyl)acetic acid (<b>83</b>, 5.0 g, 17 mmol) in THF (75 mL) was added borane in THF (1.0 M, 51 mL, 51 mmol). The mixture was stirred at 23 °C for 12 h and then quenched by addition of MeOH (10 mL). The resulting mixture was concentrated to dryness, and the residue was diluted with EtOAc (60 mL). The organic layer was washed with water (20 mL) and brine (3 × 20 mL). The organics were then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product. This material was purified by flash column chromatography eluting with 0–30% EtOAc in petroleum ether to afford compound <b>84</b> (4.72 g, 99%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.53 (s, 1H), 7.39 (m, 2H), 3.72 (t, <i>J</i> = 6.4 Hz, 2H), 2.76 (t, <i>J</i> = 6.4 Hz, 2H).</div></div><div id="sec4_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> <i>tert</i>-Butyl 2-(3,5-Dibromophenethoxy)acetate (<b>85</b>)</h4><div class="NLM_p last">A mixture of compound <b>84</b> (4.0 g, 14.3 mmol), <i>tert</i>-butyl 2-bromoacetate (22.3 g, 114 mmol), <i>n</i>Bu<sub>4</sub>NHSO<sub>4</sub> (3.88 g, 11.4 mmol), and NaOH (46 g, 1140 mmol) in toluene (80 mL) and H<sub>2</sub>O (228 mL) was stirred at 23 °C for 3 h. The reaction mixture was extracted with MTBE (3 × 50 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by chromatography on silica eluting with 0–10% EtOAc in petroleum ether to give compound <b>85</b> (5.55 g, 98%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.52 (s, 1H), 7.42 (s, 2H), 3.93 (s, 2H), 3.69 (t, <i>J</i> = 6.4 Hz, 2H), 2.84 (t, <i>J</i> = 6.4 Hz, 2H), 1.44 (s, 9H).</div></div><div id="sec4_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 2-(3,5-Dibromophenethoxy)acetic Acid (<b>86</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>85</b> (4.5 g, 11.4 mmol) in DCM (180 mL) was added TFA (36 mL). The mixture was stirred at 23 °C for 16 h and then concentrated under reduced pressure. The residue was dissolved in EtOAc (60 mL), and this solution was washed with water (3 × 20 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound <b>86</b> (3.65 g, 95%) as a yellow oil. This material was used directly in the next step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.54 (s, 1H), 7.32 (d, <i>J</i> = 1.6 Hz, 2H), 4.16 (s, 2H), 3.77 (t, <i>J</i> = 6.8 Hz, 2H), 2.89 (t, <i>J</i> = 6.8 Hz, 2H).</div></div><div id="sec4_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 2-(3,5-Dibromophenethoxy)ethan-1-ol (<b>87</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>86</b> (5.30 g, 15.7 mmol) in THF (70 mL) was added borane dimethyl sulfide complex (10 M in Me<sub>2</sub>S, 4.7 mL, 47 mmol). The reaction solution was stirred at 23 °C for 12 h and then quenched by addition of MeOH (30 mL). The resulting mixture was concentrated under reduced pressure, and the residue was dissolved in EtOAc (90 mL). This solution was washed sequentially with saturated aqueous NaHCO<sub>3</sub> (3 × 20 mL) and brine (3 × 30 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound <b>87</b> (4.60 mg, 91%) as a yellow oil. This material was used in the next step without additional purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.53 (d, <i>J</i> = 2.0 Hz, 1H), 7.32 (d, <i>J</i> = 2.0 Hz, 2H), 3.74–3.67 (m, 4H), 3.56 (t, <i>J</i> = 4.8 Hz, 2H), 2.85 (t, <i>J</i> = 6.4 Hz, 2H).</div></div><div id="sec4_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> <i>tert</i>-Butyl (2-(3,5-Dibromophenethoxy)ethoxy)dimethylsilane (<b>88</b>)</h4><div class="NLM_p last">A mixture of crude compound <b>87</b> (4.60 g, 14.2 mmol), TBSCl (3.21 g, 21.3 mmol), and imidazole (2.90 g, 42.6 mmol) in DCM (50 mL) was stirred at 23 °C for 4 h. The reaction solution was then partitioned between H<sub>2</sub>O (30 mL) and DCM (3 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The residue was purified by flash column chromatography eluting with 0–5% EtOAc in petroleum ether to give compound <b>88</b> (5.20 g, 84%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.48 (s, 1H), 7.37 (s, 2H), 3.71–3.63 (m, 4H), 3.45 (t, <i>J</i> = 5.2 Hz, 2H), 2.79 (t, <i>J</i> = 6.0 Hz, 2H), 0.84 (s, 9H), 0.0 (s, 6H).</div></div><div id="sec4_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> <i>tert</i>-Butyl (<i>E</i>)-3-(3-Bromo-5-(2-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethoxy)ethyl)phenyl)acrylate (<b>89</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>88</b> (1.38 g, 3.15 mmol) in DMF (20 mL) were added <i>n</i>Bu<sub>4</sub>NBr (1.02 mg, 3.15 mmol), <i>tert</i>-butyl acrylate (605 mg, 4.72 mmol), NaHCO<sub>3</sub> (1.06 mg, 12.6 mmol), and Pd(OAc)<sub>2</sub> (71 mg, 0.31 mmol). The resulting mixture was heated to 105 °C and was stirred at that temperature for 24 h. After cooling to 23 °C, the reaction mixture was filtered, and the filtrate was diluted with EtOAc (90 mL). This solution was washed with H<sub>2</sub>O (30 mL) and brine (3 × 30 mL) and then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was to give crude, which was purified by column chromatography (0–10% EtOAc in petroleum ether) to give compound <b>89</b> (1.23 g, 81%) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.52 (s, 1H), 7.44 (d, <i>J</i> = 16 Hz, 1H), 7.40 (s, 1H), 7.38 (s, 1H), 6.48 (d, <i>J</i> = 16 Hz, 1H), 3.71–3.65 (m, 4H), 3.46 (t, <i>J</i> = 4.8 Hz, 2H), 2.83 (t, <i>J</i> = 6.4 Hz, 2H), 1.49 (s, 9H), 0.84 (s, 9H), 0.0 (s, 6H).</div></div><div id="sec4_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> <i>tert</i>-Butyl (<i>E</i>)-3-(3-((<i>tert</i>-Butoxycarbonyl)amino)-5-(2-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethoxy)ethyl)phenyl)acrylate (<b>90</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl carbamate (445 mg, 3.8 mmol), Cs<sub>2</sub>CO<sub>3</sub> (1.65 g, 5.07 mmol), Xphos (120 mg, 0.25 mmol), and Pd(OAc)<sub>2</sub> (29 mg, 0.13 mmol) were sequentially added to a solution of compound <b>89</b> (1.23 mg, 2.53 mmol) in 1,4-dioxane (20 mL) at 23 °C. The mixture was then heated to 100 °C and was stirred at that temperature for 16 h. After cooling to 23 °C, the reaction solution was filtered, and the filtrate was diluted with EtOAc (90 mL). This solution was washed with H<sub>2</sub>O (30 mL) and brine (3 × 30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The residue was purified by column chromatography eluting with 0–17% EtOAc in petroleum ether to give compound <b>90</b> (1.18 g, 89%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.45 (d, <i>J</i> = 16 Hz, 1H), 7.43 (s, 1H), 7.30 (s, 1H), 6.33 (s, <i>J</i> = 16 Hz, 1H), 3.71–3.65 (m, 4H), 3.47 (t, <i>J</i> = 4.8 Hz, 2H), 2.80 (m, <i>J</i> = 4.8 Hz, 2H), 1.49 (s, 18H), 0.85 (s, 9H), 0.00 (s, 6H).</div></div><div id="sec4_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> <i>tert</i>-Butyl 3-(3-((<i>tert</i>-Butoxycarbonyl)amino)-5-(2-(2-hydroxyethoxy)ethyl)phenyl)propanoate (<b>91</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>90</b> (2.00 g, 3.83 mmol) in MeOH (20 mL) was added 10% palladium on carbon (408 mg). The mixture was hydrogenated at 50 °C under H<sub>2</sub> (50 psi) for 16 h and then cooled to 23 °C and filtered. The filtrate was concentrated under reduced pressure to afford the crude compound <b>91</b> (1.75 g, >100%) as a colorless oil. This material was used in the next step without additional purification. LCMS (5–95, AB, 1.5 min): RT = 0.78 min, <i>m</i>/<i>z</i> = 432.1 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.12 (s, 2H), 6.74 (s, 1H), 3.68–3.63 (m, 4H), 3.53–3.51 (m, 2H), 2.80 (t, <i>J</i> = 7.2 Hz, 4H), 2.50 (d, <i>J</i> = 7.2 Hz, 2H), 1.50 (s, 9H), 1.39 (s, 9H).</div></div><div id="sec4_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> <i>tert</i>-Butyl 3-(3-((<i>tert</i>-Butoxycarbonyl)amino)-5-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethyl)phenyl)propanoate (<b>92</b>)</h4><div class="NLM_p last"><i>tert</i>-BuONa (440 mg, 4.57 mmol) was added to a solution of crude compound <b>91</b> (1.56 g, 3.81 mmol) in THF (20 mL) at 0 °C. The mixture was stirred at 0 °C for 30 min; then, 3-bromoprop-1-yne (540 mg, 4.57 mmol) was added dropwise. The resulting solution was warmed to 23 °C and stirred at that temperature for 12 h. The reaction was quenched by addition of H<sub>2</sub>O (10 mL), and the mixture was extracted with EtOAc (2 × 30 mL). The combined organic layers were washed with brine (3 × 20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash column chromatography eluting with 0–30% EtOAc in petroleum ether to afford compound <b>92</b> (1.15 g, 68%) as a light-yellow oil. LCMS (10–80, AB, 7.0 min): RT = 4.26 min, <i>m</i>/<i>z</i> = 470.2 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.10 (d, <i>J</i> = 6.0 Hz, 3H), 6.74 (s, 1H), 4.14 (s, 2H), 3.64–3.59 (m, 6H), 2.82–2.76 (m, 5H), 2.51–2.48 (m, 2H), 1.49 (s, 9H), 1.38 (m, 9H).</div></div><div id="sec4_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> <i>tert</i>-Butyl (<i>S</i>)-3-(3-((<i>tert</i>-Butoxycarbonyl)amino)-5-(2-(2-((3-(4-(2,3,9-trimethyl-6-(thiazol-2-ylmethyl)-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)phenyl)propanoate (<b>93</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>82</b> (30 mg, 0.07 mmol) in MeCN (3 mL) were added Pd-Cy*Phine (4.4 mg, 0.003 mmol), Cs<sub>2</sub>CO<sub>3</sub> (67 mg, 0.20 mmol), and compound <b>92</b> (61 mg, 0.14 mmol). The mixture was heated to 105 °C in a microwave reactor and was maintained in that state for 1 h. After cooling to 23 °C, the reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub>f</sub> = 0.3) to afford compound <b>93</b> (26 mg, 45%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 1.07 min, <i>m</i>/<i>z</i> = 851.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> (<i>S</i>)-3-(3-Amino-5-(2-(2-((3-(4-(2,3,9-trimethyl-6-(thiazol-2-ylmethyl)-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)phenyl)propanoic Acid (<b>94</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>93</b> (47 mg, 0.06 mmol) in 1,2-dichloroethane (3 mL) was added TFA (0.6 mL). The mixture was stirred at 23 °C for 2 h and then concentrated to give the crude compound <b>94</b> (TFA salt, 38 mg, 99%) as a yellow oil. This material was used directly in the next step. LCMS (5–95, AB, 1.5 min): RT = 0.80 min, <i>m</i>/<i>z</i> = 695.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(3-(3-Amino-5-(2-(2-((3-(4-((<i>S</i>)-2,3,9-trimethyl-6-(thiazol-2-ylmethyl)-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)phenyl)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (<b>10</b>)</h4><div class="NLM_p last">A mixture of compound <b>94</b> (TFA salt, 21 mg, 0.03 mmol), compound <b>68</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> (14 mg, 0.03 mmol), DIEA (12 mg, 0.09 mmol), and HATU (13 mg, 0.03 mmol) in DMF (3 mL) was stirred at 23 °C for 1 h. The mixture was then concentrated under reduced pressure, and the residue was purified by prep-HPLC (MeCN 25–55/0.05% TFA in H<sub>2</sub>O) to give compound <b>10</b> (3.8 mg, 11%) as a light-yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.88 min, <i>m</i>/<i>z</i> =1107.4 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.86 (s, 1H), 7.73 (d, <i>J</i> = 3.6 Hz, 1H), 7.54 (d, <i>J</i> = 3.2 Hz, 1H), 7.46–7.39 (m, 10H), 6.52–6.46 (m, 3H), 4.65–4.52 (m, 7H), 4.40 (s, 2H), 4.38–4.33 (m, 1H), 4.27–4.22 (m, 1H), 4.18–4.15 (m, 1H), 4.13–4.09 (m, 1H), 3.92–3.87 (m, 1H), 3.77–3.75 (m, 1H), 3.73–3.71 (m, 2H), 3.69–3.64 (m, 5H), 2.78–2.75 (m, 4H), 2.71 (s, 3H), 2.55–2.51 (m, 2H), 2.46 (s, 3H), 2.43 (s, 3H), 2.27–2.16 (m, 1H), 2.09–2.07 (m, 1H), 1.64 (s, 2H), 0.94 (s, 9H).</div></div><div id="sec4_1_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl (3-(3-(((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)-5-(2-(2-((3-(4-((<i>S</i>)-2,3,9-trimethyl-6-(thiazol-2-ylmethyl)-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)phenyl)carbamate (<b>10a</b>)</h4><div class="NLM_p last">Pyridine (14 mg, 0.18 mmol), HOBt (3.2 mg, 0.02 mmol), and compound <b>53</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (17.3 mg, 0.02 mmol) were sequentially added to a 23 °C solution of compound <b>10</b> (20 mg, 0.02 mmol) in anhydrous DMF (2 mL), The reaction mixture was warmed to 50 °C and stirred at that temperature for 16 h. After cooling to 23 °C, the reaction solution was filtered, and the filtrate was directly purified by prep-HPLC (MeCN 46–56/0.225% FA in H<sub>2</sub>O) to afford compound <b>10a</b> (8.5 mg, 27%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.76 min, <i>m</i>/<i>z</i> = 852.9 [M/2 + H]<sup>+</sup>.</div></div><div id="sec4_1_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(3-(3-(6-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamido)-5-(2-(2-((3-(4-((<i>S</i>)-2,3,9-trimethyl-6-(thiazol-2-ylmethyl)-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)phenyl)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (<b>10b</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>10</b> (15 mg, 0.01 mmol) and commercially available compound <b>42</b> (6.3 mg, 0.02 mmol) in DMF (8 mL) was added DIEA (5.3 mg, 0.04 mmol). The mixture was stirred at 60 °C for 48 h, cooled to 23 °C, and directly purified by prep-HPLC (MeCN 38–68/0.225% FA in H<sub>2</sub>O) to afford compound <b>10b</b> (1.7 mg, 9.4%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.86 min, <i>m</i>/<i>z</i> = 1322.5 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> <i>tert</i>-Butyl (<i>S</i>)-3-(3-((<i>tert</i>-Butoxycarbonyl)amino)-5-(2-(2-((3-(4-(6-(2-methoxy-2-oxoethyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)phenyl)propanoate (<b>96</b>)</h4><div class="NLM_p last">To a 23 °C mixture of compound <b>95</b><a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> (45 mg, 0.11 mmol) in MeCN (4 mL) were added Pd-Cy*Phine (7.0 mg, 0.01 mmol), Cs<sub>2</sub>CO<sub>3</sub> (106 mg, 0.33 mmol), and compound <b>92</b> (97 mg, 0.22 mmol). The resulting mixture was then stirred at 100 °C in a microwave reactor for 1 h. After cooling to 23 °C, the reaction mixture was filtered and concentrated to give the crude product. This material was purified by flash chromatography on silica gel eluting with 0–100% EtOAc in petroleum ether to give compound <b>96</b> (70 mg, 74%) as a brown solid. LCMS (5–95, AB, 1.5 min): RT = 1.02 min, <i>m</i>/<i>z</i> = 848.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> (<i>S</i>)-3-(3-Amino-5-(2-(2-((3-(4-(6-(2-methoxy-2-oxoethyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)phenyl)propanoic Acid (<b>97</b>)</h4><div class="NLM_p last">TFA (1.5 mL) was added to a 0 °C solution of compound <b>96</b> (70 mg, 0.08 mmol) in DCM (4.5 mL). The resulting mixture was warmed to 23 °C and stirred at that temperature for 2 h. The reaction mixture was then concentrated under reduced pressure to give the crude compound <b>97</b> (TFA salt, 56 mg, 99%) as a brown oil. LCMS (5–95, AB, 1.5 min): RT = 0.78 min, <i>m</i>/<i>z</i> = 692.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> (<i>S</i>)-3-(3-((<i>tert</i>-Butoxycarbonyl)amino)-5-(2-(2-((3-(4-(6-(2-methoxy-2-oxoethyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-4-yl)phenyl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)phenyl)propanoic Acid (<b>98</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>97</b> (40 mg, 0.06 mmol) in DCM (5 mL) were added DIEA (23 mg, 0.18 mmol) and Boc<sub>2</sub>O (26. mg, 0.12 mmol). The mixture was stirred at 23 °C for 16 h and then concentrated in vacuo. The residue was purified by flash column chromatography eluting with 0–5% MeOH in DCM to afford compound <b>98</b> (35 mg, 62%) as a colorless oil. LCMS (5–95, AB, 1.5 min): RT = 0.91 min, <i>m</i>/<i>z</i> = 770.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> Methyl 2-((<i>S</i>)-4-(4-(3-(2-(3-((<i>tert</i>-Butoxycarbonyl)amino)-5-(3-(((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)phenethoxy)ethoxy)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetate (<b>99</b>)</h4><div class="NLM_p last">Compound <b>68</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> (29 mg, 0.07 mmol), HATU (21 mg, 0.05 mmol), and DIEA (30 mg, 0.23 mmol) were sequentially added to a solution of compound <b>98</b> (35 mg, 0.05 mmol) in DMF (5 mL) at 23 °C. The resulting mixture was stirred at 23 °C for 2 h, filtered, and then concentrated. The residue thus obtained was purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub>f</sub> = 0.4) to give compound <b>99</b> (30 mg, 48%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.93 min, <i>m</i>/<i>z</i> = 1205.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 2-((<i>S</i>)-4-(4-(3-(2-(3-((<i>tert</i>-Butoxycarbonyl)amino)-5-(3-(((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)phenethoxy)ethoxy)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetic Acid (<b>100</b>)</h4><div class="NLM_p last">LiOH·H<sub>2</sub>O (4.2 mg, 0.10 mmol) was added to a 23 °C mixture of compound <b>99</b> (30 mg, 0.03 mmol) in 3:1 THF/H<sub>2</sub>O (4 mL). The mixture was allowed to stir at 23 °C for 2 h and then diluted with water (10 mL) and acidified to pH = 5 with 2 M HCl. The mixture was filtered, and the yellow solid was collected and air-dried to give compound <b>100</b> (15 mg, 51%). This material was used directly in the next step without additional purification. LCMS (5–95, AB, 1.5 min): RT = 0.78 min, <i>m</i>/<i>z</i> =1168.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> 2-(2-((<i>S</i>)-4-(4-(3-(2-(3-((<i>tert</i>-Butoxycarbonyl)amino)-5-(3-(((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)phenethoxy)ethoxy)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethane-1-sulfonic Acid (<b>101</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>100</b> (15 mg, 0.013 mmol) in DMF (3 mL) were added 2-aminoethanesulfonic acid (3.2 mg, 0.03 mmol), DIEA (8.3 mg, 0.06 mmol), EDCI (4.9 mg, 0.03 mmol), and HOBt (3.5 mg, 0.03 mmol). The mixture was stirred at 23 °C for 18 h and then concentrated under reduced pressure to afford an oil. This material was purified by prep-HPLC (MeCN 35–65/0.1% TFA in H<sub>2</sub>O) to give compound <b>101</b> (8 mg, 47%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.74 min, <i>m</i>/<i>z</i> = 1276.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> 2-(2-((<i>S</i>)-4-(4-(3-(2-(3-Amino-5-(3-(((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)phenethoxy)ethoxy)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethane-1-sulfonic Acid (<b>11</b>)</h4><div class="NLM_p last">To a mixture of compound <b>101</b> (8.0 mg, 0.006 mmol) in DCM (5 mL) was added TFA (1.0 mL) at 0 °C. The reaction solution was warmed to 23 °C and stirred at that temperature for 2 h. The mixture was then concentrated, and the residue was purified by prep-HPLC (MeCN 19–49/0.1% TFA in H<sub>2</sub>O) to give compound <b>11</b> (6.6 mg, 80%) as a yellow solid. LCMS (5–95, AB, 1.5 min): RT = 0.69 min, <i>m</i>/<i>z</i> = 1175.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> 2-(2-((<i>S</i>)-4-(4-(3-(2-(3-((((4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl)oxy)carbonyl)amino)-5-(3-(((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)phenethoxy)ethoxy)prop-1-yn-1-yl)phenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)ethane-1-sulfonic Acid (<b>11a</b>)</h4><div class="NLM_p last">Pyridine (4.7 mg, 0.06 mmol), HOBt (1.1 mg, 0.01 mmol), and compound <b>53</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (5.7 mg, 0.008 mmol) were sequentially added to a 23 °C solution of compound <b>11</b> (7.0 mg, 0.006 mmol) in DMF (2 mL). The reaction solution was warmed to 50 °C and maintained at that temperature for 24 h. The mixture was cooled to 23 °C and concentrated in vacuo to remove the solvent. The residue thus obtained was purified by prep-HPLC (MeCN 0–40/0.1% HCl in H<sub>2</sub>O) to afford compound <b>11a</b> (2.0 mg, 19%) as a pale-yellow solid. LCMS (10–80, AB, 7.0 min): RT = 3.72 min, <i>m</i>/<i>z</i> = 886.6 [M/2 + H]<sup>+</sup>. HRMS: <i>m</i>/<i>z</i> = 1771.70 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> <i>tert</i>-Butyl 2-((6-Hydroxyhexa-2,4-diyn-1-yl)oxy)acetate (<b>103</b>)</h4><div class="NLM_p last">To a 0 °C mixture of NaH (60% in mineral oil, 238 mg, 5.94 mmol) in THF (10 mL) was added hexa-2,4-diyne-1,6-diol (<b>102</b>, 436 mg, 3.96 mmol). The reaction mixture was stirred at 0 °C for 30 min; then, a solution of <i>tert</i>-butyl 2-bromoacetate (772 mg, 3.96 mmol) in THF (5 mL) was slowly added. The resulting mixture was warmed to 23 °C and stirred at that temperature for 8 h. After being quenched with H<sub>2</sub>O (10 mL), the mixture was extracted with EtOAc (2 × 20 mL). The combined organic layers were washed with brine (2 × 10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product. This material was purified by flash column chromatography eluting with 20% EtOAc in petroleum ether to give compound <b>103</b> (320 mg, 36%) as a light-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.39 (s, 2H), 4.07 (s, 2H), 1.49 (s, 9H).</div></div><div id="sec4_1_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> <i>tert</i>-Butyl 2-((6-(1,3-Dioxoisoindolin-2-yl)hexa-2,4-diyn-1-yl)oxy)acetate (<b>104</b>)</h4><div class="NLM_p last">DIAD (890 mg, 4.4 mmol) was added to a 23 °C solution of compound <b>103</b> (822 mg, 3.67 mmol), phthalimide (701 mg, 4.77 mmol), and PPh<sub>3</sub> (1.15 g, 4.4 mmol) in THF (10 mL). The resulting mixture was stirred at 23 °C for 12 h and then concentrated in vacuo. The residue was purified by flash chromatography on silica gel eluting with 0–30% EtOAc in petroleum ether to give compound <b>104</b> (1.15 g, 89%) as a yellow oil. LCMS (5–95, AB, 1.5 min): RT = 0.78 min, <i>m</i>/<i>z</i> = 375.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.89–7.86 (m, 2H), 7.75–7.73 (m, 2H), 4.52 (s, 2H), 4.32 (s, 2H), 4.01 (s, 2H), 1.45 (s, 9H).</div></div><div id="sec4_1_102" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> <i>tert</i>-Butyl 2-((6-Aminohexa-2,4-diyn-1-yl)oxy)acetate (<b>105</b>)</h4><div class="NLM_p last">To a 23 °C solution of compound <b>104</b> (1.15 g, 3.25 mmol) in EtOH (5 mL) was added hydrazine monohydrate (196 mg, 3.91 mmol). The mixture was warmed to 80 °C and stirred at that temperature for 1 h. After cooling to 23 °C, the mixture was filtered, and the filtrate was concentrated to give the crude compound <b>104</b> (0.72 g, 99%) as a brown oil. This material was used in the next step without additional purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.99–4.90 (m, 2H), 4.35 (s, 2H), 4.04 (s, 2H), 3.47 (s, 2H), 1.50 (s, 9H).</div></div><div id="sec4_1_103" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> <i>tert</i>-Butyl (<i>S</i>)-2-((6-(2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)hexa-2,4-diyn-1-yl)oxy)acetate (<b>106</b>)</h4><div class="NLM_p last">To a 23 °C mixture of compound <b>13</b> (1.55 g, 3.87 mmol) and crude compound <b>105</b> (0.72 g, 3.22 mmol) in DMF (10 mL) were added DIEA (2.08 g, 16.1 mmol) and HATU (1.84 g, 4.84 mmol). The mixture was stirred for 2 h at 23 °C and then concentrated in vacuo. The residue was purified by chromatography on silica eluting with 0–10% MeOH in DCM to give compound <b>106</b> (1.72 g, 88%) as a yellow oil. LCMS (5–95, AB, 1.5 min): RT = 0.78 min, <i>m</i>/<i>z</i> = 628.0 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_104" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> (<i>S</i>)-2-((6-(2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)hexa-2,4-diyn-1-yl)oxy)acetic Acid (<b>107</b>)</h4><div class="NLM_p last">TFA (10 mL) was added to a solution of compound <b>106</b> (0.98 g, 1.62 mmol) in DCM (10 mL) at 23 °C. The reaction mixture was stirred at 23 °C for 2 h and then concentrated under reduced pressure to give a yellow oil. The crude compound <b>107</b> thus obtained (TFA salt, 0.88 g, 99%) was used directly in the next step. LCMS (5–95, AB, 1.5 min): RT = 0.81 min, <i>m</i>/<i>z</i> = 550.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_105" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-(2-((6-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)hexa-2,4-diyn-1-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (<b>12</b>)</h4><div class="NLM_p last">To a 23 °C solution of crude compound <b>107</b> (TFA salt, 0.88 g, 1.60 mmol) in DMF (5 mL) were added HATU (910 mg, 2.40 mmol) and DIEA (619 mg, 4.80 mmol). The mixture was stirred at 23 °C for 30 min and then compound <b>68</b><a onclick="showRef(event, 'cit56a'); return false;" href="javascript:void(0);" class="ref cit56a">(56a)</a> (1.03 g, 2.40 mmol) was added. The reaction mixture was stirred at 23 °C for 2 h and then concentrated in vacuo. The residue was purified by column chromatography on silica (solvent gradient: 0–10% MeOH in DCM) to give compound <b>12</b> (1.40 g, 87%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.84 min, <i>m</i>/<i>z</i> = 962.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.98 (s, 1H), 8.78 (t, <i>J</i> = 5.2 Hz, 1H), 8.60 (t, <i>J</i> = 6.0 Hz, 1H), 7.55 (d, <i>J</i> = 9.6 Hz, 1H), 7.49–7.40 (m, 8H), 4.57–4.35 (m, 6H), 4.27–4.21 (m, 1H), 4.11–4.01 (m, 4H), 3.68–3.59 (m, 3H), 3.31–3.19 (m, 2H), 2.59 (s, 3H), 2.52–2.51 (m, 1H), 2.44 (s, 3H), 2.40 (s, 3H), 2.08–2.03 (m, 1H), 1.92–1.86 (m, 1H), 1.61 (s, 3H), 0.93 (s, 9H).</div></div><div id="sec4_1_106" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> 2-(((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(2-((6-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)hexa-2,4-diyn-1-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)acetic Acid (<b>108</b>)</h4><div class="NLM_p last">A mixture of compound <b>12</b> (100 mg, 0.10 mmol) and NaH (60% in mineral oil, 17 mg, 0.42 mmol) in THF (5 mL) was stirred at 23 °C for 1 h. 2-Bromoacetic acid (22 mg, 0.16 mmol) was then added dropwise, and stirring was continued at 23 °C for an additional 2 h. The mixture was quenched by addition of aqueous NH<sub>4</sub>Cl (10 mL) and subsequently acidified to pH = 4 with 2 M HCl. The resulting mixture was extracted with 10% MeOH in DCM (3 × 20 mL), and the combined organic layers were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and filtered. The filtrate was concentrated to give the crude compound <b>108</b> (100 mg, 94%) as a light-yellow oil. This material was used in the next step without additional purification. LCMS (5–95, AB, 1.5 min): RT = 0.89 min, <i>m</i>/<i>z</i> = 1042.1 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_107" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> 2-(((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(2-((6-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)hexa-2,4-diyn-1-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)acetyl Azide (<b>109</b>)</h4><div class="NLM_p last">Isobutyl chloroformate (9.6 mg, 0.07 mmol) was added to a 23 °C solution of compound <b>108</b> (60 mg, 0.06 mmol) and Et<sub>3</sub>N (7.2 mg, 0.07 mmol) in acetone (3 mL). The resulting mixture was stirred at 23 °C for 10 min; then, a solution of NaN<sub>3</sub> (7.6 mg, 0.12 mmol) in H<sub>2</sub>O (1 mL) was added dropwise. The reaction mixture was stirred at 23 °C for 1 h, diluted with water (5 mL), and extracted with toluene (2 × 2 mL). The combined organic layers were sequentially dried over Na<sub>2</sub>SO<sub>4</sub> and 4 Å molecular sieves and then filtered. The filtrate thus obtained (containing compound <b>109</b>) was used directly in the next step.</div></div><div id="sec4_1_108" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> 4-((<i>S</i>)-2-(1-((5-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)pentyl)carbamoyl)cyclobutane-1-carboxamido)-5-ureidopentanamido)benzyl ((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(2-((6-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)hexa-2,4-diyn-1-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)methyl)carbamate (<b>12a</b>)</h4><div class="NLM_p last">To the toluene solution of compound <b>109</b> obtained in the previous step was added a solution of compound <b>20</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (33 mg, 0.06 mmol) in DMF (1 mL) and dibutyltin dilaurate (3.7 mg, 0.01 mmol) at 23 °C. The mixture was stirred at 60 °C for 1 h, cooled to 23 °C, and concentrated under reduced pressure. The residue was purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub>f</sub> = 0.4) followed by prep-HPLC (MeCN 28–53%/10 mM NH<sub>4</sub>HCO in H<sub>2</sub>O) to afford compound <b>12a</b> (3 mg, 3.2% over two steps) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.80 min, <i>m</i>/<i>z</i> = 794.9 [M/2 + H]<sup>+</sup>.</div></div><div id="sec4_1_109" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> <i>S</i>-((<i>R</i>)-1-(((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(2-((6-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)hexa-2,4-diyn-1-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)propan-2-yl)methanesulfonothioate (<b>12b</b>)</h4><div class="NLM_p last">Compound <b>24</b> (100 mg, 0.13 mmol) was deprotected using TFA as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> to afford the corresponding amine (TFA salt). Separately, a mixture of compound <b>107</b> (97 mg, 0.18 mmol), DIEA (52 mg, 0.40 mmol), and HATU (67 mg, 0.18 mmol) in DMF (5 mL) was stirred at 23 °C for 10 min. The TFA salt obtained from compound <b>24</b> was then added, and the resulting mixture was stirred at 23 °C for 2 h. The mixture was directly purified by prep-HPLC (MeCN 32–62/0.225% FA in H<sub>2</sub>O) to give the compound <b>12b</b> (19 mg, 12%) as a white solid. LCMS (10–80, AB, 7.0 min): RT = 4.38 min, <i>m</i>/<i>z</i> = 1158.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_110" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> <i>S</i>-(1-(((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(2-((6-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)hexa-2,4-diyn-1-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)-2-methylpropan-2-yl)methanesulfonothioate (<b>12c</b>)</h4><div class="NLM_p last">Compound <b>25</b> (45 mg, 0.06 mmol) was deprotected using TFA as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> to afford the corresponding amine (TFA salt). Separately, DIEA (39 mg, 0.30 mmol) was added to a 23 °C solution of compound <b>107</b> (38 mg, 0.07 mmol) and HATU (30 mg, 0.08 mmol) in DMF (5 mL). This mixture was stirred at 23 °C for 10 min, and then, the TFA salt obtained from compound <b>25</b> was added. The reaction mixture was stirred at 23 °C for 1 h and then was concentrated in vacuo. The residue was purified by prep-HPLC (MeCN 51–71/0.225% FA in H<sub>2</sub>O) to afford compound <b>12c</b> (21 mg, 29.7%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.89 min, <i>m</i>/<i>z</i> = 1172.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 8.76–8.73 (m, 1H), 8.63–8.60 (m, 1H), 7.61 (d, <i>J</i> = 8.8 Hz, 1H), 7.45–7.36 (m, 8H), 4.47–4.20 (m, 9H), 4.06–3.96 (m, 5H), 3.97–3.82 (m, 1H), 3.51 (s, 3H), 3.27–3.23 (m, 1H), 3.18–3.13 (m, 1H), 2.64–2.63 (m, 1H), 2.56 (s, 3H), 2.40 (s, 3H), 2.37 (s, 3H), 2.32–2.29 (m, 1H), 2.18–2.04 (m, 1H), 1.58 (s, 3H), 1.48–1.45 (m, 6H), 0.92 (s, 9H).</div></div><div id="sec4_1_111" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> <i>S</i>-(3-(((((3<i>R</i>,5<i>S</i>)-1-((<i>S</i>)-2-(2-((6-(2-((<i>S</i>)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6<i>H</i>-thieno[3,2-<i>f</i>][1,2,4]triazolo[4,3-<i>a</i>][1,4]diazepin-6-yl)acetamido)hexa-2,4-diyn-1-yl)oxy)acetamido)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)butan-2-yl)methanesulfonothioate (<b>12d</b>)</h4><div class="NLM_p last">Compound <b>26</b> (91 mg, 0.12 mmol) was deprotected using TFA as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> to afford the corresponding amine (TFA salt). Separately, HATU (34 mg, 0.09 mmol) and DIEA (32 mg, 0.25 mmol) were sequentially added to a solution of compound <b>107</b> (45 mg, 0.08 mmol) in DMF (4 mL) at 23 °C. This mixture was stirred at 23 °C for 15 min; then, the TFA salt obtained from compound <b>26</b> was added. The resulting reaction solution was stirred at 23 °C for an additional 1 h and then directly purified by prep-HPLC (MeCN 54–74/0.225% FA in H<sub>2</sub>O) to afford compound <b>12d</b> (22 mg, 23%) as a white solid. LCMS (5–95, AB, 1.5 min): RT = 0.89 min, <i>m</i>/<i>z</i> = 1172.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.98 (s, 1H), 8.78 (t, <i>J</i> = 5.2 Hz, 1H), 8.64 (brs, 1H), 7.63 (t, <i>J</i> = 8.8 Hz, 1H), 7.49–7.40 (m, 8H), 5.23 (brs, 1H), 4.97–4.94 (m, 1H), 4.52–4.38 (m, 4H), 4.28–4.23 (m, 1H), 4.16–3.98 (m, 4H), 3.86–3.82 (m, 2H), 3.76–3.71 (m, 2H), 3.55 (d, <i>J</i> = 2.0 Hz, 2H), 3.29–3.17 (m, 1H), 2.59 (s, 3H), 2.44 (s, 3H), 2.40 (s, 3H), 2.33 (brs, 1H), 2.17–2.11 (m, 1H), 1.61 (s, 3H), 1.44–1.37 (m, 3H), 1.34–1.23 (m, 3H), 0.95 (s, 9H).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i131"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01845" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23407" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23407" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01845?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01845</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">PC3-S1 cell line generation and characterization, BRD4 degradation assays (PC3-S1 line), in vitro inhibition of the MYC expression assay, PC3-S1 antiproliferation assays, BRD4 BD1 and BD2 binding assessments, whole-blood stability studies, PC3-S1 BRD4-degradation/antiproliferation relationships, VHL-binding assessments, BRD4–VHL–degrader ternary complex assessments, IAM assessments, intracellular quantitation of compound <b>8</b>, LNCaP antiproliferation assays and western blot assessments, ADC in vivo stability and PK data determination, full chemical structures of chimeric BRD4 degraders and related linker-drugs, analytical LCMS methods, synthesis of antibody–drug conjugates, ADC mechanisms of action, ADC unit conversion example (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">PDF</a>).</p></li><li><p class="inline">Molecular formula strings of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> compounds (<b>1</b>, <b>3</b>–<b>12</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of new compounds in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch11" aria-label="11">11</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf">jm0c01845_si_001.pdf (2.34 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_002.csv">jm0c01845_si_002.csv (12.9 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_003.csv">jm0c01845_si_003.csv (2.13 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01845" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08126" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08126" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter S. Dragovich</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7372-2862" title="Orcid link">http://orcid.org/0000-0001-7372-2862</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#482c3a292f273e212b2066382d3c2d3a082f2d262d662b2725"><span class="__cf_email__" data-cfemail="25415744424a534c464d0b55405140576542404b400b464a48">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas H. Pillow</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Blake</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jack D. Sadowsky</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0712-5450" title="Orcid link">http://orcid.org/0000-0002-0712-5450</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emel Adaligil</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pragya Adhikari</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sunil Bhakta</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole Blaquiere</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinhua Chen</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josefa dela Cruz-Chuh</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen E. Gascoigne</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven J. Hartman</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingtao He</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing, Co. Ltd., 6
Tai He Road, BDA, Beijing 100176, China</span></div></li><li><div class="authorItemInformation"><sup>∥</sup><span class="hlFld-ContribAuthor strong">Susan Kaufman</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tracy Kleinheinz</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine R. Kozak</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liang Liu</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing, Co. Ltd., 6
Tai He Road, BDA, Beijing 100176, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liling Liu</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qi Liu</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing, Co. Ltd., 6
Tai He Road, BDA, Beijing 100176, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying Lu</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fanwei Meng</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing, Co. Ltd., 6
Tai He Road, BDA, Beijing 100176, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melinda M. Mulvihill</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aimee O’Donohue</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rebecca K. Rowntree</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leanna R. Staben</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven T. Staben</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Wai</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Wang</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">BinQing Wei</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Catherine Wilson</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianfeng Xin</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing, Co. Ltd., 6
Tai He Road, BDA, Beijing 100176, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zijin Xu</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Yao</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donglu Zhang</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongyan Zhang</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Zhou</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyu Zhu</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><sup>∥</sup>Susan Kaufman passed away in August, 2020.<br /></br><br /></br></div></li></ul></div><div class="ack" id="ACK-d7e12477-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i133">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank members of the WuXi Biologics Conjugation Group for the preparation and characterization of the antibody–drug conjugates described in this work. The authors also thank Douglas Leipold for assistance with the preparation of Figure 16.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–drug conjugate</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extraterminal</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">BRD4</td><td class="NLM_def"><p class="first last">bromodomain-containing protein 4</p></td></tr><tr><td class="NLM_term">Cbz</td><td class="NLM_def"><p class="first last">benzyloxycarbonyl</p></td></tr><tr><td class="NLM_term">CLL1</td><td class="NLM_def"><p class="first last">C-type lectin-like molecule-1</p></td></tr><tr><td class="NLM_term">CRBN</td><td class="NLM_def"><p class="first last">cereblon</p></td></tr><tr><td class="NLM_term">DAR</td><td class="NLM_def"><p class="first last">drug–antibody ratio</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">DIBAL-H</td><td class="NLM_def"><p class="first last">diisobutylaluminium hydride</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DPPA</td><td class="NLM_def"><p class="first last">diphenylphosphoryl azide</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">EEDQ</td><td class="NLM_def"><p class="first last"><i>N</i>-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethyl alcohol</p></td></tr><tr><td class="NLM_term">FA</td><td class="NLM_def"><p class="first last">formic acid</p></td></tr><tr><td class="NLM_term">Fmoc</td><td class="NLM_def"><p class="first last">fluorenylmethoxycarbonyl</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyl uronium</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">HFIP</td><td class="NLM_def"><p class="first last">1,1,1,3,3,3-hexafluoropropan-2-ol</p></td></tr><tr><td class="NLM_term">HOAc</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">IAM</td><td class="NLM_def"><p class="first last">immobilized artificial membrane</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography-mass spectrometry</p></td></tr><tr><td class="NLM_term">LLOQ</td><td class="NLM_def"><p class="first last">lower limit of quantification</p></td></tr><tr><td class="NLM_term">mAb</td><td class="NLM_def"><p class="first last">monoclonal antibody</p></td></tr><tr><td class="NLM_term">MDM2</td><td class="NLM_def"><p class="first last">mouse double minute 2 homolog</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methyl alcohol</p></td></tr><tr><td class="NLM_term">MTBE</td><td class="NLM_def"><p class="first last">methyl <i>tert</i>-butyl ether</p></td></tr><tr><td class="NLM_term">MTS</td><td class="NLM_def"><p class="first last">methanethiosulfonate</p></td></tr><tr><td class="NLM_term">PAB</td><td class="NLM_def"><p class="first last"><i>para</i>-amino-benzyloxy</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">poly(ethylene glycol)</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimera (PROTAC is a registered trademark of Arvinas Operations, Inc.)</p></td></tr><tr><td class="NLM_term">siRNA</td><td class="NLM_def"><p class="first last">small interfering RNA</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">STEAP1</td><td class="NLM_def"><p class="first last">six transmembrane epithelial antigen of the prostate 1</p></td></tr><tr><td class="NLM_term">TBS</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TFAA</td><td class="NLM_def"><p class="first last">trifluoroacetic anhydride</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">TMSI</td><td class="NLM_def"><p class="first last">iodotrimethylsilane</p></td></tr><tr><td class="NLM_term">TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">Von Hippel–Lindau tumor suppressor</p></td></tr><tr><td class="NLM_term">XIAP</td><td class="NLM_def"><p class="first last">X-linked inhibitor of apoptosis protein</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i136">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55127" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55127" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 65 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">5501</span>– <span class="NLM_lpage">5516</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.18632%2Foncotarget.3551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=25849938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A280%3ADC%252BC2MjitVGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=5501-5516&author=L.-l.+Fuauthor=M.+Tianauthor=X.+Liauthor=J.-j.+Liauthor=J.+Huangauthor=L.+Ouyangauthor=Y.+Zhangauthor=B.+Liu&title=Inhibition+of+BET+bromodomains+as+a+therapeutic+strategy+for+cancer+drug+discovery&doi=10.18632%2Foncotarget.3551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery</span></div><div class="casAuthors">Fu Lei-lei; Tian Mao; Li Xiang; Li Jing-jing; Ouyang Liang; Zhang Yonghui; Liu Bo; Huang Jian; Zhang Yonghui</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5501-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As a conserved protein interaction module that recognizes and binds to acetylated lysine, bromodomain (BRD) contains a deep, largely hydrophobic acetyl lysine binding site.  Proteins that share the feature of containing two BRDs and an extra-terminal domain belong to BET family, including BRD2, BRD3, BRD4 and BRDT.  BET family proteins perform transcription regulatory function under normal conditions, while in cancer, they regulate transcription of several oncogenes, such as c-Myc and Bcl-2.  Thus, targeting BET proteins may be a promising strategy, and intense interest of BET proteins has fueled the development of structure-based bromodomain inhibitors in cancer.  In this review, we focus on summarizing several small-molecule BET inhibitors and their relevant anti-tumor mechanisms, which would provide a clue for exploiting new targeted BET inhibitors in the future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBHUaDfXsQehKDYG3bNImrfW6udTcc2eam2x5lcWUOG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjitVGiuw%253D%253D&md5=b3b070170e6da5585f87dffe1d568f47</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3551%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DL.-l.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.-j.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520BET%2520bromodomains%2520as%2520a%2520therapeutic%2520strategy%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D5501%26epage%3D5516%26doi%3D10.18632%2Foncotarget.3551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Targeting bromodomains: epigenetic readers of lysine acetylation</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1038/nrd4286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fnrd4286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=24751816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFalsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=337-356&author=P.+Filippakopoulosauthor=S.+Knapp&title=Targeting+bromodomains%3A+epigenetic+readers+of+lysine+acetylation&doi=10.1038%2Fnrd4286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting bromodomains: epigenetic readers of lysine acetylation</span></div><div class="casAuthors">Filippakopoulos, Panagis; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">337-356</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation levels have been linked to the development of several diseases.  Acetyl-lysine modifications create docking sites for bromodomains, which are small interaction modules found on diverse proteins, some of which have a key role in the acetylation-dependent assembly of transcriptional regulator complexes.  These complexes can then initiate transcriptional programs that result in phenotypic changes.  The recent discovery of potent and highly specific inhibitors for the BET (bromodomain and extra-terminal) family of bromodomains has stimulated intensive research activity in diverse therapeutic areas, particularly in oncol., where BET proteins regulate the expression of key oncogenes and anti-apoptotic proteins.  In addn., targeting BET bromodomains could hold potential for the treatment of inflammation and viral infection.  Here, we highlight recent progress in the development of bromodomain inhibitors, and their potential applications in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOSIcwBJKj4LVg90H21EOLACvtfcHk0lhy5Kz4oCp1tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFalsr4%253D&md5=77049c82ce6a19b4685e3b7950399a07</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1038%2Fnrd4286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4286%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DTargeting%2520bromodomains%253A%2520epigenetic%2520readers%2520of%2520lysine%2520acetylation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D337%26epage%3D356%26doi%3D10.1038%2Fnrd4286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Targeting Brd4 for cancer therapy: inhibitors and degraders</span>. <i>Med. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1039/C8MD00198G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2FC8MD00198G" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1779-1802&author=Y.+Duanauthor=Y.+Guanauthor=W.+Qinauthor=X.+Zhaiauthor=B.+Yuauthor=H.+Liu&title=Targeting+Brd4+for+cancer+therapy%3A+inhibitors+and+degraders&doi=10.1039%2FC8MD00198G"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1039%2FC8MD00198G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8MD00198G%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DW.%26aulast%3DZhai%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DTargeting%2520Brd4%2520for%2520cancer%2520therapy%253A%2520inhibitors%2520and%2520degraders%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1779%26epage%3D1802%26doi%3D10.1039%2FC8MD00198G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasier, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Drug discovery targeting bromodomain-containing protein 4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4533</span>– <span class="NLM_lpage">4558</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01761</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01761" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4533-4558&author=Z.+Liuauthor=P.+Wangauthor=H.+Chenauthor=E.+A.+Woldauthor=B.+Tianauthor=A.+R.+Brasierauthor=J.+Zhou&title=Drug+discovery+targeting+bromodomain-containing+protein+4&doi=10.1021%2Facs.jmedchem.6b01761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discovery Targeting Bromodomain-Containing Protein 4</span></div><div class="casAuthors">Liu, Zhiqing; Wang, Pingyuan; Chen, Haiying; Wold, Eric A.; Tian, Bing; Brasier, Allan R.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4533-4558</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  BRD4, the most extensively studied member of BET family, is an epigenetic regulator that localizes to DNA via binding acetylated histones and controls the expression of therapeutically important gene regulatory networks through recruiting transcription factors to form mediator complexes, phosphorylating RNA polymerase II and by its intrinsic histone acetyltransferase activity.  Disrupting the protein-protein interactions between BRD4 and acetyl-lysine has been shown to effectively block cell proliferation in cancer, cytokine prodn. in acute inflammation, etc.  To date, significant efforts have been devoted to the development of BRD4 inhibitors, and consequently, a dozen have progressed into human clin. trials.  Herein, the authors summarize the advances in drug discovery and development of BRD4 inhibitors by focusing on their chemotypes, in vitro and in vivo activity, selectivity, relevant mechanisms of action and therapeutic potential.  Opportunities and challenges to achieve selective and efficacious BRD4 inhibitors as a viable therapeutic strategy for human diseases are also highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6IAERH4iggrVg90H21EOLACvtfcHk0ljrdT6M-_kaNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yiurg%253D&md5=6d7ba5844073fac8c916b1249af402e5</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01761%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DTian%26aufirst%3DB.%26aulast%3DBrasier%26aufirst%3DA.%2BR.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DDrug%2520discovery%2520targeting%2520bromodomain-containing%2520protein%25204%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4533%26epage%3D4558%26doi%3D10.1021%2Facs.jmedchem.6b01761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Côte′, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span> <span> </span><span class="NLM_article-title">Disrupting acetyl-lysine recognition: progress in the development of bromodomain inhibitors.</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1271</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1271-1298&author=F.+A.+Romeroauthor=A.+M.+Taylorauthor=T.+D.+Crawfordauthor=V.+Tsuiauthor=A.+C%C3%B4te%E2%80%B2author=S.+Magnuson&title=Disrupting+acetyl-lysine+recognition%3A+progress+in+the+development+of+bromodomain+inhibitors.&doi=10.1021%2Facs.jmedchem.5b01514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors</span></div><div class="casAuthors">Romero, F. Anthony; Taylor, Alexander M.; Crawford, Terry D.; Tsui, Vickie; Cote, Alexandre; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1271-1298</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomains, small protein modules that recognize acetylated lysine on histones, play a significant role in the epigenome, where they function as "readers" that ultimately det. the functional outcome of the post-translational modification.  Because the initial discovery of selective BET inhibitors have helped define the role of that protein family in oncol. and inflammation, BET bromodomains have continued to garner the most attention of any other bromodomain.  More recently, non-BET bromodomain inhibitors that are potent and selective have been disclosed for ATAD2, CBP, BRD7/9, BRPF, BRPF/TRIM24, CECR2, SMARCA4, and BAZ2A/B.  Such novel inhibitors can be used to probe the physiol. function of these non-BET bromodomains and further understanding of their role in certain disease states.  Here, we provide an update to the progress in identifying selective bromodomain inhibitors and their use as biol. tools, as well as our perspective on the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgbRrKGlHaVLVg90H21EOLACvtfcHk0ljrdT6M-_kaNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO&md5=260352f61301aa88aad48c0b63e6152f</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01514%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DC%25C3%25B4te%25E2%2580%25B2%26aufirst%3DA.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DDisrupting%2520acetyl-lysine%2520recognition%253A%2520progress%2520in%2520the%2520development%2520of%2520bromodomain%2520inhibitors.%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1271%26epage%3D1298%26doi%3D10.1021%2Facs.jmedchem.5b01514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keates, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felletar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philpott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of BET bromodomains</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>468</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1038/nature09504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fnature09504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=20871596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1067-1073&author=P.+Filippakopoulosauthor=J.+Qiauthor=S.+Picaudauthor=Y.+Shenauthor=W.+B.+Smithauthor=O.+Fedorovauthor=E.+M.+Morseauthor=T.+Keatesauthor=T.+T.+Hickmanauthor=I.+Felletarauthor=M.+Philpottauthor=S.+Munroauthor=M.+R.+McKeownauthor=Y.+Wangauthor=A.+L.+Christieauthor=N.+Westauthor=M.+J.+Cameronauthor=B.+Schwartzauthor=T.+D.+Heightmanauthor=N.+La+Thangueauthor=C.+A.+Frenchauthor=O.+Wiestauthor=A.+L.+Kungauthor=S.+Knappauthor=J.+E.+Bradner&title=Selective+inhibition+of+BET+bromodomains&doi=10.1038%2Fnature09504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of BET bromodomains</span></div><div class="casAuthors">Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; Philpott, Martin; Munro, Shongah; McKeown, Michael R.; Wang, Yuchuan; Christie, Amanda L.; West, Nathan; Cameron, Michael J.; Schwartz, Brian; Heightman, Tom D.; La Thangue, Nicholas; French, Christopher; Wiest, Olaf; Kung, Andrew L.; Knapp, Stefan; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1067-1073</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetic proteins are intently pursued targets in ligand discovery.  So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'.  Potent inhibitors of histone binding modules have not yet been described.  Here the authors report a cell-permeable small mol. (I,JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains.  High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity.  Recurrent translocation of BRD4 is obsd. in a genetically-defined, incurable subtype of human squamous carcinoma.  Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models.  These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chem. scaffold for the development of chem. probes more broadly throughout the bromodomain family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ZbtmZM8m_LVg90H21EOLACvtfcHk0ljrdT6M-_kaNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D&md5=bd9cadac86124d2c6c3cd5b2a92d68c2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature09504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09504%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMorse%26aufirst%3DE.%2BM.%26aulast%3DKeates%26aufirst%3DT.%26aulast%3DHickman%26aufirst%3DT.%2BT.%26aulast%3DFelletar%26aufirst%3DI.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DLa%2BThangue%26aufirst%3DN.%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DSelective%2520inhibition%2520of%2520BET%2520bromodomains%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1067%26epage%3D1073%26doi%3D10.1038%2Fnature09504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amorim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyengar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magarotto, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broussais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herait, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahatt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokiec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieblemont, C.</span></span> <span> </span><span class="NLM_article-title">Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study</span>. <i>Lancet Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e196</span>– <span class="NLM_lpage">e204</span>, <span class="refDoi"> DOI: 10.1016/S2352-3026(16)00021-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2FS2352-3026%2816%2900021-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27063978" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=e196-e204&author=S.+Amorimauthor=A.+Stathisauthor=M.+Gleesonauthor=S.+Iyengarauthor=V.+Magarottoauthor=X.+Leleuauthor=F.+Morschhauserauthor=L.+Karlinauthor=F.+Broussaisauthor=K.+Rezaiauthor=P.+Heraitauthor=C.+Kahattauthor=F.+Lokiecauthor=G.+Sallesauthor=T.+Faconauthor=A.+Palumboauthor=D.+Cunninghamauthor=E.+Zuccaauthor=C.+Thieblemont&title=Bromodomain+inhibitor+OTX015+in+patients+with+lymphoma+or+multiple+myeloma%3A+a+dose-escalation%2C+open-label%2C+pharmacokinetic%2C+phase+1+study&doi=10.1016%2FS2352-3026%2816%2900021-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2816%2900021-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252816%252900021-1%26sid%3Dliteratum%253Aachs%26aulast%3DAmorim%26aufirst%3DS.%26aulast%3DStathis%26aufirst%3DA.%26aulast%3DGleeson%26aufirst%3DM.%26aulast%3DIyengar%26aufirst%3DS.%26aulast%3DMagarotto%26aufirst%3DV.%26aulast%3DLeleu%26aufirst%3DX.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DBroussais%26aufirst%3DF.%26aulast%3DRezai%26aufirst%3DK.%26aulast%3DHerait%26aufirst%3DP.%26aulast%3DKahatt%26aufirst%3DC.%26aulast%3DLokiec%26aufirst%3DF.%26aulast%3DSalles%26aufirst%3DG.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DCunningham%26aufirst%3DD.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DThieblemont%26aufirst%3DC.%26atitle%3DBromodomain%2520inhibitor%2520OTX015%2520in%2520patients%2520with%2520lymphoma%2520or%2520multiple%2520myeloma%253A%2520a%2520dose-escalation%252C%2520open-label%252C%2520pharmacokinetic%252C%2520phase%25201%2520study%26jtitle%3DLancet%2520Haematol.%26date%3D2016%26volume%3D3%26spage%3De196%26epage%3De204%26doi%3D10.1016%2FS2352-3026%2816%2900021-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J. T.</span></span> <span> </span><span class="NLM_article-title">Translational modeling of drug-induced myelosuppression and effect of pretreatment myelosuppression for AZD5153, a selective BRD4 inhibitor</span>. <i>CPT: Pharmacometrics Syst. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1002/psp4.12194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fpsp4.12194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28378926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Srsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=357-364&author=T.+A.+Collinsauthor=M.+M.+Hattersleyauthor=J.+W.+T.+Yatesauthor=E.+Clarkauthor=M.+Mondalauthor=J.+T.+Mettetal&title=Translational+modeling+of+drug-induced+myelosuppression+and+effect+of+pretreatment+myelosuppression+for+AZD5153%2C+a+selective+BRD4+inhibitor&doi=10.1002%2Fpsp4.12194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor</span></div><div class="casAuthors">Collins, T. A.; Hattersley, M. M.; Yates, J. W. T.; Clark, E.; Mondal, M.; Mettetal, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">CPT: Pharmacometrics & Systems Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">357-364</span>CODEN:
                <span class="NLM_cas:coden">CPSPBR</span>;
        ISSN:<span class="NLM_cas:issn">2163-8306</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">In this work, we evaluate the potential risk of thrombocytopenia in man for a BRD4 inhibitor, AZD5153, based on the platelet count decreases from a Han Wistar rat study.  The effects in rat were modeled and used to make clin. predictions for human populations with healthy baseline blood counts.  At doses >10 mg, a dose-dependent effect on circulating platelets is expected, with similar predicted changes for both q.d. and b.i.d. dose schedules.  These results suggest that at predicted efficacious doses, AZD5153 is likely to have some redns. in the clin. platelet counts, but within the normal range at projected efficacious doses.  The model was then extended to incorporate preexisting myelosuppression where bone marrow function is inhibited by acute myeloid leukemia.  Under these conditions, duration of platelet count recovery has the potential to be prolonged due to drug-induced myelosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnyVGxxPLv9LVg90H21EOLACvtfcHk0lgESzEkjleLkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Srsrg%253D&md5=2bdc4d7bfd3ee8501d28db2c738631ff</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fpsp4.12194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsp4.12194%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DT.%2BA.%26aulast%3DHattersley%26aufirst%3DM.%2BM.%26aulast%3DYates%26aufirst%3DJ.%2BW.%2BT.%26aulast%3DClark%26aufirst%3DE.%26aulast%3DMondal%26aufirst%3DM.%26aulast%3DMettetal%26aufirst%3DJ.%2BT.%26atitle%3DTranslational%2520modeling%2520of%2520drug-induced%2520myelosuppression%2520and%2520effect%2520of%2520pretreatment%2520myelosuppression%2520for%2520AZD5153%252C%2520a%2520selective%2520BRD4%2520inhibitor%26jtitle%3DCPT%253A%2520Pharmacometrics%2520Syst.%2520Pharmacol.%26date%3D2017%26volume%3D6%26spage%3D357%26epage%3D364%26doi%3D10.1002%2Fpsp4.12194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="note"><p class="first last">Improvements in BRD4 inhibitor clinical activity may be possible by selective inhibition of the BD1 or BD2 bromodomains. See:</p></div><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylott, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayhow, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messenger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michon, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolven, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span> <span> </span><span class="NLM_article-title">The optimization of a novel, weak bromo and extra terminal domain (BET) bromodomain fragment ligand to a potent and selective second bromodomain (BD2) inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9093</span>– <span class="NLM_lpage">9126</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00796</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00796" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVCmurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9093-9126&author=J.+T.+Sealauthor=S.+J.+Atkinsonauthor=H.+Aylottauthor=P.+Bamboroughauthor=C.-w.+Chungauthor=R.+C.+B.+Copleyauthor=L.+Gordonauthor=P.+Grandiauthor=J.+R.+J.+Grayauthor=L.+A.+Harrisonauthor=T.+G.+Hayhowauthor=M.+Lindonauthor=C.+Messengerauthor=A.-M.+Michonauthor=D.+Mitchellauthor=A.+Prestonauthor=R.+K.+Prinjhaauthor=I.+Riojaauthor=S.+Taylorauthor=I.+D.+Wallauthor=R.+J.+Watsonauthor=J.+M.+Woolvenauthor=E.+H.+Demont&title=The+optimization+of+a+novel%2C+weak+bromo+and+extra+terminal+domain+%28BET%29+bromodomain+fragment+ligand+to+a+potent+and+selective+second+bromodomain+%28BD2%29+inhibitor&doi=10.1021%2Facs.jmedchem.0c00796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor</span></div><div class="casAuthors">Seal, Jonathan T.; Atkinson, Stephen J.; Aylott, Helen; Bamborough, Paul; Chung, Chun-wa; Copley, Royston C. B.; Gordon, Laurie; Grandi, Paola; Gray, James R. J.; Harrison, Lee A.; Hayhow, Thomas G.; Lindon, Matthew; Messenger, Cassie; Michon, Anne-Marie; Mitchell, Darren; Preston, Alex; Prinjha, Rab K.; Rioja, Inmaculada; Taylor, Simon; Wall, Ian D.; Watson, Robert J.; Woolven, James M.; Demont, Emmanuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9093-9126</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The profound efficacy, yet assocd. toxicity of pan-BET inhibitors is well documented.  The possibility of an ameliorated safety profile driven by significantly selective (>100-fold) inhibition of a subset of the eight bromodomains is enticing, but challenging given the close homol.  Herein, we describe the X-ray crystal structure-directed optimization of a novel weak fragment ligand with a pan-second bromodomain (BD2) bias, to potent and highly BD2 selective inhibitors.  A template hopping approach, enabled by our parallel research into an orthogonal template (15, GSK046, I), was the basis for the high selectivity obsd.  This culminated in two tool mols., 20 (GSK620) and 56 (GSK549), which showed an anti-inflammatory phenotype in human whole blood, confirming their cellular target engagement.  Excellent broad selectivity, developability, and in vivo oral pharmacokinetics characterize these tools, which we hope will be of broad utility to the field of epigenetics research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS04XaSgoDyLVg90H21EOLACvtfcHk0lgESzEkjleLkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVCmurzI&md5=c562a8c9e4c38abac04149ee96e2f594</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00796%26sid%3Dliteratum%253Aachs%26aulast%3DSeal%26aufirst%3DJ.%2BT.%26aulast%3DAtkinson%26aufirst%3DS.%2BJ.%26aulast%3DAylott%26aufirst%3DH.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DHarrison%26aufirst%3DL.%2BA.%26aulast%3DHayhow%26aufirst%3DT.%2BG.%26aulast%3DLindon%26aufirst%3DM.%26aulast%3DMessenger%26aufirst%3DC.%26aulast%3DMichon%26aufirst%3DA.-M.%26aulast%3DMitchell%26aufirst%3DD.%26aulast%3DPreston%26aufirst%3DA.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWall%26aufirst%3DI.%2BD.%26aulast%3DWatson%26aufirst%3DR.%2BJ.%26aulast%3DWoolven%26aufirst%3DJ.%2BM.%26aulast%3DDemont%26aufirst%3DE.%2BH.%26atitle%3DThe%2520optimization%2520of%2520a%2520novel%252C%2520weak%2520bromo%2520and%2520extra%2520terminal%2520domain%2520%2528BET%2529%2520bromodomain%2520fragment%2520ligand%2520to%2520a%2520potent%2520and%2520selective%2520second%2520bromodomain%2520%2528BD2%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9093%26epage%3D9126%26doi%3D10.1021%2Facs.jmedchem.0c00796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craggs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michon, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rianjongdee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolven, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of a highly selective and in vivo-capable inhibitor of the second bromodomain of the bromodomain and extra terminal domain family of proteins</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9070</span>– <span class="NLM_lpage">9092</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00605</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00605" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWrsLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9070-9092&author=A.+Prestonauthor=S.+Atkinsonauthor=P.+Bamboroughauthor=C.-w.+Chungauthor=P.+D.+Craggsauthor=L.+Gordonauthor=P.+Grandiauthor=J.+R.+J.+Grayauthor=E.+J.+Jonesauthor=M.+Lindonauthor=A.-M.+Michonauthor=D.+J.+Mitchellauthor=R.+K.+Prinjhaauthor=F.+Rianjongdeeauthor=I.+Riojaauthor=J.+Sealauthor=S.+Taylorauthor=I.+Wallauthor=R.+J.+Watsonauthor=J.+Woolvenauthor=E.+H.+Demont&title=Design+and+synthesis+of+a+highly+selective+and+in+vivo-capable+inhibitor+of+the+second+bromodomain+of+the+bromodomain+and+extra+terminal+domain+family+of+proteins&doi=10.1021%2Facs.jmedchem.0c00605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins</span></div><div class="casAuthors">Preston, Alex; Atkinson, Stephen; Bamborough, Paul; Chung, Chun-wa; Craggs, Peter D.; Gordon, Laurie; Grandi, Paola; Gray, James R. J.; Jones, Emma J.; Lindon, Matthew; Michon, Anne-Marie; Mitchell, Darren J.; Prinjha, Rab K.; Rianjongdee, Francesco; Rioja, Inmaculada; Seal, Jonathan; Taylor, Simon; Wall, Ian; Watson, Robert J.; Woolven, James; Demont, Emmanuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9070-9092</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pan-bromodomain and extra terminal domain (BET) inhibitors interact equipotently with the eight bromodomains of the BET family of proteins and have shown profound efficacy in a no. of in vitro phenotypic assays and in vivo pre-clin. models in inflammation or oncol.  A no. of these inhibitors have progressed to the clinic where pharmacol.-driven adverse events have been reported.  To better understand the contribution of each domain to their efficacy and improve their safety profile, selective inhibitors are required.  This article discloses the profile of GSK046, also known as iBET-BD2(I), a highly selective inhibitor of the second bromodomains of the BET proteins that has undergone extensive pre-clin. in vitro and in vivo characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXn2qUNkpo27Vg90H21EOLACvtfcHk0lhlPCd3fK5NqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWrsLrK&md5=08f4c47868e0a5acd5d443adba06d016</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00605%26sid%3Dliteratum%253Aachs%26aulast%3DPreston%26aufirst%3DA.%26aulast%3DAtkinson%26aufirst%3DS.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DCraggs%26aufirst%3DP.%2BD.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DJones%26aufirst%3DE.%2BJ.%26aulast%3DLindon%26aufirst%3DM.%26aulast%3DMichon%26aufirst%3DA.-M.%26aulast%3DMitchell%26aufirst%3DD.%2BJ.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DRianjongdee%26aufirst%3DF.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DSeal%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWall%26aufirst%3DI.%26aulast%3DWatson%26aufirst%3DR.%2BJ.%26aulast%3DWoolven%26aufirst%3DJ.%26aulast%3DDemont%26aufirst%3DE.%2BH.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520highly%2520selective%2520and%2520in%2520vivo-capable%2520inhibitor%2520of%2520the%2520second%2520bromodomain%2520of%2520the%2520bromodomain%2520and%2520extra%2520terminal%2520domain%2520family%2520of%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9070%26epage%3D9092%26doi%3D10.1021%2Facs.jmedchem.0c00605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petretich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillipou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span> <span> </span><span class="NLM_article-title">GSK789: A selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9045</span>– <span class="NLM_lpage">9069</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00614</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00614" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWrsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9045-9069&author=R.+J.+Watsonauthor=P.+Bamboroughauthor=H.+Barnettauthor=C.-w.+Chungauthor=R.+Davisauthor=L.+Gordonauthor=P.+Grandiauthor=M.+Petretichauthor=A.+Phillipouauthor=R.+K.+Prinjhaauthor=I.+Riojaauthor=P.+Sodenauthor=T.+Wernerauthor=E.+H.+Demont&title=GSK789%3A+A+selective+inhibitor+of+the+first+bromodomains+%28BD1%29+of+the+bromo+and+extra+terminal+domain+%28BET%29+proteins&doi=10.1021%2Facs.jmedchem.0c00614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins</span></div><div class="casAuthors">Watson, Robert J.; Bamborough, Paul; Barnett, Heather; Chung, Chun-wa; Davis, Rob; Gordon, Laurie; Grandi, Paola; Petretich, Massimo; Phillipou, Alex; Prinjha, Rab K.; Rioja, Inmaculada; Soden, Peter; Werner, Thilo; Demont, Emmanuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9045-9069</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pan-bromodomain and extra terminal (BET) inhibitors interact equipotently with all eight bromodomains of the BET family of proteins.  They have shown profound efficacy in vitro and in vivo in oncol. and immunomodulatory models, and a no. of them are currently in clin. trials where significant safety signals have been reported.  It is therefore important to understand the functional contribution of each bromodomain to assess the opportunity to tease apart efficacy and toxicity.  This article discloses the in vitro and cellular activity profiles of GSK789(I), a potent, cell-permeable, and highly selective inhibitor of the first bromodomains of the BET family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozid6PMjhvvbVg90H21EOLACvtfcHk0lhlPCd3fK5NqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWrsLzJ&md5=c86b4d2c85dcfa62854debf225c8076c</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00614%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DR.%2BJ.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBarnett%26aufirst%3DH.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DPetretich%26aufirst%3DM.%26aulast%3DPhillipou%26aufirst%3DA.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DSoden%26aufirst%3DP.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DDemont%26aufirst%3DE.%2BH.%26atitle%3DGSK789%253A%2520A%2520selective%2520inhibitor%2520of%2520the%2520first%2520bromodomains%2520%2528BD1%2529%2520of%2520the%2520bromo%2520and%2520extra%2520terminal%2520domain%2520%2528BET%2529%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9045%26epage%3D9069%26doi%3D10.1021%2Facs.jmedchem.0c00614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wellaway, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craggs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karamshi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soden, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolven, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyspian′ska, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of a bromodomain and extraterminal domain (BET) inhibitor selective for the N-terminal bromodomains that retains an anti-inflammatory and antiproliferative phenotype</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9020</span>– <span class="NLM_lpage">9044</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00566</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00566" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsV2lt77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9020-9044&author=C.+R.+Wellawayauthor=P.+Bamboroughauthor=S.+G.+Bernardauthor=C.-w.+Chungauthor=P.+D.+Craggsauthor=L.+Cutlerauthor=E.+H.+Demontauthor=J.+P.+Evansauthor=L.+Gordonauthor=B.+Karamshiauthor=A.+J.+Lewisauthor=M.+J.+Lindonauthor=D.+J.+Mitchellauthor=I.+Riojaauthor=P.+E.+Sodenauthor=S.+Taylorauthor=R.+J.+Watsonauthor=R.+Willisauthor=J.+M.+Woolvenauthor=B.+S.+Wyspian%E2%80%B2skaauthor=W.+J.+Kerrauthor=R.+K.+Prinjha&title=Structure-based+design+of+a+bromodomain+and+extraterminal+domain+%28BET%29+inhibitor+selective+for+the+N-terminal+bromodomains+that+retains+an+anti-inflammatory+and+antiproliferative+phenotype&doi=10.1021%2Facs.jmedchem.0c00566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype</span></div><div class="casAuthors">Wellaway, Christopher R.; Bamborough, Paul; Bernard, Sharon G.; Chung, Chun-wa; Craggs, Peter D.; Cutler, Leanne; Demont, Emmanuel H.; Evans, John P.; Gordon, Laurie; Karamshi, Bhumika; Lewis, Antonia J.; Lindon, Matthew J.; Mitchell, Darren J.; Rioja, Inmaculada; Soden, Peter E.; Taylor, Simon; Watson, Robert J.; Willis, Rob; Woolven, James M.; Wyspianska, Beata S.; Kerr, William J.; Prinjha, Rab K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9020-9044</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bromodomain and extraterminal domain (BET) family of epigenetic regulators comprises four proteins (BRD2, BRD3, BRD4, BRDT), each contg. tandem bromodomains.  To date, small mol. inhibitors of these proteins typically bind all eight bromodomains of the family with similar affinity, resulting in a diverse range of biol. effects.  To enable further understanding of the broad phenotype characteristic of pan-BET inhibition, the development of inhibitors selective for individual, or sets of, bromodomains within the family is required.  In this regard, we report the discovery of a potent probe mol. possessing up to 150-fold selectivity for the N-terminal bromodomains (BD1s) over the C-terminal bromodomains (BD2s) of the BETs.  Guided by structural information, a specific amino acid difference between BD1 and BD2 domains was targeted for selective interaction with chem. functionality appended to the previously developed I-BET151 scaffold.  Data presented herein demonstrate that selective inhibition of BD1 domains is sufficient to drive anti-inflammatory and antiproliferative effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUREcHUhFfbVg90H21EOLACvtfcHk0lgGntvCVe7jhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsV2lt77M&md5=52b2505bb0a36f526a08bb9bad1f2c26</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00566%26sid%3Dliteratum%253Aachs%26aulast%3DWellaway%26aufirst%3DC.%2BR.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBernard%26aufirst%3DS.%2BG.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DCraggs%26aufirst%3DP.%2BD.%26aulast%3DCutler%26aufirst%3DL.%26aulast%3DDemont%26aufirst%3DE.%2BH.%26aulast%3DEvans%26aufirst%3DJ.%2BP.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DKaramshi%26aufirst%3DB.%26aulast%3DLewis%26aufirst%3DA.%2BJ.%26aulast%3DLindon%26aufirst%3DM.%2BJ.%26aulast%3DMitchell%26aufirst%3DD.%2BJ.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DSoden%26aufirst%3DP.%2BE.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DR.%2BJ.%26aulast%3DWillis%26aufirst%3DR.%26aulast%3DWoolven%26aufirst%3DJ.%2BM.%26aulast%3DWyspian%25E2%2580%25B2ska%26aufirst%3DB.%2BS.%26aulast%3DKerr%26aufirst%3DW.%2BJ.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26atitle%3DStructure-based%2520design%2520of%2520a%2520bromodomain%2520and%2520extraterminal%2520domain%2520%2528BET%2529%2520inhibitor%2520selective%2520for%2520the%2520N-terminal%2520bromodomains%2520that%2520retains%2520an%2520anti-inflammatory%2520and%2520antiproliferative%2520phenotype%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9020%26epage%3D9044%26doi%3D10.1021%2Facs.jmedchem.0c00566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidanze, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasvold, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magoc, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajaraman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K. F.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET bromodomain inhibitor with selectivity for the second bromodomain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5585</span>– <span class="NLM_lpage">5623</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00628</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00628" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVeisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5585-5623&author=G.+S.+Sheppardauthor=L.+Wangauthor=S.+D.+Fidanzeauthor=L.+A.+Hasvoldauthor=D.+Liuauthor=J.+K.+Prattauthor=C.+H.+Parkauthor=K.+L.+Longeneckerauthor=W.+Qiuauthor=M.+Torrentauthor=P.+Kovarauthor=M.+Buiauthor=E.+J.+Faivreauthor=X.+Huangauthor=X.+Linauthor=D.+Wilcoxauthor=L.+Zhangauthor=Y.+Shenauthor=D.+H.+Albertauthor=T.+J.+Magocauthor=G.+Rajaramanauthor=W.+M.+Katiauthor=K.+F.+McDaniel&title=Discovery+of+N-ethyl-4-%5B2-%284-fluoro-2%2C6-dimethyl-phenoxy%29-5-%281-hydroxy-1-methyl-ethyl%29phenyl%5D-6-methyl-7-oxo-1H-pyrrolo%5B2%2C3-c%5Dpyridine-2-carboxamide+%28ABBV-744%29%2C+a+BET+bromodomain+inhibitor+with+selectivity+for+the+second+bromodomain&doi=10.1021%2Facs.jmedchem.0c00628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain</span></div><div class="casAuthors">Sheppard, George S.; Wang, Le; Fidanze, Steven D.; Hasvold, Lisa A.; Liu, Dachun; Pratt, John K.; Park, Chang H.; Longenecker, Kenton; Qiu, Wei; Torrent, Maricel; Kovar, Peter J.; Bui, Mai; Faivre, Emily; Huang, Xiaoli; Lin, Xiaoyu; Wilcox, Denise; Zhang, Lu; Shen, Yu; Albert, Daniel H.; Magoc, Terrance J.; Rajaraman, Ganesh; Kati, Warren M.; McDaniel, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5585-5623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The BET family of proteins consists of BRD2, BRD3, BRD4, and BRDt.  Each protein contains two distinct bromodomains (BD1 and BD2).  BET family bromodomain inhibitors under clin. development for oncol. bind to each of the eight bromodomains with similar affinities.  We hypothesized that it may be possible to achieve an improved therapeutic index by selectively targeting subsets of the BET bromodomains.  Both BD1 and BD2 are highly conserved across family members (>70% identity), whereas BD1 and BD2 from the same protein exhibit a larger degree of divergence (~ 40% identity), suggesting selectivity between BD1 and BD2 of all family members would be more straightforward to achieve.  Exploiting the Asp144/His437 and Ile146/Val439 sequence differences (BRD4 BD1/BD2 numbering) allowed the identification of compd. 27 demonstrating greater than 100-fold selectivity for BRD4 BD2 over BRD4 BD1.  Further optimization to improve BD2 selectivity and oral bioavailability resulted in the clin. development compd. 46 (ABBV-744).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJtZIcWro0xLVg90H21EOLACvtfcHk0lgGntvCVe7jhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVeisrk%253D&md5=675827659c3c7b6099ccd667f4c60f95</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00628%26sid%3Dliteratum%253Aachs%26aulast%3DSheppard%26aufirst%3DG.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFidanze%26aufirst%3DS.%2BD.%26aulast%3DHasvold%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPratt%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLongenecker%26aufirst%3DK.%2BL.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DKovar%26aufirst%3DP.%26aulast%3DBui%26aufirst%3DM.%26aulast%3DFaivre%26aufirst%3DE.%2BJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWilcox%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DMagoc%26aufirst%3DT.%2BJ.%26aulast%3DRajaraman%26aufirst%3DG.%26aulast%3DKati%26aufirst%3DW.%2BM.%26aulast%3DMcDaniel%26aufirst%3DK.%2BF.%26atitle%3DDiscovery%2520of%2520N-ethyl-4-%255B2-%25284-fluoro-2%252C6-dimethyl-phenoxy%2529-5-%25281-hydroxy-1-methyl-ethyl%2529phenyl%255D-6-methyl-7-oxo-1H-pyrrolo%255B2%252C3-c%255Dpyridine-2-carboxamide%2520%2528ABBV-744%2529%252C%2520a%2520BET%2520bromodomain%2520inhibitor%2520with%2520selectivity%2520for%2520the%2520second%2520bromodomain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D5585%26epage%3D5623%26doi%3D10.1021%2Facs.jmedchem.0c00628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantena, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnik, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehgal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uziel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidanze, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasvold, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolette, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossey, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigelow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>578</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-1930-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41586-020-1930-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31969702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1Smsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=578&publication_year=2020&pages=306-310&author=E.+J.+Faivreauthor=K.+F.+McDanielauthor=D.+H.+Albertauthor=S.+R.+Mantenaauthor=J.+P.+Plotnikauthor=D.+Wilcoxauthor=L.+Zhangauthor=M.+H.+Buiauthor=G.+S.+Sheppardauthor=L.+Wangauthor=V.+Sehgalauthor=X.+Linauthor=X.+Huangauthor=X.+Luauthor=T.+Uzielauthor=P.+Hesslerauthor=L.+T.+Lamauthor=R.+J.+Bellinauthor=G.+Mehtaauthor=S.+Fidanzeauthor=J.+K.+Prattauthor=D.+Liuauthor=L.+A.+Hasvoldauthor=C.+Sunauthor=S.+C.+Panchalauthor=J.+J.+Nicoletteauthor=S.+L.+Fosseyauthor=C.+H.+Parkauthor=K.+Longeneckerauthor=L.+Bigelowauthor=M.+Torrentauthor=S.+H.+Rosenbergauthor=W.+M.+Katiauthor=Y.+Shen&title=Selective+inhibition+of+the+BD2+bromodomain+of+BET+proteins+in+prostate+cancer&doi=10.1038%2Fs41586-020-1930-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6fR"><div class="casContent"><span class="casTitleNuber">6f</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer</span></div><div class="casAuthors">Faivre, Emily J.; McDaniel, Keith F.; Albert, Daniel H.; Mantena, Srinivasa R.; Plotnik, Joshua P.; Wilcox, Denise; Zhang, Lu; Bui, Mai H.; Sheppard, George S.; Wang, Le; Sehgal, Vasudha; Lin, Xiaoyu; Huang, Xiaoli; Lu, Xin; Uziel, Tamar; Hessler, Paul; Lam, Lloyd T.; Bellin, Richard J.; Mehta, Gaurav; Fidanze, Steve; Pratt, John K.; Liu, Dachun; Hasvold, Lisa A.; Sun, Chaohong; Panchal, Sanjay C.; Nicolette, John J.; Fossey, Stacey L.; Park, Chang H.; Longenecker, Kenton; Bigelow, Lance; Torrent, Maricel; Rosenberg, Saul H.; Kati, Warren M.; Shen, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">578</span>
        (<span class="NLM_cas:issue">7794</span>),
    <span class="NLM_cas:pages">306-310</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Proteins of the bromodomain and extra-terminal (BET) domain family are epigenetic readers that bind acetylated histones through their bromodomains to regulate gene transcription.  Dual-bromodomain BET inhibitors (DbBi) that bind with similar affinities to the first (BD1) and second (BD2) bromodomains of BRD2, BRD3, BRD4 and BRDt have displayed modest clin. activity in monotherapy cancer trials.  A reduced no. of thrombocytes in the blood (thrombocytopenia) as well as symptoms of gastrointestinal toxicity are dose-limiting adverse events for some types of DbBi1-5.  Given that similar haematol. and gastrointestinal defects were obsd. after genetic silencing of Brd4 in mice6, the platelet and gastrointestinal toxicities may represent on-target activities assocd. with BET inhibition.  The two individual bromodomains in BET family proteins may have distinct functions7-9 and different cellular phenotypes after pharmacol. inhibition of one or both bromodomains have been reported10,11, suggesting that selectively targeting one of the bromodomains may result in a different efficacy and tolerability profile compared with DbBi.  Available compds. that are selective to individual domains lack sufficient potency and the pharmacokinetics properties that are required for in vivo efficacy and tolerability assessment10-13.  Here we carried out a medicinal chem. campaign that led to the discovery of ABBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties.  In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukemia and prostate cancer that expressed the full-length androgen receptor (AR).  ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514.  Analyses of RNA expression and chromatin immunopptn. followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-contg. super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075.  These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF98kER1y9pLVg90H21EOLACvtfcHk0lhTI7usBM_ZnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1Smsr0%253D&md5=800d9106c33084390fd8cbf1ac7f1766</span></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-1930-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-1930-8%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DE.%2BJ.%26aulast%3DMcDaniel%26aufirst%3DK.%2BF.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DMantena%26aufirst%3DS.%2BR.%26aulast%3DPlotnik%26aufirst%3DJ.%2BP.%26aulast%3DWilcox%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBui%26aufirst%3DM.%2BH.%26aulast%3DSheppard%26aufirst%3DG.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSehgal%26aufirst%3DV.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DUziel%26aufirst%3DT.%26aulast%3DHessler%26aufirst%3DP.%26aulast%3DLam%26aufirst%3DL.%2BT.%26aulast%3DBellin%26aufirst%3DR.%2BJ.%26aulast%3DMehta%26aufirst%3DG.%26aulast%3DFidanze%26aufirst%3DS.%26aulast%3DPratt%26aufirst%3DJ.%2BK.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DHasvold%26aufirst%3DL.%2BA.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DPanchal%26aufirst%3DS.%2BC.%26aulast%3DNicolette%26aufirst%3DJ.%2BJ.%26aulast%3DFossey%26aufirst%3DS.%2BL.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLongenecker%26aufirst%3DK.%26aulast%3DBigelow%26aufirst%3DL.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DKati%26aufirst%3DW.%2BM.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DSelective%2520inhibition%2520of%2520the%2520BD2%2520bromodomain%2520of%2520BET%2520proteins%2520in%2520prostate%2520cancer%26jtitle%3DNature%26date%3D2020%26volume%3D578%26spage%3D306%26epage%3D310%26doi%3D10.1038%2Fs41586-020-1930-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gilan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knezevic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harker, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, E. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petretich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassil, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassiliadis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burr, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, A. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellaway, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michon, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbetti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soden, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vappiani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tough, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. A.</span></span> <span> </span><span class="NLM_article-title">Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1126/science.aaz8455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1126%2Fscience.aaz8455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=32193360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslKrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=387-394&author=O.+Gilanauthor=I.+Riojaauthor=K.+Knezevicauthor=M.+J.+Bellauthor=M.+M.+Yeungauthor=N.+R.+Harkerauthor=E.+Y.+N.+Lamauthor=C.-w.+Chungauthor=P.+Bamboroughauthor=M.+Petretichauthor=M.+Urhauthor=S.+J.+Atkinsonauthor=A.+K.+Bassilauthor=E.+J.+Robertsauthor=D.+Vassiliadisauthor=M.+L.+Burrauthor=A.+G.+S.+Prestonauthor=C.+Wellawayauthor=T.+Wernerauthor=J.+R.+Grayauthor=A.-M.+Michonauthor=T.+Gobbettiauthor=V.+Kumarauthor=P.+E.+Sodenauthor=A.+Haynesauthor=J.+Vappianiauthor=D.+F.+Toughauthor=S.+Taylorauthor=S.-J.+Dawsonauthor=M.+Bantscheffauthor=M.+Lindonauthor=G.+Drewesauthor=E.+H.+Demontauthor=D.+L.+Danielsauthor=P.+Grandiauthor=R.+K.+Prinjhaauthor=M.+A.+Dawson&title=Selective+targeting+of+BD1+and+BD2+of+the+BET+proteins+in+cancer+and+immuno-inflammation&doi=10.1126%2Fscience.aaz8455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation</span></div><div class="casAuthors">Gilan, Omer; Rioja, Inmaculada; Knezevic, Kathy; Bell, Matthew J.; Yeung, Miriam M.; Harker, Nicola R.; Lam, Enid Y. N.; Chung, Chun-wa; Bamborough, Paul; Petretich, Massimo; Urh, Marjeta; Atkinson, Stephen J.; Bassil, Anna K.; Roberts, Emma J.; Vassiliadis, Dane; Burr, Marian L.; Preston, Alex G. S.; Wellaway, Christopher; Werner, Thilo; Gray, James R.; Michon, Anne-Marie; Gobbetti, Thomas; Kumar, Vinod; Soden, Peter E.; Haynes, Andrea; Vappiani, Johanna; Tough, David F.; Taylor, Simon; Dawson, Sarah-Jane; Bantscheff, Marcus; Lindon, Matthew; Drewes, Gerard; Demont, Emmanuel H.; Daniels, Danette L.; Grandi, Paola; Prinjha, Rab K.; Dawson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6489</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The two tandem bromodomains of the BET (bromodomain and extraterminal domain) proteins enable chromatin binding to facilitate transcription.  Drugs that inhibit both bromodomains equally have shown efficacy in certain malignant and inflammatory conditions.  To explore the individual functional contributions of the first (BD1) and second (BD2) bromodomains in biol. and therapy, we developed selective BD1 and BD2 inhibitors.  We found that steady-state gene expression primarily requires BD1, whereas the rapid increase of gene expression induced by inflammatory stimuli requires both BD1 and BD2 of all BET proteins.  BD1 inhibitors phenocopied the effects of pan-BET inhibitors in cancer models, whereas BD2 inhibitors were predominantly effective in models of inflammatory and autoimmune disease.  These insights into the differential requirement of BD1 and BD2 for the maintenance and induction of gene expression may guide future BET-targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr078AuJubsqbVg90H21EOLACvtfcHk0lhTI7usBM_ZnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslKrtrg%253D&md5=d78cfea091fcf5ee18735b02b2120dd7</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaz8455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaz8455%26sid%3Dliteratum%253Aachs%26aulast%3DGilan%26aufirst%3DO.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DKnezevic%26aufirst%3DK.%26aulast%3DBell%26aufirst%3DM.%2BJ.%26aulast%3DYeung%26aufirst%3DM.%2BM.%26aulast%3DHarker%26aufirst%3DN.%2BR.%26aulast%3DLam%26aufirst%3DE.%2BY.%2BN.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DPetretich%26aufirst%3DM.%26aulast%3DUrh%26aufirst%3DM.%26aulast%3DAtkinson%26aufirst%3DS.%2BJ.%26aulast%3DBassil%26aufirst%3DA.%2BK.%26aulast%3DRoberts%26aufirst%3DE.%2BJ.%26aulast%3DVassiliadis%26aufirst%3DD.%26aulast%3DBurr%26aufirst%3DM.%2BL.%26aulast%3DPreston%26aufirst%3DA.%2BG.%2BS.%26aulast%3DWellaway%26aufirst%3DC.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DJ.%2BR.%26aulast%3DMichon%26aufirst%3DA.-M.%26aulast%3DGobbetti%26aufirst%3DT.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DSoden%26aufirst%3DP.%2BE.%26aulast%3DHaynes%26aufirst%3DA.%26aulast%3DVappiani%26aufirst%3DJ.%26aulast%3DTough%26aufirst%3DD.%2BF.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DDawson%26aufirst%3DS.-J.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DLindon%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DDemont%26aufirst%3DE.%2BH.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26atitle%3DSelective%2520targeting%2520of%2520BD1%2520and%2520BD2%2520of%2520the%2520BET%2520proteins%2520in%2520cancer%2520and%2520immuno-inflammation%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D387%26epage%3D394%26doi%3D10.1126%2Fscience.aaz8455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K. G.</span></span> <span> </span><span class="NLM_article-title">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">7124</span>– <span class="NLM_lpage">7129</span>, <span class="refDoi"> DOI: 10.1073/pnas.1521738113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1073%2Fpnas.1521738113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27274052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=7124-7129&author=K.+Rainaauthor=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=D.+Gordonauthor=A.+M.+K.+Rossiauthor=J.+Wangauthor=X.+Chenauthor=H.+Dongauthor=K.+Siuauthor=J.+D.+Winklerauthor=A.+P.+Crewauthor=C.+M.+Crewsauthor=K.+G.+Coleman&title=PROTAC-induced+BET+protein+degradation+as+a+therapy+for+castration-resistant+prostate+cancer&doi=10.1073%2Fpnas.1521738113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span></div><div class="casAuthors">Raina, Kanak; Lu, Jing; Qian, Yimin; Altieri, Martha; Gordon, Deborah; Rossi, Ann Marie K.; Wang, Jing; Chen, Xin; Dong, Hanqing; Siu, Kam; Winkler, James D.; Crew, Andrew P.; Crews, Craig M.; Coleman, Kevin G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7124-7129</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Prostate cancer has the second highest incidence among cancers in men worldwide and is the second leading cause of cancer deaths of men in the United States.  Although androgen deprivation can initially lead to remission, the disease often progresses to castration-resistant prostate cancer (CRPC), which is still reliant on androgen receptor (AR) signaling and is assocd. with a poor prognosis.  Some success against CRPC has been achieved by drugs that target AR signaling, but secondary resistance invariably emerges, and new therapies are urgently needed.  Recently, inhibitors of bromodomain and extra-terminal (BET) family proteins have shown growth-inhibitory activity in preclin. models of CRPC.  Here, we demonstrate that ARV-771, a small-mol. pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technol., demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition.  Unlike BET inhibitors, ARV-771 results in suppression of both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model.  This study is, to our knowledge, the first to demonstrate efficacy with a small-mol. BET degrader in a solid-tumor malignancy and potentially represents an important therapeutic advance in the treatment of CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD7QtYgZVig7Vg90H21EOLACvtfcHk0lhC6TQUpsqlAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D&md5=34218e685ad72950f3eb85586110c43d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1521738113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1521738113%26sid%3Dliteratum%253Aachs%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DA.%2BM.%2BK.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DSiu%26aufirst%3DK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26aulast%3DColeman%26aufirst%3DK.%2BG.%26atitle%3DPROTAC-induced%2520BET%2520protein%2520degradation%2520as%2520a%2520therapy%2520for%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3D7124%26epage%3D7129%26doi%3D10.1073%2Fpnas.1521738113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Phthalimide conjugation as a strategy for in vivo target protein degradation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">1376</span>– <span class="NLM_lpage">1381</span>, <span class="refDoi"> DOI: 10.1126/science.aab1433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1126%2Fscience.aab1433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=25999370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=1376-1381&author=G.+E.+Winterauthor=D.+L.+Buckleyauthor=J.+Paulkauthor=J.+M.+Robertsauthor=A.+Souzaauthor=S.+Dhe-Paganonauthor=J.+E.+Bradner&title=Phthalimide+conjugation+as+a+strategy+for+in+vivo+target+protein+degradation&doi=10.1126%2Fscience.aab1433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Phthalimide conjugation as a strategy for in vivo target protein degradation</span></div><div class="casAuthors">Winter, Georg E.; Buckley, Dennis L.; Paulk, Joshiawa; Roberts, Justin M.; Souza, Amanda; Dhe-Paganon, Sirano; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6241</span>),
    <span class="NLM_cas:pages">1376-1381</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The development of effective pharmacol. inhibitors of multidomain scaffold proteins, notably transcription factors, is a particularly challenging problem.  In part, this is because many small-mol. antagonists disrupt the activity of only one domain in the target protein.  The authors devised a chem. strategy that promotes ligand-dependent target protein degrdn. using as an example the transcriptional coactivator BRD4, a protein crit. for cancer cell growth and survival.  The authors appended a competitive antagonist of BET bromodomains to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex.  The resultant compd., dBET1, induced highly selective cereblon-dependent BET protein degrdn. in vitro and in vivo and delayed leukemia progression in mice.  A second series of probes resulted in selective degrdn. of the cytosolic protein FKBP12.  This chem. strategy for controlling target protein stability may have implications for therapeutically targeting previously intractable proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZW4zjRjXi7Vg90H21EOLACvtfcHk0lhC6TQUpsqlAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D&md5=b0277cc95d318d926b96e7a119066e3b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.aab1433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aab1433%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DSouza%26aufirst%3DA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DPhthalimide%2520conjugation%2520as%2520a%2520strategy%2520for%2520in%2520vivo%2520target%2520protein%2520degradation%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D1376%26epage%3D1381%26doi%3D10.1126%2Fscience.aab1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohoka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuhira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ujikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teratani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span> <span> </span><span class="NLM_article-title"><i>In vivo</i> knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">4556</span>– <span class="NLM_lpage">4570</span>, <span class="refDoi"> DOI: 10.1074/jbc.M116.768853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1074%2Fjbc.M116.768853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28154167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVClur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=4556-4570&author=N.+Ohokaauthor=K.+Okuhiraauthor=M.+Itoauthor=K.+Nagaiauthor=N.+Shibataauthor=T.+Hattoriauthor=O.+Ujikawaauthor=K.+Shimokawaauthor=O.+Sanoauthor=R.+Koyamaauthor=H.+Fujitaauthor=M.+Terataniauthor=H.+Matsumotoauthor=Y.+Imaedaauthor=H.+Naraauthor=N.+Choauthor=M.+Naito&title=In+vivo+knockdown+of+pathogenic+proteins+via+specific+and+nongenetic+inhibitor+of+apoptosis+protein+%28IAP%29-dependent+protein+erasers+%28SNIPERs%29&doi=10.1074%2Fjbc.M116.768853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)</span></div><div class="casAuthors">Ohoka, Nobumichi; Okuhira, Keiichiro; Ito, Masahiro; Nagai, Katsunori; Shibata, Norihito; Hattori, Takayuki; Ujikawa, Osamu; Shimokawa, Kenichiro; Sano, Osamu; Koyama, Ryokichi; Fujita, Hisashi; Teratani, Mika; Matsumoto, Hirokazu; Imaeda, Yasuhiro; Nara, Hiroshi; Cho, Nobuo; Naito, Mikihiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4556-4570</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Many diseases, esp. cancers, result from aberrant or overexpression of pathogenic proteins.  Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes.  An alternative approach that may have utility in drug development relies on selective degrdn. of pathogenic proteins via small chimeric mols. linking an E3 ubiquitin ligase to the targeted protein for proteasomal degrdn.  To this end, the authors recently developed a protein knockdown system based on hybrid small mol. SNIPERs (Specific and Nongenetic IAP-dependent Protein Erasers) that recruit inhibitor of the apoptosis protein (IAP) ubiquitin ligases to specifically degrade targeted proteins.  Here, the authors extend the authors' previous study to show a proof of concept of the SNIPER technol. in vivo.  By incorporating a high affinity IAP ligand, the authors developed a novel SNIPER against estrogen receptor α (ERα), SNIPER(ER)-87, that has a potent protein knockdown activity.  The SNIPER(ER) reduced ERα levels in tumor xenografts and suppressed the growth of ERα-pos. breast tumors in mice.  Mechanistically, it preferentially recruits X-linked IAP (XIAP) rather than cellular IAP1, to degrade ERα via the ubiquitin-proteasome pathway.  With this IAP ligand, potent SNIPERs against other pathogenic proteins, BCR-ABL, bromodomain-contg. protein 4 (BRD4), and phosphodiesterase-4 (PDE4) could also be developed.  These results indicate that forced ubiquitylation by SNIPERs is a useful method to achieve efficient protein knockdown with potential therapeutic activities and could also be applied to study the role of ubiquitylation in many cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEzH5uNeAFabVg90H21EOLACvtfcHk0lhC6TQUpsqlAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVClur8%253D&md5=b09264d53c47c54343ed92d5a6d0eb79</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.768853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.768853%26sid%3Dliteratum%253Aachs%26aulast%3DOhoka%26aufirst%3DN.%26aulast%3DOkuhira%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DNagai%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DT.%26aulast%3DUjikawa%26aufirst%3DO.%26aulast%3DShimokawa%26aufirst%3DK.%26aulast%3DSano%26aufirst%3DO.%26aulast%3DKoyama%26aufirst%3DR.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DTeratani%26aufirst%3DM.%26aulast%3DMatsumoto%26aufirst%3DH.%26aulast%3DImaeda%26aufirst%3DY.%26aulast%3DNara%26aufirst%3DH.%26aulast%3DCho%26aufirst%3DN.%26aulast%3DNaito%26aufirst%3DM.%26atitle%3DIn%2520vivo%2520knockdown%2520of%2520pathogenic%2520proteins%2520via%2520specific%2520and%2520nongenetic%2520inhibitor%2520of%2520apoptosis%2520protein%2520%2528IAP%2529-dependent%2520protein%2520erasers%2520%2528SNIPERs%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D4556%26epage%3D4570%26doi%3D10.1074%2Fjbc.M116.768853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lartigue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">MDM2-recruiting PROTAC offers superior, synergistic anti-proliferative activity via simultaneous degradation of BRD4 and stabilization of p53</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-2918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F0008-5472.CAN-18-2918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30385614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFGnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=251-262&author=J.+Hinesauthor=S.+Lartigueauthor=H.+Dongauthor=Y.+Qianauthor=C.+M.+Crews&title=MDM2-recruiting+PROTAC+offers+superior%2C+synergistic+anti-proliferative+activity+via+simultaneous+degradation+of+BRD4+and+stabilization+of+p53&doi=10.1158%2F0008-5472.CAN-18-2918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53</span></div><div class="casAuthors">Hines, John; Lartigue, Schan; Dong, Hanqing; Qian, Yimin; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Although the no. of proteins effectively targeted for posttranslational degrdn. by PROTAC has grown steadily, the no. of E3 ligases successfully exploited to accomplish this has been limited to the few for which small-mol. ligands have been discovered.  Although the E3 ligase MDM2 is bound by the nutlin class of small-mol. ligands, there are few nutlin-based PROTAC.  Because a nutlin-based PROTAC should both knockdown its target protein and upregulate the tumor suppressor p53, we examd. the ability of such a PROTAC to decrease cancer cell viability.  A nutlin-based, BRD4-degrading PROTAC, A1874, was able to degrade its target protein by 98% with nanomolar potency.  Given the complementary ability of A1874 to stabilize p53, we discovered that the nutlin-based PROTAC was more effective in inhibiting proliferation of many cancer cell lines with wild-type p53 than was a corresponding VHL-utilizing PROTAC with similar potency and efficacy to degrade BRD4.  This is the first report of a PROTAC in which the E3 ligase ligand and targeting warhead combine to exert a synergistic antiproliferative effect.  Our study highlights the untapped potential that may be unlocked by expanding the repertoire of E3 ligases that can be recruited by PROTAC.  Significance: These findings present the first BRD4-targeting MDM2-based PROTAC that possesses potent, distinct, and synergistic biol. activities assocd. with both ends of this heterobifunctional mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4UdOVtfCjPLVg90H21EOLACvtfcHk0ljeA6bcAFFlWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFGnsr0%253D&md5=e5dbf80505bb32c232bce66b0445a1a9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-2918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-2918%26sid%3Dliteratum%253Aachs%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DLartigue%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DMDM2-recruiting%2520PROTAC%2520offers%2520superior%252C%2520synergistic%2520anti-proliferative%2520activity%2520via%2520simultaneous%2520degradation%2520of%2520BRD4%2520and%2520stabilization%2520of%2520p53%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D251%26epage%3D262%26doi%3D10.1158%2F0008-5472.CAN-18-2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erb, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roderick, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Iulio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachance, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastjerdi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelliher, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2017.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.molcel.2017.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28673542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmsbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2017&pages=5-18&author=G.+E.+Winterauthor=A.+Mayerauthor=D.+L.+Buckleyauthor=M.+A.+Erbauthor=J.+E.+Roderickauthor=S.+Vittoriauthor=J.+M.+Reyesauthor=J.+di+Iulioauthor=A.+Souzaauthor=C.+J.+Ottauthor=J.+M.+Robertsauthor=R.+Zeidauthor=T.+G.+Scottauthor=J.+Paulkauthor=K.+Lachanceauthor=C.+M.+Olsonauthor=S.+Dastjerdiauthor=S.+Bauerauthor=C.+Y.+Linauthor=N.+S.+Grayauthor=M.+A.+Kelliherauthor=L.+S.+Churchmanauthor=J.+E.+Bradner&title=BET+bromodomain+proteins+function+as+master+transcription+elongation+factors+independent+of+CDK9+recruitment&doi=10.1016%2Fj.molcel.2017.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment</span></div><div class="casAuthors">Winter, Georg E.; Mayer, Andreas; Buckley, Dennis L.; Erb, Michael A.; Roderick, Justine E.; Vittori, Sarah; Reyes, Jaime M.; di Iulio, Julia; Souza, Amanda; Ott, Christopher J.; Roberts, Justin M.; Zeid, Rhamy; Scott, Thomas G.; Paulk, Joshiawa; Lachance, Kate; Olson, Calla M.; Dastjerdi, Shiva; Bauer, Sophie; Lin, Charles Y.; Gray, Nathanael S.; Kelliher, Michelle A.; Churchman, L. Stirling; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-18.e19</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Processive elongation of RNA Polymerase II from a proximal promoter paused state is a rate-limiting event in human gene control.  A small no. of regulatory factors influence transcription elongation on a global scale.  Prior research using small-mol. BET bromodomain inhibitors, such as JQ1, linked BRD4 to context-specific elongation at a limited no. of genes assocd. with massive enhancer regions.  Here, the mechanistic characterization of an optimized chem. degrader of BET bromodomain proteins, dBET6, led to the unexpected identification of BET proteins as master regulators of global transcription elongation.  In contrast to the selective effect of bromodomain inhibition on transcription, BET degrdn. prompts a collapse of global elongation that phenocopies CDK9 inhibition.  Notably, BRD4 loss does not directly affect CDK9 localization.  These studies, performed in translational models of T cell leukemia, establish a mechanism-based rationale for the development of BET bromodomain degrdn. as cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqseJAHmXAb-rVg90H21EOLACvtfcHk0ljeA6bcAFFlWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmsbjM&md5=ac6f4e33a8f43008b70d4ede80a526be</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2017.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2017.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DMayer%26aufirst%3DA.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DErb%26aufirst%3DM.%2BA.%26aulast%3DRoderick%26aufirst%3DJ.%2BE.%26aulast%3DVittori%26aufirst%3DS.%26aulast%3DReyes%26aufirst%3DJ.%2BM.%26aulast%3Ddi%2BIulio%26aufirst%3DJ.%26aulast%3DSouza%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DZeid%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DT.%2BG.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DLachance%26aufirst%3DK.%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DDastjerdi%26aufirst%3DS.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKelliher%26aufirst%3DM.%2BA.%26aulast%3DChurchman%26aufirst%3DL.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DBET%2520bromodomain%2520proteins%2520function%2520as%2520master%2520transcription%2520elongation%2520factors%2520independent%2520of%2520CDK9%2520recruitment%26jtitle%3DMol.%2520Cell%26date%3D2017%26volume%3D67%26spage%3D5%26epage%3D18%26doi%3D10.1016%2Fj.molcel.2017.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two decades under the influence of the rule of five and the changing properties of approved oral drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&author=M.+D.+Shultz&title=Two+decades+under+the+influence+of+the+rule+of+five+and+the+changing+properties+of+approved+oral+drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0liEDBkfuTLKGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520decades%2520under%2520the%2520influence%2520of%2520the%2520rule%2520of%2520five%2520and%2520the%2520changing%2520properties%2520of%2520approved%2520oral%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlfinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D. F.</span></span> <span> </span><span class="NLM_article-title">Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2020.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.drudis.2020.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVeru7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=1793-1800&author=A.+Pikeauthor=B.+Williamsonauthor=S.+Harlfingerauthor=S.+Martinauthor=D.+F.+McGinnity&title=Optimising+proteolysis-targeting+chimeras+%28PROTACs%29+for+oral+drug+delivery%3A+a+drug+metabolism+and+pharmacokinetics+perspective&doi=10.1016%2Fj.drudis.2020.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective</span></div><div class="casAuthors">Pike, Andy; Williamson, Beth; Harlfinger, Stephanie; Martin, Scott; McGinnity, Dermot F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1793-1800</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality with the potential to open target space not accessible to conventional small mols. via a degrdn.-based mechanism; however, their bifunctional nature can result in physicochem. properties that breach commonly accepted limits for small-mol. oral drugs.  We offer a drug metab. and pharmacokinetics (DMPK) perspective on the optimization of oral PROTACs across a diverse set of projects within Oncol. R&D at AstraZeneca, highlighting some of the challenges that they have presented to our established screening cascade.  Furthermore, we challenge some of the perceptions and dogma surrounding the feasibility of oral PROTACS and demonstrate that acceptable oral PK properties for this modality can be regularly achievable despite the physicochem. property challenges they present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNes0zq6ODubVg90H21EOLACvtfcHk0liEDBkfuTLKGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVeru7zF&md5=a26048e1fe2eb5f9e134a9132593df23</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DA.%26aulast%3DWilliamson%26aufirst%3DB.%26aulast%3DHarlfinger%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26atitle%3DOptimising%2520proteolysis-targeting%2520chimeras%2520%2528PROTACs%2529%2520for%2520oral%2520drug%2520delivery%253A%2520a%2520drug%2520metabolism%2520and%2520pharmacokinetics%2520perspective%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D1793%26epage%3D1800%26doi%3D10.1016%2Fj.drudis.2020.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallan, C.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.bmcl.2019.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31047748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1555-1564&author=S.+D.+Edmondsonauthor=B.+Yangauthor=C.+Fallan&title=Proteolysis+targeting+chimeras+%28PROTACs%29+in+%E2%80%98beyond+rule-of-five%E2%80%99+chemical+space%3A+Recent+progress+and+future+challenges&doi=10.1016%2Fj.bmcl.2019.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges</span></div><div class="casAuthors">Edmondson, Scott D.; Yang, Bin; Fallan, Charlene</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1555-1564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional compds. with mol. wts. and other properties that lie outside the classic 'rule-of-five' space.  Consequently, PROTACs have unique challenges assocd. with their development as potential therapeutic agents.  This review summarizes and analyzes a representative set of recent PROTACs and highlights some of the potential future challenges facing this promising modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDcS0gIul-K7Vg90H21EOLACvtfcHk0liEDBkfuTLKGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D&md5=62a74500178bd711b1ddaa33d731b960</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DFallan%26aufirst%3DC.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520in%2520%25E2%2580%2598beyond%2520rule-of-five%25E2%2580%2599%2520chemical%2520space%253A%2520Recent%2520progress%2520and%2520future%2520challenges%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1555%26epage%3D1564%26doi%3D10.1016%2Fj.bmcl.2019.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Maple, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stacey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, R.</span></span> <span> </span><span class="NLM_article-title">Developing degraders: principles and perspectives on design and chemical space</span>. <i>Med. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1755</span>– <span class="NLM_lpage">1764</span>, <span class="refDoi"> DOI: 10.1039/C9MD00272C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2FC9MD00272C" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1755-1764&author=H.+J.+Mapleauthor=N.+Claydenauthor=A.+Baronauthor=C.+Staceyauthor=R.+Felix&title=Developing+degraders%3A+principles+and+perspectives+on+design+and+chemical+space&doi=10.1039%2FC9MD00272C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1039%2FC9MD00272C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9MD00272C%26sid%3Dliteratum%253Aachs%26aulast%3DMaple%26aufirst%3DH.%2BJ.%26aulast%3DClayden%26aufirst%3DN.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DStacey%26aufirst%3DC.%26aulast%3DFelix%26aufirst%3DR.%26atitle%3DDeveloping%2520degraders%253A%2520principles%2520and%2520perspectives%2520on%2520design%2520and%2520chemical%2520space%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D1755%26epage%3D1764%26doi%3D10.1039%2FC9MD00272C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01816</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01816" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVajsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=462-481&author=B.+Zhouauthor=J.+Huauthor=F.+Xuauthor=Z.+Chenauthor=L.+Baiauthor=E.+Fernandez-Salasauthor=M.+Linauthor=L.+Liuauthor=C.-Y.+Yangauthor=Y.+Zhaoauthor=D.+McEachernauthor=S.+Przybranowskiauthor=B.+Wenauthor=D.+Sunauthor=S.+Wang&title=Discovery+of+a+small-molecule+degrader+of+bromodomain+and+extra-terminal+%28BET%29+proteins+with+picomolar+cellular+potencies+and+capable+of+achieving+tumor+regression&doi=10.1021%2Facs.jmedchem.6b01816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression</span></div><div class="casAuthors">Zhou, Bing; Hu, Jiantao; Xu, Fuming; Chen, Zhuo; Bai, Longchuan; Fernandez-Salas, Ester; Lin, Mei; Liu, Liu; Yang, Chao-Yie; Zhao, Yujun; McEachern, Donna; Przybranowski, Sally; Wen, Bo; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-481</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bromodomain and extra-terminal (BET) family proteins, consisting of BRD2, BRD3, BRD4, and testis-specific BRDT members, are epigenetic "readers" and play a key role in the regulation of gene transcription.  BET proteins are considered to be attractive therapeutic targets for cancer and other human diseases.  Recently, heterobifunctional small-mol. BET degraders have been designed based upon the proteolysis targeting chimera (PROTAC) concept to induce BET protein degrdn.  Herein, we present our design, synthesis, and evaluation of a new class of PROTAC BET degraders.  One of the most promising compds., 23, effectively degrades BRD4 protein at concns. as low as 30 pM in the RS4;11 leukemia cell line, achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induces rapid tumor regression in vivo against RS4;11 xenograft tumors.  These data establish that compd. 23 (BETd-260/ZBC260) is a highly potent and efficacious BET degrader.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqz2Lwp52x1rVg90H21EOLACvtfcHk0lgO6ljA_K1QZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVajsb8%253D&md5=6b3a10ecd192a5812ef581dca1fdc82a</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01816%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520small-molecule%2520degrader%2520of%2520bromodomain%2520and%2520extra-terminal%2520%2528BET%2529%2520proteins%2520with%2520picomolar%2520cellular%2520potencies%2520and%2520capable%2520of%2520achieving%2520tumor%2520regression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D462%26epage%3D481%26doi%3D10.1021%2Facs.jmedchem.6b01816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziazadeh, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6685</span>– <span class="NLM_lpage">6704</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00506</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00506" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6685-6704&author=C.+Qinauthor=Y.+Huauthor=B.+Zhouauthor=E.+Fernandez-Salasauthor=C.-Y.+Yangauthor=L.+Liuauthor=D.+McEachernauthor=S.+Przybranowskiauthor=M.+Wangauthor=J.+Stuckeyauthor=J.+Meagherauthor=L.+Baiauthor=Z.+Chenauthor=M.+Linauthor=J.+Yangauthor=D.+N.+Ziazadehauthor=F.+Xuauthor=J.+Huauthor=W.+Xiangauthor=L.+Huangauthor=S.+Liauthor=B.+Wenauthor=D.+Sunauthor=S.+Wang&title=Discovery+of+QCA570+as+an+exceptionally+potent+and+efficacious+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+the+bromodomain+and+extra-terminal+%28BET%29+proteins+capable+of+inducing+complete+and+durable+tumor+regression&doi=10.1021%2Facs.jmedchem.8b00506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression</span></div><div class="casAuthors">Qin, Chong; Hu, Yang; Zhou, Bing; Fernandez-Salas, Ester; Yang, Chao-Yie; Liu, Liu; McEachern, Donna; Przybranowski, Sally; Wang, Mi; Stuckey, Jeanne; Meagher, Jennifer; Bai, Longchuan; Chen, Zhuo; Lin, Mei; Yang, Jiuling; Ziazadeh, Danya N.; Xu, Fuming; Hu, Jiantao; Xing, Weiguo; Huang, Liyue; Li, Siwei; Wen, Bo; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6685-6704</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proteins of the bromodomain and extra-terminal (BET) family are epigenetics "readers" and promising therapeutic targets for cancer and other human diseases.  We describe herein a structure-guided design of [1,4]oxazepines as a new class of BET inhibitors and our subsequent design, synthesis, and evaluation of proteolysis-targeting chimeric (PROTAC) small-mol. BET degraders.  Our efforts have led to the discovery of extremely potent BET degraders, exemplified by QCA570, which effectively induces degrdn. of BET proteins and inhibits cell growth in human acute leukemia cell lines even at low picomolar concns.  QCA570 achieves complete and durable tumor regression in leukemia xenograft models in mice at well-tolerated dose-schedules.  QCA570 is the most potent and efficacious BET degrader reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ZUIsfX3p6LVg90H21EOLACvtfcHk0lgoXictbUOo7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsLrE&md5=2a731730641372f4526543e03d9ac76f</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00506%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DMeagher%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZiazadeh%26aufirst%3DD.%2BN.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520QCA570%2520as%2520an%2520exceptionally%2520potent%2520and%2520efficacious%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520the%2520bromodomain%2520and%2520extra-terminal%2520%2528BET%2529%2520proteins%2520capable%2520of%2520inducing%2520complete%2520and%2520durable%2520tumor%2520regression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6685%26epage%3D6704%26doi%3D10.1021%2Facs.jmedchem.8b00506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Petrylak, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelzang, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfield, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span> <span> </span><span class="NLM_article-title">First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3500</span>, <span class="refDoi"> DOI: 10.1200/JCO.2020.38.15_suppl.3500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1200%2FJCO.2020.38.15_suppl.3500" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=3500&author=D.+P.+Petrylakauthor=X.+Gaoauthor=N.+J.+Vogelzangauthor=M.+H.+Garfieldauthor=I.+Taylorauthor=M.+D.+Mooreauthor=R.+A.+Peckauthor=H.+A.+Burris&title=First-in-human+phase+I+study+of+ARV-110%2C+an+androgen+receptor+%28AR%29+PROTAC+degrader+in+patients+%28pts%29+with+metastatic+castrate-resistant+prostate+cancer+%28mCRPC%29+following+enzalutamide+%28ENZ%29+and%2For+abiraterone+%28ABI%29&doi=10.1200%2FJCO.2020.38.15_suppl.3500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2020.38.15_suppl.3500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2020.38.15_suppl.3500%26sid%3Dliteratum%253Aachs%26aulast%3DPetrylak%26aufirst%3DD.%2BP.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DVogelzang%26aufirst%3DN.%2BJ.%26aulast%3DGarfield%26aufirst%3DM.%2BH.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DMoore%26aufirst%3DM.%2BD.%26aulast%3DPeck%26aufirst%3DR.%2BA.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%2520of%2520ARV-110%252C%2520an%2520androgen%2520receptor%2520%2528AR%2529%2520PROTAC%2520degrader%2520in%2520patients%2520%2528pts%2529%2520with%2520metastatic%2520castrate-resistant%2520prostate%2520cancer%2520%2528mCRPC%2529%2520following%2520enzalutamide%2520%2528ENZ%2529%2520and%252For%2520abiraterone%2520%2528ABI%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D3500%26doi%3D10.1200%2FJCO.2020.38.15_suppl.3500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">A chemical approach for global protein knockdown from mice to non-human primates</span>. <i>Cell Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">10</span> <span class="refDoi"> DOI: 10.1038/s41421-018-0079-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41421-018-0079-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30729032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A280%3ADC%252BB3cjpvFKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&author=X.+Sunauthor=J.+Wangauthor=X.+Yaoauthor=W.+Zhengauthor=Y.+Maoauthor=T.+Lanauthor=L.+Wangauthor=Y.+Sunauthor=X.+Zhangauthor=Q.+Zhaoauthor=J.+Zhaoauthor=R.-P.+Xiaoauthor=X.+Zhangauthor=G.+Jiauthor=Y.+Rao&title=A+chemical+approach+for+global+protein+knockdown+from+mice+to+non-human+primates&doi=10.1038%2Fs41421-018-0079-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">A chemical approach for global protein knockdown from mice to non-human primates</span></div><div class="casAuthors">Sun Xiuyun; Yao Xia; Lan Tianlong; Wang Liguo; Sun Yonghui; Zhao Qiuye; Rao Yu; Sun Xiuyun; Yao Xia; Lan Tianlong; Wang Liguo; Sun Yonghui; Zhao Qiuye; Rao Yu; Sun Xiuyun; Wang Jun; Mao Yang; Zhang Xinyi; Ji Guangju; Wang Jun; Mao Yang; Zhang Xinyi; Zheng Wen; Zhang Xiuqin; Zheng Wen; Zhang Xiuqin; Zhao Jianguo; Xiao Rui-Ping; Xiao Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cell discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10</span>
        ISSN:<span class="NLM_cas:issn">2056-5968</span>.
    </div><div class="casAbstract">Although conventional genetic modification approaches for protein knockdown work very successfully due to the increasing use of CRISPR/Cas9, effective techniques for achieving protein depletion in adult animals, especially in large animals such as non-human primates, are lacking.  Here, we report a chemical approach based on PROTACs technology that efficiently and quickly knocks down FKBP12 (12-kDa FK506-binding) protein globally in vivo.  Both intraperitoneal and oral administration led to rapid, robust, and reversible FKBP12 degradation in mice.  The efficiency and practicality of this method were successfully demonstrated in both large and small animals (mice, rats, Bama pigs, and rhesus monkeys).  Furthermore, we showed this approach can also be applied to effectively knockdown other target proteins such as Bruton's tyrosine kinase (BTK).  This chemical protein knockdown strategy provides a powerful research tool for gene function studies in animals, particularly in large animals, for which gene-targeted knockout strategies may remain unfeasible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOtjU0KY5kR9ts4TFFB11gfW6udTcc2eZVQq32CsMjxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjpvFKiug%253D%253D&md5=199267298a928382ed1a91a7c066eefa</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1038%2Fs41421-018-0079-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41421-018-0079-1%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DR.-P.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DG.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DA%2520chemical%2520approach%2520for%2520global%2520protein%2520knockdown%2520from%2520mice%2520to%2520non-human%2520primates%26jtitle%3DCell%2520Discovery%26date%3D2019%26volume%3D5%26doi%3D10.1038%2Fs41421-018-0079-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetsch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvaïa, N.</span></span> <span> </span><span class="NLM_article-title">Strategies and challenges for the next generation of antibody-drug conjugates</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fnrd.2016.268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28303026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=315-337&author=A.+Beckauthor=L.+Goetschauthor=C.+Dumontetauthor=N.+Corva%C3%AFa&title=Strategies+and+challenges+for+the+next+generation+of+antibody-drug+conjugates&doi=10.1038%2Fnrd.2016.268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and challenges for the next generation of antibody-drug conjugates</span></div><div class="casAuthors">Beck, Alain; Goetsch, Liliane; Dumontet, Charles; Corvaia, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-337</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncol. therapeutics.  After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clin. trials that are evaluating more than 60 further ADC candidates.  The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody.  Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs.  In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.  The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7lV63Ws8rbVg90H21EOLACvtfcHk0ljWmhNIBh9Oug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D&md5=7358b6080dd1aed1d21e98c078cd9ef1</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DCorva%25C3%25AFa%26aufirst%3DN.%26atitle%3DStrategies%2520and%2520challenges%2520for%2520the%2520next%2520generation%2520of%2520antibody-drug%2520conjugates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D315%26epage%3D337%26doi%3D10.1038%2Fnrd.2016.268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsaab, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashaw, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatiparti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, A. K.</span></span> <span> </span><span class="NLM_article-title">Advances in antibody-drug conjugates: A new era of targeted cancer therapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1547</span>– <span class="NLM_lpage">1556</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2017.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.drudis.2017.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28627385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCrsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1547-1556&author=S.+Sauauthor=H.+O.+Alsaabauthor=S.+K.+Kashawauthor=K.+Tatipartiauthor=A.+K.+Iyer&title=Advances+in+antibody-drug+conjugates%3A+A+new+era+of+targeted+cancer+therapy&doi=10.1016%2Fj.drudis.2017.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in antibody-drug conjugates: A new era of targeted cancer therapy</span></div><div class="casAuthors">Sau, Samaresh; Alsaab, Hashem O.; Kashaw, Sushil Kumar; Tatiparti, Katyayani; Iyer, Arun K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1547-1556</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs), a potent class of anticancer therapeutics, comprise a high-affinity antibody (Ab) and cytotoxic payload coupled via a suitable linker for selective tumor cell killing.  In the initial phase of their development, two ADCs, Mylotarg, and Adcetris were approved by the US Food and Drug Administration (FDA) for treating hematological cancer, but the real breakthrough came with the discovery of the breast cancer-targeting ADC, Kadcyla.  With advances in bioengineering, linker chem., and potent cytotoxic payload, ADC technol. has become a more powerful tool for targeted cancer therapy.  In addn., ADCs with improved safety using humanized Abs with a unified 'drug:antibody ratio' (DAR) have been achieved.  Concomitantly, there has been a significant increase in the no. of clin. trials with anticancer ADCs with high translation potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohgxck59tjx7Vg90H21EOLACvtfcHk0ljWmhNIBh9Oug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCrsLzK&md5=dc5204e59d81ffa946b5d4ea07caec70</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DSau%26aufirst%3DS.%26aulast%3DAlsaab%26aufirst%3DH.%2BO.%26aulast%3DKashaw%26aufirst%3DS.%2BK.%26aulast%3DTatiparti%26aufirst%3DK.%26aulast%3DIyer%26aufirst%3DA.%2BK.%26atitle%3DAdvances%2520in%2520antibody-drug%2520conjugates%253A%2520A%2520new%2520era%2520of%2520targeted%2520cancer%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D1547%26epage%3D1556%26doi%3D10.1016%2Fj.drudis.2017.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: An emerging concept in cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3796</span>– <span class="NLM_lpage">3827</span>, <span class="refDoi"> DOI: 10.1002/anie.201307628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fanie.201307628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-3827&author=R.+V.+J.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody-drug+conjugates%3A+An+emerging+concept+in+cancer+therapy&doi=10.1002%2Fanie.201307628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy</span></div><div class="casAuthors">Chari, Ravi V. J.; Miller, Michael L.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3796-3827</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.  Monoclonal antibodies against antigens on cancer cells offer an alternative tumor-selective treatment approach.  However, most monoclonal antibodies are not sufficiently potent to be therapeutically active on their own.  Antibody-drug conjugates (ADCs) use antibodies to deliver a potent cytotoxic compd. selectively to tumor cells, thus improving the therapeutic index of chemotherapeutic agents.  The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for cancer treatment has spurred tremendous research interest in this field.  This Review touches upon the early efforts in the field, and describes how the lessons learned from the first-generation ADCs have led to improvements in every aspect of this technol., i.e., the antibody, the cytotoxic compd., and the linker connecting them, leading to the current successes.  The design of ADCs currently in clin. development, and results from mechanistic studies and preclin. and clin. evaluation are discussed.  Emerging technologies that seek to further advance this exciting area of research are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4T2rhmji6DLVg90H21EOLACvtfcHk0ljWmhNIBh9Oug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D&md5=fbfb2f843f516654ea7c0eb98949604c</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307628%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody-drug%2520conjugates%253A%2520An%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D3827%26doi%3D10.1002%2Fanie.201307628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span>; <span class="NLM_string-name">Pillow, T. H.</span>; <span class="NLM_string-name">Blake, R. A.</span>; <span class="NLM_string-name">Sadowsky, J. D.</span>; <span class="NLM_string-name">Adaligil, E.</span>; <span class="NLM_string-name">Adhikari, P.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Corr, N.</span>; <span class="NLM_string-name">dela Cruz-Chuh, J.</span>; <span class="NLM_string-name">del-Rosario, G.</span>; <span class="NLM_string-name">Fullerton, A.</span>; <span class="NLM_string-name">Hartman, S. J.</span>; <span class="NLM_string-name">Jiang, F.</span>; <span class="NLM_string-name">Kaufman, S.</span>; <span class="NLM_string-name">Kleinheinz, T.</span>; <span class="NLM_string-name">Kozak, K. R.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">Lu, Y.</span>; <span class="NLM_string-name">Mulvihill, M. M.</span>; <span class="NLM_string-name">Murray, J. M.</span>; <span class="NLM_string-name">O’Donohue, A.</span>; <span class="NLM_string-name">Rowntree, R. K.</span>; <span class="NLM_string-name">Sawyer, W. S.</span>; <span class="NLM_string-name">Staben, L. R.</span>; <span class="NLM_string-name">Wai, J.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Wei, B.</span>; <span class="NLM_string-name">Wei, W.</span>; <span class="NLM_string-name">Xu, Z.</span>; <span class="NLM_string-name">Yao, H.</span>; <span class="NLM_string-name">Yu, S.-F.</span>; <span class="NLM_string-name">Zhang, D.</span>; <span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Zhang, S.</span>; <span class="NLM_string-name">Zhao, Y.</span>; <span class="NLM_string-name">Zhou, H.</span>; <span class="NLM_string-name">Zhu, X.</span></span> <span> </span><span class="NLM_article-title">Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: Improvement of in vitro antiproliferation activity and in vivo anti-tumor efficacy</span>.  <i>J. Med. Chem.</i>, subsequent paper in this issue, <span class="NLM_year">2021</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01846" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=P.+S.+Dragovich&author=T.+H.+Pillow&author=R.+A.+Blake&author=J.+D.+Sadowsky&author=E.+Adaligil&author=P.+Adhikari&author=J.+Chen&author=N.+Corr&author=J.+dela+Cruz-Chuh&author=G.+del-Rosario&author=A.+Fullerton&author=S.+J.+Hartman&author=F.+Jiang&author=S.+Kaufman&author=T.+Kleinheinz&author=K.+R.+Kozak&author=L.+Liu&author=Y.+Lu&author=M.+M.+Mulvihill&author=J.+M.+Murray&author=A.+O%E2%80%99Donohue&author=R.+K.+Rowntree&author=W.+S.+Sawyer&author=L.+R.+Staben&author=J.+Wai&author=J.+Wang&author=B.+Wei&author=W.+Wei&author=Z.+Xu&author=H.+Yao&author=S.-F.+Yu&author=D.+Zhang&author=H.+Zhang&author=S.+Zhang&author=Y.+Zhao&author=H.+Zhou&author=X.+Zhu&title=Antibody-mediated+delivery+of+chimeric+BRD4+degraders.+Part+2%3A+Improvement+of+in+vitro+antiproliferation+activity+and+in+vivo+anti-tumor+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01846%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DAntibody-mediated%2520delivery%2520of%2520chimeric%2520BRD4%2520degraders.%2520Part%25202%253A%2520Improvement%2520of%2520in%2520vitro%2520antiproliferation%2520activity%2520and%2520in%2520vivo%2520anti-tumor%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Besten, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowntree, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>, <span class="NLM_elocation-id">126907</span> <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.bmcl.2019.126907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31902710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFWgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&author=P.+S.+Dragovichauthor=P.+Adhikariauthor=R.+A.+Blakeauthor=N.+Blaquiereauthor=J.+Chenauthor=Y.-X.+Chengauthor=W.+den+Bestenauthor=J.+Hanauthor=S.+J.+Hartmanauthor=J.+Heauthor=M.+Heauthor=E.+R.+Ingallaauthor=A.+V.+Kamathauthor=T.+Kleinheinzauthor=T.+Laiauthor=D.+D.+Leipoldauthor=C.+S.+Liauthor=Q.+Liuauthor=J.+Luauthor=Y.+Luauthor=F.+Mengauthor=L.+Mengauthor=C.+Ngauthor=K.+Pengauthor=G.+L.+Phillipsauthor=T.+H.+Pillowauthor=R.+K.+Rowntreeauthor=J.+D.+Sadowskyauthor=D.+Sampathauthor=L.+Stabenauthor=S.+T.+Stabenauthor=J.+Waiauthor=K.+Wanauthor=X.+Wangauthor=B.+Weiauthor=I.+E.+Wertzauthor=J.+Xinauthor=K.+Xuauthor=H.+Yaoauthor=R.+Zangauthor=D.+Zhangauthor=H.+Zhouauthor=Y.+Zhao&title=Antibody-mediated+delivery+of+chimeric+protein+degraders+which+target+estrogen+receptor+alpha+%28ER%CE%B1%29&doi=10.1016%2Fj.bmcl.2019.126907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)</span></div><div class="casAuthors">Dragovich, Peter S.; Adhikari, Pragya; Blake, Robert A.; Blaquiere, Nicole; Chen, Jinhua; Cheng, Yun-Xing; den Besten, Willem; Han, Jinping; Hartman, Steven J.; He, Jintang; He, Mingtao; Rei Ingalla, Ellen; Kamath, Amrita V.; Kleinheinz, Tracy; Lai, Tommy; Leipold, Douglas D.; Li, Chun Sing; Liu, Qi; Lu, Jiawei; Lu, Ying; Meng, Fanwei; Meng, Lingyao; Ng, Carl; Peng, Kaishan; Lewis Phillips, Gail; Pillow, Thomas H.; Rowntree, Rebecca K.; Sadowsky, Jack D.; Sampath, Deepak; Staben, Leanna; Staben, Steven T.; Wai, John; Wan, Kunpeng; Wang, Xinxin; Wei, Bin Qing; Wertz, Ingrid E.; Xin, Jianfeng; Xu, Keyang; Yao, Hui; Zang, Richard; Zhang, Donglu; Zhou, Hao; Zhao, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">126907</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chimeric mols. which effect intracellular degrdn. of target proteins via E3 ligase-mediated ubiquitination (e.g., PROTACs) are currently of high interest in medicinal chem.  However, these entities are relatively large compds. that often possess mol. characteristics which may compromise oral bioavailability, soly., and/or in vivo pharmacokinetic properties.  Accordingly, we explored whether conjugation of chimeric degraders to monoclonal antibodies using technologies originally developed for cytotoxic payloads might provide alternate delivery options for these novel agents.  In this report we describe the construction of several degrader-antibody conjugates comprised of two distinct ERα-targeting degrader entities and three independent ADC linker modalities.  We subsequently demonstrate the antigen-dependent delivery to MCF7-neo/HER2 cells of the degrader payloads that are incorporated into these conjugates.  We also provide evidence for efficient intracellular degrader release from one of the employed linkers.  In addn., preliminary data are described which suggest that reasonably favorable in vivo stability properties are assocd. with the linkers utilized to construct the degrader conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdPWcGkXC85LVg90H21EOLACvtfcHk0ljspZBz-ZiFCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFWgtw%253D%253D&md5=5f196b194df7f4622825c4b901130f7c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126907%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DAdhikari%26aufirst%3DP.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DY.-X.%26aulast%3Dden%2BBesten%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DIngalla%26aufirst%3DE.%2BR.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLai%26aufirst%3DT.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DK.%26aulast%3DPhillips%26aufirst%3DG.%2BL.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DRowntree%26aufirst%3DR.%2BK.%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DStaben%26aufirst%3DL.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DXin%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DAntibody-mediated%2520delivery%2520of%2520chimeric%2520protein%2520degraders%2520which%2520target%2520estrogen%2520receptor%2520alpha%2520%2528ER%25CE%25B1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26doi%3D10.1016%2Fj.bmcl.2019.126907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoigne, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latifi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowntree, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span> <span> </span><span class="NLM_article-title">Antibody conjugation of a chimeric BET degrader enables in vivo activity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fcmdc.201900497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31674143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCmt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=17-25&author=T.+H.+Pillowauthor=P.+Adhikariauthor=R.+A.+Blakeauthor=J.+Chenauthor=G.+Del+Rosarioauthor=G.+Deshmukhauthor=I.+Figueroaauthor=K.+E.+Gascoigneauthor=A.+V.+Kamathauthor=S.+Kaufmanauthor=T.+Kleinheinzauthor=K.+R.+Kozakauthor=B.+Latifiauthor=D.+D.+Leipoldauthor=C.+S.+Liauthor=R.+Liauthor=M.+M.+Mulvihillauthor=A.+O%E2%80%99Donohueauthor=R.+K.+Rowntreeauthor=J.+D.+Sadowskyauthor=J.+Waiauthor=X.+Wangauthor=C.+Wuauthor=Z.+Xuauthor=H.+Yaoauthor=S.-F.+Yuauthor=D.+Zhangauthor=R.+Zangauthor=H.+Zhangauthor=H.+Zhouauthor=X.+Zhuauthor=P.+S.+Dragovich&title=Antibody+conjugation+of+a+chimeric+BET+degrader+enables+in+vivo+activity&doi=10.1002%2Fcmdc.201900497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity</span></div><div class="casAuthors">Pillow, Thomas H.; Adhikari, Pragya; Blake, Robert A.; Chen, Jinhua; Del Rosario, Geoffrey; Deshmukh, Gauri; Figueroa, Isabel; Gascoigne, Karen E.; Kamath, Amrita V.; Kaufman, Susan; Kleinheinz, Tracy; Kozak, Katherine R.; Latifi, Brandon; Leipold, Douglas D.; Sing Li, Chun; Li, Ruina; Mulvihill, Melinda M.; O'Donohue, Aimee; Rowntree, Rebecca K.; Sadowsky, Jack D.; Wai, John; Wang, Xinxin; Wu, Cong; Xu, Zijin; Yao, Hui; Yu, Shang-Fan; Zhang, Donglu; Zang, Richard; Zhang, Hongyan; Zhou, Hao; Zhu, Xiaoyu; Dragovich, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-25</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ability to selectively degrade proteins with bifunctional small mols. has the potential to fundamentally alter therapy in a variety of diseases.  However, the relatively large size of these chimeric mols. often results in challenging physico-chem. properties (e. g., low aq. soly.) and poor pharmacokinetics which may complicate their in vivo applications.  We recently discovered an exquisitely potent chimeric BET degrader (GNE-987) which exhibited picomolar cell potencies but also demonstrated low in vivo exposures.  In an effort to improve the pharmacokinetic properties of this mol., we discovered the first degrader-antibody conjugate by attaching GNE-987 to an anti-CLL1 antibody via a novel linker.  A single IV dose of the conjugate afforded sustained in vivo exposures that resulted in antigen-specific tumor regressions.  Enhancement of a chimeric protein degrader with poor in vivo properties through antibody conjugation thereby expands the utility of directed protein degrdn. as both a biol. tool and a therapeutic possibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPzNLh7QlBR7Vg90H21EOLACvtfcHk0ljspZBz-ZiFCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCmt7zP&md5=90f9e1b5ae453ae38d61a36587feb558</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900497%26sid%3Dliteratum%253Aachs%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DAdhikari%26aufirst%3DP.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DFigueroa%26aufirst%3DI.%26aulast%3DGascoigne%26aufirst%3DK.%2BE.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DLatifi%26aufirst%3DB.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMulvihill%26aufirst%3DM.%2BM.%26aulast%3DO%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DRowntree%26aufirst%3DR.%2BK.%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DAntibody%2520conjugation%2520of%2520a%2520chimeric%2520BET%2520degrader%2520enables%2520in%2520vivo%2520activity%26jtitle%3DChemMedChem%26date%3D2020%26volume%3D15%26spage%3D17%26epage%3D25%26doi%3D10.1002%2Fcmdc.201900497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maneiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shchepinova, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kounde, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chudasama, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, E. W.</span></span> <span> </span><span class="NLM_article-title">Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1306</span>– <span class="NLM_lpage">1312</span>, <span class="refDoi"> DOI: 10.1021/acschembio.0c00285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.0c00285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFehsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1306-1312&author=M.+Maneiroauthor=N.+Forteauthor=M.+M.+Shchepinovaauthor=C.+S.+Koundeauthor=V.+Chudasamaauthor=J.+R.+Bakerauthor=E.+W.+Tate&title=Antibody-PROTAC+conjugates+enable+HER2-dependent+targeted+protein+degradation+of+BRD4&doi=10.1021%2Facschembio.0c00285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4</span></div><div class="casAuthors">Maneiro, Maria; Forte, Nafsika; Shchepinova, Maria M.; Kounde, Cyrille S.; Chudasama, Vijay; Baker, James Richard; Tate, Edward W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1306-1312</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting protein degrdn. with Proteolysis-Targeting Chimeras (PROTACs) is an area of great current interest in drug discovery.  Nevertheless, although the high effectiveness of PROTACs against a wide variety of targets has been established, most degraders reported to date display limited intrinsic tissue selectivity and do not discriminate between cells of different types.  Here, we describe a strategy for selective protein degrdn. in a specific cell type.  We report the design and synthesis of a trastuzumab-PROTAC conjugate (Ab-PROTAC 3) in which E3 ligase-directed degrader activity is caged with an antibody linker which can be hydrolyzed following antibody-PROTAC internalization, releasing the active PROTAC and inducing catalytic protein degrdn.  We show that 3 selectively targets bromodomain-contg. protein 4 (BRD4) for degrdn. only in HER2 pos. breast cancer cell lines, while sparing HER2 neg. cells.  Using live cell confocal microscopy, we show internalization and lysosomal trafficking of the conjugate specifically in HER2 pos. cells, leading to the release of active PROTAC in quantities sufficient to induce potent BRD4 degrdn.  These studies demonstrate proof-of-concept for tissue-specific BRD4 degrdn., overcoming limitations of PROTAC selectivity, with significant potential for application to novel targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPwGNLaGmRbbVg90H21EOLACvtfcHk0livtceATZ3zJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFehsLo%253D&md5=544b53e54d3f0696f0b425c3f6e48e46</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facschembio.0c00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.0c00285%26sid%3Dliteratum%253Aachs%26aulast%3DManeiro%26aufirst%3DM.%26aulast%3DForte%26aufirst%3DN.%26aulast%3DShchepinova%26aufirst%3DM.%2BM.%26aulast%3DKounde%26aufirst%3DC.%2BS.%26aulast%3DChudasama%26aufirst%3DV.%26aulast%3DBaker%26aufirst%3DJ.%2BR.%26aulast%3DTate%26aufirst%3DE.%2BW.%26atitle%3DAntibody-PROTAC%2520conjugates%2520enable%2520HER2-dependent%2520targeted%2520protein%2520degradation%2520of%2520BRD4%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2020%26volume%3D15%26spage%3D1306%26epage%3D1312%26doi%3D10.1021%2Facschembio.0c00285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zengerle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">Selective small molecule induced degradation of the BET bromodomain protein BRD4</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1770</span>– <span class="NLM_lpage">1777</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00216</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00216" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1770-1777&author=M.+Zengerleauthor=K.-H.+Chanauthor=A.+Ciulli&title=Selective+small+molecule+induced+degradation+of+the+BET+bromodomain+protein+BRD4&doi=10.1021%2Facschembio.5b00216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4</span></div><div class="casAuthors">Zengerle, Michael; Chan, Kwok-Ho; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1770-1777</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Bromo- and Extra-Terminal (BET) proteins BRD2, BRD3, and BRD4 play important roles in transcriptional regulation, epigenetics, and cancer and are the targets of pan-BET selective bromodomain inhibitor JQ1.  However, the lack of intra-BET selectivity limits the scope of current inhibitors as probes for target validation and could lead to unwanted side effects or toxicity in a therapeutic setting.  We designed Proteolysis Targeted Chimeras (PROTACs) that tether JQ1 to a ligand for the E3 ubiquitin ligase VHL, aimed at triggering the intracellular destruction of BET proteins.  Compd. MZ1 potently and rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 over BRD2 and BRD3.  The activity of MZ1 is dependent on binding to VHL but is achieved at a sufficiently low concn. not to induce stabilization of HIF-1α.  Gene expression profiles of selected cancer-related genes responsive to JQ1 reveal distinct and more limited transcriptional responses induced by MZ1, consistent with selective suppression of BRD4.  Our discovery opens up new opportunities to elucidate the cellular phenotypes and therapeutic implications assocd. with selective targeting of BRD4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEmSv7p9MZOrVg90H21EOLACvtfcHk0livtceATZ3zJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOgu70%253D&md5=b7514fd274eff8e4bb6a771f5aaf9ab5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00216%26sid%3Dliteratum%253Aachs%26aulast%3DZengerle%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DK.-H.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DSelective%2520small%2520molecule%2520induced%2520degradation%2520of%2520the%2520BET%2520bromodomain%2520protein%2520BRD4%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D1770%26epage%3D1777%26doi%3D10.1021%2Facschembio.5b00216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barroca-Ferreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pais, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passarinha, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maia, C. J.</span></span> <span> </span><span class="NLM_article-title">Targeting STEAP1 protein in human cancer: current trends and future challenges</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.2174/1568009617666170427103732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.2174%2F1568009617666170427103732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28460619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs1entrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=222-230&author=J.+Barroca-Ferreiraauthor=J.+P.+Paisauthor=M.+M.+Santosauthor=A.+M.+Gon%C3%A7alvesauthor=I.+M.+Gomesauthor=I.+Sousaauthor=S.+M.+Rochaauthor=L.+A.+Passarinhaauthor=C.+J.+Maia&title=Targeting+STEAP1+protein+in+human+cancer%3A+current+trends+and+future+challenges&doi=10.2174%2F1568009617666170427103732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges</span></div><div class="casAuthors">Barroca-Ferreira, J.; Pais, J. P.; Santos, M. M.; Goncalves, A. M.; Gomes, I. M.; Sousa, I.; Rocha, S. M.; Passarinha, L. A.; Maia, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-230</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Cancer is a global health issue that impairs the life quality of patients and origins thousands of deaths annually worldwide.  Six-transmembrane epithelial antigen of the prostate (STEAP1) was identified to be overexpressed in several types of cancers, namely in prostate cancer (PCa).  Considering its secondary structure, assocd. with its location in the cell membrane, has been suggested a role in intercellular communication between tumor cells.  Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target.  Several strategies have been developed during the last few years for targeting STEAP1, including antibody-drug conjugates, monoclonal antibodies (mAbs), DNA vaccines and small noncoding RNAs (ncRNAs).  This review presents the current knowledge about STEAP1 protein expression in human tissues, its biochem. properties and targeting strategies with the purpose to evaluate its potential as therapeutic agent for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeZsWGBe2eNrVg90H21EOLACvtfcHk0liSPlJCyBdUeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs1entrs%253D&md5=005afcd1a4b08ec97f1b10bd6834bf8b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2174%2F1568009617666170427103732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009617666170427103732%26sid%3Dliteratum%253Aachs%26aulast%3DBarroca-Ferreira%26aufirst%3DJ.%26aulast%3DPais%26aufirst%3DJ.%2BP.%26aulast%3DSantos%26aufirst%3DM.%2BM.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DA.%2BM.%26aulast%3DGomes%26aufirst%3DI.%2BM.%26aulast%3DSousa%26aufirst%3DI.%26aulast%3DRocha%26aufirst%3DS.%2BM.%26aulast%3DPassarinha%26aufirst%3DL.%2BA.%26aulast%3DMaia%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520STEAP1%2520protein%2520in%2520human%2520cancer%253A%2520current%2520trends%2520and%2520future%2520challenges%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2018%26volume%3D18%26spage%3D222%26epage%3D230%26doi%3D10.2174%2F1568009617666170427103732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinianow, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderbilt, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinfeld, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwisscha van Scheltinga, A. G. T.</span></span> <span> </span><span class="NLM_article-title">ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">25103</span>– <span class="NLM_lpage">25112</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.18632%2Foncotarget.8390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27029064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A280%3ADC%252BC28fkvFGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=25103-25112&author=S.-P.+Williamsauthor=A.+Ogasawaraauthor=J.+N.+Tinianowauthor=J.+E.+Floresauthor=D.+Kanauthor=J.+Lauauthor=M.+A.+Goauthor=A.+N.+Vanderbiltauthor=H.+S.+Gillauthor=L.+Miaoauthor=J.+Goldsmithauthor=B.+Rubinfeldauthor=W.+Maoauthor=R.+Firesteinauthor=S.-F.+Yuauthor=J.+Marikauthor=A.+G.+T.+Terwisscha+van+Scheltinga&title=ImmunoPET+helps+predicting+the+efficacy+of+antibody-drug+conjugates+targeting+TENB2+and+STEAP1&doi=10.18632%2Foncotarget.8390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1</span></div><div class="casAuthors">Williams Simon-Peter; Ogasawara Annie; Tinianow Jeff N; Flores Judith E; Kan David; Lau Jeffrey; Go MaryAnn; Vanderbilt Alexander N; Gill Herman S; Miao Li; Goldsmith Joshua; Rubinfeld Bonnee; Mao Weiguang; Firestein Ron; Yu Shang-Fan; Marik Jan; Terwisscha van Scheltinga Anton G T; Terwisscha van Scheltinga Anton G T</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">25103-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The efficacy of antibody-drug conjugates (ADCs) targeted to solid tumors depends on biological processes that are hard to monitor in vivo. 89Zr-immunoPET of the ADC antibodies could help understand the performance of ADCs in the clinic by confirming the necessary penetration, binding, and internalization.  This work studied monomethyl auristatin E (MMAE) ADCs against two targets in metastatic castration-resistant prostate cancer, TENB2 and STEAP1, in four patient-derived tumor models (LuCaP35V, LuCaP70, LuCaP77, LuCaP96.1).  Three aspects of ADC biology were measured and compared: efficacy was measured in tumor growth inhibition studies; target expression was measured by immunohistochemistry and flow cytometry; and tumor antibody uptake was measured with 111In-mAbs and gamma counting or with 89Zr-immunoPET.  Within each model, the mAb with the highest tumor uptake showed the greatest potency as an ADC.  Sensitivity between models varied, with the LuCaP77 model showing weak efficacy despite high target expression and high antibody uptake.  Ex vivo analysis confirmed the in vivo results, showing a correlation between expression, uptake and ADC efficacy.  We conclude that 89Zr-immunoPET data can demonstrate which ADC candidates achieve the penetration, binding, and internalization necessary for efficacy in tumors sensitive to the toxic payload.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzcTozJEcZa4vKgEt20y1XfW6udTcc2eYDlxBBlUB7Nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fkvFGqsQ%253D%253D&md5=cddadecbc30365301ea959ba7883cbe1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8390%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DS.-P.%26aulast%3DOgasawara%26aufirst%3DA.%26aulast%3DTinianow%26aufirst%3DJ.%2BN.%26aulast%3DFlores%26aufirst%3DJ.%2BE.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DGo%26aufirst%3DM.%2BA.%26aulast%3DVanderbilt%26aufirst%3DA.%2BN.%26aulast%3DGill%26aufirst%3DH.%2BS.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DJ.%26aulast%3DRubinfeld%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DFirestein%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DMarik%26aufirst%3DJ.%26aulast%3DTerwisscha%2Bvan%2BScheltinga%26aufirst%3DA.%2BG.%2BT.%26atitle%3DImmunoPET%2520helps%2520predicting%2520the%2520efficacy%2520of%2520antibody-drug%2520conjugates%2520targeting%2520TENB2%2520and%2520STEAP1%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D25103%26epage%3D25112%26doi%3D10.18632%2Foncotarget.8390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asangani, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dommeti, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cieslik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escara-Wilke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilder-Romans, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanireddy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>510</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1038/nature13229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fnature13229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=24759320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1WmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=510&publication_year=2014&pages=278-282&author=I.+A.+Asanganiauthor=V.+L.+Dommetiauthor=X.+Wangauthor=R.+Malikauthor=M.+Cieslikauthor=R.+Yangauthor=J.+Escara-Wilkeauthor=K.+Wilder-Romansauthor=S.+Dhanireddyauthor=C.+Engelkeauthor=M.+K.+Iyerauthor=X.+Jingauthor=Y.-M.+Wuauthor=X.+Caoauthor=Z.+S.+Qinauthor=S.+Wangauthor=F.+Y.+Fengauthor=A.+M.+Chinnaiyan&title=Therapeutic+targeting+of+BET+bromodomain+proteins+in+castration-resistant+prostate+cancer&doi=10.1038%2Fnature13229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer</span></div><div class="casAuthors">Asangani, Irfan A.; Dommeti, Vijaya L.; Wang, Xiaoju; Malik, Rohit; Cieslik, Marcin; Yang, Rendong; Escara-Wilke, June; Wilder-Romans, Kari; Dhanireddy, Sudheer; Engelke, Carl; Iyer, Mathew K.; Jing, Xiaojun; Wu, Yi-Mi; Cao, Xuhong; Qin, Zhaohui S.; Wang, Shaomeng; Feng, Felix Y.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">510</span>
        (<span class="NLM_cas:issue">7504</span>),
    <span class="NLM_cas:pages">278-282</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease.  Progression to CRPC after androgen ablation therapy is predominantly driven by deregulated androgen receptor (AR) signaling.  Despite the success of recently approved therapies targeting AR signaling, such as abiraterone and second-generation anti-androgens including MDV3100 (also known as enzalutamide), durable responses are limited, presumably owing to acquired resistance.  Recently, JQ1 and I-BET762 two selective small-mol. inhibitors that target the N-terminal bromodomains of BRD4, have been shown to exhibit anti-proliferative effects in a range of malignancies.  AR-signaling-competent human CRPC cell lines are preferentially sensitive to bromodomain and extraterminal (BET) inhibition.  BRD4 phys. interacts with the N-terminal domain of AR and can be disrupted by JQ1 (refs 11, 13).  Like the direct AR antagonist MDV3100, JQ1 disrupted AR recruitment to target gene loci.  By contrast with MDV3100, JQ1 functions downstream of AR, and more potently abrogated BRD4 localization to AR target loci and AR-mediated gene transcription, including induction of the TMPRSS2-ERG gene fusion and its oncogenic activity.  In vivo, BET bromodomain inhibition was more efficacious than direct AR antagonism in CRPC xenograft mouse models.  Taken together, these studies provide a novel epigenetic approach for the concerted blockade of oncogenic drivers in advanced prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRfXutywHDWrVg90H21EOLACvtfcHk0liSPlJCyBdUeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1WmtLo%253D&md5=bef4b5faf5d23dc7d125ab1941c3ee39</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature13229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13229%26sid%3Dliteratum%253Aachs%26aulast%3DAsangani%26aufirst%3DI.%2BA.%26aulast%3DDommeti%26aufirst%3DV.%2BL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMalik%26aufirst%3DR.%26aulast%3DCieslik%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DEscara-Wilke%26aufirst%3DJ.%26aulast%3DWilder-Romans%26aufirst%3DK.%26aulast%3DDhanireddy%26aufirst%3DS.%26aulast%3DEngelke%26aufirst%3DC.%26aulast%3DIyer%26aufirst%3DM.%2BK.%26aulast%3DJing%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.-M.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DQin%26aufirst%3DZ.%2BS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DTherapeutic%2520targeting%2520of%2520BET%2520bromodomain%2520proteins%2520in%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DNature%26date%3D2014%26volume%3D510%26spage%3D278%26epage%3D282%26doi%3D10.1038%2Fnature13229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uziel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Exploitation of castration-resistant prostate cancer transcription factor dependencies by the novel BET inhibitor ABBV-075</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-16-0221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1541-7786.MCR-16-0221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27707886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Wmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=35-44&author=E.+J.+Faivreauthor=D.+Wilcoxauthor=X.+Linauthor=P.+Hesslerauthor=M.+Torrentauthor=W.+Heauthor=T.+Uzielauthor=D.+H.+Albertauthor=K.+McDanielauthor=W.+Katiauthor=Y.+Shen&title=Exploitation+of+castration-resistant+prostate+cancer+transcription+factor+dependencies+by+the+novel+BET+inhibitor+ABBV-075&doi=10.1158%2F1541-7786.MCR-16-0221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075</span></div><div class="casAuthors">Faivre, Emily J.; Wilcox, Denise; Lin, Xiaoyu; Hessler, Paul; Torrent, Maricel; He, Wei; Uziel, Tamar; Albert, Daniel H.; McDaniel, Keith; Kati, Warren; Shen, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-44</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and hematol. malignancies.  The function of BET family member BRD4 at enhancers/superenhancers has been shown to sustain signal-dependent or pathogenic gene expression programs.  Here, the hypothesis was tested that the transcription factor drivers of castration-resistant prostate cancer (CRPC) clin. progression, including the androgen receptor (AR), are critically dependent on BRD4 and thus represent a sensitive solid tumor indication for the BET inhibitor ABBV-075.  DHT-stimulated transcription of AR target genes was inhibited by ABBV-075 without significant effect on AR protein expression.  Furthermore, ABBV-075 disrupted DHT-stimulated recruitment of BET family member BRD4 to gene-regulatory regions cooccupied by AR, including the well-established PSA and TMPRSS2 enhancers.  Persistent BET inhibition disrupted the compn. and function of AR-occupied enhancers as measured by a redn. in AR and H3K27Ac ChIP signal and inhibition of enhancer RNA transcription.  ABBV-075 displayed potent antiproliferative activity in multiple models of resistance to second-generation antiandrogens and inhibited the activity of the AR splice variant AR-V7 and ligand-binding domain gain-of-function mutations, F877L and L702H.  ABBV-075 was also a potent inhibitor of MYC and the TMPRSS2-ETS fusion protein, important parallel transcription factor drivers of CRPC.  Implications: The ability of BET family inhibitor ABBV-075 to inhibit transcription activation downstream of the initiating events of transcription factors like AR and TMPRSS2:ETS fusion proteins provides a promising therapeutic option for CRPC patients who have developed resistance to second-generation antiandrogens.  Mol Cancer Res; 15(1); 35-44. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJhf86qetj1rVg90H21EOLACvtfcHk0lhjbzMEwXv40Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Wmtw%253D%253D&md5=3dbe9d0030a6f921345c150deb3de777</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-16-0221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-16-0221%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DE.%2BJ.%26aulast%3DWilcox%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DHessler%26aufirst%3DP.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DUziel%26aufirst%3DT.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DMcDaniel%26aufirst%3DK.%26aulast%3DKati%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DExploitation%2520of%2520castration-resistant%2520prostate%2520cancer%2520transcription%2520factor%2520dependencies%2520by%2520the%2520novel%2520BET%2520inhibitor%2520ABBV-075%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2017%26volume%3D15%26spage%3D35%26epage%3D44%26doi%3D10.1158%2F1541-7786.MCR-16-0221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selth, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyquist, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehm, S. M.</span></span> <span> </span><span class="NLM_article-title">Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">5880</span>– <span class="NLM_lpage">5897</span>, <span class="refDoi"> DOI: 10.1093/nar/gkv262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1093%2Fnar%2Fgkv262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=25908785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFaitr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=5880-5897&author=S.+C.+Chanauthor=L.+A.+Selthauthor=Y.+Liauthor=M.+D.+Nyquistauthor=L.+Miaoauthor=J.+E.+Bradnerauthor=G.+V.+Rajauthor=W.+D.+Tilleyauthor=S.+M.+Dehm&title=Targeting+chromatin+binding+regulation+of+constitutively+active+AR+variants+to+overcome+prostate+cancer+resistance+to+endocrine-based+therapies&doi=10.1093%2Fnar%2Fgkv262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies</span></div><div class="casAuthors">Chan, Siu Chiu; Selth, Luke A.; Li, Yingming; Nyquist, Michael D.; Miao, Lu; Bradner, James E.; Raj, Ganesh V.; Tilley, Wayne D.; Dehm, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5880-5897</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Androgen receptor (AR) variants (AR-Vs) expressed in prostate cancer (PCa) lack the AR ligand binding domain (LBD) and function as constitutively active transcription factors.  AR-V expression in patient tissues or circulating tumor cells is assocd. with resistance to AR-targeting endocrine therapies and poor outcomes.  Here, the authors investigated the mechanisms governing chromatin binding of AR-Vs with the goal of identifying therapeutic vulnerabilities.  By chromatin immunopptn. and sequencing (ChIP-seq) and complementary biochem. expts., the authors show that AR-Vs display a binding preference for the same canonical high-affinity androgen response elements (AREs) that are preferentially engaged by AR, albeit with lower affinity.  Dimerization was an abs. requirement for constitutive AR-V DNA binding and transcriptional activation.  Treatment with the bromodomain and extraterminal (BET) inhibitor JQ1 resulted in inhibition of AR-V chromatin binding and impaired AR-V driven PCa cell growth in vitro and in vivo.  Importantly, this was assocd. with a novel JQ1 action of down-regulating AR-V transcript and protein expression.  Overall, this study demonstrates that AR-Vs broadly restore AR chromatin binding events that are otherwise suppressed during endocrine therapy, and provides pre-clin. rationale for BET inhibition as a strategy for inhibiting expression and chromatin binding of AR-Vs in PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG8v6ocEnDu7Vg90H21EOLACvtfcHk0lhjbzMEwXv40Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFaitr%252FE&md5=0e9c52aba9c70d0fe242bc6bb9e738d7</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv262%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BC.%26aulast%3DSelth%26aufirst%3DL.%2BA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DNyquist%26aufirst%3DM.%2BD.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DRaj%26aufirst%3DG.%2BV.%26aulast%3DTilley%26aufirst%3DW.%2BD.%26aulast%3DDehm%26aufirst%3DS.%2BM.%26atitle%3DTargeting%2520chromatin%2520binding%2520regulation%2520of%2520constitutively%2520active%2520AR%2520variants%2520to%2520overcome%2520prostate%2520cancer%2520resistance%2520to%2520endocrine-based%2520therapies%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26spage%3D5880%26epage%3D5897%26doi%3D10.1093%2Fnar%2Fgkv262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wyce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouthamel, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vessella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbash, O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2419</span>– <span class="NLM_lpage">2429</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.18632%2Foncotarget.1572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=24293458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A280%3ADC%252BC2c3itFyjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=2419-2429&author=A.+Wyceauthor=Y.+Degenhardtauthor=Y.+Baiauthor=B.+C.+Leauthor=S.+Korenchukauthor=M.-C.+Crouthamelauthor=C.+F.+McHughauthor=R.+Vessellaauthor=C.+L.+Creasyauthor=P.+J.+Tumminoauthor=O.+Barbash&title=Inhibition+of+BET+bromodomain+proteins+as+a+therapeutic+approach+in+prostate+cancer&doi=10.18632%2Foncotarget.1572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25cR"><div class="casContent"><span class="casTitleNuber">25c</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer</span></div><div class="casAuthors">Wyce Anastasia; Degenhardt Yan; Bai Yuchen; Le BaoChau; Korenchuk Susan; Crouthame Ming-Chih; McHugh Charles F; Vessella Robert; Creasy Caretha L; Tummino Peter J; Barbash Olena</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2419-29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BET (bromodomain and extra-terminal) proteins regulate gene expression through their ability to bind to acetylated chromatin and subsequently activate RNA PolII-driven transcriptional elongation.  Small molecule BET inhibitors prevent binding of BET proteins to acetylated histones and inhibit transcriptional activation of BET target genes.  BET inhibitors attenuate cell growth and survival in several hematologic cancer models, partially through the down-regulation of the critical oncogene, MYC.  We hypothesized that BET inhibitors will regulate MYC expression in solid tumors that frequently over-express MYC.  Here we describe the effects of the highly specific BET inhibitor, I-BET762, on MYC expression in prostate cancer models.  I-BET762 potently reduced MYC expression in prostate cancer cell lines and a patient-derived tumor model with subsequent inhibition of cell growth and reduction of tumor burden in vivo.  Our data suggests that I-BET762 effects are partially driven by MYC down-regulation and underlines the critical importance of additional mechanisms of I-BET762 induced phenotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqgfwQ5wW2T75XHngOXiV_fW6udTcc2eaEwZqc5PQh97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3itFyjtQ%253D%253D&md5=ccc6fa48cc0ec2bfb8f5e3abab13979f</span></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1572%26sid%3Dliteratum%253Aachs%26aulast%3DWyce%26aufirst%3DA.%26aulast%3DDegenhardt%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DLe%26aufirst%3DB.%2BC.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DCrouthamel%26aufirst%3DM.-C.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DVessella%26aufirst%3DR.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DBarbash%26aufirst%3DO.%26atitle%3DInhibition%2520of%2520BET%2520bromodomain%2520proteins%2520as%2520a%2520therapeutic%2520approach%2520in%2520prostate%2520cancer%26jtitle%3DOncotarget%26date%3D2013%26volume%3D4%26spage%3D2419%26epage%3D2429%26doi%3D10.18632%2Foncotarget.1572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span>The
PC3 cell line was
more amenable to conducting routine, high-throughput BRD4 degradation
assessments via immunofluorescence relative to other prostate cancer
lines that were evaluated. See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for experimental details regarding the construction
and characterization of the PC3-S1 cell line.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The%0APC3+cell+line+was%0Amore+amenable+to+conducting+routine%2C+high-throughput+BRD4+degradation%0Aassessments+via+immunofluorescence+relative+to+other+prostate+cancer%0Alines+that+were+evaluated.+See+the+Supporting+Information+for+experimental+details+regarding+the+construction%0Aand+characterization+of+the+PC3-S1+cell+line."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nalawansha, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">PROTACs: An emerging therapeutic modality in precision medicine</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2020.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.chembiol.2020.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=32795419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Wrs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=998-1014&author=D.+A.+Nalawanshaauthor=C.+M.+Crews&title=PROTACs%3A+An+emerging+therapeutic+modality+in+precision+medicine&doi=10.1016%2Fj.chembiol.2020.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs: An Emerging Therapeutic Modality in Precision Medicine</span></div><div class="casAuthors">Nalawansha, Dhanusha A.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">998-1014</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.,.  Targeted protein degrdn. (TPD) has emerged as an exciting new era in chem. biol. and drug discovery.  PROteolysis TArgeting Chimera (PROTAC) technol. targets cellular proteins for degrdn. by co-opting the ubiquitin-proteasome system.  Over the last 5 years, numerous studies have expanded our understanding of the unique mode of action and advantages of PROTACs, which has in turn spurred interest in both academia and industry to explore PROTACs as a novel therapeutic strategy.  In this review, we first highlight the key advantages of PROTACs and then discuss the spatiotemporal regulation of protein degrdn.  Next, we explore current chem. tractable E3 ligases focusing on expanding the existing repertoire with novel E3 ligases to uncover the full potential of TPD.  Collectively, these studies are guiding the development of the PROTAC technol. as it emerges as a new modality in precision medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4GkJzvvYnp7Vg90H21EOLACvtfcHk0ljSDvwHmBHjIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Wrs7vM&md5=63c4eb78ee4fc9272b9ae2409889861e</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2020.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2020.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DNalawansha%26aufirst%3DD.%2BA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DPROTACs%253A%2520An%2520emerging%2520therapeutic%2520modality%2520in%2520precision%2520medicine%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2020%26volume%3D27%26spage%3D998%26epage%3D1014%26doi%3D10.1016%2Fj.chembiol.2020.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation: expanding the toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0047-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41573-019-0047-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31666732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=949-963&author=M.+Schapiraauthor=M.+F.+Calabreseauthor=A.+N.+Bullockauthor=C.+M.+Crews&title=Targeted+protein+degradation%3A+expanding+the+toolbox&doi=10.1038%2Fs41573-019-0047-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: expanding the toolbox</span></div><div class="casAuthors">Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-963</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review. Proteolysis-targeting chimeras (PROTACs) and related mols. that induce targeted protein degrdn. by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets.  However, the technol. is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated.  Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degrdn., and expansion of knowledge in this area is a key opportunity.  Here, we briefly discuss lessons learned about targeted protein degrdn. in chem. biol. and drug discovery and systematically review the expression profile, domain architecture and chem. tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUvM27MU3WrVg90H21EOLACvtfcHk0ljSDvwHmBHjIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM&md5=9bfd48c6c47fc1cce15129495fea7079</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCalabrese%26aufirst%3DM.%2BF.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%253A%2520expanding%2520the%2520toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D949%26epage%3D963%26doi%3D10.1038%2Fs41573-019-0047-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule modulation of protein homeostasis</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">11269</span>– <span class="NLM_lpage">11301</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ohur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=11269-11301&author=G.+M.+Burslemauthor=C.+M.+Crews&title=Small-molecule+modulation+of+protein+homeostasis&doi=10.1021%2Facs.chemrev.7b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27cR"><div class="casContent"><span class="casTitleNuber">27c</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Modulation of Protein Homeostasis</span></div><div class="casAuthors">Burslem, George M.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11269-11301</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Control of protein levels by nucleic-acid-based technologies has proven to be a useful research tool but lacks the advantages of small mols. with respect to cell permeability, temporal control, and the potential generation of therapeutics.  In this Review, we discuss the technologies available for the control of intracellular protein levels with small mols. and compare the various systems available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcARydbgPK9bVg90H21EOLACvtfcHk0ljSDvwHmBHjIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ohur3K&md5=f9f8dd98e2c71c7166d2d500b514d578</span></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00077%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DSmall-molecule%2520modulation%2520of%2520protein%2520homeostasis%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D11269%26epage%3D11301%26doi%3D10.1021%2Facs.chemrev.7b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="note"><p class="first last">The mAb nomenclature follows the EU convention described in</p></div><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gall, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotlieb, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutishauser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxdal, M. J.</span></span> <span> </span><span class="NLM_article-title">The covalent structure of an entire αG immunoglobin molecule</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1073/pnas.63.1.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1073%2Fpnas.63.1.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=5257969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADyaE3cXivFyjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1969&pages=78-85&author=G.+M.+Edelmanauthor=B.+A.+Cunninghamauthor=W.+E.+Gallauthor=P.+D.+Gotliebauthor=U.+Rutishauserauthor=M.+J.+Waxdal&title=The+covalent+structure+of+an+entire+%CE%B1G+immunoglobin+molecule&doi=10.1073%2Fpnas.63.1.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent structure of an entire γG immunoglobulin molecule</span></div><div class="casAuthors">Edelman, Gerald M.; Cunningham, Bruce A.; Gall, W. Einar; Gottlieb, Paul D.; Rutishauser, Urs; Waxdal, Myron J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-85</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The complete amino acid sequence of a human γGl immunoglobulin (Eu) has been detd. and the arrangement of all of the disulfide bonds has been established.  Comparison of the sequence with that of another myeloma protein (He) suggests that the variable regions of heavy and light chains are homologous and similar in length.  The const. portion of the heavy chain contains 3 homology regions each of which is similar in size and homologous to the const. region of the light chain.  Each variable region and each const. homology region contains 1 intrachain disulfide bond.  The half-cystines participating in the interchain bonds are all clustered within a stretch of 10 residues at the middle of the heavy chains.  These data support the hypothesis that immunoglobulins evolved by gene duplication after early divergence of V genes, which specified antigen-binding functions, and C genes, which specified other functions of antibody mols.  Each polypeptide chain may therefore be specified by 2 genes, V and C, which are fused to form a single gene (translocation hypothesis).  The internal homologies and symmetry of the mol. suggest that homology regions may have similar 3-dimensional structures each consisting of a compact domain which contributes to at least 1 active site (domain hypothesis).  Both hypotheses are in accord with the linear regional differentiation of function in antibody mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjqW9i9JX9g7Vg90H21EOLACvtfcHk0lglDPAKMjd96Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXivFyjtQ%253D%253D&md5=18ba9b6417ce609be8870e1d142e7fc9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1073%2Fpnas.63.1.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.63.1.78%26sid%3Dliteratum%253Aachs%26aulast%3DEdelman%26aufirst%3DG.%2BM.%26aulast%3DCunningham%26aufirst%3DB.%2BA.%26aulast%3DGall%26aufirst%3DW.%2BE.%26aulast%3DGotlieb%26aufirst%3DP.%2BD.%26aulast%3DRutishauser%26aufirst%3DU.%26aulast%3DWaxdal%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520covalent%2520structure%2520of%2520an%2520entire%2520%25CE%25B1G%2520immunoglobin%2520molecule%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1969%26volume%3D63%26spage%3D78%26epage%3D85%26doi%3D10.1073%2Fpnas.63.1.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For a comparison of the EU and the alternate Kabat mAb nomenclature systems, see Table S1 in ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a>a.</p></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. J.</span>; <span class="NLM_string-name">Bargh, J. D.</span>; <span class="NLM_string-name">Dannheim, F. M.</span>; <span class="NLM_string-name">Hanby, A. R.</span>; <span class="NLM_string-name">Seki, H.</span>; <span class="NLM_string-name">Counsell, A. J.</span>; <span class="NLM_string-name">Ou, X.</span>; <span class="NLM_string-name">Fowler, E.</span>; <span class="NLM_string-name">Ashman, N.</span>; <span class="NLM_string-name">Takada, Y.</span>; <span class="NLM_string-name">Isidro-Llobet, A.</span>; <span class="NLM_string-name">Parker, J. S.</span>; <span class="NLM_string-name">Carroll, J. S.</span>; <span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Site-selective modification strategies in antibody-drug conjugates</span>.  <i>Chem. Soc. Rev.</i><span class="refDoi"> DOI: 10.1039/d0cs00310g</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2Fd0cs00310g" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Walsh%2C+S.+J.%3B+Bargh%2C+J.+D.%3B+Dannheim%2C+F.+M.%3B+Hanby%2C+A.+R.%3B+Seki%2C+H.%3B+Counsell%2C+A.+J.%3B+Ou%2C+X.%3B+Fowler%2C+E.%3B+Ashman%2C+N.%3B+Takada%2C+Y.%3B+Isidro-Llobet%2C+A.%3B+Parker%2C+J.+S.%3B+Carroll%2C+J.+S.%3B+Spring%2C+D.+R.+Site-selective+modification+strategies+in+antibody-drug+conjugates.+Chem.+Soc.+Rev.+10.1039%2Fd0cs00310g."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1039%2Fd0cs00310g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fd0cs00310g%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BJ.%26atitle%3DSite-selective%2520modification%2520strategies%2520in%2520antibody-drug%2520conjugates%26jtitle%3DChem.%2520Soc.%2520Rev.%26doi%3D10.1039%2Fd0cs00310g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D. Y.</span></span> <span> </span><span class="NLM_article-title">Processes for constructing homogeneous antibody drug conjugates</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00067</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=852-866&author=D.+Y.+Jackson&title=Processes+for+constructing+homogeneous+antibody+drug+conjugates&doi=10.1021%2Facs.oprd.6b00067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Processes for Constructing Homogeneous Antibody Drug Conjugates</span></div><div class="casAuthors">Jackson, David Y.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">852-866</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) are synthesized by conjugating a cytotoxic drug or "payload" to a monoclonal antibody.  The payloads are conjugated using amino or sulfhydryl specific linkers that react with lysines or cysteines on the antibody surface.  A typical antibody contains over 60 lysines and up to 12 cysteines as potential conjugation sites.  The desired DAR (drugs/antibody ratio) depends on a no. of different factors and ranges from two to eight drugs/antibody.  The discrepancy between the no. of potential conjugation sites and the desired DAR, combined with use of conventional conjugation methods that are not site-specific, results in heterogeneous ADCs that vary in both DAR and conjugation sites.  Heterogeneous ADCs contain significant fractions with suboptimal DARs that are known to possess undesired pharmacol. properties.  As a result, new methods for synthesizing homogeneous ADCs have been developed in order to increase their potential as therapeutic agents.  This article will review recently reported processes for prepg. ADCs with improved homogeneity.  The advantages and potential limitations of each process are discussed, with emphasis on efficiency, quality, and in vivo efficacy relative to similar heterogeneous ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXoa73dqwCyrVg90H21EOLACvtfcHk0lglDPAKMjd96Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGmsbo%253D&md5=4bd838112b5dd262ab6531ec9dc22bd9</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00067%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DD.%2BY.%26atitle%3DProcesses%2520for%2520constructing%2520homogeneous%2520antibody%2520drug%2520conjugates%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D852%26epage%3D866%26doi%3D10.1021%2Facs.oprd.6b00067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit29c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, C. R.</span></span> <span> </span><span class="NLM_article-title">Site-specific antibody-drug conjugates: The nexus of bioorthogonal chemistry, protein engineering, and drug development</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1021/bc5004982</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc5004982" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=176-192&author=P.+Agarwalauthor=C.+R.+Bertozzi&title=Site-specific+antibody-drug+conjugates%3A+The+nexus+of+bioorthogonal+chemistry%2C+protein+engineering%2C+and+drug+development&doi=10.1021%2Fbc5004982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29cR"><div class="casContent"><span class="casTitleNuber">29c</span><div class="casTitle"><span class="NLM_cas:atitle">Site-Specific Antibody-Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development</span></div><div class="casAuthors">Agarwal, Paresh; Bertozzi, Carolyn R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-192</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) combine the specificity of antibodies with the potency of small mols. to create targeted drugs.  Despite the simplicity of this concept, generation of clin. successful ADCs has been very difficult.  Over the past several decades, scientists have learned a great deal about the constraints on antibodies, linkers, and drugs as they relate to successful construction of ADCs.  Once these components are in hand, most ADCs are prepd. by nonspecific modification of antibody lysine or cysteine residues with drug-linker reagents, which results in heterogeneous product mixts. that cannot be further purified.  With advances in the fields of bioorthogonal chem. and protein engineering, there is growing interest in producing ADCs by site-specific conjugation to the antibody, yielding more homogeneous products that have demonstrated benefits over their heterogeneous counterparts in vivo.  Here, we chronicle the development of a multitude of site-specific conjugation strategies for assembly of ADCs and provide a comprehensive account of key advances and their roots in the fields of bioorthogonal chem. and protein engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOcb0A3dT72bVg90H21EOLACvtfcHk0lglDPAKMjd96Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfK&md5=c3d822b0e53e5cdb074e5b63b8060ccf</span></div><a href="/servlet/linkout?suffix=cit29c&amp;dbid=16384&amp;doi=10.1021%2Fbc5004982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc5004982%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DP.%26aulast%3DBertozzi%26aufirst%3DC.%2BR.%26atitle%3DSite-specific%2520antibody-drug%2520conjugates%253A%2520The%2520nexus%2520of%2520bioorthogonal%2520chemistry%252C%2520protein%2520engineering%252C%2520and%2520drug%2520development%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26spage%3D176%26epage%3D192%26doi%3D10.1021%2Fbc5004982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farahi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandlen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span> <span> </span><span class="NLM_article-title">High-throughput cysteine scanning to identify stable antibody conjugation sites for maleimide- and disulfide-based linkers</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00791</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00791" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=473-485&author=R.+Ohriauthor=S.+Bhaktaauthor=A.+O%E2%80%99Donohueauthor=J.+Chuhauthor=S.+P.+Tsaiauthor=R.+Cookauthor=B.+Weiauthor=C.+Ngauthor=A.+W.+Wongauthor=A.+B.+Bosauthor=F.+Farahiauthor=J.+Bhaktaauthor=T.+H.+Pillowauthor=H.+Raabauthor=R.+Vandlenauthor=P.+Polakisauthor=Y.+Liuauthor=H.+Ericksonauthor=J.+R.+Junutulaauthor=K.+R.+Kozak&title=High-throughput+cysteine+scanning+to+identify+stable+antibody+conjugation+sites+for+maleimide-+and+disulfide-based+linkers&doi=10.1021%2Facs.bioconjchem.7b00791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers</span></div><div class="casAuthors">Ohri, Rachana; Bhakta, Sunil; Fourie-O'Donohue, Aimee; dela Cruz-Chuh, Josefa; Tsai, Siao Ping; Cook, Ryan; Wei, Binqing; Ng, Carl; Wong, Athena W.; Bos, Aaron B.; Farahi, Farzam; Bhakta, Jiten; Pillow, Thomas H.; Raab, Helga; Vandlen, Richard; Polakis, Paul; Liu, Yichin; Erickson, Hans; Junutula, Jagath R.; Kozak, Katherine R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">473-485</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">THIOMAB antibody technol. utilizes cysteine residues engineered onto an antibody to allow for site-specific conjugation.  The technol. has enabled the exploration of different attachment sites on the antibody in combination with small mols., peptides, or proteins to yield antibody conjugates with unique properties.  As reported previously, the specific location of the site of conjugation on an antibody can impact the stability of the linkage to the engineered cysteine for both thio-succinimide and disulfide bonds.  High stability of the linkage is usually desired to maximize the delivery of the cargo to the intended target.  In the current study, cysteines were individually substituted into every position of the anti-HER2 antibody (trastuzumab), and the stabilities of drug conjugations at those sites were evaluated.  We screened a total of 648 THIOMAB antibody-drug conjugates, each generated from a trastuzamab prepd. by sequentially mutating non-cysteine amino acids in the light and heavy chains to cysteine.  Each THIOMAB antibody variant was conjugated to either maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin E (MC-vc-PAB-MMAE) or pyridyl disulfide monomethyl auristatin E (PDS-MMAE) using a high-throughput, on-bead conjugation and purifn. method.  Greater than 50% of the THIOMAB antibody variants were successfully conjugated to both MMAE derivs. with a drug to antibody ratio (DAR) of >0.5 and <50% aggregation.  The relative in vitro plasma stabilities for approx. 750 conjugates were assessed using enzyme-linked immunosorbent assays, and stable sites were confirmed with affinity-capture LC/MS-based detection methods.  Highly stable conjugation sites for the two types of MMAE derivs. were identified on both the heavy and light chains.  Although the stabilities of maleimide conjugates were shown to be greater than those of the disulfide conjugates, many sites were identified that were stable for both.  Furthermore, in vitro stabilities of selected stable sites translated across different cytotoxic payloads and different target antibodies as well as to in vivo stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLlgFVNRmHMbVg90H21EOLACvtfcHk0lj1e-VaBBw5Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKku7g%253D&md5=318146c1baea8094b671e99b5c429627</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00791%26sid%3Dliteratum%253Aachs%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DChuh%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DCook%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DA.%2BW.%26aulast%3DBos%26aufirst%3DA.%2BB.%26aulast%3DFarahi%26aufirst%3DF.%26aulast%3DBhakta%26aufirst%3DJ.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DErickson%26aufirst%3DH.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26atitle%3DHigh-throughput%2520cysteine%2520scanning%2520to%2520identify%2520stable%2520antibody%2520conjugation%2520sites%2520for%2520maleimide-%2520and%2520disulfide-based%2520linkers%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D473%26epage%3D485%26doi%3D10.1021%2Facs.bioconjchem.7b00791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmar, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie-O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, H. K.</span></span> <span> </span><span class="NLM_article-title">Attachment site cysteine thiol pKa is a key driver for site-dependent stability of THIOMAB antibody-drug conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2538</span>– <span class="NLM_lpage">2548</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00365</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00365" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2538-2548&author=B.+S.+Vollmarauthor=B.+Weiauthor=R.+Ohriauthor=J.+Zhouauthor=J.+Heauthor=S.-F.+Yuauthor=D.+Leipoldauthor=E.+Cosinoauthor=S.+Yeeauthor=A.+Fourie-O%E2%80%99Donohueauthor=G.+Liauthor=G.+L.+Phillipsauthor=K.+R.+Kozakauthor=A.+Kamathauthor=K.+Xuauthor=G.+Leeauthor=G.+A.+Lazarauthor=H.+K.+Erickson&title=Attachment+site+cysteine+thiol+pKa+is+a+key+driver+for+site-dependent+stability+of+THIOMAB+antibody-drug+conjugates&doi=10.1021%2Facs.bioconjchem.7b00365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates</span></div><div class="casAuthors">Vollmar, Breanna S.; Wei, Binqing; Ohri, Rachana; Zhou, Jianhui; He, Jintang; Yu, Shang-Fan; Leipold, Douglas; Cosino, Ely; Yee, Sharon; Fourie-O'Donohue, Aimee; Li, Guangmin; Phillips, Gail L.; Kozak, Katherine R.; Kamath, Amrita; Xu, Keyang; Lee, Genee; Lazar, Greg A.; Erickson, Hans K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2538-2548</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The incorporation of cysteines into antibodies by mutagenesis allows for the direct conjugation of small mols. to specific sites on the antibody via disulfide bonds.  The stability of the disulfide bond linkage between the small mol. and the antibody is highly dependent on the location of the engineered cysteine in either the heavy chain (HC) or the light chain (LC) of the antibody.  Here, we explore the basis for this site-dependent stability.  We evaluated the in vivo efficacy and pharmacokinetics of five different cysteine mutants of trastuzumab conjugated to a pyrrolobenzodiazepine (PBD) via disulfide bonds.  A significant correlation was obsd. between disulfide stability and efficacy for the conjugates.  We hypothesized that the obsd. site-dependent stability of the disulfide-linked conjugates could be due to differences in the attachment site cysteine thiol pKa.  We measured the cysteine thiol pKa using isothermal titrn. calorimetry (ITC) and found that the variants with the highest thiol pKa (LC K149C and HC A140C) were found to yield the conjugates with the greatest in vivo stability.  Guided by homol. modeling, we identified several mutations adjacent to LC K149C that reduced the cysteine thiol pKa and, thus, decreased the in vivo stability of the disulfide-linked PBD conjugated to LC K149C.  We also present results suggesting that the high thiol pKa of LC K149C is responsible for the sustained circulation stability of LC K149C TDCs utilizing a maleimide-based linker.  Taken together, our results provide evidence that the site-dependent stability of cys-engineered antibody-drug conjugates may be explained by interactions between the engineered cysteine and the local protein environment that serves to modulate the side-chain thiol pKa.  The influence of cysteine thiol pKa on stability and efficacy offers a new parameter for the optimization of ADCs that utilize cysteine engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAfrN62jixCbVg90H21EOLACvtfcHk0lj1e-VaBBw5Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGks7vL&md5=ba1805c493f468d4ffbb198dbf8b3d02</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00365%26sid%3Dliteratum%253Aachs%26aulast%3DVollmar%26aufirst%3DB.%2BS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DLeipold%26aufirst%3DD.%26aulast%3DCosino%26aufirst%3DE.%26aulast%3DYee%26aufirst%3DS.%26aulast%3DFourie-O%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPhillips%26aufirst%3DG.%2BL.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DLazar%26aufirst%3DG.%2BA.%26aulast%3DErickson%26aufirst%3DH.%2BK.%26atitle%3DAttachment%2520site%2520cysteine%2520thiol%2520pKa%2520is%2520a%2520key%2520driver%2520for%2520site-dependent%2520stability%2520of%2520THIOMAB%2520antibody-drug%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2017%26volume%3D28%26spage%3D2538%26epage%3D2548%26doi%3D10.1021%2Facs.bioconjchem.7b00365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kolakowski, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haelsig, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerton, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiske, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span> <span> </span><span class="NLM_article-title">The methylene alkoxy carbamate self-immolative unit: Utilization for the targeted delivery of alcohol-containing payloads with antibody-drug conjugates</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7948</span>– <span class="NLM_lpage">7951</span>, <span class="refDoi"> DOI: 10.1002/anie.201601506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fanie.201601506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1KjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=7948-7951&author=R.+V.+Kolakowskiauthor=K.+T.+Haelsigauthor=K.+K.+Emmertonauthor=C.+I.+Leiskeauthor=J.+B.+Miyamotoauthor=J.+H.+Cochranauthor=R.+P.+Lyonauthor=P.+D.+Senterauthor=S.+C.+Jeffrey&title=The+methylene+alkoxy+carbamate+self-immolative+unit%3A+Utilization+for+the+targeted+delivery+of+alcohol-containing+payloads+with+antibody-drug+conjugates&doi=10.1002%2Fanie.201601506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates</span></div><div class="casAuthors">Kolakowski, Robert V.; Haelsig, Karl T.; Emmerton, Kim K.; Leiske, Chris I.; Miyamoto, Jamie B.; Cochran, Julia H.; Lyon, Robert P.; Senter, Peter D.; Jeffrey, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">7948-7951</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A strategy for the conjugation of alc.-contg. payloads to antibodies has been developed and involves the methylene alkoxy carbamate (MAC) self-immolative unit.  A series of MAC β-glucuronide model constructs were prepd. to evaluate stability and enzymic release, and the results demonstrated high stability at physiol. pH in a substitution-dependent manner.  All the MAC model compds. efficiently released alc. drug surrogates under the action of β-glucuronidase.  To assess the MAC technol. for ADCs, the potent microtubule-disrupting agent auristatin E (AE) was incorporated through the norephedrine alc.  Conjugation of the MAC β-glucuronide AE drug linker to the anti-CD30 antibody cAC10, and an IgG control antibody, gave potent and immunol. specific activities in vitro and in vivo.  These studies validate the MAC self-immolative unit for alc.-contg. payloads within ADCs, a class that has not been widely exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmcbliUQ1JNLVg90H21EOLACvtfcHk0lj1e-VaBBw5Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1KjtLc%253D&md5=3320828c2445a549e76bf1419d1cc614</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201601506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201601506%26sid%3Dliteratum%253Aachs%26aulast%3DKolakowski%26aufirst%3DR.%2BV.%26aulast%3DHaelsig%26aufirst%3DK.%2BT.%26aulast%3DEmmerton%26aufirst%3DK.%2BK.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DCochran%26aufirst%3DJ.%2BH.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26atitle%3DThe%2520methylene%2520alkoxy%2520carbamate%2520self-immolative%2520unit%253A%2520Utilization%2520for%2520the%2520targeted%2520delivery%2520of%2520alcohol-containing%2520payloads%2520with%2520antibody-drug%2520conjugates%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D7948%26epage%3D7951%26doi%3D10.1002%2Fanie.201601506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ogitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oitate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agatsuma, T.</span></span> <span> </span><span class="NLM_article-title">DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5097</span>– <span class="NLM_lpage">5108</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1078-0432.CCR-15-2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27026201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5097-5108&author=Y.+Ogitaniauthor=T.+Aidaauthor=K.+Hagiharaauthor=J.+Yamaguchiauthor=C.+Ishiiauthor=N.+Haradaauthor=M.+Somaauthor=H.+Okamotoauthor=M.+Oitateauthor=S.+Arakawaauthor=T.+Hiraiauthor=R.+Atsumiauthor=T.+Nakadaauthor=I.+Hayakawaauthor=Y.+Abeauthor=T.+Agatsuma&title=DS-8201a%2C+a+novel+HER2-targeting+ADC+with+a+novel+DNA+topoisomerase+I+inhibitor%2C+demonstrates+a+promising+antitumor+efficacy+with+differentiation+from+T-DM1&doi=10.1158%2F1078-0432.CCR-15-2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</span></div><div class="casAuthors">Ogitani, Yusuke; Aida, Tetsuo; Hagihara, Katsunobu; Yamaguchi, Junko; Ishii, Chiaki; Harada, Naoya; Soma, Masako; Okamoto, Hiromi; Oitate, Masataka; Arakawa, Shingo; Hirai, Takehiro; Atsumi, Ryo; Nakada, Takashi; Hayakawa, Ichiro; Abe, Yuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5097-5108</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its preclin. pharmacol. profile was assessed.  In vitro and in vivo pharmacol. activities of DS-8201a were evaluated and compared with T-DM1 in several HER2-pos. cell lines and patient-derived xenograft (PDX) models.  The mechanism of action for the efficacy was also evaluated.  Pharmacokinetics in cynomolgus monkeys and the safety profiles in rats and cynomolgus monkeys were assessed.  DS-8201a exhibited a HER2 expression-dependent cell growth-inhibitory activity and induced tumor regression with a single dosing at more than 1 mg/kg in a HER2-pos. gastric cancer NCI-N87 model.  Binding activity to HER2 and ADCC activity of DS-8201a were comparable with unconjugated anti-HER2 antibody.  DS-8201a also showed an inhibitory activity to Akt phosphorylation.  DS-8201a induced phosphorylation of Chk1 and Histone H2A.X, the markers of DNA damage.  Pharmacokinetics and safety profiles of DS-8201a were favorable and the highest non-severely toxic dose was 30 mg/kg in cynomolgus monkeys, supporting DS-8201a as being well tolerated in humans.  DS-8201a was effective in a T-DM1-insensitive PDX model with high HER2 expression.  DS-8201a, but not T-DM1, demonstrated antitumor efficacy against several breast cancer PDX models with low HER2 expression.  DS-8201a exhibited a potent antitumor activity in a broad selection of HER2-pos. models and favorable pharmacokinetics and safety profiles.  The results demonstrate that DS-8201a will be a valuable therapy with a great potential to respond to T-DM1-insensitive HER2-pos. cancers and low HER2-expressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZitEmBAqAbVg90H21EOLACvtfcHk0lg_vcfraFjdew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F&md5=3fc9a072b2ba05c80929713c843df3f5</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-2822%26sid%3Dliteratum%253Aachs%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DAida%26aufirst%3DT.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DIshii%26aufirst%3DC.%26aulast%3DHarada%26aufirst%3DN.%26aulast%3DSoma%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DH.%26aulast%3DOitate%26aufirst%3DM.%26aulast%3DArakawa%26aufirst%3DS.%26aulast%3DHirai%26aufirst%3DT.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DNakada%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DI.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DAgatsuma%26aufirst%3DT.%26atitle%3DDS-8201a%252C%2520a%2520novel%2520HER2-targeting%2520ADC%2520with%2520a%2520novel%2520DNA%2520topoisomerase%2520I%2520inhibitor%252C%2520demonstrates%2520a%2520promising%2520antitumor%2520efficacy%2520with%2520differentiation%2520from%2520T-DM1%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D5097%26epage%3D5108%26doi%3D10.1158%2F1078-0432.CCR-15-2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of peptidomimetic antibody-drug conjugate linkers with enhanced protease specificity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKitrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=989-1000&author=B.+Weiauthor=J.+Gunzner-Tosteauthor=H.+Yaoauthor=T.+Wangauthor=J.+Wangauthor=Z.+Xuauthor=J.+Chenauthor=J.+Waiauthor=J.+Nonomiyaauthor=S.+P.+Tsaiauthor=J.+Chuhauthor=K.+R.+Kozakauthor=Y.+Liuauthor=S.-F.+Yuauthor=J.+Lauauthor=G.+Liauthor=G.+D.+Phillipsauthor=D.+Leipoldauthor=A.+Kamathauthor=D.+Suauthor=K.+Xuauthor=C.+Eigenbrotauthor=S.+Steinbacherauthor=R.+Ohriauthor=H.+Raabauthor=L.+R.+Stabenauthor=G.+Zhaoauthor=J.+A.+Flygareauthor=T.+H.+Pillowauthor=V.+Vermaauthor=L.+A.+Mastersonauthor=P.+W.+Howardauthor=B.+Safina&title=Discovery+of+peptidomimetic+antibody-drug+conjugate+linkers+with+enhanced+protease+specificity&doi=10.1021%2Facs.jmedchem.7b01430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity</span></div><div class="casAuthors">Wei, BinQing; Gunzner-Toste, Janet; Yao, Hui; Wang, Tao; Wang, Jing; Xu, Zijin; Chen, Jinhua; Wai, John; Nonomiya, Jim; Tsai, Siao Ping; Chuh, Josefa; Kozak, Katherine R.; Liu, Yichin; Yu, Shang-Fan; Lau, Jeff; Li, Guangmin; Phillips, Gail D.; Leipold, Doug; Kamath, Amrita; Su, Dian; Xu, Keyang; Eigenbrot, Charles; Steinbacher, Stefan; Ohri, Rachana; Raab, Helga; Staben, Leanna R.; Zhao, Guiling; Flygare, John A.; Pillow, Thomas H.; Verma, Vishal; Safina, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">989-1000</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) have become an important therapeutic modality for oncol., with three approved by the FDA and over 60 others in clin. trials.  Despite the progress, improvements in ADC therapeutic index are desired.  Peptide-based ADC linkers that are cleaved by lysosomal proteases have shown sufficient stability in serum and effective payload-release in targeted cells.  If the linker can be preferentially hydrolyzed by tumor-specific proteases, safety margin may improve.  However, the use of peptide-based linkers limits our ability to modulate protease specificity.  Here we report the structure-guided discovery of novel, nonpeptidic ADC linkers.  We show that a cyclobutane-1,1-dicarboxamide-contg. linker is hydrolyzed predominantly by cathepsin B while the valine-citrulline dipeptide linker is not.  ADCs bearing the nonpeptidic linker are as efficacious and stable in vivo as those with the dipeptide linker.  Our results strongly support the application of the peptidomimetic linker and present new opportunities for improving the selectivity of ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohInS8FeMmxbVg90H21EOLACvtfcHk0lg_vcfraFjdew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKitrbI&md5=8646f801d6292eaa2c3e2cc1b9e2e6cc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01430%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DB.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DChuh%26aufirst%3DJ.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%26aulast%3DLeipold%26aufirst%3DD.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DStaben%26aufirst%3DL.%2BR.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DVerma%26aufirst%3DV.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DSafina%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520peptidomimetic%2520antibody-drug%2520conjugate%2520linkers%2520with%2520enhanced%2520protease%2520specificity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D989%26epage%3D1000%26doi%3D10.1021%2Facs.jmedchem.7b01430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achilles Poon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutten, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span> <span> </span><span class="NLM_article-title">An anti-CLL1 antibody-drug conjugate for the treatment of acute myeloid leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1358</span>– <span class="NLM_lpage">1368</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-0333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1078-0432.CCR-18-0333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=29959143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=1358-1368&author=B.+Zhengauthor=S.-F.+Yuauthor=G.+del+Rosarioauthor=S.+R.+Leongauthor=G.+Y.+Leeauthor=R.+Vijauthor=C.+Chiuauthor=W.-C.+Liangauthor=Y.+Wuauthor=C.+Chalouniauthor=J.+Sadowskyauthor=V.+Clarkauthor=A.+Hendricksauthor=K.+Achilles+Poonauthor=W.+Chuauthor=T.+Pillowauthor=M.+M.+Schuttenauthor=J.+Flygareauthor=A.+G.+Polson&title=An+anti-CLL1+antibody-drug+conjugate+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-18-0333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-CLL-I antibody-drug conjugate for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Zheng, Bing; Yu, Shang-Fan; del Rosario, Geoffrey; Leong, Steven R.; Lee, Genee Y.; Vij, Rajesh; Chiu, Cecilia; Liang, Wei-Ching; Wu, Yan; Chalouni, Cecile; Sadowsky, Jack; Clark, Vanessa; Hendricks, Angela; Poon, Kirsten Achilles; Chu, Wayne; Pillow, Thomas; Schutten, Melissa M.; Flygare, John; Polson, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1358</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The treatment of acute myeloid leukemia (AML) has not significantly changed in 40 years.  Cytarabine- and anthracycline-based chemotherapy induction regimens (7 + 3) remain the std. of care, and most patients have poor long-term survival.  The reapproval of Mylotarg, an anti-CD33-calicheamicin antibody-drug conjugate (ADC), has demonstrated ADCs as a clin. validated option to enhance the effectiveness of induction therapy.  We are interested in developing a next-generation ADC for AML to improve upon the initial success of Mylotarg.  Exptl. Design: The expression pattern of CLL-1 and its hematopoietic potential were investigated.  A novel anti-CLL-1-ADC, with a highly potent pyrrolobenzodiazepine (PBD) dimer conjugated through a self-immolative disulfide linker, was developed.  The efficacy and safety profiles of this ADC were evaluated in mouse xenograft models and in cynomolgus monkeys.  Results: We demonstrate that CLL-1 shares similar prevalence and trafficking properties that make CD33 an excellent ADC target for AML, but lacks expression on hematopoietic stem cells that hampers current CD33-targeted ADCs.  Our anti-CLL-1-ADC is highly effective at depleting tumor cells in AML xenograft models and lacks target independent toxicities at doses that depleted target monocytes and neutrophils in cynomolgus monkeys.  Conclusions: Collectively, our data suggest that an anti-CLL-1-ADC has the potential to become an effective and safer treatment for AML in humans, by reducing and allowing for faster recovery from initial cytopenias than the current generation of ADCs for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJdzTurW_r4LVg90H21EOLACvtfcHk0li_Yq3WUcPseA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7bE&md5=c701a514d19baec87815539f0eaa9275</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-0333%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3Ddel%2BRosario%26aufirst%3DG.%26aulast%3DLeong%26aufirst%3DS.%2BR.%26aulast%3DLee%26aufirst%3DG.%2BY.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DChiu%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DW.-C.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DV.%26aulast%3DHendricks%26aufirst%3DA.%26aulast%3DAchilles%2BPoon%26aufirst%3DK.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DPillow%26aufirst%3DT.%26aulast%3DSchutten%26aufirst%3DM.%2BM.%26aulast%3DFlygare%26aufirst%3DJ.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26atitle%3DAn%2520anti-CLL1%2520antibody-drug%2520conjugate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D1358%26epage%3D1368%26doi%3D10.1158%2F1078-0432.CCR-18-0333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamblett, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chace, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerveny, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissler, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopcha, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabinski, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisco, J. A.</span></span> <span> </span><span class="NLM_article-title">Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">7063</span>– <span class="NLM_lpage">7070</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-0789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1078-0432.CCR-04-0789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=15501986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslGlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=7063-7070&author=K.+J.+Hamblettauthor=P.+D.+Senterauthor=D.+F.+Chaceauthor=M.+M.+C.+Sunauthor=J.+Lenoxauthor=C.+G.+Cervenyauthor=K.+M.+Kisslerauthor=S.+X.+Bernhardtauthor=A.+K.+Kopchaauthor=R.+F.+Zabinskiauthor=D.+L.+Meyerauthor=J.+A.+Francisco&title=Effects+of+drug+loading+on+the+antitumor+activity+of+a+monoclonal+antibody+drug+conjugate&doi=10.1158%2F1078-0432.CCR-04-0789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate</span></div><div class="casAuthors">Hamblett, Kevin J.; Senter, Peter D.; Chace, Dana F.; Sun, Michael M. C.; Lenox, Joel; Cerveny, Charles G.; Kissler, Kim M.; Bernhardt, Starr X.; Kopcha, Anastasia K.; Zabinski, Roger F.; Meyer, Damon L.; Francisco, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7063-7070</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An antibody-drug conjugate consisting of monomethyl auristatin E (MMAE) conjugated to the anti-CD30 monoclonal antibody (mAb) cAC10, with eight drug moieties per mAb, was previously shown to have potent cytotoxic activity against CD30+ malignant cells.  To det. the effect of drug loading on antibody-drug conjugate therapeutic potential, we assessed cAC10 antibody-drug conjugates contg. different drug-mAb ratios in vitro and in vivo.  Coupling MMAE to the cysteines that comprise the interchain disulfides of cAC10 created an antibody-drug conjugate population, which was purified using hydrophobic interaction chromatog. to yield antibody-drug conjugates with two, four, and eight drugs per antibody (E2, E4, and E8, resp.).  Antibody-drug conjugate potency was tested in vitro against CD30+ lines followed by in vivo xenograft models.  The max.-tolerated dose and pharmacokinetic profiles of the antibody-drug conjugates were investigated in mice.  Although antibody-drug conjugate potency in vitro was directly dependent on drug loading (IC50 values E8<E4<E2), the in vivo antitumor activity of E4 was comparable with E8 at equal mAb doses, although the E4 contained half the amt. of MMAE per mAb.  E2 was also an active antitumor agent but required higher doses.  The max.-tolerated dose of E2 in mice was at least double that of E4, which in turn was twice that of E8.  MMAE loading affected plasma clearance, as E8 cleared 3-fold faster than E4 and 5-fold faster than E2.  By decreasing drug loading per antibody, the therapeutic index was increased demonstrating that drug loading is a key design parameter for antibody-drug conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCAEfk7W0KNbVg90H21EOLACvtfcHk0li_Yq3WUcPseA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslGlu78%253D&md5=2d2dd7a498d1181a57dcd3ab8b931e65</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0789%26sid%3Dliteratum%253Aachs%26aulast%3DHamblett%26aufirst%3DK.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DChace%26aufirst%3DD.%2BF.%26aulast%3DSun%26aufirst%3DM.%2BM.%2BC.%26aulast%3DLenox%26aufirst%3DJ.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DKissler%26aufirst%3DK.%2BM.%26aulast%3DBernhardt%26aufirst%3DS.%2BX.%26aulast%3DKopcha%26aufirst%3DA.%2BK.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DFrancisco%26aufirst%3DJ.%2BA.%26atitle%3DEffects%2520of%2520drug%2520loading%2520on%2520the%2520antitumor%2520activity%2520of%2520a%2520monoclonal%2520antibody%2520drug%2520conjugate%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D7063%26epage%3D7070%26doi%3D10.1158%2F1078-0432.CCR-04-0789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="note"><p class="first last">For other recent examples of “high-DAR” conjugates, see:</p></div><div class="NLM_citation" id="cit35a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Construction of paclitaxel-based antibody-drug conjugates with a PEGylated linker to achieve superior therapeutic index</span>. <i>Signal Transduction Targeted Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">132</span> <span class="refDoi"> DOI: 10.1038/s41392-020-00247-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41392-020-00247-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=32728048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFShsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&author=T.+Shaoauthor=T.+Chenauthor=Y.+Chenauthor=X.+Liuauthor=Y.-L.+Chenauthor=Q.+Wangauthor=T.+Zhuauthor=M.+Guoauthor=H.+Liauthor=D.+Juauthor=C.+Wang&title=Construction+of+paclitaxel-based+antibody-drug+conjugates+with+a+PEGylated+linker+to+achieve+superior+therapeutic+index&doi=10.1038%2Fs41392-020-00247-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">Construction of paclitaxel-based antibody-drug conjugates with a PEGylated linker to achieve superior therapeutic index</span></div><div class="casAuthors">Shao, Ting; Chen, Tianzhi; Chen, Yuning; Liu, Xiaoyue; Chen, Yi-Li; Wang, Qi; Zhu, Tong; Guo, Maojun; Li, Hui; Ju, Dianwen; Wang, Chunhe</div><div class="citationInfo"><span class="NLM_cas:title">Signal Transduction and Targeted Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">132</span>CODEN:
                <span class="NLM_cas:coden">STTTCB</span>;
        ISSN:<span class="NLM_cas:issn">2059-3635</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The selection of linkers and payloads plays a crucial role indetermining the therapeutic indexes of antibody-drug conjugates(ADCs).  As paclitaxel (PTX) has been used therapeutically in pancreaticcancer and TNBC, in which Trop-2 is highly expressed, it appears to be a viable payload option for Trop-2-targeting ADCs.  In cancer cell lines with diverse Trop-2 expression levels, our results indicated that free drug PTX is not as potent as MMAE, but similar to SN38.  ADC mols. employing PTX, hydrophilic linkers, and Trop-2 antibodies showed superior efficacy and safety profile in vitro and in vivo, suggesting that it is a promising targeted therapeutic for human carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUf9HH70ECrVg90H21EOLACvtfcHk0li_Yq3WUcPseA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFShsrrI&md5=6b9b5b01379dfaea90cd38c70ad51527</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1038%2Fs41392-020-00247-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-020-00247-y%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.-L.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DJu%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DConstruction%2520of%2520paclitaxel-based%2520antibody-drug%2520conjugates%2520with%2520a%2520PEGylated%2520linker%2520to%2520achieve%2520superior%2520therapeutic%2520index%26jtitle%3DSignal%2520Transduction%2520Targeted%2520Ther.%26date%3D2020%26volume%3D5%26doi%3D10.1038%2Fs41392-020-00247-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S.</span>; <span class="NLM_string-name">Wang, K.-P.</span></span> <span> </span><span class="NLM_article-title">ADCs With Thiol Multiplex Linkers</span>. <span class="NLM_patent">WO2020132655</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+Jeffrey&author=K.-P.+Wang&title=ADCs+With+Thiol+Multiplex+Linkers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%26atitle%3DADCs%2520With%2520Thiol%2520Multiplex%2520Linkers%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Le Joncour, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puhka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmikangas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laakkonen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barok, M.</span></span> <span> </span><span class="NLM_article-title">A movel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1721</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-19-0207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1535-7163.MCT-19-0207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31292166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1721-1730&author=V.+Le+Joncourauthor=A.+Martinsauthor=M.+Puhkaauthor=J.+Isolaauthor=M.+Salmikangasauthor=P.+Laakkonenauthor=H.+Joensuuauthor=M.+Barok&title=A+movel+anti-HER2+antibody-drug+conjugate+XMT-1522+for+HER2-positive+breast+and+gastric+cancers+resistant+to+trastuzumab+emtansine&doi=10.1158%2F1535-7163.MCT-19-0207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35cR"><div class="casContent"><span class="casTitleNuber">35c</span><div class="casTitle"><span class="NLM_cas:atitle">A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine</span></div><div class="casAuthors">Le Joncour, Vadim; Martins, Ana; Puhka, Maija; Isola, Jorma; Salmikangas, Marko; Laakkonen, Pirjo; Joensuu, Heikki; Barok, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1721-1730</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most patients with HER2-pos. breast or gastric cancer exhibit primary or acquired resistance to trastuzumab emtansine (T-DM1), and such patients may have limited therapeutic options.  XMT-1522 is a novel anti-HER2 antibody-drug conjugate.  We compared XMT-1522 to T-DM1 in preclin. models.  The effects of XMT-1522 and T-DM1 on cell survival and apoptosis were compared in six HER2-pos. breast cancer or gastric cancer cell lines, of which three lines were T-DM1-sensitive (N-87, OE-19, JIMT-1) and three T-DM1-resistant (RN-87, ROE-19, SNU-216).  We compared these agents also in the HER2-neg. breast cancer cell line MCF-7, and in mouse RN-87 and JIMT-1 xenograft models.  Cell survival was assessed using the AlamarBlue method and apoptosis with the Caspase-Glo 3/7 method.  XMT-1522 inhibited the growth of all six HER2-pos. cell lines.  The proportions of cells that survived XMT-1522 treatment were smaller as compared with T-DM1, particularly in the T-DM1-resistant cell lines.  XMT-1522 induced more cell apoptosis compared with T-DM1.  While RN-87 and JIMT-1 xenograft tumors progressed on T-DM1 treatment, all tumors responded to XMT-1522, and all but one tumor disappeared during the XMT-1522 treatment.  XMT-1522 had a strong antitumor effect on RN-87 and JIMT-1 xenografts that progressed on T-DM1.  We conclude that XMT-1522 was effective in HER2-pos. breast cancer and gastric cancer cell lines resistant to T-DM1, and in xenograft models resistant to T-DM1.  The results support the testing of XMT-1522 in clin. trials in patients with HER2-pos. cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Pci-NaVO6bVg90H21EOLACvtfcHk0liUxqvUT1-s3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFKlug%253D%253D&md5=71fd86427ea0bac472f679076eb4c680</span></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-19-0207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-19-0207%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BJoncour%26aufirst%3DV.%26aulast%3DMartins%26aufirst%3DA.%26aulast%3DPuhka%26aufirst%3DM.%26aulast%3DIsola%26aufirst%3DJ.%26aulast%3DSalmikangas%26aufirst%3DM.%26aulast%3DLaakkonen%26aufirst%3DP.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DBarok%26aufirst%3DM.%26atitle%3DA%2520movel%2520anti-HER2%2520antibody-drug%2520conjugate%2520XMT-1522%2520for%2520HER2-positive%2520breast%2520and%2520gastric%2520cancers%2520resistant%2520to%2520trastuzumab%2520emtansine%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26spage%3D1721%26epage%3D1730%26doi%3D10.1158%2F1535-7163.MCT-19-0207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit35d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Viricel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrial, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papotd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span> <span> </span><span class="NLM_article-title">Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4048</span>– <span class="NLM_lpage">4053</span>, <span class="refDoi"> DOI: 10.1039/C9SC00285E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2FC9SC00285E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31015945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkt1Wqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=4048-4053&author=W.+Viricelauthor=G.+Fournetauthor=S.+Beaumelauthor=E.+Perrialauthor=S.+Papotdauthor=C.+Dumontetauthor=B.+Joseph&title=Monodisperse+polysarcosine-based+highly-loaded+antibody-drug+conjugates&doi=10.1039%2FC9SC00285E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35dR"><div class="casContent"><span class="casTitleNuber">35d</span><div class="casTitle"><span class="NLM_cas:atitle">Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates</span></div><div class="casAuthors">Viricel, Warren; Fournet, Guy; Beaumel, Sabine; Perrial, Emeline; Papot, Sebastien; Dumontet, Charles; Joseph, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4048-4053</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) convey highly potent anticancer drugs to antigen-expressing tumor cells, thereby sparing healthy tissues throughout the body.  Pharmacokinetics and tolerability of ADCs are predominantly influenced by the drug-antibody ratio (DAR) of the conjugates, which is to-date limited to a value of 3-4 drugs per antibody in Antibody-drug conjugates under clin. investigations.  Here, we report the synthesis of monodisperse (i.e. discrete) polysarcosine compds. and their use as a hydrophobicity masking entity for the construction of highly-loaded homogeneous glucuronidase-responsive antibody-drug conjugates (ADCs).  The highly hydrophilic drug-linker platform described herein improves drug-loading, physicochem. properties, pharmacokinetics and in vivo antitumor efficacy of the resulting conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyJWZGJpnUOrVg90H21EOLACvtfcHk0liUxqvUT1-s3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkt1Wqurk%253D&md5=3f6556a5f22ba298ae4d504a68bca3c0</span></div><a href="/servlet/linkout?suffix=cit35d&amp;dbid=16384&amp;doi=10.1039%2FC9SC00285E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9SC00285E%26sid%3Dliteratum%253Aachs%26aulast%3DViricel%26aufirst%3DW.%26aulast%3DFournet%26aufirst%3DG.%26aulast%3DBeaumel%26aufirst%3DS.%26aulast%3DPerrial%26aufirst%3DE.%26aulast%3DPapotd%26aufirst%3DS.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJoseph%26aufirst%3DB.%26atitle%3DMonodisperse%2520polysarcosine-based%2520highly-loaded%2520antibody-drug%2520conjugates%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26spage%3D4048%26epage%3D4053%26doi%3D10.1039%2FC9SC00285E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit35e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loftus, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nix, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waight, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaval, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2633</span>– <span class="NLM_lpage">2642</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-0643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1535-7163.MCT-18-0643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30242091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1elsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=2633-2642&author=C.+S.+Neumannauthor=K.+C.+Olivasauthor=M.+E.+Andersonauthor=J.+H.+Cochranauthor=S.+Jinauthor=F.+Liauthor=L.+V.+Loftusauthor=D.+W.+Meyerauthor=J.+Nealeauthor=J.+C.+Nixauthor=P.+G.+Pittmanauthor=J.+K.+Simmonsauthor=M.+L.+Ulrichauthor=A.+B.+Waightauthor=A.+Wongauthor=M.+C.+Zavalauthor=W.+Zengauthor=R.+P.+Lyonauthor=P.+D.+Senter&title=Targeted+delivery+of+cytotoxic+NAMPT+inhibitors+using+antibody-drug+conjugates&doi=10.1158%2F1535-7163.MCT-18-0643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35eR"><div class="casContent"><span class="casTitleNuber">35e</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates</span></div><div class="casAuthors">Neumann, Christopher S.; Olivas, Kathleen C.; Anderson, Martha E.; Cochran, Julia H.; Jin, Steven; Li, Fu; Loftus, Luke V.; Meyer, David W.; Neale, Jason; Nix, Jay C.; Pittman, Paul G.; Simmons, Jessica K.; Ulrich, Michelle L.; Waight, Andrew B.; Wong, Abbie; Zaval, Margo C.; Zeng, Weiping; Lyon, Robert P.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2633-2642</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are a therapeutic modality that enables the targeted delivery of cytotoxic drugs to cancer cells.  Identification of active payloads with unique mechanisms of action is a key aim of research efforts in the field.  Herein, we report the development of inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) as a novel payload for ADC technol.  NAMPT is a component of a salvage biosynthetic pathway for NAD, and inhibition of this enzyme results in disruption of primary cellular metab. leading to cell death.  Through derivatization of the prototypical NAMPT inhibitor FK-866, we identified potent analogs with chem. functionality that enables the synthesis of hydrophilic enzyme-cleavable drug linkers.  The resulting ADCs displayed NAD depletion in both cell-based assays and tumor xenografts.  Antitumor efficacy is demonstrated in five mouse xenograft models using ADCs directed to indication-specific antigens.  In rat toxicol. models, a nonbinding control ADC was tolerated at >10-fold the typical efficacious dose used in xenografts.  Moderate, reversible hematol. effects were obsd. with ADCs in rats, but there was no evidence for the retinal and cardiac toxicities reported for small-mol. inhibitors.  These findings introduce NAMPT inhibitors as active and well-tolerated payloads for ADCs with promise to improve the therapeutic window of NAMPT inhibition and enable application in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx2rsX00yD6LVg90H21EOLACvtfcHk0ljB4P9j_pDWpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1elsL0%253D&md5=43118eed82fe96b192cac5dca45a7b44</span></div><a href="/servlet/linkout?suffix=cit35e&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0643%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DC.%2BS.%26aulast%3DOlivas%26aufirst%3DK.%2BC.%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26aulast%3DCochran%26aufirst%3DJ.%2BH.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLoftus%26aufirst%3DL.%2BV.%26aulast%3DMeyer%26aufirst%3DD.%2BW.%26aulast%3DNeale%26aufirst%3DJ.%26aulast%3DNix%26aufirst%3DJ.%2BC.%26aulast%3DPittman%26aufirst%3DP.%2BG.%26aulast%3DSimmons%26aufirst%3DJ.%2BK.%26aulast%3DUlrich%26aufirst%3DM.%2BL.%26aulast%3DWaight%26aufirst%3DA.%2BB.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DZaval%26aufirst%3DM.%2BC.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DTargeted%2520delivery%2520of%2520cytotoxic%2520NAMPT%2520inhibitors%2520using%2520antibody-drug%2520conjugates%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D2633%26epage%3D2642%26doi%3D10.1158%2F1535-7163.MCT-18-0643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit35f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, H. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiske, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerton, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waight, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span> <span> </span><span class="NLM_article-title">Glucuronide-linked antibody-tubulysin conjugates display activity in MDR+ and heterogeneous tumor models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1752</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-0073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1535-7163.MCT-18-0073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=29866744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1752-1760&author=P.+J.+Burkeauthor=J.+Z.+Hamiltonauthor=T.+A.+Piresauthor=H.+W.+H.+Laiauthor=C.+I.+Leiskeauthor=K.+K.+Emmertonauthor=A.+B.+Waightauthor=P.+D.+Senterauthor=R.+P.+Lyonauthor=S.+C.+Jeffrey&title=Glucuronide-linked+antibody-tubulysin+conjugates+display+activity+in+MDR%2B+and+heterogeneous+tumor+models&doi=10.1158%2F1535-7163.MCT-18-0073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35fR"><div class="casContent"><span class="casTitleNuber">35f</span><div class="casTitle"><span class="NLM_cas:atitle">Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models</span></div><div class="casAuthors">Burke, Patrick J.; Hamilton, Joseph Z.; Pires, Thomas A.; Lai, Holden W. H.; Leiske, Christopher I.; Emmerton, Kim K.; Waight, Andrew B.; Senter, Peter D.; Lyon, Robert P.; Jeffrey, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1752-1760</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Although antibody-drug conjugates (ADCs) find increasing applications in cancer treatment, de novo or treatment-emergent resistance mechanisms may impair clin. benefit.  Two resistance mechanisms that emerge under prolonged exposure include upregulation of transporter proteins that confer multidrug resistance (MDR+) and loss of cognate antigen expression.  Recently, we developed the quaternary ammonium linker system to expand the scope of conjugatable payloads to include tertiary amines and applied the linker to tubulysins, a highly potent class of tubulin binders that maintain activity in MDR+ cell lines.  In this work, tubulysin M, which contains an unstable acetate susceptible to enzymic hydrolysis, and two stabilized tubulysin analogs were prepd. as quaternary ammonium-linked glucuronide-linkers and assessed as ADC payloads in preclin. models.  The conjugates were potent across a panel of cancer cell lines and active in tumor xenografts, including those displaying the MDR+ phenotype.  The ADCs also demonstrated potent bystander activity in a coculture model comprised of a mixt. of antigen-pos. and -neg. cell lines, and in an antigen-heterogeneous tumor model.  Thus, the glucuronide-tubulysin drug-linkers represent a promising ADC payload class, combining conjugate potency in the presence of the MDR+ phenotype and robust activity in models of tumor heterogeneity in a structure-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi-liIa9oi_rVg90H21EOLACvtfcHk0ljB4P9j_pDWpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtrfM&md5=57268b599402601821db672b6d645936</span></div><a href="/servlet/linkout?suffix=cit35f&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0073%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DHamilton%26aufirst%3DJ.%2BZ.%26aulast%3DPires%26aufirst%3DT.%2BA.%26aulast%3DLai%26aufirst%3DH.%2BW.%2BH.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DEmmerton%26aufirst%3DK.%2BK.%26aulast%3DWaight%26aufirst%3DA.%2BB.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26atitle%3DGlucuronide-linked%2520antibody-tubulysin%2520conjugates%2520display%2520activity%2520in%2520MDR%252B%2520and%2520heterogeneous%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D1752%26epage%3D1760%26doi%3D10.1158%2F1535-7163.MCT-18-0073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fourie-O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dela Cruz Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchelepi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span> <span> </span><span class="NLM_article-title">Improved translation of stability for conjugated antibodies using an in vitro whole blood assay</span>. <i>mAbs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e1715705</span> <span class="refDoi"> DOI: 10.1080/19420862.2020.1715705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1080%2F19420862.2020.1715705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31997712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFSrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&author=A.+Fourie-O%E2%80%99Donohueauthor=P.+Y.+Chuauthor=J.+dela+Cruz+Chuhauthor=R.+Tchelepiauthor=S.+P.+Tsaiauthor=J.+C.+Tranauthor=W.+S.+Sawyerauthor=D.+Suauthor=C.+Ngauthor=K.+Xuauthor=S.-F.+Yuauthor=T.+H.+Pillowauthor=J.+Sadowskyauthor=P.+S.+Dragovichauthor=Y.+Liuauthor=K.+R.+Kozak&title=Improved+translation+of+stability+for+conjugated+antibodies+using+an+in+vitro+whole+blood+assay&doi=10.1080%2F19420862.2020.1715705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Improved translation of stability for conjugated antibodies using an in vitro whole blood assay</span></div><div class="casAuthors">Fourie-O'Donohue, Aimee; Chu, Phillip Y.; dela Cruz Chuh, Josefa; Tchelepi, Robert; Tsai, Siao Ping; Tran, John C.; Sawyer, William S.; Su, Dian; Ng, Carl; Xu, Keyang; Yu, Shang-Fan; Pillow, Thomas H.; Sadowsky, Jack; Dragovich, Peter S.; Liu, Yichin; Kozak, Katherine R.</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1715705/1</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">For antibody-drug conjugates to be efficacious and safe, they must be stable in circulation to carry the payload to the site of the targeted cell.  Several components of a drug-conjugated antibody are known to influence stability: 1) the site of drug attachment on the antibody, 2) the linker used to attach the payload to the antibody, and 3) the payload itself.  In order to support the design and optimization of a high vol. of drug conjugates and avoid unstable conjugates prior to testing in animal models, we wanted to proactively identify these potential liabilities.  Therefore, we sought to establish an in vitro screening method that best correlated with in vivo stability.  While traditionally plasma has been used to assess in vitro stability, our evaluation using a variety of THIOMABTM antibody-drug conjugates revealed several disconnects between the stability assessed in vitro and the in vivo outcomes when using plasma.  When drug conjugates were incubated in vitro for 24 h in mouse whole blood rather than plasma and then analyzed by affinity capture LC-MS, we found an improved correlation to in vivo stability with whole blood (R2 = 0.87, coeff. of detn.) compared to unfrozen or frozen mouse plasma (R2 = 0.34, 0.01, resp.).  We further showed that this whole blood assay was also able to predict in vivo stability of other preclin. species such as rat and cynomolgus monkey, as well as in human.  The screening method utilized short (24 h) incubation times, as well as a custom anal. software, allowing increased throughput and in-depth biotransformation characterization.  While some instabilities that were more challenging to identify remain, the method greatly enhanced the process of screening, optimizing, and lead candidate selection, resulting in the substantial redn. of animal studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhca0BIA00H7Vg90H21EOLACvtfcHk0ljB4P9j_pDWpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFSrt7g%253D&md5=c4b05b4fa7b3bf4d84955ec3e5e8dee5</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1080%2F19420862.2020.1715705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2020.1715705%26sid%3Dliteratum%253Aachs%26aulast%3DFourie-O%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DChu%26aufirst%3DP.%2BY.%26aulast%3Ddela%2BCruz%2BChuh%26aufirst%3DJ.%26aulast%3DTchelepi%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DTran%26aufirst%3DJ.%2BC.%26aulast%3DSawyer%26aufirst%3DW.%2BS.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26atitle%3DImproved%2520translation%2520of%2520stability%2520for%2520conjugated%2520antibodies%2520using%2520an%2520in%2520vitro%2520whole%2520blood%2520assay%26jtitle%3DmAbs%26date%3D2020%26volume%3D12%26doi%3D10.1080%2F19420862.2020.1715705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dela Cruz-Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span> <span> </span><span class="NLM_article-title">Development of efficient chemistry to generate site-specific disulfide-linked protein- and peptide-payload conjugates: Application to THIOMAB antibody-drug conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2098</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVaktLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2086-2098&author=J.+D.+Sadowskyauthor=T.+H.+Pillowauthor=J.+Chenauthor=F.+Fanauthor=C.+Heauthor=Y.+Wangauthor=G.+Yanauthor=H.+Yaoauthor=Z.+Xuauthor=S.+Martinauthor=D.+Zhangauthor=P.+Chuauthor=J.+dela+Cruz-Chuhauthor=A.+O%E2%80%99Donohueauthor=G.+Liauthor=G.+Del+Rosarioauthor=J.+Heauthor=L.+Liuauthor=C.+Ngauthor=D.+Suauthor=G.+D.+L.+Phillipsauthor=K.+R.+Kozakauthor=S.-F.+Yuauthor=K.+Xuauthor=D.+Leipoldauthor=J.+Wai&title=Development+of+efficient+chemistry+to+generate+site-specific+disulfide-linked+protein-+and+peptide-payload+conjugates%3A+Application+to+THIOMAB+antibody-drug+conjugates&doi=10.1021%2Facs.bioconjchem.7b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates</span></div><div class="casAuthors">Sadowsky, Jack D.; Pillow, Thomas H.; Chen, Jinhua; Fan, Fang; He, Changrong; Wang, Yanli; Yan, Gang; Yao, Hui; Xu, Zijin; Martin, Shanique; Zhang, Donglu; Chu, Phillip; dela Cruz-Chuh, Josefa; ODonohue, Aimee; Li, Guangmin; Del Rosario, Geoffrey; He, Jintang; Liu, Luna; Ng, Carl; Su, Dian; Lewis Phillips, Gail D.; Kozak, Katherine R.; Yu, Shang-Fan; Xu, Keyang; Leipold, Douglas; Wai, John</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2086-2098</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conjugation of small mol. payloads to specific cysteine residues on proteins via a disulfide bond represents an attractive strategy to generate redox-sensitive bioconjugates, which have value as potential diagnostic reagents or therapeutics.  Advancement of such "direct-disulfide" bioconjugates to the clinic necessitates chem. methods to form disulfide connections efficiently, without byproducts.  The disulfide connection must also be resistant to premature cleavage by thiols prior to arrival at the targeted tissue.  We show here that commonly-employed methods to generate direct disulfide-linked bioconjugates are inadequate for addressing these challenges.  We describe our efforts to optimize direct-disulfide conjugation chem., focusing on the generation of conjugates between cytotoxic payloads and cysteine-engineered antibodies (i.e., THIOMAB antibody-drug conjugates, or TDCs).  This work culminates in the development of novel, high-yielding conjugation chem. for creating direct payload disulfide connections to any of several Cys mutation sites in THIOMAB antibodies or to Cys sites in other biomols. (e.g., human serum albumin and cell-penetrating peptides).  We conclude by demonstrating that hindered direct disulfide TDCs with two Me groups adjacent to the disulfide, which have heretofore not been described for any bioconjugate, are more stable and more efficacious in mouse tumor xenograft studies than less hindered analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIap6CQnm0X7Vg90H21EOLACvtfcHk0ljsOwSWmq9SeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVaktLvL&md5=9c437d3e1aa16e51e3f571fea95785c4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00258%26sid%3Dliteratum%253Aachs%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DG.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DP.%26aulast%3Ddela%2BCruz-Chuh%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLeipold%26aufirst%3DD.%26aulast%3DWai%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520efficient%2520chemistry%2520to%2520generate%2520site-specific%2520disulfide-linked%2520protein-%2520and%2520peptide-payload%2520conjugates%253A%2520Application%2520to%2520THIOMAB%2520antibody-drug%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2017%26volume%3D28%26spage%3D2086%26epage%3D2098%26doi%3D10.1021%2Facs.bioconjchem.7b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span> <span> </span><span class="NLM_article-title">Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates</span>. <i>Chem Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1039/C6SC01831A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2FC6SC01831A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28451181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOqsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=366-370&author=T.+H.+Pillowauthor=J.+D.+Sadowskyauthor=D.+Zhangauthor=S.-F.+Yuauthor=G.+Del+Rosarioauthor=K.+Xuauthor=J.+Heauthor=S.+Bhaktaauthor=R.+Ohriauthor=K.+R.+Kozakauthor=E.+Haauthor=J.+R.+Junutulaauthor=J.+A.+Flygare&title=Decoupling+stability+and+release+in+disulfide+bonds+with+antibody-small+molecule+conjugates&doi=10.1039%2FC6SC01831A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38aR"><div class="casContent"><span class="casTitleNuber">38a</span><div class="casTitle"><span class="NLM_cas:atitle">Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates</span></div><div class="casAuthors">Pillow, Thomas H.; Sadowsky, Jack D.; Zhang, Donglu; Yu, Shang-Fan; Del Rosario, Geoffrey; Xu, Keyang; He, Jintang; Bhakta, Sunil; Ohri, Rachana; Kozak, Katherine R.; Ha, Edward; Junutula, Jagath R.; Flygare, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">366-370</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Disulfide bonds provide a bioactivatable connection with applications in imaging and therapy.  The circulation stability and intracellular release of disulfides are problematically coupled in that increasing stability causes a corresponding decrease in cleavage and payload release.  However, an antibody offers the potential for a reversible stabilization.  We examd. this by attaching a small mol. directly to engineered cysteines in an antibody.  At certain sites this unhindered disulfide was stable in circulation yet cellular internalization and antibody catabolism generated a disulfide catabolite that was rapidly reduced.  We demonstrated that this stable connection and facile release is applicable to a variety of payloads.  The ability to reversibly stabilize a labile functional group with an antibody may offer a way to improve targeted probes and therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocdfG3fjz5LLVg90H21EOLACvtfcHk0ljsOwSWmq9SeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOqsL%252FP&md5=1ef5dd94930854c9fba36a9ddea49f3a</span></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1039%2FC6SC01831A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6SC01831A%26sid%3Dliteratum%253Aachs%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DHa%26aufirst%3DE.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26atitle%3DDecoupling%2520stability%2520and%2520release%2520in%2520disulfide%2520bonds%2520with%2520antibody-small%2520molecule%2520conjugates%26jtitle%3DChem%2520Sci.%26date%3D2017%26volume%3D8%26spage%3D366%26epage%3D370%26doi%3D10.1039%2FC6SC01831A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit38b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achilles-Poon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody-Drug conjugates with self-immolative disulfide linkers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1535-7163.MCT-16-0641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28223423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFemtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=871-878&author=T.+H.+Pillowauthor=M.+Schuttenauthor=S.-F.+Yuauthor=R.+Ohriauthor=J.+Sadowskyauthor=K.+Achilles-Poonauthor=W.+Solisauthor=F.+Zhongauthor=G.+Del+Rosarioauthor=M.+A.+T.+Goauthor=J.+Lauauthor=S.+Yeeauthor=J.+Heauthor=L.+Liuauthor=C.+Ngauthor=K.+Xuauthor=D.+D.+Leipoldauthor=A.+V.+Kamathauthor=D.+Zhangauthor=L.+Mastersonauthor=S.+J.+Gregsonauthor=P.+W.+Howardauthor=F.+Fangauthor=J.+Chenauthor=J.+Gunzner-Tosteauthor=K.+R.+Kozakauthor=S.+Spencerauthor=P.+Polakisauthor=A.+G.+Polsonauthor=J.+A.+Flygareauthor=J.+R.+Junutula&title=Modulating+therapeutic+activity+and+toxicity+of+pyrrolobenzodiazepine+antibody-Drug+conjugates+with+self-immolative+disulfide+linkers&doi=10.1158%2F1535-7163.MCT-16-0641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers</span></div><div class="casAuthors">Pillow, Thomas H.; Schutten, Melissa; Yu, Shang-Fan; Ohri, Rachana; Sadowsky, Jack; Poon, Kirsten Achilles; Solis, Willy; Zhong, Fiona; Del Rosario, Geoffrey; Go, Mary Ann T.; Lau, Jeffrey; Yee, Sharon; He, Jintang; Liu, Luna; Ng, Carl; Xu, Keyang; Leipold, Douglas D.; Kamath, Amrita V.; Zhang, Donglu; Masterson, Luke; Gregson, Stephen J.; Howard, Philip W.; Fang, Fan; Chen, Jinhua; Gunzner-Toste, Janet; Kozak, Katherine K.; Spencer, Susan; Polakis, Paul; Polson, Andrew G.; Flygare, John A.; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">871-878</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody-drug conjugates (ADCs).  The ADCs composed of a cysteine-engineered antibody were armed with a PBD using a self-immolative disulfide linker.  Both the chem. linker and the antibody site were optimized for this new bioconjugation strategy to provide a highly stable and efficacious ADC.  This novel disulfide ADC was compared with a conjugate contg. the same PBD drug, but attached to the antibody via a peptide linker.  Both ADCs had similar efficacy in mice bearing human tumor xenografts.  Safety studies in rats revealed that the disulfide-linked ADC had a higher MTD than the peptide-linked ADC.  Overall, these data suggest that the novel self-immolative disulfide linker represents a valuable way to construct ADCs with equiv. efficacy and improved safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZP_imFtNeBrVg90H21EOLACvtfcHk0lhlS7I3W657Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFemtrw%253D&md5=6bf9501951de0cfad9d890a4ef9492b1</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0641%26sid%3Dliteratum%253Aachs%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSchutten%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DAchilles-Poon%26aufirst%3DK.%26aulast%3DSolis%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DGo%26aufirst%3DM.%2BA.%2BT.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DYee%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DFang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DModulating%2520therapeutic%2520activity%2520and%2520toxicity%2520of%2520pyrrolobenzodiazepine%2520antibody-Drug%2520conjugates%2520with%2520self-immolative%2520disulfide%2520linkers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D871%26epage%3D878%26doi%3D10.1158%2F1535-7163.MCT-16-0641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="note"><p class="first last">For other examples of ADCs containing carbonate-based linkers, see reference <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a>a and:</p></div><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandish, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bresson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gately, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manibusan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbaccio, R. M.</span></span> <span> </span><span class="NLM_article-title">Novel phosphate modified cathepsin B linkers: Improving aqueous solubility and enhancing payload scope of ADCs</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2081</span>– <span class="NLM_lpage">2088</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.6b00337</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00337" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GjtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=2081-2088&author=J.+C.+Kernauthor=D.+Dooneyauthor=R.+Zhangauthor=L.+Liangauthor=P.+E.+Brandishauthor=M.+Chengauthor=G.+Fengauthor=A.+Beckauthor=D.+Bressonauthor=J.+Firdosauthor=D.+Gatelyauthor=N.+Knudsenauthor=A.+Manibusanauthor=Y.+Sunauthor=R.+M.+Garbaccio&title=Novel+phosphate+modified+cathepsin+B+linkers%3A+Improving+aqueous+solubility+and+enhancing+payload+scope+of+ADCs&doi=10.1021%2Facs.bioconjchem.6b00337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs</span></div><div class="casAuthors">Kern, Jeffrey C.; Dooney, Deborah; Zhang, Rena; Liang, Linda; Brandish, Philip E.; Cheng, Mangeng; Feng, Guo; Beck, Andrew; Bresson, Damien; Firdos, Juhi; Gately, Dennis; Knudsen, Nick; Manibusan, Anthony; Sun, Ying; Garbaccio, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2081-2088</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In an effort to examine the utility of antibody-drug conjugates (ADCs) beyond oncol. indications, a novel phosphate bridged Cathepsin B sensitive linker was developed to enable the targeted delivery of glucocorticoids.  Phosphate bridging of the Cathepsin B sensitive linkers allows for payload attachment at an aliph. alc.  As small mol. drug-linkers, these aq. sol. phosphate contg. drug-linkers were found to have robust plasma stability coupled with rapid release of payload in a lysosomal environment.  Site-specific ADCs were successfully made between these drug-linkers and an antibody against human CD70, a receptor specifically expressed in immune cells but also found aberrantly expressed in multiple human carcinomas.  These ADCs demonstrated in vitro targeted delivery of glucocorticoids to a representative cell line as measured by changes in glucocorticoid receptor (GR) mediated gene mRNA levels.  This novel linker expands the scope of potential ADC payloads by allowing an aliph. alc. to be a stable, yet cleavable attachment site.  This phosphate linker may have broad utility for internalizing ADCs as well as other targeted delivery platforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9cYjuaEBF2bVg90H21EOLACvtfcHk0lhlS7I3W657Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GjtrrN&md5=5dd6102d06fd4ab58ac9cc8453ecf224</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00337%26sid%3Dliteratum%253Aachs%26aulast%3DKern%26aufirst%3DJ.%2BC.%26aulast%3DDooney%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DBresson%26aufirst%3DD.%26aulast%3DFirdos%26aufirst%3DJ.%26aulast%3DGately%26aufirst%3DD.%26aulast%3DKnudsen%26aufirst%3DN.%26aulast%3DManibusan%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DGarbaccio%26aufirst%3DR.%2BM.%26atitle%3DNovel%2520phosphate%2520modified%2520cathepsin%2520B%2520linkers%253A%2520Improving%2520aqueous%2520solubility%2520and%2520enhancing%2520payload%2520scope%2520of%2520ADCs%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D2081%26epage%3D2088%26doi%3D10.1021%2Facs.bioconjchem.6b00337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span> <span> </span><span class="NLM_article-title">Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1836</span>– <span class="NLM_lpage">1847</span>, <span class="refDoi"> DOI: 10.1021/mp5006195</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp5006195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGktbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1836-1847&author=S.+V.+Govindanauthor=T.+M.+Cardilloauthor=E.+A.+Rossiauthor=P.+Trisalauthor=W.+J.+McBrideauthor=R.+M.+Sharkeyauthor=D.+M.+Goldenberg&title=Improving+the+therapeutic+index+in+cancer+therapy+by+using+antibody-drug+conjugates+designed+with+a+moderately+cytotoxic+drug&doi=10.1021%2Fmp5006195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug</span></div><div class="casAuthors">Govindan, Serengulam V.; Cardillo, Thomas M.; Rossi, Edmund A.; Trisal, Preeti; McBride, William J.; Sharkey, Robert M.; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1836-1847</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The antibody-drug conjugate (ADC), IMMU-130, of the moderately cytotoxic topoisomerase I inhibitor, SN-38, and the CEACAM5-targeted humanized antibody (mAb), labetuzumab, was evaluated in model systems of human colon carcinoma and in phase I clin. trials of heavily pretreated patients with metastatic colorectal cancer.  The conjugate, designed with a near-homogeneous drug substitution of 7-8 SN-38/mAb and with a linker that released 50% of the drug in ∼20 h, showed significant antitumor effects compared to a nontargeted ADC in human tumor xenografts, which could be augmented in combination with bevacizumab.  The advantage of fractionated dosing was demonstrated, with potential implications for the clin. dosing schedule.  Biodistribution comparing IMMU-130 with labetuzumab showed that the conjugate cleared somewhat faster from the blood, but this did not affect tumor uptake and retention.  The use of an ultra-stable linker in the conjugate design abrogated antitumor effects.  A tolerability study in rabbits showed a high safety margin, with no-obsd.-adverse-effect level (NOAEL) corresponding to a cumulative human-equiv. protein dose of 40-60 mg/kg.  The preclin. findings appear to be corroborated in two phase I clin. trials, with high tolerability and evidence of antitumor activity, including objective responses.  The impact of the ADC design on the utility of IMMU-130, tailored to a poorly internalizing target, is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq73bJkMWKZkrVg90H21EOLACvtfcHk0lhlS7I3W657Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGktbjJ&md5=65ef4d6c6e7b6cea3fdfe68eb283cd28</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1021%2Fmp5006195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp5006195%26sid%3Dliteratum%253Aachs%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DCardillo%26aufirst%3DT.%2BM.%26aulast%3DRossi%26aufirst%3DE.%2BA.%26aulast%3DTrisal%26aufirst%3DP.%26aulast%3DMcBride%26aufirst%3DW.%2BJ.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DImproving%2520the%2520therapeutic%2520index%2520in%2520cancer%2520therapy%2520by%2520using%2520antibody-drug%2520conjugates%2520designed%2520with%2520a%2520moderately%2520cytotoxic%2520drug%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D1836%26epage%3D1847%26doi%3D10.1021%2Fmp5006195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Besten, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowntree, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandlen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Conjugation of indoles to antibodies through a novel self-immolating linker</span>. <i>Chem. – Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4830</span>– <span class="NLM_lpage">4834</span>, <span class="refDoi"> DOI: 10.1002/chem.201800859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fchem.201800859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=29493023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlslSnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=4830-4834&author=P.+S.+Dragovichauthor=R.+A.+Blakeauthor=C.+Chenauthor=J.+Chenauthor=J.+Chuhauthor=W.+den+Bestenauthor=F.+Fanauthor=A.+Fourieauthor=S.+J.+Hartmanauthor=C.+Heauthor=J.+Heauthor=E.+R.+Ingallaauthor=K.+R.+Kozakauthor=S.+R.+Leongauthor=J.+Luauthor=Y.+Maauthor=L.+Mengauthor=M.+Nanniniauthor=J.+Oehauthor=R.+Ohriauthor=G.+L.+Phillipsauthor=T.+H.+Pillowauthor=R.+K.+Rowntreeauthor=D.+Sampathauthor=R.+Vandlenauthor=B.+Vollmarauthor=J.+Waiauthor=I.+E.+Wertzauthor=K.+Xuauthor=Z.+Xuauthor=D.+Zhang&title=Conjugation+of+indoles+to+antibodies+through+a+novel+self-immolating+linker&doi=10.1002%2Fchem.201800859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker</span></div><div class="casAuthors">Dragovich, Peter S.; Blake, Robert A.; Chen, Chunjiao; Chen, Jinhua; Chuh, Josefa; den Besten, Willem; Fan, Fang; Fourie, Aimee; Hartman, Steven J.; He, Changrong; He, Jintang; Ingalla, Ellen Rei; Kozak, Katherine R.; Leong, Steven R.; Lu, Jiawei; Ma, Yong; Meng, Lingyao; Nannini, Michelle; Oeh, Jason; Ohri, Rachana; Lewis Phillips, Gail; Pillow, Thomas H.; Rowntree, Rebecca K.; Sampath, Deepak; Vandlen, Richard; Vollmar, Breanna; Wai, John; Wertz, Ingrid E.; Xu, Keyang; Xu, Zijin; Zhang, Donglu</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4830-4834</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel strategy to attach indole-contg. payloads to antibodies through a carbamate moiety and a self-immolating, disulfide-based linker is described.  This new strategy was employed to connect a selective estrogen receptor down-regulator (SERD) to various antibodies in a site-selective manner.  The resulting conjugates displayed potent, antigen-dependent down-regulation of estrogen receptor levels in MCF7-neo/HER2 and MCF7-hB7H4 cells.  They also exhibited similar antigen-dependent modulation of the estrogen receptor in tumors when administered i.v. to mice bearing MCF7-neo/HER2 tumor xenografts.  The indole-carbamate moiety present in the new linker was stable in whole blood from various species and also exhibited good in vivo stability properties in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKhcOeE6xSRLVg90H21EOLACvtfcHk0lhepyAUgAiZ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlslSnu78%253D&md5=f1c82d8a721646a690e735c3ed38b53a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fchem.201800859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201800859%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChuh%26aufirst%3DJ.%26aulast%3Dden%2BBesten%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DFourie%26aufirst%3DA.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DIngalla%26aufirst%3DE.%2BR.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DLeong%26aufirst%3DS.%2BR.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DG.%2BL.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DRowntree%26aufirst%3DR.%2BK.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DVollmar%26aufirst%3DB.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DConjugation%2520of%2520indoles%2520to%2520antibodies%2520through%2520a%2520novel%2520self-immolating%2520linker%26jtitle%3DChem.%2520%25E2%2580%2593%2520Eur.%2520J.%26date%3D2018%26volume%3D24%26spage%3D4830%26epage%3D4834%26doi%3D10.1002%2Fchem.201800859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="note"><p class="first last">For representative examples, see:</p></div><div class="NLM_citation" id="cit41a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Tubulin inhibitor-based antibody-drug conjugates for cancer therapy</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>, <span class="NLM_elocation-id">1281</span> <span class="refDoi"> DOI: 10.3390/molecules22081281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.3390%2Fmolecules22081281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28763044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&author=H.+Chenauthor=Z.+Linauthor=K.+E.+Arnstauthor=D.+D.+Millerauthor=W.+Li&title=Tubulin+inhibitor-based+antibody-drug+conjugates+for+cancer+therapy&doi=10.3390%2Fmolecules22081281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin inhibitor-based antibody-drug conjugates for cancer therapy</span></div><div class="casAuthors">Chen, Hao; Lin, Zongtao; Arnst, Kinsie E.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1281/1-1281/28</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are a class of highly potent biopharmaceutical drugs generated by conjugating cytotoxic drugs with specific monoclonal antibodies through appropriate linkers.  Specific antibodies used to guide potent warheads to tumor tissues can effectively reduce undesired side effects of the cytotoxic drugs.  An in-depth understanding of antibodies, linkers, conjugation strategies, cytotoxic drugs, and their mol. targets has led to the successful development of several approved ADCs.  These ADCs are powerful therapeutics for cancer treatment, enabling wider therapeutic windows, improved pharmacokinetic/pharmacodynamic properties, and enhanced efficacy.  Since tubulin inhibitors are one of the most successful cytotoxic drugs in the ADC armamentarium, this review focuses on the progress in tubulin inhibitor-based ADCs, as well as lessons learned from the unsuccessful ADCs contg. tubulin inhibitors.  This review should be helpful to facilitate future development of new generations of tubulin inhibitor-based ADCs for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8A0aJYR6aBLVg90H21EOLACvtfcHk0lhepyAUgAiZ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls7zI&md5=eb6efd4fdf44b5c0294a9becbeffab86</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22081281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22081281%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DTubulin%2520inhibitor-based%2520antibody-drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26doi%3D10.3390%2Fmolecules22081281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit41b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00062</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=983-987&author=A.+C.+Tiberghienauthor=J.+N.+Levyauthor=L.+A.+Mastersonauthor=N.+V.+Patelauthor=L.+R.+Adamsauthor=S.+Corbettauthor=D.+G.+Williamsauthor=J.+A.+Hartleyauthor=P.+W.+Howard&title=Design+and+synthesis+of+tesirine%2C+a+clinical+antibody-drug+conjugate+pyrrolobenzodiazepine+dimer+payload&doi=10.1021%2Facsmedchemlett.6b00062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41bR"><div class="casContent"><span class="casTitleNuber">41b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload</span></div><div class="casAuthors">Tiberghien, Arnaud C.; Levy, Jean-Noel; Masterson, Luke A.; Patel, Neki V.; Adams, Lauren R.; Corbett, Simon; Williams, David G.; Hartley, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">983-987</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrrolobenzodiazepine dimers are an emerging class of warhead in the field of antibody-drug conjugates (ADCs).  Tesirine (SG3249) was designed to combine potent antitumor activity with desirable physicochem. properties such as favorable hydrophobicity and improved conjugation characteristics.  One of the reactive imines was capped with a cathepsin B-cleavable valine-alanine linker.  A robust synthetic route was developed to allow the prodn. of tesirine on clin. scale, employing a flexible, convergent strategy.  Tesirine was evaluated in vitro both in stochastic and engineered ADC constructs and was confirmed as a potent and versatile payload.  The conjugation of tesirine to anti-DLL3 rovalpituzumab has resulted in rovalpituzumab-tesirine (Rova-T), currently under evaluation for the treatment of small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYid7RNts7s7Vg90H21EOLACvtfcHk0lhepyAUgAiZ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D&md5=7e4bbdd55b944ff712f01d31d58c0d13</span></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00062%26sid%3Dliteratum%253Aachs%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DLevy%26aufirst%3DJ.%2BN.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DPatel%26aufirst%3DN.%2BV.%26aulast%3DAdams%26aufirst%3DL.%2BR.%26aulast%3DCorbett%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tesirine%252C%2520a%2520clinical%2520antibody-drug%2520conjugate%2520pyrrolobenzodiazepine%2520dimer%2520payload%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D983%26epage%3D987%26doi%3D10.1021%2Facsmedchemlett.6b00062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit41c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiske, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholas, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1021/bc400217g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc400217g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1256-1263&author=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=R.+P.+Lyonauthor=D.+W.+Meyerauthor=D.+Sussmanauthor=M.+Andersonauthor=J.+H.+Hunterauthor=C.+I.+Leiskeauthor=J.+B.+Miyamotoauthor=N.+D.+Nicholasauthor=N.+M.+Okeleyauthor=R.+J.+Sandersonauthor=I.+J.+Stoneauthor=W.+Zengauthor=S.+J.+Gregsonauthor=L.+Mastersonauthor=A.+C.+Tiberghienauthor=P.+W.+Howardauthor=D.+E.+Thurstonauthor=C.+L.+Lawauthor=P.+D.+Senter&title=A+potent+anti-CD70+antibody-drug+conjugate+combining+a+dimeric+pyrrolobenzodiazepine+drug+with+site-specific+conjugation+technology&doi=10.1021%2Fbc400217g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41cR"><div class="casContent"><span class="casTitleNuber">41c</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology</span></div><div class="casAuthors">Jeffrey, Scott C.; Burke, Patrick J.; Lyon, Robert P.; Meyer, David W.; Sussman, Django; Anderson, Martha; Hunter, Joshua H.; Leiske, Chris I.; Miyamoto, Jamie B.; Nicholas, Nicole D.; Okeley, Nicole M.; Sanderson, Russell J.; Stone, Ivan J.; Zeng, Weiping; Gregson, Stephen J.; Masterson, Luke; Tiberghien, Arnaud C.; Howard, Philip W.; Thurston, David E.; Law, Che-Leung; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1256-1263</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly cytotoxic DNA crosslinking pyrrolobenzodiazepine (PBD) dimer with a valine-alanine dipeptide linker was conjugated to the anti-CD70 h1F6 mAb either through endogenous interchain cysteines or, site-specifically, through engineered cysteines at position 239 of the heavy chains.  The h1F6239C-PBD conjugation strategy proved to be superior to interchain cysteine conjugation, affording an antibody-drug conjugate (ADC) with high uniformity in drug-loading and low levels of aggregation.  In vitro cytotoxicity expts. demonstrated that the h1F6239C-PBD was potent and immunol. specific on CD70-pos. renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL) cell lines.  The conjugate was resistant to drug loss in plasma and in circulation, and had a pharmacokinetic profile closely matching that of the parental h1F6239C antibody capped with N-ethylmaleimide (NEM).  Evaluation in CD70-pos. RCC and NHL mouse xenograft models showed pronounced antitumor activities at single or weekly doses as low as 0.1 mg/kg of ADC.  The ADC was tolerated at 2.5 mg/kg.  These results demonstrate that PBDs can be effectively used for antibody-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVruNGtWHpsbVg90H21EOLACvtfcHk0lgJKCoK1nzpxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D&md5=31841b0267e41ae861eaf05240c97b15</span></div><a href="/servlet/linkout?suffix=cit41c&amp;dbid=16384&amp;doi=10.1021%2Fbc400217g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc400217g%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DMeyer%26aufirst%3DD.%2BW.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%2BH.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DNicholas%26aufirst%3DN.%2BD.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DStone%26aufirst%3DI.%2BJ.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DLaw%26aufirst%3DC.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DA%2520potent%2520anti-CD70%2520antibody-drug%2520conjugate%2520combining%2520a%2520dimeric%2520pyrrolobenzodiazepine%2520drug%2520with%2520site-specific%2520conjugation%2520technology%26jtitle%3DBioconjugate%2520Chem.%26date%3D2013%26volume%3D24%26spage%3D1256%26epage%3D1263%26doi%3D10.1021%2Fbc400217g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, K.</span>; <span class="NLM_string-name">Hikawa, H.</span>; <span class="NLM_string-name">Hamada, M.</span>; <span class="NLM_string-name">Endoh, J.-i.</span>; <span class="NLM_string-name">Ishibuchi, S.</span>; <span class="NLM_string-name">Fujie, N.</span>; <span class="NLM_string-name">Tanaka, M.</span>; <span class="NLM_string-name">Sugahara, K.</span>; <span class="NLM_string-name">Oshita, K.</span>; <span class="NLM_string-name">Murata, M.</span></span> <span> </span><span class="NLM_article-title">Thienotriazolodiazepine Compound and a Medicinal Use Thereof</span>. <span class="NLM_patent">EP1,887,008</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+Adachi&author=H.+Hikawa&author=M.+Hamada&author=J.-i.+Endoh&author=S.+Ishibuchi&author=N.+Fujie&author=M.+Tanaka&author=K.+Sugahara&author=K.+Oshita&author=M.+Murata&title=Thienotriazolodiazepine+Compound+and+a+Medicinal+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DK.%26atitle%3DThienotriazolodiazepine%2520Compound%2520and%2520a%2520Medicinal%2520Use%2520Thereof%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span>; <span class="NLM_string-name">Dong, H.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Berlin, M.</span>; <span class="NLM_string-name">Siu, K.</span>; <span class="NLM_string-name">Crew, A. P.</span>; <span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Compounds and Methods for the Targeted Degradation of Bromodomain-Containing Proteins</span>. <span class="NLM_patent">WO2017030814</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Qian&author=H.+Dong&author=J.+Wang&author=M.+Berlin&author=K.+Siu&author=A.+P.+Crew&author=C.+M.+Crews&title=Compounds+and+Methods+for+the+Targeted+Degradation+of+Bromodomain-Containing+Proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DY.%26atitle%3DCompounds%2520and%2520Methods%2520for%2520the%2520Targeted%2520Degradation%2520of%2520Bromodomain-Containing%2520Proteins%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnaby, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumpel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00092</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00092" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVCisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=361-368&author=M.+Royauthor=S.+Winklerauthor=S.+J.+Hughesauthor=C.+Whitworthauthor=M.+Galantauthor=W.+Farnabyauthor=K.+Rumpelauthor=A.+Ciulli&title=SPR-measured+dissociation+kinetics+of+PROTAC+ternary+complexes+influence+target+degradation+rate&doi=10.1021%2Facschembio.9b00092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate</span></div><div class="casAuthors">Roy, Michael J.; Winkler, Sandra; Hughes, Scott J.; Whitworth, Claire; Galant, Michael; Farnaby, William; Rumpel, Klaus; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">361-368</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bifunctional degrader mols., known as proteolysis-targeting chimeras (PROTACs), function by recruiting a target to an E3 ligase, forming a target/PROTAC/ligase ternary complex.  Despite the importance of this key intermediate species, no detailed validation of a method to directly det. binding parameters for ternary complex kinetics has been reported, and it remains to be addressed whether tuning the kinetics of PROTAC ternary complexes may be an effective strategy to improve the efficiency of targeted protein degrdn.  Here, we develop an SPR-based assay to quantify the stability of PROTAC-induced ternary complexes by measuring for the first time the kinetics of their formation and dissocn. in vitro using purified proteins.  We benchmark our assay using four PROTACs that target the bromodomains (BDs) of bromodomain and extraterminal domain proteins Brd2, Brd3, and Brd4 to the von Hippel-Lindau E3 ligase (VHL).  We reveal marked differences in ternary complex off-rates for different PROTACs that exhibit either pos. or neg. cooperativity for ternary complex formation relative to binary binding.  The pos. cooperative degrader MZ1 forms comparatively stable and long-lived ternary complexes with either Brd4BD2 or Brd2BD2 and VHL.  Equivalent complexes with Brd3BD2 are destabilized due to a single amino acid difference (Glu/Gly swap) present in the bromodomain.  We observe that this difference in ternary complex dissociative half-life correlates to a greater initial rate of intracellular degrdn. of Brd2 and Brd4 relative to Brd3.  These findings establish a novel assay to measure the kinetics of PROTAC ternary complexes and elucidate the important kinetic parameters that drive effective target degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzFhvuKYztcbVg90H21EOLACvtfcHk0lgJKCoK1nzpxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVCisrg%253D&md5=629d1acbd218b668a2696b727946962b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00092%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DM.%26aulast%3DWinkler%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DWhitworth%26aufirst%3DC.%26aulast%3DGalant%26aufirst%3DM.%26aulast%3DFarnaby%26aufirst%3DW.%26aulast%3DRumpel%26aufirst%3DK.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DSPR-measured%2520dissociation%2520kinetics%2520of%2520PROTAC%2520ternary%2520complexes%2520influence%2520target%2520degradation%2520rate%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D361%26epage%3D368%26doi%3D10.1021%2Facschembio.9b00092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadd, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zengerl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">Structural basis of PROTAC cooperative recognition for selective protein degradation</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fnchembio.2329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28288108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFahtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=514-521&author=M.+S.+Gaddauthor=A.+Testaauthor=X.+Lucasauthor=K.-H.+Chanauthor=W.+Chenauthor=D.+J.+Lamontauthor=M.+Zengerlauthor=A.+Ciulli&title=Structural+basis+of+PROTAC+cooperative+recognition+for+selective+protein+degradation&doi=10.1038%2Fnchembio.2329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of PROTAC cooperative recognition for selective protein degradation</span></div><div class="casAuthors">Gadd, Morgan S.; Testa, Andrea; Lucas, Xavier; Chan, Kwok-Ho; Chen, Wenzhang; Lamont, Douglas J.; Zengerle, Michael; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">514-521</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inducing macromol. interactions with small mols. to activate cellular signaling is a challenging goal.  PROTACs (proteolysis-targeting chimeras) are bifunctional mols. that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degrdn.  Structural elucidation of the key ternary ligase-PROTAC-target species and its impact on target degrdn. selectivity remain elusive.  Here, we solved the crystal structure of Brd4 degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4BD2).  The ligand folds into itself to allow formation of specific intermol. interactions in the ternary complex.  Isothermal titrn. calorimetry studies, supported by surface mutagenesis and proximity assays, were consistent with pronounced cooperative formation of ternary complexes with Brd4BD2.  Structure-based-designed compd. AT1 exhibited highly selective depletion of Brd4 in cells.  These results elucidate how PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a stable and cooperative complex with an E3 ligase for selective degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJri00jB5YJLVg90H21EOLACvtfcHk0ljFGtde-5eJ4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFahtbg%253D&md5=dfee13913106d362d0972d7b1a62d700</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2329%26sid%3Dliteratum%253Aachs%26aulast%3DGadd%26aufirst%3DM.%2BS.%26aulast%3DTesta%26aufirst%3DA.%26aulast%3DLucas%26aufirst%3DX.%26aulast%3DChan%26aufirst%3DK.-H.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DLamont%26aufirst%3DD.%2BJ.%26aulast%3DZengerl%26aufirst%3DM.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DStructural%2520basis%2520of%2520PROTAC%2520cooperative%2520recognition%2520for%2520selective%2520protein%2520degradation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D514%26epage%3D521%26doi%3D10.1038%2Fnchembio.2329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavens, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Readshaw, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayne, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, A.</span></span> <span> </span><span class="NLM_article-title">Direct measurement of intracellular compound concentration by Rapid Fire mass spectrometry offers insights into cell permeability</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1177/1087057115604141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1177%2F1087057115604141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=26336900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvVSrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=156-164&author=L.+J.+Gordonauthor=M.+Allenauthor=P.+Arturssonauthor=M.+M.+Hannauthor=B.+J.+Leavensauthor=A.+Mateusauthor=S.+Readshawauthor=K.+Valkoauthor=G.+J.+Wayneauthor=A.+West&title=Direct+measurement+of+intracellular+compound+concentration+by+Rapid+Fire+mass+spectrometry+offers+insights+into+cell+permeability&doi=10.1177%2F1087057115604141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46aR"><div class="casContent"><span class="casTitleNuber">46a</span><div class="casTitle"><span class="NLM_cas:atitle">Direct measurement of intracellular compound concentration by RapidFire mass spectrometry offers insights into cell permeability</span></div><div class="casAuthors">Gordon, Laurie J.; Allen, Morven; Artursson, Per; Hann, Michael M.; Leavens, Bill J.; Mateus, Andre; Readshaw, Simon; Valko, Klara; Wayne, Gareth J.; West, Andy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">One of the key challenges facing early stage drug discovery is understanding the commonly obsd. difference between the activity of compds. in biochem. assays and cellular assays.  Traditionally, indirect or estd. cell permeability measurements such as estns. from logP or artificial membrane permeability are used to explain the differences.  The missing link is a direct measurement of intracellular compd. concn. in whole cells.  This can, in some circumstances, be estd. from the cellular activity, but this may also be problematic if cellular activity is weak or absent.  Advances in sensitivity and throughput of anal. techniques have enabled us to develop a high-throughput assay for the measurement of intracellular compd. concn. for routine use to support lead optimization.  The assay uses a RapidFire-MS based readout of compd. concn. in HeLa cells following incubation of cells with test compd.  The initial assay validation was performed by ultra-high performance liq. chromatog. tandem mass spectrometry, and the assay was subsequently transferred to RapidFire tandem mass spectrometry.  Further miniaturization and optimization were performed to streamline the process, increase sample throughput, and reduce cycle time.  This optimization has delivered a semi-automated platform with the potential of prodn. scale compd. profiling up to 100 compds. per day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLd62-6firibVg90H21EOLACvtfcHk0ljFGtde-5eJ4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvVSrtLc%253D&md5=34a5d2a18c1a36973425d00b87112f20</span></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=10.1177%2F1087057115604141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057115604141%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DL.%2BJ.%26aulast%3DAllen%26aufirst%3DM.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DLeavens%26aufirst%3DB.%2BJ.%26aulast%3DMateus%26aufirst%3DA.%26aulast%3DReadshaw%26aufirst%3DS.%26aulast%3DValko%26aufirst%3DK.%26aulast%3DWayne%26aufirst%3DG.%2BJ.%26aulast%3DWest%26aufirst%3DA.%26atitle%3DDirect%2520measurement%2520of%2520intracellular%2520compound%2520concentration%2520by%2520Rapid%2520Fire%2520mass%2520spectrometry%2520offers%2520insights%2520into%2520cell%2520permeability%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2016%26volume%3D21%26spage%3D156%26epage%3D164%26doi%3D10.1177%2F1087057115604141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit46b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Beigi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottschalk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hägglund, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haneskog, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekkan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Österberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundahl, P.</span></span> <span> </span><span class="NLM_article-title">Immobilized liposome and biomembrane partitioning chromatography of drugs for prediction of drug transport</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/S0378-5173(97)00398-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2FS0378-5173%2897%2900398-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADyaK1cXitlSrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=1998&pages=129-137&author=F.+Beigiauthor=I.+Gottschalkauthor=C.+L.+H%C3%A4gglundauthor=L.+Haneskogauthor=E.+Brekkanauthor=Y.+Zhangauthor=T.+%C3%96sterbergauthor=P.+Lundahl&title=Immobilized+liposome+and+biomembrane+partitioning+chromatography+of+drugs+for+prediction+of+drug+transport&doi=10.1016%2FS0378-5173%2897%2900398-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46bR"><div class="casContent"><span class="casTitleNuber">46b</span><div class="casTitle"><span class="NLM_cas:atitle">Immobilized liposome and biomembrane partitioning chromatography of drugs for prediction of drug transport</span></div><div class="casAuthors">Beigi, Farideh; Gottschalk, Ingo; Lagerquist Hagglund, Christine; Haneskog, Lars; Brekkan, Eggert; Zhang, Yanxiao; Osterberg, Thomas; Lundahl, Per</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">129-137</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Drug partitioning into lipid bilayers was studied by chromatog. on liposomes and biomembranes immobilized in gel beads by freeze-thawing.  The drug retention vol. was expressed as a capacity factor, Ks, normalized with respect to the amt. of immobilized phospholipid.  Log Ks values for pos. charged drugs on brain phosphatidylserine (PS)/egg phosphatidylcholine (PC) liposomes decreased as the ionic strength was increased, increased as the PS:PC ratio or the pH was increased and varied linearly with the temp.  Log Ks values for beta-blockers, phenothiazines and benzodiazepines on egg phospholipid (EPL) liposomes correlated well with corresponding values on red cell membrane lipid liposomes (r2=0.96), and on human red cell membrane vesicles contg. transmembrane proteins (r2=0.96).  A fair correlation was obsd. between the values on EPL liposomes and those on native membranes of adsorbed red cells (r2=0.86).  Compared to the data obtained with liposomes, the retentions of hydrophilic drugs became larger and the range of log Ks values more narrow on the vesicles and the membranes, which expose hydrophilic protein surfaces and oligosaccharides.  Lower correlations were obsd. between drug retention on EPL liposomes and egg PC liposomes; and between retention on liposomes (or vesicles) and immobilized artificial membrane (IAM) monolayers of PC analogs.  Absorption of orally administered drugs in humans (literature data) was nearly complete for drugs of log Ks values in the interval 1.2-2.5 on vesicles.  Both vesicles and liposomes can thus be used for chromatog. anal. of drug-membrane interaction and prediction of drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_r5N-IU8WaLVg90H21EOLACvtfcHk0ljFGtde-5eJ4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitlSrt7g%253D&md5=f930fe3b4f61a23889e2dc42f510b8bc</span></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=10.1016%2FS0378-5173%2897%2900398-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5173%252897%252900398-0%26sid%3Dliteratum%253Aachs%26aulast%3DBeigi%26aufirst%3DF.%26aulast%3DGottschalk%26aufirst%3DI.%26aulast%3DH%25C3%25A4gglund%26aufirst%3DC.%2BL.%26aulast%3DHaneskog%26aufirst%3DL.%26aulast%3DBrekkan%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3D%25C3%2596sterberg%26aufirst%3DT.%26aulast%3DLundahl%26aufirst%3DP.%26atitle%3DImmobilized%2520liposome%2520and%2520biomembrane%2520partitioning%2520chromatography%2520of%2520drugs%2520for%2520prediction%2520of%2520drug%2520transport%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D1998%26volume%3D164%26spage%3D129%26epage%3D137%26doi%3D10.1016%2FS0378-5173%2897%2900398-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R. A.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3341</span>– <span class="NLM_lpage">3346</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(98)00609-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2FS0960-894X%2898%2900609-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=9873731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADyaK1cXotFagtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=3341-3346&author=G.+M.+Dubowchikauthor=R.+A.+Firestone&title=Cathepsin+B-sensitive+dipeptide+prodrugs.+1.+A+model+study+of+structural+requirements+for+efficient+release+of+doxorubicin&doi=10.1016%2FS0960-894X%2898%2900609-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin</span></div><div class="casAuthors">Dubowchik, Gene M.; Firestone, Raymond A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3341-3346</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of lysosomal protease-sensitive peptides attached to doxorubicin (DOX) was prepd. as model substrates for internalizing anticancer immunoconjugates and potential antimetastasis prodrugs.  Rates of cathepsin B-mediated release of free drug was measured for each, and human plasma stabilities for representative examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOzOf1WKrZurVg90H21EOLACvtfcHk0lhzOxgoI4slTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotFagtbY%253D&md5=946bb31dc62701634c946beb1f1cc1bc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900609-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900609-X%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26atitle%3DCathepsin%2520B-sensitive%2520dipeptide%2520prodrugs.%25201.%2520A%2520model%2520study%2520of%2520structural%2520requirements%2520for%2520efficient%2520release%2520of%2520doxorubicin%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D3341%26epage%3D3346%26doi%3D10.1016%2FS0960-894X%2898%2900609-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meekin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phipps, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebelatto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimasi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span> <span> </span><span class="NLM_article-title">SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6570</span>– <span class="NLM_lpage">6582</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1078-0432.CCR-18-1300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30131388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=6570-6582&author=K.+Kinneerauthor=J.+Meekinauthor=A.+C.+Tiberghienauthor=Y.-T.+Taiauthor=S.+Phippsauthor=C.+M.+Kieferauthor=M.+C.+Rebelattoauthor=N.+Dimasiauthor=A.+Moriartyauthor=K.+P.+Papadopoulosauthor=S.+Sridharauthor=S.+J.+Gregsonauthor=M.+J.+Wickauthor=L.+Mastersonauthor=K.+C.+Andersonauthor=R.+Herbstauthor=P.+W.+Howardauthor=D.+A.+Tice&title=SLC46A3+as+a+potential+predictive+biomarker+for+antibody-drug+conjugates+bearing+noncleavable+linked+maytansinoid+and+pyrrolobenzodiazepine+warheads&doi=10.1158%2F1078-0432.CCR-18-1300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48aR"><div class="casContent"><span class="casTitleNuber">48a</span><div class="casTitle"><span class="NLM_cas:atitle">SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span></div><div class="casAuthors">Kinneer, Krista; Meekin, John; Tiberghien, Arnaud C.; Tai, Yu-Tzu; Phipps, Sandrina; Kiefer, Christine Mione; Rebelatto, Marlon C.; Dimasi, Nazzareno; Moriarty, Alyssa; Papadopoulos, Kyriakos P.; Sridhar, Sriram; Gregson, Stephen J.; Wick, Michael J.; Masterson, Luke; Anderson, Kenneth C.; Herbst, Ronald; Howard, Philip W.; Tice, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6570-6582</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Antibody-drug conjugates (ADC) utilizing noncleavable linker drugs have been approved for clin. use, and several are in development targeting solid and hematol. malignancies including multiple myeloma.  Currently, there are no reliable biomarkers of activity for these ADCs other than presence of the targeted antigen.  We obsd. that certain cell lines are innately resistant to such ADCs, and sought to uncover the underlying mechanism of resistance.  Exptl. Design: The expression of 43 lysosomal membrane target genes was evaluated in cell lines resistant to ADCs bearing the noncleavable linker, pyrrolobenzodiazepine payload SG3376, in vitro.  The functional relevance of SLC46A3, a lysosomal transporter of noncleavable ADC catabolites whose expression uniquely correlated with SG3376 resistance, was assessed using EPHA2-, HER2-, and BCMA-targeted ADCs and isogenic cells overexpressing or genetically inactivated for SLC46A3.  SLC46A3 expression was also examd. in patient-derived xenograft and in vitro models of acquired T-DM1 resistance and multiple myeloma bone marrow samples by RT-PCR.  Results: Loss of SLC46A3 expression was found to be a mechanism of innate and acquired resistance to ADCs bearing DM1 and SG3376.  Sensitivity was restored in refractory lines upon introduction of SLC46A3, suggesting that expression of SLC46A3 may be more predictive of activity than target antigen levels alone.  Interrogation of primary multiple myeloma samples indicated a range of SLC46A3 expression, including samples with undetectable levels like multiple myeloma cell lines resistant to BCMA-targeting DM1 and SG3376 ADCs.  Conclusions: Our findings support SLC46A3 as a potential patient selection biomarker with immediate relevance to clin. trials involving these ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMBCbYdUVXbVg90H21EOLACvtfcHk0lhzOxgoI4slTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI&md5=e3b5550bd7a96683d9f3ccac137eeb66</span></div><a href="/servlet/linkout?suffix=cit48a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1300%26sid%3Dliteratum%253Aachs%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DMeekin%26aufirst%3DJ.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DPhipps%26aufirst%3DS.%26aulast%3DKiefer%26aufirst%3DC.%2BM.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DDimasi%26aufirst%3DN.%26aulast%3DMoriarty%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DSridhar%26aufirst%3DS.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DWick%26aufirst%3DM.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DSLC46A3%2520as%2520a%2520potential%2520predictive%2520biomarker%2520for%2520antibody-drug%2520conjugates%2520bearing%2520noncleavable%2520linked%2520maytansinoid%2520and%2520pyrrolobenzodiazepine%2520warheads%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D6570%26epage%3D6582%26doi%3D10.1158%2F1078-0432.CCR-18-1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit48b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblett, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurgel, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tometsko, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borths, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bio, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quon, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanslow, W. C.</span></span> <span> </span><span class="NLM_article-title">SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">5329</span>– <span class="NLM_lpage">5340</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-1610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F0008-5472.CAN-15-1610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=26631267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWrt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=5329-5340&author=K.+J.+Hamblettauthor=A.+P.+Jacobauthor=J.+L.+Gurgelauthor=M.+E.+Tometskoauthor=B.+M.+Rockauthor=S.+K.+Patelauthor=R.+R.+Milburnauthor=S.+Siuauthor=S.+P.+Raganauthor=D.+A.+Rockauthor=C.+J.+Borthsauthor=J.+W.+O%E2%80%99Neillauthor=W.+S.+Changauthor=M.+F.+Weidnerauthor=M.+M.+Bioauthor=K.+C.+Quonauthor=W.+C.+Fanslow&title=SLC46A3+is+required+to+transport+catabolites+of+noncleavable+antibody+maytansine+conjugates+from+the+lysosome+to+the+cytoplasm&doi=10.1158%2F0008-5472.CAN-15-1610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48bR"><div class="casContent"><span class="casTitleNuber">48b</span><div class="casTitle"><span class="NLM_cas:atitle">SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm</span></div><div class="casAuthors">Hamblett, Kevin J.; Jacob, Allison P.; Gurgel, Jesse L.; Tometsko, Mark E.; Rock, Brooke M.; Patel, Sonal K.; Milburn, Robert R.; Siu, Sophia; Ragan, Seamus P.; Rock, Dan A.; Borths, Christopher J.; O'Neill, Jason W.; Chang, Wesley S.; Weidner, Margaret F.; Bio, Matthew M.; Quon, Kim C.; Fanslow, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5329-5340</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADC) target cytotoxic drugs to antigen-pos. cells for treating cancer.  After internalization, ADCs with noncleavable linkers are catabolized to amino acid-linker-warheads within the lysosome, which then enter the cytoplasm by an unknown mechanism.  We hypothesized that a lysosomal transporter was responsible for delivering noncleavable ADC catabolites into the cytoplasm.  To identify candidate transporters, we performed a phenotypic shRNA screen with an anti-CD70 maytansine-based ADC.  This screen revealed the lysosomal membrane protein SLC46A3, the genetic attenuation of which inhibited the potency of multiple noncleavable antibody-maytansine ADCs, including ado-trastuzumab emtansine.  In contrast, the potencies of noncleavable ADCs carrying the structurally distinct monomethyl auristatin F were unaffected by SLC46A3 attenuation.  Structure-activity expts. suggested that maytansine is a substrate for SLC46A3.  Notably, SLC46A3 silencing led to relative increases in catabolite concns. in the lysosome.  Taken together, our results establish SLC46A3 as a direct transporter of maytansine-based catabolites from the lysosome to the cytoplasm, prompting further investigation of SLC46A3 as a predictive response marker in breast cancer specimens.  Cancer Res; 75(24); 5329-40. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm_J2q_2qRbLVg90H21EOLACvtfcHk0lh9Q0UzKJ1yUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWrt7fN&md5=ba203524dd29addcf5295ee40cbc5e88</span></div><a href="/servlet/linkout?suffix=cit48b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-1610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-1610%26sid%3Dliteratum%253Aachs%26aulast%3DHamblett%26aufirst%3DK.%2BJ.%26aulast%3DJacob%26aufirst%3DA.%2BP.%26aulast%3DGurgel%26aufirst%3DJ.%2BL.%26aulast%3DTometsko%26aufirst%3DM.%2BE.%26aulast%3DRock%26aufirst%3DB.%2BM.%26aulast%3DPatel%26aufirst%3DS.%2BK.%26aulast%3DMilburn%26aufirst%3DR.%2BR.%26aulast%3DSiu%26aufirst%3DS.%26aulast%3DRagan%26aufirst%3DS.%2BP.%26aulast%3DRock%26aufirst%3DD.%2BA.%26aulast%3DBorths%26aufirst%3DC.%2BJ.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DJ.%2BW.%26aulast%3DChang%26aufirst%3DW.%2BS.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DBio%26aufirst%3DM.%2BM.%26aulast%3DQuon%26aufirst%3DK.%2BC.%26aulast%3DFanslow%26aufirst%3DW.%2BC.%26atitle%3DSLC46A3%2520is%2520required%2520to%2520transport%2520catabolites%2520of%2520noncleavable%2520antibody%2520maytansine%2520conjugates%2520from%2520the%2520lysosome%2520to%2520the%2520cytoplasm%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D5329%26epage%3D5340%26doi%3D10.1158%2F0008-5472.CAN-15-1610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="note"><p class="first last">For one example where antibody-mediated delivery of a cell-impermeable payload improved biological outcomes relative to a permeable cargo, see:</p></div><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brandish, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonenko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancilla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayadat-Dilman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbaccio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garvin-Queen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gately, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hseih, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasnjuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manibusan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomazela, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielstorf, M.</span></span> <span> </span><span class="NLM_article-title">Development of anti-CD74 antibody-drug conjugates to target glucocorticoids to immune cells</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2357</span>– <span class="NLM_lpage">2369</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.8b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.8b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGlsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=2357-2369&author=P.+E.+Brandishauthor=A.+Palmieriauthor=S.+Antonenkoauthor=M.+Beaumontauthor=L.+Bensoauthor=M.+Cancillaauthor=M.+Chengauthor=L.+Fayadat-Dilmanauthor=G.+Fengauthor=I.+Figueroaauthor=J.+Firdosauthor=R.+Garbaccioauthor=L.+Garvin-Queenauthor=D.+Gatelyauthor=P.+Gedaauthor=C.+Hainesauthor=S.+C.+Hseihauthor=D.+Hodgesauthor=J.+Kernauthor=N.+Knudsenauthor=K.+Kwasnjukauthor=L.+Liangauthor=H.+Maauthor=A.+Manibusanauthor=P.+L.+Millerauthor=L.+Y.+Moyauthor=Y.+Quauthor=S.+Shahauthor=J.+S.+Shinauthor=P.+Stiversauthor=Y.+Sunauthor=D.+Tomazelaauthor=H.+C.+Wooauthor=D.+Zallerauthor=S.+Zhangauthor=Y.+Zhangauthor=M.+Zielstorf&title=Development+of+anti-CD74+antibody-drug+conjugates+to+target+glucocorticoids+to+immune+cells&doi=10.1021%2Facs.bioconjchem.8b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Development of anti-CD74 antibody-drug conjugates to target glucocorticoids to immune cells</span></div><div class="casAuthors">Brandish, Philip E.; Palmieri, Anthony; Antonenko, Svetlana; Beaumont, Maribel; Benso, Lia; Cancilla, Mark; Cheng, Mangeng; Fayadat-Dilman, Laurence; Feng, Guo; Figueroa, Isabel; Firdos, Juhi; Garbaccio, Robert; Garvin-Queen, Laura; Gately, Dennis; Geda, Prasanthi; Haines, Christopher; Hseih, SuChun; Hodges, Douglas; Kern, Jeffrey; Knudsen, Nickolas; Kwasnjuk, Kristen; Liang, Linda; Ma, Huiping; Manibusan, Anthony; Miller, Paul L.; Moy, Lily Y.; Qu, Yujie; Shah, Sanjiv; Shin, John S.; Stivers, Peter; Sun, Ying; Tomazela, Daniela; Woo, Hyun Chong; Zaller, Dennis; Zhang, Shuli; Zhang, Yiwei; Zielstorff, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2357-2369</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucocorticoids (GCs) are excellent anti-inflammatory drugs but are dose-limited by on-target toxicity.  We sought to solve this problem by delivering GCs to immune cells with antibody-drug conjugates (ADCs) using antibodies contg. site-specific incorporation of a non-natural amino acid, novel linker chem. for in vitro and in vivo stability, and existing and novel glucocorticoid receptor (GR) agonists as payloads.  We directed fluticasone propionate to human antigen-presenting immune cells to afford GR activation that was dependent on the targeted antigen.  However, mechanism of action studies pointed to accumulation of free payload in the tissue culture supernatant as the dominant driver of activity and indeed administration of the ADC to human CD74 transgenic mice failed to activate GR target genes in splenic B cells.  Suspecting dissipation of released payload, we designed an ADC bearing a novel GR agonist payload with reduced permeability which afforded cell-intrinsic activity in human B cells.  Our work shows that antibody-targeting offers significant potential for rescuing existing and new dose-limited drugs outside the field of oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL223IFiibVrVg90H21EOLACvtfcHk0lh9Q0UzKJ1yUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGlsb7P&md5=16f03a31902538a233676f30cc1c26c7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.8b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.8b00312%26sid%3Dliteratum%253Aachs%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DPalmieri%26aufirst%3DA.%26aulast%3DAntonenko%26aufirst%3DS.%26aulast%3DBeaumont%26aufirst%3DM.%26aulast%3DBenso%26aufirst%3DL.%26aulast%3DCancilla%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DFayadat-Dilman%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DFigueroa%26aufirst%3DI.%26aulast%3DFirdos%26aufirst%3DJ.%26aulast%3DGarbaccio%26aufirst%3DR.%26aulast%3DGarvin-Queen%26aufirst%3DL.%26aulast%3DGately%26aufirst%3DD.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DHaines%26aufirst%3DC.%26aulast%3DHseih%26aufirst%3DS.%2BC.%26aulast%3DHodges%26aufirst%3DD.%26aulast%3DKern%26aufirst%3DJ.%26aulast%3DKnudsen%26aufirst%3DN.%26aulast%3DKwasnjuk%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DManibusan%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DP.%2BL.%26aulast%3DMoy%26aufirst%3DL.%2BY.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DJ.%2BS.%26aulast%3DStivers%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DTomazela%26aufirst%3DD.%26aulast%3DWoo%26aufirst%3DH.%2BC.%26aulast%3DZaller%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZielstorf%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520anti-CD74%2520antibody-drug%2520conjugates%2520to%2520target%2520glucocorticoids%2520to%2520immune%2520cells%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D2357%26epage%3D2369%26doi%3D10.1021%2Facs.bioconjchem.8b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Costoplus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veale, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponte, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setiady, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaletskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartle, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span> <span> </span><span class="NLM_article-title">Peptide-cleavable self-immolative maytansinoid antibody-drug conjugates designed to provide improved bystander killing</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1399</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGgtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1393-1399&author=J.+A.+Costoplusauthor=K.+H.+Vealeauthor=Q.+Qiuauthor=J.+F.+Ponteauthor=L.+Lanieriauthor=Y.+Setiadyauthor=L.+Dongauthor=A.+Skaletskayaauthor=L.+M.+Bartleauthor=P.+Salomonauthor=R.+Wuauthor=E.+K.+Maloneyauthor=Y.+V.+Kovtunauthor=O.+Abauthor=K.+Laiauthor=R.+V.+J.+Chariauthor=W.+C.+Widdison&title=Peptide-cleavable+self-immolative+maytansinoid+antibody-drug+conjugates+designed+to+provide+improved+bystander+killing&doi=10.1021%2Facsmedchemlett.9b00310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50aR"><div class="casContent"><span class="casTitleNuber">50a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing</span></div><div class="casAuthors">Costoplus, Juliet A.; Veale, Karen H.; Qiu, Qifeng; Ponte, Jose F.; Lanieri, Leanne; Setiady, Yulius; Dong, Ling; Skaletskaya, Anna; Bartle, Laura M.; Salomon, Paulin; Wu, Rui; Maloney, Erin K.; Kovtun, Yelena V.; Ab, Olga; Lai, Kate; Chari, Ravi V. J.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1393-1399</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new type of antibody-drug conjugate (ADC) has been prepd. that contains a sulfur-bearing maytansinoid attached to an antibody via a highly stable tripeptide linker.  Once internalized by cells, proteases in catabolic vesicles cleave the peptide of the ADC's linker causing self-immolation that releases a thiol-bearing metabolite, which is then S-methylated.  Conjugates were prepd. with peptide linkers contg. only alanyl residues, which were all L isomers or had a single D residue in one of the three positions.  A D-alanyl residue in the linker did not significantly impair a conjugate's cytotoxicity or bystander killing unless it was directly attached to the immolative moiety.  Increasing the no. of methylene units in the maytansinoid side chain of a conjugate did not typically affect an ADC's cytotoxicity to targeted cells but did increase bystander killing activity.  ADCs with the highest in vitro bystander killing were then evaluated in vivo in mice, where they displayed improved efficacy compared to previously described types of maytansinoid conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVorbrpE2efbVg90H21EOLACvtfcHk0lj_S6EkypVXZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGgtLzI&md5=5bbc21126af25e33a52971fbeef6be32</span></div><a href="/servlet/linkout?suffix=cit50a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00310%26sid%3Dliteratum%253Aachs%26aulast%3DCostoplus%26aufirst%3DJ.%2BA.%26aulast%3DVeale%26aufirst%3DK.%2BH.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DPonte%26aufirst%3DJ.%2BF.%26aulast%3DLanieri%26aufirst%3DL.%26aulast%3DSetiady%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DSkaletskaya%26aufirst%3DA.%26aulast%3DBartle%26aufirst%3DL.%2BM.%26aulast%3DSalomon%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DPeptide-cleavable%2520self-immolative%2520maytansinoid%2520antibody-drug%2520conjugates%2520designed%2520to%2520provide%2520improved%2520bystander%2520killing%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1393%26epage%3D1399%26doi%3D10.1021%2Facsmedchemlett.9b00310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit50b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ogitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oitate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agatsuma, T.</span></span> <span> </span><span class="NLM_article-title">Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1111/cas.12966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1111%2Fcas.12966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27166974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVahu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=1039-1046&author=Y.+Ogitaniauthor=K.+Hagiharaauthor=M.+Oitateauthor=H.+Naitoauthor=T.+Agatsuma&title=Bystander+killing+effect+of+DS-8201a%2C+a+novel+anti-human+epidermal+growth+factor+receptor+2+antibody-drug+conjugate%2C+in+tumors+with+human+epidermal+growth+factor+receptor+2+heterogeneity&doi=10.1111%2Fcas.12966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50bR"><div class="casContent"><span class="casTitleNuber">50b</span><div class="casTitle"><span class="NLM_cas:atitle">Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity</span></div><div class="casAuthors">Ogitani, Yusuke; Hagihara, Katsunobu; Oitate, Masataka; Naito, Hiroyuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1039-1046</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window.  DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepd. using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan deriv. (DX-8951 deriv., DXd).  It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression.  In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1.  We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability.  Under a coculture condition of HER2-pos. KPL-4 cells and neg. MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not.  In vivo evaluation was carried out using mice inoculated with a mixt. of HER2-pos. NCI-N87 cells and HER2-neg. MDA-MB-468-Luc cells by using an in vivo imaging system.  In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not.  Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is obsd. only in cells neighboring HER2-pos. cells, indicating low concern in terms of systemic toxicity.  These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroroEcCVHueLVg90H21EOLACvtfcHk0lj_S6EkypVXZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVahu7zO&md5=1e65fee32e1333a1c446aff844a7c67d</span></div><a href="/servlet/linkout?suffix=cit50b&amp;dbid=16384&amp;doi=10.1111%2Fcas.12966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12966%26sid%3Dliteratum%253Aachs%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DOitate%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DAgatsuma%26aufirst%3DT.%26atitle%3DBystander%2520killing%2520effect%2520of%2520DS-8201a%252C%2520a%2520novel%2520anti-human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520antibody-drug%2520conjugate%252C%2520in%2520tumors%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520heterogeneity%26jtitle%3DCancer%2520Sci.%26date%3D2016%26volume%3D107%26spage%3D1039%26epage%3D1046%26doi%3D10.1111%2Fcas.12966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit50c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerton, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholas, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, C.-L.</span></span> <span> </span><span class="NLM_article-title">Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2710</span>– <span class="NLM_lpage">2719</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-1795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F0008-5472.CAN-15-1795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=26921341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVers74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2710-2719&author=F.+Liauthor=K.+K.+Emmertonauthor=M.+Jonasauthor=X.+Zhangauthor=J.+B.+Miyamotoauthor=J.+R.+Setterauthor=N.+D.+Nicholasauthor=N.+M.+Okeleyauthor=R.+P.+Lyonauthor=D.+R.+Benjaminauthor=C.-L.+Law&title=Intracellular+released+payload+influences+potency+and+bystander-killing+effects+of+antibody-drug+conjugates+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-15-1795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50cR"><div class="casContent"><span class="casTitleNuber">50c</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models</span></div><div class="casAuthors">Li, Fu; Emmerton, Kim K.; Jonas, Mechthild; Zhang, Xinqun; Miyamoto, Jamie B.; Setter, Jocelyn R.; Nicholas, Nicole D.; Okeley, Nicole M.; Lyon, Robert P.; Benjamin, Dennis R.; Law, Che-Leung</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2710-2719</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-mol. payloads.  ADCs demonstrate specific cell killing in clinic, but the basis of their antitumor activity is not fully understood.  In this study, we investigated the degree to which payload release predicts ADC activity in vitro and in vivo.  ADCs were generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and we found that the intracellular concn. of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios.  Intratumoral MMAE concns. consistently correlated with the extent of tumor growth inhibition in tumor xenograft models.  In addn., we developed a robust admixed tumor model consisting of CD30+ and CD30- cancer cells to study how heterogeneity of target antigen expression, a phenomenon often obsd. in cancer specimens, affects the treatment response.  CD30-targeting ADC delivering membrane permeable MMAE or pyrrolobenzodiazepine dimers demonstrated potent bystander killing of neighboring CD30- cells.  In contrast, a less membrane permeable payload, MMAF, failed to mediate bystander killing in vivo, suggesting local diffusion and distribution of released payloads represents a potential mechanism of ADC-mediated bystander killing.  Collectively, our findings establish that the biophys. properties and amt. of released payloads are chief factors detg. the overall ADC potency and bystander killing.  Cancer Res; 76(9); 2710-9. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoylCMD1xAFdLVg90H21EOLACvtfcHk0lj_S6EkypVXZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVers74%253D&md5=bb7e7c2e6b4ea6f92d522d6c086454d2</span></div><a href="/servlet/linkout?suffix=cit50c&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-1795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-1795%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DEmmerton%26aufirst%3DK.%2BK.%26aulast%3DJonas%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DSetter%26aufirst%3DJ.%2BR.%26aulast%3DNicholas%26aufirst%3DN.%2BD.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DLaw%26aufirst%3DC.-L.%26atitle%3DIntracellular%2520released%2520payload%2520influences%2520potency%2520and%2520bystander-killing%2520effects%2520of%2520antibody-drug%2520conjugates%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2710%26epage%3D2719%26doi%3D10.1158%2F0008-5472.CAN-15-1795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">131</span> <span class="refDoi"> DOI: 10.1038/s41467-018-08027-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41467-018-08027-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30631068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A280%3ADC%252BB3cjgt1Sksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=B.+E.+Smithauthor=S.+L.+Wangauthor=S.+Jaime-Figueroaauthor=A.+Harbinauthor=J.+Wangauthor=B.+D.+Hammanauthor=C.+M.+Crews&title=Differential+PROTAC+substrate+specificity+dictated+by+orientation+of+recruited+E3+ligase&doi=10.1038%2Fs41467-018-08027-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51aR"><div class="casContent"><span class="casTitleNuber">51a</span><div class="casTitle"><span class="NLM_cas:atitle">Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase</span></div><div class="casAuthors">Smith Blake E; Wang Stephen L; Jaime-Figueroa Saul; Crews Craig M; Harbin Alicia; Wang Jing; Hamman Brian D; Crews Craig M; Crews Craig M</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation.  Many potent PROTACs with specificity for dissimilar targets have been developed; however, the factors governing degradation selectivity within closely-related protein families remain elusive.  Here, we generate isoform-selective PROTACs for the p38 MAPK family using a single warhead (foretinib) and recruited E3 ligase (von Hippel-Lindau).  Based on their distinct linker attachments and lengths, these two PROTACs differentially recruit VHL, resulting in degradation of p38α or p38δ.  We characterize the role of ternary complex formation in driving selectivity, showing that it is necessary, but insufficient, for PROTAC-induced substrate ubiquitination.  Lastly, we explore the p38δ:PROTAC:VHL complex to explain the different selectivity profiles of these PROTACs.  Our work attributes the selective degradation of two closely-related proteins using the same warhead and E3 ligase to heretofore underappreciated aspects of the ternary complex model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYPr3dBOGbeuR_TJajKxJDfW6udTcc2eaVwussCAWzh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjgt1Sksg%253D%253D&md5=bd56c51f5966709ca5d1ff3dadb7cc79</span></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08027-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08027-7%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DWang%26aufirst%3DS.%2BL.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DHarbin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DDifferential%2520PROTAC%2520substrate%2520specificity%2520dictated%2520by%2520orientation%2520of%2520recruited%2520E3%2520ligase%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26doi%3D10.1038%2Fs41467-018-08027-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit51b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Farnaby, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karolyi-Oezguer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedmueller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmaschitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dank, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumpel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petermann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstabl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss-Puxbaum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrenhöfer-Wölfer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wöhrle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehmelt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinnenthal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnhof, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiechens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen-Hughes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">672</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0294-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41589-019-0294-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31178587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFeqtLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=672-680&author=W.+Farnabyauthor=M.+Koeglauthor=M.+J.+Royauthor=C.+Whitworthauthor=E.+Diersauthor=N.+Trainorauthor=D.+Zollmanauthor=S.+Steurerauthor=J.+Karolyi-Oezguerauthor=C.+Riedmuellerauthor=T.+Gmaschitzauthor=J.+Wachterauthor=C.+Dankauthor=M.+Galantauthor=B.+Sharpsauthor=K.+Rumpelauthor=E.+Traxlerauthor=T.+Gerstbergerauthor=R.+Schnitzerauthor=O.+Petermannauthor=P.+Grebauthor=H.+Weinstablauthor=G.+Baderauthor=A.+Zoephelauthor=A.+Weiss-Puxbaumauthor=K.+Ehrenh%C3%B6fer-W%C3%B6lferauthor=S.+W%C3%B6hrleauthor=G.+Boehmeltauthor=J.+Rinnenthalauthor=H.+Arnhofauthor=N.+Wiechensauthor=M.-Y.+Wuauthor=T.+Owen-Hughesauthor=P.+Ettmayerauthor=M.+Pearsonauthor=D.+B.+McConnellauthor=A.+Ciulli&title=BAF+complex+vulnerabilities+in+cancer+demonstrated+via+structure-based+PROTAC+design&doi=10.1038%2Fs41589-019-0294-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51bR"><div class="casContent"><span class="casTitleNuber">51b</span><div class="casTitle"><span class="NLM_cas:atitle">BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design</span></div><div class="casAuthors">Farnaby, William; Koegl, Manfred; Roy, Michael J.; Whitworth, Claire; Diers, Emelyne; Trainor, Nicole; Zollman, David; Steurer, Steffen; Karolyi-Oezguer, Jale; Riedmueller, Carina; Gmaschitz, Teresa; Wachter, Johannes; Dank, Christian; Galant, Michael; Sharps, Bernadette; Rumpel, Klaus; Traxler, Elisabeth; Gerstberger, Thomas; Schnitzer, Renate; Petermann, Oliver; Greb, Peter; Weinstabl, Harald; Bader, Gerd; Zoephel, Andreas; Weiss-Puxbaum, Alexander; Ehrenhofer-Wolfer, Katharina; Wohrle, Simon; Boehmelt, Guido; Rinnenthal, Joerg; Arnhof, Heribert; Wiechens, Nicola; Wu, Meng-Ying; Owen-Hughes, Tom; Ettmayer, Peter; Pearson, Mark; McConnell, Darryl B.; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">672-680</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Targeting subunits of BAF/PBAF chromatin remodeling complexes has been proposed as an approach to exploit cancer vulnerabilities.  Here, we develop proteolysis targeting chimera (PROTAC) degraders of the BAF ATPase subunits SMARCA2 and SMARCA4 using a bromodomain ligand and recruitment of the E3 ubiquitin ligase VHL.  High-resoln. ternary complex crystal structures and biophys. investigation guided rational and efficient optimization toward ACBI1(I), a potent and cooperative degrader of SMARCA2, SMARCA4 and PBRM1.  I induced anti-proliferative effects and cell death caused by SMARCA2 depletion in SMARCA4 mutant cancer cells, and in acute myeloid leukemia cells dependent on SMARCA4 ATPase activity.  These findings exemplify a successful biophysics- and structure-based PROTAC design approach to degrade high profile drug targets, and pave the way toward new therapeutics for the treatment of tumors sensitive to the loss of BAF complex ATPases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonEh4pux4Bs7Vg90H21EOLACvtfcHk0liW4EurT2RqfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFeqtLfJ&md5=e95fad12c727aedcf08aed9320dae905</span></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0294-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0294-6%26sid%3Dliteratum%253Aachs%26aulast%3DFarnaby%26aufirst%3DW.%26aulast%3DKoegl%26aufirst%3DM.%26aulast%3DRoy%26aufirst%3DM.%2BJ.%26aulast%3DWhitworth%26aufirst%3DC.%26aulast%3DDiers%26aufirst%3DE.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DZollman%26aufirst%3DD.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DKarolyi-Oezguer%26aufirst%3DJ.%26aulast%3DRiedmueller%26aufirst%3DC.%26aulast%3DGmaschitz%26aufirst%3DT.%26aulast%3DWachter%26aufirst%3DJ.%26aulast%3DDank%26aufirst%3DC.%26aulast%3DGalant%26aufirst%3DM.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DRumpel%26aufirst%3DK.%26aulast%3DTraxler%26aufirst%3DE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DPetermann%26aufirst%3DO.%26aulast%3DGreb%26aufirst%3DP.%26aulast%3DWeinstabl%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DWeiss-Puxbaum%26aufirst%3DA.%26aulast%3DEhrenh%25C3%25B6fer-W%25C3%25B6lfer%26aufirst%3DK.%26aulast%3DW%25C3%25B6hrle%26aufirst%3DS.%26aulast%3DBoehmelt%26aufirst%3DG.%26aulast%3DRinnenthal%26aufirst%3DJ.%26aulast%3DArnhof%26aufirst%3DH.%26aulast%3DWiechens%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DM.-Y.%26aulast%3DOwen-Hughes%26aufirst%3DT.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DBAF%2520complex%2520vulnerabilities%2520in%2520cancer%2520demonstrated%2520via%2520structure-based%2520PROTAC%2520design%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D672%26epage%3D680%26doi%3D10.1038%2Fs41589-019-0294-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit51c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span>; <span class="NLM_string-name">Crew, A.</span>; <span class="NLM_string-name">Dong, H.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Siu, K.</span>; <span class="NLM_string-name">Ferraro, C.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Qian, Y.</span></span> <span> </span><span class="NLM_article-title">Compounds and Methods for the Targeted Degradation of the Androgen Receptor</span>. <span class="NLM_patent">WO2016118666</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Jin&author=A.+Crew&author=H.+Dong&author=J.+Wang&author=K.+Siu&author=C.+Ferraro&author=X.+Chen&author=Y.+Qian&title=Compounds+and+Methods+for+the+Targeted+Degradation+of+the+Androgen+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%26atitle%3DCompounds%2520and%2520Methods%2520for%2520the%2520Targeted%2520Degradation%2520of%2520the%2520Androgen%2520Receptor%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Endo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumichika, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunitomo
Adachi, K.</span></span> <span> </span><span class="NLM_article-title">A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1365</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.01.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.bmcl.2016.01.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=26869194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVahsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1365-1370&author=J.+Endoauthor=H.+Hikawaauthor=M.+Hamadaauthor=S.+Ishibuchiauthor=N.+Fujieauthor=N.+Sugiyamaauthor=M.+Tanakaauthor=H.+Kobayashiauthor=K.+Sugaharaauthor=K.+Oshitaauthor=K.+Iwataauthor=S.+Ooikeauthor=M.+Murataauthor=H.+Sumichikaauthor=K.+Chibaauthor=K.+Kunitomo%0AAdachi&title=A+phenotypic+drug+discovery+study+on+thienodiazepine+derivatives+as+inhibitors+of+T+cell+proliferation+induced+by+CD28+co-stimulation+leads+to+the+discovery+of+a+first+bromodomain+inhibitor&doi=10.1016%2Fj.bmcl.2016.01.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor</span></div><div class="casAuthors">Endo, Junichi; Hikawa, Hidemasa; Hamada, Maiko; Ishibuchi, Seigo; Fujie, Naoto; Sugiyama, Naoki; Tanaka, Minoru; Kobayashi, Haruhito; Sugahara, Kunio; Oshita, Koichi; Iwata, Kazunori; Ooike, Shinsuke; Murata, Meguru; Sumichika, Hiroshi; Chiba, Kenji; Adachi, Kunitomo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1365-1370</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A phenotypic screening of thienodiazepines derived from a hit compd. found through a binding assay targeting co-stimulatory mols. on T cells and antigen presenting cells successfully led to the discovery of a thienotriazolodiazepine compd. (7f) possessing potent immunosuppressive activity.  A chem. biol. approach has succeeded in revealing that 7f is a first inhibitor of epigenetic bromodomain-contg. proteins. 7f is expected to become an anti-cancer agent as well as an immunosuppressive agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeajoPFavBUbVg90H21EOLACvtfcHk0lhY_RCBuheSfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVahsL8%253D&md5=e414d4c7fad718d7b2c5a76a20aed0d7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.01.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.01.084%26sid%3Dliteratum%253Aachs%26aulast%3DEndo%26aufirst%3DJ.%26aulast%3DHikawa%26aufirst%3DH.%26aulast%3DHamada%26aufirst%3DM.%26aulast%3DIshibuchi%26aufirst%3DS.%26aulast%3DFujie%26aufirst%3DN.%26aulast%3DSugiyama%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DSugahara%26aufirst%3DK.%26aulast%3DOshita%26aufirst%3DK.%26aulast%3DIwata%26aufirst%3DK.%26aulast%3DOoike%26aufirst%3DS.%26aulast%3DMurata%26aufirst%3DM.%26aulast%3DSumichika%26aufirst%3DH.%26aulast%3DChiba%26aufirst%3DK.%26aulast%3DKunitomo%2BAdachi%26aufirst%3DK.%26atitle%3DA%2520phenotypic%2520drug%2520discovery%2520study%2520on%2520thienodiazepine%2520derivatives%2520as%2520inhibitors%2520of%2520T%2520cell%2520proliferation%2520induced%2520by%2520CD28%2520co-stimulation%2520leads%2520to%2520the%2520discovery%2520of%2520a%2520first%2520bromodomain%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1365%26epage%3D1370%26doi%3D10.1016%2Fj.bmcl.2016.01.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Rapid measurement of intracellular unbound drug concentrations</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2467</span>– <span class="NLM_lpage">2478</span>, <span class="refDoi"> DOI: 10.1021/mp4000822</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp4000822" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVShs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=2467-2478&author=A.+Mateusauthor=P.+Matssonauthor=P.+Artursson&title=Rapid+measurement+of+intracellular+unbound+drug+concentrations&doi=10.1021%2Fmp4000822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Measurement of Intracellular Unbound Drug Concentrations</span></div><div class="casAuthors">Mateus, Andre; Matsson, Paer; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2467-2478</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Intracellular unbound drug concns. det. affinity to targets in the cell interior.  However, due to difficulties in measuring them, they are often overlooked in pharmacol.  Here we present a simple exptl. technique for the detn. of unbound intracellular drug concns. in cultured cells that is based on parallel measurements of cellular drug binding and steady-state intracellular drug concns.  Binding in HEK293 cells was highly correlated with binding in liver-derived systems, whereas binding in plasma did not compare well with cellular binding.  Compd. lipophilicity increased drug binding, while neg. charge and arom. functional groups decreased binding.  Intracellular accumulation of unbound drug was consistent with pH-dependent subcellular sequestration, as confirmed by modeling and by inhibition of subcellular pH gradients.  The approach developed here can be used to measure intracellular unbound drug concns. in more complex systems, for example, cell lines with controlled expression of transporters and enzymes or primary cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAI-LcAqDSybVg90H21EOLACvtfcHk0lhY_RCBuheSfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVShs70%253D&md5=de56aeff7c7ae6149eae187298d371a8</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fmp4000822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp4000822%26sid%3Dliteratum%253Aachs%26aulast%3DMateus%26aufirst%3DA.%26aulast%3DMatsson%26aufirst%3DP.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DRapid%2520measurement%2520of%2520intracellular%2520unbound%2520drug%2520concentrations%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D2467%26epage%3D2478%26doi%3D10.1021%2Fmp4000822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caculitan, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dela Cruz Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akita, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B Is dispensable for cellular processing of cathepsin B-cleavable antibody-drug conjugates</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">7027</span>– <span class="NLM_lpage">7037</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-2391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F0008-5472.CAN-17-2391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=29046337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=7027-7037&author=N.+G.+Caculitanauthor=J.+dela+Cruz+Chuhauthor=Y.+Maauthor=D.+Zhangauthor=K.+R.+Kozakauthor=Y.+Liuauthor=T.+H.+Pillowauthor=J.+Sadowskyauthor=T.+K.+Cheungauthor=Q.+Phungauthor=B.+Haleyauthor=B.-C.+Leeauthor=R.+W.+Akitaauthor=M.+X.+Sliwkowskiauthor=A.+G.+Polson&title=Cathepsin+B+Is+dispensable+for+cellular+processing+of+cathepsin+B-cleavable+antibody-drug+conjugates&doi=10.1158%2F0008-5472.CAN-17-2391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates</span></div><div class="casAuthors">Caculitan, Nina G.; dela Cruz Chuh, Josefa; Ma, Yong; Zhang, Donglu; Kozak, Katherine R.; Liu, Yichin; Pillow, Thomas H.; Sadowsky, Jack; Cheung, Tommy K.; Phung, Qui; Haley, Benjamin; Lee, Byoung-Chul; Akita, Robert W.; Sliwkowski, Mark X.; Polson, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7027-7037</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADC) are designed to selectively bind to tumor antigens via the antibody and release their cytotoxic payload upon internalization.  Controllable payload release through judicious design of the linker has been an early technol. milestone.  Here, we examine the effect of the protease-cleavable valine-citrulline [VC(S)] linker on ADC efficacy.  The VC(S) linker was designed to be cleaved by cathepsin B, a lysosomal cysteine protease.  Surprisingly, suppression of cathepsin B expression via CRISPR-Cas9 gene deletion or shRNA knockdown had no effect on the efficacy of ADCs with VC(S) linkers armed with a monomethyl auristatin E (MMAE) payload.  Mass spectrometry studies of payload release suggested that other cysteine cathepsins can cleave the VC(S) linker.  Also, ADCs with a nonprotease-cleavable enantiomer, the VC(R) isomer, mediated effective cell killing with a cysteine-VC(R)-MMAE catabolite generated by lysosomal catabolism.  Based on these observations, we altered the payload to a pyrrolo[2,1-c][1,4]benzodiazepine dimer (PBD) conjugate that requires linker cleavage in order to bind its DNA target.  Unlike the VC-MMAE ADCs, the VC(S)-PBD ADC is at least 20-fold more cytotoxic than the VC(R)-PBD ADC.  Our findings reveal that the VC(S) linker has multiple paths to produce active catabolites and that antibody and intracellular targets are more crit. to ADC efficacy.  These results suggest that protease-cleavable linkers are unlikely to increase the therapeutic index of ADCs and that resistance based on linker processing is improbable.  Cancer Res; 77(24); 7027-37. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR45ou6LPL1bVg90H21EOLACvtfcHk0lhY_RCBuheSfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur%252FO&md5=dd6c5c61ec81fef214b9d19d83e8e22c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-2391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-2391%26sid%3Dliteratum%253Aachs%26aulast%3DCaculitan%26aufirst%3DN.%2BG.%26aulast%3Ddela%2BCruz%2BChuh%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DT.%2BK.%26aulast%3DPhung%26aufirst%3DQ.%26aulast%3DHaley%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DB.-C.%26aulast%3DAkita%26aufirst%3DR.%2BW.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26atitle%3DCathepsin%2520B%2520Is%2520dispensable%2520for%2520cellular%2520processing%2520of%2520cathepsin%2520B-cleavable%2520antibody-drug%2520conjugates%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D7027%26epage%3D7037%26doi%3D10.1158%2F0008-5472.CAN-17-2391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masih, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latifi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dere, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco-Triguero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuillemenot, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laing, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia</span>. <i>mAbs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1312</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1080/19420862.2018.1517565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1080%2F19420862.2018.1517565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30183491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGjtLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1312-1321&author=D.+D.+Leipoldauthor=I.+Figueroaauthor=S.+Masihauthor=B.+Latifiauthor=V.+Yipauthor=B.-Q.+Shenauthor=R.+C.+Dereauthor=M.+Carrasco-Trigueroauthor=M.+V.+Leeauthor=O.+M.+Saadauthor=L.+Liuauthor=J.+Heauthor=D.+Suauthor=K.+Xuauthor=B.+R.+Vuillemenotauthor=S.+T.+Laingauthor=M.+Schuttenauthor=K.+R.+Kozakauthor=B.+Zhengauthor=A.+G.+Polsonauthor=A.+V.+Kamath&title=Preclinical+pharmacokinetics+and+pharmacodynamics+of+DCLL9718A%3A+An+antibody-drug+conjugate+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1080%2F19420862.2018.1517565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Leipold, Douglas D.; Figueroa, Isabel; Masih, Shabkhaiz; Latifi, Brandon; Yip, Victor; Shen, Ben-Quan; Dere, Randall C.; Carrasco-Triguero, Montserrat; Lee, M. Violet; Saad, Ola M.; Liu, Luna; He, Jintang; Su, Dian; Xu, Keyang; Vuillemenot, Brian R.; Laing, Steven T.; Schutten, Melissa; Kozak, Katherine R.; Zheng, Bing; Polson, Andrew G.; Kamath, Amrita V.</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1312-1321</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Few treatment options are available for acute myeloid leukemia (AML) patients.  DCLL9718A is an antibody-drug conjugate that targets C-type lectin-like mol.-1 (CLL-1).  Here, we characterize the in vitro and in vivo stability, the pharmacokinetics (PK) and pharmacodynamics (PD) of DCLL9718A and MCLL0517A in rodents and cynomolgus monkeys.  Three key PK analytes were measured in these studies: total antibody, antibody-conjugated PBD dimer and unconjugated PBD dimer.  In vitro, DCLL9718A, was stable with most (> 80%) of the PBD dimer payload remaining conjugated to the antibody over 96 h.  This was recapitulated in vivo with antibody-conjugated PBD dimer clearance ests. similar to DCLL9718A total antibody clearance.  Both DCLL9718A and MCLL0517A showed linear PK in the non-binding rodent species, and non-linear PK in cynomolgus monkeys, a binding species.  The PK data indicated minimal impact of conjugation on the disposition of DCLL9718A total antibody.  Finally, in cynomolgus monkey, MCLL0517A showed target engagement at all doses tested (0.5 and 20 mg/kg) as measured by receptor occupancy, and DCLL9718A (at doses of 0.05, 0.1 and 0.2 mg/kg) showed strong PD activity as evidenced by notable redn. in monocytes and neutrophils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsFXdb4ZZBT7Vg90H21EOLACvtfcHk0lg5sOYFEUEj6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGjtLjN&md5=d1370e943ab7a89e07a60f56b624785b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1080%2F19420862.2018.1517565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2018.1517565%26sid%3Dliteratum%253Aachs%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DFigueroa%26aufirst%3DI.%26aulast%3DMasih%26aufirst%3DS.%26aulast%3DLatifi%26aufirst%3DB.%26aulast%3DYip%26aufirst%3DV.%26aulast%3DShen%26aufirst%3DB.-Q.%26aulast%3DDere%26aufirst%3DR.%2BC.%26aulast%3DCarrasco-Triguero%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DM.%2BV.%26aulast%3DSaad%26aufirst%3DO.%2BM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DVuillemenot%26aufirst%3DB.%2BR.%26aulast%3DLaing%26aufirst%3DS.%2BT.%26aulast%3DSchutten%26aufirst%3DM.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520DCLL9718A%253A%2520An%2520antibody-drug%2520conjugate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DmAbs%26date%3D2018%26volume%3D10%26spage%3D1312%26epage%3D1321%26doi%3D10.1080%2F19420862.2018.1517565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delproposto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01631</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01631" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=941-964&author=X.+Hanauthor=C.+Wangauthor=C.+Qinauthor=W.+Xiangauthor=E.+Fernandez-Salasauthor=C.-Y.+Yangauthor=M.+Wangauthor=L.+Zhaoauthor=T.+Xuauthor=K.+Chinnaswamyauthor=J.+Delpropostoauthor=J.+Stuckeyauthor=S.+Wang&title=Discovery+of+ARD-69+as+a+highly+potent+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+androgen+receptor+%28AR%29+for+the+treatment+of+prostate+cancer&doi=10.1021%2Facs.jmedchem.8b01631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56aR"><div class="casContent"><span class="casTitleNuber">56a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span></div><div class="casAuthors">Han, Xin; Wang, Chao; Qin, Chong; Xiang, Weiguo; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Mi; Zhao, Lijie; Xu, Tianfeng; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">941-964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by IARD-69.  I induces degrdn. of AR protein in AR-pos. prostate cancer cell lines in a dose- and time-dependent manner.  I achieves DC50 values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, resp.  I is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.  I potently inhibits cell growth in these AR-pos. prostate cancer cell lines and is >100 times more potent than AR antagonists.  A single dose of I effectively reduces the level of AR protein in xenograft tumor tissue in mice.  Further optimization of I may ultimately lead to a new therapy for AR+, castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTlOD69tfhtbVg90H21EOLACvtfcHk0lg5sOYFEUEj6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D&md5=2376573fb1a1e19c517d64c70199700a</span></div><a href="/servlet/linkout?suffix=cit56a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01631%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DDelproposto%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520ARD-69%2520as%2520a%2520highly%2520potent%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520androgen%2520receptor%2520%2528AR%2529%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D941%26epage%3D964%26doi%3D10.1021%2Facs.jmedchem.8b01631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit56b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Galdeano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadd, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaffidi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Molle, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birced, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8657</span>– <span class="NLM_lpage">8663</span>, <span class="refDoi"> DOI: 10.1021/jm5011258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5011258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8657-8663&author=C.+Galdeanoauthor=M.+S.+Gaddauthor=P.+Soaresauthor=S.+Scaffidiauthor=I.+Van+Molleauthor=I.+Bircedauthor=S.+Hewittauthor=D.+M.+Diasauthor=A.+Ciulli&title=Structure-guided+design+and+optimization+of+small+molecules+targeting+the+protein-protein+interaction+between+the+von+Hippel-Lindau+%28VHL%29+E3+ubiquitin+ligase+and+the+hypoxia+inducible+factor+%28HIF%29+alpha+subunit+with+in+vitro+nanomolar+affinities&doi=10.1021%2Fjm5011258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56bR"><div class="casContent"><span class="casTitleNuber">56b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design and Optimization of Small Molecules Targeting the Protein-Protein Interaction between the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities</span></div><div class="casAuthors">Galdeano, Carles; Gadd, Morgan S.; Soares, Pedro; Scaffidi, Salvatore; Van Molle, Inge; Birced, Ipek; Hewitt, Sarah; Dias, David M.; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8657-8663</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">E3 ubiquitin ligases are attractive targets in the ubiquitin-proteasome system, however, the development of small-mol. ligands has been rewarded with limited success.  The von Hippel-Lindau protein (pVHL) is the substrate recognition subunit of the VHL E3 ligase that targets HIF-1α for degrdn.  The authors recently reported inhibitors of the pVHL:HIF-1α interaction, however they exhibited moderate potency.  Herein, the authors report the design and optimization, guided by x-ray crystal structures, of a ligand series with nanomolar binding affinities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpixK3qp1ctJrVg90H21EOLACvtfcHk0lg5sOYFEUEj6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtb%252FP&md5=831aa2387d94cb03d735a4be7bdd2cdd</span></div><a href="/servlet/linkout?suffix=cit56b&amp;dbid=16384&amp;doi=10.1021%2Fjm5011258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5011258%26sid%3Dliteratum%253Aachs%26aulast%3DGaldeano%26aufirst%3DC.%26aulast%3DGadd%26aufirst%3DM.%2BS.%26aulast%3DSoares%26aufirst%3DP.%26aulast%3DScaffidi%26aufirst%3DS.%26aulast%3DVan%2BMolle%26aufirst%3DI.%26aulast%3DBirced%26aufirst%3DI.%26aulast%3DHewitt%26aufirst%3DS.%26aulast%3DDias%26aufirst%3DD.%2BM.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DStructure-guided%2520design%2520and%2520optimization%2520of%2520small%2520molecules%2520targeting%2520the%2520protein-protein%2520interaction%2520between%2520the%2520von%2520Hippel-Lindau%2520%2528VHL%2529%2520E3%2520ubiquitin%2520ligase%2520and%2520the%2520hypoxia%2520inducible%2520factor%2520%2528HIF%2529%2520alpha%2520subunit%2520with%2520in%2520vitro%2520nanomolar%2520affinities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8657%26epage%3D8663%26doi%3D10.1021%2Fjm5011258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J.</span>; <span class="NLM_string-name">Gunzner-Toste, J.</span>; <span class="NLM_string-name">Pillow, T.</span>; <span class="NLM_string-name">Safina, B.</span>; <span class="NLM_string-name">Verma, V.</span>; <span class="NLM_string-name">Wei, B.</span>; <span class="NLM_string-name">Zhao, G.</span>; <span class="NLM_string-name">Staben, L.</span></span> <span> </span><span class="NLM_article-title">Peptidomimetic Compounds and Antibody-conjugates Thereof</span>. <span class="NLM_patent">WO2015095223</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Flygare&author=J.+Gunzner-Toste&author=T.+Pillow&author=B.+Safina&author=V.+Verma&author=B.+Wei&author=G.+Zhao&author=L.+Staben&title=Peptidomimetic+Compounds+and+Antibody-conjugates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlygare%26aufirst%3DJ.%26atitle%3DPeptidomimetic%2520Compounds%2520and%2520Antibody-conjugates%2520Thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dela Cruz-Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas
Leipold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span> <span> </span><span class="NLM_article-title">Development of efficient chemistry to generate site-specific disulfide-linked protein and peptide-payload conjugates: Application to THIOMAB antibody-drug conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2098</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVaktLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2086-2098&author=J.+D.+Sadowskyauthor=T.+H.+Pillowauthor=J.+Chenauthor=F.+Fanauthor=C.+Heauthor=Y.+Wangauthor=G.+Yanauthor=H.+Yaoauthor=Z.+Xuauthor=S.+Martinauthor=D.+Zhangauthor=P.+Chuauthor=J.+dela+Cruz-Chuhauthor=A.+O%E2%80%99Donohueauthor=G.+Liauthor=G.+Del+Rosarioauthor=J.+Heauthor=L.+Liuauthor=C.+Ngauthor=D.+Suauthor=G.+D.+L.+Phillipsauthor=K.+R.+Kozakauthor=S.-F.+Yuauthor=K.+Xuauthor=D.+Douglas%0ALeipoldauthor=J.+Wai&title=Development+of+efficient+chemistry+to+generate+site-specific+disulfide-linked+protein+and+peptide-payload+conjugates%3A+Application+to+THIOMAB+antibody-drug+conjugates&doi=10.1021%2Facs.bioconjchem.7b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates</span></div><div class="casAuthors">Sadowsky, Jack D.; Pillow, Thomas H.; Chen, Jinhua; Fan, Fang; He, Changrong; Wang, Yanli; Yan, Gang; Yao, Hui; Xu, Zijin; Martin, Shanique; Zhang, Donglu; Chu, Phillip; dela Cruz-Chuh, Josefa; ODonohue, Aimee; Li, Guangmin; Del Rosario, Geoffrey; He, Jintang; Liu, Luna; Ng, Carl; Su, Dian; Lewis Phillips, Gail D.; Kozak, Katherine R.; Yu, Shang-Fan; Xu, Keyang; Leipold, Douglas; Wai, John</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2086-2098</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conjugation of small mol. payloads to specific cysteine residues on proteins via a disulfide bond represents an attractive strategy to generate redox-sensitive bioconjugates, which have value as potential diagnostic reagents or therapeutics.  Advancement of such "direct-disulfide" bioconjugates to the clinic necessitates chem. methods to form disulfide connections efficiently, without byproducts.  The disulfide connection must also be resistant to premature cleavage by thiols prior to arrival at the targeted tissue.  We show here that commonly-employed methods to generate direct disulfide-linked bioconjugates are inadequate for addressing these challenges.  We describe our efforts to optimize direct-disulfide conjugation chem., focusing on the generation of conjugates between cytotoxic payloads and cysteine-engineered antibodies (i.e., THIOMAB antibody-drug conjugates, or TDCs).  This work culminates in the development of novel, high-yielding conjugation chem. for creating direct payload disulfide connections to any of several Cys mutation sites in THIOMAB antibodies or to Cys sites in other biomols. (e.g., human serum albumin and cell-penetrating peptides).  We conclude by demonstrating that hindered direct disulfide TDCs with two Me groups adjacent to the disulfide, which have heretofore not been described for any bioconjugate, are more stable and more efficacious in mouse tumor xenograft studies than less hindered analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIap6CQnm0X7Vg90H21EOLACvtfcHk0likRbXtMQpqyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVaktLvL&md5=9c437d3e1aa16e51e3f571fea95785c4</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00258%26sid%3Dliteratum%253Aachs%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DG.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DP.%26aulast%3Ddela%2BCruz-Chuh%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DDouglas%2BLeipold%26aufirst%3DD.%26aulast%3DWai%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520efficient%2520chemistry%2520to%2520generate%2520site-specific%2520disulfide-linked%2520protein%2520and%2520peptide-payload%2520conjugates%253A%2520Application%2520to%2520THIOMAB%2520antibody-drug%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2017%26volume%3D28%26spage%3D2086%26epage%3D2098%26doi%3D10.1021%2Facs.bioconjchem.7b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Popow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnhof, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dank, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmaschitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karolyi-Özguer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinnenthal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roessler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieshofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span> <span> </span><span class="NLM_article-title">Highly selective PTK2 proteolysis targeting chimeras to probe focal adhesion kinase scaffolding functions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2508</span>– <span class="NLM_lpage">2520</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01826</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01826" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisl2ls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2508-2520&author=J.+Popowauthor=H.+Arnhofauthor=G.+Baderauthor=H.+Bergerauthor=A.+Ciulliauthor=D.+Coviniauthor=C.+Dankauthor=T.+Gmaschitzauthor=P.+Grebauthor=J.+Karolyi-%C3%96zguerauthor=M.+Koeglauthor=D.+B.+McConnellauthor=M.+Pearsonauthor=M.+Riegerauthor=J.+Rinnenthalauthor=V.+Roesslerauthor=A.+Schrenkauthor=M.+Spinaauthor=S.+Steurerauthor=N.+Trainorauthor=E.+Traxlerauthor=C.+Wieshoferauthor=A.+Zoephelauthor=P.+Ettmayer&title=Highly+selective+PTK2+proteolysis+targeting+chimeras+to+probe+focal+adhesion+kinase+scaffolding+functions&doi=10.1021%2Facs.jmedchem.8b01826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59aR"><div class="casContent"><span class="casTitleNuber">59a</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions</span></div><div class="casAuthors">Popow, Johannes; Arnhof, Heribert; Bader, Gerd; Berger, Helmut; Ciulli, Alessio; Covini, David; Dank, Christian; Gmaschitz, Teresa; Greb, Peter; Karolyi-Oezguer, Jale; Koegl, Manfred; McConnell, Darryl B.; Pearson, Mark; Rieger, Maria; Rinnenthal, Joerg; Roessler, Vanessa; Schrenk, Andreas; Spina, Markus; Steurer, Steffen; Trainor, Nicole; Traxler, Elisabeth; Wieshofer, Corinna; Zoephel, Andreas; Ettmayer, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2508-2520</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Focal adhesion tyrosine kinase (PTK2) is often overexpressed in human hepatocellular carcinoma (HCC), and several reports have linked PTK2 depletion and/or pharmacol. inhibition to reduced tumorigenicity.  However, the clin. relevance of targeting PTK2 still remains to be proven.  Here, we present two highly selective and functional PTK2 proteolysis-targeting chimeras utilizing von Hippel-Lindau and cereblon ligands to hijack E3 ligases for PTK2 degrdn.  BI-3663 (cereblon-based) degrades PTK2 with a median DC50 of 30 nM to >80% across a panel of 11 HCC cell lines.  Despite effective PTK2 degrdn., these compds. did not phenocopy the reported antiproliferative effects of PTK2 depletion in any of the cell lines tested.  By disclosing these compds., we hope to provide valuable tools for the study of PTK2 degrdn. across different biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsL2R_QBrfk7Vg90H21EOLACvtfcHk0likRbXtMQpqyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisl2ls78%253D&md5=f0ad27d3ff46ab12e8a90e8d40a6f3c6</span></div><a href="/servlet/linkout?suffix=cit59a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01826%26sid%3Dliteratum%253Aachs%26aulast%3DPopow%26aufirst%3DJ.%26aulast%3DArnhof%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DH.%26aulast%3DCiulli%26aufirst%3DA.%26aulast%3DCovini%26aufirst%3DD.%26aulast%3DDank%26aufirst%3DC.%26aulast%3DGmaschitz%26aufirst%3DT.%26aulast%3DGreb%26aufirst%3DP.%26aulast%3DKarolyi-%25C3%2596zguer%26aufirst%3DJ.%26aulast%3DKoegl%26aufirst%3DM.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DRieger%26aufirst%3DM.%26aulast%3DRinnenthal%26aufirst%3DJ.%26aulast%3DRoessler%26aufirst%3DV.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSpina%26aufirst%3DM.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DTraxler%26aufirst%3DE.%26aulast%3DWieshofer%26aufirst%3DC.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DEttmayer%26aufirst%3DP.%26atitle%3DHighly%2520selective%2520PTK2%2520proteolysis%2520targeting%2520chimeras%2520to%2520probe%2520focal%2520adhesion%2520kinase%2520scaffolding%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2508%26epage%3D2520%26doi%3D10.1021%2Facs.jmedchem.8b01826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit59b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zengerle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">impact of target warhead and linkage vector on inducing protein degradation: Comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">504</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=504-513&author=K.-H.+Chanauthor=M.+Zengerleauthor=A.+Testaauthor=A.+Ciulli&title=impact+of+target+warhead+and+linkage+vector+on+inducing+protein+degradation%3A+Comparison+of+bromodomain+and+extra-terminal+%28BET%29+degraders+derived+from+triazolodiazepine+%28JQ1%29+and+tetrahydroquinoline+%28I-BET726%29+BET+inhibitor+scaffolds&doi=10.1021%2Facs.jmedchem.6b01912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59bR"><div class="casContent"><span class="casTitleNuber">59b</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds</span></div><div class="casAuthors">Chan, Kwok-Ho; Zengerle, Michael; Testa, Andrea; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">504-513</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design of proteolysis-targeting chimeras (PROTACs) is a powerful small-mol. approach for inducing protein degrdn.  PROTACs conjugate a target warhead to an E3 ubiquitin ligase ligand via a linker.  Here the authors examd. the impact of derivatizing two different BET bromodomain inhibitors, triazolodiazepine JQ1 and the more potent tetrahydroquinoline I-BET726, via distinct exit vectors, using different polyethylene glycol linkers to VHL ligand VH032.  Triazolodiazepine PROTACs exhibited pos. cooperativities of ternary complex formation and were more potent degraders than tetrahydroquinoline compds., which showed neg. cooperativities instead.  Marked dependency on linker length was obsd. for BET-degrading and cMyc-driven antiproliferative activities in acute myeloid leukemia cell lines.  This work exemplifies as a cautionary tale how a more potent inhibitor does not necessarily generate more potent PROTACs and underscores the key roles played by the conjugation.  The provided insights and framework for structure-activity relationships of bivalent degraders are anticipated to have wide future applicability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEL41TefwTbVg90H21EOLACvtfcHk0lj8cP10-5gdUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSktL4%253D&md5=c3bfd9377d8e7805ba962cd0180431af</span></div><a href="/servlet/linkout?suffix=cit59b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01912%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DK.-H.%26aulast%3DZengerle%26aufirst%3DM.%26aulast%3DTesta%26aufirst%3DA.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3Dimpact%2520of%2520target%2520warhead%2520and%2520linkage%2520vector%2520on%2520inducing%2520protein%2520degradation%253A%2520Comparison%2520of%2520bromodomain%2520and%2520extra-terminal%2520%2528BET%2529%2520degraders%2520derived%2520from%2520triazolodiazepine%2520%2528JQ1%2529%2520and%2520tetrahydroquinoline%2520%2528I-BET726%2529%2520BET%2520inhibitor%2520scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D504%26epage%3D513%26doi%3D10.1021%2Facs.jmedchem.6b01912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span>; <span class="NLM_string-name">Dragovich, P.</span>; <span class="NLM_string-name">Pillow, T. H.</span>; <span class="NLM_string-name">Yu, S.-F.</span></span> <span> </span><span class="NLM_article-title">Antibodies and Immunoconjugates</span>. <span class="NLM_patent">WO2016205176</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+Polakis&author=P.+Dragovich&author=T.+H.+Pillow&author=S.-F.+Yu&title=Antibodies+and+Immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPolakis%26aufirst%3DP.%26atitle%3DAntibodies%2520and%2520Immunoconjugates%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinebach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricelj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosič, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnakenburg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gütschow, M.</span></span> <span> </span><span class="NLM_article-title">A facile synthesis of ligands for the von Hippel-Lindau E3 ligase</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2521</span>– <span class="NLM_lpage">2527</span>, <span class="refDoi"> DOI: 10.1055/s-0040-1707400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1055%2Fs-0040-1707400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVanu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2020&pages=2521-2527&author=C.+Steinebachauthor=S.+A.+Voellauthor=L.+P.+Vuauthor=A.+Briceljauthor=I.+Sosi%C4%8Dauthor=G.+Schnakenburgauthor=M.+G%C3%BCtschow&title=A+facile+synthesis+of+ligands+for+the+von+Hippel-Lindau+E3+ligase&doi=10.1055%2Fs-0040-1707400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A facile synthesis of ligands for the von Hippel-Lindau E3 ligase</span></div><div class="casAuthors">Steinebach, Christian; Voell, Sabine Anna; Vu, Lan Phuong; Bricelj, Alesa; Sosic, Izidor; Schnakenburg, Gregor; Guetschow, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2521-2527</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">The proteolysis-targeting chimeras (PROTACs) have become an integral part of different stages of drug discovery.  This growing field, therefore, benefits from advancements in all segments of the design of these compds.  Herein, an efficient and optimized synthetic protocol to various von Hippel-Lindau (VHL) ligands is presented, which enables easy access to multigram quantities of these essential PROTAC building blocks.  Moreover, the elaborated synthesis represents a straightforward approach to further explore the chem. space of VHL ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyw4H4Rq7HfrVg90H21EOLACvtfcHk0lj8cP10-5gdUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVanu7bN&md5=893543d726fa49e0ddb2a251c7efb792</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1055%2Fs-0040-1707400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0040-1707400%26sid%3Dliteratum%253Aachs%26aulast%3DSteinebach%26aufirst%3DC.%26aulast%3DVoell%26aufirst%3DS.%2BA.%26aulast%3DVu%26aufirst%3DL.%2BP.%26aulast%3DBricelj%26aufirst%3DA.%26aulast%3DSosi%25C4%258D%26aufirst%3DI.%26aulast%3DSchnakenburg%26aufirst%3DG.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26atitle%3DA%2520facile%2520synthesis%2520of%2520ligands%2520for%2520the%2520von%2520Hippel-Lindau%2520E3%2520ligase%26jtitle%3DSynthesis%26date%3D2020%26volume%3D52%26spage%3D2521%26epage%3D2527%26doi%3D10.1055%2Fs-0040-1707400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span>; <span class="NLM_string-name">Maniaci, C.</span>; <span class="NLM_string-name">Hughes, S. J.</span>; <span class="NLM_string-name">Testa, A.</span></span> <span> </span><span class="NLM_article-title">Small Molecules</span>. <span class="NLM_patent">WO2018189554</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Ciulli&author=C.+Maniaci&author=S.+J.+Hughes&author=A.+Testa&title=Small+Molecules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DSmall%2520Molecules%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kinney, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petkanas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenneman, D. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of KLS-13019, a cannabidiol-derived neuroprotective agent, with improved potency, safety, and permeability</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">428</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVWmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=424-428&author=W.+A.+Kinneyauthor=M.+E.+McDonnellauthor=H.+M.+Zhongauthor=C.+Liuauthor=L.+Yangauthor=W.+Lingauthor=T.+Qianauthor=Y.+Chenauthor=Z.+Caiauthor=D.+Petkanasauthor=D.+E.+Brenneman&title=Discovery+of+KLS-13019%2C+a+cannabidiol-derived+neuroprotective+agent%2C+with+improved+potency%2C+safety%2C+and+permeability&doi=10.1021%2Facsmedchemlett.6b00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63aR"><div class="casContent"><span class="casTitleNuber">63a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability</span></div><div class="casAuthors">Kinney, William A.; McDonnell, Mark E.; Zhong, Hua Marlon; Liu, Chaomin; Yang, Lanyi; Ling, Wei; Qian, Tao; Chen, Yu; Cai, Zhijie; Petkanas, Dean; Brenneman, Douglas E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-428</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cannabidiol is the nonpsychoactive natural component of C. sativa that has been shown to be neuroprotective in multiple animal models.  Our interest is to advance a therapeutic candidate for the orphan indication hepatic encephalopathy (HE).  HE is a serious neurol. disorder that occurs in patients with cirrhosis or liver failure.  Although cannabidiol is effective in models of HE, it has limitations in terms of safety and oral bioavailability.  Herein, we describe a series of side chain modified resorcinols that were designed for greater hydrophilicity and "drug likeness", while varying hydrogen bond donors, acceptors, architecture, basicity, neutrality, acidity, and polar surface area within the pendent group.  Our primary screen evaluated the ability of the test agents to prevent damage to hippocampal neurons induced by ammonium acetate and ethanol at clin. relevant concns.  Notably, KLS-13019 was 50-fold more potent and >400-fold safer than cannabidiol and exhibited an in vitro profile consistent with improved oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotem6Cj2XcN7Vg90H21EOLACvtfcHk0lhb18jGTcZBSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVWmt7Y%253D&md5=32249f294f3baf8d6ffa0ffd743ab0c8</span></div><a href="/servlet/linkout?suffix=cit63a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00009%26sid%3Dliteratum%253Aachs%26aulast%3DKinney%26aufirst%3DW.%2BA.%26aulast%3DMcDonnell%26aufirst%3DM.%2BE.%26aulast%3DZhong%26aufirst%3DH.%2BM.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DW.%26aulast%3DQian%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DPetkanas%26aufirst%3DD.%26aulast%3DBrenneman%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520KLS-13019%252C%2520a%2520cannabidiol-derived%2520neuroprotective%2520agent%252C%2520with%2520improved%2520potency%252C%2520safety%252C%2520and%2520permeability%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D424%26epage%3D428%26doi%3D10.1021%2Facsmedchemlett.6b00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit63b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tauber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opatz, T.</span></span> <span> </span><span class="NLM_article-title">Synthetic approaches to anti-inflammatory macrolactones of the oxacyclododecindione type</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_fpage">3587</span>– <span class="NLM_lpage">3608</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201500275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fejoc.201500275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsleqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=3587-3608&author=J.+Tauberauthor=K.+Rudolphauthor=M.+Rohrauthor=G.+Erkelauthor=T.+Opatz&title=Synthetic+approaches+to+anti-inflammatory+macrolactones+of+the+oxacyclododecindione+type&doi=10.1002%2Fejoc.201500275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63bR"><div class="casContent"><span class="casTitleNuber">63b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to Anti-Inflammatory Macrolactones of the Oxacyclododecindione Type</span></div><div class="casAuthors">Tauber, Johannes; Rudolph, Kristina; Rohr, Markus; Erkel, Gerhard; Opatz, Till</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3587-3608</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Various synthetic approaches to the oxacyclododecindione-type macrolactones, known for their potent anti-inflammatory activity were presented.  These included an attempted carbonylative ring closure, a hydroacylation route, and an approach by ring-closing metathesis and double bond isomerization, as well as a strategy including ring-closing metathesis/unsatn.  The last route allowed the prepn. of a bioactive analog of the recently described 14-deoxyoxacyclododecindione.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Gi4gQnumW7Vg90H21EOLACvtfcHk0lhb18jGTcZBSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsleqsLc%253D&md5=3b2785e8d4cb73ed41b14f19d386aa73</span></div><a href="/servlet/linkout?suffix=cit63b&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201500275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201500275%26sid%3Dliteratum%253Aachs%26aulast%3DTauber%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DK.%26aulast%3DRohr%26aufirst%3DM.%26aulast%3DErkel%26aufirst%3DG.%26aulast%3DOpatz%26aufirst%3DT.%26atitle%3DSynthetic%2520approaches%2520to%2520anti-inflammatory%2520macrolactones%2520of%2520the%2520oxacyclododecindione%2520type%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2015%26spage%3D3587%26epage%3D3608%26doi%3D10.1002%2Fejoc.201500275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Žinić, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alihodžić, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Škarić, V.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-Benzyloxycarbonylaziridine in the syntheses of 2-aminoethyl armed lariats and selectively <i>N</i>-protected polyazacrown ethers</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1039/P19930000021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2FP19930000021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADyaK3sXisFCrurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&pages=21-26&author=M.+%C5%BDini%C4%87author=S.+Alihod%C5%BEi%C4%87author=V.+%C5%A0kari%C4%87&title=N-Benzyloxycarbonylaziridine+in+the+syntheses+of+2-aminoethyl+armed+lariats+and+selectively+N-protected+polyazacrown+ethers&doi=10.1039%2FP19930000021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">N-Benzyloxycarbonylaziridine in the syntheses of 2-aminoethyl armed lariats and selectively N-protected polyazacrown ethers</span></div><div class="casAuthors">Zinic, Mladen; Alihodzic, Sulejman; Skaric, Vinko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1:  Organic and Bio-Organic Chemistry (1972-1999)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-6</span>CODEN:
                <span class="NLM_cas:coden">JCPRB4</span>;
        ISSN:<span class="NLM_cas:issn">0300-922X</span>.
    </div><div class="casAbstract">In this abstr. R = N-aminoethylene.  The 15- and 18-membered mono- and bibracchial N-aminoethylene armed lariats I, II, and III are prepd. by alkylations of parent azacrowns using N-benzyloxycarbonylaziridine (IV) and subsequent removal of Z-protecting groups by catalytic hydrogenolysis.  Extn. expts. with M+-picrates (M+ = Li+, Na+, K+, Cs+) showed medium efficacy of I, II, and III and only slight selectivity of I for Cs+.  The syntheses of selectively N-protected polyazacrowns 10-benzyl-1,4-dioxa-7,10,13-triazacyclopentadecane V, 10,19-dibenzyl-1,4,13,16-tetraoxa-7,10,19,22-tetraazacyclotetracosane VI, and 4,16-dibenzyl-1,10-dioxa-4,7,13,16-tetraazacyclooctadecane VII exemplify the application of IV as a suitable building block for prepns. of selectively N-protected polyaza-macrocycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7m9NjgVieh7Vg90H21EOLACvtfcHk0lhb18jGTcZBSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisFCrurY%253D&md5=5e39bb9739deb781024c0c8f4ae1501e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1039%2FP19930000021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FP19930000021%26sid%3Dliteratum%253Aachs%26aulast%3D%25C5%25BDini%25C4%2587%26aufirst%3DM.%26aulast%3DAlihod%25C5%25BEi%25C4%2587%26aufirst%3DS.%26aulast%3D%25C5%25A0kari%25C4%2587%26aufirst%3DV.%26atitle%3DN-Benzyloxycarbonylaziridine%2520in%2520the%2520syntheses%2520of%25202-aminoethyl%2520armed%2520lariats%2520and%2520selectively%2520N-protected%2520polyazacrown%2520ethers%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1993%26spage%3D21%26epage%3D26%26doi%3D10.1039%2FP19930000021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Endo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumichika, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, K.</span></span> <span> </span><span class="NLM_article-title">A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1365</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.01.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.bmcl.2016.01.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=26869194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVahsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1365-1370&author=J.+Endoauthor=H.+Hikawaauthor=M.+Hamadaauthor=S.+Ishibuchiauthor=N.+Fujieauthor=N.+Sugiyamaauthor=M.+Tanakaauthor=H.+Kobayashiauthor=K.+Sugaharaauthor=K.+Oshitaauthor=K.+Iwataauthor=S.+Ooikeauthor=M.+Murataauthor=H.+Sumichikaauthor=K.+Chibaauthor=K.+Adachi&title=A+phenotypic+drug+discovery+study+on+thienodiazepine+derivatives+as+inhibitors+of+T+cell+proliferation+induced+by+CD28+co-stimulation+leads+to+the+discovery+of+a+first+bromodomain+inhibitor&doi=10.1016%2Fj.bmcl.2016.01.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor</span></div><div class="casAuthors">Endo, Junichi; Hikawa, Hidemasa; Hamada, Maiko; Ishibuchi, Seigo; Fujie, Naoto; Sugiyama, Naoki; Tanaka, Minoru; Kobayashi, Haruhito; Sugahara, Kunio; Oshita, Koichi; Iwata, Kazunori; Ooike, Shinsuke; Murata, Meguru; Sumichika, Hiroshi; Chiba, Kenji; Adachi, Kunitomo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1365-1370</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A phenotypic screening of thienodiazepines derived from a hit compd. found through a binding assay targeting co-stimulatory mols. on T cells and antigen presenting cells successfully led to the discovery of a thienotriazolodiazepine compd. (7f) possessing potent immunosuppressive activity.  A chem. biol. approach has succeeded in revealing that 7f is a first inhibitor of epigenetic bromodomain-contg. proteins. 7f is expected to become an anti-cancer agent as well as an immunosuppressive agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeajoPFavBUbVg90H21EOLACvtfcHk0ljG0jxHtYdWww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVahsL8%253D&md5=e414d4c7fad718d7b2c5a76a20aed0d7</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.01.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.01.084%26sid%3Dliteratum%253Aachs%26aulast%3DEndo%26aufirst%3DJ.%26aulast%3DHikawa%26aufirst%3DH.%26aulast%3DHamada%26aufirst%3DM.%26aulast%3DIshibuchi%26aufirst%3DS.%26aulast%3DFujie%26aufirst%3DN.%26aulast%3DSugiyama%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DSugahara%26aufirst%3DK.%26aulast%3DOshita%26aufirst%3DK.%26aulast%3DIwata%26aufirst%3DK.%26aulast%3DOoike%26aufirst%3DS.%26aulast%3DMurata%26aufirst%3DM.%26aulast%3DSumichika%26aufirst%3DH.%26aulast%3DChiba%26aufirst%3DK.%26aulast%3DAdachi%26aufirst%3DK.%26atitle%3DA%2520phenotypic%2520drug%2520discovery%2520study%2520on%2520thienodiazepine%2520derivatives%2520as%2520inhibitors%2520of%2520T%2520cell%2520proliferation%2520induced%2520by%2520CD28%2520co-stimulation%2520leads%2520to%2520the%2520discovery%2520of%2520a%2520first%2520bromodomain%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1365%26epage%3D1370%26doi%3D10.1016%2Fj.bmcl.2016.01.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b','cit2c'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e','cit6f','cit6g'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c'],'ref14':['cit14a','cit14b'],'ref15':['cit15a','cit15b'],'ref16':['cit16a','cit16b','cit16c'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b','cit25c'],'ref26':['cit26'],'ref27':['cit27a','cit27b','cit27c'],'ref28':['cit28'],'ref29':['cit29a','cit29b','cit29c'],'ref30':['cit30a','cit30b'],'ref31':['cit31a','cit31b'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35a','cit35b','cit35c','cit35d','cit35e','cit35f'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38a','cit38b'],'ref39':['cit39a','cit39b'],'ref40':['cit40'],'ref41':['cit41a','cit41b','cit41c'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46a','cit46b'],'ref47':['cit47'],'ref48':['cit48a','cit48b'],'ref49':['cit49'],'ref50':['cit50a','cit50b','cit50c'],'ref51':['cit51a','cit51b','cit51c'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56a','cit56b'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59a','cit59b'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63a','cit63b'],'ref64':['cit64'],'ref65':['cit65']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jing Liu, He Chen, Yi Liu, Yudao Shen, Fanye Meng, H. Ümit Kaniskan, Jian Jin, <span class="NLM_string-name hlFld-ContribAuthor">Wenyi Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Cancer Selective Target Degradation by Folate-Caged PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (19)
                                     , 7380-7387. <a href="https://doi.org/10.1021/jacs.1c00451" title="DOI URL">https://doi.org/10.1021/jacs.1c00451</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c00451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c00451%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DCancer%252BSelective%252BTarget%252BDegradation%252Bby%252BFolate-Caged%252BPROTACs%26aulast%3DLiu%26aufirst%3DJing%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D13012021%26date%3D10052021%26volume%3D143%26issue%3D19%26spage%3D7380%26epage%3D7387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingliang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi-Chao  Zheng</span>, <span class="hlFld-ContribAuthor ">Jin-Ge  Zhang</span>, <span class="hlFld-ContribAuthor ">Haiwei  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">The design, synthesis and cellular imaging of a tumor-anchored, potent and cell-permeable BRD4-targeted fluorescent ligands. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105120. <a href="https://doi.org/10.1016/j.bioorg.2021.105120" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105120%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DThe%252Bdesign%25252C%252Bsynthesis%252Band%252Bcellular%252Bimaging%252Bof%252Ba%252Btumor-anchored%25252C%252Bpotent%252Band%252Bcell-permeable%252BBRD4-targeted%252Bfluorescent%252Bligands%26aulast%3DZhang%26aufirst%3DHang%26date%3D2021%26volume%3D114%26spage%3D105120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Yunhua  Peng</span>, <span class="hlFld-ContribAuthor ">Wenyi  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Light-Controllable PROTACs for Temporospatial Control of Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.678077" title="DOI URL">https://doi.org/10.3389/fcell.2021.678077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.678077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.678077%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DLight-Controllable%252BPROTACs%252Bfor%252BTemporospatial%252BControl%252Bof%252BProtein%252BDegradation%26aulast%3DLiu%26aufirst%3DJing%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qun  Zhou</span>, <span class="hlFld-ContribAuthor ">Josephine  Kyazike</span>, <span class="hlFld-ContribAuthor ">Ekaterina  Boudanova</span>, <span class="hlFld-ContribAuthor ">Michael  Drzyzga</span>, <span class="hlFld-ContribAuthor ">Denise  Honey</span>, <span class="hlFld-ContribAuthor ">Robert  Cost</span>, <span class="hlFld-ContribAuthor ">Lihui  Hou</span>, <span class="hlFld-ContribAuthor ">Francis  Duffieux</span>, <span class="hlFld-ContribAuthor ">Marie-Priscille  Brun</span>, <span class="hlFld-ContribAuthor ">Anna  Park</span>, <span class="hlFld-ContribAuthor ">Huawei  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (7)
                                     , 672. <a href="https://doi.org/10.3390/ph14070672" title="DOI URL">https://doi.org/10.3390/ph14070672</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14070672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14070672%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DSite-Specific%252BAntibody%252BConjugation%252Bto%252BEngineered%252BDouble%252BCysteine%252BResidues%26aulast%3DZhou%26aufirst%3DQun%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D7%26spage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0030.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0002.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative BRD4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0003.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of chimeric BRD4 degrader <b>3</b> (MZ1) and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0004.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of compound <b>1</b> bound to the BD1 bromodomain of BRD4. The <i>para</i>-Cl moiety is highlighted in the pink circle. The pink arrow indicates a vector from the bound molecule that protrudes away from the protein and out into the solvent. The figure was created using the published structure: PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MXF">3MXF</a> (ref <a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0005.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of chimeric BRD4 degraders <b>4</b> and <b>5</b> and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0006.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Correlation between SPR half-life of the ternary complex formed between the listed chimeric degrader molecules, BRD4 (BD1 + BD2), and VHL and PC3-S1 BRD4 degradation pDC<sub>50</sub> values. To generate the values depicted on the <i>x</i>-axis, the SPR half-lives determined independently for each compound with the BRD4 BD1 and BD2 bromodomains (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Table S3</a>) were added together. The number next to each point indicates the compound number from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Most compounds exhibited BRD4 degradation <i>S</i><sub>inf</sub> values >85% with the exception of <b>5</b> (<i>S</i><sub>inf</sub> = 79%). <i>R</i><sup>2</sup> = 0.61. See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for a discussion of the assay error.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0007.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of chimeric BRD4 degraders <b>6</b> and <b>7</b> and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0008.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of chimeric BRD4 degraders <b>8</b> and <b>9</b> and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0009.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of chimeric BRD4 degraders <b>10</b> and <b>11</b> and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0010.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of chimeric BRD4 degrader <b>12</b> and corresponding linker-drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0011.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Graphical depiction of the BRD4 DC<sub>50</sub> and <i>S</i><sub>inf</sub> values for the DAR6 conjugates described in this work (grouped by the conjugation method). The >85% BRD4 <i>S</i><sub>inf</sub> threshold was purposefully chosen to highlight the suspected requirement for achieving antiproliferation activity (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S6</a>). See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for a discussion of the assay error.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0012.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Graphical depiction of the BRD4 DC<sub>50</sub> and <i>S</i><sub>inf</sub> values for selected DAR6 conjugates described in this work (comparison of cleavable and noncleavable linkers). The >85% BRD4 <i>S</i><sub>inf</sub> threshold was purposefully chosen to highlight the suspected requirement for achieving antiproliferation activity (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S6</a>). See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for a discussion of the assay error.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0013.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Graphical correlation of BRD4 DC<sub>50</sub> values for unconjugated chimeric degraders <b>3</b>–<b>12</b> and the corresponding DAR6 STEAP1 conjugates described in this work. The number next to each point indicates the linker-drug employed to prepare each DAR6 STEAP1 conjugate (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>–<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). The <i>x</i>-axis location of a given point reflects the PC3-S1 DC<sub>50</sub> value of the unconjugated degrader, which corresponds to a depicted linker-drug (e.g., the DC<sub>50</sub> value of unconjugated degrader <b>12</b> establishes the <i>x</i>-axis location of conjugates derived from linker-drugs <b>12a</b>–<b>d</b>; see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> for DC<sub>50</sub> values of all unconjugated degraders). The BRD4 degradation <i>S</i><sub>inf</sub> values of the conjugates are depicted by the point sizes in the figure. See <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> for DC<sub>50</sub> and <i>S</i><sub>inf</sub> values of all conjugated degraders. Unconjugated degrader time point is 4 h. Conjugated degrader time point is 72 h. The >85% BRD4 <i>S</i><sub>inf</sub> threshold was purposefully chosen to highlight the suspected requirement for achieving antiproliferation activity (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Figure S6</a>). See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for a discussion of the assay error.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0014.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Intracellular quantitation of chimeric degrader <b>8</b> in PC3-S1 cells following non-antibody-mediated delivery or delivery via STEAP1–<b>8a</b>-D2 or STEAP1–<b>8a</b>-D6 ADCs. Time points are listed at the top of each plot. Non-antibody-mediated delivery: compound <b>8</b> (solid purple). ADC delivery: STEAP1–<b>8a</b>-D2 (solid blue), CLL1–<b>8a</b> (dashed blue), STEAP1–<b>8a</b>-D6 (solid red), CLL1–<b>8a</b>-D6 (dashed red). Extracellular conjugate concentrations were absolute (i.e., not the drug-equivalent concentrations employed elsewhere in this work). For comparison purposes, an extracellular conjugate concentration of 100 nM corresponds to approximately 15 μg/mL. Intracellular values for compound <b>8</b> associated with the 0.1 nM concentrations of the test articles were often below the 0.002 nM lower limit of quantification (LLOQ) and are not depicted in the plots.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0015.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Antiproliferation activity of STEAP1–<b>8a</b>-D6 (blue trace) and CLL1–<b>8a</b>-D6 (red trace) in LNCaP cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0016.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. In vivo stabilities of CLL1–<b>8a</b>-D6 (5 mg/kg) and CLL1–<b>12d</b> (10 mg/kg) following single IV administration of the indicated dose to mice (normalized Ave DAR plot).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0017.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Pharmacokinetic properties of conjugate CLL1–<b>8a</b>-D6 and corresponding unconjugated mAb following single administrations of a 5 mg/kg IV dose of each entity to mice (analyte = total antibody).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0018.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Several Key Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) trifluoroacetic acid (TFA), dichloromethane (DCM), 23 °C, 1 h, 97%; (b) HCl, 1:1 DCM/ethyl acetate (EtOAc), 23 °C, 1 h, 100%; (c) <i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide (DCC), <i>N</i>-hydroxysuccinimide, <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA), tetrahydrofuran (THF), 23 °C, 12 h, 100%; then, <b>15</b>, DIEA, dimethylformamide (DMF), 17 °C, 6 h, 38%.</p></p></figure><figure data-id="sch2" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0019.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Linker-Drugs <b>3a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, BrCH<sub>2</sub>CO<sub>2</sub>H, THF, 23 °C, 2 h, 57%; (b) HCl, 1:1 DCM/EtOAc, 23 °C, 1 h, 71%; (c) HATU, DIEA, <b>16</b>, DMF, 23 °C, 2 h, 17–83%; (d) Et<sub>3</sub>N, DPPA, DMF, 23 °C, 1 h; then, <b>20</b>, dibutyltin dilaurate, DMF, 80 °C, 1 h, 6%; (e) <b>21</b>, <b>22</b>, or <b>23</b>, triphosgene, pyridine, DCM, 15 °C, 30 min; then, <b>17</b>, Et<sub>3</sub>N, DCM, 15–23 °C, 2 h, 32–44%; (f) TFA, 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP), 23 °C, 1 h, 87–100%.</p></p></figure><figure data-id="sch3" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0020.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Chimeric Degrader <b>4</b> and Linker-Drugs <b>4a</b> and <b>4b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ph<sub>2</sub>C═NH, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, SPhos, toluene, 110 °C, 16 h, 60%; (b) 1 M HCl, THF, 23 °C, 3 h, 95%; (c) trifluoroacetic anhydride (TFAA), pyridine, 23 °C, 12 h, 78%; (d) 4 M HCl, EtOAc, 23 °C, 3 h, 98%; (e) HATU, DIEA, <b>31</b>, DMF, 23 °C, 2 h, 76%; (f) LiOH·H<sub>2</sub>O, 1:1 MeOH/THF, 50 °C, 12 h, 45%; (g) Fmoc-<span class="smallcaps smallerCapital">l</span>-Cit-OH, <i>N</i>-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), DMF, 23 °C, 48 h, 48%; (h) piperidine, DMF, 23 °C, 2 h, 96%; (i) HATU, DIEA, <b>33</b>, DMF, 23 °C, 12 h, 24%; (j) triphosgene, THF, 40 °C, 2 h; then, <b>20</b>, Et<sub>3</sub>N, DCM, 23 °C, 4 h, 8%; (k) 1:1 TFA/DCM, 23 °C, 2 h, 99%; (l) HATU, DIEA, <b>31</b>, DMF, 23 °C, 2 h, 12%.</p></p></figure><figure data-id="sch4" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0021.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Chimeric Degrader <b>5</b> and Linker-Drugs <b>5a</b> and <b>5b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) propargyl amine, Pd(Cy*Phine)<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C (microwave), 1 h, 24%; (b) Fmoc-Cl, Na<sub>2</sub>CO<sub>3</sub>, 1:1 THF/H<sub>2</sub>O, 23 °C, 4 h, 61%; (c) TFA, DCM, 23 °C, 1 h, 97–99%; (d) HATU, DIEA, <b>31</b>, DMF, 23 °C, 3 h, 33–59%; (e) piperidine, DMF, 23 °C, 2 h, 43–99%; (f) Fmoc-<span class="smallcaps smallerCapital">l</span>-Cit-OH, HATU, DIEA, DMF, 23 °C, 12 h, 78%; (g) HATU, DIEA, <b>33</b>, DMF, 23 °C, 12 h, 58%; (h) HATU, DIEA, <b>31</b>, DMF, 23 °C, 12 h, 43%; (i) DIEA, <b>42</b>, DMF, 23 °C, 2 h, 94%.</p></p></figure><figure data-id="sch5" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0022.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Chimeric Degrader <b>6</b> and Linker-Drugs <b>6a</b> and <b>6b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, Et<sub>3</sub>N, THF, 23 °C, 2 h, 48%; (b) CbzN(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>OH, PPh<sub>3</sub>, diisopropyl azodicarboxylate (DIAD), 0–70 °C, 16 h, 64%; (c) 4 M HCl in EtOAc, 23 °C, 1 h, 38%; (d) HATU, DIEA, <b>49</b>, DMF, 23 °C, 1 h, 53%; (e) TFA, HFIP, 23 °C, 1 h, 100%; (f) HATU, DIEA, <b>14</b>, DMF, 23 °C, 15 h, 81%; (g) HATU, DIEA, <b>13</b>, DMF, 23 °C, 15 h, 33%; (h) TMSI, DCM, 23 °C, 16 h, 12%; (i) DIEA, <b>53</b>, DMF, 23 °C, 12 h, 46%; (j) DIEA, <b>42</b>, DMF, 23 °C, 12 h, 68%.</p></p></figure><figure data-id="sch6" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0023.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Chimeric Degrader <b>7</b> and Linker-Drugs <b>7a</b> and <b>7b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>o</i>-NO<sub>2</sub>PhSO<sub>2</sub>Cl, Et<sub>3</sub>N, 4-dimethylaminopyridine (DMAP), DCM, 23 °C, 12 h, 36%; (b) Cs<sub>2</sub>CO<sub>3</sub>, <b>55</b>, DMF, 50 °C, 13 h, 53%; (c) TFA, DCM, 23 °C, 0.5 or 2 h, 97–98%; (d) HATU, DIEA, <b>14</b>, DMF, 23 °C, 2 h, 74%; (e) HATU, DIEA, <b>13</b>, DMF, 23 °C, 2 h, 80%; (f) TMSI, DCM, 23 °C, 20 min, 13%; (g) DIEA, <b>53</b>, DMF, 23 °C, 12 h, 12%; (h) DIEA, <b>42</b>, DMF, 23 °C, 3 h, 17%.</p></p></figure><figure data-id="sch7" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0024.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Chimeric Degrader <b>8</b> and Linker-Drug <b>8a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BrCH<sub>2</sub>CO<sub>2</sub><i>t</i>Bu, NaOH, <i>n</i>Bu<sub>4</sub>HSO<sub>4</sub>, 1:2 toluene/H<sub>2</sub>O, 23 °C, 2 h, 64%; (b) Pd/C, H<sub>2</sub>, MeOH, 23 °C, 16 h, 87%; (c) CbzNHCH<sub>2</sub>CH<sub>2</sub>Br, K<sub>2</sub>CO<sub>3</sub>, KI, MeCN, 70 °C, 12 h, 26%; (d) Tf<sub>2</sub>O, pyridine, 23 °C, 1 h, 100%; (e) BocNH<sub>2</sub>, Xphos, Cs<sub>2</sub>CO<sub>3</sub>, Pd(OAc)<sub>2</sub>, 1,4-dioxane, 100 °C, 16 h, 43%; (f) Pd/C, H<sub>2</sub>, THF, 23 °C, 1 h, 91%; (g) HATU, DIEA, <b>13</b>, DMF, 23 °C, 2 h, 73%; (h) 4 M HCl, EtOAc, 23 °C, 1 h, 100%; (i) HATU, DIEA, <b>68</b>, DMF, 23 °C, 1 h, 17%; (j) triphosgene, 4 Å sieves, Et<sub>3</sub>N, DCM, 23 °C, 30 min; then, <b>20</b>, Et<sub>3</sub>N, DMF, 23 °C, 12 h, 6%.</p></p></figure><figure data-id="sch8" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0025.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Chimeric Degrader <b>9</b> and Linker-Drugs <b>9a</b> and <b>9b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PtO<sub>2</sub>·H<sub>2</sub>O, H<sub>2</sub>, AcOH, 45 °C, 12 h, 97%; (b) Boc<sub>2</sub>O, NaHCO<sub>3</sub>, 4:1 THF/H<sub>2</sub>O, 23 °C, 2 h, 75%; (c) DIBAL-H, THF, −78 °C, 2 h, 38%; (d) N<sub>2</sub>CHCO<sub>2</sub>Et, Rh<sub>2</sub>(OAc)<sub>4</sub>, DCM, 0 to 23 °C, 12 h, 30%; (e) <b>74</b>, Sc(OTf)<sub>3</sub>, DCM, −78 to 23 °C, 12 h, 13%; (f) Pd/C, H<sub>2</sub>, THF, 23 °C, 1 h, 100%; (g) HATU, DIEA, <b>13</b>, DMF, 23 °C, 1 h, 92%; (h) LiOH·H<sub>2</sub>O, 5:1:1 THF/MeOH/H<sub>2</sub>O, 23 °C, 1 h, 58%; (i) HATU, DIEA, <b>68</b>, DMF, 50 °C, 6 h, 36%; (j) HCl, EtOAc, 23 °C, 1 h, 85%; (k) DIEA, <b>53</b>, DMF, 23 °C, 12 h, 43%; (l) DIEA, <b>42</b>, DMF, 23 °C, 12 h, 23%. Intermediates <b>73</b>–<b>76</b> are racemic cis-isomers. Intermediates <b>77</b>–<b>79</b> and compounds <b>9</b>, <b>9a</b>, and <b>9b</b> are 1:1 mixtures of diastereomers.</p></p></figure><figure data-id="sch9" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0026.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Chimeric Degrader <b>10</b> and Linker-Drugs <b>10a</b> and <b>10b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>4</sub>Cl, HATU, DIEA, DMF, 23 °C, 2 h, 98%; (b) Lawesson’s reagent, THF, 40 °C, 2 h, 71%; (c) BrCH<sub>2</sub>CH(OCH<sub>3</sub>)<sub>2</sub>, TsOH, AcOH, 90 °C, 1 h, 87%; (d) BH<sub>3</sub>, THF, 23 °C, 12 h, 99%; (e) BrCH<sub>2</sub>CO<sub>2</sub><i>t</i>Bu, <i>n</i>Bu<sub>4</sub>NHSO<sub>4</sub>, NaOH, 1:3 toluene/H<sub>2</sub>O, 23 °C, 3 h, 98%; (f) TFA, DCM, 23 °C, 16 h, 95%; (g) BH<sub>3</sub>·S(CH<sub>3</sub>)<sub>2</sub> THF, 23 °C, 12 h, 91%; (h) <i>tert</i>-butyldimethylsilyl chloride (TBSCl), imidazole, DCM, 23 °C, 4 h, 84%; (i) CH<sub>2</sub>═CHCO<sub>2</sub><i>t</i>Bu, <i>n</i>Bu<sub>4</sub>NBr, NaHCO<sub>3</sub>, Pd(OAc)<sub>2</sub>, DMF, 105 °C, 24 h, 81%; (j) BocNH<sub>2</sub>, Xphos, Cs<sub>2</sub>CO<sub>3</sub>, Pd(OAc)<sub>2</sub>, 1,4-dioxane, 100 °C, 16 h, 89%; (k) Pd/C, H<sub>2</sub>, MeOH, 50 °C, 16 h, >100%; (l) propargyl bromide, <i>t-</i>BuONa, THF, 0–23 °C, 12 h, 68%; (m) <b>82</b>, Pd-Cy*Phine, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 105 °C, microwave, 1 h, 45%; (n) TFA, 1,2-dichloroethane, 23 °C, 2 h, 99%; (o) HATU, DIEA, <b>68</b>, DMF, 23 °C, 1 h, 11%; (p) DIEA, <b>53</b>, hydroxybenzotriazole (HOBt), DMF, 50 °C, 16 h, 27%; (q) DIEA, <b>42</b>, DMF, 60 °C, 48 h, 9%.</p></p></figure><figure data-id="sch10" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0027.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Chimeric Degrader <b>11</b> and Linker-Drug <b>11a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>92</b>, Pd-Cy*Phine, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 100 °C, microwave, 1 h, 74%; (b) TFA, DCM, 23 °C, 2 h, 80–99%; (c) Boc<sub>2</sub>O, DIEA, DCM, 23 °C, 16 h, 62%; (d) HATU, DIEA, <b>68</b>, DMF, 23 °C, 2 h, 48%; (e) LiOH·H<sub>2</sub>O, 3:1 THF/H<sub>2</sub>O, 23 °C, 2 h, 51%; (f) H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), HOBt, DIEA, 23 °C, 18 h, 47%; (g) <b>53</b>, pyridine, HOBt, 50 °C, 24 h, 19%.</p></p></figure><figure data-id="sch11" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/medium/jm0c01845_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0028.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Chimeric Degrader <b>12</b> and Linker-Drugs <b>12a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01845/20210305/images/large/jm0c01845_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01845&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, BrCH<sub>2</sub>CO<sub>2</sub><i>t</i>Bu, THF, 0–23 °C, 8 h, 36%; (b) phthalimide, PPh<sub>3</sub>, DIAD, THF, 23 °C, 12 h, 89%; (c) H<sub>2</sub>NNH<sub>2</sub>·H<sub>2</sub>O, ethyl alcohol (EtOH), 80 °C, 1 h, 99%; (d) HATU, DIEA, <b>13</b>, DMF, 23 °C, 2 h, 88%; (e) TFA, DCM, 23 °C, 2 h, 99%; (f) HATU, DIEA, <b>68</b>, DMF, 23 °C, 2 h, 87%; (g) NaH, BrCH<sub>2</sub>CO<sub>2</sub>H, THF, 23 °C, 2 h, 94%; (h) (CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>OC(O)Cl, Et<sub>3</sub>N, NaN<sub>3</sub>, acetone, 23 °C, 1 h; (i) <b>20</b>, dibutyltin dilaurate, DMF, 60 °C, 1 h, 3% over two steps; (j) TFA, HFIP, 23 °C, 1 h, 87–100%; (k) HATU, DIEA, DMF, 23 °C, 1–2 h, 12–30%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i136">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76754" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76754" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 65 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">5501</span>– <span class="NLM_lpage">5516</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.18632%2Foncotarget.3551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=25849938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A280%3ADC%252BC2MjitVGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=5501-5516&author=L.-l.+Fuauthor=M.+Tianauthor=X.+Liauthor=J.-j.+Liauthor=J.+Huangauthor=L.+Ouyangauthor=Y.+Zhangauthor=B.+Liu&title=Inhibition+of+BET+bromodomains+as+a+therapeutic+strategy+for+cancer+drug+discovery&doi=10.18632%2Foncotarget.3551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery</span></div><div class="casAuthors">Fu Lei-lei; Tian Mao; Li Xiang; Li Jing-jing; Ouyang Liang; Zhang Yonghui; Liu Bo; Huang Jian; Zhang Yonghui</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5501-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As a conserved protein interaction module that recognizes and binds to acetylated lysine, bromodomain (BRD) contains a deep, largely hydrophobic acetyl lysine binding site.  Proteins that share the feature of containing two BRDs and an extra-terminal domain belong to BET family, including BRD2, BRD3, BRD4 and BRDT.  BET family proteins perform transcription regulatory function under normal conditions, while in cancer, they regulate transcription of several oncogenes, such as c-Myc and Bcl-2.  Thus, targeting BET proteins may be a promising strategy, and intense interest of BET proteins has fueled the development of structure-based bromodomain inhibitors in cancer.  In this review, we focus on summarizing several small-molecule BET inhibitors and their relevant anti-tumor mechanisms, which would provide a clue for exploiting new targeted BET inhibitors in the future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBHUaDfXsQehKDYG3bNImrfW6udTcc2eZSl2ErJ52AH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjitVGiuw%253D%253D&md5=b3b070170e6da5585f87dffe1d568f47</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3551%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DL.-l.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.-j.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520BET%2520bromodomains%2520as%2520a%2520therapeutic%2520strategy%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D5501%26epage%3D5516%26doi%3D10.18632%2Foncotarget.3551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Targeting bromodomains: epigenetic readers of lysine acetylation</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1038/nrd4286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fnrd4286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=24751816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFalsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=337-356&author=P.+Filippakopoulosauthor=S.+Knapp&title=Targeting+bromodomains%3A+epigenetic+readers+of+lysine+acetylation&doi=10.1038%2Fnrd4286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting bromodomains: epigenetic readers of lysine acetylation</span></div><div class="casAuthors">Filippakopoulos, Panagis; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">337-356</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation levels have been linked to the development of several diseases.  Acetyl-lysine modifications create docking sites for bromodomains, which are small interaction modules found on diverse proteins, some of which have a key role in the acetylation-dependent assembly of transcriptional regulator complexes.  These complexes can then initiate transcriptional programs that result in phenotypic changes.  The recent discovery of potent and highly specific inhibitors for the BET (bromodomain and extra-terminal) family of bromodomains has stimulated intensive research activity in diverse therapeutic areas, particularly in oncol., where BET proteins regulate the expression of key oncogenes and anti-apoptotic proteins.  In addn., targeting BET bromodomains could hold potential for the treatment of inflammation and viral infection.  Here, we highlight recent progress in the development of bromodomain inhibitors, and their potential applications in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOSIcwBJKj4LVg90H21EOLACvtfcHk0liU415kcSuuBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFalsr4%253D&md5=77049c82ce6a19b4685e3b7950399a07</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1038%2Fnrd4286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4286%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DTargeting%2520bromodomains%253A%2520epigenetic%2520readers%2520of%2520lysine%2520acetylation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D337%26epage%3D356%26doi%3D10.1038%2Fnrd4286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Targeting Brd4 for cancer therapy: inhibitors and degraders</span>. <i>Med. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1039/C8MD00198G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2FC8MD00198G" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1779-1802&author=Y.+Duanauthor=Y.+Guanauthor=W.+Qinauthor=X.+Zhaiauthor=B.+Yuauthor=H.+Liu&title=Targeting+Brd4+for+cancer+therapy%3A+inhibitors+and+degraders&doi=10.1039%2FC8MD00198G"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1039%2FC8MD00198G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8MD00198G%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DW.%26aulast%3DZhai%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DTargeting%2520Brd4%2520for%2520cancer%2520therapy%253A%2520inhibitors%2520and%2520degraders%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1779%26epage%3D1802%26doi%3D10.1039%2FC8MD00198G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasier, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Drug discovery targeting bromodomain-containing protein 4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4533</span>– <span class="NLM_lpage">4558</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01761</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01761" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4533-4558&author=Z.+Liuauthor=P.+Wangauthor=H.+Chenauthor=E.+A.+Woldauthor=B.+Tianauthor=A.+R.+Brasierauthor=J.+Zhou&title=Drug+discovery+targeting+bromodomain-containing+protein+4&doi=10.1021%2Facs.jmedchem.6b01761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discovery Targeting Bromodomain-Containing Protein 4</span></div><div class="casAuthors">Liu, Zhiqing; Wang, Pingyuan; Chen, Haiying; Wold, Eric A.; Tian, Bing; Brasier, Allan R.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4533-4558</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  BRD4, the most extensively studied member of BET family, is an epigenetic regulator that localizes to DNA via binding acetylated histones and controls the expression of therapeutically important gene regulatory networks through recruiting transcription factors to form mediator complexes, phosphorylating RNA polymerase II and by its intrinsic histone acetyltransferase activity.  Disrupting the protein-protein interactions between BRD4 and acetyl-lysine has been shown to effectively block cell proliferation in cancer, cytokine prodn. in acute inflammation, etc.  To date, significant efforts have been devoted to the development of BRD4 inhibitors, and consequently, a dozen have progressed into human clin. trials.  Herein, the authors summarize the advances in drug discovery and development of BRD4 inhibitors by focusing on their chemotypes, in vitro and in vivo activity, selectivity, relevant mechanisms of action and therapeutic potential.  Opportunities and challenges to achieve selective and efficacious BRD4 inhibitors as a viable therapeutic strategy for human diseases are also highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6IAERH4iggrVg90H21EOLACvtfcHk0liU415kcSuuBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yiurg%253D&md5=6d7ba5844073fac8c916b1249af402e5</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01761%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DTian%26aufirst%3DB.%26aulast%3DBrasier%26aufirst%3DA.%2BR.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DDrug%2520discovery%2520targeting%2520bromodomain-containing%2520protein%25204%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4533%26epage%3D4558%26doi%3D10.1021%2Facs.jmedchem.6b01761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Côte′, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span> <span> </span><span class="NLM_article-title">Disrupting acetyl-lysine recognition: progress in the development of bromodomain inhibitors.</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1271</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1271-1298&author=F.+A.+Romeroauthor=A.+M.+Taylorauthor=T.+D.+Crawfordauthor=V.+Tsuiauthor=A.+C%C3%B4te%E2%80%B2author=S.+Magnuson&title=Disrupting+acetyl-lysine+recognition%3A+progress+in+the+development+of+bromodomain+inhibitors.&doi=10.1021%2Facs.jmedchem.5b01514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors</span></div><div class="casAuthors">Romero, F. Anthony; Taylor, Alexander M.; Crawford, Terry D.; Tsui, Vickie; Cote, Alexandre; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1271-1298</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomains, small protein modules that recognize acetylated lysine on histones, play a significant role in the epigenome, where they function as "readers" that ultimately det. the functional outcome of the post-translational modification.  Because the initial discovery of selective BET inhibitors have helped define the role of that protein family in oncol. and inflammation, BET bromodomains have continued to garner the most attention of any other bromodomain.  More recently, non-BET bromodomain inhibitors that are potent and selective have been disclosed for ATAD2, CBP, BRD7/9, BRPF, BRPF/TRIM24, CECR2, SMARCA4, and BAZ2A/B.  Such novel inhibitors can be used to probe the physiol. function of these non-BET bromodomains and further understanding of their role in certain disease states.  Here, we provide an update to the progress in identifying selective bromodomain inhibitors and their use as biol. tools, as well as our perspective on the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgbRrKGlHaVLVg90H21EOLACvtfcHk0liuAlDZ-VXq3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsr%252FO&md5=260352f61301aa88aad48c0b63e6152f</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01514%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DF.%2BA.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DC%25C3%25B4te%25E2%2580%25B2%26aufirst%3DA.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DDisrupting%2520acetyl-lysine%2520recognition%253A%2520progress%2520in%2520the%2520development%2520of%2520bromodomain%2520inhibitors.%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1271%26epage%3D1298%26doi%3D10.1021%2Facs.jmedchem.5b01514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keates, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felletar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philpott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of BET bromodomains</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>468</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1038/nature09504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fnature09504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=20871596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1067-1073&author=P.+Filippakopoulosauthor=J.+Qiauthor=S.+Picaudauthor=Y.+Shenauthor=W.+B.+Smithauthor=O.+Fedorovauthor=E.+M.+Morseauthor=T.+Keatesauthor=T.+T.+Hickmanauthor=I.+Felletarauthor=M.+Philpottauthor=S.+Munroauthor=M.+R.+McKeownauthor=Y.+Wangauthor=A.+L.+Christieauthor=N.+Westauthor=M.+J.+Cameronauthor=B.+Schwartzauthor=T.+D.+Heightmanauthor=N.+La+Thangueauthor=C.+A.+Frenchauthor=O.+Wiestauthor=A.+L.+Kungauthor=S.+Knappauthor=J.+E.+Bradner&title=Selective+inhibition+of+BET+bromodomains&doi=10.1038%2Fnature09504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of BET bromodomains</span></div><div class="casAuthors">Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; Philpott, Martin; Munro, Shongah; McKeown, Michael R.; Wang, Yuchuan; Christie, Amanda L.; West, Nathan; Cameron, Michael J.; Schwartz, Brian; Heightman, Tom D.; La Thangue, Nicholas; French, Christopher; Wiest, Olaf; Kung, Andrew L.; Knapp, Stefan; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1067-1073</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetic proteins are intently pursued targets in ligand discovery.  So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'.  Potent inhibitors of histone binding modules have not yet been described.  Here the authors report a cell-permeable small mol. (I,JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains.  High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity.  Recurrent translocation of BRD4 is obsd. in a genetically-defined, incurable subtype of human squamous carcinoma.  Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models.  These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chem. scaffold for the development of chem. probes more broadly throughout the bromodomain family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ZbtmZM8m_LVg90H21EOLACvtfcHk0liuAlDZ-VXq3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D&md5=bd9cadac86124d2c6c3cd5b2a92d68c2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature09504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09504%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMorse%26aufirst%3DE.%2BM.%26aulast%3DKeates%26aufirst%3DT.%26aulast%3DHickman%26aufirst%3DT.%2BT.%26aulast%3DFelletar%26aufirst%3DI.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DLa%2BThangue%26aufirst%3DN.%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DSelective%2520inhibition%2520of%2520BET%2520bromodomains%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1067%26epage%3D1073%26doi%3D10.1038%2Fnature09504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amorim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyengar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magarotto, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leleu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broussais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herait, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahatt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokiec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieblemont, C.</span></span> <span> </span><span class="NLM_article-title">Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study</span>. <i>Lancet Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e196</span>– <span class="NLM_lpage">e204</span>, <span class="refDoi"> DOI: 10.1016/S2352-3026(16)00021-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2FS2352-3026%2816%2900021-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27063978" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=e196-e204&author=S.+Amorimauthor=A.+Stathisauthor=M.+Gleesonauthor=S.+Iyengarauthor=V.+Magarottoauthor=X.+Leleuauthor=F.+Morschhauserauthor=L.+Karlinauthor=F.+Broussaisauthor=K.+Rezaiauthor=P.+Heraitauthor=C.+Kahattauthor=F.+Lokiecauthor=G.+Sallesauthor=T.+Faconauthor=A.+Palumboauthor=D.+Cunninghamauthor=E.+Zuccaauthor=C.+Thieblemont&title=Bromodomain+inhibitor+OTX015+in+patients+with+lymphoma+or+multiple+myeloma%3A+a+dose-escalation%2C+open-label%2C+pharmacokinetic%2C+phase+1+study&doi=10.1016%2FS2352-3026%2816%2900021-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2816%2900021-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252816%252900021-1%26sid%3Dliteratum%253Aachs%26aulast%3DAmorim%26aufirst%3DS.%26aulast%3DStathis%26aufirst%3DA.%26aulast%3DGleeson%26aufirst%3DM.%26aulast%3DIyengar%26aufirst%3DS.%26aulast%3DMagarotto%26aufirst%3DV.%26aulast%3DLeleu%26aufirst%3DX.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DBroussais%26aufirst%3DF.%26aulast%3DRezai%26aufirst%3DK.%26aulast%3DHerait%26aufirst%3DP.%26aulast%3DKahatt%26aufirst%3DC.%26aulast%3DLokiec%26aufirst%3DF.%26aulast%3DSalles%26aufirst%3DG.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DCunningham%26aufirst%3DD.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DThieblemont%26aufirst%3DC.%26atitle%3DBromodomain%2520inhibitor%2520OTX015%2520in%2520patients%2520with%2520lymphoma%2520or%2520multiple%2520myeloma%253A%2520a%2520dose-escalation%252C%2520open-label%252C%2520pharmacokinetic%252C%2520phase%25201%2520study%26jtitle%3DLancet%2520Haematol.%26date%3D2016%26volume%3D3%26spage%3De196%26epage%3De204%26doi%3D10.1016%2FS2352-3026%2816%2900021-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J. T.</span></span> <span> </span><span class="NLM_article-title">Translational modeling of drug-induced myelosuppression and effect of pretreatment myelosuppression for AZD5153, a selective BRD4 inhibitor</span>. <i>CPT: Pharmacometrics Syst. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1002/psp4.12194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fpsp4.12194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28378926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Srsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=357-364&author=T.+A.+Collinsauthor=M.+M.+Hattersleyauthor=J.+W.+T.+Yatesauthor=E.+Clarkauthor=M.+Mondalauthor=J.+T.+Mettetal&title=Translational+modeling+of+drug-induced+myelosuppression+and+effect+of+pretreatment+myelosuppression+for+AZD5153%2C+a+selective+BRD4+inhibitor&doi=10.1002%2Fpsp4.12194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor</span></div><div class="casAuthors">Collins, T. A.; Hattersley, M. M.; Yates, J. W. T.; Clark, E.; Mondal, M.; Mettetal, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">CPT: Pharmacometrics & Systems Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">357-364</span>CODEN:
                <span class="NLM_cas:coden">CPSPBR</span>;
        ISSN:<span class="NLM_cas:issn">2163-8306</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">In this work, we evaluate the potential risk of thrombocytopenia in man for a BRD4 inhibitor, AZD5153, based on the platelet count decreases from a Han Wistar rat study.  The effects in rat were modeled and used to make clin. predictions for human populations with healthy baseline blood counts.  At doses >10 mg, a dose-dependent effect on circulating platelets is expected, with similar predicted changes for both q.d. and b.i.d. dose schedules.  These results suggest that at predicted efficacious doses, AZD5153 is likely to have some redns. in the clin. platelet counts, but within the normal range at projected efficacious doses.  The model was then extended to incorporate preexisting myelosuppression where bone marrow function is inhibited by acute myeloid leukemia.  Under these conditions, duration of platelet count recovery has the potential to be prolonged due to drug-induced myelosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnyVGxxPLv9LVg90H21EOLACvtfcHk0lgsj7IWk5He0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Srsrg%253D&md5=2bdc4d7bfd3ee8501d28db2c738631ff</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fpsp4.12194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsp4.12194%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DT.%2BA.%26aulast%3DHattersley%26aufirst%3DM.%2BM.%26aulast%3DYates%26aufirst%3DJ.%2BW.%2BT.%26aulast%3DClark%26aufirst%3DE.%26aulast%3DMondal%26aufirst%3DM.%26aulast%3DMettetal%26aufirst%3DJ.%2BT.%26atitle%3DTranslational%2520modeling%2520of%2520drug-induced%2520myelosuppression%2520and%2520effect%2520of%2520pretreatment%2520myelosuppression%2520for%2520AZD5153%252C%2520a%2520selective%2520BRD4%2520inhibitor%26jtitle%3DCPT%253A%2520Pharmacometrics%2520Syst.%2520Pharmacol.%26date%3D2017%26volume%3D6%26spage%3D357%26epage%3D364%26doi%3D10.1002%2Fpsp4.12194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="note"><p class="first last">Improvements in BRD4 inhibitor clinical activity may be possible by selective inhibition of the BD1 or BD2 bromodomains. See:</p></div><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylott, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayhow, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messenger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michon, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolven, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span> <span> </span><span class="NLM_article-title">The optimization of a novel, weak bromo and extra terminal domain (BET) bromodomain fragment ligand to a potent and selective second bromodomain (BD2) inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9093</span>– <span class="NLM_lpage">9126</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00796</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00796" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVCmurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9093-9126&author=J.+T.+Sealauthor=S.+J.+Atkinsonauthor=H.+Aylottauthor=P.+Bamboroughauthor=C.-w.+Chungauthor=R.+C.+B.+Copleyauthor=L.+Gordonauthor=P.+Grandiauthor=J.+R.+J.+Grayauthor=L.+A.+Harrisonauthor=T.+G.+Hayhowauthor=M.+Lindonauthor=C.+Messengerauthor=A.-M.+Michonauthor=D.+Mitchellauthor=A.+Prestonauthor=R.+K.+Prinjhaauthor=I.+Riojaauthor=S.+Taylorauthor=I.+D.+Wallauthor=R.+J.+Watsonauthor=J.+M.+Woolvenauthor=E.+H.+Demont&title=The+optimization+of+a+novel%2C+weak+bromo+and+extra+terminal+domain+%28BET%29+bromodomain+fragment+ligand+to+a+potent+and+selective+second+bromodomain+%28BD2%29+inhibitor&doi=10.1021%2Facs.jmedchem.0c00796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor</span></div><div class="casAuthors">Seal, Jonathan T.; Atkinson, Stephen J.; Aylott, Helen; Bamborough, Paul; Chung, Chun-wa; Copley, Royston C. B.; Gordon, Laurie; Grandi, Paola; Gray, James R. J.; Harrison, Lee A.; Hayhow, Thomas G.; Lindon, Matthew; Messenger, Cassie; Michon, Anne-Marie; Mitchell, Darren; Preston, Alex; Prinjha, Rab K.; Rioja, Inmaculada; Taylor, Simon; Wall, Ian D.; Watson, Robert J.; Woolven, James M.; Demont, Emmanuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9093-9126</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The profound efficacy, yet assocd. toxicity of pan-BET inhibitors is well documented.  The possibility of an ameliorated safety profile driven by significantly selective (>100-fold) inhibition of a subset of the eight bromodomains is enticing, but challenging given the close homol.  Herein, we describe the X-ray crystal structure-directed optimization of a novel weak fragment ligand with a pan-second bromodomain (BD2) bias, to potent and highly BD2 selective inhibitors.  A template hopping approach, enabled by our parallel research into an orthogonal template (15, GSK046, I), was the basis for the high selectivity obsd.  This culminated in two tool mols., 20 (GSK620) and 56 (GSK549), which showed an anti-inflammatory phenotype in human whole blood, confirming their cellular target engagement.  Excellent broad selectivity, developability, and in vivo oral pharmacokinetics characterize these tools, which we hope will be of broad utility to the field of epigenetics research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS04XaSgoDyLVg90H21EOLACvtfcHk0lgsj7IWk5He0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVCmurzI&md5=c562a8c9e4c38abac04149ee96e2f594</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00796%26sid%3Dliteratum%253Aachs%26aulast%3DSeal%26aufirst%3DJ.%2BT.%26aulast%3DAtkinson%26aufirst%3DS.%2BJ.%26aulast%3DAylott%26aufirst%3DH.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DHarrison%26aufirst%3DL.%2BA.%26aulast%3DHayhow%26aufirst%3DT.%2BG.%26aulast%3DLindon%26aufirst%3DM.%26aulast%3DMessenger%26aufirst%3DC.%26aulast%3DMichon%26aufirst%3DA.-M.%26aulast%3DMitchell%26aufirst%3DD.%26aulast%3DPreston%26aufirst%3DA.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWall%26aufirst%3DI.%2BD.%26aulast%3DWatson%26aufirst%3DR.%2BJ.%26aulast%3DWoolven%26aufirst%3DJ.%2BM.%26aulast%3DDemont%26aufirst%3DE.%2BH.%26atitle%3DThe%2520optimization%2520of%2520a%2520novel%252C%2520weak%2520bromo%2520and%2520extra%2520terminal%2520domain%2520%2528BET%2529%2520bromodomain%2520fragment%2520ligand%2520to%2520a%2520potent%2520and%2520selective%2520second%2520bromodomain%2520%2528BD2%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9093%26epage%3D9126%26doi%3D10.1021%2Facs.jmedchem.0c00796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craggs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michon, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rianjongdee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolven, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of a highly selective and in vivo-capable inhibitor of the second bromodomain of the bromodomain and extra terminal domain family of proteins</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9070</span>– <span class="NLM_lpage">9092</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00605</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00605" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWrsLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9070-9092&author=A.+Prestonauthor=S.+Atkinsonauthor=P.+Bamboroughauthor=C.-w.+Chungauthor=P.+D.+Craggsauthor=L.+Gordonauthor=P.+Grandiauthor=J.+R.+J.+Grayauthor=E.+J.+Jonesauthor=M.+Lindonauthor=A.-M.+Michonauthor=D.+J.+Mitchellauthor=R.+K.+Prinjhaauthor=F.+Rianjongdeeauthor=I.+Riojaauthor=J.+Sealauthor=S.+Taylorauthor=I.+Wallauthor=R.+J.+Watsonauthor=J.+Woolvenauthor=E.+H.+Demont&title=Design+and+synthesis+of+a+highly+selective+and+in+vivo-capable+inhibitor+of+the+second+bromodomain+of+the+bromodomain+and+extra+terminal+domain+family+of+proteins&doi=10.1021%2Facs.jmedchem.0c00605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins</span></div><div class="casAuthors">Preston, Alex; Atkinson, Stephen; Bamborough, Paul; Chung, Chun-wa; Craggs, Peter D.; Gordon, Laurie; Grandi, Paola; Gray, James R. J.; Jones, Emma J.; Lindon, Matthew; Michon, Anne-Marie; Mitchell, Darren J.; Prinjha, Rab K.; Rianjongdee, Francesco; Rioja, Inmaculada; Seal, Jonathan; Taylor, Simon; Wall, Ian; Watson, Robert J.; Woolven, James; Demont, Emmanuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9070-9092</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pan-bromodomain and extra terminal domain (BET) inhibitors interact equipotently with the eight bromodomains of the BET family of proteins and have shown profound efficacy in a no. of in vitro phenotypic assays and in vivo pre-clin. models in inflammation or oncol.  A no. of these inhibitors have progressed to the clinic where pharmacol.-driven adverse events have been reported.  To better understand the contribution of each domain to their efficacy and improve their safety profile, selective inhibitors are required.  This article discloses the profile of GSK046, also known as iBET-BD2(I), a highly selective inhibitor of the second bromodomains of the BET proteins that has undergone extensive pre-clin. in vitro and in vivo characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXn2qUNkpo27Vg90H21EOLACvtfcHk0lhJ-Wu46dPipg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWrsLrK&md5=08f4c47868e0a5acd5d443adba06d016</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00605%26sid%3Dliteratum%253Aachs%26aulast%3DPreston%26aufirst%3DA.%26aulast%3DAtkinson%26aufirst%3DS.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DCraggs%26aufirst%3DP.%2BD.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DJones%26aufirst%3DE.%2BJ.%26aulast%3DLindon%26aufirst%3DM.%26aulast%3DMichon%26aufirst%3DA.-M.%26aulast%3DMitchell%26aufirst%3DD.%2BJ.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DRianjongdee%26aufirst%3DF.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DSeal%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWall%26aufirst%3DI.%26aulast%3DWatson%26aufirst%3DR.%2BJ.%26aulast%3DWoolven%26aufirst%3DJ.%26aulast%3DDemont%26aufirst%3DE.%2BH.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520highly%2520selective%2520and%2520in%2520vivo-capable%2520inhibitor%2520of%2520the%2520second%2520bromodomain%2520of%2520the%2520bromodomain%2520and%2520extra%2520terminal%2520domain%2520family%2520of%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9070%26epage%3D9092%26doi%3D10.1021%2Facs.jmedchem.0c00605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petretich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillipou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span> <span> </span><span class="NLM_article-title">GSK789: A selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9045</span>– <span class="NLM_lpage">9069</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00614</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00614" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWrsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9045-9069&author=R.+J.+Watsonauthor=P.+Bamboroughauthor=H.+Barnettauthor=C.-w.+Chungauthor=R.+Davisauthor=L.+Gordonauthor=P.+Grandiauthor=M.+Petretichauthor=A.+Phillipouauthor=R.+K.+Prinjhaauthor=I.+Riojaauthor=P.+Sodenauthor=T.+Wernerauthor=E.+H.+Demont&title=GSK789%3A+A+selective+inhibitor+of+the+first+bromodomains+%28BD1%29+of+the+bromo+and+extra+terminal+domain+%28BET%29+proteins&doi=10.1021%2Facs.jmedchem.0c00614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins</span></div><div class="casAuthors">Watson, Robert J.; Bamborough, Paul; Barnett, Heather; Chung, Chun-wa; Davis, Rob; Gordon, Laurie; Grandi, Paola; Petretich, Massimo; Phillipou, Alex; Prinjha, Rab K.; Rioja, Inmaculada; Soden, Peter; Werner, Thilo; Demont, Emmanuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9045-9069</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pan-bromodomain and extra terminal (BET) inhibitors interact equipotently with all eight bromodomains of the BET family of proteins.  They have shown profound efficacy in vitro and in vivo in oncol. and immunomodulatory models, and a no. of them are currently in clin. trials where significant safety signals have been reported.  It is therefore important to understand the functional contribution of each bromodomain to assess the opportunity to tease apart efficacy and toxicity.  This article discloses the in vitro and cellular activity profiles of GSK789(I), a potent, cell-permeable, and highly selective inhibitor of the first bromodomains of the BET family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozid6PMjhvvbVg90H21EOLACvtfcHk0lhJ-Wu46dPipg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWrsLzJ&md5=c86b4d2c85dcfa62854debf225c8076c</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00614%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DR.%2BJ.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBarnett%26aufirst%3DH.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DPetretich%26aufirst%3DM.%26aulast%3DPhillipou%26aufirst%3DA.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DSoden%26aufirst%3DP.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DDemont%26aufirst%3DE.%2BH.%26atitle%3DGSK789%253A%2520A%2520selective%2520inhibitor%2520of%2520the%2520first%2520bromodomains%2520%2528BD1%2529%2520of%2520the%2520bromo%2520and%2520extra%2520terminal%2520domain%2520%2528BET%2529%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9045%26epage%3D9069%26doi%3D10.1021%2Facs.jmedchem.0c00614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wellaway, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craggs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karamshi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soden, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolven, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyspian′ska, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of a bromodomain and extraterminal domain (BET) inhibitor selective for the N-terminal bromodomains that retains an anti-inflammatory and antiproliferative phenotype</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9020</span>– <span class="NLM_lpage">9044</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00566</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00566" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsV2lt77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9020-9044&author=C.+R.+Wellawayauthor=P.+Bamboroughauthor=S.+G.+Bernardauthor=C.-w.+Chungauthor=P.+D.+Craggsauthor=L.+Cutlerauthor=E.+H.+Demontauthor=J.+P.+Evansauthor=L.+Gordonauthor=B.+Karamshiauthor=A.+J.+Lewisauthor=M.+J.+Lindonauthor=D.+J.+Mitchellauthor=I.+Riojaauthor=P.+E.+Sodenauthor=S.+Taylorauthor=R.+J.+Watsonauthor=R.+Willisauthor=J.+M.+Woolvenauthor=B.+S.+Wyspian%E2%80%B2skaauthor=W.+J.+Kerrauthor=R.+K.+Prinjha&title=Structure-based+design+of+a+bromodomain+and+extraterminal+domain+%28BET%29+inhibitor+selective+for+the+N-terminal+bromodomains+that+retains+an+anti-inflammatory+and+antiproliferative+phenotype&doi=10.1021%2Facs.jmedchem.0c00566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype</span></div><div class="casAuthors">Wellaway, Christopher R.; Bamborough, Paul; Bernard, Sharon G.; Chung, Chun-wa; Craggs, Peter D.; Cutler, Leanne; Demont, Emmanuel H.; Evans, John P.; Gordon, Laurie; Karamshi, Bhumika; Lewis, Antonia J.; Lindon, Matthew J.; Mitchell, Darren J.; Rioja, Inmaculada; Soden, Peter E.; Taylor, Simon; Watson, Robert J.; Willis, Rob; Woolven, James M.; Wyspianska, Beata S.; Kerr, William J.; Prinjha, Rab K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9020-9044</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bromodomain and extraterminal domain (BET) family of epigenetic regulators comprises four proteins (BRD2, BRD3, BRD4, BRDT), each contg. tandem bromodomains.  To date, small mol. inhibitors of these proteins typically bind all eight bromodomains of the family with similar affinity, resulting in a diverse range of biol. effects.  To enable further understanding of the broad phenotype characteristic of pan-BET inhibition, the development of inhibitors selective for individual, or sets of, bromodomains within the family is required.  In this regard, we report the discovery of a potent probe mol. possessing up to 150-fold selectivity for the N-terminal bromodomains (BD1s) over the C-terminal bromodomains (BD2s) of the BETs.  Guided by structural information, a specific amino acid difference between BD1 and BD2 domains was targeted for selective interaction with chem. functionality appended to the previously developed I-BET151 scaffold.  Data presented herein demonstrate that selective inhibition of BD1 domains is sufficient to drive anti-inflammatory and antiproliferative effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUREcHUhFfbVg90H21EOLACvtfcHk0lhJ-Wu46dPipg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsV2lt77M&md5=52b2505bb0a36f526a08bb9bad1f2c26</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00566%26sid%3Dliteratum%253Aachs%26aulast%3DWellaway%26aufirst%3DC.%2BR.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBernard%26aufirst%3DS.%2BG.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DCraggs%26aufirst%3DP.%2BD.%26aulast%3DCutler%26aufirst%3DL.%26aulast%3DDemont%26aufirst%3DE.%2BH.%26aulast%3DEvans%26aufirst%3DJ.%2BP.%26aulast%3DGordon%26aufirst%3DL.%26aulast%3DKaramshi%26aufirst%3DB.%26aulast%3DLewis%26aufirst%3DA.%2BJ.%26aulast%3DLindon%26aufirst%3DM.%2BJ.%26aulast%3DMitchell%26aufirst%3DD.%2BJ.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DSoden%26aufirst%3DP.%2BE.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DR.%2BJ.%26aulast%3DWillis%26aufirst%3DR.%26aulast%3DWoolven%26aufirst%3DJ.%2BM.%26aulast%3DWyspian%25E2%2580%25B2ska%26aufirst%3DB.%2BS.%26aulast%3DKerr%26aufirst%3DW.%2BJ.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26atitle%3DStructure-based%2520design%2520of%2520a%2520bromodomain%2520and%2520extraterminal%2520domain%2520%2528BET%2529%2520inhibitor%2520selective%2520for%2520the%2520N-terminal%2520bromodomains%2520that%2520retains%2520an%2520anti-inflammatory%2520and%2520antiproliferative%2520phenotype%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9020%26epage%3D9044%26doi%3D10.1021%2Facs.jmedchem.0c00566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidanze, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasvold, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magoc, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajaraman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K. F.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET bromodomain inhibitor with selectivity for the second bromodomain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5585</span>– <span class="NLM_lpage">5623</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00628</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00628" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVeisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5585-5623&author=G.+S.+Sheppardauthor=L.+Wangauthor=S.+D.+Fidanzeauthor=L.+A.+Hasvoldauthor=D.+Liuauthor=J.+K.+Prattauthor=C.+H.+Parkauthor=K.+L.+Longeneckerauthor=W.+Qiuauthor=M.+Torrentauthor=P.+Kovarauthor=M.+Buiauthor=E.+J.+Faivreauthor=X.+Huangauthor=X.+Linauthor=D.+Wilcoxauthor=L.+Zhangauthor=Y.+Shenauthor=D.+H.+Albertauthor=T.+J.+Magocauthor=G.+Rajaramanauthor=W.+M.+Katiauthor=K.+F.+McDaniel&title=Discovery+of+N-ethyl-4-%5B2-%284-fluoro-2%2C6-dimethyl-phenoxy%29-5-%281-hydroxy-1-methyl-ethyl%29phenyl%5D-6-methyl-7-oxo-1H-pyrrolo%5B2%2C3-c%5Dpyridine-2-carboxamide+%28ABBV-744%29%2C+a+BET+bromodomain+inhibitor+with+selectivity+for+the+second+bromodomain&doi=10.1021%2Facs.jmedchem.0c00628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain</span></div><div class="casAuthors">Sheppard, George S.; Wang, Le; Fidanze, Steven D.; Hasvold, Lisa A.; Liu, Dachun; Pratt, John K.; Park, Chang H.; Longenecker, Kenton; Qiu, Wei; Torrent, Maricel; Kovar, Peter J.; Bui, Mai; Faivre, Emily; Huang, Xiaoli; Lin, Xiaoyu; Wilcox, Denise; Zhang, Lu; Shen, Yu; Albert, Daniel H.; Magoc, Terrance J.; Rajaraman, Ganesh; Kati, Warren M.; McDaniel, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5585-5623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The BET family of proteins consists of BRD2, BRD3, BRD4, and BRDt.  Each protein contains two distinct bromodomains (BD1 and BD2).  BET family bromodomain inhibitors under clin. development for oncol. bind to each of the eight bromodomains with similar affinities.  We hypothesized that it may be possible to achieve an improved therapeutic index by selectively targeting subsets of the BET bromodomains.  Both BD1 and BD2 are highly conserved across family members (>70% identity), whereas BD1 and BD2 from the same protein exhibit a larger degree of divergence (~ 40% identity), suggesting selectivity between BD1 and BD2 of all family members would be more straightforward to achieve.  Exploiting the Asp144/His437 and Ile146/Val439 sequence differences (BRD4 BD1/BD2 numbering) allowed the identification of compd. 27 demonstrating greater than 100-fold selectivity for BRD4 BD2 over BRD4 BD1.  Further optimization to improve BD2 selectivity and oral bioavailability resulted in the clin. development compd. 46 (ABBV-744).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJtZIcWro0xLVg90H21EOLACvtfcHk0lhw_Ulni9OJwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVeisrk%253D&md5=675827659c3c7b6099ccd667f4c60f95</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00628%26sid%3Dliteratum%253Aachs%26aulast%3DSheppard%26aufirst%3DG.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFidanze%26aufirst%3DS.%2BD.%26aulast%3DHasvold%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPratt%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLongenecker%26aufirst%3DK.%2BL.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DKovar%26aufirst%3DP.%26aulast%3DBui%26aufirst%3DM.%26aulast%3DFaivre%26aufirst%3DE.%2BJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWilcox%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DMagoc%26aufirst%3DT.%2BJ.%26aulast%3DRajaraman%26aufirst%3DG.%26aulast%3DKati%26aufirst%3DW.%2BM.%26aulast%3DMcDaniel%26aufirst%3DK.%2BF.%26atitle%3DDiscovery%2520of%2520N-ethyl-4-%255B2-%25284-fluoro-2%252C6-dimethyl-phenoxy%2529-5-%25281-hydroxy-1-methyl-ethyl%2529phenyl%255D-6-methyl-7-oxo-1H-pyrrolo%255B2%252C3-c%255Dpyridine-2-carboxamide%2520%2528ABBV-744%2529%252C%2520a%2520BET%2520bromodomain%2520inhibitor%2520with%2520selectivity%2520for%2520the%2520second%2520bromodomain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D5585%26epage%3D5623%26doi%3D10.1021%2Facs.jmedchem.0c00628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantena, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnik, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehgal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uziel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidanze, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasvold, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolette, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossey, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigelow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>578</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-1930-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41586-020-1930-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31969702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1Smsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=578&publication_year=2020&pages=306-310&author=E.+J.+Faivreauthor=K.+F.+McDanielauthor=D.+H.+Albertauthor=S.+R.+Mantenaauthor=J.+P.+Plotnikauthor=D.+Wilcoxauthor=L.+Zhangauthor=M.+H.+Buiauthor=G.+S.+Sheppardauthor=L.+Wangauthor=V.+Sehgalauthor=X.+Linauthor=X.+Huangauthor=X.+Luauthor=T.+Uzielauthor=P.+Hesslerauthor=L.+T.+Lamauthor=R.+J.+Bellinauthor=G.+Mehtaauthor=S.+Fidanzeauthor=J.+K.+Prattauthor=D.+Liuauthor=L.+A.+Hasvoldauthor=C.+Sunauthor=S.+C.+Panchalauthor=J.+J.+Nicoletteauthor=S.+L.+Fosseyauthor=C.+H.+Parkauthor=K.+Longeneckerauthor=L.+Bigelowauthor=M.+Torrentauthor=S.+H.+Rosenbergauthor=W.+M.+Katiauthor=Y.+Shen&title=Selective+inhibition+of+the+BD2+bromodomain+of+BET+proteins+in+prostate+cancer&doi=10.1038%2Fs41586-020-1930-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6fR"><div class="casContent"><span class="casTitleNuber">6f</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer</span></div><div class="casAuthors">Faivre, Emily J.; McDaniel, Keith F.; Albert, Daniel H.; Mantena, Srinivasa R.; Plotnik, Joshua P.; Wilcox, Denise; Zhang, Lu; Bui, Mai H.; Sheppard, George S.; Wang, Le; Sehgal, Vasudha; Lin, Xiaoyu; Huang, Xiaoli; Lu, Xin; Uziel, Tamar; Hessler, Paul; Lam, Lloyd T.; Bellin, Richard J.; Mehta, Gaurav; Fidanze, Steve; Pratt, John K.; Liu, Dachun; Hasvold, Lisa A.; Sun, Chaohong; Panchal, Sanjay C.; Nicolette, John J.; Fossey, Stacey L.; Park, Chang H.; Longenecker, Kenton; Bigelow, Lance; Torrent, Maricel; Rosenberg, Saul H.; Kati, Warren M.; Shen, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">578</span>
        (<span class="NLM_cas:issue">7794</span>),
    <span class="NLM_cas:pages">306-310</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Proteins of the bromodomain and extra-terminal (BET) domain family are epigenetic readers that bind acetylated histones through their bromodomains to regulate gene transcription.  Dual-bromodomain BET inhibitors (DbBi) that bind with similar affinities to the first (BD1) and second (BD2) bromodomains of BRD2, BRD3, BRD4 and BRDt have displayed modest clin. activity in monotherapy cancer trials.  A reduced no. of thrombocytes in the blood (thrombocytopenia) as well as symptoms of gastrointestinal toxicity are dose-limiting adverse events for some types of DbBi1-5.  Given that similar haematol. and gastrointestinal defects were obsd. after genetic silencing of Brd4 in mice6, the platelet and gastrointestinal toxicities may represent on-target activities assocd. with BET inhibition.  The two individual bromodomains in BET family proteins may have distinct functions7-9 and different cellular phenotypes after pharmacol. inhibition of one or both bromodomains have been reported10,11, suggesting that selectively targeting one of the bromodomains may result in a different efficacy and tolerability profile compared with DbBi.  Available compds. that are selective to individual domains lack sufficient potency and the pharmacokinetics properties that are required for in vivo efficacy and tolerability assessment10-13.  Here we carried out a medicinal chem. campaign that led to the discovery of ABBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties.  In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukemia and prostate cancer that expressed the full-length androgen receptor (AR).  ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514.  Analyses of RNA expression and chromatin immunopptn. followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-contg. super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075.  These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF98kER1y9pLVg90H21EOLACvtfcHk0lhw_Ulni9OJwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1Smsr0%253D&md5=800d9106c33084390fd8cbf1ac7f1766</span></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-1930-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-1930-8%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DE.%2BJ.%26aulast%3DMcDaniel%26aufirst%3DK.%2BF.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DMantena%26aufirst%3DS.%2BR.%26aulast%3DPlotnik%26aufirst%3DJ.%2BP.%26aulast%3DWilcox%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBui%26aufirst%3DM.%2BH.%26aulast%3DSheppard%26aufirst%3DG.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSehgal%26aufirst%3DV.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DUziel%26aufirst%3DT.%26aulast%3DHessler%26aufirst%3DP.%26aulast%3DLam%26aufirst%3DL.%2BT.%26aulast%3DBellin%26aufirst%3DR.%2BJ.%26aulast%3DMehta%26aufirst%3DG.%26aulast%3DFidanze%26aufirst%3DS.%26aulast%3DPratt%26aufirst%3DJ.%2BK.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DHasvold%26aufirst%3DL.%2BA.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DPanchal%26aufirst%3DS.%2BC.%26aulast%3DNicolette%26aufirst%3DJ.%2BJ.%26aulast%3DFossey%26aufirst%3DS.%2BL.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLongenecker%26aufirst%3DK.%26aulast%3DBigelow%26aufirst%3DL.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DKati%26aufirst%3DW.%2BM.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DSelective%2520inhibition%2520of%2520the%2520BD2%2520bromodomain%2520of%2520BET%2520proteins%2520in%2520prostate%2520cancer%26jtitle%3DNature%26date%3D2020%26volume%3D578%26spage%3D306%26epage%3D310%26doi%3D10.1038%2Fs41586-020-1930-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gilan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioja, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knezevic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harker, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, E. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petretich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassil, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassiliadis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burr, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, A. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellaway, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michon, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbetti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soden, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vappiani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tough, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. A.</span></span> <span> </span><span class="NLM_article-title">Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1126/science.aaz8455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1126%2Fscience.aaz8455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=32193360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslKrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=387-394&author=O.+Gilanauthor=I.+Riojaauthor=K.+Knezevicauthor=M.+J.+Bellauthor=M.+M.+Yeungauthor=N.+R.+Harkerauthor=E.+Y.+N.+Lamauthor=C.-w.+Chungauthor=P.+Bamboroughauthor=M.+Petretichauthor=M.+Urhauthor=S.+J.+Atkinsonauthor=A.+K.+Bassilauthor=E.+J.+Robertsauthor=D.+Vassiliadisauthor=M.+L.+Burrauthor=A.+G.+S.+Prestonauthor=C.+Wellawayauthor=T.+Wernerauthor=J.+R.+Grayauthor=A.-M.+Michonauthor=T.+Gobbettiauthor=V.+Kumarauthor=P.+E.+Sodenauthor=A.+Haynesauthor=J.+Vappianiauthor=D.+F.+Toughauthor=S.+Taylorauthor=S.-J.+Dawsonauthor=M.+Bantscheffauthor=M.+Lindonauthor=G.+Drewesauthor=E.+H.+Demontauthor=D.+L.+Danielsauthor=P.+Grandiauthor=R.+K.+Prinjhaauthor=M.+A.+Dawson&title=Selective+targeting+of+BD1+and+BD2+of+the+BET+proteins+in+cancer+and+immuno-inflammation&doi=10.1126%2Fscience.aaz8455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation</span></div><div class="casAuthors">Gilan, Omer; Rioja, Inmaculada; Knezevic, Kathy; Bell, Matthew J.; Yeung, Miriam M.; Harker, Nicola R.; Lam, Enid Y. N.; Chung, Chun-wa; Bamborough, Paul; Petretich, Massimo; Urh, Marjeta; Atkinson, Stephen J.; Bassil, Anna K.; Roberts, Emma J.; Vassiliadis, Dane; Burr, Marian L.; Preston, Alex G. S.; Wellaway, Christopher; Werner, Thilo; Gray, James R.; Michon, Anne-Marie; Gobbetti, Thomas; Kumar, Vinod; Soden, Peter E.; Haynes, Andrea; Vappiani, Johanna; Tough, David F.; Taylor, Simon; Dawson, Sarah-Jane; Bantscheff, Marcus; Lindon, Matthew; Drewes, Gerard; Demont, Emmanuel H.; Daniels, Danette L.; Grandi, Paola; Prinjha, Rab K.; Dawson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6489</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The two tandem bromodomains of the BET (bromodomain and extraterminal domain) proteins enable chromatin binding to facilitate transcription.  Drugs that inhibit both bromodomains equally have shown efficacy in certain malignant and inflammatory conditions.  To explore the individual functional contributions of the first (BD1) and second (BD2) bromodomains in biol. and therapy, we developed selective BD1 and BD2 inhibitors.  We found that steady-state gene expression primarily requires BD1, whereas the rapid increase of gene expression induced by inflammatory stimuli requires both BD1 and BD2 of all BET proteins.  BD1 inhibitors phenocopied the effects of pan-BET inhibitors in cancer models, whereas BD2 inhibitors were predominantly effective in models of inflammatory and autoimmune disease.  These insights into the differential requirement of BD1 and BD2 for the maintenance and induction of gene expression may guide future BET-targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr078AuJubsqbVg90H21EOLACvtfcHk0lj2CiLeyAfRSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslKrtrg%253D&md5=d78cfea091fcf5ee18735b02b2120dd7</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaz8455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaz8455%26sid%3Dliteratum%253Aachs%26aulast%3DGilan%26aufirst%3DO.%26aulast%3DRioja%26aufirst%3DI.%26aulast%3DKnezevic%26aufirst%3DK.%26aulast%3DBell%26aufirst%3DM.%2BJ.%26aulast%3DYeung%26aufirst%3DM.%2BM.%26aulast%3DHarker%26aufirst%3DN.%2BR.%26aulast%3DLam%26aufirst%3DE.%2BY.%2BN.%26aulast%3DChung%26aufirst%3DC.-w.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DPetretich%26aufirst%3DM.%26aulast%3DUrh%26aufirst%3DM.%26aulast%3DAtkinson%26aufirst%3DS.%2BJ.%26aulast%3DBassil%26aufirst%3DA.%2BK.%26aulast%3DRoberts%26aufirst%3DE.%2BJ.%26aulast%3DVassiliadis%26aufirst%3DD.%26aulast%3DBurr%26aufirst%3DM.%2BL.%26aulast%3DPreston%26aufirst%3DA.%2BG.%2BS.%26aulast%3DWellaway%26aufirst%3DC.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DJ.%2BR.%26aulast%3DMichon%26aufirst%3DA.-M.%26aulast%3DGobbetti%26aufirst%3DT.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DSoden%26aufirst%3DP.%2BE.%26aulast%3DHaynes%26aufirst%3DA.%26aulast%3DVappiani%26aufirst%3DJ.%26aulast%3DTough%26aufirst%3DD.%2BF.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DDawson%26aufirst%3DS.-J.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DLindon%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DDemont%26aufirst%3DE.%2BH.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26atitle%3DSelective%2520targeting%2520of%2520BD1%2520and%2520BD2%2520of%2520the%2520BET%2520proteins%2520in%2520cancer%2520and%2520immuno-inflammation%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D387%26epage%3D394%26doi%3D10.1126%2Fscience.aaz8455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K. G.</span></span> <span> </span><span class="NLM_article-title">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">7124</span>– <span class="NLM_lpage">7129</span>, <span class="refDoi"> DOI: 10.1073/pnas.1521738113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1073%2Fpnas.1521738113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27274052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=7124-7129&author=K.+Rainaauthor=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=D.+Gordonauthor=A.+M.+K.+Rossiauthor=J.+Wangauthor=X.+Chenauthor=H.+Dongauthor=K.+Siuauthor=J.+D.+Winklerauthor=A.+P.+Crewauthor=C.+M.+Crewsauthor=K.+G.+Coleman&title=PROTAC-induced+BET+protein+degradation+as+a+therapy+for+castration-resistant+prostate+cancer&doi=10.1073%2Fpnas.1521738113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span></div><div class="casAuthors">Raina, Kanak; Lu, Jing; Qian, Yimin; Altieri, Martha; Gordon, Deborah; Rossi, Ann Marie K.; Wang, Jing; Chen, Xin; Dong, Hanqing; Siu, Kam; Winkler, James D.; Crew, Andrew P.; Crews, Craig M.; Coleman, Kevin G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7124-7129</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Prostate cancer has the second highest incidence among cancers in men worldwide and is the second leading cause of cancer deaths of men in the United States.  Although androgen deprivation can initially lead to remission, the disease often progresses to castration-resistant prostate cancer (CRPC), which is still reliant on androgen receptor (AR) signaling and is assocd. with a poor prognosis.  Some success against CRPC has been achieved by drugs that target AR signaling, but secondary resistance invariably emerges, and new therapies are urgently needed.  Recently, inhibitors of bromodomain and extra-terminal (BET) family proteins have shown growth-inhibitory activity in preclin. models of CRPC.  Here, we demonstrate that ARV-771, a small-mol. pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technol., demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition.  Unlike BET inhibitors, ARV-771 results in suppression of both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model.  This study is, to our knowledge, the first to demonstrate efficacy with a small-mol. BET degrader in a solid-tumor malignancy and potentially represents an important therapeutic advance in the treatment of CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD7QtYgZVig7Vg90H21EOLACvtfcHk0ljSFL6rX6WIzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D&md5=34218e685ad72950f3eb85586110c43d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1521738113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1521738113%26sid%3Dliteratum%253Aachs%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DA.%2BM.%2BK.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DSiu%26aufirst%3DK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26aulast%3DColeman%26aufirst%3DK.%2BG.%26atitle%3DPROTAC-induced%2520BET%2520protein%2520degradation%2520as%2520a%2520therapy%2520for%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3D7124%26epage%3D7129%26doi%3D10.1073%2Fpnas.1521738113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Phthalimide conjugation as a strategy for in vivo target protein degradation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">1376</span>– <span class="NLM_lpage">1381</span>, <span class="refDoi"> DOI: 10.1126/science.aab1433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1126%2Fscience.aab1433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=25999370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=1376-1381&author=G.+E.+Winterauthor=D.+L.+Buckleyauthor=J.+Paulkauthor=J.+M.+Robertsauthor=A.+Souzaauthor=S.+Dhe-Paganonauthor=J.+E.+Bradner&title=Phthalimide+conjugation+as+a+strategy+for+in+vivo+target+protein+degradation&doi=10.1126%2Fscience.aab1433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Phthalimide conjugation as a strategy for in vivo target protein degradation</span></div><div class="casAuthors">Winter, Georg E.; Buckley, Dennis L.; Paulk, Joshiawa; Roberts, Justin M.; Souza, Amanda; Dhe-Paganon, Sirano; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6241</span>),
    <span class="NLM_cas:pages">1376-1381</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The development of effective pharmacol. inhibitors of multidomain scaffold proteins, notably transcription factors, is a particularly challenging problem.  In part, this is because many small-mol. antagonists disrupt the activity of only one domain in the target protein.  The authors devised a chem. strategy that promotes ligand-dependent target protein degrdn. using as an example the transcriptional coactivator BRD4, a protein crit. for cancer cell growth and survival.  The authors appended a competitive antagonist of BET bromodomains to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex.  The resultant compd., dBET1, induced highly selective cereblon-dependent BET protein degrdn. in vitro and in vivo and delayed leukemia progression in mice.  A second series of probes resulted in selective degrdn. of the cytosolic protein FKBP12.  This chem. strategy for controlling target protein stability may have implications for therapeutically targeting previously intractable proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZW4zjRjXi7Vg90H21EOLACvtfcHk0ljSFL6rX6WIzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D&md5=b0277cc95d318d926b96e7a119066e3b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.aab1433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aab1433%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DSouza%26aufirst%3DA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DPhthalimide%2520conjugation%2520as%2520a%2520strategy%2520for%2520in%2520vivo%2520target%2520protein%2520degradation%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D1376%26epage%3D1381%26doi%3D10.1126%2Fscience.aab1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohoka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuhira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ujikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teratani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span> <span> </span><span class="NLM_article-title"><i>In vivo</i> knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">4556</span>– <span class="NLM_lpage">4570</span>, <span class="refDoi"> DOI: 10.1074/jbc.M116.768853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1074%2Fjbc.M116.768853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28154167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVClur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=4556-4570&author=N.+Ohokaauthor=K.+Okuhiraauthor=M.+Itoauthor=K.+Nagaiauthor=N.+Shibataauthor=T.+Hattoriauthor=O.+Ujikawaauthor=K.+Shimokawaauthor=O.+Sanoauthor=R.+Koyamaauthor=H.+Fujitaauthor=M.+Terataniauthor=H.+Matsumotoauthor=Y.+Imaedaauthor=H.+Naraauthor=N.+Choauthor=M.+Naito&title=In+vivo+knockdown+of+pathogenic+proteins+via+specific+and+nongenetic+inhibitor+of+apoptosis+protein+%28IAP%29-dependent+protein+erasers+%28SNIPERs%29&doi=10.1074%2Fjbc.M116.768853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)</span></div><div class="casAuthors">Ohoka, Nobumichi; Okuhira, Keiichiro; Ito, Masahiro; Nagai, Katsunori; Shibata, Norihito; Hattori, Takayuki; Ujikawa, Osamu; Shimokawa, Kenichiro; Sano, Osamu; Koyama, Ryokichi; Fujita, Hisashi; Teratani, Mika; Matsumoto, Hirokazu; Imaeda, Yasuhiro; Nara, Hiroshi; Cho, Nobuo; Naito, Mikihiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4556-4570</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Many diseases, esp. cancers, result from aberrant or overexpression of pathogenic proteins.  Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes.  An alternative approach that may have utility in drug development relies on selective degrdn. of pathogenic proteins via small chimeric mols. linking an E3 ubiquitin ligase to the targeted protein for proteasomal degrdn.  To this end, the authors recently developed a protein knockdown system based on hybrid small mol. SNIPERs (Specific and Nongenetic IAP-dependent Protein Erasers) that recruit inhibitor of the apoptosis protein (IAP) ubiquitin ligases to specifically degrade targeted proteins.  Here, the authors extend the authors' previous study to show a proof of concept of the SNIPER technol. in vivo.  By incorporating a high affinity IAP ligand, the authors developed a novel SNIPER against estrogen receptor α (ERα), SNIPER(ER)-87, that has a potent protein knockdown activity.  The SNIPER(ER) reduced ERα levels in tumor xenografts and suppressed the growth of ERα-pos. breast tumors in mice.  Mechanistically, it preferentially recruits X-linked IAP (XIAP) rather than cellular IAP1, to degrade ERα via the ubiquitin-proteasome pathway.  With this IAP ligand, potent SNIPERs against other pathogenic proteins, BCR-ABL, bromodomain-contg. protein 4 (BRD4), and phosphodiesterase-4 (PDE4) could also be developed.  These results indicate that forced ubiquitylation by SNIPERs is a useful method to achieve efficient protein knockdown with potential therapeutic activities and could also be applied to study the role of ubiquitylation in many cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEzH5uNeAFabVg90H21EOLACvtfcHk0lgnBS2Ybm1xcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVClur8%253D&md5=b09264d53c47c54343ed92d5a6d0eb79</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.768853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.768853%26sid%3Dliteratum%253Aachs%26aulast%3DOhoka%26aufirst%3DN.%26aulast%3DOkuhira%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DNagai%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DT.%26aulast%3DUjikawa%26aufirst%3DO.%26aulast%3DShimokawa%26aufirst%3DK.%26aulast%3DSano%26aufirst%3DO.%26aulast%3DKoyama%26aufirst%3DR.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DTeratani%26aufirst%3DM.%26aulast%3DMatsumoto%26aufirst%3DH.%26aulast%3DImaeda%26aufirst%3DY.%26aulast%3DNara%26aufirst%3DH.%26aulast%3DCho%26aufirst%3DN.%26aulast%3DNaito%26aufirst%3DM.%26atitle%3DIn%2520vivo%2520knockdown%2520of%2520pathogenic%2520proteins%2520via%2520specific%2520and%2520nongenetic%2520inhibitor%2520of%2520apoptosis%2520protein%2520%2528IAP%2529-dependent%2520protein%2520erasers%2520%2528SNIPERs%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D4556%26epage%3D4570%26doi%3D10.1074%2Fjbc.M116.768853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lartigue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">MDM2-recruiting PROTAC offers superior, synergistic anti-proliferative activity via simultaneous degradation of BRD4 and stabilization of p53</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-2918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F0008-5472.CAN-18-2918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30385614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFGnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=251-262&author=J.+Hinesauthor=S.+Lartigueauthor=H.+Dongauthor=Y.+Qianauthor=C.+M.+Crews&title=MDM2-recruiting+PROTAC+offers+superior%2C+synergistic+anti-proliferative+activity+via+simultaneous+degradation+of+BRD4+and+stabilization+of+p53&doi=10.1158%2F0008-5472.CAN-18-2918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53</span></div><div class="casAuthors">Hines, John; Lartigue, Schan; Dong, Hanqing; Qian, Yimin; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Although the no. of proteins effectively targeted for posttranslational degrdn. by PROTAC has grown steadily, the no. of E3 ligases successfully exploited to accomplish this has been limited to the few for which small-mol. ligands have been discovered.  Although the E3 ligase MDM2 is bound by the nutlin class of small-mol. ligands, there are few nutlin-based PROTAC.  Because a nutlin-based PROTAC should both knockdown its target protein and upregulate the tumor suppressor p53, we examd. the ability of such a PROTAC to decrease cancer cell viability.  A nutlin-based, BRD4-degrading PROTAC, A1874, was able to degrade its target protein by 98% with nanomolar potency.  Given the complementary ability of A1874 to stabilize p53, we discovered that the nutlin-based PROTAC was more effective in inhibiting proliferation of many cancer cell lines with wild-type p53 than was a corresponding VHL-utilizing PROTAC with similar potency and efficacy to degrade BRD4.  This is the first report of a PROTAC in which the E3 ligase ligand and targeting warhead combine to exert a synergistic antiproliferative effect.  Our study highlights the untapped potential that may be unlocked by expanding the repertoire of E3 ligases that can be recruited by PROTAC.  Significance: These findings present the first BRD4-targeting MDM2-based PROTAC that possesses potent, distinct, and synergistic biol. activities assocd. with both ends of this heterobifunctional mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4UdOVtfCjPLVg90H21EOLACvtfcHk0lgnBS2Ybm1xcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFGnsr0%253D&md5=e5dbf80505bb32c232bce66b0445a1a9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-2918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-2918%26sid%3Dliteratum%253Aachs%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DLartigue%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DMDM2-recruiting%2520PROTAC%2520offers%2520superior%252C%2520synergistic%2520anti-proliferative%2520activity%2520via%2520simultaneous%2520degradation%2520of%2520BRD4%2520and%2520stabilization%2520of%2520p53%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D251%26epage%3D262%26doi%3D10.1158%2F0008-5472.CAN-18-2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erb, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roderick, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Iulio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachance, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastjerdi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelliher, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2017.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.molcel.2017.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28673542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmsbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2017&pages=5-18&author=G.+E.+Winterauthor=A.+Mayerauthor=D.+L.+Buckleyauthor=M.+A.+Erbauthor=J.+E.+Roderickauthor=S.+Vittoriauthor=J.+M.+Reyesauthor=J.+di+Iulioauthor=A.+Souzaauthor=C.+J.+Ottauthor=J.+M.+Robertsauthor=R.+Zeidauthor=T.+G.+Scottauthor=J.+Paulkauthor=K.+Lachanceauthor=C.+M.+Olsonauthor=S.+Dastjerdiauthor=S.+Bauerauthor=C.+Y.+Linauthor=N.+S.+Grayauthor=M.+A.+Kelliherauthor=L.+S.+Churchmanauthor=J.+E.+Bradner&title=BET+bromodomain+proteins+function+as+master+transcription+elongation+factors+independent+of+CDK9+recruitment&doi=10.1016%2Fj.molcel.2017.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment</span></div><div class="casAuthors">Winter, Georg E.; Mayer, Andreas; Buckley, Dennis L.; Erb, Michael A.; Roderick, Justine E.; Vittori, Sarah; Reyes, Jaime M.; di Iulio, Julia; Souza, Amanda; Ott, Christopher J.; Roberts, Justin M.; Zeid, Rhamy; Scott, Thomas G.; Paulk, Joshiawa; Lachance, Kate; Olson, Calla M.; Dastjerdi, Shiva; Bauer, Sophie; Lin, Charles Y.; Gray, Nathanael S.; Kelliher, Michelle A.; Churchman, L. Stirling; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-18.e19</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Processive elongation of RNA Polymerase II from a proximal promoter paused state is a rate-limiting event in human gene control.  A small no. of regulatory factors influence transcription elongation on a global scale.  Prior research using small-mol. BET bromodomain inhibitors, such as JQ1, linked BRD4 to context-specific elongation at a limited no. of genes assocd. with massive enhancer regions.  Here, the mechanistic characterization of an optimized chem. degrader of BET bromodomain proteins, dBET6, led to the unexpected identification of BET proteins as master regulators of global transcription elongation.  In contrast to the selective effect of bromodomain inhibition on transcription, BET degrdn. prompts a collapse of global elongation that phenocopies CDK9 inhibition.  Notably, BRD4 loss does not directly affect CDK9 localization.  These studies, performed in translational models of T cell leukemia, establish a mechanism-based rationale for the development of BET bromodomain degrdn. as cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqseJAHmXAb-rVg90H21EOLACvtfcHk0lh8Iv1FR7RqdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmsbjM&md5=ac6f4e33a8f43008b70d4ede80a526be</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2017.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2017.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DMayer%26aufirst%3DA.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DErb%26aufirst%3DM.%2BA.%26aulast%3DRoderick%26aufirst%3DJ.%2BE.%26aulast%3DVittori%26aufirst%3DS.%26aulast%3DReyes%26aufirst%3DJ.%2BM.%26aulast%3Ddi%2BIulio%26aufirst%3DJ.%26aulast%3DSouza%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DZeid%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DT.%2BG.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DLachance%26aufirst%3DK.%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DDastjerdi%26aufirst%3DS.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKelliher%26aufirst%3DM.%2BA.%26aulast%3DChurchman%26aufirst%3DL.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DBET%2520bromodomain%2520proteins%2520function%2520as%2520master%2520transcription%2520elongation%2520factors%2520independent%2520of%2520CDK9%2520recruitment%26jtitle%3DMol.%2520Cell%26date%3D2017%26volume%3D67%26spage%3D5%26epage%3D18%26doi%3D10.1016%2Fj.molcel.2017.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two decades under the influence of the rule of five and the changing properties of approved oral drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&author=M.+D.+Shultz&title=Two+decades+under+the+influence+of+the+rule+of+five+and+the+changing+properties+of+approved+oral+drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0lhELedl4ReMAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520decades%2520under%2520the%2520influence%2520of%2520the%2520rule%2520of%2520five%2520and%2520the%2520changing%2520properties%2520of%2520approved%2520oral%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlfinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D. F.</span></span> <span> </span><span class="NLM_article-title">Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2020.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.drudis.2020.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVeru7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=1793-1800&author=A.+Pikeauthor=B.+Williamsonauthor=S.+Harlfingerauthor=S.+Martinauthor=D.+F.+McGinnity&title=Optimising+proteolysis-targeting+chimeras+%28PROTACs%29+for+oral+drug+delivery%3A+a+drug+metabolism+and+pharmacokinetics+perspective&doi=10.1016%2Fj.drudis.2020.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective</span></div><div class="casAuthors">Pike, Andy; Williamson, Beth; Harlfinger, Stephanie; Martin, Scott; McGinnity, Dermot F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1793-1800</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality with the potential to open target space not accessible to conventional small mols. via a degrdn.-based mechanism; however, their bifunctional nature can result in physicochem. properties that breach commonly accepted limits for small-mol. oral drugs.  We offer a drug metab. and pharmacokinetics (DMPK) perspective on the optimization of oral PROTACs across a diverse set of projects within Oncol. R&D at AstraZeneca, highlighting some of the challenges that they have presented to our established screening cascade.  Furthermore, we challenge some of the perceptions and dogma surrounding the feasibility of oral PROTACS and demonstrate that acceptable oral PK properties for this modality can be regularly achievable despite the physicochem. property challenges they present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNes0zq6ODubVg90H21EOLACvtfcHk0lhELedl4ReMAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVeru7zF&md5=a26048e1fe2eb5f9e134a9132593df23</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DA.%26aulast%3DWilliamson%26aufirst%3DB.%26aulast%3DHarlfinger%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26atitle%3DOptimising%2520proteolysis-targeting%2520chimeras%2520%2528PROTACs%2529%2520for%2520oral%2520drug%2520delivery%253A%2520a%2520drug%2520metabolism%2520and%2520pharmacokinetics%2520perspective%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D1793%26epage%3D1800%26doi%3D10.1016%2Fj.drudis.2020.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallan, C.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.bmcl.2019.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31047748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1555-1564&author=S.+D.+Edmondsonauthor=B.+Yangauthor=C.+Fallan&title=Proteolysis+targeting+chimeras+%28PROTACs%29+in+%E2%80%98beyond+rule-of-five%E2%80%99+chemical+space%3A+Recent+progress+and+future+challenges&doi=10.1016%2Fj.bmcl.2019.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges</span></div><div class="casAuthors">Edmondson, Scott D.; Yang, Bin; Fallan, Charlene</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1555-1564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional compds. with mol. wts. and other properties that lie outside the classic 'rule-of-five' space.  Consequently, PROTACs have unique challenges assocd. with their development as potential therapeutic agents.  This review summarizes and analyzes a representative set of recent PROTACs and highlights some of the potential future challenges facing this promising modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDcS0gIul-K7Vg90H21EOLACvtfcHk0lgGCSKrT-Gn5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D&md5=62a74500178bd711b1ddaa33d731b960</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DFallan%26aufirst%3DC.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520in%2520%25E2%2580%2598beyond%2520rule-of-five%25E2%2580%2599%2520chemical%2520space%253A%2520Recent%2520progress%2520and%2520future%2520challenges%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1555%26epage%3D1564%26doi%3D10.1016%2Fj.bmcl.2019.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Maple, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stacey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, R.</span></span> <span> </span><span class="NLM_article-title">Developing degraders: principles and perspectives on design and chemical space</span>. <i>Med. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1755</span>– <span class="NLM_lpage">1764</span>, <span class="refDoi"> DOI: 10.1039/C9MD00272C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2FC9MD00272C" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1755-1764&author=H.+J.+Mapleauthor=N.+Claydenauthor=A.+Baronauthor=C.+Staceyauthor=R.+Felix&title=Developing+degraders%3A+principles+and+perspectives+on+design+and+chemical+space&doi=10.1039%2FC9MD00272C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1039%2FC9MD00272C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9MD00272C%26sid%3Dliteratum%253Aachs%26aulast%3DMaple%26aufirst%3DH.%2BJ.%26aulast%3DClayden%26aufirst%3DN.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DStacey%26aufirst%3DC.%26aulast%3DFelix%26aufirst%3DR.%26atitle%3DDeveloping%2520degraders%253A%2520principles%2520and%2520perspectives%2520on%2520design%2520and%2520chemical%2520space%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D1755%26epage%3D1764%26doi%3D10.1039%2FC9MD00272C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01816</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01816" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVajsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=462-481&author=B.+Zhouauthor=J.+Huauthor=F.+Xuauthor=Z.+Chenauthor=L.+Baiauthor=E.+Fernandez-Salasauthor=M.+Linauthor=L.+Liuauthor=C.-Y.+Yangauthor=Y.+Zhaoauthor=D.+McEachernauthor=S.+Przybranowskiauthor=B.+Wenauthor=D.+Sunauthor=S.+Wang&title=Discovery+of+a+small-molecule+degrader+of+bromodomain+and+extra-terminal+%28BET%29+proteins+with+picomolar+cellular+potencies+and+capable+of+achieving+tumor+regression&doi=10.1021%2Facs.jmedchem.6b01816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression</span></div><div class="casAuthors">Zhou, Bing; Hu, Jiantao; Xu, Fuming; Chen, Zhuo; Bai, Longchuan; Fernandez-Salas, Ester; Lin, Mei; Liu, Liu; Yang, Chao-Yie; Zhao, Yujun; McEachern, Donna; Przybranowski, Sally; Wen, Bo; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-481</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bromodomain and extra-terminal (BET) family proteins, consisting of BRD2, BRD3, BRD4, and testis-specific BRDT members, are epigenetic "readers" and play a key role in the regulation of gene transcription.  BET proteins are considered to be attractive therapeutic targets for cancer and other human diseases.  Recently, heterobifunctional small-mol. BET degraders have been designed based upon the proteolysis targeting chimera (PROTAC) concept to induce BET protein degrdn.  Herein, we present our design, synthesis, and evaluation of a new class of PROTAC BET degraders.  One of the most promising compds., 23, effectively degrades BRD4 protein at concns. as low as 30 pM in the RS4;11 leukemia cell line, achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induces rapid tumor regression in vivo against RS4;11 xenograft tumors.  These data establish that compd. 23 (BETd-260/ZBC260) is a highly potent and efficacious BET degrader.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqz2Lwp52x1rVg90H21EOLACvtfcHk0lgGCSKrT-Gn5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVajsb8%253D&md5=6b3a10ecd192a5812ef581dca1fdc82a</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01816%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520small-molecule%2520degrader%2520of%2520bromodomain%2520and%2520extra-terminal%2520%2528BET%2529%2520proteins%2520with%2520picomolar%2520cellular%2520potencies%2520and%2520capable%2520of%2520achieving%2520tumor%2520regression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D462%26epage%3D481%26doi%3D10.1021%2Facs.jmedchem.6b01816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziazadeh, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6685</span>– <span class="NLM_lpage">6704</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00506</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00506" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6685-6704&author=C.+Qinauthor=Y.+Huauthor=B.+Zhouauthor=E.+Fernandez-Salasauthor=C.-Y.+Yangauthor=L.+Liuauthor=D.+McEachernauthor=S.+Przybranowskiauthor=M.+Wangauthor=J.+Stuckeyauthor=J.+Meagherauthor=L.+Baiauthor=Z.+Chenauthor=M.+Linauthor=J.+Yangauthor=D.+N.+Ziazadehauthor=F.+Xuauthor=J.+Huauthor=W.+Xiangauthor=L.+Huangauthor=S.+Liauthor=B.+Wenauthor=D.+Sunauthor=S.+Wang&title=Discovery+of+QCA570+as+an+exceptionally+potent+and+efficacious+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+the+bromodomain+and+extra-terminal+%28BET%29+proteins+capable+of+inducing+complete+and+durable+tumor+regression&doi=10.1021%2Facs.jmedchem.8b00506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression</span></div><div class="casAuthors">Qin, Chong; Hu, Yang; Zhou, Bing; Fernandez-Salas, Ester; Yang, Chao-Yie; Liu, Liu; McEachern, Donna; Przybranowski, Sally; Wang, Mi; Stuckey, Jeanne; Meagher, Jennifer; Bai, Longchuan; Chen, Zhuo; Lin, Mei; Yang, Jiuling; Ziazadeh, Danya N.; Xu, Fuming; Hu, Jiantao; Xing, Weiguo; Huang, Liyue; Li, Siwei; Wen, Bo; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6685-6704</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proteins of the bromodomain and extra-terminal (BET) family are epigenetics "readers" and promising therapeutic targets for cancer and other human diseases.  We describe herein a structure-guided design of [1,4]oxazepines as a new class of BET inhibitors and our subsequent design, synthesis, and evaluation of proteolysis-targeting chimeric (PROTAC) small-mol. BET degraders.  Our efforts have led to the discovery of extremely potent BET degraders, exemplified by QCA570, which effectively induces degrdn. of BET proteins and inhibits cell growth in human acute leukemia cell lines even at low picomolar concns.  QCA570 achieves complete and durable tumor regression in leukemia xenograft models in mice at well-tolerated dose-schedules.  QCA570 is the most potent and efficacious BET degrader reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ZUIsfX3p6LVg90H21EOLACvtfcHk0lhl0al0v00JKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsLrE&md5=2a731730641372f4526543e03d9ac76f</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00506%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DMeagher%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZiazadeh%26aufirst%3DD.%2BN.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520QCA570%2520as%2520an%2520exceptionally%2520potent%2520and%2520efficacious%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520the%2520bromodomain%2520and%2520extra-terminal%2520%2528BET%2529%2520proteins%2520capable%2520of%2520inducing%2520complete%2520and%2520durable%2520tumor%2520regression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6685%26epage%3D6704%26doi%3D10.1021%2Facs.jmedchem.8b00506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Petrylak, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelzang, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfield, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span> <span> </span><span class="NLM_article-title">First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3500</span>, <span class="refDoi"> DOI: 10.1200/JCO.2020.38.15_suppl.3500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1200%2FJCO.2020.38.15_suppl.3500" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=3500&author=D.+P.+Petrylakauthor=X.+Gaoauthor=N.+J.+Vogelzangauthor=M.+H.+Garfieldauthor=I.+Taylorauthor=M.+D.+Mooreauthor=R.+A.+Peckauthor=H.+A.+Burris&title=First-in-human+phase+I+study+of+ARV-110%2C+an+androgen+receptor+%28AR%29+PROTAC+degrader+in+patients+%28pts%29+with+metastatic+castrate-resistant+prostate+cancer+%28mCRPC%29+following+enzalutamide+%28ENZ%29+and%2For+abiraterone+%28ABI%29&doi=10.1200%2FJCO.2020.38.15_suppl.3500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2020.38.15_suppl.3500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2020.38.15_suppl.3500%26sid%3Dliteratum%253Aachs%26aulast%3DPetrylak%26aufirst%3DD.%2BP.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DVogelzang%26aufirst%3DN.%2BJ.%26aulast%3DGarfield%26aufirst%3DM.%2BH.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DMoore%26aufirst%3DM.%2BD.%26aulast%3DPeck%26aufirst%3DR.%2BA.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%2520of%2520ARV-110%252C%2520an%2520androgen%2520receptor%2520%2528AR%2529%2520PROTAC%2520degrader%2520in%2520patients%2520%2528pts%2529%2520with%2520metastatic%2520castrate-resistant%2520prostate%2520cancer%2520%2528mCRPC%2529%2520following%2520enzalutamide%2520%2528ENZ%2529%2520and%252For%2520abiraterone%2520%2528ABI%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D3500%26doi%3D10.1200%2FJCO.2020.38.15_suppl.3500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">A chemical approach for global protein knockdown from mice to non-human primates</span>. <i>Cell Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">10</span> <span class="refDoi"> DOI: 10.1038/s41421-018-0079-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41421-018-0079-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30729032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A280%3ADC%252BB3cjpvFKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&author=X.+Sunauthor=J.+Wangauthor=X.+Yaoauthor=W.+Zhengauthor=Y.+Maoauthor=T.+Lanauthor=L.+Wangauthor=Y.+Sunauthor=X.+Zhangauthor=Q.+Zhaoauthor=J.+Zhaoauthor=R.-P.+Xiaoauthor=X.+Zhangauthor=G.+Jiauthor=Y.+Rao&title=A+chemical+approach+for+global+protein+knockdown+from+mice+to+non-human+primates&doi=10.1038%2Fs41421-018-0079-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">A chemical approach for global protein knockdown from mice to non-human primates</span></div><div class="casAuthors">Sun Xiuyun; Yao Xia; Lan Tianlong; Wang Liguo; Sun Yonghui; Zhao Qiuye; Rao Yu; Sun Xiuyun; Yao Xia; Lan Tianlong; Wang Liguo; Sun Yonghui; Zhao Qiuye; Rao Yu; Sun Xiuyun; Wang Jun; Mao Yang; Zhang Xinyi; Ji Guangju; Wang Jun; Mao Yang; Zhang Xinyi; Zheng Wen; Zhang Xiuqin; Zheng Wen; Zhang Xiuqin; Zhao Jianguo; Xiao Rui-Ping; Xiao Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cell discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10</span>
        ISSN:<span class="NLM_cas:issn">2056-5968</span>.
    </div><div class="casAbstract">Although conventional genetic modification approaches for protein knockdown work very successfully due to the increasing use of CRISPR/Cas9, effective techniques for achieving protein depletion in adult animals, especially in large animals such as non-human primates, are lacking.  Here, we report a chemical approach based on PROTACs technology that efficiently and quickly knocks down FKBP12 (12-kDa FK506-binding) protein globally in vivo.  Both intraperitoneal and oral administration led to rapid, robust, and reversible FKBP12 degradation in mice.  The efficiency and practicality of this method were successfully demonstrated in both large and small animals (mice, rats, Bama pigs, and rhesus monkeys).  Furthermore, we showed this approach can also be applied to effectively knockdown other target proteins such as Bruton's tyrosine kinase (BTK).  This chemical protein knockdown strategy provides a powerful research tool for gene function studies in animals, particularly in large animals, for which gene-targeted knockout strategies may remain unfeasible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOtjU0KY5kR9ts4TFFB11gfW6udTcc2eazJg5aTYF9Lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjpvFKiug%253D%253D&md5=199267298a928382ed1a91a7c066eefa</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1038%2Fs41421-018-0079-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41421-018-0079-1%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DR.-P.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DG.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DA%2520chemical%2520approach%2520for%2520global%2520protein%2520knockdown%2520from%2520mice%2520to%2520non-human%2520primates%26jtitle%3DCell%2520Discovery%26date%3D2019%26volume%3D5%26doi%3D10.1038%2Fs41421-018-0079-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetsch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvaïa, N.</span></span> <span> </span><span class="NLM_article-title">Strategies and challenges for the next generation of antibody-drug conjugates</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fnrd.2016.268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28303026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=315-337&author=A.+Beckauthor=L.+Goetschauthor=C.+Dumontetauthor=N.+Corva%C3%AFa&title=Strategies+and+challenges+for+the+next+generation+of+antibody-drug+conjugates&doi=10.1038%2Fnrd.2016.268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and challenges for the next generation of antibody-drug conjugates</span></div><div class="casAuthors">Beck, Alain; Goetsch, Liliane; Dumontet, Charles; Corvaia, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-337</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncol. therapeutics.  After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clin. trials that are evaluating more than 60 further ADC candidates.  The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody.  Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs.  In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.  The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7lV63Ws8rbVg90H21EOLACvtfcHk0lhL42f-LRiSfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D&md5=7358b6080dd1aed1d21e98c078cd9ef1</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DCorva%25C3%25AFa%26aufirst%3DN.%26atitle%3DStrategies%2520and%2520challenges%2520for%2520the%2520next%2520generation%2520of%2520antibody-drug%2520conjugates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D315%26epage%3D337%26doi%3D10.1038%2Fnrd.2016.268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsaab, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashaw, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatiparti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, A. K.</span></span> <span> </span><span class="NLM_article-title">Advances in antibody-drug conjugates: A new era of targeted cancer therapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1547</span>– <span class="NLM_lpage">1556</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2017.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.drudis.2017.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28627385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCrsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1547-1556&author=S.+Sauauthor=H.+O.+Alsaabauthor=S.+K.+Kashawauthor=K.+Tatipartiauthor=A.+K.+Iyer&title=Advances+in+antibody-drug+conjugates%3A+A+new+era+of+targeted+cancer+therapy&doi=10.1016%2Fj.drudis.2017.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in antibody-drug conjugates: A new era of targeted cancer therapy</span></div><div class="casAuthors">Sau, Samaresh; Alsaab, Hashem O.; Kashaw, Sushil Kumar; Tatiparti, Katyayani; Iyer, Arun K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1547-1556</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs), a potent class of anticancer therapeutics, comprise a high-affinity antibody (Ab) and cytotoxic payload coupled via a suitable linker for selective tumor cell killing.  In the initial phase of their development, two ADCs, Mylotarg, and Adcetris were approved by the US Food and Drug Administration (FDA) for treating hematological cancer, but the real breakthrough came with the discovery of the breast cancer-targeting ADC, Kadcyla.  With advances in bioengineering, linker chem., and potent cytotoxic payload, ADC technol. has become a more powerful tool for targeted cancer therapy.  In addn., ADCs with improved safety using humanized Abs with a unified 'drug:antibody ratio' (DAR) have been achieved.  Concomitantly, there has been a significant increase in the no. of clin. trials with anticancer ADCs with high translation potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohgxck59tjx7Vg90H21EOLACvtfcHk0ljGdDTF8asQ4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCrsLzK&md5=dc5204e59d81ffa946b5d4ea07caec70</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DSau%26aufirst%3DS.%26aulast%3DAlsaab%26aufirst%3DH.%2BO.%26aulast%3DKashaw%26aufirst%3DS.%2BK.%26aulast%3DTatiparti%26aufirst%3DK.%26aulast%3DIyer%26aufirst%3DA.%2BK.%26atitle%3DAdvances%2520in%2520antibody-drug%2520conjugates%253A%2520A%2520new%2520era%2520of%2520targeted%2520cancer%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D1547%26epage%3D1556%26doi%3D10.1016%2Fj.drudis.2017.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: An emerging concept in cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3796</span>– <span class="NLM_lpage">3827</span>, <span class="refDoi"> DOI: 10.1002/anie.201307628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fanie.201307628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-3827&author=R.+V.+J.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody-drug+conjugates%3A+An+emerging+concept+in+cancer+therapy&doi=10.1002%2Fanie.201307628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy</span></div><div class="casAuthors">Chari, Ravi V. J.; Miller, Michael L.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3796-3827</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.  Monoclonal antibodies against antigens on cancer cells offer an alternative tumor-selective treatment approach.  However, most monoclonal antibodies are not sufficiently potent to be therapeutically active on their own.  Antibody-drug conjugates (ADCs) use antibodies to deliver a potent cytotoxic compd. selectively to tumor cells, thus improving the therapeutic index of chemotherapeutic agents.  The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for cancer treatment has spurred tremendous research interest in this field.  This Review touches upon the early efforts in the field, and describes how the lessons learned from the first-generation ADCs have led to improvements in every aspect of this technol., i.e., the antibody, the cytotoxic compd., and the linker connecting them, leading to the current successes.  The design of ADCs currently in clin. development, and results from mechanistic studies and preclin. and clin. evaluation are discussed.  Emerging technologies that seek to further advance this exciting area of research are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4T2rhmji6DLVg90H21EOLACvtfcHk0ljGdDTF8asQ4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D&md5=fbfb2f843f516654ea7c0eb98949604c</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307628%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody-drug%2520conjugates%253A%2520An%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D3827%26doi%3D10.1002%2Fanie.201307628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span>; <span class="NLM_string-name">Pillow, T. H.</span>; <span class="NLM_string-name">Blake, R. A.</span>; <span class="NLM_string-name">Sadowsky, J. D.</span>; <span class="NLM_string-name">Adaligil, E.</span>; <span class="NLM_string-name">Adhikari, P.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Corr, N.</span>; <span class="NLM_string-name">dela Cruz-Chuh, J.</span>; <span class="NLM_string-name">del-Rosario, G.</span>; <span class="NLM_string-name">Fullerton, A.</span>; <span class="NLM_string-name">Hartman, S. J.</span>; <span class="NLM_string-name">Jiang, F.</span>; <span class="NLM_string-name">Kaufman, S.</span>; <span class="NLM_string-name">Kleinheinz, T.</span>; <span class="NLM_string-name">Kozak, K. R.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">Lu, Y.</span>; <span class="NLM_string-name">Mulvihill, M. M.</span>; <span class="NLM_string-name">Murray, J. M.</span>; <span class="NLM_string-name">O’Donohue, A.</span>; <span class="NLM_string-name">Rowntree, R. K.</span>; <span class="NLM_string-name">Sawyer, W. S.</span>; <span class="NLM_string-name">Staben, L. R.</span>; <span class="NLM_string-name">Wai, J.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Wei, B.</span>; <span class="NLM_string-name">Wei, W.</span>; <span class="NLM_string-name">Xu, Z.</span>; <span class="NLM_string-name">Yao, H.</span>; <span class="NLM_string-name">Yu, S.-F.</span>; <span class="NLM_string-name">Zhang, D.</span>; <span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Zhang, S.</span>; <span class="NLM_string-name">Zhao, Y.</span>; <span class="NLM_string-name">Zhou, H.</span>; <span class="NLM_string-name">Zhu, X.</span></span> <span> </span><span class="NLM_article-title">Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: Improvement of in vitro antiproliferation activity and in vivo anti-tumor efficacy</span>.  <i>J. Med. Chem.</i>, subsequent paper in this issue, <span class="NLM_year">2021</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01846" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=P.+S.+Dragovich&author=T.+H.+Pillow&author=R.+A.+Blake&author=J.+D.+Sadowsky&author=E.+Adaligil&author=P.+Adhikari&author=J.+Chen&author=N.+Corr&author=J.+dela+Cruz-Chuh&author=G.+del-Rosario&author=A.+Fullerton&author=S.+J.+Hartman&author=F.+Jiang&author=S.+Kaufman&author=T.+Kleinheinz&author=K.+R.+Kozak&author=L.+Liu&author=Y.+Lu&author=M.+M.+Mulvihill&author=J.+M.+Murray&author=A.+O%E2%80%99Donohue&author=R.+K.+Rowntree&author=W.+S.+Sawyer&author=L.+R.+Staben&author=J.+Wai&author=J.+Wang&author=B.+Wei&author=W.+Wei&author=Z.+Xu&author=H.+Yao&author=S.-F.+Yu&author=D.+Zhang&author=H.+Zhang&author=S.+Zhang&author=Y.+Zhao&author=H.+Zhou&author=X.+Zhu&title=Antibody-mediated+delivery+of+chimeric+BRD4+degraders.+Part+2%3A+Improvement+of+in+vitro+antiproliferation+activity+and+in+vivo+anti-tumor+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01846%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DAntibody-mediated%2520delivery%2520of%2520chimeric%2520BRD4%2520degraders.%2520Part%25202%253A%2520Improvement%2520of%2520in%2520vitro%2520antiproliferation%2520activity%2520and%2520in%2520vivo%2520anti-tumor%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Besten, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowntree, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>, <span class="NLM_elocation-id">126907</span> <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.bmcl.2019.126907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31902710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFWgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&author=P.+S.+Dragovichauthor=P.+Adhikariauthor=R.+A.+Blakeauthor=N.+Blaquiereauthor=J.+Chenauthor=Y.-X.+Chengauthor=W.+den+Bestenauthor=J.+Hanauthor=S.+J.+Hartmanauthor=J.+Heauthor=M.+Heauthor=E.+R.+Ingallaauthor=A.+V.+Kamathauthor=T.+Kleinheinzauthor=T.+Laiauthor=D.+D.+Leipoldauthor=C.+S.+Liauthor=Q.+Liuauthor=J.+Luauthor=Y.+Luauthor=F.+Mengauthor=L.+Mengauthor=C.+Ngauthor=K.+Pengauthor=G.+L.+Phillipsauthor=T.+H.+Pillowauthor=R.+K.+Rowntreeauthor=J.+D.+Sadowskyauthor=D.+Sampathauthor=L.+Stabenauthor=S.+T.+Stabenauthor=J.+Waiauthor=K.+Wanauthor=X.+Wangauthor=B.+Weiauthor=I.+E.+Wertzauthor=J.+Xinauthor=K.+Xuauthor=H.+Yaoauthor=R.+Zangauthor=D.+Zhangauthor=H.+Zhouauthor=Y.+Zhao&title=Antibody-mediated+delivery+of+chimeric+protein+degraders+which+target+estrogen+receptor+alpha+%28ER%CE%B1%29&doi=10.1016%2Fj.bmcl.2019.126907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)</span></div><div class="casAuthors">Dragovich, Peter S.; Adhikari, Pragya; Blake, Robert A.; Blaquiere, Nicole; Chen, Jinhua; Cheng, Yun-Xing; den Besten, Willem; Han, Jinping; Hartman, Steven J.; He, Jintang; He, Mingtao; Rei Ingalla, Ellen; Kamath, Amrita V.; Kleinheinz, Tracy; Lai, Tommy; Leipold, Douglas D.; Li, Chun Sing; Liu, Qi; Lu, Jiawei; Lu, Ying; Meng, Fanwei; Meng, Lingyao; Ng, Carl; Peng, Kaishan; Lewis Phillips, Gail; Pillow, Thomas H.; Rowntree, Rebecca K.; Sadowsky, Jack D.; Sampath, Deepak; Staben, Leanna; Staben, Steven T.; Wai, John; Wan, Kunpeng; Wang, Xinxin; Wei, Bin Qing; Wertz, Ingrid E.; Xin, Jianfeng; Xu, Keyang; Yao, Hui; Zang, Richard; Zhang, Donglu; Zhou, Hao; Zhao, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">126907</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chimeric mols. which effect intracellular degrdn. of target proteins via E3 ligase-mediated ubiquitination (e.g., PROTACs) are currently of high interest in medicinal chem.  However, these entities are relatively large compds. that often possess mol. characteristics which may compromise oral bioavailability, soly., and/or in vivo pharmacokinetic properties.  Accordingly, we explored whether conjugation of chimeric degraders to monoclonal antibodies using technologies originally developed for cytotoxic payloads might provide alternate delivery options for these novel agents.  In this report we describe the construction of several degrader-antibody conjugates comprised of two distinct ERα-targeting degrader entities and three independent ADC linker modalities.  We subsequently demonstrate the antigen-dependent delivery to MCF7-neo/HER2 cells of the degrader payloads that are incorporated into these conjugates.  We also provide evidence for efficient intracellular degrader release from one of the employed linkers.  In addn., preliminary data are described which suggest that reasonably favorable in vivo stability properties are assocd. with the linkers utilized to construct the degrader conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdPWcGkXC85LVg90H21EOLACvtfcHk0ljhCnrrJ9O_rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFWgtw%253D%253D&md5=5f196b194df7f4622825c4b901130f7c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126907%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DAdhikari%26aufirst%3DP.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DY.-X.%26aulast%3Dden%2BBesten%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DIngalla%26aufirst%3DE.%2BR.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLai%26aufirst%3DT.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DK.%26aulast%3DPhillips%26aufirst%3DG.%2BL.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DRowntree%26aufirst%3DR.%2BK.%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DStaben%26aufirst%3DL.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DXin%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DAntibody-mediated%2520delivery%2520of%2520chimeric%2520protein%2520degraders%2520which%2520target%2520estrogen%2520receptor%2520alpha%2520%2528ER%25CE%25B1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26doi%3D10.1016%2Fj.bmcl.2019.126907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoigne, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latifi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvihill, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowntree, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span> <span> </span><span class="NLM_article-title">Antibody conjugation of a chimeric BET degrader enables in vivo activity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fcmdc.201900497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31674143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCmt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=17-25&author=T.+H.+Pillowauthor=P.+Adhikariauthor=R.+A.+Blakeauthor=J.+Chenauthor=G.+Del+Rosarioauthor=G.+Deshmukhauthor=I.+Figueroaauthor=K.+E.+Gascoigneauthor=A.+V.+Kamathauthor=S.+Kaufmanauthor=T.+Kleinheinzauthor=K.+R.+Kozakauthor=B.+Latifiauthor=D.+D.+Leipoldauthor=C.+S.+Liauthor=R.+Liauthor=M.+M.+Mulvihillauthor=A.+O%E2%80%99Donohueauthor=R.+K.+Rowntreeauthor=J.+D.+Sadowskyauthor=J.+Waiauthor=X.+Wangauthor=C.+Wuauthor=Z.+Xuauthor=H.+Yaoauthor=S.-F.+Yuauthor=D.+Zhangauthor=R.+Zangauthor=H.+Zhangauthor=H.+Zhouauthor=X.+Zhuauthor=P.+S.+Dragovich&title=Antibody+conjugation+of+a+chimeric+BET+degrader+enables+in+vivo+activity&doi=10.1002%2Fcmdc.201900497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity</span></div><div class="casAuthors">Pillow, Thomas H.; Adhikari, Pragya; Blake, Robert A.; Chen, Jinhua; Del Rosario, Geoffrey; Deshmukh, Gauri; Figueroa, Isabel; Gascoigne, Karen E.; Kamath, Amrita V.; Kaufman, Susan; Kleinheinz, Tracy; Kozak, Katherine R.; Latifi, Brandon; Leipold, Douglas D.; Sing Li, Chun; Li, Ruina; Mulvihill, Melinda M.; O'Donohue, Aimee; Rowntree, Rebecca K.; Sadowsky, Jack D.; Wai, John; Wang, Xinxin; Wu, Cong; Xu, Zijin; Yao, Hui; Yu, Shang-Fan; Zhang, Donglu; Zang, Richard; Zhang, Hongyan; Zhou, Hao; Zhu, Xiaoyu; Dragovich, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-25</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ability to selectively degrade proteins with bifunctional small mols. has the potential to fundamentally alter therapy in a variety of diseases.  However, the relatively large size of these chimeric mols. often results in challenging physico-chem. properties (e. g., low aq. soly.) and poor pharmacokinetics which may complicate their in vivo applications.  We recently discovered an exquisitely potent chimeric BET degrader (GNE-987) which exhibited picomolar cell potencies but also demonstrated low in vivo exposures.  In an effort to improve the pharmacokinetic properties of this mol., we discovered the first degrader-antibody conjugate by attaching GNE-987 to an anti-CLL1 antibody via a novel linker.  A single IV dose of the conjugate afforded sustained in vivo exposures that resulted in antigen-specific tumor regressions.  Enhancement of a chimeric protein degrader with poor in vivo properties through antibody conjugation thereby expands the utility of directed protein degrdn. as both a biol. tool and a therapeutic possibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPzNLh7QlBR7Vg90H21EOLACvtfcHk0lhlRn_W2fVs4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCmt7zP&md5=90f9e1b5ae453ae38d61a36587feb558</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900497%26sid%3Dliteratum%253Aachs%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DAdhikari%26aufirst%3DP.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DFigueroa%26aufirst%3DI.%26aulast%3DGascoigne%26aufirst%3DK.%2BE.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DLatifi%26aufirst%3DB.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMulvihill%26aufirst%3DM.%2BM.%26aulast%3DO%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DRowntree%26aufirst%3DR.%2BK.%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DAntibody%2520conjugation%2520of%2520a%2520chimeric%2520BET%2520degrader%2520enables%2520in%2520vivo%2520activity%26jtitle%3DChemMedChem%26date%3D2020%26volume%3D15%26spage%3D17%26epage%3D25%26doi%3D10.1002%2Fcmdc.201900497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maneiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shchepinova, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kounde, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chudasama, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, E. W.</span></span> <span> </span><span class="NLM_article-title">Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1306</span>– <span class="NLM_lpage">1312</span>, <span class="refDoi"> DOI: 10.1021/acschembio.0c00285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.0c00285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFehsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1306-1312&author=M.+Maneiroauthor=N.+Forteauthor=M.+M.+Shchepinovaauthor=C.+S.+Koundeauthor=V.+Chudasamaauthor=J.+R.+Bakerauthor=E.+W.+Tate&title=Antibody-PROTAC+conjugates+enable+HER2-dependent+targeted+protein+degradation+of+BRD4&doi=10.1021%2Facschembio.0c00285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4</span></div><div class="casAuthors">Maneiro, Maria; Forte, Nafsika; Shchepinova, Maria M.; Kounde, Cyrille S.; Chudasama, Vijay; Baker, James Richard; Tate, Edward W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1306-1312</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting protein degrdn. with Proteolysis-Targeting Chimeras (PROTACs) is an area of great current interest in drug discovery.  Nevertheless, although the high effectiveness of PROTACs against a wide variety of targets has been established, most degraders reported to date display limited intrinsic tissue selectivity and do not discriminate between cells of different types.  Here, we describe a strategy for selective protein degrdn. in a specific cell type.  We report the design and synthesis of a trastuzumab-PROTAC conjugate (Ab-PROTAC 3) in which E3 ligase-directed degrader activity is caged with an antibody linker which can be hydrolyzed following antibody-PROTAC internalization, releasing the active PROTAC and inducing catalytic protein degrdn.  We show that 3 selectively targets bromodomain-contg. protein 4 (BRD4) for degrdn. only in HER2 pos. breast cancer cell lines, while sparing HER2 neg. cells.  Using live cell confocal microscopy, we show internalization and lysosomal trafficking of the conjugate specifically in HER2 pos. cells, leading to the release of active PROTAC in quantities sufficient to induce potent BRD4 degrdn.  These studies demonstrate proof-of-concept for tissue-specific BRD4 degrdn., overcoming limitations of PROTAC selectivity, with significant potential for application to novel targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPwGNLaGmRbbVg90H21EOLACvtfcHk0lhlRn_W2fVs4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFehsLo%253D&md5=544b53e54d3f0696f0b425c3f6e48e46</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facschembio.0c00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.0c00285%26sid%3Dliteratum%253Aachs%26aulast%3DManeiro%26aufirst%3DM.%26aulast%3DForte%26aufirst%3DN.%26aulast%3DShchepinova%26aufirst%3DM.%2BM.%26aulast%3DKounde%26aufirst%3DC.%2BS.%26aulast%3DChudasama%26aufirst%3DV.%26aulast%3DBaker%26aufirst%3DJ.%2BR.%26aulast%3DTate%26aufirst%3DE.%2BW.%26atitle%3DAntibody-PROTAC%2520conjugates%2520enable%2520HER2-dependent%2520targeted%2520protein%2520degradation%2520of%2520BRD4%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2020%26volume%3D15%26spage%3D1306%26epage%3D1312%26doi%3D10.1021%2Facschembio.0c00285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zengerle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">Selective small molecule induced degradation of the BET bromodomain protein BRD4</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1770</span>– <span class="NLM_lpage">1777</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00216</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00216" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1770-1777&author=M.+Zengerleauthor=K.-H.+Chanauthor=A.+Ciulli&title=Selective+small+molecule+induced+degradation+of+the+BET+bromodomain+protein+BRD4&doi=10.1021%2Facschembio.5b00216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4</span></div><div class="casAuthors">Zengerle, Michael; Chan, Kwok-Ho; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1770-1777</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Bromo- and Extra-Terminal (BET) proteins BRD2, BRD3, and BRD4 play important roles in transcriptional regulation, epigenetics, and cancer and are the targets of pan-BET selective bromodomain inhibitor JQ1.  However, the lack of intra-BET selectivity limits the scope of current inhibitors as probes for target validation and could lead to unwanted side effects or toxicity in a therapeutic setting.  We designed Proteolysis Targeted Chimeras (PROTACs) that tether JQ1 to a ligand for the E3 ubiquitin ligase VHL, aimed at triggering the intracellular destruction of BET proteins.  Compd. MZ1 potently and rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 over BRD2 and BRD3.  The activity of MZ1 is dependent on binding to VHL but is achieved at a sufficiently low concn. not to induce stabilization of HIF-1α.  Gene expression profiles of selected cancer-related genes responsive to JQ1 reveal distinct and more limited transcriptional responses induced by MZ1, consistent with selective suppression of BRD4.  Our discovery opens up new opportunities to elucidate the cellular phenotypes and therapeutic implications assocd. with selective targeting of BRD4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEmSv7p9MZOrVg90H21EOLACvtfcHk0liS0JFMD4QbHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOgu70%253D&md5=b7514fd274eff8e4bb6a771f5aaf9ab5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00216%26sid%3Dliteratum%253Aachs%26aulast%3DZengerle%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DK.-H.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DSelective%2520small%2520molecule%2520induced%2520degradation%2520of%2520the%2520BET%2520bromodomain%2520protein%2520BRD4%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D1770%26epage%3D1777%26doi%3D10.1021%2Facschembio.5b00216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barroca-Ferreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pais, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passarinha, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maia, C. J.</span></span> <span> </span><span class="NLM_article-title">Targeting STEAP1 protein in human cancer: current trends and future challenges</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.2174/1568009617666170427103732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.2174%2F1568009617666170427103732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28460619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs1entrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=222-230&author=J.+Barroca-Ferreiraauthor=J.+P.+Paisauthor=M.+M.+Santosauthor=A.+M.+Gon%C3%A7alvesauthor=I.+M.+Gomesauthor=I.+Sousaauthor=S.+M.+Rochaauthor=L.+A.+Passarinhaauthor=C.+J.+Maia&title=Targeting+STEAP1+protein+in+human+cancer%3A+current+trends+and+future+challenges&doi=10.2174%2F1568009617666170427103732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges</span></div><div class="casAuthors">Barroca-Ferreira, J.; Pais, J. P.; Santos, M. M.; Goncalves, A. M.; Gomes, I. M.; Sousa, I.; Rocha, S. M.; Passarinha, L. A.; Maia, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-230</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Cancer is a global health issue that impairs the life quality of patients and origins thousands of deaths annually worldwide.  Six-transmembrane epithelial antigen of the prostate (STEAP1) was identified to be overexpressed in several types of cancers, namely in prostate cancer (PCa).  Considering its secondary structure, assocd. with its location in the cell membrane, has been suggested a role in intercellular communication between tumor cells.  Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target.  Several strategies have been developed during the last few years for targeting STEAP1, including antibody-drug conjugates, monoclonal antibodies (mAbs), DNA vaccines and small noncoding RNAs (ncRNAs).  This review presents the current knowledge about STEAP1 protein expression in human tissues, its biochem. properties and targeting strategies with the purpose to evaluate its potential as therapeutic agent for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeZsWGBe2eNrVg90H21EOLACvtfcHk0liS0JFMD4QbHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs1entrs%253D&md5=005afcd1a4b08ec97f1b10bd6834bf8b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2174%2F1568009617666170427103732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009617666170427103732%26sid%3Dliteratum%253Aachs%26aulast%3DBarroca-Ferreira%26aufirst%3DJ.%26aulast%3DPais%26aufirst%3DJ.%2BP.%26aulast%3DSantos%26aufirst%3DM.%2BM.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DA.%2BM.%26aulast%3DGomes%26aufirst%3DI.%2BM.%26aulast%3DSousa%26aufirst%3DI.%26aulast%3DRocha%26aufirst%3DS.%2BM.%26aulast%3DPassarinha%26aufirst%3DL.%2BA.%26aulast%3DMaia%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520STEAP1%2520protein%2520in%2520human%2520cancer%253A%2520current%2520trends%2520and%2520future%2520challenges%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2018%26volume%3D18%26spage%3D222%26epage%3D230%26doi%3D10.2174%2F1568009617666170427103732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinianow, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderbilt, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinfeld, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwisscha van Scheltinga, A. G. T.</span></span> <span> </span><span class="NLM_article-title">ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">25103</span>– <span class="NLM_lpage">25112</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.18632%2Foncotarget.8390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27029064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A280%3ADC%252BC28fkvFGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=25103-25112&author=S.-P.+Williamsauthor=A.+Ogasawaraauthor=J.+N.+Tinianowauthor=J.+E.+Floresauthor=D.+Kanauthor=J.+Lauauthor=M.+A.+Goauthor=A.+N.+Vanderbiltauthor=H.+S.+Gillauthor=L.+Miaoauthor=J.+Goldsmithauthor=B.+Rubinfeldauthor=W.+Maoauthor=R.+Firesteinauthor=S.-F.+Yuauthor=J.+Marikauthor=A.+G.+T.+Terwisscha+van+Scheltinga&title=ImmunoPET+helps+predicting+the+efficacy+of+antibody-drug+conjugates+targeting+TENB2+and+STEAP1&doi=10.18632%2Foncotarget.8390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1</span></div><div class="casAuthors">Williams Simon-Peter; Ogasawara Annie; Tinianow Jeff N; Flores Judith E; Kan David; Lau Jeffrey; Go MaryAnn; Vanderbilt Alexander N; Gill Herman S; Miao Li; Goldsmith Joshua; Rubinfeld Bonnee; Mao Weiguang; Firestein Ron; Yu Shang-Fan; Marik Jan; Terwisscha van Scheltinga Anton G T; Terwisscha van Scheltinga Anton G T</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">25103-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The efficacy of antibody-drug conjugates (ADCs) targeted to solid tumors depends on biological processes that are hard to monitor in vivo. 89Zr-immunoPET of the ADC antibodies could help understand the performance of ADCs in the clinic by confirming the necessary penetration, binding, and internalization.  This work studied monomethyl auristatin E (MMAE) ADCs against two targets in metastatic castration-resistant prostate cancer, TENB2 and STEAP1, in four patient-derived tumor models (LuCaP35V, LuCaP70, LuCaP77, LuCaP96.1).  Three aspects of ADC biology were measured and compared: efficacy was measured in tumor growth inhibition studies; target expression was measured by immunohistochemistry and flow cytometry; and tumor antibody uptake was measured with 111In-mAbs and gamma counting or with 89Zr-immunoPET.  Within each model, the mAb with the highest tumor uptake showed the greatest potency as an ADC.  Sensitivity between models varied, with the LuCaP77 model showing weak efficacy despite high target expression and high antibody uptake.  Ex vivo analysis confirmed the in vivo results, showing a correlation between expression, uptake and ADC efficacy.  We conclude that 89Zr-immunoPET data can demonstrate which ADC candidates achieve the penetration, binding, and internalization necessary for efficacy in tumors sensitive to the toxic payload.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzcTozJEcZa4vKgEt20y1XfW6udTcc2eYC1Bva3tDHVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fkvFGqsQ%253D%253D&md5=cddadecbc30365301ea959ba7883cbe1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8390%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DS.-P.%26aulast%3DOgasawara%26aufirst%3DA.%26aulast%3DTinianow%26aufirst%3DJ.%2BN.%26aulast%3DFlores%26aufirst%3DJ.%2BE.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DGo%26aufirst%3DM.%2BA.%26aulast%3DVanderbilt%26aufirst%3DA.%2BN.%26aulast%3DGill%26aufirst%3DH.%2BS.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DJ.%26aulast%3DRubinfeld%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DFirestein%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DMarik%26aufirst%3DJ.%26aulast%3DTerwisscha%2Bvan%2BScheltinga%26aufirst%3DA.%2BG.%2BT.%26atitle%3DImmunoPET%2520helps%2520predicting%2520the%2520efficacy%2520of%2520antibody-drug%2520conjugates%2520targeting%2520TENB2%2520and%2520STEAP1%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D25103%26epage%3D25112%26doi%3D10.18632%2Foncotarget.8390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asangani, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dommeti, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cieslik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escara-Wilke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilder-Romans, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanireddy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>510</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1038/nature13229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fnature13229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=24759320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1WmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=510&publication_year=2014&pages=278-282&author=I.+A.+Asanganiauthor=V.+L.+Dommetiauthor=X.+Wangauthor=R.+Malikauthor=M.+Cieslikauthor=R.+Yangauthor=J.+Escara-Wilkeauthor=K.+Wilder-Romansauthor=S.+Dhanireddyauthor=C.+Engelkeauthor=M.+K.+Iyerauthor=X.+Jingauthor=Y.-M.+Wuauthor=X.+Caoauthor=Z.+S.+Qinauthor=S.+Wangauthor=F.+Y.+Fengauthor=A.+M.+Chinnaiyan&title=Therapeutic+targeting+of+BET+bromodomain+proteins+in+castration-resistant+prostate+cancer&doi=10.1038%2Fnature13229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer</span></div><div class="casAuthors">Asangani, Irfan A.; Dommeti, Vijaya L.; Wang, Xiaoju; Malik, Rohit; Cieslik, Marcin; Yang, Rendong; Escara-Wilke, June; Wilder-Romans, Kari; Dhanireddy, Sudheer; Engelke, Carl; Iyer, Mathew K.; Jing, Xiaojun; Wu, Yi-Mi; Cao, Xuhong; Qin, Zhaohui S.; Wang, Shaomeng; Feng, Felix Y.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">510</span>
        (<span class="NLM_cas:issue">7504</span>),
    <span class="NLM_cas:pages">278-282</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease.  Progression to CRPC after androgen ablation therapy is predominantly driven by deregulated androgen receptor (AR) signaling.  Despite the success of recently approved therapies targeting AR signaling, such as abiraterone and second-generation anti-androgens including MDV3100 (also known as enzalutamide), durable responses are limited, presumably owing to acquired resistance.  Recently, JQ1 and I-BET762 two selective small-mol. inhibitors that target the N-terminal bromodomains of BRD4, have been shown to exhibit anti-proliferative effects in a range of malignancies.  AR-signaling-competent human CRPC cell lines are preferentially sensitive to bromodomain and extraterminal (BET) inhibition.  BRD4 phys. interacts with the N-terminal domain of AR and can be disrupted by JQ1 (refs 11, 13).  Like the direct AR antagonist MDV3100, JQ1 disrupted AR recruitment to target gene loci.  By contrast with MDV3100, JQ1 functions downstream of AR, and more potently abrogated BRD4 localization to AR target loci and AR-mediated gene transcription, including induction of the TMPRSS2-ERG gene fusion and its oncogenic activity.  In vivo, BET bromodomain inhibition was more efficacious than direct AR antagonism in CRPC xenograft mouse models.  Taken together, these studies provide a novel epigenetic approach for the concerted blockade of oncogenic drivers in advanced prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRfXutywHDWrVg90H21EOLACvtfcHk0li-4ttboTTWUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1WmtLo%253D&md5=bef4b5faf5d23dc7d125ab1941c3ee39</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature13229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13229%26sid%3Dliteratum%253Aachs%26aulast%3DAsangani%26aufirst%3DI.%2BA.%26aulast%3DDommeti%26aufirst%3DV.%2BL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMalik%26aufirst%3DR.%26aulast%3DCieslik%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DEscara-Wilke%26aufirst%3DJ.%26aulast%3DWilder-Romans%26aufirst%3DK.%26aulast%3DDhanireddy%26aufirst%3DS.%26aulast%3DEngelke%26aufirst%3DC.%26aulast%3DIyer%26aufirst%3DM.%2BK.%26aulast%3DJing%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.-M.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DQin%26aufirst%3DZ.%2BS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DTherapeutic%2520targeting%2520of%2520BET%2520bromodomain%2520proteins%2520in%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DNature%26date%3D2014%26volume%3D510%26spage%3D278%26epage%3D282%26doi%3D10.1038%2Fnature13229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uziel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Exploitation of castration-resistant prostate cancer transcription factor dependencies by the novel BET inhibitor ABBV-075</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-16-0221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1541-7786.MCR-16-0221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27707886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Wmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=35-44&author=E.+J.+Faivreauthor=D.+Wilcoxauthor=X.+Linauthor=P.+Hesslerauthor=M.+Torrentauthor=W.+Heauthor=T.+Uzielauthor=D.+H.+Albertauthor=K.+McDanielauthor=W.+Katiauthor=Y.+Shen&title=Exploitation+of+castration-resistant+prostate+cancer+transcription+factor+dependencies+by+the+novel+BET+inhibitor+ABBV-075&doi=10.1158%2F1541-7786.MCR-16-0221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075</span></div><div class="casAuthors">Faivre, Emily J.; Wilcox, Denise; Lin, Xiaoyu; Hessler, Paul; Torrent, Maricel; He, Wei; Uziel, Tamar; Albert, Daniel H.; McDaniel, Keith; Kati, Warren; Shen, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-44</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and hematol. malignancies.  The function of BET family member BRD4 at enhancers/superenhancers has been shown to sustain signal-dependent or pathogenic gene expression programs.  Here, the hypothesis was tested that the transcription factor drivers of castration-resistant prostate cancer (CRPC) clin. progression, including the androgen receptor (AR), are critically dependent on BRD4 and thus represent a sensitive solid tumor indication for the BET inhibitor ABBV-075.  DHT-stimulated transcription of AR target genes was inhibited by ABBV-075 without significant effect on AR protein expression.  Furthermore, ABBV-075 disrupted DHT-stimulated recruitment of BET family member BRD4 to gene-regulatory regions cooccupied by AR, including the well-established PSA and TMPRSS2 enhancers.  Persistent BET inhibition disrupted the compn. and function of AR-occupied enhancers as measured by a redn. in AR and H3K27Ac ChIP signal and inhibition of enhancer RNA transcription.  ABBV-075 displayed potent antiproliferative activity in multiple models of resistance to second-generation antiandrogens and inhibited the activity of the AR splice variant AR-V7 and ligand-binding domain gain-of-function mutations, F877L and L702H.  ABBV-075 was also a potent inhibitor of MYC and the TMPRSS2-ETS fusion protein, important parallel transcription factor drivers of CRPC.  Implications: The ability of BET family inhibitor ABBV-075 to inhibit transcription activation downstream of the initiating events of transcription factors like AR and TMPRSS2:ETS fusion proteins provides a promising therapeutic option for CRPC patients who have developed resistance to second-generation antiandrogens.  Mol Cancer Res; 15(1); 35-44. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJhf86qetj1rVg90H21EOLACvtfcHk0ljKGMz9BkU1qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Wmtw%253D%253D&md5=3dbe9d0030a6f921345c150deb3de777</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-16-0221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-16-0221%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DE.%2BJ.%26aulast%3DWilcox%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DHessler%26aufirst%3DP.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DUziel%26aufirst%3DT.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DMcDaniel%26aufirst%3DK.%26aulast%3DKati%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DExploitation%2520of%2520castration-resistant%2520prostate%2520cancer%2520transcription%2520factor%2520dependencies%2520by%2520the%2520novel%2520BET%2520inhibitor%2520ABBV-075%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2017%26volume%3D15%26spage%3D35%26epage%3D44%26doi%3D10.1158%2F1541-7786.MCR-16-0221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selth, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyquist, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raj, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehm, S. M.</span></span> <span> </span><span class="NLM_article-title">Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">5880</span>– <span class="NLM_lpage">5897</span>, <span class="refDoi"> DOI: 10.1093/nar/gkv262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1093%2Fnar%2Fgkv262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=25908785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFaitr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=5880-5897&author=S.+C.+Chanauthor=L.+A.+Selthauthor=Y.+Liauthor=M.+D.+Nyquistauthor=L.+Miaoauthor=J.+E.+Bradnerauthor=G.+V.+Rajauthor=W.+D.+Tilleyauthor=S.+M.+Dehm&title=Targeting+chromatin+binding+regulation+of+constitutively+active+AR+variants+to+overcome+prostate+cancer+resistance+to+endocrine-based+therapies&doi=10.1093%2Fnar%2Fgkv262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies</span></div><div class="casAuthors">Chan, Siu Chiu; Selth, Luke A.; Li, Yingming; Nyquist, Michael D.; Miao, Lu; Bradner, James E.; Raj, Ganesh V.; Tilley, Wayne D.; Dehm, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5880-5897</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Androgen receptor (AR) variants (AR-Vs) expressed in prostate cancer (PCa) lack the AR ligand binding domain (LBD) and function as constitutively active transcription factors.  AR-V expression in patient tissues or circulating tumor cells is assocd. with resistance to AR-targeting endocrine therapies and poor outcomes.  Here, the authors investigated the mechanisms governing chromatin binding of AR-Vs with the goal of identifying therapeutic vulnerabilities.  By chromatin immunopptn. and sequencing (ChIP-seq) and complementary biochem. expts., the authors show that AR-Vs display a binding preference for the same canonical high-affinity androgen response elements (AREs) that are preferentially engaged by AR, albeit with lower affinity.  Dimerization was an abs. requirement for constitutive AR-V DNA binding and transcriptional activation.  Treatment with the bromodomain and extraterminal (BET) inhibitor JQ1 resulted in inhibition of AR-V chromatin binding and impaired AR-V driven PCa cell growth in vitro and in vivo.  Importantly, this was assocd. with a novel JQ1 action of down-regulating AR-V transcript and protein expression.  Overall, this study demonstrates that AR-Vs broadly restore AR chromatin binding events that are otherwise suppressed during endocrine therapy, and provides pre-clin. rationale for BET inhibition as a strategy for inhibiting expression and chromatin binding of AR-Vs in PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG8v6ocEnDu7Vg90H21EOLACvtfcHk0ljKGMz9BkU1qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFaitr%252FE&md5=0e9c52aba9c70d0fe242bc6bb9e738d7</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv262%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BC.%26aulast%3DSelth%26aufirst%3DL.%2BA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DNyquist%26aufirst%3DM.%2BD.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DRaj%26aufirst%3DG.%2BV.%26aulast%3DTilley%26aufirst%3DW.%2BD.%26aulast%3DDehm%26aufirst%3DS.%2BM.%26atitle%3DTargeting%2520chromatin%2520binding%2520regulation%2520of%2520constitutively%2520active%2520AR%2520variants%2520to%2520overcome%2520prostate%2520cancer%2520resistance%2520to%2520endocrine-based%2520therapies%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26spage%3D5880%26epage%3D5897%26doi%3D10.1093%2Fnar%2Fgkv262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wyce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouthamel, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vessella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbash, O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2419</span>– <span class="NLM_lpage">2429</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.18632%2Foncotarget.1572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=24293458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A280%3ADC%252BC2c3itFyjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=2419-2429&author=A.+Wyceauthor=Y.+Degenhardtauthor=Y.+Baiauthor=B.+C.+Leauthor=S.+Korenchukauthor=M.-C.+Crouthamelauthor=C.+F.+McHughauthor=R.+Vessellaauthor=C.+L.+Creasyauthor=P.+J.+Tumminoauthor=O.+Barbash&title=Inhibition+of+BET+bromodomain+proteins+as+a+therapeutic+approach+in+prostate+cancer&doi=10.18632%2Foncotarget.1572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25cR"><div class="casContent"><span class="casTitleNuber">25c</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer</span></div><div class="casAuthors">Wyce Anastasia; Degenhardt Yan; Bai Yuchen; Le BaoChau; Korenchuk Susan; Crouthame Ming-Chih; McHugh Charles F; Vessella Robert; Creasy Caretha L; Tummino Peter J; Barbash Olena</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2419-29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BET (bromodomain and extra-terminal) proteins regulate gene expression through their ability to bind to acetylated chromatin and subsequently activate RNA PolII-driven transcriptional elongation.  Small molecule BET inhibitors prevent binding of BET proteins to acetylated histones and inhibit transcriptional activation of BET target genes.  BET inhibitors attenuate cell growth and survival in several hematologic cancer models, partially through the down-regulation of the critical oncogene, MYC.  We hypothesized that BET inhibitors will regulate MYC expression in solid tumors that frequently over-express MYC.  Here we describe the effects of the highly specific BET inhibitor, I-BET762, on MYC expression in prostate cancer models.  I-BET762 potently reduced MYC expression in prostate cancer cell lines and a patient-derived tumor model with subsequent inhibition of cell growth and reduction of tumor burden in vivo.  Our data suggests that I-BET762 effects are partially driven by MYC down-regulation and underlines the critical importance of additional mechanisms of I-BET762 induced phenotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqgfwQ5wW2T75XHngOXiV_fW6udTcc2eaiKzbGr-ZnV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3itFyjtQ%253D%253D&md5=ccc6fa48cc0ec2bfb8f5e3abab13979f</span></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1572%26sid%3Dliteratum%253Aachs%26aulast%3DWyce%26aufirst%3DA.%26aulast%3DDegenhardt%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DLe%26aufirst%3DB.%2BC.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DCrouthamel%26aufirst%3DM.-C.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DVessella%26aufirst%3DR.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DBarbash%26aufirst%3DO.%26atitle%3DInhibition%2520of%2520BET%2520bromodomain%2520proteins%2520as%2520a%2520therapeutic%2520approach%2520in%2520prostate%2520cancer%26jtitle%3DOncotarget%26date%3D2013%26volume%3D4%26spage%3D2419%26epage%3D2429%26doi%3D10.18632%2Foncotarget.1572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span>The
PC3 cell line was
more amenable to conducting routine, high-throughput BRD4 degradation
assessments via immunofluorescence relative to other prostate cancer
lines that were evaluated. See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf" class="ext-link">Supporting Information</a> for experimental details regarding the construction
and characterization of the PC3-S1 cell line.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The%0APC3+cell+line+was%0Amore+amenable+to+conducting+routine%2C+high-throughput+BRD4+degradation%0Aassessments+via+immunofluorescence+relative+to+other+prostate+cancer%0Alines+that+were+evaluated.+See+the+Supporting+Information+for+experimental+details+regarding+the+construction%0Aand+characterization+of+the+PC3-S1+cell+line."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nalawansha, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">PROTACs: An emerging therapeutic modality in precision medicine</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2020.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.chembiol.2020.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=32795419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Wrs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=998-1014&author=D.+A.+Nalawanshaauthor=C.+M.+Crews&title=PROTACs%3A+An+emerging+therapeutic+modality+in+precision+medicine&doi=10.1016%2Fj.chembiol.2020.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs: An Emerging Therapeutic Modality in Precision Medicine</span></div><div class="casAuthors">Nalawansha, Dhanusha A.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">998-1014</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.,.  Targeted protein degrdn. (TPD) has emerged as an exciting new era in chem. biol. and drug discovery.  PROteolysis TArgeting Chimera (PROTAC) technol. targets cellular proteins for degrdn. by co-opting the ubiquitin-proteasome system.  Over the last 5 years, numerous studies have expanded our understanding of the unique mode of action and advantages of PROTACs, which has in turn spurred interest in both academia and industry to explore PROTACs as a novel therapeutic strategy.  In this review, we first highlight the key advantages of PROTACs and then discuss the spatiotemporal regulation of protein degrdn.  Next, we explore current chem. tractable E3 ligases focusing on expanding the existing repertoire with novel E3 ligases to uncover the full potential of TPD.  Collectively, these studies are guiding the development of the PROTAC technol. as it emerges as a new modality in precision medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4GkJzvvYnp7Vg90H21EOLACvtfcHk0liloujAs2a1IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Wrs7vM&md5=63c4eb78ee4fc9272b9ae2409889861e</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2020.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2020.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DNalawansha%26aufirst%3DD.%2BA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DPROTACs%253A%2520An%2520emerging%2520therapeutic%2520modality%2520in%2520precision%2520medicine%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2020%26volume%3D27%26spage%3D998%26epage%3D1014%26doi%3D10.1016%2Fj.chembiol.2020.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation: expanding the toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0047-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41573-019-0047-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31666732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=949-963&author=M.+Schapiraauthor=M.+F.+Calabreseauthor=A.+N.+Bullockauthor=C.+M.+Crews&title=Targeted+protein+degradation%3A+expanding+the+toolbox&doi=10.1038%2Fs41573-019-0047-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: expanding the toolbox</span></div><div class="casAuthors">Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-963</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review. Proteolysis-targeting chimeras (PROTACs) and related mols. that induce targeted protein degrdn. by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets.  However, the technol. is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated.  Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degrdn., and expansion of knowledge in this area is a key opportunity.  Here, we briefly discuss lessons learned about targeted protein degrdn. in chem. biol. and drug discovery and systematically review the expression profile, domain architecture and chem. tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUvM27MU3WrVg90H21EOLACvtfcHk0lh9rMECxUAF5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM&md5=9bfd48c6c47fc1cce15129495fea7079</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCalabrese%26aufirst%3DM.%2BF.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%253A%2520expanding%2520the%2520toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D949%26epage%3D963%26doi%3D10.1038%2Fs41573-019-0047-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule modulation of protein homeostasis</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">11269</span>– <span class="NLM_lpage">11301</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ohur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=11269-11301&author=G.+M.+Burslemauthor=C.+M.+Crews&title=Small-molecule+modulation+of+protein+homeostasis&doi=10.1021%2Facs.chemrev.7b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27cR"><div class="casContent"><span class="casTitleNuber">27c</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Modulation of Protein Homeostasis</span></div><div class="casAuthors">Burslem, George M.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11269-11301</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Control of protein levels by nucleic-acid-based technologies has proven to be a useful research tool but lacks the advantages of small mols. with respect to cell permeability, temporal control, and the potential generation of therapeutics.  In this Review, we discuss the technologies available for the control of intracellular protein levels with small mols. and compare the various systems available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcARydbgPK9bVg90H21EOLACvtfcHk0lh9rMECxUAF5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ohur3K&md5=f9f8dd98e2c71c7166d2d500b514d578</span></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00077%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DSmall-molecule%2520modulation%2520of%2520protein%2520homeostasis%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D11269%26epage%3D11301%26doi%3D10.1021%2Facs.chemrev.7b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="note"><p class="first last">The mAb nomenclature follows the EU convention described in</p></div><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gall, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotlieb, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutishauser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxdal, M. J.</span></span> <span> </span><span class="NLM_article-title">The covalent structure of an entire αG immunoglobin molecule</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1073/pnas.63.1.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1073%2Fpnas.63.1.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=5257969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADyaE3cXivFyjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1969&pages=78-85&author=G.+M.+Edelmanauthor=B.+A.+Cunninghamauthor=W.+E.+Gallauthor=P.+D.+Gotliebauthor=U.+Rutishauserauthor=M.+J.+Waxdal&title=The+covalent+structure+of+an+entire+%CE%B1G+immunoglobin+molecule&doi=10.1073%2Fpnas.63.1.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent structure of an entire γG immunoglobulin molecule</span></div><div class="casAuthors">Edelman, Gerald M.; Cunningham, Bruce A.; Gall, W. Einar; Gottlieb, Paul D.; Rutishauser, Urs; Waxdal, Myron J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-85</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The complete amino acid sequence of a human γGl immunoglobulin (Eu) has been detd. and the arrangement of all of the disulfide bonds has been established.  Comparison of the sequence with that of another myeloma protein (He) suggests that the variable regions of heavy and light chains are homologous and similar in length.  The const. portion of the heavy chain contains 3 homology regions each of which is similar in size and homologous to the const. region of the light chain.  Each variable region and each const. homology region contains 1 intrachain disulfide bond.  The half-cystines participating in the interchain bonds are all clustered within a stretch of 10 residues at the middle of the heavy chains.  These data support the hypothesis that immunoglobulins evolved by gene duplication after early divergence of V genes, which specified antigen-binding functions, and C genes, which specified other functions of antibody mols.  Each polypeptide chain may therefore be specified by 2 genes, V and C, which are fused to form a single gene (translocation hypothesis).  The internal homologies and symmetry of the mol. suggest that homology regions may have similar 3-dimensional structures each consisting of a compact domain which contributes to at least 1 active site (domain hypothesis).  Both hypotheses are in accord with the linear regional differentiation of function in antibody mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjqW9i9JX9g7Vg90H21EOLACvtfcHk0lgvCjQUTrUn0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXivFyjtQ%253D%253D&md5=18ba9b6417ce609be8870e1d142e7fc9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1073%2Fpnas.63.1.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.63.1.78%26sid%3Dliteratum%253Aachs%26aulast%3DEdelman%26aufirst%3DG.%2BM.%26aulast%3DCunningham%26aufirst%3DB.%2BA.%26aulast%3DGall%26aufirst%3DW.%2BE.%26aulast%3DGotlieb%26aufirst%3DP.%2BD.%26aulast%3DRutishauser%26aufirst%3DU.%26aulast%3DWaxdal%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520covalent%2520structure%2520of%2520an%2520entire%2520%25CE%25B1G%2520immunoglobin%2520molecule%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1969%26volume%3D63%26spage%3D78%26epage%3D85%26doi%3D10.1073%2Fpnas.63.1.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For a comparison of the EU and the alternate Kabat mAb nomenclature systems, see Table S1 in ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a>a.</p></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. J.</span>; <span class="NLM_string-name">Bargh, J. D.</span>; <span class="NLM_string-name">Dannheim, F. M.</span>; <span class="NLM_string-name">Hanby, A. R.</span>; <span class="NLM_string-name">Seki, H.</span>; <span class="NLM_string-name">Counsell, A. J.</span>; <span class="NLM_string-name">Ou, X.</span>; <span class="NLM_string-name">Fowler, E.</span>; <span class="NLM_string-name">Ashman, N.</span>; <span class="NLM_string-name">Takada, Y.</span>; <span class="NLM_string-name">Isidro-Llobet, A.</span>; <span class="NLM_string-name">Parker, J. S.</span>; <span class="NLM_string-name">Carroll, J. S.</span>; <span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Site-selective modification strategies in antibody-drug conjugates</span>.  <i>Chem. Soc. Rev.</i><span class="refDoi"> DOI: 10.1039/d0cs00310g</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2Fd0cs00310g" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Walsh%2C+S.+J.%3B+Bargh%2C+J.+D.%3B+Dannheim%2C+F.+M.%3B+Hanby%2C+A.+R.%3B+Seki%2C+H.%3B+Counsell%2C+A.+J.%3B+Ou%2C+X.%3B+Fowler%2C+E.%3B+Ashman%2C+N.%3B+Takada%2C+Y.%3B+Isidro-Llobet%2C+A.%3B+Parker%2C+J.+S.%3B+Carroll%2C+J.+S.%3B+Spring%2C+D.+R.+Site-selective+modification+strategies+in+antibody-drug+conjugates.+Chem.+Soc.+Rev.+10.1039%2Fd0cs00310g."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1039%2Fd0cs00310g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fd0cs00310g%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BJ.%26atitle%3DSite-selective%2520modification%2520strategies%2520in%2520antibody-drug%2520conjugates%26jtitle%3DChem.%2520Soc.%2520Rev.%26doi%3D10.1039%2Fd0cs00310g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D. Y.</span></span> <span> </span><span class="NLM_article-title">Processes for constructing homogeneous antibody drug conjugates</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00067</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=852-866&author=D.+Y.+Jackson&title=Processes+for+constructing+homogeneous+antibody+drug+conjugates&doi=10.1021%2Facs.oprd.6b00067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Processes for Constructing Homogeneous Antibody Drug Conjugates</span></div><div class="casAuthors">Jackson, David Y.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">852-866</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) are synthesized by conjugating a cytotoxic drug or "payload" to a monoclonal antibody.  The payloads are conjugated using amino or sulfhydryl specific linkers that react with lysines or cysteines on the antibody surface.  A typical antibody contains over 60 lysines and up to 12 cysteines as potential conjugation sites.  The desired DAR (drugs/antibody ratio) depends on a no. of different factors and ranges from two to eight drugs/antibody.  The discrepancy between the no. of potential conjugation sites and the desired DAR, combined with use of conventional conjugation methods that are not site-specific, results in heterogeneous ADCs that vary in both DAR and conjugation sites.  Heterogeneous ADCs contain significant fractions with suboptimal DARs that are known to possess undesired pharmacol. properties.  As a result, new methods for synthesizing homogeneous ADCs have been developed in order to increase their potential as therapeutic agents.  This article will review recently reported processes for prepg. ADCs with improved homogeneity.  The advantages and potential limitations of each process are discussed, with emphasis on efficiency, quality, and in vivo efficacy relative to similar heterogeneous ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXoa73dqwCyrVg90H21EOLACvtfcHk0lj2oFjno0AfxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGmsbo%253D&md5=4bd838112b5dd262ab6531ec9dc22bd9</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00067%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DD.%2BY.%26atitle%3DProcesses%2520for%2520constructing%2520homogeneous%2520antibody%2520drug%2520conjugates%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D852%26epage%3D866%26doi%3D10.1021%2Facs.oprd.6b00067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit29c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, C. R.</span></span> <span> </span><span class="NLM_article-title">Site-specific antibody-drug conjugates: The nexus of bioorthogonal chemistry, protein engineering, and drug development</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1021/bc5004982</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc5004982" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=176-192&author=P.+Agarwalauthor=C.+R.+Bertozzi&title=Site-specific+antibody-drug+conjugates%3A+The+nexus+of+bioorthogonal+chemistry%2C+protein+engineering%2C+and+drug+development&doi=10.1021%2Fbc5004982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29cR"><div class="casContent"><span class="casTitleNuber">29c</span><div class="casTitle"><span class="NLM_cas:atitle">Site-Specific Antibody-Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development</span></div><div class="casAuthors">Agarwal, Paresh; Bertozzi, Carolyn R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-192</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) combine the specificity of antibodies with the potency of small mols. to create targeted drugs.  Despite the simplicity of this concept, generation of clin. successful ADCs has been very difficult.  Over the past several decades, scientists have learned a great deal about the constraints on antibodies, linkers, and drugs as they relate to successful construction of ADCs.  Once these components are in hand, most ADCs are prepd. by nonspecific modification of antibody lysine or cysteine residues with drug-linker reagents, which results in heterogeneous product mixts. that cannot be further purified.  With advances in the fields of bioorthogonal chem. and protein engineering, there is growing interest in producing ADCs by site-specific conjugation to the antibody, yielding more homogeneous products that have demonstrated benefits over their heterogeneous counterparts in vivo.  Here, we chronicle the development of a multitude of site-specific conjugation strategies for assembly of ADCs and provide a comprehensive account of key advances and their roots in the fields of bioorthogonal chem. and protein engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOcb0A3dT72bVg90H21EOLACvtfcHk0lj2oFjno0AfxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrsrfK&md5=c3d822b0e53e5cdb074e5b63b8060ccf</span></div><a href="/servlet/linkout?suffix=cit29c&amp;dbid=16384&amp;doi=10.1021%2Fbc5004982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc5004982%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DP.%26aulast%3DBertozzi%26aufirst%3DC.%2BR.%26atitle%3DSite-specific%2520antibody-drug%2520conjugates%253A%2520The%2520nexus%2520of%2520bioorthogonal%2520chemistry%252C%2520protein%2520engineering%252C%2520and%2520drug%2520development%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26spage%3D176%26epage%3D192%26doi%3D10.1021%2Fbc5004982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farahi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandlen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span> <span> </span><span class="NLM_article-title">High-throughput cysteine scanning to identify stable antibody conjugation sites for maleimide- and disulfide-based linkers</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00791</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00791" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=473-485&author=R.+Ohriauthor=S.+Bhaktaauthor=A.+O%E2%80%99Donohueauthor=J.+Chuhauthor=S.+P.+Tsaiauthor=R.+Cookauthor=B.+Weiauthor=C.+Ngauthor=A.+W.+Wongauthor=A.+B.+Bosauthor=F.+Farahiauthor=J.+Bhaktaauthor=T.+H.+Pillowauthor=H.+Raabauthor=R.+Vandlenauthor=P.+Polakisauthor=Y.+Liuauthor=H.+Ericksonauthor=J.+R.+Junutulaauthor=K.+R.+Kozak&title=High-throughput+cysteine+scanning+to+identify+stable+antibody+conjugation+sites+for+maleimide-+and+disulfide-based+linkers&doi=10.1021%2Facs.bioconjchem.7b00791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers</span></div><div class="casAuthors">Ohri, Rachana; Bhakta, Sunil; Fourie-O'Donohue, Aimee; dela Cruz-Chuh, Josefa; Tsai, Siao Ping; Cook, Ryan; Wei, Binqing; Ng, Carl; Wong, Athena W.; Bos, Aaron B.; Farahi, Farzam; Bhakta, Jiten; Pillow, Thomas H.; Raab, Helga; Vandlen, Richard; Polakis, Paul; Liu, Yichin; Erickson, Hans; Junutula, Jagath R.; Kozak, Katherine R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">473-485</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">THIOMAB antibody technol. utilizes cysteine residues engineered onto an antibody to allow for site-specific conjugation.  The technol. has enabled the exploration of different attachment sites on the antibody in combination with small mols., peptides, or proteins to yield antibody conjugates with unique properties.  As reported previously, the specific location of the site of conjugation on an antibody can impact the stability of the linkage to the engineered cysteine for both thio-succinimide and disulfide bonds.  High stability of the linkage is usually desired to maximize the delivery of the cargo to the intended target.  In the current study, cysteines were individually substituted into every position of the anti-HER2 antibody (trastuzumab), and the stabilities of drug conjugations at those sites were evaluated.  We screened a total of 648 THIOMAB antibody-drug conjugates, each generated from a trastuzamab prepd. by sequentially mutating non-cysteine amino acids in the light and heavy chains to cysteine.  Each THIOMAB antibody variant was conjugated to either maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin E (MC-vc-PAB-MMAE) or pyridyl disulfide monomethyl auristatin E (PDS-MMAE) using a high-throughput, on-bead conjugation and purifn. method.  Greater than 50% of the THIOMAB antibody variants were successfully conjugated to both MMAE derivs. with a drug to antibody ratio (DAR) of >0.5 and <50% aggregation.  The relative in vitro plasma stabilities for approx. 750 conjugates were assessed using enzyme-linked immunosorbent assays, and stable sites were confirmed with affinity-capture LC/MS-based detection methods.  Highly stable conjugation sites for the two types of MMAE derivs. were identified on both the heavy and light chains.  Although the stabilities of maleimide conjugates were shown to be greater than those of the disulfide conjugates, many sites were identified that were stable for both.  Furthermore, in vitro stabilities of selected stable sites translated across different cytotoxic payloads and different target antibodies as well as to in vivo stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLlgFVNRmHMbVg90H21EOLACvtfcHk0ljGSeGIH_191g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKku7g%253D&md5=318146c1baea8094b671e99b5c429627</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00791%26sid%3Dliteratum%253Aachs%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DChuh%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DCook%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DA.%2BW.%26aulast%3DBos%26aufirst%3DA.%2BB.%26aulast%3DFarahi%26aufirst%3DF.%26aulast%3DBhakta%26aufirst%3DJ.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DErickson%26aufirst%3DH.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26atitle%3DHigh-throughput%2520cysteine%2520scanning%2520to%2520identify%2520stable%2520antibody%2520conjugation%2520sites%2520for%2520maleimide-%2520and%2520disulfide-based%2520linkers%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D473%26epage%3D485%26doi%3D10.1021%2Facs.bioconjchem.7b00791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmar, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie-O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, H. K.</span></span> <span> </span><span class="NLM_article-title">Attachment site cysteine thiol pKa is a key driver for site-dependent stability of THIOMAB antibody-drug conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2538</span>– <span class="NLM_lpage">2548</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00365</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00365" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2538-2548&author=B.+S.+Vollmarauthor=B.+Weiauthor=R.+Ohriauthor=J.+Zhouauthor=J.+Heauthor=S.-F.+Yuauthor=D.+Leipoldauthor=E.+Cosinoauthor=S.+Yeeauthor=A.+Fourie-O%E2%80%99Donohueauthor=G.+Liauthor=G.+L.+Phillipsauthor=K.+R.+Kozakauthor=A.+Kamathauthor=K.+Xuauthor=G.+Leeauthor=G.+A.+Lazarauthor=H.+K.+Erickson&title=Attachment+site+cysteine+thiol+pKa+is+a+key+driver+for+site-dependent+stability+of+THIOMAB+antibody-drug+conjugates&doi=10.1021%2Facs.bioconjchem.7b00365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates</span></div><div class="casAuthors">Vollmar, Breanna S.; Wei, Binqing; Ohri, Rachana; Zhou, Jianhui; He, Jintang; Yu, Shang-Fan; Leipold, Douglas; Cosino, Ely; Yee, Sharon; Fourie-O'Donohue, Aimee; Li, Guangmin; Phillips, Gail L.; Kozak, Katherine R.; Kamath, Amrita; Xu, Keyang; Lee, Genee; Lazar, Greg A.; Erickson, Hans K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2538-2548</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The incorporation of cysteines into antibodies by mutagenesis allows for the direct conjugation of small mols. to specific sites on the antibody via disulfide bonds.  The stability of the disulfide bond linkage between the small mol. and the antibody is highly dependent on the location of the engineered cysteine in either the heavy chain (HC) or the light chain (LC) of the antibody.  Here, we explore the basis for this site-dependent stability.  We evaluated the in vivo efficacy and pharmacokinetics of five different cysteine mutants of trastuzumab conjugated to a pyrrolobenzodiazepine (PBD) via disulfide bonds.  A significant correlation was obsd. between disulfide stability and efficacy for the conjugates.  We hypothesized that the obsd. site-dependent stability of the disulfide-linked conjugates could be due to differences in the attachment site cysteine thiol pKa.  We measured the cysteine thiol pKa using isothermal titrn. calorimetry (ITC) and found that the variants with the highest thiol pKa (LC K149C and HC A140C) were found to yield the conjugates with the greatest in vivo stability.  Guided by homol. modeling, we identified several mutations adjacent to LC K149C that reduced the cysteine thiol pKa and, thus, decreased the in vivo stability of the disulfide-linked PBD conjugated to LC K149C.  We also present results suggesting that the high thiol pKa of LC K149C is responsible for the sustained circulation stability of LC K149C TDCs utilizing a maleimide-based linker.  Taken together, our results provide evidence that the site-dependent stability of cys-engineered antibody-drug conjugates may be explained by interactions between the engineered cysteine and the local protein environment that serves to modulate the side-chain thiol pKa.  The influence of cysteine thiol pKa on stability and efficacy offers a new parameter for the optimization of ADCs that utilize cysteine engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAfrN62jixCbVg90H21EOLACvtfcHk0ljGSeGIH_191g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGks7vL&md5=ba1805c493f468d4ffbb198dbf8b3d02</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00365%26sid%3Dliteratum%253Aachs%26aulast%3DVollmar%26aufirst%3DB.%2BS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DLeipold%26aufirst%3DD.%26aulast%3DCosino%26aufirst%3DE.%26aulast%3DYee%26aufirst%3DS.%26aulast%3DFourie-O%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPhillips%26aufirst%3DG.%2BL.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DLazar%26aufirst%3DG.%2BA.%26aulast%3DErickson%26aufirst%3DH.%2BK.%26atitle%3DAttachment%2520site%2520cysteine%2520thiol%2520pKa%2520is%2520a%2520key%2520driver%2520for%2520site-dependent%2520stability%2520of%2520THIOMAB%2520antibody-drug%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2017%26volume%3D28%26spage%3D2538%26epage%3D2548%26doi%3D10.1021%2Facs.bioconjchem.7b00365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kolakowski, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haelsig, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerton, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiske, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span> <span> </span><span class="NLM_article-title">The methylene alkoxy carbamate self-immolative unit: Utilization for the targeted delivery of alcohol-containing payloads with antibody-drug conjugates</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7948</span>– <span class="NLM_lpage">7951</span>, <span class="refDoi"> DOI: 10.1002/anie.201601506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fanie.201601506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1KjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=7948-7951&author=R.+V.+Kolakowskiauthor=K.+T.+Haelsigauthor=K.+K.+Emmertonauthor=C.+I.+Leiskeauthor=J.+B.+Miyamotoauthor=J.+H.+Cochranauthor=R.+P.+Lyonauthor=P.+D.+Senterauthor=S.+C.+Jeffrey&title=The+methylene+alkoxy+carbamate+self-immolative+unit%3A+Utilization+for+the+targeted+delivery+of+alcohol-containing+payloads+with+antibody-drug+conjugates&doi=10.1002%2Fanie.201601506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates</span></div><div class="casAuthors">Kolakowski, Robert V.; Haelsig, Karl T.; Emmerton, Kim K.; Leiske, Chris I.; Miyamoto, Jamie B.; Cochran, Julia H.; Lyon, Robert P.; Senter, Peter D.; Jeffrey, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">7948-7951</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A strategy for the conjugation of alc.-contg. payloads to antibodies has been developed and involves the methylene alkoxy carbamate (MAC) self-immolative unit.  A series of MAC β-glucuronide model constructs were prepd. to evaluate stability and enzymic release, and the results demonstrated high stability at physiol. pH in a substitution-dependent manner.  All the MAC model compds. efficiently released alc. drug surrogates under the action of β-glucuronidase.  To assess the MAC technol. for ADCs, the potent microtubule-disrupting agent auristatin E (AE) was incorporated through the norephedrine alc.  Conjugation of the MAC β-glucuronide AE drug linker to the anti-CD30 antibody cAC10, and an IgG control antibody, gave potent and immunol. specific activities in vitro and in vivo.  These studies validate the MAC self-immolative unit for alc.-contg. payloads within ADCs, a class that has not been widely exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmcbliUQ1JNLVg90H21EOLACvtfcHk0lh-_qtbossePQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1KjtLc%253D&md5=3320828c2445a549e76bf1419d1cc614</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201601506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201601506%26sid%3Dliteratum%253Aachs%26aulast%3DKolakowski%26aufirst%3DR.%2BV.%26aulast%3DHaelsig%26aufirst%3DK.%2BT.%26aulast%3DEmmerton%26aufirst%3DK.%2BK.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DCochran%26aufirst%3DJ.%2BH.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26atitle%3DThe%2520methylene%2520alkoxy%2520carbamate%2520self-immolative%2520unit%253A%2520Utilization%2520for%2520the%2520targeted%2520delivery%2520of%2520alcohol-containing%2520payloads%2520with%2520antibody-drug%2520conjugates%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D7948%26epage%3D7951%26doi%3D10.1002%2Fanie.201601506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ogitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oitate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agatsuma, T.</span></span> <span> </span><span class="NLM_article-title">DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5097</span>– <span class="NLM_lpage">5108</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1078-0432.CCR-15-2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27026201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5097-5108&author=Y.+Ogitaniauthor=T.+Aidaauthor=K.+Hagiharaauthor=J.+Yamaguchiauthor=C.+Ishiiauthor=N.+Haradaauthor=M.+Somaauthor=H.+Okamotoauthor=M.+Oitateauthor=S.+Arakawaauthor=T.+Hiraiauthor=R.+Atsumiauthor=T.+Nakadaauthor=I.+Hayakawaauthor=Y.+Abeauthor=T.+Agatsuma&title=DS-8201a%2C+a+novel+HER2-targeting+ADC+with+a+novel+DNA+topoisomerase+I+inhibitor%2C+demonstrates+a+promising+antitumor+efficacy+with+differentiation+from+T-DM1&doi=10.1158%2F1078-0432.CCR-15-2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</span></div><div class="casAuthors">Ogitani, Yusuke; Aida, Tetsuo; Hagihara, Katsunobu; Yamaguchi, Junko; Ishii, Chiaki; Harada, Naoya; Soma, Masako; Okamoto, Hiromi; Oitate, Masataka; Arakawa, Shingo; Hirai, Takehiro; Atsumi, Ryo; Nakada, Takashi; Hayakawa, Ichiro; Abe, Yuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5097-5108</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its preclin. pharmacol. profile was assessed.  In vitro and in vivo pharmacol. activities of DS-8201a were evaluated and compared with T-DM1 in several HER2-pos. cell lines and patient-derived xenograft (PDX) models.  The mechanism of action for the efficacy was also evaluated.  Pharmacokinetics in cynomolgus monkeys and the safety profiles in rats and cynomolgus monkeys were assessed.  DS-8201a exhibited a HER2 expression-dependent cell growth-inhibitory activity and induced tumor regression with a single dosing at more than 1 mg/kg in a HER2-pos. gastric cancer NCI-N87 model.  Binding activity to HER2 and ADCC activity of DS-8201a were comparable with unconjugated anti-HER2 antibody.  DS-8201a also showed an inhibitory activity to Akt phosphorylation.  DS-8201a induced phosphorylation of Chk1 and Histone H2A.X, the markers of DNA damage.  Pharmacokinetics and safety profiles of DS-8201a were favorable and the highest non-severely toxic dose was 30 mg/kg in cynomolgus monkeys, supporting DS-8201a as being well tolerated in humans.  DS-8201a was effective in a T-DM1-insensitive PDX model with high HER2 expression.  DS-8201a, but not T-DM1, demonstrated antitumor efficacy against several breast cancer PDX models with low HER2 expression.  DS-8201a exhibited a potent antitumor activity in a broad selection of HER2-pos. models and favorable pharmacokinetics and safety profiles.  The results demonstrate that DS-8201a will be a valuable therapy with a great potential to respond to T-DM1-insensitive HER2-pos. cancers and low HER2-expressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZitEmBAqAbVg90H21EOLACvtfcHk0lh-_qtbossePQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F&md5=3fc9a072b2ba05c80929713c843df3f5</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-2822%26sid%3Dliteratum%253Aachs%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DAida%26aufirst%3DT.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DIshii%26aufirst%3DC.%26aulast%3DHarada%26aufirst%3DN.%26aulast%3DSoma%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DH.%26aulast%3DOitate%26aufirst%3DM.%26aulast%3DArakawa%26aufirst%3DS.%26aulast%3DHirai%26aufirst%3DT.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DNakada%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DI.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DAgatsuma%26aufirst%3DT.%26atitle%3DDS-8201a%252C%2520a%2520novel%2520HER2-targeting%2520ADC%2520with%2520a%2520novel%2520DNA%2520topoisomerase%2520I%2520inhibitor%252C%2520demonstrates%2520a%2520promising%2520antitumor%2520efficacy%2520with%2520differentiation%2520from%2520T-DM1%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D5097%26epage%3D5108%26doi%3D10.1158%2F1078-0432.CCR-15-2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of peptidomimetic antibody-drug conjugate linkers with enhanced protease specificity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKitrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=989-1000&author=B.+Weiauthor=J.+Gunzner-Tosteauthor=H.+Yaoauthor=T.+Wangauthor=J.+Wangauthor=Z.+Xuauthor=J.+Chenauthor=J.+Waiauthor=J.+Nonomiyaauthor=S.+P.+Tsaiauthor=J.+Chuhauthor=K.+R.+Kozakauthor=Y.+Liuauthor=S.-F.+Yuauthor=J.+Lauauthor=G.+Liauthor=G.+D.+Phillipsauthor=D.+Leipoldauthor=A.+Kamathauthor=D.+Suauthor=K.+Xuauthor=C.+Eigenbrotauthor=S.+Steinbacherauthor=R.+Ohriauthor=H.+Raabauthor=L.+R.+Stabenauthor=G.+Zhaoauthor=J.+A.+Flygareauthor=T.+H.+Pillowauthor=V.+Vermaauthor=L.+A.+Mastersonauthor=P.+W.+Howardauthor=B.+Safina&title=Discovery+of+peptidomimetic+antibody-drug+conjugate+linkers+with+enhanced+protease+specificity&doi=10.1021%2Facs.jmedchem.7b01430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity</span></div><div class="casAuthors">Wei, BinQing; Gunzner-Toste, Janet; Yao, Hui; Wang, Tao; Wang, Jing; Xu, Zijin; Chen, Jinhua; Wai, John; Nonomiya, Jim; Tsai, Siao Ping; Chuh, Josefa; Kozak, Katherine R.; Liu, Yichin; Yu, Shang-Fan; Lau, Jeff; Li, Guangmin; Phillips, Gail D.; Leipold, Doug; Kamath, Amrita; Su, Dian; Xu, Keyang; Eigenbrot, Charles; Steinbacher, Stefan; Ohri, Rachana; Raab, Helga; Staben, Leanna R.; Zhao, Guiling; Flygare, John A.; Pillow, Thomas H.; Verma, Vishal; Safina, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">989-1000</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) have become an important therapeutic modality for oncol., with three approved by the FDA and over 60 others in clin. trials.  Despite the progress, improvements in ADC therapeutic index are desired.  Peptide-based ADC linkers that are cleaved by lysosomal proteases have shown sufficient stability in serum and effective payload-release in targeted cells.  If the linker can be preferentially hydrolyzed by tumor-specific proteases, safety margin may improve.  However, the use of peptide-based linkers limits our ability to modulate protease specificity.  Here we report the structure-guided discovery of novel, nonpeptidic ADC linkers.  We show that a cyclobutane-1,1-dicarboxamide-contg. linker is hydrolyzed predominantly by cathepsin B while the valine-citrulline dipeptide linker is not.  ADCs bearing the nonpeptidic linker are as efficacious and stable in vivo as those with the dipeptide linker.  Our results strongly support the application of the peptidomimetic linker and present new opportunities for improving the selectivity of ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohInS8FeMmxbVg90H21EOLACvtfcHk0lj9RILrsdnHqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKitrbI&md5=8646f801d6292eaa2c3e2cc1b9e2e6cc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01430%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DB.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DChuh%26aufirst%3DJ.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%26aulast%3DLeipold%26aufirst%3DD.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DStaben%26aufirst%3DL.%2BR.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DVerma%26aufirst%3DV.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DSafina%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520peptidomimetic%2520antibody-drug%2520conjugate%2520linkers%2520with%2520enhanced%2520protease%2520specificity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D989%26epage%3D1000%26doi%3D10.1021%2Facs.jmedchem.7b01430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achilles Poon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutten, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span> <span> </span><span class="NLM_article-title">An anti-CLL1 antibody-drug conjugate for the treatment of acute myeloid leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1358</span>– <span class="NLM_lpage">1368</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-0333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1078-0432.CCR-18-0333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=29959143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=1358-1368&author=B.+Zhengauthor=S.-F.+Yuauthor=G.+del+Rosarioauthor=S.+R.+Leongauthor=G.+Y.+Leeauthor=R.+Vijauthor=C.+Chiuauthor=W.-C.+Liangauthor=Y.+Wuauthor=C.+Chalouniauthor=J.+Sadowskyauthor=V.+Clarkauthor=A.+Hendricksauthor=K.+Achilles+Poonauthor=W.+Chuauthor=T.+Pillowauthor=M.+M.+Schuttenauthor=J.+Flygareauthor=A.+G.+Polson&title=An+anti-CLL1+antibody-drug+conjugate+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-18-0333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-CLL-I antibody-drug conjugate for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Zheng, Bing; Yu, Shang-Fan; del Rosario, Geoffrey; Leong, Steven R.; Lee, Genee Y.; Vij, Rajesh; Chiu, Cecilia; Liang, Wei-Ching; Wu, Yan; Chalouni, Cecile; Sadowsky, Jack; Clark, Vanessa; Hendricks, Angela; Poon, Kirsten Achilles; Chu, Wayne; Pillow, Thomas; Schutten, Melissa M.; Flygare, John; Polson, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1358</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The treatment of acute myeloid leukemia (AML) has not significantly changed in 40 years.  Cytarabine- and anthracycline-based chemotherapy induction regimens (7 + 3) remain the std. of care, and most patients have poor long-term survival.  The reapproval of Mylotarg, an anti-CD33-calicheamicin antibody-drug conjugate (ADC), has demonstrated ADCs as a clin. validated option to enhance the effectiveness of induction therapy.  We are interested in developing a next-generation ADC for AML to improve upon the initial success of Mylotarg.  Exptl. Design: The expression pattern of CLL-1 and its hematopoietic potential were investigated.  A novel anti-CLL-1-ADC, with a highly potent pyrrolobenzodiazepine (PBD) dimer conjugated through a self-immolative disulfide linker, was developed.  The efficacy and safety profiles of this ADC were evaluated in mouse xenograft models and in cynomolgus monkeys.  Results: We demonstrate that CLL-1 shares similar prevalence and trafficking properties that make CD33 an excellent ADC target for AML, but lacks expression on hematopoietic stem cells that hampers current CD33-targeted ADCs.  Our anti-CLL-1-ADC is highly effective at depleting tumor cells in AML xenograft models and lacks target independent toxicities at doses that depleted target monocytes and neutrophils in cynomolgus monkeys.  Conclusions: Collectively, our data suggest that an anti-CLL-1-ADC has the potential to become an effective and safer treatment for AML in humans, by reducing and allowing for faster recovery from initial cytopenias than the current generation of ADCs for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJdzTurW_r4LVg90H21EOLACvtfcHk0li_WGt2fF6zSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7bE&md5=c701a514d19baec87815539f0eaa9275</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-0333%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3Ddel%2BRosario%26aufirst%3DG.%26aulast%3DLeong%26aufirst%3DS.%2BR.%26aulast%3DLee%26aufirst%3DG.%2BY.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DChiu%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DW.-C.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DV.%26aulast%3DHendricks%26aufirst%3DA.%26aulast%3DAchilles%2BPoon%26aufirst%3DK.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DPillow%26aufirst%3DT.%26aulast%3DSchutten%26aufirst%3DM.%2BM.%26aulast%3DFlygare%26aufirst%3DJ.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26atitle%3DAn%2520anti-CLL1%2520antibody-drug%2520conjugate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D1358%26epage%3D1368%26doi%3D10.1158%2F1078-0432.CCR-18-0333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamblett, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chace, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerveny, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissler, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopcha, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabinski, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisco, J. A.</span></span> <span> </span><span class="NLM_article-title">Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">7063</span>– <span class="NLM_lpage">7070</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-0789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1078-0432.CCR-04-0789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=15501986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslGlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=7063-7070&author=K.+J.+Hamblettauthor=P.+D.+Senterauthor=D.+F.+Chaceauthor=M.+M.+C.+Sunauthor=J.+Lenoxauthor=C.+G.+Cervenyauthor=K.+M.+Kisslerauthor=S.+X.+Bernhardtauthor=A.+K.+Kopchaauthor=R.+F.+Zabinskiauthor=D.+L.+Meyerauthor=J.+A.+Francisco&title=Effects+of+drug+loading+on+the+antitumor+activity+of+a+monoclonal+antibody+drug+conjugate&doi=10.1158%2F1078-0432.CCR-04-0789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate</span></div><div class="casAuthors">Hamblett, Kevin J.; Senter, Peter D.; Chace, Dana F.; Sun, Michael M. C.; Lenox, Joel; Cerveny, Charles G.; Kissler, Kim M.; Bernhardt, Starr X.; Kopcha, Anastasia K.; Zabinski, Roger F.; Meyer, Damon L.; Francisco, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7063-7070</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An antibody-drug conjugate consisting of monomethyl auristatin E (MMAE) conjugated to the anti-CD30 monoclonal antibody (mAb) cAC10, with eight drug moieties per mAb, was previously shown to have potent cytotoxic activity against CD30+ malignant cells.  To det. the effect of drug loading on antibody-drug conjugate therapeutic potential, we assessed cAC10 antibody-drug conjugates contg. different drug-mAb ratios in vitro and in vivo.  Coupling MMAE to the cysteines that comprise the interchain disulfides of cAC10 created an antibody-drug conjugate population, which was purified using hydrophobic interaction chromatog. to yield antibody-drug conjugates with two, four, and eight drugs per antibody (E2, E4, and E8, resp.).  Antibody-drug conjugate potency was tested in vitro against CD30+ lines followed by in vivo xenograft models.  The max.-tolerated dose and pharmacokinetic profiles of the antibody-drug conjugates were investigated in mice.  Although antibody-drug conjugate potency in vitro was directly dependent on drug loading (IC50 values E8<E4<E2), the in vivo antitumor activity of E4 was comparable with E8 at equal mAb doses, although the E4 contained half the amt. of MMAE per mAb.  E2 was also an active antitumor agent but required higher doses.  The max.-tolerated dose of E2 in mice was at least double that of E4, which in turn was twice that of E8.  MMAE loading affected plasma clearance, as E8 cleared 3-fold faster than E4 and 5-fold faster than E2.  By decreasing drug loading per antibody, the therapeutic index was increased demonstrating that drug loading is a key design parameter for antibody-drug conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCAEfk7W0KNbVg90H21EOLACvtfcHk0li_WGt2fF6zSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslGlu78%253D&md5=2d2dd7a498d1181a57dcd3ab8b931e65</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0789%26sid%3Dliteratum%253Aachs%26aulast%3DHamblett%26aufirst%3DK.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DChace%26aufirst%3DD.%2BF.%26aulast%3DSun%26aufirst%3DM.%2BM.%2BC.%26aulast%3DLenox%26aufirst%3DJ.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DKissler%26aufirst%3DK.%2BM.%26aulast%3DBernhardt%26aufirst%3DS.%2BX.%26aulast%3DKopcha%26aufirst%3DA.%2BK.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DFrancisco%26aufirst%3DJ.%2BA.%26atitle%3DEffects%2520of%2520drug%2520loading%2520on%2520the%2520antitumor%2520activity%2520of%2520a%2520monoclonal%2520antibody%2520drug%2520conjugate%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D7063%26epage%3D7070%26doi%3D10.1158%2F1078-0432.CCR-04-0789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="note"><p class="first last">For other recent examples of “high-DAR” conjugates, see:</p></div><div class="NLM_citation" id="rightTab-cit35a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Construction of paclitaxel-based antibody-drug conjugates with a PEGylated linker to achieve superior therapeutic index</span>. <i>Signal Transduction Targeted Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">132</span> <span class="refDoi"> DOI: 10.1038/s41392-020-00247-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41392-020-00247-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=32728048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFShsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&author=T.+Shaoauthor=T.+Chenauthor=Y.+Chenauthor=X.+Liuauthor=Y.-L.+Chenauthor=Q.+Wangauthor=T.+Zhuauthor=M.+Guoauthor=H.+Liauthor=D.+Juauthor=C.+Wang&title=Construction+of+paclitaxel-based+antibody-drug+conjugates+with+a+PEGylated+linker+to+achieve+superior+therapeutic+index&doi=10.1038%2Fs41392-020-00247-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">Construction of paclitaxel-based antibody-drug conjugates with a PEGylated linker to achieve superior therapeutic index</span></div><div class="casAuthors">Shao, Ting; Chen, Tianzhi; Chen, Yuning; Liu, Xiaoyue; Chen, Yi-Li; Wang, Qi; Zhu, Tong; Guo, Maojun; Li, Hui; Ju, Dianwen; Wang, Chunhe</div><div class="citationInfo"><span class="NLM_cas:title">Signal Transduction and Targeted Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">132</span>CODEN:
                <span class="NLM_cas:coden">STTTCB</span>;
        ISSN:<span class="NLM_cas:issn">2059-3635</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The selection of linkers and payloads plays a crucial role indetermining the therapeutic indexes of antibody-drug conjugates(ADCs).  As paclitaxel (PTX) has been used therapeutically in pancreaticcancer and TNBC, in which Trop-2 is highly expressed, it appears to be a viable payload option for Trop-2-targeting ADCs.  In cancer cell lines with diverse Trop-2 expression levels, our results indicated that free drug PTX is not as potent as MMAE, but similar to SN38.  ADC mols. employing PTX, hydrophilic linkers, and Trop-2 antibodies showed superior efficacy and safety profile in vitro and in vivo, suggesting that it is a promising targeted therapeutic for human carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUf9HH70ECrVg90H21EOLACvtfcHk0lj_7EnuscfUyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFShsrrI&md5=6b9b5b01379dfaea90cd38c70ad51527</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1038%2Fs41392-020-00247-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-020-00247-y%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.-L.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DJu%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DConstruction%2520of%2520paclitaxel-based%2520antibody-drug%2520conjugates%2520with%2520a%2520PEGylated%2520linker%2520to%2520achieve%2520superior%2520therapeutic%2520index%26jtitle%3DSignal%2520Transduction%2520Targeted%2520Ther.%26date%3D2020%26volume%3D5%26doi%3D10.1038%2Fs41392-020-00247-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S.</span>; <span class="NLM_string-name">Wang, K.-P.</span></span> <span> </span><span class="NLM_article-title">ADCs With Thiol Multiplex Linkers</span>. <span class="NLM_patent">WO2020132655</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+Jeffrey&author=K.-P.+Wang&title=ADCs+With+Thiol+Multiplex+Linkers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%26atitle%3DADCs%2520With%2520Thiol%2520Multiplex%2520Linkers%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Le Joncour, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puhka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmikangas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laakkonen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barok, M.</span></span> <span> </span><span class="NLM_article-title">A movel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1721</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-19-0207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1535-7163.MCT-19-0207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31292166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1721-1730&author=V.+Le+Joncourauthor=A.+Martinsauthor=M.+Puhkaauthor=J.+Isolaauthor=M.+Salmikangasauthor=P.+Laakkonenauthor=H.+Joensuuauthor=M.+Barok&title=A+movel+anti-HER2+antibody-drug+conjugate+XMT-1522+for+HER2-positive+breast+and+gastric+cancers+resistant+to+trastuzumab+emtansine&doi=10.1158%2F1535-7163.MCT-19-0207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35cR"><div class="casContent"><span class="casTitleNuber">35c</span><div class="casTitle"><span class="NLM_cas:atitle">A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine</span></div><div class="casAuthors">Le Joncour, Vadim; Martins, Ana; Puhka, Maija; Isola, Jorma; Salmikangas, Marko; Laakkonen, Pirjo; Joensuu, Heikki; Barok, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1721-1730</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most patients with HER2-pos. breast or gastric cancer exhibit primary or acquired resistance to trastuzumab emtansine (T-DM1), and such patients may have limited therapeutic options.  XMT-1522 is a novel anti-HER2 antibody-drug conjugate.  We compared XMT-1522 to T-DM1 in preclin. models.  The effects of XMT-1522 and T-DM1 on cell survival and apoptosis were compared in six HER2-pos. breast cancer or gastric cancer cell lines, of which three lines were T-DM1-sensitive (N-87, OE-19, JIMT-1) and three T-DM1-resistant (RN-87, ROE-19, SNU-216).  We compared these agents also in the HER2-neg. breast cancer cell line MCF-7, and in mouse RN-87 and JIMT-1 xenograft models.  Cell survival was assessed using the AlamarBlue method and apoptosis with the Caspase-Glo 3/7 method.  XMT-1522 inhibited the growth of all six HER2-pos. cell lines.  The proportions of cells that survived XMT-1522 treatment were smaller as compared with T-DM1, particularly in the T-DM1-resistant cell lines.  XMT-1522 induced more cell apoptosis compared with T-DM1.  While RN-87 and JIMT-1 xenograft tumors progressed on T-DM1 treatment, all tumors responded to XMT-1522, and all but one tumor disappeared during the XMT-1522 treatment.  XMT-1522 had a strong antitumor effect on RN-87 and JIMT-1 xenografts that progressed on T-DM1.  We conclude that XMT-1522 was effective in HER2-pos. breast cancer and gastric cancer cell lines resistant to T-DM1, and in xenograft models resistant to T-DM1.  The results support the testing of XMT-1522 in clin. trials in patients with HER2-pos. cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Pci-NaVO6bVg90H21EOLACvtfcHk0lj_7EnuscfUyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFKlug%253D%253D&md5=71fd86427ea0bac472f679076eb4c680</span></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-19-0207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-19-0207%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BJoncour%26aufirst%3DV.%26aulast%3DMartins%26aufirst%3DA.%26aulast%3DPuhka%26aufirst%3DM.%26aulast%3DIsola%26aufirst%3DJ.%26aulast%3DSalmikangas%26aufirst%3DM.%26aulast%3DLaakkonen%26aufirst%3DP.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DBarok%26aufirst%3DM.%26atitle%3DA%2520movel%2520anti-HER2%2520antibody-drug%2520conjugate%2520XMT-1522%2520for%2520HER2-positive%2520breast%2520and%2520gastric%2520cancers%2520resistant%2520to%2520trastuzumab%2520emtansine%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26spage%3D1721%26epage%3D1730%26doi%3D10.1158%2F1535-7163.MCT-19-0207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit35d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Viricel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrial, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papotd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span> <span> </span><span class="NLM_article-title">Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4048</span>– <span class="NLM_lpage">4053</span>, <span class="refDoi"> DOI: 10.1039/C9SC00285E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2FC9SC00285E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31015945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkt1Wqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=4048-4053&author=W.+Viricelauthor=G.+Fournetauthor=S.+Beaumelauthor=E.+Perrialauthor=S.+Papotdauthor=C.+Dumontetauthor=B.+Joseph&title=Monodisperse+polysarcosine-based+highly-loaded+antibody-drug+conjugates&doi=10.1039%2FC9SC00285E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35dR"><div class="casContent"><span class="casTitleNuber">35d</span><div class="casTitle"><span class="NLM_cas:atitle">Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates</span></div><div class="casAuthors">Viricel, Warren; Fournet, Guy; Beaumel, Sabine; Perrial, Emeline; Papot, Sebastien; Dumontet, Charles; Joseph, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4048-4053</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) convey highly potent anticancer drugs to antigen-expressing tumor cells, thereby sparing healthy tissues throughout the body.  Pharmacokinetics and tolerability of ADCs are predominantly influenced by the drug-antibody ratio (DAR) of the conjugates, which is to-date limited to a value of 3-4 drugs per antibody in Antibody-drug conjugates under clin. investigations.  Here, we report the synthesis of monodisperse (i.e. discrete) polysarcosine compds. and their use as a hydrophobicity masking entity for the construction of highly-loaded homogeneous glucuronidase-responsive antibody-drug conjugates (ADCs).  The highly hydrophilic drug-linker platform described herein improves drug-loading, physicochem. properties, pharmacokinetics and in vivo antitumor efficacy of the resulting conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyJWZGJpnUOrVg90H21EOLACvtfcHk0ljh1SO5ERXyng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkt1Wqurk%253D&md5=3f6556a5f22ba298ae4d504a68bca3c0</span></div><a href="/servlet/linkout?suffix=cit35d&amp;dbid=16384&amp;doi=10.1039%2FC9SC00285E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9SC00285E%26sid%3Dliteratum%253Aachs%26aulast%3DViricel%26aufirst%3DW.%26aulast%3DFournet%26aufirst%3DG.%26aulast%3DBeaumel%26aufirst%3DS.%26aulast%3DPerrial%26aufirst%3DE.%26aulast%3DPapotd%26aufirst%3DS.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJoseph%26aufirst%3DB.%26atitle%3DMonodisperse%2520polysarcosine-based%2520highly-loaded%2520antibody-drug%2520conjugates%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26spage%3D4048%26epage%3D4053%26doi%3D10.1039%2FC9SC00285E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit35e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivas, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loftus, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nix, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waight, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaval, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2633</span>– <span class="NLM_lpage">2642</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-0643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1535-7163.MCT-18-0643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30242091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1elsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=2633-2642&author=C.+S.+Neumannauthor=K.+C.+Olivasauthor=M.+E.+Andersonauthor=J.+H.+Cochranauthor=S.+Jinauthor=F.+Liauthor=L.+V.+Loftusauthor=D.+W.+Meyerauthor=J.+Nealeauthor=J.+C.+Nixauthor=P.+G.+Pittmanauthor=J.+K.+Simmonsauthor=M.+L.+Ulrichauthor=A.+B.+Waightauthor=A.+Wongauthor=M.+C.+Zavalauthor=W.+Zengauthor=R.+P.+Lyonauthor=P.+D.+Senter&title=Targeted+delivery+of+cytotoxic+NAMPT+inhibitors+using+antibody-drug+conjugates&doi=10.1158%2F1535-7163.MCT-18-0643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35eR"><div class="casContent"><span class="casTitleNuber">35e</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates</span></div><div class="casAuthors">Neumann, Christopher S.; Olivas, Kathleen C.; Anderson, Martha E.; Cochran, Julia H.; Jin, Steven; Li, Fu; Loftus, Luke V.; Meyer, David W.; Neale, Jason; Nix, Jay C.; Pittman, Paul G.; Simmons, Jessica K.; Ulrich, Michelle L.; Waight, Andrew B.; Wong, Abbie; Zaval, Margo C.; Zeng, Weiping; Lyon, Robert P.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2633-2642</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are a therapeutic modality that enables the targeted delivery of cytotoxic drugs to cancer cells.  Identification of active payloads with unique mechanisms of action is a key aim of research efforts in the field.  Herein, we report the development of inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) as a novel payload for ADC technol.  NAMPT is a component of a salvage biosynthetic pathway for NAD, and inhibition of this enzyme results in disruption of primary cellular metab. leading to cell death.  Through derivatization of the prototypical NAMPT inhibitor FK-866, we identified potent analogs with chem. functionality that enables the synthesis of hydrophilic enzyme-cleavable drug linkers.  The resulting ADCs displayed NAD depletion in both cell-based assays and tumor xenografts.  Antitumor efficacy is demonstrated in five mouse xenograft models using ADCs directed to indication-specific antigens.  In rat toxicol. models, a nonbinding control ADC was tolerated at >10-fold the typical efficacious dose used in xenografts.  Moderate, reversible hematol. effects were obsd. with ADCs in rats, but there was no evidence for the retinal and cardiac toxicities reported for small-mol. inhibitors.  These findings introduce NAMPT inhibitors as active and well-tolerated payloads for ADCs with promise to improve the therapeutic window of NAMPT inhibition and enable application in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx2rsX00yD6LVg90H21EOLACvtfcHk0ljh1SO5ERXyng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1elsL0%253D&md5=43118eed82fe96b192cac5dca45a7b44</span></div><a href="/servlet/linkout?suffix=cit35e&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0643%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DC.%2BS.%26aulast%3DOlivas%26aufirst%3DK.%2BC.%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26aulast%3DCochran%26aufirst%3DJ.%2BH.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLoftus%26aufirst%3DL.%2BV.%26aulast%3DMeyer%26aufirst%3DD.%2BW.%26aulast%3DNeale%26aufirst%3DJ.%26aulast%3DNix%26aufirst%3DJ.%2BC.%26aulast%3DPittman%26aufirst%3DP.%2BG.%26aulast%3DSimmons%26aufirst%3DJ.%2BK.%26aulast%3DUlrich%26aufirst%3DM.%2BL.%26aulast%3DWaight%26aufirst%3DA.%2BB.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DZaval%26aufirst%3DM.%2BC.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DTargeted%2520delivery%2520of%2520cytotoxic%2520NAMPT%2520inhibitors%2520using%2520antibody-drug%2520conjugates%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D2633%26epage%3D2642%26doi%3D10.1158%2F1535-7163.MCT-18-0643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit35f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, H. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiske, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerton, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waight, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span> <span> </span><span class="NLM_article-title">Glucuronide-linked antibody-tubulysin conjugates display activity in MDR+ and heterogeneous tumor models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1752</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-0073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1535-7163.MCT-18-0073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=29866744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1752-1760&author=P.+J.+Burkeauthor=J.+Z.+Hamiltonauthor=T.+A.+Piresauthor=H.+W.+H.+Laiauthor=C.+I.+Leiskeauthor=K.+K.+Emmertonauthor=A.+B.+Waightauthor=P.+D.+Senterauthor=R.+P.+Lyonauthor=S.+C.+Jeffrey&title=Glucuronide-linked+antibody-tubulysin+conjugates+display+activity+in+MDR%2B+and+heterogeneous+tumor+models&doi=10.1158%2F1535-7163.MCT-18-0073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35fR"><div class="casContent"><span class="casTitleNuber">35f</span><div class="casTitle"><span class="NLM_cas:atitle">Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models</span></div><div class="casAuthors">Burke, Patrick J.; Hamilton, Joseph Z.; Pires, Thomas A.; Lai, Holden W. H.; Leiske, Christopher I.; Emmerton, Kim K.; Waight, Andrew B.; Senter, Peter D.; Lyon, Robert P.; Jeffrey, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1752-1760</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Although antibody-drug conjugates (ADCs) find increasing applications in cancer treatment, de novo or treatment-emergent resistance mechanisms may impair clin. benefit.  Two resistance mechanisms that emerge under prolonged exposure include upregulation of transporter proteins that confer multidrug resistance (MDR+) and loss of cognate antigen expression.  Recently, we developed the quaternary ammonium linker system to expand the scope of conjugatable payloads to include tertiary amines and applied the linker to tubulysins, a highly potent class of tubulin binders that maintain activity in MDR+ cell lines.  In this work, tubulysin M, which contains an unstable acetate susceptible to enzymic hydrolysis, and two stabilized tubulysin analogs were prepd. as quaternary ammonium-linked glucuronide-linkers and assessed as ADC payloads in preclin. models.  The conjugates were potent across a panel of cancer cell lines and active in tumor xenografts, including those displaying the MDR+ phenotype.  The ADCs also demonstrated potent bystander activity in a coculture model comprised of a mixt. of antigen-pos. and -neg. cell lines, and in an antigen-heterogeneous tumor model.  Thus, the glucuronide-tubulysin drug-linkers represent a promising ADC payload class, combining conjugate potency in the presence of the MDR+ phenotype and robust activity in models of tumor heterogeneity in a structure-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi-liIa9oi_rVg90H21EOLACvtfcHk0lh5gJj1OCmGOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtrfM&md5=57268b599402601821db672b6d645936</span></div><a href="/servlet/linkout?suffix=cit35f&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0073%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DHamilton%26aufirst%3DJ.%2BZ.%26aulast%3DPires%26aufirst%3DT.%2BA.%26aulast%3DLai%26aufirst%3DH.%2BW.%2BH.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DEmmerton%26aufirst%3DK.%2BK.%26aulast%3DWaight%26aufirst%3DA.%2BB.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26atitle%3DGlucuronide-linked%2520antibody-tubulysin%2520conjugates%2520display%2520activity%2520in%2520MDR%252B%2520and%2520heterogeneous%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D1752%26epage%3D1760%26doi%3D10.1158%2F1535-7163.MCT-18-0073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fourie-O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dela Cruz Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchelepi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span> <span> </span><span class="NLM_article-title">Improved translation of stability for conjugated antibodies using an in vitro whole blood assay</span>. <i>mAbs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e1715705</span> <span class="refDoi"> DOI: 10.1080/19420862.2020.1715705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1080%2F19420862.2020.1715705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31997712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFSrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&author=A.+Fourie-O%E2%80%99Donohueauthor=P.+Y.+Chuauthor=J.+dela+Cruz+Chuhauthor=R.+Tchelepiauthor=S.+P.+Tsaiauthor=J.+C.+Tranauthor=W.+S.+Sawyerauthor=D.+Suauthor=C.+Ngauthor=K.+Xuauthor=S.-F.+Yuauthor=T.+H.+Pillowauthor=J.+Sadowskyauthor=P.+S.+Dragovichauthor=Y.+Liuauthor=K.+R.+Kozak&title=Improved+translation+of+stability+for+conjugated+antibodies+using+an+in+vitro+whole+blood+assay&doi=10.1080%2F19420862.2020.1715705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Improved translation of stability for conjugated antibodies using an in vitro whole blood assay</span></div><div class="casAuthors">Fourie-O'Donohue, Aimee; Chu, Phillip Y.; dela Cruz Chuh, Josefa; Tchelepi, Robert; Tsai, Siao Ping; Tran, John C.; Sawyer, William S.; Su, Dian; Ng, Carl; Xu, Keyang; Yu, Shang-Fan; Pillow, Thomas H.; Sadowsky, Jack; Dragovich, Peter S.; Liu, Yichin; Kozak, Katherine R.</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1715705/1</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">For antibody-drug conjugates to be efficacious and safe, they must be stable in circulation to carry the payload to the site of the targeted cell.  Several components of a drug-conjugated antibody are known to influence stability: 1) the site of drug attachment on the antibody, 2) the linker used to attach the payload to the antibody, and 3) the payload itself.  In order to support the design and optimization of a high vol. of drug conjugates and avoid unstable conjugates prior to testing in animal models, we wanted to proactively identify these potential liabilities.  Therefore, we sought to establish an in vitro screening method that best correlated with in vivo stability.  While traditionally plasma has been used to assess in vitro stability, our evaluation using a variety of THIOMABTM antibody-drug conjugates revealed several disconnects between the stability assessed in vitro and the in vivo outcomes when using plasma.  When drug conjugates were incubated in vitro for 24 h in mouse whole blood rather than plasma and then analyzed by affinity capture LC-MS, we found an improved correlation to in vivo stability with whole blood (R2 = 0.87, coeff. of detn.) compared to unfrozen or frozen mouse plasma (R2 = 0.34, 0.01, resp.).  We further showed that this whole blood assay was also able to predict in vivo stability of other preclin. species such as rat and cynomolgus monkey, as well as in human.  The screening method utilized short (24 h) incubation times, as well as a custom anal. software, allowing increased throughput and in-depth biotransformation characterization.  While some instabilities that were more challenging to identify remain, the method greatly enhanced the process of screening, optimizing, and lead candidate selection, resulting in the substantial redn. of animal studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhca0BIA00H7Vg90H21EOLACvtfcHk0lh5gJj1OCmGOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFSrt7g%253D&md5=c4b05b4fa7b3bf4d84955ec3e5e8dee5</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1080%2F19420862.2020.1715705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2020.1715705%26sid%3Dliteratum%253Aachs%26aulast%3DFourie-O%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DChu%26aufirst%3DP.%2BY.%26aulast%3Ddela%2BCruz%2BChuh%26aufirst%3DJ.%26aulast%3DTchelepi%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DTran%26aufirst%3DJ.%2BC.%26aulast%3DSawyer%26aufirst%3DW.%2BS.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26atitle%3DImproved%2520translation%2520of%2520stability%2520for%2520conjugated%2520antibodies%2520using%2520an%2520in%2520vitro%2520whole%2520blood%2520assay%26jtitle%3DmAbs%26date%3D2020%26volume%3D12%26doi%3D10.1080%2F19420862.2020.1715705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dela Cruz-Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span> <span> </span><span class="NLM_article-title">Development of efficient chemistry to generate site-specific disulfide-linked protein- and peptide-payload conjugates: Application to THIOMAB antibody-drug conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2098</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVaktLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2086-2098&author=J.+D.+Sadowskyauthor=T.+H.+Pillowauthor=J.+Chenauthor=F.+Fanauthor=C.+Heauthor=Y.+Wangauthor=G.+Yanauthor=H.+Yaoauthor=Z.+Xuauthor=S.+Martinauthor=D.+Zhangauthor=P.+Chuauthor=J.+dela+Cruz-Chuhauthor=A.+O%E2%80%99Donohueauthor=G.+Liauthor=G.+Del+Rosarioauthor=J.+Heauthor=L.+Liuauthor=C.+Ngauthor=D.+Suauthor=G.+D.+L.+Phillipsauthor=K.+R.+Kozakauthor=S.-F.+Yuauthor=K.+Xuauthor=D.+Leipoldauthor=J.+Wai&title=Development+of+efficient+chemistry+to+generate+site-specific+disulfide-linked+protein-+and+peptide-payload+conjugates%3A+Application+to+THIOMAB+antibody-drug+conjugates&doi=10.1021%2Facs.bioconjchem.7b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates</span></div><div class="casAuthors">Sadowsky, Jack D.; Pillow, Thomas H.; Chen, Jinhua; Fan, Fang; He, Changrong; Wang, Yanli; Yan, Gang; Yao, Hui; Xu, Zijin; Martin, Shanique; Zhang, Donglu; Chu, Phillip; dela Cruz-Chuh, Josefa; ODonohue, Aimee; Li, Guangmin; Del Rosario, Geoffrey; He, Jintang; Liu, Luna; Ng, Carl; Su, Dian; Lewis Phillips, Gail D.; Kozak, Katherine R.; Yu, Shang-Fan; Xu, Keyang; Leipold, Douglas; Wai, John</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2086-2098</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conjugation of small mol. payloads to specific cysteine residues on proteins via a disulfide bond represents an attractive strategy to generate redox-sensitive bioconjugates, which have value as potential diagnostic reagents or therapeutics.  Advancement of such "direct-disulfide" bioconjugates to the clinic necessitates chem. methods to form disulfide connections efficiently, without byproducts.  The disulfide connection must also be resistant to premature cleavage by thiols prior to arrival at the targeted tissue.  We show here that commonly-employed methods to generate direct disulfide-linked bioconjugates are inadequate for addressing these challenges.  We describe our efforts to optimize direct-disulfide conjugation chem., focusing on the generation of conjugates between cytotoxic payloads and cysteine-engineered antibodies (i.e., THIOMAB antibody-drug conjugates, or TDCs).  This work culminates in the development of novel, high-yielding conjugation chem. for creating direct payload disulfide connections to any of several Cys mutation sites in THIOMAB antibodies or to Cys sites in other biomols. (e.g., human serum albumin and cell-penetrating peptides).  We conclude by demonstrating that hindered direct disulfide TDCs with two Me groups adjacent to the disulfide, which have heretofore not been described for any bioconjugate, are more stable and more efficacious in mouse tumor xenograft studies than less hindered analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIap6CQnm0X7Vg90H21EOLACvtfcHk0lgHvCtgN3iZXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVaktLvL&md5=9c437d3e1aa16e51e3f571fea95785c4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00258%26sid%3Dliteratum%253Aachs%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DG.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DP.%26aulast%3Ddela%2BCruz-Chuh%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLeipold%26aufirst%3DD.%26aulast%3DWai%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520efficient%2520chemistry%2520to%2520generate%2520site-specific%2520disulfide-linked%2520protein-%2520and%2520peptide-payload%2520conjugates%253A%2520Application%2520to%2520THIOMAB%2520antibody-drug%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2017%26volume%3D28%26spage%3D2086%26epage%3D2098%26doi%3D10.1021%2Facs.bioconjchem.7b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span> <span> </span><span class="NLM_article-title">Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates</span>. <i>Chem Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1039/C6SC01831A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2FC6SC01831A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28451181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOqsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=366-370&author=T.+H.+Pillowauthor=J.+D.+Sadowskyauthor=D.+Zhangauthor=S.-F.+Yuauthor=G.+Del+Rosarioauthor=K.+Xuauthor=J.+Heauthor=S.+Bhaktaauthor=R.+Ohriauthor=K.+R.+Kozakauthor=E.+Haauthor=J.+R.+Junutulaauthor=J.+A.+Flygare&title=Decoupling+stability+and+release+in+disulfide+bonds+with+antibody-small+molecule+conjugates&doi=10.1039%2FC6SC01831A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38aR"><div class="casContent"><span class="casTitleNuber">38a</span><div class="casTitle"><span class="NLM_cas:atitle">Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates</span></div><div class="casAuthors">Pillow, Thomas H.; Sadowsky, Jack D.; Zhang, Donglu; Yu, Shang-Fan; Del Rosario, Geoffrey; Xu, Keyang; He, Jintang; Bhakta, Sunil; Ohri, Rachana; Kozak, Katherine R.; Ha, Edward; Junutula, Jagath R.; Flygare, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">366-370</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Disulfide bonds provide a bioactivatable connection with applications in imaging and therapy.  The circulation stability and intracellular release of disulfides are problematically coupled in that increasing stability causes a corresponding decrease in cleavage and payload release.  However, an antibody offers the potential for a reversible stabilization.  We examd. this by attaching a small mol. directly to engineered cysteines in an antibody.  At certain sites this unhindered disulfide was stable in circulation yet cellular internalization and antibody catabolism generated a disulfide catabolite that was rapidly reduced.  We demonstrated that this stable connection and facile release is applicable to a variety of payloads.  The ability to reversibly stabilize a labile functional group with an antibody may offer a way to improve targeted probes and therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocdfG3fjz5LLVg90H21EOLACvtfcHk0lgHvCtgN3iZXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOqsL%252FP&md5=1ef5dd94930854c9fba36a9ddea49f3a</span></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1039%2FC6SC01831A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6SC01831A%26sid%3Dliteratum%253Aachs%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DHa%26aufirst%3DE.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26atitle%3DDecoupling%2520stability%2520and%2520release%2520in%2520disulfide%2520bonds%2520with%2520antibody-small%2520molecule%2520conjugates%26jtitle%3DChem%2520Sci.%26date%3D2017%26volume%3D8%26spage%3D366%26epage%3D370%26doi%3D10.1039%2FC6SC01831A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit38b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achilles-Poon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody-Drug conjugates with self-immolative disulfide linkers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1535-7163.MCT-16-0641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28223423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFemtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=871-878&author=T.+H.+Pillowauthor=M.+Schuttenauthor=S.-F.+Yuauthor=R.+Ohriauthor=J.+Sadowskyauthor=K.+Achilles-Poonauthor=W.+Solisauthor=F.+Zhongauthor=G.+Del+Rosarioauthor=M.+A.+T.+Goauthor=J.+Lauauthor=S.+Yeeauthor=J.+Heauthor=L.+Liuauthor=C.+Ngauthor=K.+Xuauthor=D.+D.+Leipoldauthor=A.+V.+Kamathauthor=D.+Zhangauthor=L.+Mastersonauthor=S.+J.+Gregsonauthor=P.+W.+Howardauthor=F.+Fangauthor=J.+Chenauthor=J.+Gunzner-Tosteauthor=K.+R.+Kozakauthor=S.+Spencerauthor=P.+Polakisauthor=A.+G.+Polsonauthor=J.+A.+Flygareauthor=J.+R.+Junutula&title=Modulating+therapeutic+activity+and+toxicity+of+pyrrolobenzodiazepine+antibody-Drug+conjugates+with+self-immolative+disulfide+linkers&doi=10.1158%2F1535-7163.MCT-16-0641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers</span></div><div class="casAuthors">Pillow, Thomas H.; Schutten, Melissa; Yu, Shang-Fan; Ohri, Rachana; Sadowsky, Jack; Poon, Kirsten Achilles; Solis, Willy; Zhong, Fiona; Del Rosario, Geoffrey; Go, Mary Ann T.; Lau, Jeffrey; Yee, Sharon; He, Jintang; Liu, Luna; Ng, Carl; Xu, Keyang; Leipold, Douglas D.; Kamath, Amrita V.; Zhang, Donglu; Masterson, Luke; Gregson, Stephen J.; Howard, Philip W.; Fang, Fan; Chen, Jinhua; Gunzner-Toste, Janet; Kozak, Katherine K.; Spencer, Susan; Polakis, Paul; Polson, Andrew G.; Flygare, John A.; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">871-878</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody-drug conjugates (ADCs).  The ADCs composed of a cysteine-engineered antibody were armed with a PBD using a self-immolative disulfide linker.  Both the chem. linker and the antibody site were optimized for this new bioconjugation strategy to provide a highly stable and efficacious ADC.  This novel disulfide ADC was compared with a conjugate contg. the same PBD drug, but attached to the antibody via a peptide linker.  Both ADCs had similar efficacy in mice bearing human tumor xenografts.  Safety studies in rats revealed that the disulfide-linked ADC had a higher MTD than the peptide-linked ADC.  Overall, these data suggest that the novel self-immolative disulfide linker represents a valuable way to construct ADCs with equiv. efficacy and improved safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZP_imFtNeBrVg90H21EOLACvtfcHk0lgq0YfKOMRn6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFemtrw%253D&md5=6bf9501951de0cfad9d890a4ef9492b1</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0641%26sid%3Dliteratum%253Aachs%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSchutten%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DAchilles-Poon%26aufirst%3DK.%26aulast%3DSolis%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DGo%26aufirst%3DM.%2BA.%2BT.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DYee%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DFang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DModulating%2520therapeutic%2520activity%2520and%2520toxicity%2520of%2520pyrrolobenzodiazepine%2520antibody-Drug%2520conjugates%2520with%2520self-immolative%2520disulfide%2520linkers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D871%26epage%3D878%26doi%3D10.1158%2F1535-7163.MCT-16-0641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="note"><p class="first last">For other examples of ADCs containing carbonate-based linkers, see reference <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a>a and:</p></div><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandish, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bresson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gately, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manibusan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbaccio, R. M.</span></span> <span> </span><span class="NLM_article-title">Novel phosphate modified cathepsin B linkers: Improving aqueous solubility and enhancing payload scope of ADCs</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2081</span>– <span class="NLM_lpage">2088</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.6b00337</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00337" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GjtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=2081-2088&author=J.+C.+Kernauthor=D.+Dooneyauthor=R.+Zhangauthor=L.+Liangauthor=P.+E.+Brandishauthor=M.+Chengauthor=G.+Fengauthor=A.+Beckauthor=D.+Bressonauthor=J.+Firdosauthor=D.+Gatelyauthor=N.+Knudsenauthor=A.+Manibusanauthor=Y.+Sunauthor=R.+M.+Garbaccio&title=Novel+phosphate+modified+cathepsin+B+linkers%3A+Improving+aqueous+solubility+and+enhancing+payload+scope+of+ADCs&doi=10.1021%2Facs.bioconjchem.6b00337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs</span></div><div class="casAuthors">Kern, Jeffrey C.; Dooney, Deborah; Zhang, Rena; Liang, Linda; Brandish, Philip E.; Cheng, Mangeng; Feng, Guo; Beck, Andrew; Bresson, Damien; Firdos, Juhi; Gately, Dennis; Knudsen, Nick; Manibusan, Anthony; Sun, Ying; Garbaccio, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2081-2088</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In an effort to examine the utility of antibody-drug conjugates (ADCs) beyond oncol. indications, a novel phosphate bridged Cathepsin B sensitive linker was developed to enable the targeted delivery of glucocorticoids.  Phosphate bridging of the Cathepsin B sensitive linkers allows for payload attachment at an aliph. alc.  As small mol. drug-linkers, these aq. sol. phosphate contg. drug-linkers were found to have robust plasma stability coupled with rapid release of payload in a lysosomal environment.  Site-specific ADCs were successfully made between these drug-linkers and an antibody against human CD70, a receptor specifically expressed in immune cells but also found aberrantly expressed in multiple human carcinomas.  These ADCs demonstrated in vitro targeted delivery of glucocorticoids to a representative cell line as measured by changes in glucocorticoid receptor (GR) mediated gene mRNA levels.  This novel linker expands the scope of potential ADC payloads by allowing an aliph. alc. to be a stable, yet cleavable attachment site.  This phosphate linker may have broad utility for internalizing ADCs as well as other targeted delivery platforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9cYjuaEBF2bVg90H21EOLACvtfcHk0lgq0YfKOMRn6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GjtrrN&md5=5dd6102d06fd4ab58ac9cc8453ecf224</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00337%26sid%3Dliteratum%253Aachs%26aulast%3DKern%26aufirst%3DJ.%2BC.%26aulast%3DDooney%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DBresson%26aufirst%3DD.%26aulast%3DFirdos%26aufirst%3DJ.%26aulast%3DGately%26aufirst%3DD.%26aulast%3DKnudsen%26aufirst%3DN.%26aulast%3DManibusan%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DGarbaccio%26aufirst%3DR.%2BM.%26atitle%3DNovel%2520phosphate%2520modified%2520cathepsin%2520B%2520linkers%253A%2520Improving%2520aqueous%2520solubility%2520and%2520enhancing%2520payload%2520scope%2520of%2520ADCs%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D2081%26epage%3D2088%26doi%3D10.1021%2Facs.bioconjchem.6b00337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span> <span> </span><span class="NLM_article-title">Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1836</span>– <span class="NLM_lpage">1847</span>, <span class="refDoi"> DOI: 10.1021/mp5006195</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp5006195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGktbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1836-1847&author=S.+V.+Govindanauthor=T.+M.+Cardilloauthor=E.+A.+Rossiauthor=P.+Trisalauthor=W.+J.+McBrideauthor=R.+M.+Sharkeyauthor=D.+M.+Goldenberg&title=Improving+the+therapeutic+index+in+cancer+therapy+by+using+antibody-drug+conjugates+designed+with+a+moderately+cytotoxic+drug&doi=10.1021%2Fmp5006195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug</span></div><div class="casAuthors">Govindan, Serengulam V.; Cardillo, Thomas M.; Rossi, Edmund A.; Trisal, Preeti; McBride, William J.; Sharkey, Robert M.; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1836-1847</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The antibody-drug conjugate (ADC), IMMU-130, of the moderately cytotoxic topoisomerase I inhibitor, SN-38, and the CEACAM5-targeted humanized antibody (mAb), labetuzumab, was evaluated in model systems of human colon carcinoma and in phase I clin. trials of heavily pretreated patients with metastatic colorectal cancer.  The conjugate, designed with a near-homogeneous drug substitution of 7-8 SN-38/mAb and with a linker that released 50% of the drug in ∼20 h, showed significant antitumor effects compared to a nontargeted ADC in human tumor xenografts, which could be augmented in combination with bevacizumab.  The advantage of fractionated dosing was demonstrated, with potential implications for the clin. dosing schedule.  Biodistribution comparing IMMU-130 with labetuzumab showed that the conjugate cleared somewhat faster from the blood, but this did not affect tumor uptake and retention.  The use of an ultra-stable linker in the conjugate design abrogated antitumor effects.  A tolerability study in rabbits showed a high safety margin, with no-obsd.-adverse-effect level (NOAEL) corresponding to a cumulative human-equiv. protein dose of 40-60 mg/kg.  The preclin. findings appear to be corroborated in two phase I clin. trials, with high tolerability and evidence of antitumor activity, including objective responses.  The impact of the ADC design on the utility of IMMU-130, tailored to a poorly internalizing target, is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq73bJkMWKZkrVg90H21EOLACvtfcHk0liGzYesoenAEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGktbjJ&md5=65ef4d6c6e7b6cea3fdfe68eb283cd28</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1021%2Fmp5006195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp5006195%26sid%3Dliteratum%253Aachs%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DCardillo%26aufirst%3DT.%2BM.%26aulast%3DRossi%26aufirst%3DE.%2BA.%26aulast%3DTrisal%26aufirst%3DP.%26aulast%3DMcBride%26aufirst%3DW.%2BJ.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DImproving%2520the%2520therapeutic%2520index%2520in%2520cancer%2520therapy%2520by%2520using%2520antibody-drug%2520conjugates%2520designed%2520with%2520a%2520moderately%2520cytotoxic%2520drug%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D1836%26epage%3D1847%26doi%3D10.1021%2Fmp5006195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Besten, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowntree, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandlen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Conjugation of indoles to antibodies through a novel self-immolating linker</span>. <i>Chem. – Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4830</span>– <span class="NLM_lpage">4834</span>, <span class="refDoi"> DOI: 10.1002/chem.201800859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fchem.201800859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=29493023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlslSnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=4830-4834&author=P.+S.+Dragovichauthor=R.+A.+Blakeauthor=C.+Chenauthor=J.+Chenauthor=J.+Chuhauthor=W.+den+Bestenauthor=F.+Fanauthor=A.+Fourieauthor=S.+J.+Hartmanauthor=C.+Heauthor=J.+Heauthor=E.+R.+Ingallaauthor=K.+R.+Kozakauthor=S.+R.+Leongauthor=J.+Luauthor=Y.+Maauthor=L.+Mengauthor=M.+Nanniniauthor=J.+Oehauthor=R.+Ohriauthor=G.+L.+Phillipsauthor=T.+H.+Pillowauthor=R.+K.+Rowntreeauthor=D.+Sampathauthor=R.+Vandlenauthor=B.+Vollmarauthor=J.+Waiauthor=I.+E.+Wertzauthor=K.+Xuauthor=Z.+Xuauthor=D.+Zhang&title=Conjugation+of+indoles+to+antibodies+through+a+novel+self-immolating+linker&doi=10.1002%2Fchem.201800859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker</span></div><div class="casAuthors">Dragovich, Peter S.; Blake, Robert A.; Chen, Chunjiao; Chen, Jinhua; Chuh, Josefa; den Besten, Willem; Fan, Fang; Fourie, Aimee; Hartman, Steven J.; He, Changrong; He, Jintang; Ingalla, Ellen Rei; Kozak, Katherine R.; Leong, Steven R.; Lu, Jiawei; Ma, Yong; Meng, Lingyao; Nannini, Michelle; Oeh, Jason; Ohri, Rachana; Lewis Phillips, Gail; Pillow, Thomas H.; Rowntree, Rebecca K.; Sampath, Deepak; Vandlen, Richard; Vollmar, Breanna; Wai, John; Wertz, Ingrid E.; Xu, Keyang; Xu, Zijin; Zhang, Donglu</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4830-4834</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel strategy to attach indole-contg. payloads to antibodies through a carbamate moiety and a self-immolating, disulfide-based linker is described.  This new strategy was employed to connect a selective estrogen receptor down-regulator (SERD) to various antibodies in a site-selective manner.  The resulting conjugates displayed potent, antigen-dependent down-regulation of estrogen receptor levels in MCF7-neo/HER2 and MCF7-hB7H4 cells.  They also exhibited similar antigen-dependent modulation of the estrogen receptor in tumors when administered i.v. to mice bearing MCF7-neo/HER2 tumor xenografts.  The indole-carbamate moiety present in the new linker was stable in whole blood from various species and also exhibited good in vivo stability properties in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKhcOeE6xSRLVg90H21EOLACvtfcHk0liGzYesoenAEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlslSnu78%253D&md5=f1c82d8a721646a690e735c3ed38b53a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fchem.201800859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201800859%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChuh%26aufirst%3DJ.%26aulast%3Dden%2BBesten%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DFourie%26aufirst%3DA.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DIngalla%26aufirst%3DE.%2BR.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DLeong%26aufirst%3DS.%2BR.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DG.%2BL.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DRowntree%26aufirst%3DR.%2BK.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DVollmar%26aufirst%3DB.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DConjugation%2520of%2520indoles%2520to%2520antibodies%2520through%2520a%2520novel%2520self-immolating%2520linker%26jtitle%3DChem.%2520%25E2%2580%2593%2520Eur.%2520J.%26date%3D2018%26volume%3D24%26spage%3D4830%26epage%3D4834%26doi%3D10.1002%2Fchem.201800859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="note"><p class="first last">For representative examples, see:</p></div><div class="NLM_citation" id="rightTab-cit41a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Tubulin inhibitor-based antibody-drug conjugates for cancer therapy</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>, <span class="NLM_elocation-id">1281</span> <span class="refDoi"> DOI: 10.3390/molecules22081281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.3390%2Fmolecules22081281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28763044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&author=H.+Chenauthor=Z.+Linauthor=K.+E.+Arnstauthor=D.+D.+Millerauthor=W.+Li&title=Tubulin+inhibitor-based+antibody-drug+conjugates+for+cancer+therapy&doi=10.3390%2Fmolecules22081281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin inhibitor-based antibody-drug conjugates for cancer therapy</span></div><div class="casAuthors">Chen, Hao; Lin, Zongtao; Arnst, Kinsie E.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1281/1-1281/28</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are a class of highly potent biopharmaceutical drugs generated by conjugating cytotoxic drugs with specific monoclonal antibodies through appropriate linkers.  Specific antibodies used to guide potent warheads to tumor tissues can effectively reduce undesired side effects of the cytotoxic drugs.  An in-depth understanding of antibodies, linkers, conjugation strategies, cytotoxic drugs, and their mol. targets has led to the successful development of several approved ADCs.  These ADCs are powerful therapeutics for cancer treatment, enabling wider therapeutic windows, improved pharmacokinetic/pharmacodynamic properties, and enhanced efficacy.  Since tubulin inhibitors are one of the most successful cytotoxic drugs in the ADC armamentarium, this review focuses on the progress in tubulin inhibitor-based ADCs, as well as lessons learned from the unsuccessful ADCs contg. tubulin inhibitors.  This review should be helpful to facilitate future development of new generations of tubulin inhibitor-based ADCs for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8A0aJYR6aBLVg90H21EOLACvtfcHk0liEzgo6f-Xg1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls7zI&md5=eb6efd4fdf44b5c0294a9becbeffab86</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22081281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22081281%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DTubulin%2520inhibitor-based%2520antibody-drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26doi%3D10.3390%2Fmolecules22081281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit41b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00062</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=983-987&author=A.+C.+Tiberghienauthor=J.+N.+Levyauthor=L.+A.+Mastersonauthor=N.+V.+Patelauthor=L.+R.+Adamsauthor=S.+Corbettauthor=D.+G.+Williamsauthor=J.+A.+Hartleyauthor=P.+W.+Howard&title=Design+and+synthesis+of+tesirine%2C+a+clinical+antibody-drug+conjugate+pyrrolobenzodiazepine+dimer+payload&doi=10.1021%2Facsmedchemlett.6b00062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41bR"><div class="casContent"><span class="casTitleNuber">41b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload</span></div><div class="casAuthors">Tiberghien, Arnaud C.; Levy, Jean-Noel; Masterson, Luke A.; Patel, Neki V.; Adams, Lauren R.; Corbett, Simon; Williams, David G.; Hartley, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">983-987</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrrolobenzodiazepine dimers are an emerging class of warhead in the field of antibody-drug conjugates (ADCs).  Tesirine (SG3249) was designed to combine potent antitumor activity with desirable physicochem. properties such as favorable hydrophobicity and improved conjugation characteristics.  One of the reactive imines was capped with a cathepsin B-cleavable valine-alanine linker.  A robust synthetic route was developed to allow the prodn. of tesirine on clin. scale, employing a flexible, convergent strategy.  Tesirine was evaluated in vitro both in stochastic and engineered ADC constructs and was confirmed as a potent and versatile payload.  The conjugation of tesirine to anti-DLL3 rovalpituzumab has resulted in rovalpituzumab-tesirine (Rova-T), currently under evaluation for the treatment of small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYid7RNts7s7Vg90H21EOLACvtfcHk0liEzgo6f-Xg1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D&md5=7e4bbdd55b944ff712f01d31d58c0d13</span></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00062%26sid%3Dliteratum%253Aachs%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DLevy%26aufirst%3DJ.%2BN.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DPatel%26aufirst%3DN.%2BV.%26aulast%3DAdams%26aufirst%3DL.%2BR.%26aulast%3DCorbett%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tesirine%252C%2520a%2520clinical%2520antibody-drug%2520conjugate%2520pyrrolobenzodiazepine%2520dimer%2520payload%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D983%26epage%3D987%26doi%3D10.1021%2Facsmedchemlett.6b00062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit41c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiske, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholas, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1021/bc400217g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc400217g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1256-1263&author=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=R.+P.+Lyonauthor=D.+W.+Meyerauthor=D.+Sussmanauthor=M.+Andersonauthor=J.+H.+Hunterauthor=C.+I.+Leiskeauthor=J.+B.+Miyamotoauthor=N.+D.+Nicholasauthor=N.+M.+Okeleyauthor=R.+J.+Sandersonauthor=I.+J.+Stoneauthor=W.+Zengauthor=S.+J.+Gregsonauthor=L.+Mastersonauthor=A.+C.+Tiberghienauthor=P.+W.+Howardauthor=D.+E.+Thurstonauthor=C.+L.+Lawauthor=P.+D.+Senter&title=A+potent+anti-CD70+antibody-drug+conjugate+combining+a+dimeric+pyrrolobenzodiazepine+drug+with+site-specific+conjugation+technology&doi=10.1021%2Fbc400217g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41cR"><div class="casContent"><span class="casTitleNuber">41c</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology</span></div><div class="casAuthors">Jeffrey, Scott C.; Burke, Patrick J.; Lyon, Robert P.; Meyer, David W.; Sussman, Django; Anderson, Martha; Hunter, Joshua H.; Leiske, Chris I.; Miyamoto, Jamie B.; Nicholas, Nicole D.; Okeley, Nicole M.; Sanderson, Russell J.; Stone, Ivan J.; Zeng, Weiping; Gregson, Stephen J.; Masterson, Luke; Tiberghien, Arnaud C.; Howard, Philip W.; Thurston, David E.; Law, Che-Leung; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1256-1263</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly cytotoxic DNA crosslinking pyrrolobenzodiazepine (PBD) dimer with a valine-alanine dipeptide linker was conjugated to the anti-CD70 h1F6 mAb either through endogenous interchain cysteines or, site-specifically, through engineered cysteines at position 239 of the heavy chains.  The h1F6239C-PBD conjugation strategy proved to be superior to interchain cysteine conjugation, affording an antibody-drug conjugate (ADC) with high uniformity in drug-loading and low levels of aggregation.  In vitro cytotoxicity expts. demonstrated that the h1F6239C-PBD was potent and immunol. specific on CD70-pos. renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL) cell lines.  The conjugate was resistant to drug loss in plasma and in circulation, and had a pharmacokinetic profile closely matching that of the parental h1F6239C antibody capped with N-ethylmaleimide (NEM).  Evaluation in CD70-pos. RCC and NHL mouse xenograft models showed pronounced antitumor activities at single or weekly doses as low as 0.1 mg/kg of ADC.  The ADC was tolerated at 2.5 mg/kg.  These results demonstrate that PBDs can be effectively used for antibody-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVruNGtWHpsbVg90H21EOLACvtfcHk0ljdiieDF5YlVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D&md5=31841b0267e41ae861eaf05240c97b15</span></div><a href="/servlet/linkout?suffix=cit41c&amp;dbid=16384&amp;doi=10.1021%2Fbc400217g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc400217g%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DMeyer%26aufirst%3DD.%2BW.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%2BH.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DNicholas%26aufirst%3DN.%2BD.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DStone%26aufirst%3DI.%2BJ.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DLaw%26aufirst%3DC.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DA%2520potent%2520anti-CD70%2520antibody-drug%2520conjugate%2520combining%2520a%2520dimeric%2520pyrrolobenzodiazepine%2520drug%2520with%2520site-specific%2520conjugation%2520technology%26jtitle%3DBioconjugate%2520Chem.%26date%3D2013%26volume%3D24%26spage%3D1256%26epage%3D1263%26doi%3D10.1021%2Fbc400217g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, K.</span>; <span class="NLM_string-name">Hikawa, H.</span>; <span class="NLM_string-name">Hamada, M.</span>; <span class="NLM_string-name">Endoh, J.-i.</span>; <span class="NLM_string-name">Ishibuchi, S.</span>; <span class="NLM_string-name">Fujie, N.</span>; <span class="NLM_string-name">Tanaka, M.</span>; <span class="NLM_string-name">Sugahara, K.</span>; <span class="NLM_string-name">Oshita, K.</span>; <span class="NLM_string-name">Murata, M.</span></span> <span> </span><span class="NLM_article-title">Thienotriazolodiazepine Compound and a Medicinal Use Thereof</span>. <span class="NLM_patent">EP1,887,008</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+Adachi&author=H.+Hikawa&author=M.+Hamada&author=J.-i.+Endoh&author=S.+Ishibuchi&author=N.+Fujie&author=M.+Tanaka&author=K.+Sugahara&author=K.+Oshita&author=M.+Murata&title=Thienotriazolodiazepine+Compound+and+a+Medicinal+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DK.%26atitle%3DThienotriazolodiazepine%2520Compound%2520and%2520a%2520Medicinal%2520Use%2520Thereof%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span>; <span class="NLM_string-name">Dong, H.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Berlin, M.</span>; <span class="NLM_string-name">Siu, K.</span>; <span class="NLM_string-name">Crew, A. P.</span>; <span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Compounds and Methods for the Targeted Degradation of Bromodomain-Containing Proteins</span>. <span class="NLM_patent">WO2017030814</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Qian&author=H.+Dong&author=J.+Wang&author=M.+Berlin&author=K.+Siu&author=A.+P.+Crew&author=C.+M.+Crews&title=Compounds+and+Methods+for+the+Targeted+Degradation+of+Bromodomain-Containing+Proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DY.%26atitle%3DCompounds%2520and%2520Methods%2520for%2520the%2520Targeted%2520Degradation%2520of%2520Bromodomain-Containing%2520Proteins%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnaby, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumpel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00092</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00092" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVCisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=361-368&author=M.+Royauthor=S.+Winklerauthor=S.+J.+Hughesauthor=C.+Whitworthauthor=M.+Galantauthor=W.+Farnabyauthor=K.+Rumpelauthor=A.+Ciulli&title=SPR-measured+dissociation+kinetics+of+PROTAC+ternary+complexes+influence+target+degradation+rate&doi=10.1021%2Facschembio.9b00092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate</span></div><div class="casAuthors">Roy, Michael J.; Winkler, Sandra; Hughes, Scott J.; Whitworth, Claire; Galant, Michael; Farnaby, William; Rumpel, Klaus; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">361-368</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bifunctional degrader mols., known as proteolysis-targeting chimeras (PROTACs), function by recruiting a target to an E3 ligase, forming a target/PROTAC/ligase ternary complex.  Despite the importance of this key intermediate species, no detailed validation of a method to directly det. binding parameters for ternary complex kinetics has been reported, and it remains to be addressed whether tuning the kinetics of PROTAC ternary complexes may be an effective strategy to improve the efficiency of targeted protein degrdn.  Here, we develop an SPR-based assay to quantify the stability of PROTAC-induced ternary complexes by measuring for the first time the kinetics of their formation and dissocn. in vitro using purified proteins.  We benchmark our assay using four PROTACs that target the bromodomains (BDs) of bromodomain and extraterminal domain proteins Brd2, Brd3, and Brd4 to the von Hippel-Lindau E3 ligase (VHL).  We reveal marked differences in ternary complex off-rates for different PROTACs that exhibit either pos. or neg. cooperativity for ternary complex formation relative to binary binding.  The pos. cooperative degrader MZ1 forms comparatively stable and long-lived ternary complexes with either Brd4BD2 or Brd2BD2 and VHL.  Equivalent complexes with Brd3BD2 are destabilized due to a single amino acid difference (Glu/Gly swap) present in the bromodomain.  We observe that this difference in ternary complex dissociative half-life correlates to a greater initial rate of intracellular degrdn. of Brd2 and Brd4 relative to Brd3.  These findings establish a novel assay to measure the kinetics of PROTAC ternary complexes and elucidate the important kinetic parameters that drive effective target degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzFhvuKYztcbVg90H21EOLACvtfcHk0lizT_CJRcCNPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVCisrg%253D&md5=629d1acbd218b668a2696b727946962b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00092%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DM.%26aulast%3DWinkler%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DWhitworth%26aufirst%3DC.%26aulast%3DGalant%26aufirst%3DM.%26aulast%3DFarnaby%26aufirst%3DW.%26aulast%3DRumpel%26aufirst%3DK.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DSPR-measured%2520dissociation%2520kinetics%2520of%2520PROTAC%2520ternary%2520complexes%2520influence%2520target%2520degradation%2520rate%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D361%26epage%3D368%26doi%3D10.1021%2Facschembio.9b00092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadd, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zengerl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">Structural basis of PROTAC cooperative recognition for selective protein degradation</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fnchembio.2329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=28288108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFahtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=514-521&author=M.+S.+Gaddauthor=A.+Testaauthor=X.+Lucasauthor=K.-H.+Chanauthor=W.+Chenauthor=D.+J.+Lamontauthor=M.+Zengerlauthor=A.+Ciulli&title=Structural+basis+of+PROTAC+cooperative+recognition+for+selective+protein+degradation&doi=10.1038%2Fnchembio.2329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of PROTAC cooperative recognition for selective protein degradation</span></div><div class="casAuthors">Gadd, Morgan S.; Testa, Andrea; Lucas, Xavier; Chan, Kwok-Ho; Chen, Wenzhang; Lamont, Douglas J.; Zengerle, Michael; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">514-521</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inducing macromol. interactions with small mols. to activate cellular signaling is a challenging goal.  PROTACs (proteolysis-targeting chimeras) are bifunctional mols. that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degrdn.  Structural elucidation of the key ternary ligase-PROTAC-target species and its impact on target degrdn. selectivity remain elusive.  Here, we solved the crystal structure of Brd4 degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4BD2).  The ligand folds into itself to allow formation of specific intermol. interactions in the ternary complex.  Isothermal titrn. calorimetry studies, supported by surface mutagenesis and proximity assays, were consistent with pronounced cooperative formation of ternary complexes with Brd4BD2.  Structure-based-designed compd. AT1 exhibited highly selective depletion of Brd4 in cells.  These results elucidate how PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a stable and cooperative complex with an E3 ligase for selective degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJri00jB5YJLVg90H21EOLACvtfcHk0lizT_CJRcCNPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFahtbg%253D&md5=dfee13913106d362d0972d7b1a62d700</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2329%26sid%3Dliteratum%253Aachs%26aulast%3DGadd%26aufirst%3DM.%2BS.%26aulast%3DTesta%26aufirst%3DA.%26aulast%3DLucas%26aufirst%3DX.%26aulast%3DChan%26aufirst%3DK.-H.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DLamont%26aufirst%3DD.%2BJ.%26aulast%3DZengerl%26aufirst%3DM.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DStructural%2520basis%2520of%2520PROTAC%2520cooperative%2520recognition%2520for%2520selective%2520protein%2520degradation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D514%26epage%3D521%26doi%3D10.1038%2Fnchembio.2329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavens, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Readshaw, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayne, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, A.</span></span> <span> </span><span class="NLM_article-title">Direct measurement of intracellular compound concentration by Rapid Fire mass spectrometry offers insights into cell permeability</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1177/1087057115604141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1177%2F1087057115604141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=26336900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvVSrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=156-164&author=L.+J.+Gordonauthor=M.+Allenauthor=P.+Arturssonauthor=M.+M.+Hannauthor=B.+J.+Leavensauthor=A.+Mateusauthor=S.+Readshawauthor=K.+Valkoauthor=G.+J.+Wayneauthor=A.+West&title=Direct+measurement+of+intracellular+compound+concentration+by+Rapid+Fire+mass+spectrometry+offers+insights+into+cell+permeability&doi=10.1177%2F1087057115604141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46aR"><div class="casContent"><span class="casTitleNuber">46a</span><div class="casTitle"><span class="NLM_cas:atitle">Direct measurement of intracellular compound concentration by RapidFire mass spectrometry offers insights into cell permeability</span></div><div class="casAuthors">Gordon, Laurie J.; Allen, Morven; Artursson, Per; Hann, Michael M.; Leavens, Bill J.; Mateus, Andre; Readshaw, Simon; Valko, Klara; Wayne, Gareth J.; West, Andy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">One of the key challenges facing early stage drug discovery is understanding the commonly obsd. difference between the activity of compds. in biochem. assays and cellular assays.  Traditionally, indirect or estd. cell permeability measurements such as estns. from logP or artificial membrane permeability are used to explain the differences.  The missing link is a direct measurement of intracellular compd. concn. in whole cells.  This can, in some circumstances, be estd. from the cellular activity, but this may also be problematic if cellular activity is weak or absent.  Advances in sensitivity and throughput of anal. techniques have enabled us to develop a high-throughput assay for the measurement of intracellular compd. concn. for routine use to support lead optimization.  The assay uses a RapidFire-MS based readout of compd. concn. in HeLa cells following incubation of cells with test compd.  The initial assay validation was performed by ultra-high performance liq. chromatog. tandem mass spectrometry, and the assay was subsequently transferred to RapidFire tandem mass spectrometry.  Further miniaturization and optimization were performed to streamline the process, increase sample throughput, and reduce cycle time.  This optimization has delivered a semi-automated platform with the potential of prodn. scale compd. profiling up to 100 compds. per day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLd62-6firibVg90H21EOLACvtfcHk0lik7tAyC2Uc3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvVSrtLc%253D&md5=34a5d2a18c1a36973425d00b87112f20</span></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=10.1177%2F1087057115604141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057115604141%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DL.%2BJ.%26aulast%3DAllen%26aufirst%3DM.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DLeavens%26aufirst%3DB.%2BJ.%26aulast%3DMateus%26aufirst%3DA.%26aulast%3DReadshaw%26aufirst%3DS.%26aulast%3DValko%26aufirst%3DK.%26aulast%3DWayne%26aufirst%3DG.%2BJ.%26aulast%3DWest%26aufirst%3DA.%26atitle%3DDirect%2520measurement%2520of%2520intracellular%2520compound%2520concentration%2520by%2520Rapid%2520Fire%2520mass%2520spectrometry%2520offers%2520insights%2520into%2520cell%2520permeability%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2016%26volume%3D21%26spage%3D156%26epage%3D164%26doi%3D10.1177%2F1087057115604141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit46b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Beigi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottschalk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hägglund, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haneskog, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekkan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Österberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundahl, P.</span></span> <span> </span><span class="NLM_article-title">Immobilized liposome and biomembrane partitioning chromatography of drugs for prediction of drug transport</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/S0378-5173(97)00398-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2FS0378-5173%2897%2900398-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADyaK1cXitlSrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=1998&pages=129-137&author=F.+Beigiauthor=I.+Gottschalkauthor=C.+L.+H%C3%A4gglundauthor=L.+Haneskogauthor=E.+Brekkanauthor=Y.+Zhangauthor=T.+%C3%96sterbergauthor=P.+Lundahl&title=Immobilized+liposome+and+biomembrane+partitioning+chromatography+of+drugs+for+prediction+of+drug+transport&doi=10.1016%2FS0378-5173%2897%2900398-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46bR"><div class="casContent"><span class="casTitleNuber">46b</span><div class="casTitle"><span class="NLM_cas:atitle">Immobilized liposome and biomembrane partitioning chromatography of drugs for prediction of drug transport</span></div><div class="casAuthors">Beigi, Farideh; Gottschalk, Ingo; Lagerquist Hagglund, Christine; Haneskog, Lars; Brekkan, Eggert; Zhang, Yanxiao; Osterberg, Thomas; Lundahl, Per</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">129-137</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Drug partitioning into lipid bilayers was studied by chromatog. on liposomes and biomembranes immobilized in gel beads by freeze-thawing.  The drug retention vol. was expressed as a capacity factor, Ks, normalized with respect to the amt. of immobilized phospholipid.  Log Ks values for pos. charged drugs on brain phosphatidylserine (PS)/egg phosphatidylcholine (PC) liposomes decreased as the ionic strength was increased, increased as the PS:PC ratio or the pH was increased and varied linearly with the temp.  Log Ks values for beta-blockers, phenothiazines and benzodiazepines on egg phospholipid (EPL) liposomes correlated well with corresponding values on red cell membrane lipid liposomes (r2=0.96), and on human red cell membrane vesicles contg. transmembrane proteins (r2=0.96).  A fair correlation was obsd. between the values on EPL liposomes and those on native membranes of adsorbed red cells (r2=0.86).  Compared to the data obtained with liposomes, the retentions of hydrophilic drugs became larger and the range of log Ks values more narrow on the vesicles and the membranes, which expose hydrophilic protein surfaces and oligosaccharides.  Lower correlations were obsd. between drug retention on EPL liposomes and egg PC liposomes; and between retention on liposomes (or vesicles) and immobilized artificial membrane (IAM) monolayers of PC analogs.  Absorption of orally administered drugs in humans (literature data) was nearly complete for drugs of log Ks values in the interval 1.2-2.5 on vesicles.  Both vesicles and liposomes can thus be used for chromatog. anal. of drug-membrane interaction and prediction of drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_r5N-IU8WaLVg90H21EOLACvtfcHk0lik7tAyC2Uc3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitlSrt7g%253D&md5=f930fe3b4f61a23889e2dc42f510b8bc</span></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=10.1016%2FS0378-5173%2897%2900398-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5173%252897%252900398-0%26sid%3Dliteratum%253Aachs%26aulast%3DBeigi%26aufirst%3DF.%26aulast%3DGottschalk%26aufirst%3DI.%26aulast%3DH%25C3%25A4gglund%26aufirst%3DC.%2BL.%26aulast%3DHaneskog%26aufirst%3DL.%26aulast%3DBrekkan%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3D%25C3%2596sterberg%26aufirst%3DT.%26aulast%3DLundahl%26aufirst%3DP.%26atitle%3DImmobilized%2520liposome%2520and%2520biomembrane%2520partitioning%2520chromatography%2520of%2520drugs%2520for%2520prediction%2520of%2520drug%2520transport%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D1998%26volume%3D164%26spage%3D129%26epage%3D137%26doi%3D10.1016%2FS0378-5173%2897%2900398-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R. A.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3341</span>– <span class="NLM_lpage">3346</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(98)00609-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2FS0960-894X%2898%2900609-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=9873731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADyaK1cXotFagtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=3341-3346&author=G.+M.+Dubowchikauthor=R.+A.+Firestone&title=Cathepsin+B-sensitive+dipeptide+prodrugs.+1.+A+model+study+of+structural+requirements+for+efficient+release+of+doxorubicin&doi=10.1016%2FS0960-894X%2898%2900609-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin</span></div><div class="casAuthors">Dubowchik, Gene M.; Firestone, Raymond A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3341-3346</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of lysosomal protease-sensitive peptides attached to doxorubicin (DOX) was prepd. as model substrates for internalizing anticancer immunoconjugates and potential antimetastasis prodrugs.  Rates of cathepsin B-mediated release of free drug was measured for each, and human plasma stabilities for representative examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOzOf1WKrZurVg90H21EOLACvtfcHk0lh3MDk6PQNk4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotFagtbY%253D&md5=946bb31dc62701634c946beb1f1cc1bc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900609-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900609-X%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26atitle%3DCathepsin%2520B-sensitive%2520dipeptide%2520prodrugs.%25201.%2520A%2520model%2520study%2520of%2520structural%2520requirements%2520for%2520efficient%2520release%2520of%2520doxorubicin%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D3341%26epage%3D3346%26doi%3D10.1016%2FS0960-894X%2898%2900609-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meekin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phipps, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebelatto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimasi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span> <span> </span><span class="NLM_article-title">SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6570</span>– <span class="NLM_lpage">6582</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F1078-0432.CCR-18-1300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30131388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=6570-6582&author=K.+Kinneerauthor=J.+Meekinauthor=A.+C.+Tiberghienauthor=Y.-T.+Taiauthor=S.+Phippsauthor=C.+M.+Kieferauthor=M.+C.+Rebelattoauthor=N.+Dimasiauthor=A.+Moriartyauthor=K.+P.+Papadopoulosauthor=S.+Sridharauthor=S.+J.+Gregsonauthor=M.+J.+Wickauthor=L.+Mastersonauthor=K.+C.+Andersonauthor=R.+Herbstauthor=P.+W.+Howardauthor=D.+A.+Tice&title=SLC46A3+as+a+potential+predictive+biomarker+for+antibody-drug+conjugates+bearing+noncleavable+linked+maytansinoid+and+pyrrolobenzodiazepine+warheads&doi=10.1158%2F1078-0432.CCR-18-1300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48aR"><div class="casContent"><span class="casTitleNuber">48a</span><div class="casTitle"><span class="NLM_cas:atitle">SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span></div><div class="casAuthors">Kinneer, Krista; Meekin, John; Tiberghien, Arnaud C.; Tai, Yu-Tzu; Phipps, Sandrina; Kiefer, Christine Mione; Rebelatto, Marlon C.; Dimasi, Nazzareno; Moriarty, Alyssa; Papadopoulos, Kyriakos P.; Sridhar, Sriram; Gregson, Stephen J.; Wick, Michael J.; Masterson, Luke; Anderson, Kenneth C.; Herbst, Ronald; Howard, Philip W.; Tice, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6570-6582</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Antibody-drug conjugates (ADC) utilizing noncleavable linker drugs have been approved for clin. use, and several are in development targeting solid and hematol. malignancies including multiple myeloma.  Currently, there are no reliable biomarkers of activity for these ADCs other than presence of the targeted antigen.  We obsd. that certain cell lines are innately resistant to such ADCs, and sought to uncover the underlying mechanism of resistance.  Exptl. Design: The expression of 43 lysosomal membrane target genes was evaluated in cell lines resistant to ADCs bearing the noncleavable linker, pyrrolobenzodiazepine payload SG3376, in vitro.  The functional relevance of SLC46A3, a lysosomal transporter of noncleavable ADC catabolites whose expression uniquely correlated with SG3376 resistance, was assessed using EPHA2-, HER2-, and BCMA-targeted ADCs and isogenic cells overexpressing or genetically inactivated for SLC46A3.  SLC46A3 expression was also examd. in patient-derived xenograft and in vitro models of acquired T-DM1 resistance and multiple myeloma bone marrow samples by RT-PCR.  Results: Loss of SLC46A3 expression was found to be a mechanism of innate and acquired resistance to ADCs bearing DM1 and SG3376.  Sensitivity was restored in refractory lines upon introduction of SLC46A3, suggesting that expression of SLC46A3 may be more predictive of activity than target antigen levels alone.  Interrogation of primary multiple myeloma samples indicated a range of SLC46A3 expression, including samples with undetectable levels like multiple myeloma cell lines resistant to BCMA-targeting DM1 and SG3376 ADCs.  Conclusions: Our findings support SLC46A3 as a potential patient selection biomarker with immediate relevance to clin. trials involving these ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMBCbYdUVXbVg90H21EOLACvtfcHk0lh3MDk6PQNk4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI&md5=e3b5550bd7a96683d9f3ccac137eeb66</span></div><a href="/servlet/linkout?suffix=cit48a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1300%26sid%3Dliteratum%253Aachs%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DMeekin%26aufirst%3DJ.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DPhipps%26aufirst%3DS.%26aulast%3DKiefer%26aufirst%3DC.%2BM.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DDimasi%26aufirst%3DN.%26aulast%3DMoriarty%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DSridhar%26aufirst%3DS.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DWick%26aufirst%3DM.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DSLC46A3%2520as%2520a%2520potential%2520predictive%2520biomarker%2520for%2520antibody-drug%2520conjugates%2520bearing%2520noncleavable%2520linked%2520maytansinoid%2520and%2520pyrrolobenzodiazepine%2520warheads%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D6570%26epage%3D6582%26doi%3D10.1158%2F1078-0432.CCR-18-1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit48b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblett, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurgel, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tometsko, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borths, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bio, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quon, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanslow, W. C.</span></span> <span> </span><span class="NLM_article-title">SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">5329</span>– <span class="NLM_lpage">5340</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-1610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F0008-5472.CAN-15-1610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=26631267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWrt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=5329-5340&author=K.+J.+Hamblettauthor=A.+P.+Jacobauthor=J.+L.+Gurgelauthor=M.+E.+Tometskoauthor=B.+M.+Rockauthor=S.+K.+Patelauthor=R.+R.+Milburnauthor=S.+Siuauthor=S.+P.+Raganauthor=D.+A.+Rockauthor=C.+J.+Borthsauthor=J.+W.+O%E2%80%99Neillauthor=W.+S.+Changauthor=M.+F.+Weidnerauthor=M.+M.+Bioauthor=K.+C.+Quonauthor=W.+C.+Fanslow&title=SLC46A3+is+required+to+transport+catabolites+of+noncleavable+antibody+maytansine+conjugates+from+the+lysosome+to+the+cytoplasm&doi=10.1158%2F0008-5472.CAN-15-1610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48bR"><div class="casContent"><span class="casTitleNuber">48b</span><div class="casTitle"><span class="NLM_cas:atitle">SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm</span></div><div class="casAuthors">Hamblett, Kevin J.; Jacob, Allison P.; Gurgel, Jesse L.; Tometsko, Mark E.; Rock, Brooke M.; Patel, Sonal K.; Milburn, Robert R.; Siu, Sophia; Ragan, Seamus P.; Rock, Dan A.; Borths, Christopher J.; O'Neill, Jason W.; Chang, Wesley S.; Weidner, Margaret F.; Bio, Matthew M.; Quon, Kim C.; Fanslow, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5329-5340</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADC) target cytotoxic drugs to antigen-pos. cells for treating cancer.  After internalization, ADCs with noncleavable linkers are catabolized to amino acid-linker-warheads within the lysosome, which then enter the cytoplasm by an unknown mechanism.  We hypothesized that a lysosomal transporter was responsible for delivering noncleavable ADC catabolites into the cytoplasm.  To identify candidate transporters, we performed a phenotypic shRNA screen with an anti-CD70 maytansine-based ADC.  This screen revealed the lysosomal membrane protein SLC46A3, the genetic attenuation of which inhibited the potency of multiple noncleavable antibody-maytansine ADCs, including ado-trastuzumab emtansine.  In contrast, the potencies of noncleavable ADCs carrying the structurally distinct monomethyl auristatin F were unaffected by SLC46A3 attenuation.  Structure-activity expts. suggested that maytansine is a substrate for SLC46A3.  Notably, SLC46A3 silencing led to relative increases in catabolite concns. in the lysosome.  Taken together, our results establish SLC46A3 as a direct transporter of maytansine-based catabolites from the lysosome to the cytoplasm, prompting further investigation of SLC46A3 as a predictive response marker in breast cancer specimens.  Cancer Res; 75(24); 5329-40. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm_J2q_2qRbLVg90H21EOLACvtfcHk0lgGhBQI-yOp4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWrt7fN&md5=ba203524dd29addcf5295ee40cbc5e88</span></div><a href="/servlet/linkout?suffix=cit48b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-1610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-1610%26sid%3Dliteratum%253Aachs%26aulast%3DHamblett%26aufirst%3DK.%2BJ.%26aulast%3DJacob%26aufirst%3DA.%2BP.%26aulast%3DGurgel%26aufirst%3DJ.%2BL.%26aulast%3DTometsko%26aufirst%3DM.%2BE.%26aulast%3DRock%26aufirst%3DB.%2BM.%26aulast%3DPatel%26aufirst%3DS.%2BK.%26aulast%3DMilburn%26aufirst%3DR.%2BR.%26aulast%3DSiu%26aufirst%3DS.%26aulast%3DRagan%26aufirst%3DS.%2BP.%26aulast%3DRock%26aufirst%3DD.%2BA.%26aulast%3DBorths%26aufirst%3DC.%2BJ.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DJ.%2BW.%26aulast%3DChang%26aufirst%3DW.%2BS.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DBio%26aufirst%3DM.%2BM.%26aulast%3DQuon%26aufirst%3DK.%2BC.%26aulast%3DFanslow%26aufirst%3DW.%2BC.%26atitle%3DSLC46A3%2520is%2520required%2520to%2520transport%2520catabolites%2520of%2520noncleavable%2520antibody%2520maytansine%2520conjugates%2520from%2520the%2520lysosome%2520to%2520the%2520cytoplasm%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D5329%26epage%3D5340%26doi%3D10.1158%2F0008-5472.CAN-15-1610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="note"><p class="first last">For one example where antibody-mediated delivery of a cell-impermeable payload improved biological outcomes relative to a permeable cargo, see:</p></div><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brandish, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonenko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancilla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayadat-Dilman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbaccio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garvin-Queen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gately, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hseih, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasnjuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manibusan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomazela, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielstorf, M.</span></span> <span> </span><span class="NLM_article-title">Development of anti-CD74 antibody-drug conjugates to target glucocorticoids to immune cells</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2357</span>– <span class="NLM_lpage">2369</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.8b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.8b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGlsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=2357-2369&author=P.+E.+Brandishauthor=A.+Palmieriauthor=S.+Antonenkoauthor=M.+Beaumontauthor=L.+Bensoauthor=M.+Cancillaauthor=M.+Chengauthor=L.+Fayadat-Dilmanauthor=G.+Fengauthor=I.+Figueroaauthor=J.+Firdosauthor=R.+Garbaccioauthor=L.+Garvin-Queenauthor=D.+Gatelyauthor=P.+Gedaauthor=C.+Hainesauthor=S.+C.+Hseihauthor=D.+Hodgesauthor=J.+Kernauthor=N.+Knudsenauthor=K.+Kwasnjukauthor=L.+Liangauthor=H.+Maauthor=A.+Manibusanauthor=P.+L.+Millerauthor=L.+Y.+Moyauthor=Y.+Quauthor=S.+Shahauthor=J.+S.+Shinauthor=P.+Stiversauthor=Y.+Sunauthor=D.+Tomazelaauthor=H.+C.+Wooauthor=D.+Zallerauthor=S.+Zhangauthor=Y.+Zhangauthor=M.+Zielstorf&title=Development+of+anti-CD74+antibody-drug+conjugates+to+target+glucocorticoids+to+immune+cells&doi=10.1021%2Facs.bioconjchem.8b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Development of anti-CD74 antibody-drug conjugates to target glucocorticoids to immune cells</span></div><div class="casAuthors">Brandish, Philip E.; Palmieri, Anthony; Antonenko, Svetlana; Beaumont, Maribel; Benso, Lia; Cancilla, Mark; Cheng, Mangeng; Fayadat-Dilman, Laurence; Feng, Guo; Figueroa, Isabel; Firdos, Juhi; Garbaccio, Robert; Garvin-Queen, Laura; Gately, Dennis; Geda, Prasanthi; Haines, Christopher; Hseih, SuChun; Hodges, Douglas; Kern, Jeffrey; Knudsen, Nickolas; Kwasnjuk, Kristen; Liang, Linda; Ma, Huiping; Manibusan, Anthony; Miller, Paul L.; Moy, Lily Y.; Qu, Yujie; Shah, Sanjiv; Shin, John S.; Stivers, Peter; Sun, Ying; Tomazela, Daniela; Woo, Hyun Chong; Zaller, Dennis; Zhang, Shuli; Zhang, Yiwei; Zielstorff, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2357-2369</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucocorticoids (GCs) are excellent anti-inflammatory drugs but are dose-limited by on-target toxicity.  We sought to solve this problem by delivering GCs to immune cells with antibody-drug conjugates (ADCs) using antibodies contg. site-specific incorporation of a non-natural amino acid, novel linker chem. for in vitro and in vivo stability, and existing and novel glucocorticoid receptor (GR) agonists as payloads.  We directed fluticasone propionate to human antigen-presenting immune cells to afford GR activation that was dependent on the targeted antigen.  However, mechanism of action studies pointed to accumulation of free payload in the tissue culture supernatant as the dominant driver of activity and indeed administration of the ADC to human CD74 transgenic mice failed to activate GR target genes in splenic B cells.  Suspecting dissipation of released payload, we designed an ADC bearing a novel GR agonist payload with reduced permeability which afforded cell-intrinsic activity in human B cells.  Our work shows that antibody-targeting offers significant potential for rescuing existing and new dose-limited drugs outside the field of oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL223IFiibVrVg90H21EOLACvtfcHk0ljDIr1oc5kvhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGlsb7P&md5=16f03a31902538a233676f30cc1c26c7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.8b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.8b00312%26sid%3Dliteratum%253Aachs%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DPalmieri%26aufirst%3DA.%26aulast%3DAntonenko%26aufirst%3DS.%26aulast%3DBeaumont%26aufirst%3DM.%26aulast%3DBenso%26aufirst%3DL.%26aulast%3DCancilla%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DFayadat-Dilman%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DFigueroa%26aufirst%3DI.%26aulast%3DFirdos%26aufirst%3DJ.%26aulast%3DGarbaccio%26aufirst%3DR.%26aulast%3DGarvin-Queen%26aufirst%3DL.%26aulast%3DGately%26aufirst%3DD.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DHaines%26aufirst%3DC.%26aulast%3DHseih%26aufirst%3DS.%2BC.%26aulast%3DHodges%26aufirst%3DD.%26aulast%3DKern%26aufirst%3DJ.%26aulast%3DKnudsen%26aufirst%3DN.%26aulast%3DKwasnjuk%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DManibusan%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DP.%2BL.%26aulast%3DMoy%26aufirst%3DL.%2BY.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DJ.%2BS.%26aulast%3DStivers%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DTomazela%26aufirst%3DD.%26aulast%3DWoo%26aufirst%3DH.%2BC.%26aulast%3DZaller%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZielstorf%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520anti-CD74%2520antibody-drug%2520conjugates%2520to%2520target%2520glucocorticoids%2520to%2520immune%2520cells%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D2357%26epage%3D2369%26doi%3D10.1021%2Facs.bioconjchem.8b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Costoplus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veale, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponte, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setiady, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaletskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartle, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span> <span> </span><span class="NLM_article-title">Peptide-cleavable self-immolative maytansinoid antibody-drug conjugates designed to provide improved bystander killing</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1399</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGgtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1393-1399&author=J.+A.+Costoplusauthor=K.+H.+Vealeauthor=Q.+Qiuauthor=J.+F.+Ponteauthor=L.+Lanieriauthor=Y.+Setiadyauthor=L.+Dongauthor=A.+Skaletskayaauthor=L.+M.+Bartleauthor=P.+Salomonauthor=R.+Wuauthor=E.+K.+Maloneyauthor=Y.+V.+Kovtunauthor=O.+Abauthor=K.+Laiauthor=R.+V.+J.+Chariauthor=W.+C.+Widdison&title=Peptide-cleavable+self-immolative+maytansinoid+antibody-drug+conjugates+designed+to+provide+improved+bystander+killing&doi=10.1021%2Facsmedchemlett.9b00310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50aR"><div class="casContent"><span class="casTitleNuber">50a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing</span></div><div class="casAuthors">Costoplus, Juliet A.; Veale, Karen H.; Qiu, Qifeng; Ponte, Jose F.; Lanieri, Leanne; Setiady, Yulius; Dong, Ling; Skaletskaya, Anna; Bartle, Laura M.; Salomon, Paulin; Wu, Rui; Maloney, Erin K.; Kovtun, Yelena V.; Ab, Olga; Lai, Kate; Chari, Ravi V. J.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1393-1399</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new type of antibody-drug conjugate (ADC) has been prepd. that contains a sulfur-bearing maytansinoid attached to an antibody via a highly stable tripeptide linker.  Once internalized by cells, proteases in catabolic vesicles cleave the peptide of the ADC's linker causing self-immolation that releases a thiol-bearing metabolite, which is then S-methylated.  Conjugates were prepd. with peptide linkers contg. only alanyl residues, which were all L isomers or had a single D residue in one of the three positions.  A D-alanyl residue in the linker did not significantly impair a conjugate's cytotoxicity or bystander killing unless it was directly attached to the immolative moiety.  Increasing the no. of methylene units in the maytansinoid side chain of a conjugate did not typically affect an ADC's cytotoxicity to targeted cells but did increase bystander killing activity.  ADCs with the highest in vitro bystander killing were then evaluated in vivo in mice, where they displayed improved efficacy compared to previously described types of maytansinoid conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVorbrpE2efbVg90H21EOLACvtfcHk0ljDIr1oc5kvhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGgtLzI&md5=5bbc21126af25e33a52971fbeef6be32</span></div><a href="/servlet/linkout?suffix=cit50a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00310%26sid%3Dliteratum%253Aachs%26aulast%3DCostoplus%26aufirst%3DJ.%2BA.%26aulast%3DVeale%26aufirst%3DK.%2BH.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DPonte%26aufirst%3DJ.%2BF.%26aulast%3DLanieri%26aufirst%3DL.%26aulast%3DSetiady%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DSkaletskaya%26aufirst%3DA.%26aulast%3DBartle%26aufirst%3DL.%2BM.%26aulast%3DSalomon%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DPeptide-cleavable%2520self-immolative%2520maytansinoid%2520antibody-drug%2520conjugates%2520designed%2520to%2520provide%2520improved%2520bystander%2520killing%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1393%26epage%3D1399%26doi%3D10.1021%2Facsmedchemlett.9b00310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit50b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ogitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oitate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agatsuma, T.</span></span> <span> </span><span class="NLM_article-title">Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1111/cas.12966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1111%2Fcas.12966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=27166974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVahu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=1039-1046&author=Y.+Ogitaniauthor=K.+Hagiharaauthor=M.+Oitateauthor=H.+Naitoauthor=T.+Agatsuma&title=Bystander+killing+effect+of+DS-8201a%2C+a+novel+anti-human+epidermal+growth+factor+receptor+2+antibody-drug+conjugate%2C+in+tumors+with+human+epidermal+growth+factor+receptor+2+heterogeneity&doi=10.1111%2Fcas.12966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50bR"><div class="casContent"><span class="casTitleNuber">50b</span><div class="casTitle"><span class="NLM_cas:atitle">Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity</span></div><div class="casAuthors">Ogitani, Yusuke; Hagihara, Katsunobu; Oitate, Masataka; Naito, Hiroyuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1039-1046</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window.  DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepd. using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan deriv. (DX-8951 deriv., DXd).  It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression.  In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1.  We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability.  Under a coculture condition of HER2-pos. KPL-4 cells and neg. MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not.  In vivo evaluation was carried out using mice inoculated with a mixt. of HER2-pos. NCI-N87 cells and HER2-neg. MDA-MB-468-Luc cells by using an in vivo imaging system.  In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not.  Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is obsd. only in cells neighboring HER2-pos. cells, indicating low concern in terms of systemic toxicity.  These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroroEcCVHueLVg90H21EOLACvtfcHk0lhtA9ErLkokVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVahu7zO&md5=1e65fee32e1333a1c446aff844a7c67d</span></div><a href="/servlet/linkout?suffix=cit50b&amp;dbid=16384&amp;doi=10.1111%2Fcas.12966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12966%26sid%3Dliteratum%253Aachs%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DOitate%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DAgatsuma%26aufirst%3DT.%26atitle%3DBystander%2520killing%2520effect%2520of%2520DS-8201a%252C%2520a%2520novel%2520anti-human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520antibody-drug%2520conjugate%252C%2520in%2520tumors%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520heterogeneity%26jtitle%3DCancer%2520Sci.%26date%3D2016%26volume%3D107%26spage%3D1039%26epage%3D1046%26doi%3D10.1111%2Fcas.12966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit50c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerton, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholas, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, C.-L.</span></span> <span> </span><span class="NLM_article-title">Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2710</span>– <span class="NLM_lpage">2719</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-1795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F0008-5472.CAN-15-1795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=26921341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVers74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2710-2719&author=F.+Liauthor=K.+K.+Emmertonauthor=M.+Jonasauthor=X.+Zhangauthor=J.+B.+Miyamotoauthor=J.+R.+Setterauthor=N.+D.+Nicholasauthor=N.+M.+Okeleyauthor=R.+P.+Lyonauthor=D.+R.+Benjaminauthor=C.-L.+Law&title=Intracellular+released+payload+influences+potency+and+bystander-killing+effects+of+antibody-drug+conjugates+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-15-1795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50cR"><div class="casContent"><span class="casTitleNuber">50c</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models</span></div><div class="casAuthors">Li, Fu; Emmerton, Kim K.; Jonas, Mechthild; Zhang, Xinqun; Miyamoto, Jamie B.; Setter, Jocelyn R.; Nicholas, Nicole D.; Okeley, Nicole M.; Lyon, Robert P.; Benjamin, Dennis R.; Law, Che-Leung</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2710-2719</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-mol. payloads.  ADCs demonstrate specific cell killing in clinic, but the basis of their antitumor activity is not fully understood.  In this study, we investigated the degree to which payload release predicts ADC activity in vitro and in vivo.  ADCs were generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and we found that the intracellular concn. of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios.  Intratumoral MMAE concns. consistently correlated with the extent of tumor growth inhibition in tumor xenograft models.  In addn., we developed a robust admixed tumor model consisting of CD30+ and CD30- cancer cells to study how heterogeneity of target antigen expression, a phenomenon often obsd. in cancer specimens, affects the treatment response.  CD30-targeting ADC delivering membrane permeable MMAE or pyrrolobenzodiazepine dimers demonstrated potent bystander killing of neighboring CD30- cells.  In contrast, a less membrane permeable payload, MMAF, failed to mediate bystander killing in vivo, suggesting local diffusion and distribution of released payloads represents a potential mechanism of ADC-mediated bystander killing.  Collectively, our findings establish that the biophys. properties and amt. of released payloads are chief factors detg. the overall ADC potency and bystander killing.  Cancer Res; 76(9); 2710-9. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoylCMD1xAFdLVg90H21EOLACvtfcHk0lhtA9ErLkokVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVers74%253D&md5=bb7e7c2e6b4ea6f92d522d6c086454d2</span></div><a href="/servlet/linkout?suffix=cit50c&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-1795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-1795%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DEmmerton%26aufirst%3DK.%2BK.%26aulast%3DJonas%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DSetter%26aufirst%3DJ.%2BR.%26aulast%3DNicholas%26aufirst%3DN.%2BD.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DLaw%26aufirst%3DC.-L.%26atitle%3DIntracellular%2520released%2520payload%2520influences%2520potency%2520and%2520bystander-killing%2520effects%2520of%2520antibody-drug%2520conjugates%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2710%26epage%3D2719%26doi%3D10.1158%2F0008-5472.CAN-15-1795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">131</span> <span class="refDoi"> DOI: 10.1038/s41467-018-08027-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41467-018-08027-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30631068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A280%3ADC%252BB3cjgt1Sksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=B.+E.+Smithauthor=S.+L.+Wangauthor=S.+Jaime-Figueroaauthor=A.+Harbinauthor=J.+Wangauthor=B.+D.+Hammanauthor=C.+M.+Crews&title=Differential+PROTAC+substrate+specificity+dictated+by+orientation+of+recruited+E3+ligase&doi=10.1038%2Fs41467-018-08027-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51aR"><div class="casContent"><span class="casTitleNuber">51a</span><div class="casTitle"><span class="NLM_cas:atitle">Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase</span></div><div class="casAuthors">Smith Blake E; Wang Stephen L; Jaime-Figueroa Saul; Crews Craig M; Harbin Alicia; Wang Jing; Hamman Brian D; Crews Craig M; Crews Craig M</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation.  Many potent PROTACs with specificity for dissimilar targets have been developed; however, the factors governing degradation selectivity within closely-related protein families remain elusive.  Here, we generate isoform-selective PROTACs for the p38 MAPK family using a single warhead (foretinib) and recruited E3 ligase (von Hippel-Lindau).  Based on their distinct linker attachments and lengths, these two PROTACs differentially recruit VHL, resulting in degradation of p38α or p38δ.  We characterize the role of ternary complex formation in driving selectivity, showing that it is necessary, but insufficient, for PROTAC-induced substrate ubiquitination.  Lastly, we explore the p38δ:PROTAC:VHL complex to explain the different selectivity profiles of these PROTACs.  Our work attributes the selective degradation of two closely-related proteins using the same warhead and E3 ligase to heretofore underappreciated aspects of the ternary complex model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYPr3dBOGbeuR_TJajKxJDfW6udTcc2eb_ci14tyxWV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjgt1Sksg%253D%253D&md5=bd56c51f5966709ca5d1ff3dadb7cc79</span></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08027-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08027-7%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DWang%26aufirst%3DS.%2BL.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DHarbin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DDifferential%2520PROTAC%2520substrate%2520specificity%2520dictated%2520by%2520orientation%2520of%2520recruited%2520E3%2520ligase%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26doi%3D10.1038%2Fs41467-018-08027-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit51b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Farnaby, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karolyi-Oezguer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedmueller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmaschitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dank, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumpel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petermann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstabl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss-Puxbaum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrenhöfer-Wölfer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wöhrle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehmelt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinnenthal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnhof, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiechens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen-Hughes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">672</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0294-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1038%2Fs41589-019-0294-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=31178587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFeqtLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=672-680&author=W.+Farnabyauthor=M.+Koeglauthor=M.+J.+Royauthor=C.+Whitworthauthor=E.+Diersauthor=N.+Trainorauthor=D.+Zollmanauthor=S.+Steurerauthor=J.+Karolyi-Oezguerauthor=C.+Riedmuellerauthor=T.+Gmaschitzauthor=J.+Wachterauthor=C.+Dankauthor=M.+Galantauthor=B.+Sharpsauthor=K.+Rumpelauthor=E.+Traxlerauthor=T.+Gerstbergerauthor=R.+Schnitzerauthor=O.+Petermannauthor=P.+Grebauthor=H.+Weinstablauthor=G.+Baderauthor=A.+Zoephelauthor=A.+Weiss-Puxbaumauthor=K.+Ehrenh%C3%B6fer-W%C3%B6lferauthor=S.+W%C3%B6hrleauthor=G.+Boehmeltauthor=J.+Rinnenthalauthor=H.+Arnhofauthor=N.+Wiechensauthor=M.-Y.+Wuauthor=T.+Owen-Hughesauthor=P.+Ettmayerauthor=M.+Pearsonauthor=D.+B.+McConnellauthor=A.+Ciulli&title=BAF+complex+vulnerabilities+in+cancer+demonstrated+via+structure-based+PROTAC+design&doi=10.1038%2Fs41589-019-0294-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51bR"><div class="casContent"><span class="casTitleNuber">51b</span><div class="casTitle"><span class="NLM_cas:atitle">BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design</span></div><div class="casAuthors">Farnaby, William; Koegl, Manfred; Roy, Michael J.; Whitworth, Claire; Diers, Emelyne; Trainor, Nicole; Zollman, David; Steurer, Steffen; Karolyi-Oezguer, Jale; Riedmueller, Carina; Gmaschitz, Teresa; Wachter, Johannes; Dank, Christian; Galant, Michael; Sharps, Bernadette; Rumpel, Klaus; Traxler, Elisabeth; Gerstberger, Thomas; Schnitzer, Renate; Petermann, Oliver; Greb, Peter; Weinstabl, Harald; Bader, Gerd; Zoephel, Andreas; Weiss-Puxbaum, Alexander; Ehrenhofer-Wolfer, Katharina; Wohrle, Simon; Boehmelt, Guido; Rinnenthal, Joerg; Arnhof, Heribert; Wiechens, Nicola; Wu, Meng-Ying; Owen-Hughes, Tom; Ettmayer, Peter; Pearson, Mark; McConnell, Darryl B.; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">672-680</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Targeting subunits of BAF/PBAF chromatin remodeling complexes has been proposed as an approach to exploit cancer vulnerabilities.  Here, we develop proteolysis targeting chimera (PROTAC) degraders of the BAF ATPase subunits SMARCA2 and SMARCA4 using a bromodomain ligand and recruitment of the E3 ubiquitin ligase VHL.  High-resoln. ternary complex crystal structures and biophys. investigation guided rational and efficient optimization toward ACBI1(I), a potent and cooperative degrader of SMARCA2, SMARCA4 and PBRM1.  I induced anti-proliferative effects and cell death caused by SMARCA2 depletion in SMARCA4 mutant cancer cells, and in acute myeloid leukemia cells dependent on SMARCA4 ATPase activity.  These findings exemplify a successful biophysics- and structure-based PROTAC design approach to degrade high profile drug targets, and pave the way toward new therapeutics for the treatment of tumors sensitive to the loss of BAF complex ATPases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonEh4pux4Bs7Vg90H21EOLACvtfcHk0ljcWRv4_kxyow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFeqtLfJ&md5=e95fad12c727aedcf08aed9320dae905</span></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0294-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0294-6%26sid%3Dliteratum%253Aachs%26aulast%3DFarnaby%26aufirst%3DW.%26aulast%3DKoegl%26aufirst%3DM.%26aulast%3DRoy%26aufirst%3DM.%2BJ.%26aulast%3DWhitworth%26aufirst%3DC.%26aulast%3DDiers%26aufirst%3DE.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DZollman%26aufirst%3DD.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DKarolyi-Oezguer%26aufirst%3DJ.%26aulast%3DRiedmueller%26aufirst%3DC.%26aulast%3DGmaschitz%26aufirst%3DT.%26aulast%3DWachter%26aufirst%3DJ.%26aulast%3DDank%26aufirst%3DC.%26aulast%3DGalant%26aufirst%3DM.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DRumpel%26aufirst%3DK.%26aulast%3DTraxler%26aufirst%3DE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DPetermann%26aufirst%3DO.%26aulast%3DGreb%26aufirst%3DP.%26aulast%3DWeinstabl%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DWeiss-Puxbaum%26aufirst%3DA.%26aulast%3DEhrenh%25C3%25B6fer-W%25C3%25B6lfer%26aufirst%3DK.%26aulast%3DW%25C3%25B6hrle%26aufirst%3DS.%26aulast%3DBoehmelt%26aufirst%3DG.%26aulast%3DRinnenthal%26aufirst%3DJ.%26aulast%3DArnhof%26aufirst%3DH.%26aulast%3DWiechens%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DM.-Y.%26aulast%3DOwen-Hughes%26aufirst%3DT.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DBAF%2520complex%2520vulnerabilities%2520in%2520cancer%2520demonstrated%2520via%2520structure-based%2520PROTAC%2520design%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D672%26epage%3D680%26doi%3D10.1038%2Fs41589-019-0294-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit51c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span>; <span class="NLM_string-name">Crew, A.</span>; <span class="NLM_string-name">Dong, H.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Siu, K.</span>; <span class="NLM_string-name">Ferraro, C.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Qian, Y.</span></span> <span> </span><span class="NLM_article-title">Compounds and Methods for the Targeted Degradation of the Androgen Receptor</span>. <span class="NLM_patent">WO2016118666</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Jin&author=A.+Crew&author=H.+Dong&author=J.+Wang&author=K.+Siu&author=C.+Ferraro&author=X.+Chen&author=Y.+Qian&title=Compounds+and+Methods+for+the+Targeted+Degradation+of+the+Androgen+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%26atitle%3DCompounds%2520and%2520Methods%2520for%2520the%2520Targeted%2520Degradation%2520of%2520the%2520Androgen%2520Receptor%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Endo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumichika, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunitomo
Adachi, K.</span></span> <span> </span><span class="NLM_article-title">A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1365</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.01.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.bmcl.2016.01.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=26869194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVahsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1365-1370&author=J.+Endoauthor=H.+Hikawaauthor=M.+Hamadaauthor=S.+Ishibuchiauthor=N.+Fujieauthor=N.+Sugiyamaauthor=M.+Tanakaauthor=H.+Kobayashiauthor=K.+Sugaharaauthor=K.+Oshitaauthor=K.+Iwataauthor=S.+Ooikeauthor=M.+Murataauthor=H.+Sumichikaauthor=K.+Chibaauthor=K.+Kunitomo%0AAdachi&title=A+phenotypic+drug+discovery+study+on+thienodiazepine+derivatives+as+inhibitors+of+T+cell+proliferation+induced+by+CD28+co-stimulation+leads+to+the+discovery+of+a+first+bromodomain+inhibitor&doi=10.1016%2Fj.bmcl.2016.01.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor</span></div><div class="casAuthors">Endo, Junichi; Hikawa, Hidemasa; Hamada, Maiko; Ishibuchi, Seigo; Fujie, Naoto; Sugiyama, Naoki; Tanaka, Minoru; Kobayashi, Haruhito; Sugahara, Kunio; Oshita, Koichi; Iwata, Kazunori; Ooike, Shinsuke; Murata, Meguru; Sumichika, Hiroshi; Chiba, Kenji; Adachi, Kunitomo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1365-1370</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A phenotypic screening of thienodiazepines derived from a hit compd. found through a binding assay targeting co-stimulatory mols. on T cells and antigen presenting cells successfully led to the discovery of a thienotriazolodiazepine compd. (7f) possessing potent immunosuppressive activity.  A chem. biol. approach has succeeded in revealing that 7f is a first inhibitor of epigenetic bromodomain-contg. proteins. 7f is expected to become an anti-cancer agent as well as an immunosuppressive agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeajoPFavBUbVg90H21EOLACvtfcHk0ljcWRv4_kxyow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVahsL8%253D&md5=e414d4c7fad718d7b2c5a76a20aed0d7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.01.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.01.084%26sid%3Dliteratum%253Aachs%26aulast%3DEndo%26aufirst%3DJ.%26aulast%3DHikawa%26aufirst%3DH.%26aulast%3DHamada%26aufirst%3DM.%26aulast%3DIshibuchi%26aufirst%3DS.%26aulast%3DFujie%26aufirst%3DN.%26aulast%3DSugiyama%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DSugahara%26aufirst%3DK.%26aulast%3DOshita%26aufirst%3DK.%26aulast%3DIwata%26aufirst%3DK.%26aulast%3DOoike%26aufirst%3DS.%26aulast%3DMurata%26aufirst%3DM.%26aulast%3DSumichika%26aufirst%3DH.%26aulast%3DChiba%26aufirst%3DK.%26aulast%3DKunitomo%2BAdachi%26aufirst%3DK.%26atitle%3DA%2520phenotypic%2520drug%2520discovery%2520study%2520on%2520thienodiazepine%2520derivatives%2520as%2520inhibitors%2520of%2520T%2520cell%2520proliferation%2520induced%2520by%2520CD28%2520co-stimulation%2520leads%2520to%2520the%2520discovery%2520of%2520a%2520first%2520bromodomain%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1365%26epage%3D1370%26doi%3D10.1016%2Fj.bmcl.2016.01.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Rapid measurement of intracellular unbound drug concentrations</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2467</span>– <span class="NLM_lpage">2478</span>, <span class="refDoi"> DOI: 10.1021/mp4000822</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp4000822" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVShs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=2467-2478&author=A.+Mateusauthor=P.+Matssonauthor=P.+Artursson&title=Rapid+measurement+of+intracellular+unbound+drug+concentrations&doi=10.1021%2Fmp4000822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Measurement of Intracellular Unbound Drug Concentrations</span></div><div class="casAuthors">Mateus, Andre; Matsson, Paer; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2467-2478</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Intracellular unbound drug concns. det. affinity to targets in the cell interior.  However, due to difficulties in measuring them, they are often overlooked in pharmacol.  Here we present a simple exptl. technique for the detn. of unbound intracellular drug concns. in cultured cells that is based on parallel measurements of cellular drug binding and steady-state intracellular drug concns.  Binding in HEK293 cells was highly correlated with binding in liver-derived systems, whereas binding in plasma did not compare well with cellular binding.  Compd. lipophilicity increased drug binding, while neg. charge and arom. functional groups decreased binding.  Intracellular accumulation of unbound drug was consistent with pH-dependent subcellular sequestration, as confirmed by modeling and by inhibition of subcellular pH gradients.  The approach developed here can be used to measure intracellular unbound drug concns. in more complex systems, for example, cell lines with controlled expression of transporters and enzymes or primary cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAI-LcAqDSybVg90H21EOLACvtfcHk0lgIWFUV1wO32A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVShs70%253D&md5=de56aeff7c7ae6149eae187298d371a8</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fmp4000822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp4000822%26sid%3Dliteratum%253Aachs%26aulast%3DMateus%26aufirst%3DA.%26aulast%3DMatsson%26aufirst%3DP.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DRapid%2520measurement%2520of%2520intracellular%2520unbound%2520drug%2520concentrations%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D2467%26epage%3D2478%26doi%3D10.1021%2Fmp4000822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caculitan, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dela Cruz Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akita, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B Is dispensable for cellular processing of cathepsin B-cleavable antibody-drug conjugates</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">7027</span>– <span class="NLM_lpage">7037</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-2391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1158%2F0008-5472.CAN-17-2391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=29046337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=7027-7037&author=N.+G.+Caculitanauthor=J.+dela+Cruz+Chuhauthor=Y.+Maauthor=D.+Zhangauthor=K.+R.+Kozakauthor=Y.+Liuauthor=T.+H.+Pillowauthor=J.+Sadowskyauthor=T.+K.+Cheungauthor=Q.+Phungauthor=B.+Haleyauthor=B.-C.+Leeauthor=R.+W.+Akitaauthor=M.+X.+Sliwkowskiauthor=A.+G.+Polson&title=Cathepsin+B+Is+dispensable+for+cellular+processing+of+cathepsin+B-cleavable+antibody-drug+conjugates&doi=10.1158%2F0008-5472.CAN-17-2391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates</span></div><div class="casAuthors">Caculitan, Nina G.; dela Cruz Chuh, Josefa; Ma, Yong; Zhang, Donglu; Kozak, Katherine R.; Liu, Yichin; Pillow, Thomas H.; Sadowsky, Jack; Cheung, Tommy K.; Phung, Qui; Haley, Benjamin; Lee, Byoung-Chul; Akita, Robert W.; Sliwkowski, Mark X.; Polson, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7027-7037</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADC) are designed to selectively bind to tumor antigens via the antibody and release their cytotoxic payload upon internalization.  Controllable payload release through judicious design of the linker has been an early technol. milestone.  Here, we examine the effect of the protease-cleavable valine-citrulline [VC(S)] linker on ADC efficacy.  The VC(S) linker was designed to be cleaved by cathepsin B, a lysosomal cysteine protease.  Surprisingly, suppression of cathepsin B expression via CRISPR-Cas9 gene deletion or shRNA knockdown had no effect on the efficacy of ADCs with VC(S) linkers armed with a monomethyl auristatin E (MMAE) payload.  Mass spectrometry studies of payload release suggested that other cysteine cathepsins can cleave the VC(S) linker.  Also, ADCs with a nonprotease-cleavable enantiomer, the VC(R) isomer, mediated effective cell killing with a cysteine-VC(R)-MMAE catabolite generated by lysosomal catabolism.  Based on these observations, we altered the payload to a pyrrolo[2,1-c][1,4]benzodiazepine dimer (PBD) conjugate that requires linker cleavage in order to bind its DNA target.  Unlike the VC-MMAE ADCs, the VC(S)-PBD ADC is at least 20-fold more cytotoxic than the VC(R)-PBD ADC.  Our findings reveal that the VC(S) linker has multiple paths to produce active catabolites and that antibody and intracellular targets are more crit. to ADC efficacy.  These results suggest that protease-cleavable linkers are unlikely to increase the therapeutic index of ADCs and that resistance based on linker processing is improbable.  Cancer Res; 77(24); 7027-37. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR45ou6LPL1bVg90H21EOLACvtfcHk0lgIWFUV1wO32A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur%252FO&md5=dd6c5c61ec81fef214b9d19d83e8e22c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-2391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-2391%26sid%3Dliteratum%253Aachs%26aulast%3DCaculitan%26aufirst%3DN.%2BG.%26aulast%3Ddela%2BCruz%2BChuh%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DT.%2BK.%26aulast%3DPhung%26aufirst%3DQ.%26aulast%3DHaley%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DB.-C.%26aulast%3DAkita%26aufirst%3DR.%2BW.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26atitle%3DCathepsin%2520B%2520Is%2520dispensable%2520for%2520cellular%2520processing%2520of%2520cathepsin%2520B-cleavable%2520antibody-drug%2520conjugates%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D7027%26epage%3D7037%26doi%3D10.1158%2F0008-5472.CAN-17-2391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masih, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latifi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dere, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco-Triguero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuillemenot, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laing, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia</span>. <i>mAbs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1312</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1080/19420862.2018.1517565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1080%2F19420862.2018.1517565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=30183491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGjtLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1312-1321&author=D.+D.+Leipoldauthor=I.+Figueroaauthor=S.+Masihauthor=B.+Latifiauthor=V.+Yipauthor=B.-Q.+Shenauthor=R.+C.+Dereauthor=M.+Carrasco-Trigueroauthor=M.+V.+Leeauthor=O.+M.+Saadauthor=L.+Liuauthor=J.+Heauthor=D.+Suauthor=K.+Xuauthor=B.+R.+Vuillemenotauthor=S.+T.+Laingauthor=M.+Schuttenauthor=K.+R.+Kozakauthor=B.+Zhengauthor=A.+G.+Polsonauthor=A.+V.+Kamath&title=Preclinical+pharmacokinetics+and+pharmacodynamics+of+DCLL9718A%3A+An+antibody-drug+conjugate+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1080%2F19420862.2018.1517565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Leipold, Douglas D.; Figueroa, Isabel; Masih, Shabkhaiz; Latifi, Brandon; Yip, Victor; Shen, Ben-Quan; Dere, Randall C.; Carrasco-Triguero, Montserrat; Lee, M. Violet; Saad, Ola M.; Liu, Luna; He, Jintang; Su, Dian; Xu, Keyang; Vuillemenot, Brian R.; Laing, Steven T.; Schutten, Melissa; Kozak, Katherine R.; Zheng, Bing; Polson, Andrew G.; Kamath, Amrita V.</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1312-1321</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Few treatment options are available for acute myeloid leukemia (AML) patients.  DCLL9718A is an antibody-drug conjugate that targets C-type lectin-like mol.-1 (CLL-1).  Here, we characterize the in vitro and in vivo stability, the pharmacokinetics (PK) and pharmacodynamics (PD) of DCLL9718A and MCLL0517A in rodents and cynomolgus monkeys.  Three key PK analytes were measured in these studies: total antibody, antibody-conjugated PBD dimer and unconjugated PBD dimer.  In vitro, DCLL9718A, was stable with most (> 80%) of the PBD dimer payload remaining conjugated to the antibody over 96 h.  This was recapitulated in vivo with antibody-conjugated PBD dimer clearance ests. similar to DCLL9718A total antibody clearance.  Both DCLL9718A and MCLL0517A showed linear PK in the non-binding rodent species, and non-linear PK in cynomolgus monkeys, a binding species.  The PK data indicated minimal impact of conjugation on the disposition of DCLL9718A total antibody.  Finally, in cynomolgus monkey, MCLL0517A showed target engagement at all doses tested (0.5 and 20 mg/kg) as measured by receptor occupancy, and DCLL9718A (at doses of 0.05, 0.1 and 0.2 mg/kg) showed strong PD activity as evidenced by notable redn. in monocytes and neutrophils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsFXdb4ZZBT7Vg90H21EOLACvtfcHk0lilSYYpLTfzmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGjtLjN&md5=d1370e943ab7a89e07a60f56b624785b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1080%2F19420862.2018.1517565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2018.1517565%26sid%3Dliteratum%253Aachs%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DFigueroa%26aufirst%3DI.%26aulast%3DMasih%26aufirst%3DS.%26aulast%3DLatifi%26aufirst%3DB.%26aulast%3DYip%26aufirst%3DV.%26aulast%3DShen%26aufirst%3DB.-Q.%26aulast%3DDere%26aufirst%3DR.%2BC.%26aulast%3DCarrasco-Triguero%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DM.%2BV.%26aulast%3DSaad%26aufirst%3DO.%2BM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DVuillemenot%26aufirst%3DB.%2BR.%26aulast%3DLaing%26aufirst%3DS.%2BT.%26aulast%3DSchutten%26aufirst%3DM.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520DCLL9718A%253A%2520An%2520antibody-drug%2520conjugate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DmAbs%26date%3D2018%26volume%3D10%26spage%3D1312%26epage%3D1321%26doi%3D10.1080%2F19420862.2018.1517565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delproposto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01631</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01631" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=941-964&author=X.+Hanauthor=C.+Wangauthor=C.+Qinauthor=W.+Xiangauthor=E.+Fernandez-Salasauthor=C.-Y.+Yangauthor=M.+Wangauthor=L.+Zhaoauthor=T.+Xuauthor=K.+Chinnaswamyauthor=J.+Delpropostoauthor=J.+Stuckeyauthor=S.+Wang&title=Discovery+of+ARD-69+as+a+highly+potent+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+androgen+receptor+%28AR%29+for+the+treatment+of+prostate+cancer&doi=10.1021%2Facs.jmedchem.8b01631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56aR"><div class="casContent"><span class="casTitleNuber">56a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span></div><div class="casAuthors">Han, Xin; Wang, Chao; Qin, Chong; Xiang, Weiguo; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Mi; Zhao, Lijie; Xu, Tianfeng; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">941-964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by IARD-69.  I induces degrdn. of AR protein in AR-pos. prostate cancer cell lines in a dose- and time-dependent manner.  I achieves DC50 values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, resp.  I is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.  I potently inhibits cell growth in these AR-pos. prostate cancer cell lines and is >100 times more potent than AR antagonists.  A single dose of I effectively reduces the level of AR protein in xenograft tumor tissue in mice.  Further optimization of I may ultimately lead to a new therapy for AR+, castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTlOD69tfhtbVg90H21EOLACvtfcHk0lhxIBBSAU7fsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D&md5=2376573fb1a1e19c517d64c70199700a</span></div><a href="/servlet/linkout?suffix=cit56a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01631%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DDelproposto%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520ARD-69%2520as%2520a%2520highly%2520potent%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520androgen%2520receptor%2520%2528AR%2529%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D941%26epage%3D964%26doi%3D10.1021%2Facs.jmedchem.8b01631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit56b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Galdeano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadd, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaffidi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Molle, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birced, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8657</span>– <span class="NLM_lpage">8663</span>, <span class="refDoi"> DOI: 10.1021/jm5011258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5011258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8657-8663&author=C.+Galdeanoauthor=M.+S.+Gaddauthor=P.+Soaresauthor=S.+Scaffidiauthor=I.+Van+Molleauthor=I.+Bircedauthor=S.+Hewittauthor=D.+M.+Diasauthor=A.+Ciulli&title=Structure-guided+design+and+optimization+of+small+molecules+targeting+the+protein-protein+interaction+between+the+von+Hippel-Lindau+%28VHL%29+E3+ubiquitin+ligase+and+the+hypoxia+inducible+factor+%28HIF%29+alpha+subunit+with+in+vitro+nanomolar+affinities&doi=10.1021%2Fjm5011258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56bR"><div class="casContent"><span class="casTitleNuber">56b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design and Optimization of Small Molecules Targeting the Protein-Protein Interaction between the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities</span></div><div class="casAuthors">Galdeano, Carles; Gadd, Morgan S.; Soares, Pedro; Scaffidi, Salvatore; Van Molle, Inge; Birced, Ipek; Hewitt, Sarah; Dias, David M.; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8657-8663</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">E3 ubiquitin ligases are attractive targets in the ubiquitin-proteasome system, however, the development of small-mol. ligands has been rewarded with limited success.  The von Hippel-Lindau protein (pVHL) is the substrate recognition subunit of the VHL E3 ligase that targets HIF-1α for degrdn.  The authors recently reported inhibitors of the pVHL:HIF-1α interaction, however they exhibited moderate potency.  Herein, the authors report the design and optimization, guided by x-ray crystal structures, of a ligand series with nanomolar binding affinities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpixK3qp1ctJrVg90H21EOLACvtfcHk0lhCUrdNlKEb6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtb%252FP&md5=831aa2387d94cb03d735a4be7bdd2cdd</span></div><a href="/servlet/linkout?suffix=cit56b&amp;dbid=16384&amp;doi=10.1021%2Fjm5011258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5011258%26sid%3Dliteratum%253Aachs%26aulast%3DGaldeano%26aufirst%3DC.%26aulast%3DGadd%26aufirst%3DM.%2BS.%26aulast%3DSoares%26aufirst%3DP.%26aulast%3DScaffidi%26aufirst%3DS.%26aulast%3DVan%2BMolle%26aufirst%3DI.%26aulast%3DBirced%26aufirst%3DI.%26aulast%3DHewitt%26aufirst%3DS.%26aulast%3DDias%26aufirst%3DD.%2BM.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DStructure-guided%2520design%2520and%2520optimization%2520of%2520small%2520molecules%2520targeting%2520the%2520protein-protein%2520interaction%2520between%2520the%2520von%2520Hippel-Lindau%2520%2528VHL%2529%2520E3%2520ubiquitin%2520ligase%2520and%2520the%2520hypoxia%2520inducible%2520factor%2520%2528HIF%2529%2520alpha%2520subunit%2520with%2520in%2520vitro%2520nanomolar%2520affinities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8657%26epage%3D8663%26doi%3D10.1021%2Fjm5011258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J.</span>; <span class="NLM_string-name">Gunzner-Toste, J.</span>; <span class="NLM_string-name">Pillow, T.</span>; <span class="NLM_string-name">Safina, B.</span>; <span class="NLM_string-name">Verma, V.</span>; <span class="NLM_string-name">Wei, B.</span>; <span class="NLM_string-name">Zhao, G.</span>; <span class="NLM_string-name">Staben, L.</span></span> <span> </span><span class="NLM_article-title">Peptidomimetic Compounds and Antibody-conjugates Thereof</span>. <span class="NLM_patent">WO2015095223</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Flygare&author=J.+Gunzner-Toste&author=T.+Pillow&author=B.+Safina&author=V.+Verma&author=B.+Wei&author=G.+Zhao&author=L.+Staben&title=Peptidomimetic+Compounds+and+Antibody-conjugates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlygare%26aufirst%3DJ.%26atitle%3DPeptidomimetic%2520Compounds%2520and%2520Antibody-conjugates%2520Thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dela Cruz-Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donohue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas
Leipold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span> <span> </span><span class="NLM_article-title">Development of efficient chemistry to generate site-specific disulfide-linked protein and peptide-payload conjugates: Application to THIOMAB antibody-drug conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2098</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVaktLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2086-2098&author=J.+D.+Sadowskyauthor=T.+H.+Pillowauthor=J.+Chenauthor=F.+Fanauthor=C.+Heauthor=Y.+Wangauthor=G.+Yanauthor=H.+Yaoauthor=Z.+Xuauthor=S.+Martinauthor=D.+Zhangauthor=P.+Chuauthor=J.+dela+Cruz-Chuhauthor=A.+O%E2%80%99Donohueauthor=G.+Liauthor=G.+Del+Rosarioauthor=J.+Heauthor=L.+Liuauthor=C.+Ngauthor=D.+Suauthor=G.+D.+L.+Phillipsauthor=K.+R.+Kozakauthor=S.-F.+Yuauthor=K.+Xuauthor=D.+Douglas%0ALeipoldauthor=J.+Wai&title=Development+of+efficient+chemistry+to+generate+site-specific+disulfide-linked+protein+and+peptide-payload+conjugates%3A+Application+to+THIOMAB+antibody-drug+conjugates&doi=10.1021%2Facs.bioconjchem.7b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates</span></div><div class="casAuthors">Sadowsky, Jack D.; Pillow, Thomas H.; Chen, Jinhua; Fan, Fang; He, Changrong; Wang, Yanli; Yan, Gang; Yao, Hui; Xu, Zijin; Martin, Shanique; Zhang, Donglu; Chu, Phillip; dela Cruz-Chuh, Josefa; ODonohue, Aimee; Li, Guangmin; Del Rosario, Geoffrey; He, Jintang; Liu, Luna; Ng, Carl; Su, Dian; Lewis Phillips, Gail D.; Kozak, Katherine R.; Yu, Shang-Fan; Xu, Keyang; Leipold, Douglas; Wai, John</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2086-2098</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conjugation of small mol. payloads to specific cysteine residues on proteins via a disulfide bond represents an attractive strategy to generate redox-sensitive bioconjugates, which have value as potential diagnostic reagents or therapeutics.  Advancement of such "direct-disulfide" bioconjugates to the clinic necessitates chem. methods to form disulfide connections efficiently, without byproducts.  The disulfide connection must also be resistant to premature cleavage by thiols prior to arrival at the targeted tissue.  We show here that commonly-employed methods to generate direct disulfide-linked bioconjugates are inadequate for addressing these challenges.  We describe our efforts to optimize direct-disulfide conjugation chem., focusing on the generation of conjugates between cytotoxic payloads and cysteine-engineered antibodies (i.e., THIOMAB antibody-drug conjugates, or TDCs).  This work culminates in the development of novel, high-yielding conjugation chem. for creating direct payload disulfide connections to any of several Cys mutation sites in THIOMAB antibodies or to Cys sites in other biomols. (e.g., human serum albumin and cell-penetrating peptides).  We conclude by demonstrating that hindered direct disulfide TDCs with two Me groups adjacent to the disulfide, which have heretofore not been described for any bioconjugate, are more stable and more efficacious in mouse tumor xenograft studies than less hindered analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIap6CQnm0X7Vg90H21EOLACvtfcHk0lhCUrdNlKEb6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVaktLvL&md5=9c437d3e1aa16e51e3f571fea95785c4</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00258%26sid%3Dliteratum%253Aachs%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DG.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DP.%26aulast%3Ddela%2BCruz-Chuh%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Donohue%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DDouglas%2BLeipold%26aufirst%3DD.%26aulast%3DWai%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520efficient%2520chemistry%2520to%2520generate%2520site-specific%2520disulfide-linked%2520protein%2520and%2520peptide-payload%2520conjugates%253A%2520Application%2520to%2520THIOMAB%2520antibody-drug%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2017%26volume%3D28%26spage%3D2086%26epage%3D2098%26doi%3D10.1021%2Facs.bioconjchem.7b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Popow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnhof, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dank, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmaschitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karolyi-Özguer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinnenthal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roessler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieshofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span> <span> </span><span class="NLM_article-title">Highly selective PTK2 proteolysis targeting chimeras to probe focal adhesion kinase scaffolding functions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2508</span>– <span class="NLM_lpage">2520</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01826</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01826" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisl2ls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2508-2520&author=J.+Popowauthor=H.+Arnhofauthor=G.+Baderauthor=H.+Bergerauthor=A.+Ciulliauthor=D.+Coviniauthor=C.+Dankauthor=T.+Gmaschitzauthor=P.+Grebauthor=J.+Karolyi-%C3%96zguerauthor=M.+Koeglauthor=D.+B.+McConnellauthor=M.+Pearsonauthor=M.+Riegerauthor=J.+Rinnenthalauthor=V.+Roesslerauthor=A.+Schrenkauthor=M.+Spinaauthor=S.+Steurerauthor=N.+Trainorauthor=E.+Traxlerauthor=C.+Wieshoferauthor=A.+Zoephelauthor=P.+Ettmayer&title=Highly+selective+PTK2+proteolysis+targeting+chimeras+to+probe+focal+adhesion+kinase+scaffolding+functions&doi=10.1021%2Facs.jmedchem.8b01826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59aR"><div class="casContent"><span class="casTitleNuber">59a</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions</span></div><div class="casAuthors">Popow, Johannes; Arnhof, Heribert; Bader, Gerd; Berger, Helmut; Ciulli, Alessio; Covini, David; Dank, Christian; Gmaschitz, Teresa; Greb, Peter; Karolyi-Oezguer, Jale; Koegl, Manfred; McConnell, Darryl B.; Pearson, Mark; Rieger, Maria; Rinnenthal, Joerg; Roessler, Vanessa; Schrenk, Andreas; Spina, Markus; Steurer, Steffen; Trainor, Nicole; Traxler, Elisabeth; Wieshofer, Corinna; Zoephel, Andreas; Ettmayer, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2508-2520</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Focal adhesion tyrosine kinase (PTK2) is often overexpressed in human hepatocellular carcinoma (HCC), and several reports have linked PTK2 depletion and/or pharmacol. inhibition to reduced tumorigenicity.  However, the clin. relevance of targeting PTK2 still remains to be proven.  Here, we present two highly selective and functional PTK2 proteolysis-targeting chimeras utilizing von Hippel-Lindau and cereblon ligands to hijack E3 ligases for PTK2 degrdn.  BI-3663 (cereblon-based) degrades PTK2 with a median DC50 of 30 nM to >80% across a panel of 11 HCC cell lines.  Despite effective PTK2 degrdn., these compds. did not phenocopy the reported antiproliferative effects of PTK2 depletion in any of the cell lines tested.  By disclosing these compds., we hope to provide valuable tools for the study of PTK2 degrdn. across different biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsL2R_QBrfk7Vg90H21EOLACvtfcHk0lhCxhYLq_fBjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisl2ls78%253D&md5=f0ad27d3ff46ab12e8a90e8d40a6f3c6</span></div><a href="/servlet/linkout?suffix=cit59a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01826%26sid%3Dliteratum%253Aachs%26aulast%3DPopow%26aufirst%3DJ.%26aulast%3DArnhof%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DH.%26aulast%3DCiulli%26aufirst%3DA.%26aulast%3DCovini%26aufirst%3DD.%26aulast%3DDank%26aufirst%3DC.%26aulast%3DGmaschitz%26aufirst%3DT.%26aulast%3DGreb%26aufirst%3DP.%26aulast%3DKarolyi-%25C3%2596zguer%26aufirst%3DJ.%26aulast%3DKoegl%26aufirst%3DM.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DRieger%26aufirst%3DM.%26aulast%3DRinnenthal%26aufirst%3DJ.%26aulast%3DRoessler%26aufirst%3DV.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSpina%26aufirst%3DM.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DTraxler%26aufirst%3DE.%26aulast%3DWieshofer%26aufirst%3DC.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DEttmayer%26aufirst%3DP.%26atitle%3DHighly%2520selective%2520PTK2%2520proteolysis%2520targeting%2520chimeras%2520to%2520probe%2520focal%2520adhesion%2520kinase%2520scaffolding%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2508%26epage%3D2520%26doi%3D10.1021%2Facs.jmedchem.8b01826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit59b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zengerle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">impact of target warhead and linkage vector on inducing protein degradation: Comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">504</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=504-513&author=K.-H.+Chanauthor=M.+Zengerleauthor=A.+Testaauthor=A.+Ciulli&title=impact+of+target+warhead+and+linkage+vector+on+inducing+protein+degradation%3A+Comparison+of+bromodomain+and+extra-terminal+%28BET%29+degraders+derived+from+triazolodiazepine+%28JQ1%29+and+tetrahydroquinoline+%28I-BET726%29+BET+inhibitor+scaffolds&doi=10.1021%2Facs.jmedchem.6b01912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59bR"><div class="casContent"><span class="casTitleNuber">59b</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds</span></div><div class="casAuthors">Chan, Kwok-Ho; Zengerle, Michael; Testa, Andrea; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">504-513</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design of proteolysis-targeting chimeras (PROTACs) is a powerful small-mol. approach for inducing protein degrdn.  PROTACs conjugate a target warhead to an E3 ubiquitin ligase ligand via a linker.  Here the authors examd. the impact of derivatizing two different BET bromodomain inhibitors, triazolodiazepine JQ1 and the more potent tetrahydroquinoline I-BET726, via distinct exit vectors, using different polyethylene glycol linkers to VHL ligand VH032.  Triazolodiazepine PROTACs exhibited pos. cooperativities of ternary complex formation and were more potent degraders than tetrahydroquinoline compds., which showed neg. cooperativities instead.  Marked dependency on linker length was obsd. for BET-degrading and cMyc-driven antiproliferative activities in acute myeloid leukemia cell lines.  This work exemplifies as a cautionary tale how a more potent inhibitor does not necessarily generate more potent PROTACs and underscores the key roles played by the conjugation.  The provided insights and framework for structure-activity relationships of bivalent degraders are anticipated to have wide future applicability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEL41TefwTbVg90H21EOLACvtfcHk0lhCxhYLq_fBjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSktL4%253D&md5=c3bfd9377d8e7805ba962cd0180431af</span></div><a href="/servlet/linkout?suffix=cit59b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01912%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DK.-H.%26aulast%3DZengerle%26aufirst%3DM.%26aulast%3DTesta%26aufirst%3DA.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3Dimpact%2520of%2520target%2520warhead%2520and%2520linkage%2520vector%2520on%2520inducing%2520protein%2520degradation%253A%2520Comparison%2520of%2520bromodomain%2520and%2520extra-terminal%2520%2528BET%2529%2520degraders%2520derived%2520from%2520triazolodiazepine%2520%2528JQ1%2529%2520and%2520tetrahydroquinoline%2520%2528I-BET726%2529%2520BET%2520inhibitor%2520scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D504%26epage%3D513%26doi%3D10.1021%2Facs.jmedchem.6b01912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span>; <span class="NLM_string-name">Dragovich, P.</span>; <span class="NLM_string-name">Pillow, T. H.</span>; <span class="NLM_string-name">Yu, S.-F.</span></span> <span> </span><span class="NLM_article-title">Antibodies and Immunoconjugates</span>. <span class="NLM_patent">WO2016205176</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+Polakis&author=P.+Dragovich&author=T.+H.+Pillow&author=S.-F.+Yu&title=Antibodies+and+Immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPolakis%26aufirst%3DP.%26atitle%3DAntibodies%2520and%2520Immunoconjugates%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinebach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricelj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosič, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnakenburg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gütschow, M.</span></span> <span> </span><span class="NLM_article-title">A facile synthesis of ligands for the von Hippel-Lindau E3 ligase</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2521</span>– <span class="NLM_lpage">2527</span>, <span class="refDoi"> DOI: 10.1055/s-0040-1707400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1055%2Fs-0040-1707400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVanu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2020&pages=2521-2527&author=C.+Steinebachauthor=S.+A.+Voellauthor=L.+P.+Vuauthor=A.+Briceljauthor=I.+Sosi%C4%8Dauthor=G.+Schnakenburgauthor=M.+G%C3%BCtschow&title=A+facile+synthesis+of+ligands+for+the+von+Hippel-Lindau+E3+ligase&doi=10.1055%2Fs-0040-1707400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A facile synthesis of ligands for the von Hippel-Lindau E3 ligase</span></div><div class="casAuthors">Steinebach, Christian; Voell, Sabine Anna; Vu, Lan Phuong; Bricelj, Alesa; Sosic, Izidor; Schnakenburg, Gregor; Guetschow, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2521-2527</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">The proteolysis-targeting chimeras (PROTACs) have become an integral part of different stages of drug discovery.  This growing field, therefore, benefits from advancements in all segments of the design of these compds.  Herein, an efficient and optimized synthetic protocol to various von Hippel-Lindau (VHL) ligands is presented, which enables easy access to multigram quantities of these essential PROTAC building blocks.  Moreover, the elaborated synthesis represents a straightforward approach to further explore the chem. space of VHL ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyw4H4Rq7HfrVg90H21EOLACvtfcHk0lg4lOIiAwR8nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVanu7bN&md5=893543d726fa49e0ddb2a251c7efb792</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1055%2Fs-0040-1707400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0040-1707400%26sid%3Dliteratum%253Aachs%26aulast%3DSteinebach%26aufirst%3DC.%26aulast%3DVoell%26aufirst%3DS.%2BA.%26aulast%3DVu%26aufirst%3DL.%2BP.%26aulast%3DBricelj%26aufirst%3DA.%26aulast%3DSosi%25C4%258D%26aufirst%3DI.%26aulast%3DSchnakenburg%26aufirst%3DG.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26atitle%3DA%2520facile%2520synthesis%2520of%2520ligands%2520for%2520the%2520von%2520Hippel-Lindau%2520E3%2520ligase%26jtitle%3DSynthesis%26date%3D2020%26volume%3D52%26spage%3D2521%26epage%3D2527%26doi%3D10.1055%2Fs-0040-1707400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span>; <span class="NLM_string-name">Maniaci, C.</span>; <span class="NLM_string-name">Hughes, S. J.</span>; <span class="NLM_string-name">Testa, A.</span></span> <span> </span><span class="NLM_article-title">Small Molecules</span>. <span class="NLM_patent">WO2018189554</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Ciulli&author=C.+Maniaci&author=S.+J.+Hughes&author=A.+Testa&title=Small+Molecules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DSmall%2520Molecules%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kinney, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petkanas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenneman, D. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of KLS-13019, a cannabidiol-derived neuroprotective agent, with improved potency, safety, and permeability</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">428</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVWmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=424-428&author=W.+A.+Kinneyauthor=M.+E.+McDonnellauthor=H.+M.+Zhongauthor=C.+Liuauthor=L.+Yangauthor=W.+Lingauthor=T.+Qianauthor=Y.+Chenauthor=Z.+Caiauthor=D.+Petkanasauthor=D.+E.+Brenneman&title=Discovery+of+KLS-13019%2C+a+cannabidiol-derived+neuroprotective+agent%2C+with+improved+potency%2C+safety%2C+and+permeability&doi=10.1021%2Facsmedchemlett.6b00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63aR"><div class="casContent"><span class="casTitleNuber">63a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability</span></div><div class="casAuthors">Kinney, William A.; McDonnell, Mark E.; Zhong, Hua Marlon; Liu, Chaomin; Yang, Lanyi; Ling, Wei; Qian, Tao; Chen, Yu; Cai, Zhijie; Petkanas, Dean; Brenneman, Douglas E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-428</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cannabidiol is the nonpsychoactive natural component of C. sativa that has been shown to be neuroprotective in multiple animal models.  Our interest is to advance a therapeutic candidate for the orphan indication hepatic encephalopathy (HE).  HE is a serious neurol. disorder that occurs in patients with cirrhosis or liver failure.  Although cannabidiol is effective in models of HE, it has limitations in terms of safety and oral bioavailability.  Herein, we describe a series of side chain modified resorcinols that were designed for greater hydrophilicity and "drug likeness", while varying hydrogen bond donors, acceptors, architecture, basicity, neutrality, acidity, and polar surface area within the pendent group.  Our primary screen evaluated the ability of the test agents to prevent damage to hippocampal neurons induced by ammonium acetate and ethanol at clin. relevant concns.  Notably, KLS-13019 was 50-fold more potent and >400-fold safer than cannabidiol and exhibited an in vitro profile consistent with improved oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotem6Cj2XcN7Vg90H21EOLACvtfcHk0lg4lOIiAwR8nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVWmt7Y%253D&md5=32249f294f3baf8d6ffa0ffd743ab0c8</span></div><a href="/servlet/linkout?suffix=cit63a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00009%26sid%3Dliteratum%253Aachs%26aulast%3DKinney%26aufirst%3DW.%2BA.%26aulast%3DMcDonnell%26aufirst%3DM.%2BE.%26aulast%3DZhong%26aufirst%3DH.%2BM.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DW.%26aulast%3DQian%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DPetkanas%26aufirst%3DD.%26aulast%3DBrenneman%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520KLS-13019%252C%2520a%2520cannabidiol-derived%2520neuroprotective%2520agent%252C%2520with%2520improved%2520potency%252C%2520safety%252C%2520and%2520permeability%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D424%26epage%3D428%26doi%3D10.1021%2Facsmedchemlett.6b00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit63b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tauber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opatz, T.</span></span> <span> </span><span class="NLM_article-title">Synthetic approaches to anti-inflammatory macrolactones of the oxacyclododecindione type</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_fpage">3587</span>– <span class="NLM_lpage">3608</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201500275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1002%2Fejoc.201500275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsleqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=3587-3608&author=J.+Tauberauthor=K.+Rudolphauthor=M.+Rohrauthor=G.+Erkelauthor=T.+Opatz&title=Synthetic+approaches+to+anti-inflammatory+macrolactones+of+the+oxacyclododecindione+type&doi=10.1002%2Fejoc.201500275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63bR"><div class="casContent"><span class="casTitleNuber">63b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to Anti-Inflammatory Macrolactones of the Oxacyclododecindione Type</span></div><div class="casAuthors">Tauber, Johannes; Rudolph, Kristina; Rohr, Markus; Erkel, Gerhard; Opatz, Till</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3587-3608</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Various synthetic approaches to the oxacyclododecindione-type macrolactones, known for their potent anti-inflammatory activity were presented.  These included an attempted carbonylative ring closure, a hydroacylation route, and an approach by ring-closing metathesis and double bond isomerization, as well as a strategy including ring-closing metathesis/unsatn.  The last route allowed the prepn. of a bioactive analog of the recently described 14-deoxyoxacyclododecindione.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Gi4gQnumW7Vg90H21EOLACvtfcHk0lj7RZXqJJea7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsleqsLc%253D&md5=3b2785e8d4cb73ed41b14f19d386aa73</span></div><a href="/servlet/linkout?suffix=cit63b&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201500275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201500275%26sid%3Dliteratum%253Aachs%26aulast%3DTauber%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DK.%26aulast%3DRohr%26aufirst%3DM.%26aulast%3DErkel%26aufirst%3DG.%26aulast%3DOpatz%26aufirst%3DT.%26atitle%3DSynthetic%2520approaches%2520to%2520anti-inflammatory%2520macrolactones%2520of%2520the%2520oxacyclododecindione%2520type%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2015%26spage%3D3587%26epage%3D3608%26doi%3D10.1002%2Fejoc.201500275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Žinić, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alihodžić, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Škarić, V.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-Benzyloxycarbonylaziridine in the syntheses of 2-aminoethyl armed lariats and selectively <i>N</i>-protected polyazacrown ethers</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1039/P19930000021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1039%2FP19930000021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADyaK3sXisFCrurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&pages=21-26&author=M.+%C5%BDini%C4%87author=S.+Alihod%C5%BEi%C4%87author=V.+%C5%A0kari%C4%87&title=N-Benzyloxycarbonylaziridine+in+the+syntheses+of+2-aminoethyl+armed+lariats+and+selectively+N-protected+polyazacrown+ethers&doi=10.1039%2FP19930000021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">N-Benzyloxycarbonylaziridine in the syntheses of 2-aminoethyl armed lariats and selectively N-protected polyazacrown ethers</span></div><div class="casAuthors">Zinic, Mladen; Alihodzic, Sulejman; Skaric, Vinko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1:  Organic and Bio-Organic Chemistry (1972-1999)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-6</span>CODEN:
                <span class="NLM_cas:coden">JCPRB4</span>;
        ISSN:<span class="NLM_cas:issn">0300-922X</span>.
    </div><div class="casAbstract">In this abstr. R = N-aminoethylene.  The 15- and 18-membered mono- and bibracchial N-aminoethylene armed lariats I, II, and III are prepd. by alkylations of parent azacrowns using N-benzyloxycarbonylaziridine (IV) and subsequent removal of Z-protecting groups by catalytic hydrogenolysis.  Extn. expts. with M+-picrates (M+ = Li+, Na+, K+, Cs+) showed medium efficacy of I, II, and III and only slight selectivity of I for Cs+.  The syntheses of selectively N-protected polyazacrowns 10-benzyl-1,4-dioxa-7,10,13-triazacyclopentadecane V, 10,19-dibenzyl-1,4,13,16-tetraoxa-7,10,19,22-tetraazacyclotetracosane VI, and 4,16-dibenzyl-1,10-dioxa-4,7,13,16-tetraazacyclooctadecane VII exemplify the application of IV as a suitable building block for prepns. of selectively N-protected polyaza-macrocycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7m9NjgVieh7Vg90H21EOLACvtfcHk0lj7RZXqJJea7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisFCrurY%253D&md5=5e39bb9739deb781024c0c8f4ae1501e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1039%2FP19930000021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FP19930000021%26sid%3Dliteratum%253Aachs%26aulast%3D%25C5%25BDini%25C4%2587%26aufirst%3DM.%26aulast%3DAlihod%25C5%25BEi%25C4%2587%26aufirst%3DS.%26aulast%3D%25C5%25A0kari%25C4%2587%26aufirst%3DV.%26atitle%3DN-Benzyloxycarbonylaziridine%2520in%2520the%2520syntheses%2520of%25202-aminoethyl%2520armed%2520lariats%2520and%2520selectively%2520N-protected%2520polyazacrown%2520ethers%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1993%26spage%3D21%26epage%3D26%26doi%3D10.1039%2FP19930000021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Endo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumichika, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, K.</span></span> <span> </span><span class="NLM_article-title">A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1365</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.01.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=10.1016%2Fj.bmcl.2016.01.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=26869194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVahsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1365-1370&author=J.+Endoauthor=H.+Hikawaauthor=M.+Hamadaauthor=S.+Ishibuchiauthor=N.+Fujieauthor=N.+Sugiyamaauthor=M.+Tanakaauthor=H.+Kobayashiauthor=K.+Sugaharaauthor=K.+Oshitaauthor=K.+Iwataauthor=S.+Ooikeauthor=M.+Murataauthor=H.+Sumichikaauthor=K.+Chibaauthor=K.+Adachi&title=A+phenotypic+drug+discovery+study+on+thienodiazepine+derivatives+as+inhibitors+of+T+cell+proliferation+induced+by+CD28+co-stimulation+leads+to+the+discovery+of+a+first+bromodomain+inhibitor&doi=10.1016%2Fj.bmcl.2016.01.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor</span></div><div class="casAuthors">Endo, Junichi; Hikawa, Hidemasa; Hamada, Maiko; Ishibuchi, Seigo; Fujie, Naoto; Sugiyama, Naoki; Tanaka, Minoru; Kobayashi, Haruhito; Sugahara, Kunio; Oshita, Koichi; Iwata, Kazunori; Ooike, Shinsuke; Murata, Meguru; Sumichika, Hiroshi; Chiba, Kenji; Adachi, Kunitomo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1365-1370</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A phenotypic screening of thienodiazepines derived from a hit compd. found through a binding assay targeting co-stimulatory mols. on T cells and antigen presenting cells successfully led to the discovery of a thienotriazolodiazepine compd. (7f) possessing potent immunosuppressive activity.  A chem. biol. approach has succeeded in revealing that 7f is a first inhibitor of epigenetic bromodomain-contg. proteins. 7f is expected to become an anti-cancer agent as well as an immunosuppressive agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeajoPFavBUbVg90H21EOLACvtfcHk0ligNl6JKUITHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVahsL8%253D&md5=e414d4c7fad718d7b2c5a76a20aed0d7</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.01.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.01.084%26sid%3Dliteratum%253Aachs%26aulast%3DEndo%26aufirst%3DJ.%26aulast%3DHikawa%26aufirst%3DH.%26aulast%3DHamada%26aufirst%3DM.%26aulast%3DIshibuchi%26aufirst%3DS.%26aulast%3DFujie%26aufirst%3DN.%26aulast%3DSugiyama%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DSugahara%26aufirst%3DK.%26aulast%3DOshita%26aufirst%3DK.%26aulast%3DIwata%26aufirst%3DK.%26aulast%3DOoike%26aufirst%3DS.%26aulast%3DMurata%26aufirst%3DM.%26aulast%3DSumichika%26aufirst%3DH.%26aulast%3DChiba%26aufirst%3DK.%26aulast%3DAdachi%26aufirst%3DK.%26atitle%3DA%2520phenotypic%2520drug%2520discovery%2520study%2520on%2520thienodiazepine%2520derivatives%2520as%2520inhibitors%2520of%2520T%2520cell%2520proliferation%2520induced%2520by%2520CD28%2520co-stimulation%2520leads%2520to%2520the%2520discovery%2520of%2520a%2520first%2520bromodomain%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1365%26epage%3D1370%26doi%3D10.1016%2Fj.bmcl.2016.01.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MXF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MXF','PDB','3MXF'); return false;">PDB: 3MXF</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i131"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01845">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_65677"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01845?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01845</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">PC3-S1 cell line generation and characterization, BRD4 degradation assays (PC3-S1 line), in vitro inhibition of the MYC expression assay, PC3-S1 antiproliferation assays, BRD4 BD1 and BD2 binding assessments, whole-blood stability studies, PC3-S1 BRD4-degradation/antiproliferation relationships, VHL-binding assessments, BRD4–VHL–degrader ternary complex assessments, IAM assessments, intracellular quantitation of compound <b>8</b>, LNCaP antiproliferation assays and western blot assessments, ADC in vivo stability and PK data determination, full chemical structures of chimeric BRD4 degraders and related linker-drugs, analytical LCMS methods, synthesis of antibody–drug conjugates, ADC mechanisms of action, ADC unit conversion example (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf">PDF</a>).</p></li><li><p class="inline">Molecular formula strings of <a class="ref showTableEvent internalNav" href="#tbl1">Table <a class="ref showTableEvent internalNav" href="#tbl1">1</a></a> compounds (<b>1</b>, <b>3</b>–<b>12</b>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_002.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of new compounds in <a class="ref internalNav" href="#sch1">Schemes 1</a>–<a class="ref internalNav" href="#sch11">11</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_001.pdf">jm0c01845_si_001.pdf (2.34 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_002.csv">jm0c01845_si_002.csv (12.9 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01845/suppl_file/jm0c01845_si_003.csv">jm0c01845_si_003.csv (2.13 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01845&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01845%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01845" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a85feaac6d18b","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
